_id,batch,concept_code,concept_code_system,end,experiencer,inserted_date,job_id,negation,nlpql_feature,owner,phenotype_final,pipeline_id,pipeline_type,report_date,report_id,report_type,section,sentence,solr_id,source,start,subject,temporality,term
5c7430378625dd02b7867f88,560,,,124,Patient,13:11.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_505251,Clinical Trial Inclusion Criteria,UNKNOWN,Menarche >2year - Subject treated by chemotherapy-induced ovarian failure including alkylant agents (except less than 8 ABVD),ct_inc_505251,AACT,120,NCT01160315,Recent,ABVD
5c7430378625dd02b7867f89,560,,,48,Patient,13:11.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_495191,Clinical Trial Exclusion Criteria,UNKNOWN,lower than 60 points - Incapable to fulfill ABVD - Patients with cognitive deterioration - Patients with diagnosis of ictus in the last 6 months,ct_exc_495191,AACT,44,NCT01291966,Recent,ABVD
5c7430388625dd02b7867f8a,560,,,125,Patient,13:12.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_486815,Clinical Trial Inclusion Criteria,UNKNOWN,"All subjects must have a confirmed diagnosis of malignancy and receiving highly emetogenic chemotherapy first time (VAC, ABVD and CDDP/Doxorubicin) - Age group 5-18 years with weight between 15-65 kg - Children/adolescents and their caregiver who can understand Hindi or English and willing to participate in the study (with written informed consent)",ct_inc_486815,AACT,121,NCT01402024,Recent,ABVD
5c7430388625dd02b7867f8b,560,,,21,Patient,13:12.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_486975,Clinical Trial Inclusion Criteria,UNKNOWN,- Treatment with ABVD x 4 (early stage) - Consolidation Radiotherapy on bulky lesion,ct_inc_486975,AACT,17,NCT01399931,Recent,ABVD
5c7430428625dd0334867f87,400,,,4,Patient,13:22.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_419623,Clinical Trial Inclusion Criteria,UNKNOWN,ABVD,ct_inc_419623,AACT,0,NCT02280993,Recent,ABVD
5c74304d8625dd0381867f9e,230,,,188,Patient,13:33.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_478897,Clinical Trial Inclusion Criteria,UNKNOWN,#NAME?,ct_inc_478897,AACT,184,NCT01505712,Recent,ABVD
5c74304d8625dd0381867f9f,230,,,50,Patient,13:33.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_478897,Clinical Trial Inclusion Criteria,UNKNOWN,Patients with advanced-stage cHL treated with ABVD at the British Columbia Cancer Agency (BCCA),ct_inc_478897,AACT,46,NCT01505712,Recent,ABVD
5c74304d8625dd0381867fa2,230,,,89,Patient,13:33.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_559601,Clinical Trial Inclusion Criteria,UNKNOWN,"18 years - Received and failed potentially curative chemotherapeutic regimens (e.g., ABVD, Stanford V, or BEACOPP) - Relapsed following autologous bone marrow transplantation (BMT), or are ineligible, or refused BMT - Completed radiotherapy, chemotherapy, and/or treatment with other investigational agents at least 3 weeks prior to study entry - Completed autologous BMT (if received) at least 3 months prior to study entry; completed allogeneic BMT (if received); at least 6 months prior to study entry - Eastern Cooperative Oncology Group (ECOG) status of <2 - Life expectancy of >3 months -",ct_inc_559601,AACT,85,NCT00441818,Historical,ABVD
5c7430538625dd03c7867f95,0,,,6,Patient,13:39.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_392418,Clinical Trial Inclusion Criteria,UNKNOWN,- ABVD - ICE R - 7+3 - Conditioning therapy for stem cell transplantation: - BEAM - Bu/Cy ATG - Bu/Flu ATG - FluCy ATG - FluCy + TBI - BuMel - FluBuCy - Melphalan - Etoposide + TBI - Cyclophosphamide + TBI,ct_inc_392418,AACT,2,NCT02635984,Recent,ABVD
5c74305a8625dd0426867f8c,660,,,92,Patient,13:46.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_592770,Clinical Trial Inclusion Criteria,UNKNOWN,- Previously untreated Hodgkin's disease patients who are scheduled to receive standard ABVD chemo.-,ct_inc_592770,AACT,88,NCT00038558,Recent,ABVD
5c74305a8625dd0426867f8d,660,,,381,Patient,13:46.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_524904,Clinical Trial Inclusion Criteria,UNKNOWN,Any tumor mass measurable in two dimensions and > 2 cm is acceptable (or 1.5 cm if 0.5 cm slices are used as in spiral CT scans) - Age 18 - Patients must have at least one hypermetabolic lesion identifiable on initial PET scan - LVEF by ECHO or MUGA within institutional normal limits - Initial laboratory data should be compatible with the administration of standard doses of ABVD chemotherapy,ct_inc_524904,AACT,377,NCT00901303,Hypothetical,ABVD
5c74305e8625dd0457867f8b,70,,,107,Patient,13:50.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_448591,Clinical Trial Inclusion Criteria,UNKNOWN,"Be designated to receive cytotoxic chemotherapy including one or more of the following agents: R-CHOP, ABVD, Liposomal doxorubicin (Caelyx) or liposomal daunorubicin (Daunoxome) or Paclitaxel",ct_inc_448591,AACT,103,NCT01902693,Recent,ABVD
5c7430618625dd043c867f9b,50,,,58,Patient,13:53.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_587871,Clinical Trial Inclusion Criteria,UNKNOWN,"Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) MOPP/ABV Stanford 5 OR Refractory to a second line regimen, such as: Mesna, ifosfamide, mitoxantrone, and etoposide (MINE) Etoposide, methylprednisolone, high dose cytarabine, and cisplatin",ct_inc_587871,AACT,54,NCT00005595,Recent,ABVD
5c7430628625dd0452867f97,40,,,165,Patient,13:54.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_590819,Clinical Trial Inclusion Criteria,UNKNOWN,"- Histologically confirmed Hodgkin's lymphoma - Early or late first relapse - Complete or partial remission for at least 3 months after completion of prior COPP/ABVD, COPP/ABV/IMEP, MOPP/ABV, ABVD, BEACOPP, or other polychemotherapy regimen with or withou",ct_inc_590819,AACT,161,NCT00025636,Historical,ABVD
5c7430668625dd0489867f87,1260,,,107,Patient,13:58.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_481760,Clinical Trial Exclusion Criteria,UNKNOWN,"2.1.2.1 Patients who have relapsed from their initial Adriamycin, bleomycin, vinblastine, dacarbazine) ABVD or similar standard treatment regimen and have not received any other chemotherapy or salvage systemic treatment.2.1.2.2 Patients that have received prior radioimmunotherapy.2.1.2.",ct_exc_481760,AACT,103,NCT01468311,Historical,ABVD
5c7430678625dd04b5867f86,860,,,43,Patient,13:59.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_361894,Clinical Trial Inclusion Criteria,UNKNOWN,OR if their PET scan after 2 cycles of ABVD is positive,ct_inc_361894,AACT,39,NCT03033914,Recent,ABVD
5c7430678625dd04b5867f87,860,,,61,Patient,13:59.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_361894,Clinical Trial Inclusion Criteria,UNKNOWN,Patients may enroll anytime within the first 2 cycles of ABVD or after PET-2.- Cohort B overview: Patients 60 or older with untreated classical Hodgkin lymphoma (regardless of stage) will be eligible for cohort B.The following eligibility criteria applies to both cohort A and B except when stated otherwise: - Histologic diagnosis of classical Hodgkin lymphoma - FDG-avid disease by FDG-PET/CT - Ann Arbor Stage III or IV disease (Cohort A only) - WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug.,ct_inc_361894,AACT,57,NCT03033914,Historical,ABVD
5c7430678625dd049f867f89,960,,,196,Patient,13:59.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_473305,Clinical Trial Exclusion Criteria,UNKNOWN,"Cardiac disease with left ventricular ejection fraction of less than 45% - Known hypersensitivity to any excipient contained in the drug formulation of brentuximab vedotin or any component of ABVD - Medical or other condition that would represent an inappropriate risk to the patient or would likely compromise achievement of the primary study objective - Other active malignancies with the exception of: - Non-melanoma skin cancer - Cervical carcinoma in situ without evidence of disease - Prostatic intraepithelial neoplasia without evidence of prostate cancer - Pregnant or lactating women Prior to Day 1 of brentuximab vedotin, please verify the patient does not meet the criteria below: - Symptomatic pulmonary disease currently requiring regular medication including but not restricted to bronchodilators",ct_exc_473305,AACT,192,NCT01578967,Historical,ABVD
5c7430688625dd04c0867f91,30,,,242,Patient,14:00.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_344464,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Complete response of lymphoma (Cheson criteria 2007) after initial treatment - Malin lymphoma (Hodgkin or not) treated with anthracyclines for at least 6 cycles : Adriamycin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) or BEACOPP, Cyclophosphamide, hydroxydaunomycin, Oncovin, and prednisone (CHOP) et Rituximab (R-CHOP), miniCHOP et RminiCHOP, RACVBP having received or not an intensification with autologous hematopoietic stem cell transplantation in first-line - Registered the consent to be included in this study",ct_inc_344464,AACT,238,NCT03260855,Recent,ABVD
5c7430688625dd04b5867f88,860,,,150,Patient,14:00.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_473305,Clinical Trial Inclusion Criteria,UNKNOWN,"x ULN - Serum creatinine 2.0 mg/dL - Negative serum human chorionic gonadotropin (-hCG) pregnancy test within 72 hours of day 1 of treatment with ABVD in women of child-bearing potential - Females of childbearing potential, and males who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 6 months following the last dose of brentuximab vedotin.",ct_inc_473305,AACT,146,NCT01578967,Recent,ABVD
5c7430688625dd04b5867f89,860,,,75,Patient,14:00.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_473305,Clinical Trial Inclusion Criteria,UNKNOWN,#NAME?,ct_inc_473305,AACT,71,NCT01578967,Recent,ABVD
5c74306c8625dd04cb867f98,260,,,117,Patient,14:04.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_504535,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients must have failed (relapsed or refractory) front-line standard anthracycline-containing regimen, such as ABVD, Stanford V, or BEACOPP.",ct_inc_504535,AACT,113,NCT01169636,Recent,ABVD
5c74306c8625dd04cb867f9b,260,,,97,Patient,14:04.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_519899,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients must have received a front-line standard anthracycline- containing regimen, such as ABVD, Stanford V, or BEACOPP.",ct_inc_519899,AACT,93,NCT00967369,Recent,ABVD
5c74306e8625dd04f7867f8d,550,,,637,Patient,14:06.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_487451,Clinical Trial Inclusion Criteria,UNKNOWN,"> 1.5 cm evidenced by computed tomography (CT) scan of the neck/chest/abdomen(abd)/pelvis or CT/positron emission tomography (PET) scans - Patient must be either primary refractory to one frontline induction therapy or relapsed after one frontline induction therapy; patients who do not achieve complete remission after induction therapy are also eligible - Patients cannot have had a second line salvage treatment (chemotherapy, biologic agents, investigational drugs, or radiation) or have had an autologous or allogeneic hematopoietic stem cell transplantation; patients can have had mixed frontline therapy such as 2-4 cycles of ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) followed by 2-4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) as long as the induction chemotherapy is not more than 8 cycles in total length - Radiation use as part of induction regimen or consolidation (within 90 days after completion of induction chemotherapy) is allowed -",ct_inc_487451,AACT,633,NCT01393717,Recent,ABVD
5c7430778625dd057f867f86,810,,,242,Patient,14:16.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_486815,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Significant organ dysfunction - Active infection - Pregnancy - Uncontrolled medical condition other than malignancy - Need for contraindicated concomitant medication - Patients receiving chemotherapy other than VAC, ABVD and CDDP/Doxorubicin - Treatment with another investigational drug within 4 weeks of study",ct_exc_486815,AACT,238,NCT01402024,Recent,ABVD
5c7430848625dd0603867f8a,600,,,235,Patient,14:28.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_486591,Clinical Trial Inclusion Criteria,UNKNOWN,"Hodgkin's disease patients who relapse after radiation therapy alone, or in combination with Novantrone, Oncovin, Velban, and Prednisone (NOVP); and previously untreated patients with stage III and IV who are eligible for standard ABVD therapy.",ct_inc_486591,AACT,231,NCT01404936,Recent,ABVD
5c7430888625dd0628867f92,90,,,325,Patient,14:32.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_585900,Clinical Trial Inclusion Criteria,UNKNOWN,"No evidence of disease - Prior treatment on 1 of the following protocols during the years 1987-2001: - Children's Cancer Group (CCG) CCG-5942, CCG-59704 - Pediatric Oncology Group (POG) POG-8625, POG-8725, POG-9425, POG-9426 - Pediatric Hodgkin's Consortium: VAMP, VEPA, VAMP/COP - Institutional protocols COPP/ABV, MOPP/ABVD, ABVD - Childhood Cancer Survivor Study (CCSS)",ct_inc_585900,AACT,321,NCT00091091,Historical,ABVD
5c74308b8625dd0642867f8a,610,,,75,Patient,14:35.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_587010,Clinical Trial Inclusion Criteria,UNKNOWN,(CR) Relapsed within 1 year following completion of front-line MOPP or ABVD Relapsed at any time following front-line MOPP/ABVD or other hybrid Eligible,ct_inc_587010,AACT,71,NCT00002552,Recent,ABVD
5c74308b8625dd063a867f84,390,,,188,Patient,14:35.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_586346,Clinical Trial Inclusion Criteria,UNKNOWN,"Measurable disease Must have failed the following regimens: Mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) AND Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)",ct_inc_586346,AACT,184,NCT00003936,Recent,ABVD
5c74308b8625dd063a867f87,390,,,71,Patient,14:35.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_317216,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically confirmed Classical Hodgkin's Lymphoma treated with ABVD regimen with PET scan/CT performed before, during and after treatment, and also one of the following: - positive result (Deauville 4 and 5) of early PET scan after 2 ABVD courses - disease progression or relapse after first-line ABVD treatment or ABVD and radiotherapy combination treatment - No contraindications for salvage chemotherapy and ASCT - At least one measurable malignancy - ECOG performance status 3 - Written signed and dated informed consent prior to any study procedures being performed",ct_inc_317216,AACT,67,NCT03615664,Historical,ABVD
5c74309e8625dd06f5867f8b,440,,,32,Patient,14:54.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_516131,Clinical Trial Inclusion Criteria,UNKNOWN,"- Hodgkin lymphoma - Failed ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and received salvage chemotherapy with at least 1 salvage combination regimen - Indolent or low-grade lymphoma - Failed at least 1 combination regimen containing ritux",ct_inc_516131,AACT,28,NCT01016990,Recent,ABVD
5c74309e8625dd070b867f87,510,,,360,Patient,14:54.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_520262,Clinical Trial Inclusion Criteria,UNKNOWN,"- Histologically confirmed diagnosis of one of the following: - Hodgkin or non-Hodgkin lymphoma (including small lymphocytic lymphoma [SLL]) - Any histology, including B, T, or NK/T cell allowed - Multiple myeloma (MM) - Relapsed or refractory disease - P",ct_inc_520262,AACT,356,NCT00962507,Recent,ABVD
5c7430a18625dd0700867f92,200,,,635,Patient,14:57.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_591291,Clinical Trial Inclusion Criteria,UNKNOWN,"In second or greater complete or partial response if treated at diagnosis without clinical symptoms necessitating treatment - T-cell lymphoma (nonlymphoblastic, intermediate, or high grade lymphomas) after initial therapy whether or not complete response is achieved - Hodgkin's lymphoma - Stage I and II disease treated with primary radiotherapy and failure of at least one combination chemotherapy regimen - Stage III and IV disease with failure on mechlorethamine, vincristine, procarbazine, and prednisone (MOPP)-like regimen, alternative noncross resistant regimen (e.g., doxorubicin, bleomycin, vinblastine, and dacarbazine [ABVD]), or a combination (e.g., MOPP-ABV) - High risk features allowed including: - Failure to achieve initial complete remission with MOPP and/or ABVD and crossover or hybrid therapy - Relapse within 6 months after initial therapy - Relapse after initial radiotherapy with complete response longer than 1 year since initial therapy and subsequent failure on MOPP and/or ABVD or hybrid - Bulky mediastinal disease after initial therapy and residual mass of at least 5 cm with other features of persisting disease (e.g., Gallium scan positive, high LDH, enlarging on serial x-rays, or positive biopsy) - No HIV or HTLV-1 associated lymphomas -",ct_inc_591291,AACT,631,NCT00005985,Recent,ABVD
5c7430a78625dd0767867f84,670,,,160,Patient,15:03.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_554863,Clinical Trial Inclusion Criteria,UNKNOWN,"Hodgkin's disease patients who relapse after radiation therapy alone and previously untreated patients with stage II bulky, III and IV who are eligible for ABVD.",ct_inc_554863,AACT,156,NCT00504504,Recent,ABVD
5c7430a98625dd0758867f90,460,,,103,Patient,15:05.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_592784,Clinical Trial Inclusion Criteria,UNKNOWN,Patients with Hodgkin's disease will be eligible only if they have failed at least a MOPP-like and ABVD-like regimen.,ct_inc_592784,AACT,99,NCT00038376,Hypothetical,ABVD
5c7430ab8625dd0763867f93,730,,,209,Patient,15:07.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_339049,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients must have cHL that has not been previously treated (patients who have received one dose [day 1 cycle 1] of standard doxorubicin hydrochloride [adriamycin], bleomycin, vinblastine and dacarbazine [ABVD] or doxorubicin hydrochloride, vinblastine, dacarbazine [AVD] may be enrolled as long as they completed all the required standard of care baseline studies before enrollment and initiate study therapy by day 15 cycle 1) - Patients must be appropriate candidates for at least 2 cycles of ABVD or AVD (this could include patients ranging from favorable risk early stage disease to poor prognosis advanced stage disease) - Patients must have measurable FDG-avid disease defined by standard criteria (Lugano 2014) and a minimum of 1.0 cm in diameter - Patients must have a FDG-PET-computed tomography (CT) of chest, abdomen, and pelvis within 28 days of enrollment - Patients should not have evidence of active central nervous system lymphoma - Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 - Patients must have a left ventricular ejection (LVEF) >= 50% within 56 days of enrollment - Patients must have adequate labs within 7 days of treatment unless cytopenia is thought to be due to underlying disease - Absolute neutrophil count (ANC) >= 1,500/mm^3 (without transfusion or growth factor support) -",ct_inc_339049,AACT,205,NCT03331341,Recent,ABVD
5c7430ae8625dd079a867f88,380,,,109,Patient,15:10.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_354846,Clinical Trial Inclusion Criteria,UNKNOWN,"For advanced (stage III/IV) Hodgkin disease, patients must have failed an Adriamycin containing regimen (ABVD) or an alternative non-cross resistant regimen (e.g.MOPP) - Patients with any high-risk features will also be eligible, including those who: 1. fail to achieve complete remission with initial combination chemotherapy 2. have bulky disease after initial therapy (chemotherapy or radiation) defined as residual mediastinal mass 5 cm or other residual mass 10 cm accompanied by other features of persisting disease (e.g., PET scan positive; high LDH; enlarging on serial x-rays or biopsy positive) will be eligible - if feasible, persistent disease should be proven by biopsy - Patients should receive chemotherapy to attempt to achieve CR or minimal disease state for all patients pre-transplantation.",ct_inc_354846,AACT,105,NCT03125642,Recent,ABVD
5c7430ae8625dd0779867f8e,520,,,46,Patient,15:10.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_317216,Clinical Trial Exclusion Criteria,UNKNOWN,"Classical Hodgkin's Lymphoma - Other than ABVD first-line treatment, preceding patient's inclusion - Lack of PET scans performed in accordance with inclusin criteria during ABVD treatment - Transformation of Hodgkin's Lymphoma - Central Nervous System (CNS)",ct_exc_317216,AACT,42,NCT03615664,Recent,ABVD
5c7430b48625dd07d1867f8b,1040,,,87,Patient,15:16.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_418297,Clinical Trial Inclusion Criteria,UNKNOWN,I or II Mandatory PET scan performed at diagnosis Patients treated with first-line ABVD and PET scan positive after 2 cycles (Deauville score 4 & 6.,ct_inc_418297,AACT,83,NCT02298283,Recent,ABVD
5c7430b58625dd07d1867f8c,1040,,,451,Patient,15:17.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_361894,Clinical Trial Exclusion Criteria,UNKNOWN,"I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.- Subjects with a condition requiring systemic treatment with systemic corticosteroids (equivalent of >10mg/day of prednisone).Patients may receive steroid therapy up to 10 days prior to starting ABVD to control lymphoma-related symptoms.- Any of the following cardiovascular conditions or values within 6 months before the first dose of study",ct_exc_361894,AACT,447,NCT03033914,Historical,ABVD
5c7430b58625dd07d1867f8d,1040,,,127,Patient,15:17.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_339019,Clinical Trial Inclusion Criteria,UNKNOWN,The patient must meet one of the following criteria: Age 65 Considered by the investigator to be ineligible for front-line ABVD combination chemotherapy due to reasons of,ct_inc_339019,AACT,123,NCT03331731,Recent,ABVD
5c7430ba8625dd083f867f86,240,,,241,Patient,15:22.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_559790,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically confirmed relapsed or refractory classical Hodgkin lymphoma (nodular sclerosis, mixed cellularity, or lymphocyte-rich classical HL).- Patients must have failed front-line standard anthracycline-containing regimen, such as ABVD, Stanford V, or BEACOPP.-",ct_inc_559790,AACT,237,NCT00439361,Recent,ABVD
5c7430bb8625dd083f867f8c,240,,,148,Patient,15:23.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_378685,Clinical Trial Inclusion Criteria,UNKNOWN,"Pathologically confirmed, recent diagnosis of classical Hodgkin Lymphoma - treatment planned with Adriamycin Bleamycin Vinblastine Dacarbazine (ABVD) or Bleomycin Etoposide",ct_inc_378685,AACT,144,NCT02815137,Recent,ABVD
5c7430bb8625dd083f867f8e,240,,,39,Patient,15:23.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_378685,Clinical Trial Exclusion Criteria,UNKNOWN,No informed consent - Treatment by ABVD or BEACOPP not indicated - Previously treated Hodgkin lymphoma (including corticosteroids) - Patients who are pregnant or lactating - Active Hepatitis B or Hepatitis C infection - Known human immunodeficiency virus,ct_exc_378685,AACT,35,NCT02815137,Recent,ABVD
5c7430bc8625dd0859867f84,1160,,,74,Patient,15:24.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_589018,Clinical Trial Inclusion Criteria,CHEMOTHERAPEUTICS,"- No prior chemotherapy for Hodgkin's disease except single course of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) within 35 days of study Endocrine therapy:",ct_inc_589018,AACT,70,NCT00005090,Historical,ABVD
5c7430bd8625dd0859867f85,1160,,,18,Patient,15:25.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_507348,Clinical Trial Inclusion Criteria,COMMENT,"- 1 course of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) allowed and will be considered the first course",ct_inc_507348,AACT,14,NCT01132807,Recent,ABVD
5c74306f8625dd0518867f8b,100,,,74,Patient,14:07.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_392688,Clinical Trial Inclusion Criteria,UNKNOWN,"- Planned to start trastuzumab based neo/adjuvant therapy: FEC-DH or AC-DH, or; dose-dense AC-TH, or docetaxel/cyclophosphamide/trastuzumab or docetaxel/carboplatin/trastuzumab, or weekly paclitaxel with trastuzumab.- 19 years of age - Able to provide ver",ct_inc_392688,AACT,69,NCT02632435,Recent,AC-DH
5c74306f8625dd0518867f8c,100,,,96,Patient,14:07.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_392688,Clinical Trial Inclusion Criteria,UNKNOWN,"- Planned to start trastuzumab based neo/adjuvant therapy: FEC-DH or AC-DH, or; dose-dense AC-TH, or docetaxel/cyclophosphamide/trastuzumab or docetaxel/carboplatin/trastuzumab, or weekly paclitaxel with trastuzumab.- 19 years of age - Able to provide ver",ct_inc_392688,AACT,91,NCT02632435,Recent,AC-TH
5c7430b88625dd07fd867f92,210,,,226,Patient,15:20.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_311832,Clinical Trial Inclusion Criteria,UNKNOWN,Treatment naive CLL patients - Cohort 2: Subjects must be receiving ibrutinib monotherapy for at least 6 months prior to administration of the first vaccine dose - Cohort 3: Subjects must be receiving acalabrutinib monotherapy for at least 6 months prior to administration of the first vaccine dose - Age greater than or equal to 18 years.- ECOG performance status of 0-1 - Able to comprehend the investigational nature of the protocol and provide informed consent.,ct_inc_311832,AACT,201,NCT03685708,Historical,acalabrutinib monotherapy
5c7430398625dd02ba867f8b,900,,,122,Patient,13:13.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_582481,Clinical Trial Exclusion Criteria,UNKNOWN,Any previous therapy for lymphoma except for short-term corticosteroids before inclusion.- Inability to tolerate the ACVBP regimen according to investigator's judgement.- Positive serology for HIV.- Poor renal function (creatinin > 150 mol/,ct_exc_582481,AACT,117,NCT00136565,Recent,ACVBP
5c7430528625dd03c7867f8a,0,,,225,Patient,13:38.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_356471,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - DLBCL patients that will be eligible in front-line treatment for a combination of anthracycline-based chemotherapy plus anti-CD20 monoclonal antibody,Rituximab: R-CHOP 14, R-CHOP 21, R mini-CHOP, R-ACVBP, R-COPADEM.Patients",ct_inc_356471,AACT,220,NCT03104478,Recent,ACVBP
5c7430538625dd03c7867f9d,0,,,368,Patient,13:39.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_338682,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Patient with a recent diffuse large B cell lymphoma (LBDGC), histologically proven, with treatment not started - a priori likely to be treated by rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone every 21 days (R-CHOP21) for 8 cycles or rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (R-ACVBP).- Index international prognosis (IPI) measurable (IPI-aa), adjusted for age.",ct_inc_338682,AACT,363,NCT03336138,Recent,ACVBP
5c7430548625dd03c7867fba,0,,,86,Patient,13:40.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_415115,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Patient who cannot receive polychemotherapy like R-CHOP, R-ACVBP, or R-CHOP like - Patient who cannot benefit from standard extension assessment and follow-up by with Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET) - Pregnant or breast-feeding woman - Guardianship, curatorship - Patient who cannot follow the medical procedures of the study for geographic, social, psychological,linguistic or physical reasons",ct_exc_415115,AACT,81,NCT02339805,Recent,ACVBP
5c7430728625dd0544867f95,280,,,175,Patient,14:10.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_586830,Clinical Trial Inclusion Criteria,UNKNOWN,"No more than 1 prior combination chemotherapy regimen Chemotherapy consisted of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or a CHOP-like regimen, ACVBP, or other similar regimen",ct_inc_586830,AACT,170,NCT00002905,Historical,ACVBP
5c74307e8625dd05b6867f92,10,,,220,Patient,14:22.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_415115,Clinical Trial Inclusion Criteria,UNKNOWN,"With a diagnosis formally established of DLBCL or transformed straightaway follicular lymphoma or 3B grade follicular lymphoma or Burkitt-like lymphoma - Eligible to a treatment by immunochemotherapy like R-CHOP, R-ACVBP or R-CHOP like - First line of treatment - Being able to benefit from standard extension assessment ( Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET) and bone marrow biopsy with a bone marrow aspiration)",ct_inc_415115,AACT,215,NCT02339805,Recent,ACVBP
5c74308d8625dd065b867f95,20,,,84,Patient,14:37.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_540944,Clinical Trial Inclusion Criteria,UNKNOWN,"Previously treated with chemotherapy regimen containing rituximab: R CHOP or R ACVBP - Chemo-sensitive disease - PET Scan prior transplant - Eligible for autologous stem cell transplantation - With a minimum life expectancy of 3 months.- Negative HIV, HBV and HCV serologies (in the last 4 weeks except after vaccination).- Having previously signed a written informed consent.",ct_inc_540944,AACT,79,NCT00689169,Historical,ACVBP
5c7430878625dd060e867f87,470,,,218,Patient,14:31.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_423783,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically confirmed stage IV non-squamous NSCLC patients.- Patients must have been detected with an activating EGFR mutation at baseline and must have yet progressed on erlotinib, gefitinib or afatinib monotherapy in daily dose of 150 mg, 250 mg or 40 mg respectively.(Patients with unknown mutation status that have exhibited a response to these agents or stable disease for at least 6 months while on treatment with gefitinib or erlotinib are also eligible).- Rebiopsy after having acquired resistance to TKI-treatment must have been performed and HER2-overexpression (positive immunohistochemistry staining) must have been detected.-",ct_inc_423783,AACT,198,NCT02226757,Recent,afatinib monotherapy
5c7430ba8625dd0813867f95,370,,,66,Patient,15:22.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_404103,Clinical Trial Inclusion Criteria,UNKNOWN,Patient for whom a decision of treatment with afatinib monotherapy has been taken in the frame of its marketing authorization.,ct_inc_404103,AACT,46,NCT02483416,Recent,afatinib monotherapy
5c74309a8625dd06df867f8a,850,,,342,Patient,14:50.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_348908,Clinical Trial Inclusion Criteria,COMMENT,"Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.- Patients with untreated, controlled asymptomatic central nervous system (CNS) lesions are allowed in this trial as long as the CNS is not a site of progressive disease on alectinib monotherapy.",ct_inc_348908,AACT,321,NCT03202940,Recent,alectinib monotherapy
5c74309a8625dd06df867f8b,850,,,68,Patient,14:50.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_348908,Clinical Trial Inclusion Criteria,COMMENT,"If the CNS is a site of progressive disease on alectinib monotherapy, treatment of CNS lesions is required for enrollment.-",ct_inc_348908,AACT,47,NCT03202940,Hypothetical,alectinib monotherapy
5c7430a58625dd072c867f87,1270,,,282,Patient,15:01.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_348908,Clinical Trial Exclusion Criteria,UNKNOWN,"In addition, subjects who are unable to tolerate the 600 mg twice daily (BID) dose of alectinib will not be permitted to enroll unless doses of alectinib below the entry level are being investigated (e.g.dose level -1 and -2) and they have previously tolerated alectinib monotherapy at the dose being investigated.- Participants with prior allogeneic stem cell or solid organ transplantation.- History of extensive, disseminated, bilateral or presence of Grade 3 or 4 interstitial fibrosis or interstitial lung disease including pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis or pulmonary fibrosis.",ct_exc_348908,AACT,261,NCT03202940,Historical,alectinib monotherapy
5c7430bb8625dd0813867f9a,370,,,222,Patient,15:23.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_314937,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Patients 20 years of age or older at the time of signed consent.- Patients with locally advanced or metastatic non-small cell lung cancer.- Patients who are scheduled to start Atezolizumab monotherapy, based on the Atezolizumab package insert and the Optimal Use Promotion Guideline.- Patients who signed informed consent form before enrolling the study.",ct_inc_314937,AACT,198,NCT03645330,Recent,Atezolizumab monotherapy
5c7430658625dd049f867f87,960,,,95,Patient,13:58.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_403273,Clinical Trial Inclusion Criteria,UNKNOWN,The Investigator believes the subject is tolerating treatment with oral azacitidine monotherapy and continued oral azacitidine treatment is of benefit to the subject.,ct_inc_403273,AACT,72,NCT02494258,Recent,azacitidine monotherapy
5c7430558625dd03e4867f85,800,,,131,Patient,13:41.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_573909,Clinical Trial Inclusion Criteria,UNKNOWN,"A patient will be eligible for inclusion in this study if s/he meets all of the following criteria: - Has previously undergone BEAC or BEAM autologus SCT with PBSC rescue for any stage aggressive B-cell NHL, including transformed indolent NHL or mantle cell lymphoma according to REAL classification - only B-cell lymphomas are permitted.- ECOG performance status 0",ct_inc_573909,AACT,127,NCT00250861,Hypothetical,BEAC
5c74306c8625dd04e1867f8b,500,,,44,Patient,14:04.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_510997,Clinical Trial Inclusion Criteria,UNKNOWN,"Melphalan 140 mg/m2 or 200 mg/m2, BEAM, BEAC, BUCY or CBV",ct_inc_510997,AACT,40,NCT01085058,Recent,BEAC
5c7430888625dd0624867f8a,420,,,221,Patient,14:32.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_348847,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Patients between 16 and 99 years of age diagnosed with lymphoma or myeloma - Able to communicate in Swedish - Treated with bis-chloroethylnitrosourea, etoposide, cytarabine, and cyclophosphamide(BEAC) or bis-chloroethylnitrosourea, etoposide, cytarabine, and melphalan (BEAM) (lymphoma diagnosis), melphalan (myeloma diagnosis), before stem cell transplantation (SCT)",ct_inc_348847,AACT,217,NCT03203733,Recent,BEAC
5c74309d8625dd070b867f84,510,,,121,Patient,14:53.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_549591,Clinical Trial Inclusion Criteria,UNKNOWN,"etc.).These patients would be enrolled in a high-dose protocol using carmustine, etoposide, cytarabine, and cytoxan (BEAC) with autologous hematopoietic rescue.",ct_inc_549591,AACT,117,NCT00574626,Recent,BEAC
5c7430428625dd0334867f86,400,,,71,Patient,13:22.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_419623,Clinical Trial Inclusion Criteria,UNKNOWN,"(Adriamycin, bleomycin, vinblastine, and dacarbazine), baseline BEACOPP ( bleomycin, etoposide, Adriamycin, cyclophosphamide, Oncovin, procarbazine, and prednisone) or escalated BEACOPP, or other induction regimens) -",ct_inc_419623,AACT,64,NCT02280993,Recent,BEACOPP
5c74304d8625dd0381867fa1,230,,,113,Patient,13:33.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_559601,Clinical Trial Inclusion Criteria,UNKNOWN,"18 years - Received and failed potentially curative chemotherapeutic regimens (e.g., ABVD, Stanford V, or BEACOPP) - Relapsed following autologous bone marrow transplantation (BMT), or are ineligible, or refused BMT - Completed radiotherapy, chemotherapy, and/or treatment with other investigational agents at least 3 weeks prior to study entry - Completed autologous BMT (if received) at least 3 months prior to study entry; completed allogeneic BMT (if received); at least 6 months prior to study entry - Eastern Cooperative Oncology Group (ECOG) status of <2 - Life expectancy of >3 months -",ct_inc_559601,AACT,106,NCT00441818,Historical,BEACOPP
5c7430628625dd0452867f96,40,,,205,Patient,13:54.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_590819,Clinical Trial Inclusion Criteria,UNKNOWN,"- Histologically confirmed Hodgkin's lymphoma - Early or late first relapse - Complete or partial remission for at least 3 months after completion of prior COPP/ABVD, COPP/ABV/IMEP, MOPP/ABV, ABVD, BEACOPP, or other polychemotherapy regimen with or withou",ct_inc_590819,AACT,198,NCT00025636,Historical,BEACOPP
5c7430688625dd04c0867f8e,30,,,254,Patient,14:00.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_344464,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Complete response of lymphoma (Cheson criteria 2007) after initial treatment - Malin lymphoma (Hodgkin or not) treated with anthracyclines for at least 6 cycles : Adriamycin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) or BEACOPP, Cyclophosphamide, hydroxydaunomycin, Oncovin, and prednisone (CHOP) et Rituximab (R-CHOP), miniCHOP et RminiCHOP, RACVBP having received or not an intensification with autologous hematopoietic stem cell transplantation in first-line - Registered the consent to be included in this study",ct_inc_344464,AACT,247,NCT03260855,Recent,BEACOPP
5c74306c8625dd04cb867f97,260,,,141,Patient,14:04.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_504535,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients must have failed (relapsed or refractory) front-line standard anthracycline-containing regimen, such as ABVD, Stanford V, or BEACOPP.",ct_inc_504535,AACT,134,NCT01169636,Recent,BEACOPP
5c74306c8625dd04cb867f9a,260,,,121,Patient,14:04.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_519899,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients must have received a front-line standard anthracycline- containing regimen, such as ABVD, Stanford V, or BEACOPP.",ct_inc_519899,AACT,114,NCT00967369,Recent,BEACOPP
5c74306e8625dd04f7867f8c,550,,,821,Patient,14:06.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_487451,Clinical Trial Inclusion Criteria,UNKNOWN,"> 1.5 cm evidenced by computed tomography (CT) scan of the neck/chest/abdomen(abd)/pelvis or CT/positron emission tomography (PET) scans - Patient must be either primary refractory to one frontline induction therapy or relapsed after one frontline induction therapy; patients who do not achieve complete remission after induction therapy are also eligible - Patients cannot have had a second line salvage treatment (chemotherapy, biologic agents, investigational drugs, or radiation) or have had an autologous or allogeneic hematopoietic stem cell transplantation; patients can have had mixed frontline therapy such as 2-4 cycles of ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) followed by 2-4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) as long as the induction chemotherapy is not more than 8 cycles in total length - Radiation use as part of induction regimen or consolidation (within 90 days after completion of induction chemotherapy) is allowed -",ct_inc_487451,AACT,814,NCT01393717,Recent,BEACOPP
5c7430ba8625dd083f867f85,240,,,265,Patient,15:22.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_559790,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically confirmed relapsed or refractory classical Hodgkin lymphoma (nodular sclerosis, mixed cellularity, or lymphocyte-rich classical HL).- Patients must have failed front-line standard anthracycline-containing regimen, such as ABVD, Stanford V, or BEACOPP.-",ct_inc_559790,AACT,258,NCT00439361,Recent,BEACOPP
5c7430bb8625dd083f867f8b,240,,,72,Patient,15:23.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_378685,Clinical Trial Inclusion Criteria,UNKNOWN,Adriamycin Cyclophosphamide Vincristine Procarbazine Prednisone (BEACOPP) regimen (and radiotherapy if applicable) - all stages (Ann Arbor I - IV),ct_inc_378685,AACT,65,NCT02815137,Hypothetical,BEACOPP
5c7430bb8625dd083f867f8d,240,,,50,Patient,15:23.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_378685,Clinical Trial Exclusion Criteria,UNKNOWN,No informed consent - Treatment by ABVD or BEACOPP not indicated - Previously treated Hodgkin lymphoma (including corticosteroids) - Patients who are pregnant or lactating - Active Hepatitis B or Hepatitis C infection - Known human immunodeficiency virus,ct_exc_378685,AACT,43,NCT02815137,Recent,BEACOPP
5c7430bd8625dd0855867f88,1070,,,118,Patient,15:25.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_422460,Clinical Trial Exclusion Criteria,UNKNOWN,Peripheral neuropathy > Grade 1 Histologic diagnosis different from Hodgkin Lymphoma First line treatment with BEACOPP Compressive symptoms caused by the presence of Lymphoma Patients treated previously with any anti-CD30 antibody.,ct_exc_422460,AACT,111,NCT02244021,Recent,BEACOPP
5c7430558625dd03e4867f84,800,,,104,Patient,13:41.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_427713,Clinical Trial Inclusion Criteria,UNKNOWN,"As part of their first line maintenance treatment, patients may have received: - Bevacizumab monotherapy - Bevacizumab in combination with endocrine treatment - Nothing (for a period 6 weeks from the last Bevacizumab treatment) - ECOG performance status (PS) of 0-2.- At least 28 days since prior radiation therapy or surgery and recovery from treatment.- Patients must have measurable disease which must be evaluable per RECIST v1.1.- Estimated life expectancy of 12 weeks.",ct_inc_427713,AACT,81,NCT02175446,Historical,Bevacizumab monotherapy
5c74306f8625dd04fb867f8d,1030,,,177,Patient,14:07.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_379682,Clinical Trial Inclusion Criteria,UNKNOWN,"At least 6 weeks (two doses) must have passed since the last chemotherapy administration, while in treatment with bevacizumab alone, in order to consider bevacizumab monotherapy as maintenance therapy.",ct_inc_379682,AACT,154,NCT02802098,Recent,bevacizumab monotherapy
5c7430468625dd034a867f8a,650,,,293,Patient,13:26.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_348683,Clinical Trial Inclusion Criteria,UNKNOWN,1%.All patients must be refractory to or not eligible for available therapies expected to provide clinical benefit with the exception that if a patient would meet National Comprehensive Cancer Center Network (NCCN) guidelines for consideration of treatment with brentuximab vedotin monotherapy then that patient can be enrolled to this trial as this is a combination trial of brentuximab vedotin plus TAK228.,ct_inc_348683,AACT,262,NCT03205891,Recent,brentuximab vedotin monotherapy
5c7430478625dd0355867f8e,160,,,52,Patient,13:27.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_480284,Clinical Trial Inclusion Criteria,UNIT,"Examples include but are not limited to Cy/TBI, BuCy 200, etc.- Patients 16 years old must have a Karnofsky score 70%, and patients < 16 years old must have a Lansky score 70%.-",ct_inc_480284,AACT,48,NCT01487577,Recent,BuCy
5c74306c8625dd04e1867f8c,500,,,50,Patient,14:04.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_510997,Clinical Trial Inclusion Criteria,UNKNOWN,"Melphalan 140 mg/m2 or 200 mg/m2, BEAM, BEAC, BUCY or CBV",ct_inc_510997,AACT,46,NCT01085058,Recent,BUCY
5c7430a58625dd0737867f99,180,,,601,Patient,15:01.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_511665,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Hematologic malignancy considered eligible and suitable for allogeneic stem cell transplantation (syngeneic transplantation is acceptable); diagnoses include acute myeloid or lymphoid leukemias, chronic myeloid or lymphoid leukemias, multiple myeloma, lymphoma or myelodysplasia; subjects suitable for this study will primarily receive transplant on a standard treatment plan (non research regimen) - Organ function, performance status and age suitable for an ablative regimen consisting of TBI >= 10Gy or a chemotherapy regimen consisting of busulphan and cyclophosphamide (BuCY) or busulphan and melphalan (BuMel) - Availability of a fully matched sibling donor - Ability to understand and willingness to sign an informed consent - No uncontrolled infections -",ct_inc_511665,AACT,597,NCT01076270,Recent,BuCY
5c7430538625dd03c7867f94,0,,,140,Patient,13:39.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_392418,Clinical Trial Inclusion Criteria,UNKNOWN,- ABVD - ICE R - 7+3 - Conditioning therapy for stem cell transplantation: - BEAM - Bu/Cy ATG - Bu/Flu ATG - FluCy ATG - FluCy + TBI - BuMel - FluBuCy - Melphalan - Etoposide + TBI - Cyclophosphamide + TBI,ct_inc_392418,AACT,135,NCT02635984,Recent,BuMel
5c7430a58625dd0737867f98,180,,,636,Patient,15:01.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_511665,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Hematologic malignancy considered eligible and suitable for allogeneic stem cell transplantation (syngeneic transplantation is acceptable); diagnoses include acute myeloid or lymphoid leukemias, chronic myeloid or lymphoid leukemias, multiple myeloma, lymphoma or myelodysplasia; subjects suitable for this study will primarily receive transplant on a standard treatment plan (non research regimen) - Organ function, performance status and age suitable for an ablative regimen consisting of TBI >= 10Gy or a chemotherapy regimen consisting of busulphan and cyclophosphamide (BuCY) or busulphan and melphalan (BuMel) - Availability of a fully matched sibling donor - Ability to understand and willingness to sign an informed consent - No uncontrolled infections -",ct_inc_511665,AACT,631,NCT01076270,Recent,BuMel
5c7430a78625dd0758867f84,460,,,87,Patient,15:03.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_351801,Clinical Trial Inclusion Criteria,UNKNOWN,3.- mIBG scintigraphy positive at diagnosis and after induction chemotherapy (pre BuMel evaluation).4.- Metastatic response after induction chemotherapy lower than the ongoing High Risk Neuroblastoma SIOPEN trial criteria to be eligible for High Dose Chemotherapy (metastatic response worse than partial response (< PR) or SIOPEN score 5.- Females of childbearing potential must have a negative serum pregnancy test within 7 days prior to initiation of treatment.,ct_inc_351801,AACT,82,NCT03165292,Historical,BuMel
5c7430bb8625dd083f867f95,240,,,234,Patient,15:23.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_591782,Clinical Trial Inclusion Criteria,DIAGNOSES,"In PR or CR after 1-2 other salvage chemotherapy regimens (e.g., 3 courses of dexamethasone, high-dose cytarabine, and cisplatin (DHAP); 2 courses of cyclophosphamide, mechlorethamine, vincristine, procarbazine, and prednisone (C-MOPP)) -",ct_inc_591782,AACT,228,NCT00002697,Recent,C-MOPP
5c74307d8625dd05b6867f8e,10,,,174,Patient,14:21.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_407421,Clinical Trial Inclusion Criteria,UNKNOWN,"patients with newly diagnosed acute lymphoid leukemia who approve to get induction chemotherapy with VPDL (vincristine + prednisolone + daunorubicin + L-asparaginase), C-VPDL (cyclophosphamide + vincristine + prednisolone + daunorubicin + L-asparaginase), or (R)-hyperCVAD ((Rituximab) + cyclophosphamide + vincristine + Adriamycin + dexamethasone)",ct_inc_407421,AACT,168,NCT02440178,Recent,C-VPDL
5c7430378625dd02b7867f87,560,,,112,Patient,13:11.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_488438,Clinical Trial Inclusion Criteria,UNKNOWN,"Disease progression after anthracycline and/or taxane regimen therapy and candidate for capecitabine monotherapy Patients previously treated by capecitabine containing regimen should response to the chemotherapy containing capecitabine and progressed at least 4 months after the last capecitabine treatment Karnofsky score more than 70ECOG 0 2 Normal functions with heart, liver,renal and bone marrow 8.",ct_inc_488438,AACT,88,NCT01380808,Recent,capecitabine monotherapy
5c7430458625dd033f867f95,310,,,34,Patient,13:25.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_493334,Clinical Trial Inclusion Criteria,UNKNOWN,Are under capecitabine monotherapy for treatment of colon or breast cancer at a regimen of 2 weeks on and 1 week off (14+7) and a daily doses between 2000 and 2500 mg/m2.- Diagnosis of PPES grade 1 in any hand or foot according to the NCI CTCAE v4.03,ct_inc_493334,AACT,10,NCT01316406,Recent,capecitabine monotherapy
5c7430458625dd033f867f96,310,,,96,Patient,13:25.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_493334,Clinical Trial Inclusion Criteria,UNKNOWN,"In Part I, subjects still have to undergo at least 1 planned cycle with capecitabine monotherapy.-",ct_inc_493334,AACT,72,NCT01316406,Recent,capecitabine monotherapy
5c7430458625dd033f867f97,310,,,98,Patient,13:25.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_493334,Clinical Trial Inclusion Criteria,UNKNOWN,"In Part II, subjects still have to undergo at least 2 planned cycles with capecitabine monotherapy.",ct_inc_493334,AACT,74,NCT01316406,Recent,capecitabine monotherapy
5c7430698625dd04b5867f8a,860,,,71,Patient,14:01.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_570660,Clinical Trial Inclusion Criteria,UNKNOWN,Any patient in whom the investigator considers capecitabine monotherapy appropriate - Measurable,ct_inc_570660,AACT,47,NCT00294359,Recent,capecitabine monotherapy
5c7430858625dd05f1867f8c,1000,,,490,Patient,14:29.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_331936,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria Stage 1 - ECOG Performance Status of 0 or 1 - Metastatic or locally advanced, histologically documented TNBC (absence of HER2, ER, and PR expression) - Radiologic/objective evidence of recurrence or disease progression after one line of chemotherapy for metastatic breast cancer MBC - Availability of a representative tumor specimen that is suitable for determination of PD-L1 and/or additional biomarker status via central testing - Eligible for capecitabine monotherapy - Adequate hematologic and end-organ function, laboratory test results, obtained within 14 days prior to initiation of study treatment.- Negative HIV test at screening - Negative hepatitis B surface antigen .- Negative hepatitis C virus (HCV) antibody test at screening or positive HCV antibody test followed by a negative HCV RNA test at screening Inclusion Criteria for Stage 1 and Stage 2 - Measurable disease according to Response Evaluation Criteria in Solid Tumors",ct_inc_331936,AACT,466,NCT03424005,Historical,capecitabine monotherapy
5c7430ad8625dd07a5867f84,740,,,128,Patient,15:09.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_338160,Clinical Trial Inclusion Criteria,UNKNOWN,"In the setting of metastatic disease requiring local palliation, only radiosensitizing doses of 5-FU or capecitabine monotherapy are permitted.- Prior radiation therapy is permitted, provided is completed at least 28 days prior to the start of study drug.- Age 18 years with ability to understand and willingness to provide informed consent.- ECOG performance status of 0 or 1.- Adequate organ and marrow function as defined below by the following:",ct_inc_338160,AACT,104,NCT03342937,Historical,capecitabine monotherapy
5c7430bb8625dd083f867f8f,240,,,211,Patient,15:23.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_494688,Clinical Trial Inclusion Criteria,COMMENT,"As an example, a patient who is begun on FOLFOX or CapeOx (capecitabine with oxaliplatin, with or without bevacizumab), whose oxaliplatin is held for neurotoxicity and who is switched to capecitabine monotherapy or capecitabine with bevacizumab, would be considered to have had one prior therapy.",ct_inc_494688,AACT,187,NCT01298570,Historical,capecitabine monotherapy
5c7430548625dd03b8867f8b,430,,,150,Patient,13:40.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_390264,Clinical Trial Inclusion Criteria,UNKNOWN,"The patient must be able to swallow oral medication.- The patient must have completed at least 4 months of adjuvant chemotherapy (i.e., FOLFOX, CapeOx, or other, such as 5-fluorouracil, leucovorin, oxaliplatin (FLOX), 5-fluorouracil/leucovorin (5FU/LV), capecitabine).- The interval between completion of standard adjuvant chemotherapy and randomization must be less than or equal to 60 days.- Blood counts performed within 28 days prior to randomization must meet the following criteria: - Absolute neutrophil count (ANC) must be greater than or equal to 1500/mm3; - platelet count must be greater than or equal to 100,000/mm3; and - hemoglobin must be greater than or equal to 9 g/dL.-",ct_inc_390264,AACT,144,NCT02664077,Historical,CapeOx
5c7430548625dd03b8867f8c,430,,,150,Patient,13:41.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_390264,Clinical Trial Inclusion Criteria,UNKNOWN,"The patient must be able to swallow oral medication.- The patient must have completed at least 4 months of adjuvant chemotherapy (i.e., FOLFOX, CapeOx, or other, such as 5-fluorouracil, leucovorin, oxaliplatin (FLOX), 5-fluorouracil/leucovorin (5FU/LV), capecitabine).- The interval between completion of standard adjuvant chemotherapy and randomization must be less than or equal to 60 days.- Blood counts performed within 28 days prior to randomization must meet the following criteria: - Absolute neutrophil count (ANC) must be greater than or equal to 1500/mm3; - platelet count must be greater than or equal to 100,000/mm3; and - hemoglobin must be greater than or equal to 9 g/dL.-",ct_inc_390264,AACT,144,NCT02664077,Historical,CapeOx
5c74305b8625dd0411867f8c,300,,,135,Patient,13:47.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_411196,Clinical Trial Inclusion Criteria,COMMENT,"A.When adjuvant therapy including oxaliplatin was previously used, at least 9 courses of FOLFOX (2 weeks regimens), 6 courses of CapeOX (3 week regimen), or 750mg/m^2 cumulative consumption of oxaliplatin, are required.",ct_inc_411196,AACT,129,NCT02390947,Recent,CapeOX
5c74305b8625dd0411867f8d,300,,,135,Patient,13:47.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_411196,Clinical Trial Inclusion Criteria,COMMENT,"A.When adjuvant therapy including oxaliplatin was previously used, at least 9 courses of FOLFOX (2 weeks regimens), 6 courses of CapeOX (3 week regimen), or 750mg/m^2 cumulative consumption of oxaliplatin, are required.",ct_inc_411196,AACT,129,NCT02390947,Recent,CapeOX
5c74305c8625dd0447867f84,250,,,143,Patient,13:48.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_354820,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - End-stage cachexia patients; - Cardiopulmonary dysfunction or liver and kidney dysfunction, and unable to tolerate CapeOX chemotherapy; - Metastatic carcinoma; - Moderate or above anemia caused by serious local tumor bleeding; - Incomplete or complete intestinal obstruction; - Known to be allergic to oxaliplatin or capecitabine; - Active hepatitis, severe coagulation disorder patients; - Pregnant or lactating women; or women who have fertility but have not taken at taken adequate contraceptive measures; - Known to have deficient dihydropyrimidine dehydrogenase (DPD) -",ct_exc_354820,AACT,137,NCT03125980,Historical,CapeOX
5c74305c8625dd0447867f85,250,,,143,Patient,13:48.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_354820,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - End-stage cachexia patients; - Cardiopulmonary dysfunction or liver and kidney dysfunction, and unable to tolerate CapeOX chemotherapy; - Metastatic carcinoma; - Moderate or above anemia caused by serious local tumor bleeding; - Incomplete or complete intestinal obstruction; - Known to be allergic to oxaliplatin or capecitabine; - Active hepatitis, severe coagulation disorder patients; - Pregnant or lactating women; or women who have fertility but have not taken at taken adequate contraceptive measures; - Known to have deficient dihydropyrimidine dehydrogenase (DPD) -",ct_exc_354820,AACT,137,NCT03125980,Historical,CapeOX
5c7430658625dd048d867f8a,1200,,,13,Patient,13:57.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_324880,Clinical Trial Inclusion Criteria,PAST_SURGICAL_HISTORY,Either CAPEOX or FOLFOX is allowed.,ct_inc_324880,AACT,7,NCT03515941,Recent,CAPEOX
5c7430658625dd048d867f8b,1200,,,13,Patient,13:57.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_324880,Clinical Trial Inclusion Criteria,PAST_SURGICAL_HISTORY,Either CAPEOX or FOLFOX is allowed.,ct_inc_324880,AACT,7,NCT03515941,Recent,CAPEOX
5c7430bb8625dd083f867f90,240,,,57,Patient,15:23.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_494688,Clinical Trial Inclusion Criteria,COMMENT,"As an example, a patient who is begun on FOLFOX or CapeOx (capecitabine with oxaliplatin, with or without bevacizumab), whose oxaliplatin is held for neurotoxicity and who is switched to capecitabine monotherapy or capecitabine with bevacizumab, would be considered to have had one prior therapy.",ct_inc_494688,AACT,51,NCT01298570,Historical,CapeOx
5c7430bb8625dd083f867f91,240,,,57,Patient,15:23.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_494688,Clinical Trial Inclusion Criteria,COMMENT,"As an example, a patient who is begun on FOLFOX or CapeOx (capecitabine with oxaliplatin, with or without bevacizumab), whose oxaliplatin is held for neurotoxicity and who is switched to capecitabine monotherapy or capecitabine with bevacizumab, would be considered to have had one prior therapy.",ct_inc_494688,AACT,51,NCT01298570,Historical,CapeOx
5c7430bd8625dd084a867f8a,140,,,465,Patient,15:25.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_490966,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients may be entered in the study only if they meet all of the following criteria: Male or female patient greater than or equal to 18 years of age; Histologically or cytologically confirmed nonresectable locally advanced or metastatic colorectal adenocarcinoma; Patients must have failed a first-line chemotherapy regimen for nonresectable locally advanced or mCRC (first-line 5-FU-based therapies, including but not limited to FOLFOX, FOLFOX 4, mFOLFOX6, CapeOX, single-agent capecitabine, infusional 5-FU, or other chemotherapies.",ct_inc_490966,AACT,459,NCT01347645,Hypothetical,CapeOX
5c7430bd8625dd084a867f8b,140,,,465,Patient,15:25.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_490966,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients may be entered in the study only if they meet all of the following criteria: Male or female patient greater than or equal to 18 years of age; Histologically or cytologically confirmed nonresectable locally advanced or metastatic colorectal adenocarcinoma; Patients must have failed a first-line chemotherapy regimen for nonresectable locally advanced or mCRC (first-line 5-FU-based therapies, including but not limited to FOLFOX, FOLFOX 4, mFOLFOX6, CapeOX, single-agent capecitabine, infusional 5-FU, or other chemotherapies.",ct_inc_490966,AACT,459,NCT01347645,Hypothetical,CapeOX
5c7430c08625dd086b867f94,60,,,43,Patient,15:28.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_427406,Clinical Trial Inclusion Criteria,HISTORY_PRESENT_ILLNESS,"Chemotherapy with FOLFOX4, mFOLFOX6, CapeOx or Capecitabine(the current standard treatment; it can be modified in the future in the two groups, if the standard is modified)",ct_inc_427406,AACT,37,NCT02179489,Hypothetical,CapeOx
5c7430c08625dd086b867f95,60,,,43,Patient,15:28.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_427406,Clinical Trial Inclusion Criteria,HISTORY_PRESENT_ILLNESS,"Chemotherapy with FOLFOX4, mFOLFOX6, CapeOx or Capecitabine(the current standard treatment; it can be modified in the future in the two groups, if the standard is modified)",ct_inc_427406,AACT,37,NCT02179489,Hypothetical,CapeOx
5c7430488625dd036b867f87,190,,,391,Patient,13:28.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_461817,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically confirmed colorectal cancer - Evaluable or measurable radiographic evidence of colorectal cancer - Patients with unresected metastases from colorectal cancer; patients may be either untreated with chemotherapy or currently receiving first-line 5-FU based chemotherapy (folinic acid-fluorouracil-irinotecan hydrochloride [FOLFIRI], capecitabine-irinotecan hydrochloride [CAPIRI], fluorouracil-leucovorin calcium-oxaliplatin [FOLFOX], or capecitabine-oxaliplatin [CAPOX] with or without bevacizumab) within 10 months of beginning ADAPT therapy with at least stable disease radiographically; patients who received prior adjuvant chemotherapy with 5-FU, capecitabine, or FOLFOX are eligible if adjuvant therapy was completed greater than 6 months ago - History of histological confirmation for recurrent disease, or if recurrent disease is not readily accessible to biopsy, must have two consecutive carcinoembryonic antigen (CEA) or cancer antigen (CA) 19-9 increases, or positron emission tomography (PET) avidity - Men and women from all ethnic and racial groups - Eastern Cooperative Oncology Group (ECOG) performance status =< 2 - Total bilirubin",ct_inc_461817,AACT,385,NCT01729923,Hypothetical,CAPIRI
5c7430448625dd033f867f91,310,,,407,Patient,13:24.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_438969,Clinical Trial Exclusion Criteria,UNKNOWN,"Any other medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent Phase II Specific Exclusion Criteria: - Progression on first line therapy - A complete response on first line therapy - Use of first line therapy for longer than 4 months - Use of any first line treatment with a chemotherapy regimen other than FOLFOX, FOLFIRI or CAPOX (each with or without bevacizumab) - More than 6 weeks since the last administration of 5 FU, capecitabine, oxaliplatin or irinotecan",ct_exc_438969,AACT,402,NCT02028442,Recent,CAPOX
5c7430488625dd036b867f89,190,,,482,Patient,13:28.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_461817,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically confirmed colorectal cancer - Evaluable or measurable radiographic evidence of colorectal cancer - Patients with unresected metastases from colorectal cancer; patients may be either untreated with chemotherapy or currently receiving first-line 5-FU based chemotherapy (folinic acid-fluorouracil-irinotecan hydrochloride [FOLFIRI], capecitabine-irinotecan hydrochloride [CAPIRI], fluorouracil-leucovorin calcium-oxaliplatin [FOLFOX], or capecitabine-oxaliplatin [CAPOX] with or without bevacizumab) within 10 months of beginning ADAPT therapy with at least stable disease radiographically; patients who received prior adjuvant chemotherapy with 5-FU, capecitabine, or FOLFOX are eligible if adjuvant therapy was completed greater than 6 months ago - History of histological confirmation for recurrent disease, or if recurrent disease is not readily accessible to biopsy, must have two consecutive carcinoembryonic antigen (CEA) or cancer antigen (CA) 19-9 increases, or positron emission tomography (PET) avidity - Men and women from all ethnic and racial groups - Eastern Cooperative Oncology Group (ECOG) performance status =< 2 - Total bilirubin",ct_inc_461817,AACT,477,NCT01729923,Hypothetical,CAPOX
5c7430528625dd03a2867f9a,130,,,257,Patient,13:38.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_439263,Clinical Trial Inclusion Criteria,UNKNOWN,"A histologically confirmed solid tumor of the gastrointestinal tract including Advanced unresectable, metastatic or recurrent colorectal carcinoma (CRC) for which treatment with FOLFOX6 with or without bevacizumab, FOLFIRI with or without bevacizumab, CAPOX, or regorafenib would be acceptable as determined by the Investigator.",ct_inc_439263,AACT,252,NCT02024607,Recent,CAPOX
5c7430528625dd03a2867f9b,130,,,66,Patient,13:38.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_439263,Clinical Trial Inclusion Criteria,UNKNOWN,Hepatocellular carcinoma for which treatment with FOLFOX6 or CAPOX would be acceptable as determined by the Investigator.,ct_inc_439263,AACT,61,NCT02024607,Recent,CAPOX
5c7430528625dd03a2867f9c,130,,,65,Patient,13:38.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_439263,Clinical Trial Inclusion Criteria,UNKNOWN,"Pancreatic adenocarcinoma for which treatment with FOLFOX6, CAPOX, FOLFIRI, or irinotecan would be acceptable as determined by the Investigator.",ct_inc_439263,AACT,60,NCT02024607,Recent,CAPOX
5c7430528625dd03a2867f9d,130,,,60,Patient,13:38.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_439263,Clinical Trial Inclusion Criteria,UNKNOWN,Cholangiocarcinoma for which treatment with FOLFOX6 or CAPOX would be acceptable as determined by the Investigator.,ct_inc_439263,AACT,55,NCT02024607,Recent,CAPOX
5c7430528625dd03a2867f9e,130,,,81,Patient,13:38.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_439263,Clinical Trial Inclusion Criteria,UNKNOWN,"Gastric, GEJ or esophageal adenocarcinoma for which treatment with FOLFOX6, CAPOX, FOLFIRI, or irinotecan would be acceptable as determined by the Investigator.",ct_inc_439263,AACT,76,NCT02024607,Recent,CAPOX
5c7430638625dd045a867f8c,1190,,,727,Patient,13:55.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_314308,Clinical Trial Exclusion Criteria,UNKNOWN,"Subject using a physiologic replacement dose of hydrocortisone or its equivalent (defined as up to 30 mg per day of hydrocortisone or up to 10 mg per day of prednisone) or a single dose of systemic corticosteroids is eligible.- Subject has received other investigational agents or devices within 28 days prior to first dose of study treatment.- Subject has prior severe allergic reaction or intolerance to known ingredients of zolbetuximab or other monoclonal antibodies, including humanized or chimeric antibodies.- Subject has known immediate or delayed hypersensitivity, intolerance or contraindication to any component of study treatment.- Subject has prior severe allergic reaction or intolerance to any component of CAPOX.- Subject has known dihydropyrimidine dehydrogenase (DPD) deficiency.- Subject has gastric outlet syndrome or persistent/recurrent",ct_exc_314308,AACT,722,NCT03653507,Historical,CAPOX
5c7430698625dd04c0867fa0,30,,,89,Patient,14:01.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_441288,Clinical Trial Inclusion Criteria,UNKNOWN,"IV colorectal cancer - Scheduled for treatment with first line chemotherapy, either CAPOX(-B), FOLFOX(-B) or capecitabine(-B) -",ct_inc_441288,AACT,84,NCT01998152,Recent,CAPOX
5c7430788625dd0574867f91,270,,,130,Patient,14:16.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_344540,Clinical Trial Inclusion Criteria,UNKNOWN,"If mCRC, they should have received at least one regimen of 5-fluouracil based systemic chemotherapy such as FOLFOX, FOLFIRI, CAPOX, or XELOX, with or without a VEGF or EGFR receptor inhibitor.",ct_inc_344540,AACT,125,NCT03259867,Hypothetical,CAPOX
5c7430838625dd05e2867f8c,330,,,97,Patient,14:27.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_438969,Clinical Trial Inclusion Criteria,LABORATORY_AND_RADIOLOGY_DATA,"mCRC - Have received 3 - 4 months of first line chemotherapy with either FOLFOX, FOLFIRI or CAPOX, with or without bevacizumab - At least one measurable lesion according to RECIST 1.1 criteria - Documented partial response or stable disease - Eligible to receive chemotherapy with FOLFOX or CAPOX after a short chemotherapy interruption (3 to 4 weeks)",ct_inc_438969,AACT,92,NCT02028442,Recent,CAPOX
5c7430838625dd05e2867f93,330,,,316,Patient,14:28.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_342075,Clinical Trial Inclusion Criteria,UNKNOWN,"Men and women 18 years - Newly diagnosed with histologically confirmed stage II-Ill colon cancer - Completed curative-intent surgical resection - Currently prescribed one of the following adjuvant chemotherapy regimens: (IV 5-fluorouracil [5-FU] / leucovorin [LV], capecitabine, FOLFOX [5-FU, LV, oxaliplatin], CAPOX [capecitabine and oxaliplatin] - Patients must have started chemotherapy or plan to start within 4 weeks of planned receipt of the first exercise visit.",ct_inc_342075,AACT,311,NCT03291951,Recent,CAPOX
5c7430998625dd06df867f88,850,,,20,Patient,14:49.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_513432,Clinical Trial Inclusion Criteria,ONCOLOGY_FAMILY_HISTORY,d1 q 3 weekly (CAPOX) - capecitabine,ct_inc_513432,AACT,15,NCT01053104,Recent,CAPOX
5c7430af8625dd079a867f8d,380,,,382,Patient,15:11.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_567473,Clinical Trial Inclusion Criteria,UNKNOWN,"There must be histologic confirmation of adenocarcinoma of the colon or rectum.- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 - Estimated life expectancy of at least 12 weeks.- One prior therapy for metastatic disease is permitted.- Recurrence within 12 months of adjuvant therapy with FOLFOX or a similar regimen (i.e FLOX, CapOX) is considered one regimen and allowed for study - There must be evidence of adequate organ function - Patients with a history of prior non-colorectal malignancies are eligible if they have been disease-free for 5 years prior to study entry and are deemed by the physician to be at low risk for recurrence.- Age > 18 yrs.",ct_inc_567473,AACT,377,NCT00336856,Hypothetical,CapOX
5c7430b48625dd07dc867f88,630,,,36,Patient,15:16.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_529621,Clinical Trial Inclusion Criteria,COMMENT,"Those who had initiated FOLFOX/CapOx but stopped oxaliplatin because of intolerable toxicity are also eligible.- At least 4 weeks have elapsed since the last chemotherapy, radiotherapy, immunotherapy, or biologic therapy prior to enrollment (except at least 6 weeks in the case of nitrosourea and mitomycin).- Have not received any other investigational agents within 4 weeks of study entry and have fully recovered from any adverse event due to prior therapy.-",ct_inc_529621,AACT,31,NCT00838578,Historical,CapOx
5c7430b88625dd0808867f95,320,,,166,Patient,15:20.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_387169,Clinical Trial Exclusion Criteria,UNKNOWN,"Are contraindicated for chemoradiotherapy (CRT) Hypersensitivity or contraindication to the drug(s) associated with the planned choice of systemic chemotherapy (CAPOX, FOLFOX or single agent 5-FU or capecitabine) as stated in the SmPC for each of the drugs.",ct_exc_387169,AACT,161,NCT02704520,Recent,CAPOX
5c7430cc8625dd0855867f90,1070,,,415,Patient,15:41.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_501602,Clinical Trial Inclusion Criteria,UNKNOWN,"Negative serum or urine pregnancy test in women with childbearing potential (defined as not post-menopausal for 12 months or no previous surgical sterilization), within one week prior to initiation of treatment - Patients must sign an Informed Consent and Authorization indicating that they are aware of the investigational nature of this study and the known risks involved - The effects of the combination of CAPOX and bevacizumab on the developing fetus are unknown.",ct_inc_501602,AACT,410,NCT01208103,Historical,CAPOX
5c74308b8625dd063a867f86,390,,,112,Patient,14:35.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_346250,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - No prior chemotherapy - Confirmed malignancy, scheduled to receive carboplatin monotherapy, or carboplatin in combination with agents of minimal, low, or moderate emetic potential - Laboratory parameters adequate for chemotherapy",ct_inc_346250,AACT,89,NCT03237611,Historical,carboplatin monotherapy
5c74308b8625dd0642867f8c,610,,,696,Patient,14:35.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_357498,Clinical Trial Inclusion Criteria,UNKNOWN,"At least one administration of carfilzomib in a combination regimen (ie, not monotherapy) has been received - Provided written informed consent prior to abstraction of any data, in countries where written informed consent is required.- Subjects who previously completed treatment with carfilzomib in a clinical trial, a compassionate use program or through routine practice, are eligible to take part in the study.- Subjects who receive radiotherapy concurrently with carfilzomib treatment are also eligible to take part in the study.- Subjects who initiate carfilzomib treatment on a combination regimen, subsequently discontinue all concomitant medications but remain on carfilzomib monotherapy in later cycles, remain eligible for participation in the study.- Subjects who are also enrolled in other observational studies in which standard of care is not altered are eligible to take part in the study,",ct_inc_357498,AACT,673,NCT03091127,Historical,carfilzomib monotherapy
5c7430808625dd05cc867f84,1280,,,146,Patient,14:24.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_412406,Clinical Trial Inclusion Criteria,COMMENT,"Prior Treatment - Must have received 3-6 cycles of cisplatin-based chemotherapy as part of first-line (initial) chemotherapy.- Prior POMBACE, CBOP-BEP, or GAMEC are allowed.-",ct_inc_412406,AACT,142,NCT02375204,Historical,CBOP
5c7430868625dd060e867f86,470,,,22,Patient,14:30.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_319905,Clinical Trial Inclusion Criteria,UNKNOWN,Cemiplimab monotherapy cohort: Anti-PD-1/PD-L1 nave patients who have received 1 to 2 prior lines of cytotoxic chemotherapy including a platinum doublet-containing regimen Expansion cohort(s):,ct_inc_319905,AACT,0,NCT03580694,Historical,Cemiplimab monotherapy
5c74306a8625dd04c0867fa3,30,,,108,Patient,14:02.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_454155,Clinical Trial Inclusion Criteria,UNKNOWN,"Previously untreated for DLBCL - Intended initial treatment to include 2 cycles of R-CHOP, R-EPOCH or R-CEPP using standard doses and schedule.(68, 69) R-CHOP chemoimmunotherapy may be given every 14 days or every 21 days.(4, 70)",ct_inc_454155,AACT,104,NCT01829958,Recent,CEPP
5c7430398625dd02bd867f8b,1140,,,260,Patient,13:14.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_468851,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients must have histologically-confirmed advanced solid tumors - Patients who are refractory to standard therapy; patients with metastatic, irinotecan-refractory colon cancer, or recurrent/metastatic head and neck cancer may enroll, as cetuximab monotherapy is among the standard options for such patients; patients with locally advanced, treatment-nave head and neck cancer who are candidates for radiation with cetuximab are not eligible, as radiation provides them a survival benefit, and the number of projected cetuximab doses would be only seven - Development of new lesions or an increase in preexisting lesions on bone scintigraphy, computed tomography (CT), magnetic resonance imaging (MRI) or by physical examination; patients in whom the sole criterion for progression is an increase in a biochemical marker, e.g., carcinoembryonic antigen (CEA), or an increase in symptoms, are not eligible -",ct_inc_468851,AACT,239,NCT01637194,Recent,cetuximab monotherapy
5c74308e8625dd063a867f91,390,,,45,Patient,14:38.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_525088,Clinical Trial Inclusion Criteria,UNKNOWN,Previously treated with cetuximab monotherapy or cetuximab-based combination therapy - Sufficient biological material available for analysis,ct_inc_525088,AACT,24,NCT00898742,Recent,cetuximab monotherapy
5c74303c8625dd02f6867f8b,120,,,46,Patient,13:16.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_524716,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Subjects receiving CHOEP ((CHOP = Cytoxan, Hydroxyrubicin (Adriamycin), Oncovin (Vincristine),Etoposide, Prednisone Chemotherapy )or",ct_exc_524716,AACT,41,NCT00903812,Recent,CHOEP
5c7430428625dd0334867f88,400,,,345,Patient,13:22.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_341633,Clinical Trial Inclusion Criteria,UNKNOWN,"Eligible histologies include: peripheral T-cell lymphoma, not otherwise specified; angioimmunoblastic T-cell lymphoma; anaplastic large cell lymphoma, ALK negative; and anaplastic large cell lymphoma, ALK positive.- Plan for treatment with frontline multi-agent anthracycline containing chemotherapy for curative intent (for example, CHOP, CHOEP, EPOCH).A frontline therapy program can include different sequential phases of treatment, including high-dose therapy and autologous stem cell transplantation.- Availability of pre-treatment test specimen from bone marrow, blood, lymph node, or alternate site to identify tumor-specific clonotype, or willingness to undergo biopsy if sufficient tissue is not available at time of enrollment (e.g.15 slides from fixed formalin-fixed paraffin embedded tumor tissue",ct_inc_341633,AACT,340,NCT03297697,Hypothetical,CHOEP
5c7430548625dd03c7867fb0,0,,,89,Patient,13:40.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_567491,Clinical Trial Inclusion Criteria,UNKNOWN,"B-cell Non-Hodgkins lymphoma (NHL) planned to receive at least 2 cycles of CHOP-14, CHOEP-14, CHOP-DI-14, EPOCH-14 or CHOP-21 +/-",ct_inc_567491,AACT,84,NCT00336609,Recent,CHOEP
5c7430588625dd03fe867f97,290,,,164,Patient,13:44.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_460571,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Prior anti-lymphoma chemotherapy (except steroids/radiotherapy for urgent palliation, one prior cycle of CHOP or up to 2 prior cycles of CHOEP) -",ct_exc_460571,AACT,159,NCT01746173,Historical,CHOEP
5c74305f8625dd0452867f8b,40,,,182,Patient,13:51.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_344212,Clinical Trial Inclusion Criteria,COMMENT,"Prior Treatment: Previously untreated or has received a maximum of one cycle of any combination chemotherapy (e.g.cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP), CHOEP, DA-EPOCH, doxorubicin, cyclophosphamide, cytarabine, vincristine, methotrexate/Etoposide, ifosfamide, cytarabine, methotrexate (CODOX-M/IVAC), HyperCVAD) within 4 weeks of study entry.",ct_inc_344212,AACT,177,NCT03264131,Historical,CHOEP
5c74307f8625dd05b6867fa0,10,,,35,Patient,14:23.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_362663,Clinical Trial Inclusion Criteria,UNKNOWN,[14 or 21] or R-DA-EPOCH or R-CHOEP) of 6 cycles.,ct_inc_362663,AACT,30,NCT03023878,Recent,CHOEP
5c7430ba8625dd083f867f87,240,,,142,Patient,15:22.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_311621,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - CD20 positive diffuse large b-cell lymphoma undergoing treatment with systemic rituximab in combination with CHOP, CHOEP, or EPOCH and deemed high risk of CNS relapse and eligible for central nervous system prophylaxis with intrathecal therapy.",ct_inc_311621,AACT,137,NCT03688451,Recent,CHOEP
5c7430548625dd03c7867fa7,0,,,92,Patient,13:40.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_567491,Clinical Trial Inclusion Criteria,UNKNOWN,"B-cell Non-Hodgkins lymphoma (NHL) planned to receive at least 2 cycles of CHOP-14, CHOEP-14, CHOP-DI-14, EPOCH-14 or CHOP-21 +/-",ct_inc_567491,AACT,84,NCT00336609,Recent,CHOEP-14
5c7430368625dd02b4867f86,1020,,,149,Patient,13:10.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_490345,Clinical Trial Inclusion Criteria,LABORATORY_AND_RADIOLOGY_DATA,"Prior chemotherapy, immunotherapy, denileukin diftitox, or investigational agent(s) for this lymphoma, with the exception that a single cycle of CHOP (or CHOP-based therapy) is allowed if the last dose of CHOP (or CHOP-based therapy) was administered 28 days before study enrollment (Lead-In) or randomization (Main Study).",ct_inc_490345,AACT,145,NCT01355783,Hypothetical,CHOP
5c74303b8625dd02f6867f85,120,,,49,Patient,13:15.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_514128,Clinical Trial Inclusion Criteria,LABORATORY_DATA,Inclusion criteria for patients undergoing R-CHOP,ct_inc_514128,AACT,45,NCT01044004,Recent,CHOP
5c74303b8625dd02f6867f87,120,,,50,Patient,13:15.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_514128,Clinical Trial Inclusion Criteria,CHEMOTHERAPEUTICS,"- Scheduled to receive 6 cycles of standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy as first-line treatment Inclusion criteria for patients in remission following chemotherapy",ct_inc_514128,AACT,46,NCT01044004,Recent,CHOP
5c74303c8625dd02f6867f8c,120,,,53,Patient,13:16.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_524716,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Subjects receiving CHOEP ((CHOP = Cytoxan, Hydroxyrubicin (Adriamycin), Oncovin (Vincristine),Etoposide, Prednisone Chemotherapy )or",ct_exc_524716,AACT,49,NCT00903812,Recent,CHOP
5c74303c8625dd0310867f84,970,,,120,Other,13:16.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_318007,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Participation in pilot virtual reality (VR) study at the Children's Hospital of Philadelphia (CHOP) - Personal or family history of seizures or a seizure disorder - Primary sensory impairment (e.g., blindness, deafness) - Personal or family history of migraines - History of vertigo - History of strabismus, other eye muscle problems, or eye surgery - History of concussion with hospitalization - Diagnosis of a known genetic syndrome (e.g., Down syndrome, Fragile X syndrome) - History of a medical condition which has affected/affects cognitive, sensory, or motor functioning (e.g., Fetal Alcohol Syndrome, brain injury, stroke, brain tumor)",ct_exc_318007,AACT,116,NCT03605368,Historical,CHOP
5c74303c8625dd0310867f85,970,,,77,Patient,13:16.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_311607,Clinical Trial Inclusion Criteria,UNKNOWN,All the patients have to be treated with the same chemotherapy protocol (CHOP with or without Rituximab) to avoid confounding factors - Normal renal function as measured by CKD-EPI > 30 mmol / min / 1.73 m2 - Serum potassium < 5.5 mmol / l - Systolic arterial pressure,ct_inc_311607,AACT,73,NCT03688633,Recent,CHOP
5c74303d8625dd0310867f86,970,,,30,Patient,13:17.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_338774,Clinical Trial Inclusion Criteria,UNKNOWN,Received treatment in the CHOP ED or trauma unit for an injury resulting from a qualifying interpersonal assault Child must be able to speak English well enough to participate in study activities Child must reside in Philadelphia County (191xx zip code),ct_inc_338774,AACT,26,NCT03334942,Recent,CHOP
5c74303d8625dd0310867f87,970,,,140,Patient,13:17.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_563633,Clinical Trial Exclusion Criteria,PAST_MEDICAL_HISTORY,"(exception: administration on short time of glucocorticoids 7 days, one administration of vincristine or cyclophosphamide, one cycle of CHOP, urgent administration of the another cytostatics).- With another malignant tumour in the last 5 year.- Women in fertile age must give positive in the pregnancy test or nursing mother.- Mental disability or emotional or psychiatric significant disorder were the patient can't understand nor cooperate with treatment.- Patients is enrolled in another clinical research study.",ct_exc_563633,AACT,136,NCT00388193,Recent,CHOP
5c74303d8625dd0310867f88,970,,,73,Patient,13:17.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_511463,Clinical Trial Inclusion Criteria,UNKNOWN,"Pts must have failed standard of care (SOC) therapy w/rituximab plus CHOP or its equivalent & not considered hematopoietic stem cell transplant (HSCT) candidates based on investigator's discretion - Pts must have measurable disease radiographically on CT and/or PET scans and/or bone marrow biopsy.- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 - Age 18 years.",ct_inc_511463,AACT,69,NCT01078922,Recent,CHOP
5c74303d8625dd02f6867f97,120,,,689,Patient,13:17.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_408953,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically confirmed DLBCL, cluster of differentiation (CD)20 positive by flow or immunohistochemistry (IHC); transformed DLBCL is allowed as long as no prior therapy has been given - No prior therapy for DLBCL, except =< 1 week of corticosteroids given on an emergent basis or as a temporizing measure (pre-phase where indicated by the treating physician) - Measurable disease by computed tomography (CT), magnetic resonance imaging (MRI), and/or positron emission tomography (PET) with at least one target lesion measuring 1.5 cm or larger - Patients must be considered ineligible for rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone (R-CHOP) standard therapy; to be ineligible for R-CHOP, patients must meet at least one of the following criteria are met: -",ct_inc_408953,AACT,685,NCT02420210,Historical,CHOP
5c74303d8625dd02f6867f98,120,,,250,Patient,13:17.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_408953,Clinical Trial Inclusion Criteria,UNKNOWN,"Prior anthracycline therapy for other malignancies or other disorders whereby if additional anthracyclines are given for DLBCL, the maximum lifetime allowable dose will be exceeded - Meeting the geriatric criteria of ineligibility for standard R-CHOP if one of the following criteria is present: - Three or more organ systems with a score of 3 or any 1 organ system with a score of 4 (using the Cumulative Illness Rating Scale for Geriatrics, [CIRS-G]) - Score of 3 or above on the Vulnerable Elders Survey (VES-13) -",ct_inc_408953,AACT,246,NCT02420210,Hypothetical,CHOP
5c74303d8625dd0310867f89,970,,,172,Patient,13:17.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_451245,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - male or female subjects age 18 to 80 years, inclusive, with any International Prognostic Index score; treated with 6 or more cycles of first-line CHOP chemotherapy and achieved a PR, CRu, or CR - de novo diffuse large B-cell NHL according to the REAL classification;",ct_inc_451245,AACT,168,NCT01868035,Recent,CHOP
5c74303e8625dd02f6867f9d,120,,,73,Patient,13:18.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_413963,Clinical Trial Inclusion Criteria,UNKNOWN,Previously untreated DLBCL patients who are suitable for receiving R-CHOP chemotherapy - Serum ALT no more than 2 x ULN (including normal ALT) - Life expectancy 6 months - A negative serum or urine pregnancy test prior to treatment must be available both for pre menopausal women and for women who are no more than 1 years after the onset of menopause.- Informed consent,ct_inc_413963,AACT,69,NCT02354846,Historical,CHOP
5c7430428625dd0329867f8a,1210,,,15,Patient,13:22.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_353317,Clinical Trial Inclusion Criteria,PROCEDURES,negative.- CHOP bone marrow transplant,ct_inc_353317,AACT,11,NCT03145545,Recent,CHOP
5c7430428625dd0329867f8b,1210,,,54,Patient,13:22.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_381928,Clinical Trial Exclusion Criteria,UNKNOWN,Known allergic reactions against any component of CHOP regimen.,ct_exc_381928,AACT,50,NCT02772822,Recent,CHOP
5c7430428625dd0334867f89,400,,,338,Patient,13:22.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_341633,Clinical Trial Inclusion Criteria,UNKNOWN,"Eligible histologies include: peripheral T-cell lymphoma, not otherwise specified; angioimmunoblastic T-cell lymphoma; anaplastic large cell lymphoma, ALK negative; and anaplastic large cell lymphoma, ALK positive.- Plan for treatment with frontline multi-agent anthracycline containing chemotherapy for curative intent (for example, CHOP, CHOEP, EPOCH).A frontline therapy program can include different sequential phases of treatment, including high-dose therapy and autologous stem cell transplantation.- Availability of pre-treatment test specimen from bone marrow, blood, lymph node, or alternate site to identify tumor-specific clonotype, or willingness to undergo biopsy if sufficient tissue is not available at time of enrollment (e.g.15 slides from fixed formalin-fixed paraffin embedded tumor tissue",ct_inc_341633,AACT,334,NCT03297697,Hypothetical,CHOP
5c7430438625dd0329867f8c,1210,,,742,Patient,13:23.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_312971,Clinical Trial Exclusion Criteria,UNKNOWN,"Patients who are or plan to be immunized with live virus vaccine within 28 days (or within 5 half-lives of the drug) before enrollment; Patients who underwent or plan to undergo major surgery within 28 days before enrollment, or patients whose surgical wounds have not healed; Patients who are receiving continuous corticosteroid treatment, with > 30 mg/day prednisone or equivalent dose of corticosteroids for 10 days of continuous treatment; Have a history of gastrointestinal perforation and/or fistula within 6 months before enrollment; Known to be allergic to monoclonal antibody (mAb) therapy or rituximab,or patients with known sensitivity or allergy to murine products; Patients who have contraindications to any component of the CHOP regimen; Have previously received treatment for DLBCL, including: chemotherapy, immunotherapy, local radiotherapy for lymphoma, surgical treatment (except for tumor or pathologic biopsy and surgical resection not for lymphoma), and any monoclonal antibody therapy within 3 months prior to enrollment; Have previously received cytotoxic drugs or anti-CD20 monoclonal antibody therapy for other diseases (such as rheumatoid arthritis); Have a history of other malignancies that may affect study protocol compliance or result analysis; Also suffering from severe non-malignant diseases that can affect study protocol compliance, such as severe cardiovascular diseases, uncontrolled diabetes and hypertension, peripheral nervous system or central nervous system diseases; Known to have uncontrollable active infectious diseases or any major infection events (other than neoplastic fever) requiring intravenous antibiotic treatment or hospitalization within four weeks prior to enrollment",ct_exc_312971,AACT,738,NCT03670901,Historical,CHOP
5c7430438625dd0329867f8d,1210,,,36,Patient,13:23.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_314506,Clinical Trial Exclusion Criteria,UNKNOWN,Contraindicative to any drug in CHOP.,ct_exc_314506,AACT,32,NCT03650933,Recent,CHOP
5c7430448625dd0329867f8e,1210,,,657,Patient,13:24.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_590915,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Histologically confirmed B-cell lymphoma - Eligible subtypes: - Intermediate or high-grade non-Hodgkin's lymphoma (NHL), defined as follicular large cell, mantle cell, diffuse mixed cell, diffuse large cell and variants, Burkitt or Burkitt-like, or unclassifiable aggressive histologies - Body cavity-based lymphoma or primary effusion lymphoma - Evidence of HIV infection - Received at least 1 prior systemic chemotherapy regimen with failure to respond or relapse after completion of first-line therapy, including one of the following doxorubicin-based combinations: - Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) - Infusional cyclophosphamide, doxorubicin, and etoposide (CDE) - Etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (EPOCH)",ct_inc_590915,AACT,653,NCT00022555,Historical,CHOP
5c7430448625dd0334867f8d,400,,,319,Patient,13:24.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_409176,Clinical Trial Inclusion Criteria,UNKNOWN,"Entry Criteria Specific for Dose-Escalation Phase (Part A) Subjects with CD20 positive, histologically or cytologically-confirmed, diffuse large B-cell lymphoma (DLBCL)(including transformed low grade lymphoma) who have relapsed or refractory disease following at least two prior standard treatment regimens (eg, R-CHOP or similar first-lineregimen and at least one second-line salvage regimen) and/or autologous stem cell transplant (ASCT) in chemotherapy-sensitive patients, with the following",ct_inc_409176,AACT,315,NCT02417285,Historical,CHOP
5c7430458625dd0355867f85,160,,,114,Patient,13:25.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_580022,Clinical Trial Exclusion Criteria,UNKNOWN,"Central nervous system or meningeal involvement by lymphoma.- Contra-indication to any drug included in the R-CHOP regimen.- Concurrent severe disease (according to the investigator's decision).- Active bacterial, viral or fungal infection.- Poor renal function (serum creatinine level",ct_exc_580022,AACT,110,NCT00169156,Recent,CHOP
5c7430468625dd0355867f8b,160,,,1427,Patient,13:27.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_537364,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Significant medical disease other than cancer including: Any bleeding or coagulation disorder including a history of autoimmune hemolytic anemia or autoimmune thrombocytopenia; Severe pulmonary disease; Uncontrolled congestive heart failure; New York Heart Association class III or IV disease; Uncontrolled seizure disorder; and Active infections - Less than 3 weeks from prior major surgery - Prior organ allograft - Known HIV infection (due to expected frequent occurrence of myelo-suppression and immunosuppression) - Women who are pregnant (confirmed by a serum pregnancy test in females of reproductive potential) or breast-feeding (women of child-bearing potential and sexually active males must be advised to take precautions to prevent pregnancy during treatment or remain abstinent) - Women of child-bearing potential and sexually active males must be advised to take precautions to prevent pregnancy during treatment (unless the subject or subject's partner(s) is sterile, i.e., women who have had a hysterectomy or have been post-menopausal for at least twelve consecutive months) or remain abstinent - Known hypersensitivity to phosphorothiate-containing oligonucleotides - Concurrent investigational, corticosteroid therapy or any other anti-cancer treatments (such as chemotherapy, radiation, biologic or investigational therapies) while receiving protocol therapy; other than one cycle CHOP-R allowed based on current diagnosis, clinical condition, and availability/feasibility of initiating Genasense; other than chronic steroid use for another indication (For stage I/II or as clinically indicated- involved field irradiation as per standard practice is accepted) -",ct_exc_537364,AACT,1423,NCT00736450,Historical,CHOP
5c7430468625dd0355867f8c,160,,,280,Patient,13:27.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_537364,Clinical Trial Exclusion Criteria,UNKNOWN,"No active CNS disease defined as symptomatic meningeal lymphoma or known CNS parenchymal lymphoma - Concomitant anticoagulant therapy is not permitted (with the exception of 1 mg/day of warfarin for central line prophylaxis) - Known hypersensitivity to G3139 (Genasense) or R-CHOP - Neurologic disorders, overt psychosis, mental disability or evidence of limited capacity to provide fully informed consent or cooperation with the complexities of the treatment program",ct_exc_537364,AACT,276,NCT00736450,Recent,CHOP
5c74304a8625dd0381867f85,230,,,34,Patient,13:30.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_483422,Clinical Trial Inclusion Criteria,UNKNOWN,"Induction chemotherapy with R-CHOP should also be completed at the participating centre, but exceptions can be made according to the discretion of the centre's primary investigator.- Protocol treatment is to begin within 5 working days of patient registration",ct_inc_483422,AACT,30,NCT01446562,Recent,CHOP
5c74304a8625dd0355867f9d,160,,,25,Patient,13:30.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_415937,Clinical Trial Inclusion Criteria,UNKNOWN,One-two courses of R-CHOP combination as upfront therapy are admitted in patients with large amount,ct_inc_415937,AACT,21,NCT02329080,Recent,CHOP
5c74304a8625dd0355867f9e,160,,,44,Patient,13:30.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_415937,Clinical Trial Inclusion Criteria,UNKNOWN,Local investigator decides if initial R-CHOP is needed based on patient's conditions Age 18-70 years 6.,ct_inc_415937,AACT,40,NCT02329080,Hypothetical,CHOP
5c74304a8625dd0381867f87,230,,,68,Patient,13:30.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_452289,Clinical Trial Inclusion Criteria,UNKNOWN,"No prior lymphoma treatment, with one exception: One cycle of R-CHOP regimen is permitted (consisting of one single dose each of Rituximab, of cyclophosphamide, of doxorubicine, and of vincristine, as well as up to 5 doses of Prednisone when part of chemotherapy).",ct_inc_452289,AACT,64,NCT01854372,Historical,CHOP
5c74304a8625dd0381867f89,230,,,168,Patient,13:30.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_492710,Clinical Trial Exclusion Criteria,UNKNOWN,"Reactivation of latent infection has been reported with the use of bortezomib in this population (along obviously with the well recognised reactivation following R-CHOP).For these patient safety reasons, these patients should be excluded.",ct_exc_492710,AACT,164,NCT01324596,Recent,CHOP
5c74304a8625dd038c867f84,640,,,88,Patient,13:30.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_387831,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria: Participation in a Center for Injury Research and Prevention at CHOP teen driving study within the past 6 months Unable to follow study procedures,ct_exc_387831,AACT,84,NCT02695888,Recent,CHOP
5c74304a8625dd038c867f85,640,,,39,Patient,13:30.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_470229,Clinical Trial Exclusion Criteria,UNKNOWN,Previously participated in another CHOP driving simulator study - Non-English Speaking,ct_exc_470229,AACT,35,NCT01619202,Recent,CHOP
5c74304a8625dd038c867f86,640,,,192,Patient,13:31.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_549055,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Histologically confirmed CD20+ mantle cell lymphoma, with measurable or evaluable disease, no prior chemotherapy, immunotherapy or radiotherapy except for 1 cycle of CHOP-like chemotherapy.",ct_inc_549055,AACT,188,NCT00581776,Historical,CHOP
5c74304b8625dd038c867f87,640,,,54,Patient,13:31.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_550480,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - PGY 1 or 2 in pediatrics at CHOP, St. Christopher's Hospital for Children, or A.I.DuPont Hospital for Children",ct_inc_550480,AACT,50,NCT00562744,Recent,CHOP
5c74304b8625dd0381867f93,230,,,496,Patient,13:31.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_363654,Clinical Trial Inclusion Criteria,COMMENT,"Has EITHER histologically confirmed B-cell lymphomas including but not limited to diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), primary mediastinal B-cell lymphoma (PMBCL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), or Hodgkin lymphoma (HL) and has relapsed or refractory disease following at least two lines of prior standard therapy, including alkylator/anthracycline (unless anthracycline-based chemotherapy is contraindicated)/anti-CD20-based therapy (R-CHOP, rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisolone or dexamethasone, or equivalent for non-Hodgkin lymphoma), AND must be considered unable to benefit from intensification treatment with autologous hematopoietic stem cell transplantation (ASCT) , as defined by meeting at least one of the following criteria: - Relapsed following, or refractory to, previous ASCT - Did not achieve at least a partial response to a standard salvage regimen (e.g., R-ICE, rituximab, ifosfamide, carboplatin, etoposide, or R-DHAP, rituximab, dexamethasone, cytarabine, cisplatin) -",ct_inc_363654,AACT,492,NCT03010982,Historical,CHOP
5c74304c8625dd0381867f98,230,,,627,Patient,13:32.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_362341,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion criteria Male or female 18 years of age at time of consent Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 Has histologically confirmed diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL) or histologically and/or cytologically confirmed advanced or metastatic solid tumor and have relapsed or refractory disease following at least two lines of prior standard therapy, including alkylator/anthracycline (unless anthracycline-based chemotherapy is contraindicated)/anti-CD20-based therapy (R-CHOP; rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisolone or prednisone, or equivalent) AND must be considered unable to benefit from intensification treatment with autologous hematopoietic stem cell transplantation (ASCT), as defined by meeting at least one of the following criteria: Relapsed following, or refractory to:",ct_inc_362341,AACT,623,NCT03028103,Historical,CHOP
5c74304c8625dd036b867f93,190,,,9,Patient,13:32.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_328608,Clinical Trial Exclusion Criteria,GRAVIDA,"or R-CHOP infusion on Cycle 1/Day 1 - History of treatment-emergent immune-related AEs associated with prior immunotherapeutic agents - Contraindication to any of the individual components of the chemotherapy - Documented refractoriness to an obinutuzumab-monotherapy regimen - Treatment with standard radiotherapy, any chemotherapeutic agent, or treatment with any other investigational anti-cancer agent within 4 weeks prior to study treatment at Cycle 1/Day 1 infusion - Prior solid organ transplantation - Prior allogeneic stem cell transplantation - Autologous stem cell transplantation within 100 days prior to Cycle 1/Day 1 - History of autoimmune disease - History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibody therapy - A history of confirmed progressive multifocal leukoencephalopathy - Current or past history of central nervous system (CNS)",ct_exc_328608,AACT,5,NCT03467373,Historical,CHOP
5c74304d8625dd036b867f95,190,,,754,Patient,13:33.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_394735,Clinical Trial Inclusion Criteria,COMMENT,"subjects must have received at least 2 cycles of alkylator-based chemotherapy to be eligible Previously received rituximab, either as single agent or as part of any combination regimen, and also meet one of the following requirements: Progressed within 24 months of initiating alkylator-based chemotherapy in the first line and received no additional anticancer therapy Progressed within 24 months of initiating alkylator-based chemotherapy in the first line and subsequently progressed within 24 months of receiving any second-line treatment and received no additional anticancer therapy Progressed within 24 months of initiating alkylator-based chemotherapy in the second line and received no additional anticancer therapy Appropriate to receive R-CHOP",ct_inc_394735,AACT,750,NCT02605694,Recent,CHOP
5c74304d8625dd036b867f97,190,,,58,Patient,13:33.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_437757,Clinical Trial Exclusion Criteria,UNKNOWN,A prephase to reduce tumor burden prior to start of R-CHOP is allowed.,ct_exc_437757,AACT,54,NCT02044276,Historical,CHOP
5c74304e8625dd03a2867f85,130,,,102,Patient,13:34.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_325663,Clinical Trial Exclusion Criteria,UNKNOWN,CD4 count < 50 - Diagnosis of primary central nervous system (CNS) lymphoma - Unable to receive R-CHOP chemotherapy - History of severe (i.e.anaphylactic) allergic reactions attributed to compounds of similar chemical or biologic composition to glucocorticoids and other component of,ct_exc_325663,AACT,98,NCT03505762,Historical,CHOP
5c74304e8625dd036b867f99,190,,,388,Patient,13:34.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_435552,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Patients who have not recovered from adverse events due to agents administered more than 4 weeks earlier - Patients who are receiving any other investigational agents - Known central nervous system (CNS) involvement by lymphoma - History of allergic reactions attributed to compounds of similar chemical or biologic composition to carfilzomib or other agents (R-CHOP) used in this study - Active congestive heart failure (New York heart Association Class III or IV), symptomatic ischemia, or conduction abnormalities uncontrolled by conventional intervention or myocardial infarction within four months prior to enrollment - Patients with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements - Pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with carfilzomib - Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible - Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin, or low-risk prostate cancer after curative therapy - Patients who have had major surgical procedures or significant traumatic injury within 28 days prior to study treatment - Patients who are reported to be of direct Asian-Pacific (China, Japan, Taiwan, Singapore, Republic of Korea, and Thailand) ancestry.",ct_exc_435552,AACT,384,NCT02073097,Hypothetical,CHOP
5c74304e8625dd03a2867f87,130,,,117,Patient,13:34.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_474009,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Histopathologically-confirmed CD20-positive B-cell non Hodgkin lymphoma disease for whom R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) is an appropriate therapy (diffuse large B-cell lymphoma, mantle cell lymphoma, or follicular lymphoma); for the expansion cohort, at least 1 cohort will only include patients with newly diagnosed diffuse large B-cell lymphoma - Stage I AX (bulk defined as single lymph node mass >=10 cm in diameter) to Stage IV disease -",ct_inc_474009,AACT,113,NCT01569750,Recent,CHOP
5c74304e8625dd036b867f9b,190,,,225,Patient,13:34.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_451469,Clinical Trial Inclusion Criteria,UNKNOWN,"During the run-in period of 6 months starting from the date of the first randomization in the trial: in case of direct randomization into maintenance phase, patient must have been treated in first line by 6-8 cycles of R-CHOP.",ct_inc_451469,AACT,221,NCT01865110,Recent,CHOP
5c74304e8625dd036b867f9d,190,,,73,Patient,13:34.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_469683,Clinical Trial Inclusion Criteria,UNKNOWN,"Newly diagnosed, stage III-IV DLBCL considered poor candidates for R-CHOP.",ct_inc_469683,AACT,69,NCT01626352,Recent,CHOP
5c7430508625dd03a2867f8e,130,,,606,Patient,13:36.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_485391,Clinical Trial Inclusion Criteria,UNKNOWN,"Patient has one of the following peripheral T-cell lymphoma (PTCL) subtypes confirmed by an independent central pathology reviewer, using the Revised European American Lymphoma World Health Organization disease classification: - T/natural killer (NK)-cell leukemia/lymphoma - Adult T-cell lymphoma (TCL)/leukemia (human T-cell leukemia virus 1+) - Angioimmunoblastic TCL - Anaplastic large cell lymphoma (ALCL), primary systemic type, excluding anaplastic lymphoma kinase positive (ALK+) with International Prognostic Index (IPI) score less than 2 at initial diagnosis and complete response (CR) after CHOP-based therapy - PTCL-unspecified - Enteropathy-type intestinal lymphoma - Hepatosplenic TCL - Subcutaneous panniculitis TCL - Transformed mycosis fungoides (tMF) - Extranodal T/NK-cell lymphoma nasal or nasal type - Primary cutaneous gamma-delta TCL - Primary cutaneous CD8+ aggressive epidermic cytotoxic TCL - Documented completion of at least 6 cycles of CHOP-based therapy: - CHOP 21 - CHOP 14 - CHOP + etoposide - Other CHOP variants: substitution allowed for 1 component with a drug of the same mechanism of action.",ct_inc_485391,AACT,602,NCT01420679,Recent,CHOP
5c7430508625dd03a2867f8f,130,,,182,Patient,13:36.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_485391,Clinical Trial Inclusion Criteria,UNKNOWN,"Rituximab may be added if not given within 3 cycles of randomization.- Patient has achieved CR or partial response (PR) per per investigator's assessment following completion of CHOP-based therapy and has had radiological assessment within 21 days prior to randomization.- Eastern Cooperative Oncology Group performance status less than or equal to 2.- Adequate blood, liver, and kidney function as defined by laboratory tests.- Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to randomization and agree to practice a medically acceptable contraceptive regimen from study treatment initiation until at least 30 days after the last administration of pralatrexate.- Men who are sexually active, including those with a pregnant partner, must agree to practice a medically acceptable barrier method contraceptive regimen (eg, condoms) while receiving pralatrexate and for 90 days after the last administration of pralatrexate.- Has given written informed consent.",ct_inc_485391,AACT,178,NCT01420679,Historical,CHOP
5c7430518625dd0397867f8b,1090,,,157,Patient,13:37.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_360830,Clinical Trial Exclusion Criteria,LABORATORY_AND_RADIOLOGY_DATA,"- Unrelated donor meets National Marrow Donor Program criteria for donation - For partially matched related donors, Children's Hospital of Philadelphia (CHOP) bone marrow transplant (BMT) standard procedures apply for determining donor eligibility, includ",ct_exc_360830,AACT,153,NCT03047746,Recent,CHOP
5c7430518625dd0397867f8c,1090,,,38,Patient,13:37.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_370639,Clinical Trial Inclusion Criteria,UNKNOWN,Volunteers - Patients who come to CHOP for a clinically indicated MRI.- The ability to extend the clinical MRI an extra 15-20 minutes.-,ct_inc_370639,AACT,34,NCT02919956,Recent,CHOP
5c7430518625dd03a2867f91,130,,,128,Patient,13:37.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_487779,Clinical Trial Exclusion Criteria,UNKNOWN,"Other types of lymphomas, e.g.B-cell lymphoma, Contraindication to any drug contained in the three chemotherapy regimens (R-CHOP, R-FC, R-DHA), Tested positive for HIV, Active Hepatitis B",ct_exc_487779,AACT,124,NCT01389427,Recent,CHOP
5c7430518625dd0397867f8d,1090,,,229,Patient,13:38.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_403181,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products Contraindication to any of the individual components of CHOP, including prior receipt of anthracyclines History of other malignancies within 5 years prior to study entry except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer Stage I without bulky Patients with transformed lymphoma Prior therapy for DLBCL, with the exception of nodal biopsy or local irradiation Previous exposure to cytotoxic agents Suspect or clinical evidence of CNS involvement by lymphoma 9.",ct_exc_403181,AACT,225,NCT02495454,Historical,CHOP
5c7430528625dd0397867f8e,1090,,,438,Patient,13:38.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_318276,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Diabetic patients - Pregnant or lactated women - Patient with history of severe thrombosis - Concomitant radiotherapy - Known hypersensitivity yo thalidomide, palonosetron, or dexamethasone.- Concurrent administration of any other drug which affect antiemetic effect evaluation such as proton pump inhibitor, H2 blocker, amifostine, sedative drugs - Cyclophosphamide, hydroxydaunomycin, Oncovin, and prednisone (CHOP )regiment or taxanes-based regiment - Existing emesis within 24 hours before chemotherapy administration - Symptomatic brain metastasis or suspected clinical brain metastasis - Serious uncontrolled systemic illness or medical",ct_exc_318276,AACT,434,NCT03601871,Historical,CHOP
5c7430528625dd03c7867f8b,0,,,189,Patient,13:38.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_356471,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - DLBCL patients that will be eligible in front-line treatment for a combination of anthracycline-based chemotherapy plus anti-CD20 monoclonal antibody,Rituximab: R-CHOP 14, R-CHOP 21, R mini-CHOP, R-ACVBP, R-COPADEM.Patients",ct_inc_356471,AACT,185,NCT03104478,Recent,CHOP
5c7430528625dd03c7867f8c,0,,,20,Patient,13:38.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_356471,Clinical Trial Inclusion Criteria,UNKNOWN," treated with R-CHOP associated with an experimental drug ((polatuzumab, tazemetostat, venetoclax, entospletinib, lenalidomide, ibrutinib, anti PD1/anti PDL1 .)-",ct_inc_356471,AACT,16,NCT03104478,Recent,CHOP
5c7430538625dd03c7867f92,0,,,216,Patient,13:39.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_316883,Clinical Trial Inclusion Criteria,UNKNOWN,Patients with early breast cancer planned to receive 3 weekly or dose-dense anthracycline/cyclophosphamide combination or 3 weekly taxane containing chemotherapy regimen or patients with NHL planned to receive R-CHOP-14 or R-CHOP-21 immunochemotherapy as 1st-line treatment with the indication for G-CSF prophylaxis with pegfilgrastim for the prevention of FN and reduction in CIN duration.,ct_inc_316883,AACT,212,NCT03619993,Recent,CHOP
5c7430538625dd03ad867f8e,590,,,146,Patient,13:39.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_463308,Clinical Trial Inclusion Criteria,UNKNOWN,Eligible mentees will be caregivers of 0-3 year old children who are enrolled in Early Head Start at The Children's Hospital of Philadelphia (CHOP EHS) at the time of recruitment.,ct_inc_463308,AACT,142,NCT01710423,Recent,CHOP
5c7430538625dd03ad867f8f,590,,,28,Patient,13:39.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_463308,Clinical Trial Inclusion Criteria,UNKNOWN,Caregiver enrollment in CHOP EHS requires the following: Children are 0-3 years old (Expectant mothers are also eligible to enroll),ct_inc_463308,AACT,24,NCT01710423,Recent,CHOP
5c7430538625dd03ad867f90,590,,,139,Patient,13:39.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_463308,Clinical Trial Inclusion Criteria,UNKNOWN,"The family has an income at or below federal poverty level The family lives in West Philadelphia, within the geographic area served by CHOP EHS.",ct_inc_463308,AACT,135,NCT01710423,Recent,CHOP
5c7430538625dd03ad867f91,590,,,72,Patient,13:39.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_463308,Clinical Trial Inclusion Criteria,UNKNOWN,"If a mentee caregiver has more than one child currently enrolled in CHOP EHS, then all their eligible children will be enrolled in the study.",ct_inc_463308,AACT,68,NCT01710423,Recent,CHOP
5c7430538625dd03ad867f92,590,,,70,Patient,13:39.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_455981,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Primary care pediatric practices within the CHOP Care Network,ct_inc_455981,AACT,66,NCT01806103,Recent,CHOP
5c7430538625dd03ad867f93,590,,,93,Patient,13:39.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_545357,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Pediatric or Emergency Medicine Residents rotating through PICU in CHOP.,ct_inc_545357,AACT,89,NCT00631176,Recent,CHOP
5c7430538625dd03c7867f9b,0,,,184,Patient,13:39.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_411113,Clinical Trial Inclusion Criteria,UNKNOWN,"Planned to receive chemotherapy for 6 cycles which the treating physician plans to utilize for pegfilgrastim to minimize risk for neutropenic fever, including but not limited to R-CHOP, R-EPOCH, and R-HyperCVAD, CHOP, and SMILE.",ct_inc_411113,AACT,180,NCT02392039,Recent,CHOP
5c7430538625dd03c7867fa4,0,,,408,Patient,13:39.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_486155,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Subjects with significant concurrent medical complications that in the judgment of the Principal Investigator(s) could affect the patient's ability to complete the planned trial, including the multiple imaging studies.- Patients with history of prior lymphoma (e.g., follicular lymphoma) and/or second cancers other than basal cell carcinoma.- Patients planned to be treated with R-CHOP-14 (i.e.:",ct_exc_486155,AACT,404,NCT01410630,Historical,CHOP
5c7430538625dd03c7867fa5,0,,,6,Patient,13:39.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_486155,Clinical Trial Exclusion Criteria,UNKNOWN,"R-CHOP given every 14 days) will be excluded (this should be extremely rare, if at all, since R-CHOP-21 is the standard treatment.- Patients who are scheduled to receive Rituxan or any other therapy (e.g., XRT, radioimmunotherapy) as adjuvant therapy after completion of R-CHOP-21.- Pregnant women will be excluded.- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) after study entry and for the duration of study participation.",ct_exc_486155,AACT,2,NCT01410630,Hypothetical,CHOP
5c7430548625dd03c7867fb1,0,,,79,Patient,13:40.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_567491,Clinical Trial Inclusion Criteria,UNKNOWN,"B-cell Non-Hodgkins lymphoma (NHL) planned to receive at least 2 cycles of CHOP-14, CHOEP-14, CHOP-DI-14, EPOCH-14 or CHOP-21 +/-",ct_inc_567491,AACT,75,NCT00336609,Recent,CHOP
5c7430548625dd03c7867fbb,0,,,77,Patient,13:40.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_415115,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Patient who cannot receive polychemotherapy like R-CHOP, R-ACVBP, or R-CHOP like - Patient who cannot benefit from standard extension assessment and follow-up by with Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET) - Pregnant or breast-feeding woman - Guardianship, curatorship - Patient who cannot follow the medical procedures of the study for geographic, social, psychological,linguistic or physical reasons",ct_exc_415115,AACT,73,NCT02339805,Recent,CHOP
5c7430558625dd03c7867fc3,0,,,103,Patient,13:41.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_544174,Clinical Trial Inclusion Criteria,UNKNOWN,"- Obtain no partial response after first-line chemotherapy including anthracyclines + rituximab (R-CHOP, R-MegaCHOP, R-EPOCH or the like), or else - Absence of partial response after having received salvage (post-induction) chemotherapy including R-IFE, R",ct_inc_544174,AACT,99,NCT00646750,Recent,CHOP
5c7430558625dd03ef867f84,1170,,,68,Patient,13:41.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_567392,Clinical Trial Inclusion Criteria,UNKNOWN,Treatment naive except for prior radiation or a single cycle of CHOP.- Patients must have at least one clear-cut bidimensionally measurable site by physical exam and/or computed tomography.,ct_inc_567392,AACT,64,NCT00337987,Historical,CHOP
5c7430568625dd03fe867f85,290,,,278,Patient,13:42.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_480769,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients under consideration for participation in this study must meet all of the following inclusion criteria: - Histologically confirmed CD20 positive diffuse large B-cell lymphoma.- Progressing or relapsed following prior treatment including but not limited to rituximab-CHOP chemotherapy regimen.- Not suitable for ASCT (age > 60 years, PS 2, prior ASCT as a part of the previous treatment for DLBCL, and/or other medical conditions that unable the patients to undergo the ASCT, e.g.",ct_inc_480769,AACT,274,NCT01481272,Historical,CHOP
5c7430568625dd03fe867f87,290,,,130,Patient,13:42.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_522644,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically proven diffuse large B-cell or follicular B-cell non-Hodgkin's lymphoma, for which chemotherapy with rituximab-CHOP chemotherapy is considered treatment-of-choice.",ct_inc_522644,AACT,126,NCT00931229,Recent,CHOP
5c7430568625dd03ef867f85,1170,,,17,Patient,13:42.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_588787,Clinical Trial Inclusion Criteria,COMMENT,vincristine (CHOP) chemotherapy,ct_inc_588787,AACT,13,NCT00070447,Recent,CHOP
5c7430578625dd03ef867f86,1170,,,94,Patient,13:43.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_481870,Clinical Trial Inclusion Criteria,UNKNOWN,"There is no maximal limit on the number of prior therapies - Prior treatment must include CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) -like chemotherapy in combination with rituximab.",ct_inc_481870,AACT,90,NCT01466868,Historical,CHOP
5c7430578625dd03e4867f86,800,,,69,Patient,13:43.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_549583,Clinical Trial Inclusion Criteria,UNKNOWN,"No prior anthracycline/anthracenedione-based chemotherapy (e.g., CHOP, CNOP)",ct_inc_549583,AACT,65,NCT00574730,Historical,CHOP
5c7430578625dd03e4867f88,800,,,77,Patient,13:43.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_552657,Clinical Trial Inclusion Criteria,UNKNOWN,CD20 positive B-cell non-Hodgkin's lymphoma Treatment with rituximab and CHOP or COP Performance status 0 or 1 according to the WHO scale (Appendix),ct_inc_552657,AACT,73,NCT00533728,Recent,CHOP
5c7430578625dd03ef867f87,1170,,,60,Patient,13:43.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_442102,Clinical Trial Exclusion Criteria,COMMENT,"Contraindication to any of the individual components of CHOP (cyclophosphamide, vincristine, doxorubicin and prednisone), including prior anthracycline treatment.- For participants with",ct_exc_442102,AACT,56,NCT01987505,Historical,CHOP
5c7430578625dd03fe867f8d,290,,,429,Patient,13:43.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_448981,Clinical Trial Exclusion Criteria,COMMENT,"Subjects must satisfy all of the following criteria: Have histologically confirmed DLBCL (including primary mediastinal B-cell lymphoma), with relapsed or refractory disease following at least 2 lines of prior standard therapy, including alkylator/anthracycline (unless anthracycline-based chemotherapy is contraindicated)/anti-CD20-based therapy (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP] or equivalent) AND must be considered unable to benefit from intensification treatment with autologous hematopoietic stem cell transplantation (ASCT) as defined by meeting at least 1 of the following criteria: - Relapsed following, or refractory to, previous ASCT - Did not achieve at least a partial response to a standard salvage regimen (eg, rituximab, ifosfamide, carboplatin, and etoposide phosphate [R-ICE] or rituximab, dexamethasone, cytarabine, and cisplatin [R-DHAP]) -",ct_exc_448981,AACT,425,NCT01897571,Historical,CHOP
5c7430578625dd03e4867f89,800,,,153,Patient,13:43.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_416684,Clinical Trial Inclusion Criteria,UNKNOWN,Pennsylvania driver's license for 90 days or less at time of assent Personal email address and computer and internet access Willingness to travel to CHOP twice to complete simulated assessment Ability to read and write English,ct_inc_416684,AACT,149,NCT02319317,Recent,CHOP
5c7430578625dd03e4867f8a,800,,,126,Patient,13:44.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_364409,Clinical Trial Inclusion Criteria,UNKNOWN,"gestation - Birth weight 2000 grams - Parents plan to receive well-child care in the Children's Hospital of Philadelphia (CHOP) network, Society Hill Pediatrics, Center City Pediatrics, Penn Medicine or South Philly",ct_inc_364409,AACT,122,NCT03001167,Recent,CHOP
5c7430588625dd03ef867f88,1170,,,69,Patient,13:44.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_465159,Clinical Trial Inclusion Criteria,AGE,Age elder than 81 or Age 61 to 80 and CIRS >6 not qualifying for CHOP-therapy -,ct_inc_465159,AACT,65,NCT01686321,Recent,CHOP
5c7430588625dd03e4867f8b,800,,,200,Patient,13:44.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_316489,Clinical Trial Inclusion Criteria,UNKNOWN,Child is <30 months old at time of enrollment - Child was born >35 weeks estimated gestational age - Parent-child dyad reside in Philadelphia and present at a Children's Hospital of Philadelphia (CHOP) primary care practice located in Philadelphia - Parents are,ct_inc_316489,AACT,196,NCT03625115,Recent,CHOP
5c7430588625dd03e4867f8c,800,,,5,Patient,13:44.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_505035,Clinical Trial Inclusion Criteria,UNKNOWN,"(CHOP) admitted to the neonatal, pediatric, or cardiac intensive care unit (NICU, PICU, or CICU), or who have been referred to the Pediatric Advanced Care Team (PACT) for palliative care services.",ct_inc_505035,AACT,1,NCT01163136,Recent,CHOP
5c7430588625dd03e4867f8d,800,,,110,Patient,13:44.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_450223,Clinical Trial Inclusion Criteria,UNKNOWN,"Cohort 1:lymphoma patients - minimum lesion size of 2cm - not pretreated but scheduled to be treated with CHOP (Cyclophosphamide, Hydroxydaunomycin,Oncovin and Prednisolone)",ct_inc_450223,AACT,106,NCT01881386,Recent,CHOP
5c7430588625dd03fe867f98,290,,,131,Patient,13:44.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_460571,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Prior anti-lymphoma chemotherapy (except steroids/radiotherapy for urgent palliation, one prior cycle of CHOP or up to 2 prior cycles of CHOEP) -",ct_exc_460571,AACT,127,NCT01746173,Historical,CHOP
5c7430588625dd03fb867f8f,620,,,260,Patient,13:44.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_474461,Clinical Trial Inclusion Criteria,UNKNOWN,"- Diffuse large B-cell lymphoma - Initial diagnostic tissue block, or 4 unstained slides - Tissue from patients with limited-stage DLBCL enrolled on SWOG trials treated with cyclophosphamide, doxorubicin hydrochloride, prednisone, and vincristine sulfate ",ct_inc_474461,AACT,256,NCT01563861,Recent,CHOP
5c7430588625dd03fb867f90,620,,,70,Patient,13:45.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_529797,Clinical Trial Inclusion Criteria,UNKNOWN,"Scheduled for day surgery T&A with expected same day discharge at CHOP Main in Philadelphia, Pennsylvania (PA) or the CHOP Ambulatory Surgical Facilities (ASFs) in Chalfont, PA; Exton, PA; or Voorhees, New Jersey (",ct_inc_529797,AACT,66,NCT00836264,Recent,CHOP
5c7430598625dd03ef867f89,1170,,,568,Patient,13:45.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_492076,Clinical Trial Exclusion Criteria,UNKNOWN,"For participants with follicular lymphoma: prior treatment for non-Hodgkin's lymphoma with chemotherapy, immunotherapy, or radiotherapy - For participants with non-follicular lymphoma: prior treatment with chemotherapy or immunotherapy - Regular treatment with corticosteroids during the 4 weeks prior to the start of Cycle 1 - Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results - For participants who will be receiving cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP): left ventricular ejection fraction (LVEF) less than (<) 50% by multiple-gated acquisition (MUGA) scan or echocardiogram - History of prior other malignancy with the exception of curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix at any time prior to study - Known active infection, or major episode of infection within 4 week prior to the start of Cycle 1 - Vaccination with a live vaccine within 28 days prior to randomization - Recent major surgery (within 4 weeks prior to start of Cycle 1), other than for diagnosis - Abnormal laboratory values as defined by protocol for creatinine, creatinine clearance, aspartate transaminase (AST) or alanine transaminase (ALT), total bilirubin, international normalized ration (INR), partial thromboplastin time (PTT) or activated partial thromboplastin time (aPPT), unless these abnormalities are due to underlying lymphoma - Positive test results for human immunodeficiency virus (HIV), human T-lymphotropic virus 1 (HTLV1), hepatitis C or chronic hepatitis B - Pregnant or lactating women - Life expectancy <12 months - Participation in another clinical trial with drug intervention within 28 days prior to start of Cycle 1 and during study",ct_exc_492076,AACT,564,NCT01332968,Historical,CHOP
5c7430598625dd0426867f87,660,,,131,Patient,13:45.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_407270,Clinical Trial Inclusion Criteria,UNKNOWN,Scheduled for intubation/anesthesia for clinical purposes for a surgical procedure in the Children's Hospital of Philadelphia (CHOP),ct_inc_407270,AACT,127,NCT02442141,Recent,CHOP
5c7430598625dd0426867f88,660,,,93,Patient,13:45.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_453459,Clinical Trial Inclusion Criteria,UNKNOWN,Histologically confirmed diagnosis of PTCL - Patients with transformed CTCL eligible for CHOP regimen - Measurable disease based on Cheson 2007 criteria - Eastern Cooperative Oncology Group (ECOG) performance status < 2,ct_inc_453459,AACT,89,NCT01839097,Recent,CHOP
5c7430598625dd0426867f89,660,,,79,Patient,13:45.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_455981,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria: - Academic primary care pediatric practices within the CHOP Care Network - Providers entering a practice after the start of the intervention - Providers with less than 25 antibiotic prescriptions in the 6 months prior to the start of the intervention,ct_exc_455981,AACT,75,NCT01806103,Historical,CHOP
5c7430598625dd03ef867f8a,1170,,,155,Patient,13:45.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_475230,Clinical Trial Exclusion Criteria,UNKNOWN,Any previous therapy for lymphoma except short-term corticosteroids (maximum 10 days) before inclusion.- Contra-indication to any drug included in the CHOP regimen.-,ct_exc_475230,AACT,151,NCT01553786,Recent,CHOP
5c7430598625dd0426867f8a,660,,,8,Patient,13:45.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_549060,Clinical Trial Exclusion Criteria,UNKNOWN,All CHOP primary care pediatric and ENT sites are eligible for participation.,ct_exc_549060,AACT,4,NCT00581711,Recent,CHOP
5c74305a8625dd0411867f87,300,,,94,Patient,13:46.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_459251,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Histologically diagnosed non-Hodgkin's lymphoma patients treated by CHOP-regimen or R (Rituximab)-CHOP regimen at 215 days interval - Age >= 20 years old -,ct_inc_459251,AACT,90,NCT01763398,Recent,CHOP
5c74305a8625dd0414867f87,690,,,75,Patient,13:46.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_530645,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - For R/R participants recruited in Obinutuzumab + CHOP regimen, prior use of anthracyclines.",ct_exc_530645,AACT,71,NCT00825149,Historical,CHOP
5c74305a8625dd0414867f88,690,,,785,Patient,13:46.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_530645,Clinical Trial Exclusion Criteria,UNKNOWN,"For first-line recruited participants, prior systemic therapy - Prior administration of rituximab within 56 days of study entry, or 3 months for any radioimmunotherapy - Central nervous system lymphoma - History of other malignancies within 2 years of study entry which could affect compliance with the protocol or interpretation of results - Known active bacterial, viral (including human immunodeficiency virus [HIV]), fungal, mycobacterial, or other infection (excluding fungal infections of nail beds) or any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of dosing - Contraindication to any of the individual components of chemotherapy (as per local prescribing information), of the selected chemotherapy combination (FC, CHOP or bendamustine)",ct_exc_530645,AACT,781,NCT00825149,Historical,CHOP
5c74305a8625dd0414867f89,690,,,112,Patient,13:46.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_429926,Clinical Trial Inclusion Criteria,UNKNOWN,-Patient Dyads Parent/guardian of a child who has been admitted to the Children's Hospital of Philadelphia (CHOP) PICU for 7 days after onset of the study Parent/guardian 18 years old Parent/guardian is English-speaking Child <18 years old at time of enro,ct_inc_429926,AACT,108,NCT02146573,Hypothetical,CHOP
5c74305a8625dd03ef867f8b,1170,,,133,Patient,13:46.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_579006,Clinical Trial Inclusion Criteria,UNKNOWN,"Biologic therapy - Concurrent epoetin alfa for treatment of anemia allowed Chemotherapy - Concurrent chemotherapy allowed except CHOP therapy Endocrine therapy - No concurrent chronic systemic steroids Radiotherapy - Not specified Surgery - More than 4 weeks since prior major surgery Other - No prior ginseng capsules for fatigue - Prior ginseng-containing teas or drinks purchased at a grocery store allowed - No concurrent pharmacologic agents for the treatment of fatigue, including any of the following: - Psychostimulants - Antidepressants - Antidepressants used to treat conditions other than fatigue (e.g., hot flashes) are allowed provided the patient has been on a stable dose for 1 month and plans to continue antidepressant for 1 month -",ct_inc_579006,AACT,129,NCT00182780,Historical,CHOP
5c74305a8625dd0414867f8a,690,,,191,Patient,13:46.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_566986,Clinical Trial Inclusion Criteria,UNKNOWN,"Phase 2: Patients with Measurable Non-Hodgkin's Lymphomas (Indolent or Aggressive) only.- Patients with Indolent NHL must be relapsed or refractory to at least one prior line of therapy (CHOP, CVP, chlorambucil or fludaribine).Prior treatment with Rituximab is required.- Patients with Aggressive NHL refractory to (or relapsed from) at least one CHOP-based therapy who have had prior treatment with Rituximab and who are not candidates for high-dose chemotherapy or autologous stem cell transplantation.- ECOG performance status 0-2 - Autologous stem cell transplant recipients are eligible if 100 days have elapsed since procedure.",ct_inc_566986,AACT,187,NCT00343564,Historical,CHOP
5c74305a8625dd0431867f86,220,,,89,Patient,13:46.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_347600,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Participants who have had chemotherapy other than R-EPOCH or R-CHOP, or radiotherapy other than palliative radiation for medical emergencies (like cord compression), within the last 4 weeks - Prior cytotoxic chemotherapy or radiotherapy for this lymphoma - Rituximab within 12 months prior to study registration; only exception will be if rituximab was given for indications other than the treatment of aggressive lymphoma, or for one prior cycle of treatment - Participants who are receiving any other investigational agents - Participants who have previously received ibrutinib for another indication - Expected survival < 2 months - Participants with a history of an opportunistic fungal infection or active fungal infection requiring, or at high risk of requiring, prophylactic or treatment with fluconazole, voriconazole or posaconazole - Participants with known brain metastases from solid tumors should be excluded from this clinical trial - Presence of second active tumor, other than non-melanoma skin cancer, carcinoma in situ of the cervix, or Kaposi's sarcoma (KS) that requires systemic therapy -",ct_exc_347600,AACT,85,NCT03220022,Hypothetical,CHOP
5c74305a8625dd0414867f8b,690,,,165,Patient,13:46.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_567493,Clinical Trial Inclusion Criteria,UNKNOWN,"to achieve a complete remission with the initial induction chemotherapy, or recurrent disease - Performance status (ECOG) 3 - Age 75 - Treated with at least one CHOP or CHOP-derived doxorubicin containing regimen -",ct_inc_567493,AACT,161,NCT00336583,Recent,CHOP
5c74305a8625dd0414867f8c,690,,,198,Patient,13:46.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_495515,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products or to any component of CHOP or obinutuzumab - Contraindication to any of the individual components of CHOP, including prior receipt of anthracyclines - Participants with transformed lymphoma and participants with follicular lymphoma IIIB - Prior therapy for DLBCL, with the exception of nodal biopsy or local irradiation - Prior treatment with cytotoxic drugs or rituximab for another condition (for example, rheumatoid arthritis) or prior use of an anti-CD20 antibody - Prior use of any monoclonal antibody within 3 months of the start of Cycle 1 - Corticosteroid use of >30 milligrams per day (mg/day) of prednisone or equivalent, for purposes other than lymphoma symptom control - Primary central nervous system (",ct_exc_495515,AACT,194,NCT01287741,Historical,CHOP
5c74305b8625dd03ef867f8c,1170,,,468,Patient,13:47.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_576405,Clinical Trial Inclusion Criteria,UNKNOWN,"(5 times ULN if due to hepatic involvement with lymphoma) - PT, INR, and PTT 1.5 times normal - Creatinine 2.0 mg/dL - Urinary protein:creatinine ratio 1 - History of deep venous thrombosis allowed provided patient is on a stable dose of anticoagulants for at least 2 weeks prior to study entry - LVEF 50% - History of pulmonary embolism allowed provided patient is on a stable dose of anticoagulants for at least 2 weeks prior to study entry - One prior cycle of CHOP for PTCL allowed - More than 4 weeks since prior major invasive surgery or open biopsy - At least 7 days since prior minor surgery.",ct_inc_576405,AACT,464,NCT00217425,Historical,CHOP
5c74305b8625dd03ef867f8d,1170,,,67,Patient,13:47.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_576875,Clinical Trial Inclusion Criteria,UNKNOWN,Treatment nave except for prior radiation or a single cycle of CHOP.- Patients must have at least one clear-cut bidimensionally measurable site by physical exam and/or computed tomography.-,ct_inc_576875,AACT,63,NCT00211185,Historical,CHOP
5c74305b8625dd0431867f8e,220,,,105,Patient,13:47.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_571475,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically confirmed Hodgkin's lymphoma or Non-Hodgkin's lymphoma receiving Q14, Q21, or Q28 day CHOP, ICE, ESHAP, or DHAP chemotherapy; with or without Rituximab - Has adequate bone marrow function; platelet count > 100 x 10^9/L on the day of initiation of the on study chemotherapy of the next treatment cycle and absolute neutrophil count, ANC > or = 1 x 10^9/L, and hemoglobin > or = 9.5 g/dL - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - Has adequate liver function - must be able to receive the same chemotherapy regimen during the first treatment cycle as was received during the prior qualifying cycle - must experience Common Terminology Criteria (CTC) grade 3 or 4 thrombocytopenia (",ct_inc_571475,AACT,101,NCT00283439,Historical,CHOP
5c74305b8625dd0414867f8d,690,,,26,Patient,13:47.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_486852,Clinical Trial Inclusion Criteria,UNKNOWN,- Patients subject to CHOP therapy and without a history of prior treatment with anthracycline or anthraquinone anticancer drugs (just for the administration of E7777 in combination with CHOP therapy) - Eastern Cooperative Oncology Group (ECOG) performanc,ct_inc_486852,AACT,22,NCT01401530,Historical,CHOP
5c74305c8625dd0431867f91,220,,,45,Patient,13:48.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_570939,Clinical Trial Inclusion Criteria,UNKNOWN,Ages 16 - 60 years (due to the fact that CHOP-R is not studied enough in younger patients and is not considered standard of care).,ct_inc_570939,AACT,41,NCT00290498,Recent,CHOP
5c74305c8625dd0414867f8e,690,,,119,Patient,13:48.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_547943,Clinical Trial Inclusion Criteria,UNKNOWN,Intrathecal Morphine Group: All patients with idiopathic scoliosis aged 11 through and including 18 who present to CHOP for posterior spinal fusion,ct_inc_547943,AACT,115,NCT00596609,Recent,CHOP
5c74305c8625dd0414867f8f,690,,,206,Patient,13:48.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_547943,Clinical Trial Inclusion Criteria,UNKNOWN,Only patients given intrathecal morphine after curve correction and instrumentation will be studied Control Group: All patients with idiopathic scoliosis aged 11 through and including 18 who present to CHOP for posterior spinal fusion will be eligible Patients with procedures not anticipated to extend to or below the second lumbar vertebral level Patients who do not receive IT morphine injection as part of their routine anesthetic care,ct_inc_547943,AACT,202,NCT00596609,Recent,CHOP
5c74305c8625dd0411867f91,300,,,7,Patient,13:48.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_324497,Clinical Trial Inclusion Criteria,UNKNOWN,R- CHOP) or CVP+/- R for DLBCL Cohort 2:,ct_inc_324497,AACT,3,NCT03520920,Recent,CHOP
5c74305c8625dd0431867f92,220,,,4,Patient,13:48.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_355420,Clinical Trial Inclusion Criteria,RESPIRATORY_RATE,CHOP) with SD duration,ct_inc_355420,AACT,0,NCT03118180,Recent,CHOP
5c74305c8625dd043c867f8b,50,,,131,Patient,13:48.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_437757,Clinical Trial Inclusion Criteria,UNKNOWN,"Histological documentation of aggressive B cell NHL Planned to receive systemic anticancer therapy with at least 6 cycles of R-CHOP-21, according to local standards 5.",ct_inc_437757,AACT,127,NCT02044276,Recent,CHOP
5c74305d8625dd0431867f94,220,,,912,Patient,13:49.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_484338,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients must have a histologically confirmed diagnosis of aggressive B-cell lymphoma (diffuse large B-cell lymphoma [DLBCL], Burkitt lymphoma [BL], etc.)expressing the CD20 antigen and have failed at least one prior standard systemic therapy - Patients must have relapsed after high-dose therapy and autologous transplantation or be ineligible for high-dose therapy and autologous transplantation; patients that have failed autologous transplantation are those with persistent disease > 30 days after transplant; those ineligible for autologous transplant include those with chemoresistant disease (i.e., patients who have not achieved a partial response or better with their most recent chemotherapy regimen), are expected to have a poor outcome from autologous transplant (e.g., DLBCL relapsing within one year of rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone [R-CHOP]-like chemotherapy, double hit lymphoma, v-myc myelocytomatosis viral oncogene homolog (avian) positive [MYC+] lymphoma, persistent positron emission tomography [PET] positivity after chemotherapy), are unable to collect sufficient or tumor-free autologous stem cells per Seattle Cancer Care Alliance (SCCA) standard practice, are unable to tolerate the high-dose autologous conditioning regimens, or who refuse a high-dose autologous transplant regimen - Creatinine (Cr) < 2.0 - Bilirubin",ct_inc_484338,AACT,908,NCT01434472,Historical,CHOP
5c74305d8625dd0457867f86,70,,,261,Patient,13:49.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_420797,Clinical Trial Inclusion Criteria,UNKNOWN,"Participants must have histologically documented diagnosis of NHL (and exhausted options considered standard of care) as defined in the World Health Organization classification scheme and relapsed following or be refractory to standard treatments such as R-CHOP, R-CVP, or fludarabine based regimens.",ct_inc_420797,AACT,257,NCT02265731,Recent,CHOP
5c74305e8625dd0457867f89,70,,,91,Patient,13:50.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_492405,Clinical Trial Exclusion Criteria,UNKNOWN,"Subject must have relapsed following or be refractory to standard treatments such as R-CHOP, R-CVP, or fludarabine based regimens.",ct_exc_492405,AACT,87,NCT01328626,Recent,CHOP
5c74305e8625dd0457867f8c,70,,,101,Patient,13:50.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_448591,Clinical Trial Inclusion Criteria,UNKNOWN,"Be designated to receive cytotoxic chemotherapy including one or more of the following agents: R-CHOP, ABVD, Liposomal doxorubicin (Caelyx) or liposomal daunorubicin (Daunoxome) or Paclitaxel",ct_inc_448591,AACT,97,NCT01902693,Recent,CHOP
5c74305e8625dd0457867f8f,70,,,62,Patient,13:50.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_548371,Clinical Trial Inclusion Criteria,UNKNOWN, may be enrolled in this study after the first cycle of R-CHOP if all screening evaluations were performed prior to the first cycle of chemotherapy.- Ann Arbor stage 3 or 4 - Age greater than or equal to 18 years - Patient must give written informed consent.-,ct_inc_548371,AACT,58,NCT00590941,Hypothetical,CHOP
5c74305e8625dd0457867f90,70,,,107,Patient,13:50.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_548371,Clinical Trial Inclusion Criteria,UNKNOWN,A patient enrolled in another clinical trial may also enroll in this study if the other trial has an R-CHOP treatment arm and the patient is randomized to the R-CHOP only arm.,ct_inc_548371,AACT,103,NCT00590941,Hypothetical,CHOP
5c74305e8625dd0457867f93,70,,,203,Patient,13:51.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_392045,Clinical Trial Inclusion Criteria,UNKNOWN,"(MCL Wave 3 only) - Subject has evaluable disease and requires treatment in the opinion of the investigator.- Subject must have relapsed following or be refractory to 1 standard treatments such as R-CHOP, R-CVP, bendamustine, lenalidomide-rituximab, or fludarabine-based regimens.- Subject has an Eastern Cooperative Oncology Group (ECOG) performance score of less than or equal to 2.- Subject must have adequate bone marrow independent of growth factor support per local laboratory reference range at Screening.- Subject must have adequate coagulation, renal, and hepatic function, per laboratory reference range at Screening.- NHL subjects who have a history of an autologous stem cell transplant (e.g., bone marrow) must be > 6 months post-transplant (prior to the first dose of study drug) and must not require any growth factor support.",ct_inc_392045,AACT,199,NCT02640833,Historical,CHOP
5c74305f8625dd0457867f97,70,,,243,Patient,13:51.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_524716,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Subjects greater than or equal to 18 years old - Subjects diagnosed with any histological type of NHL (including both chemotherapy nave and pre-treated subjects) - Subjects planned to receive a minimum of 3 cycles of CHOP-14 or CHOP-21 with or without Rituximab (for subjects enrolled retrospectively, eligibility should be assessed on the profile at time of planning treatment, where treatment initiates on or after 01 Jan 2005, with specific focus on planned chemotherapy and not outcome or number of delivered cycles) -",ct_inc_524716,AACT,239,NCT00903812,Recent,CHOP
5c74305f8625dd0452867f8c,40,,,174,Patient,13:51.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_344212,Clinical Trial Inclusion Criteria,COMMENT,"Prior Treatment: Previously untreated or has received a maximum of one cycle of any combination chemotherapy (e.g.cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP), CHOEP, DA-EPOCH, doxorubicin, cyclophosphamide, cytarabine, vincristine, methotrexate/Etoposide, ifosfamide, cytarabine, methotrexate (CODOX-M/IVAC), HyperCVAD) within 4 weeks of study entry.",ct_inc_344212,AACT,170,NCT03264131,Historical,CHOP
5c74305f8625dd043c867f93,50,,,76,Patient,13:51.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_493723,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria: Patients who had received chemotherapy other than R-CHOP or R-CVP after diagnosis 2.,ct_exc_493723,AACT,72,NCT01311232,Recent,CHOP
5c74305f8625dd0457867f99,70,,,71,Patient,13:51.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_404784,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - 19 or older - newly diagnosed with DLBCL - R-CHOP chemotherapy - offer informed consent,ct_inc_404784,AACT,67,NCT02474550,Recent,CHOP
5c7430608625dd043c867f97,50,,,143,Patient,13:52.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_472146,Clinical Trial Exclusion Criteria,UNKNOWN,"The subject must have received first line therapy with Rituximab-Cyclophosphamide, Hydroxydaunomycin, Vincristine (Oncovin), Prednisone (R-CHOP) [or a similar standard rituximab-containing front-line chemoimmunotherapy regimen including, but not limited to Etoposide, Prednisone, Vincristine (Oncovin), Cyclophosphamide, Doxorubicin (Hydrochloride) + Rituximab (EPOCH + R); Rituximab, Cyclophosphamide, Etoposide, Procarbazine, Prednisone (RCEPP); Rituximab, Cyclophosphamide, Mitoxantrone (Novantrone), Vincristine (Oncovin), Prednisone (RCNOP); Dose-adjusted-Etoposide, Prednisone, Vincristine(Oncovin), Cyclophosphamide, Doxorubicin (Hydrocloride) (DA-EPOCH); and Rituximab, Cyclophosphamide, Etoposide, Vincristine (Oncovin), Prednisone (RCEOP)].- Subject must have adequate coagulation, renal, and hepatic function, per laboratory reference range at Screening.",ct_exc_472146,AACT,139,NCT01594229,Recent,CHOP
5c7430608625dd043c867f98,50,,,564,Patient,13:52.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_472146,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Subject has been diagnosed with Post-Transplant Lymphoproliferative Disease, Burkitt's lymphoma, Burkitt-like lymphoma, lymphoblastic lymphoma/leukemia, chronic lymphocytic leukemia, small lymphocytic lymphoma or mantle cell lymphoma (MCL).- Subject has refractory diffuse large B-cell lymphoma, defined as meeting any of the following criteria: - Subject progressed during or within 3 months of completion of a planned course of first-line therapy with Rituximab-Cyclophosphamide, Hydroxydaunomycin, Vincristine (Oncovin), Prednisone (R-CHOP) or an equivalent regimen; - Subject had no response (i.e., stable disease only) to first-line therapy with R-Cyclophosphamide, Hydroxydaunomycin, Vincristine (Oncovin), Prednisone (R-CHOP) or an equivalent regimen; - Subject progressed during or within 2 months of completion of their last planned course of salvage therapy with chemotherapy (with or without rituximab, may include autologous stem cell transplant).- Subject has tested positive for human immunodeficiency virus (HIV).- Subject has a cardiovascular disability status of New York Heart Association Class greater or equal to Class 2 is defined as cardiac disease in which patients are comfortable at rest but ordinary physical activity, results in fatigue, palpitations, dyspnea or anginal pain.- Subject has a significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, or hepatic disease that in the opinion of the Investigator would adversely affect his/her participating in this study.",ct_exc_472146,AACT,560,NCT01594229,Historical,CHOP
5c7430608625dd0457867fa1,70,,,116,Patient,13:52.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_398599,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Patients with newly diagnosed CD20+ DLBCL - 65 years old or over - Scheduled to receive R-CHOP chemotherapy - Informed consent,ct_inc_398599,AACT,112,NCT02555267,Recent,CHOP
5c7430608625dd0452867f91,40,,,63,Patient,13:52.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_493723,Clinical Trial Inclusion Criteria,UNKNOWN,Patients who had received at least two cycles of rituximab-CHOP or rituximab-CVP as a primary treatment Patients with a history of previous exposure to HBV - HBV surface antigen (HBs Ag) positive Or - HBV core antibody (IgG anti-HBc antibody) positive Patients with documented HBV reactivation (definite or presumptive) occurring during treatment (at least two cycles of R-CHOP or R-CVP) or within 12 months after the last dose of rituximab - Definitive HBV reactivation - Elevation of serum HBV DNA level >1 log IU/mL from baseline or absolute increase of HBV DNA by 6 log10 IU/mL in HBsAg positive patients - Presumptive HBV reactivation - Increase of ALT (3x baseline value or absolute value of 100 U/L) and positive conversion of HBs Ag in previously HBsAg-negative patients,ct_inc_493723,AACT,59,NCT01311232,Historical,CHOP
5c7430618625dd0452867f94,40,,,64,Patient,13:53.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_447673,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Previously untreated NHL suitable for CHOP/R-CHOP treatment - Age range 18-80 years old - HBsAg positive with high level of HBV DNA - Eastern Cooperative Oncology Group performance status 0-2 - Life expectancy of more than 3 months -,ct_inc_447673,AACT,60,NCT01914744,Recent,CHOP
5c7430618625dd043c867fa0,50,,,169,Patient,13:53.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_452271,Clinical Trial Inclusion Criteria,UNKNOWN,Patients who are not transplant eligible or who did not respond to chemotherapy may be considered for the study following a single regimen of chemotherapy such as R-CHOP or R-EPOCH.There,ct_inc_452271,AACT,165,NCT01854606,Recent,CHOP
5c7430628625dd043c867fa3,50,,,130,Patient,13:54.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_486783,Clinical Trial Inclusion Criteria,UNKNOWN,Patients who are not transplant eligible may be considered for the study following a single regimen of chemotherapy such as R-CHOP or R-EPOCH alone.,ct_inc_486783,AACT,126,NCT01402440,Recent,CHOP
5c7430628625dd0452867f9f,40,,,244,Patient,13:54.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_471737,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients will be eligible if the treatment phase consisting in a Rituximab combined with any anthracycline-containing chemotherapy regimen without consolidation with autologous stem cell support (e.g., 6 cycles of CHOP14-21, DA-EPOCH, Mega-CHOP or 12 weeks of VACOP-B or MACOP-B).-",ct_inc_471737,AACT,240,NCT01599559,Hypothetical,CHOP
5c7430628625dd047e867f86,910,,,26,Patient,13:54.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_504403,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - CHOP or CHOP-like anthracycline containing treatment for DLBCL within 6 months prior to registration.- Known central nervous system (CNS) involvement of B-CLL.- Any malignancy that requires active treatment with the exception of basal cell carcinoma and non-invasive squamous cell carcinoma.- Chronic or ongoing active infectious disease requiring systemic treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active hepatitis.- Subjects meeting any of the following criteria must not be enrolled in the",ct_exc_504403,AACT,22,NCT01171378,Historical,CHOP
5c7430638625dd0452867fa6,40,,,193,Patient,13:55.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_359513,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Histological confirmation of relapsed/refractory diffuse large B-cell lymphoma after prior rituximab and anthracycline-containing systemic treatment regimen such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), R-EPOCH (rituximab, etoposide phosphate, prednisone, vincristine sulfate, cyclophosphamide, doxorubicin hydrochloride), R-HyperCVAD (rituximab, cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone) etc.",ct_inc_359513,AACT,189,NCT03064867,Historical,CHOP
5c7430658625dd04aa867f8a,530,,,102,Patient,13:57.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_594611,Clinical Trial Inclusion Criteria,UNKNOWN,"Verification of bone marrow status must be performed at the time of response evaluation following CHOP chemotherapy and within 56 days of study enrollment.- Patients must have been treated with 6 or more cycles of first-line CHOP chemotherapy and have achieved a PR, CRu, or CR.Patients",ct_inc_594611,AACT,98,NCT00022932,Recent,CHOP
5c7430658625dd04aa867f8b,530,,,173,Patient,13:57.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_594611,Clinical Trial Inclusion Criteria,UNKNOWN," must have available computed tomography (CT) scans of the chest, abdomen, and pelvis, and a bone marrow biopsy that were performed within 56 days prior to the start of CHOP.In addition, they must have written documentation (i.e., copies of original medical notes and radiographic reports) describing the pre-CHOP staging evaluation, the number of cycles of CHOP administered, the dose of each agent, the start and stop dates of each cycle, and the post-CHOP response evaluation.",ct_inc_594611,AACT,169,NCT00022932,Historical,CHOP
5c7430658625dd04aa867f8c,530,,,13,Patient,13:57.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_594611,Clinical Trial Inclusion Criteria,UNKNOWN,"The post-CHOP response evaluation must include a CT scan of the chest, abdomen, and pelvis (gallium scan is optional).For patients who have palpable cervical lymphadenopathy, a CT scan of the neck must be performed following CHOP chemotherapy.",ct_inc_594611,AACT,9,NCT00022932,Recent,CHOP
5c7430658625dd04aa867f8d,530,,,8,Patient,13:57.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_594611,Clinical Trial Inclusion Criteria,UNKNOWN,"The CHOP chemotherapy should consist of standard doses of each agent, although dose-reduction is permitted.",ct_inc_594611,AACT,4,NCT00022932,Recent,CHOP
5c7430658625dd04aa867f8e,530,,,4,Patient,13:57.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_594611,Clinical Trial Inclusion Criteria,UNKNOWN,"CHOP cycle delay is also permitted.- The patient must be enrolled within 56 days of the first day of the last cycle of CHOP chemotherapy and within 35 days following response evaluation after CHOP chemotherapy.- Patients must have evidence that their tumor tissue expresses the CD20 antigen.- Patients must have a performance status of at least 60% on the Karnofsky Performance Scale and an anticipated survival of at least 3 months.- Patients must have an ANC greater than or equal to 1500 cells/mm3 and a platelet count greater than or equal to 100,000 cells/mm3 within 14 days of study enrollment.",ct_inc_594611,AACT,0,NCT00022932,Recent,CHOP
5c7430678625dd04c0867f88,30,,,279,Patient,13:59.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_515733,Clinical Trial Inclusion Criteria,UNKNOWN,"Subjects with histologically proven follicular lymphoma (grade 1, 2, or 3a), in clinical relapse/progression requiring treatment - Subjects must have had first line treatment consisting of rituximab with or without rituximab maintenance therapy (i.e.rituximab monotherapy, R-CHOP, R-CVP, R-FND, etc) -",ct_inc_515733,AACT,275,NCT01022255,Recent,CHOP
5c7430678625dd04c0867f8d,30,,,106,Patient,14:00.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_507723,Clinical Trial Inclusion Criteria,UNKNOWN,"Follicular lymphoma patients previously treated with the combination of rituximab and chemotherapy (R-CHOP, R-CVP, R-fludarabine), having received rituximab maintenance, refractory to a first line (excluding radiotherapy) or relapsed after having achieved any response to previous treatment.4.",ct_inc_507723,AACT,102,NCT01127841,Recent,CHOP
5c7430688625dd04c0867f92,30,,,322,Patient,14:00.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_344464,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Complete response of lymphoma (Cheson criteria 2007) after initial treatment - Malin lymphoma (Hodgkin or not) treated with anthracyclines for at least 6 cycles : Adriamycin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) or BEACOPP, Cyclophosphamide, hydroxydaunomycin, Oncovin, and prednisone (CHOP) et Rituximab (R-CHOP), miniCHOP et RminiCHOP, RACVBP having received or not an intensification with autologous hematopoietic stem cell transplantation in first-line - Registered the consent to be included in this study",ct_inc_344464,AACT,318,NCT03260855,Recent,CHOP
5c7430688625dd04c0867f98,30,,,162,Patient,14:00.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_381550,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - DLBCL and concomitant initial CNS involvement - PMBL (primary mediastinal B-cell lymphoma) - treatment with another chemotherapy than R CHOP or DA EPOCH R - HIV positive, or active hepatitis B or C - other concomitant serious disease (based on the decision of the physician-investigator) - non-compliance of a patient - any contraindication for application of anthracycline based chemotherapy or high dose methotrexate - pregnancy or",ct_exc_381550,AACT,158,NCT02777736,Recent,CHOP
5c7430698625dd049f867f8c,960,,,244,Patient,14:01.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_411183,Clinical Trial Inclusion Criteria,UNKNOWN,Diagnosis of Diffuse large B-cell lymphoma (DLBCL) (de novo or DLBCL transformed from follicular lymphoma on the basis of a tissue biopsy).- Received at least one prior therapy for aggressive Non-Hodgkin's Lymphoma (NHL) (DLBCL).- Received CHOP + rituximab or equivalent regimen.- Patients must have measurable disease.- Not eligible or not willing to receive the high-dose (myeloablative) chemotherapy (HDC) and SCT.- A fresh tumor biopsy collected during screening and /or archival tumor tissue collected after the last relapse/disease progression.- ECOG (Eastern Cooperative Oncology Group) performance status (PS) 2.- Left ventricular ejection fraction (LVEF) the lower limit of normal (LLN) for the Institution.(as per local standard of care) as measured by echocardiogram (ECHO) or Multiple gated acquisition (MUGA) scan.-,ct_inc_411183,AACT,240,NCT02391116,Historical,CHOP
5c7430698625dd04cb867f8b,260,,,407,Patient,14:01.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_407198,Clinical Trial Inclusion Criteria,UNKNOWN,"< 3 x upper limit of normal (ULN) - Creatinine =< 2.0 mg/dL OR creatinine clearance (calculated clearance permitted) >= 40 mL/min by Cockcroft-Gault formula - Prothrombin time (PT)/ international normalized ration (INR) < 1.5 x ULN and partial thromboplastin time (PTT) (activated [a]PTT) < 1.5 x ULN - Patient must have progressed or be refractory to prior anthracycline-containing chemotherapy (e.g.R-CHOP, DA-EPOCH-R, etc) -",ct_inc_407198,AACT,403,NCT02443077,Historical,CHOP
5c7430698625dd049f867f8d,960,,,369,Patient,14:01.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_425585,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Diabetic patients - Pregnant or lactated women - Patient with history of thrombosis - Concomitant radiotherapy - Known hypersensitivity to thalidomide, palonosetron, or dexamethasone.- Concurrent administration of any other drug which affect antiemetic effect evaluation such as proton pump inhibitor, H2 blocker, amifostine, sedative drugs - CHOP regiment or taxanes-based regiment - Existing emesis within 24 hours before chemotherapy administration - Symptomatic brain metastasis or suspected clinical brain metastasis - Serious uncontrolled systemic illness or medical",ct_exc_425585,AACT,365,NCT02203253,Historical,CHOP
5c7430698625dd04c0867f9e,30,,,311,Patient,14:01.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_387514,Clinical Trial Inclusion Criteria,UNKNOWN," may enroll in the study based on the local laboratory evaluation, but these should be confirmed by the UNC Hematopathology Laboratory retrospectively - Positive for CD20 via immunophenotyping - Prior Treatment: Previously untreated or who received a maximum of one cycle of combination chemotherapy (i.e.R-CHOP, R-EPOCH, or R-hyperCVAD) within 4 weeks of study entry except patients who require dose reduction after the first cycle of off-study R-EPOCH.- Measurable disease as assessed by 2 dimensional measurements by CT ( 1.5 cm).- Adequate organ function as demonstrated by: - Bone marrow function (without platelet transfusion or myeloid growth factor support within two weeks of screening) as demonstrated by: - Hemoglobin 8 g/dL - Absolute neutrophil count (ANC) 1,000 cells/mm3 - Platelet count 75,000/mm3 - And hepatic and renal function as demonstrated by: - Aspartate aminotransferase (AST) and Alanine Aminotransferase (ALT)",ct_inc_387514,AACT,307,NCT02700022,Historical,CHOP
5c7430698625dd049f867f8e,960,,,82,Patient,14:01.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_365204,Clinical Trial Exclusion Criteria,UNKNOWN,"Maternal donor preferred over paternal donor if both equally haploidentical.- CHOP BMT procedures apply for determining donor eligibility, including donor screening and testing for relevant communicable disease agents and diseases.- Unrelated donor identified through the National Marrow Donor Program (NMDP) and fulfills the NMDP criteria for donation.",ct_exc_365204,AACT,78,NCT02990819,Hypothetical,CHOP
5c74306a8625dd04c0867fa4,30,,,89,Patient,14:02.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_454155,Clinical Trial Inclusion Criteria,UNKNOWN,"Previously untreated for DLBCL - Intended initial treatment to include 2 cycles of R-CHOP, R-EPOCH or R-CEPP using standard doses and schedule.(68, 69) R-CHOP chemoimmunotherapy may be given every 14 days or every 21 days.(4, 70)",ct_inc_454155,AACT,85,NCT01829958,Recent,CHOP
5c74306b8625dd04d6867f87,890,,,513,Patient,14:03.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_347600,Clinical Trial Inclusion Criteria,COMMENT,"a licensed assay refers to a United States (U.S.) Food and Drug Administration (FDA)-approved assay, which is required for all investigational food drug (IND) studies - Only participants whose lymphoma is untreated are allowed for the dose-finding portion; for the dose expansion cohort both untreated and participants who have received a maximum of one cycle of combination chemotherapy, including rituximab-containing regimens R-cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone (CHOP) and R-EPOCH, prior are eligible; the start of previous chemotherapy cycle must occur at least 21 days prior and 28 days maximum to beginning treatment under this protocol, and such cycle will count towards the maximum of 6 cycles under this study (i.e.cycle off study will count as cycle 1) - Eastern Cooperative Oncology Group (ECOG) performance status =< 2",ct_inc_347600,AACT,509,NCT03220022,Historical,CHOP
5c74306b8625dd04cb867f95,260,,,151,Patient,14:03.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_342748,Clinical Trial Inclusion Criteria,UNKNOWN,T-cell/histiocyte-rich DLBCL Subject is considered an appropriate candidate (per Investigator assessment) for induction therapy with 6 cycles of R-CHOP-21 immunochemotherapy.,ct_inc_342748,AACT,147,NCT03283202,Recent,CHOP
5c74306c8625dd04ec867f85,1130,,,127,Patient,14:04.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_348153,Clinical Trial Inclusion Criteria,UNKNOWN,Patients must have received at least one course (1 - 6 cycles) of Immunochemotherapy for example Rituximab + Chemotherapy (CHOP or CHOP like) and must have relapsed or refractory disease at the time of trial entry.,ct_inc_348153,AACT,123,NCT03212807,Recent,CHOP
5c74306d8625dd0506867f85,80,,,116,Patient,14:05.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_348238,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Patients with newly diagnosed CD20+ DLBCL - 65 years old or over - Scheduled to receive R-CHOP chemotherapy - Informed consent,ct_inc_348238,AACT,112,NCT03211702,Recent,CHOP
5c74306d8625dd0506867f87,80,,,87,Patient,14:05.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_536023,Clinical Trial Exclusion Criteria,UNKNOWN,"Patients who are, in the opinion of their treating oncologist, unable to undergo R/CHOP chemotherapy.",ct_exc_536023,AACT,83,NCT00754117,Recent,CHOP
5c74306d8625dd0506867f89,80,,,74,Patient,14:05.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_573486,Clinical Trial Inclusion Criteria,UNKNOWN,"Hodgkins lymphoma, CD20 positive - Chemotherapy treatments planned (R-CHOP) but not started",ct_inc_573486,AACT,70,NCT00256490,Recent,CHOP
5c74306d8625dd0506867f8b,80,,,64,Patient,14:05.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_507469,Clinical Trial Inclusion Criteria,UNKNOWN,- Diagnosis of diffuse large B-cell lymphoma - Treated with CHOP or R-CHOP on ECOG-E4494,ct_inc_507469,AACT,60,NCT01131208,Recent,CHOP
5c74306d8625dd0506867f8d,80,,,217,Patient,14:05.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_548984,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Histologically confirmed, CD20+ B cell diffuse large cell lymphoma, with measurable or evaluable disease - Having no prior chemotherapy, immunotherapy or radiotherapy except for one cycle of CHOP or R-CHOP.",ct_inc_548984,AACT,213,NCT00582725,Historical,CHOP
5c74306d8625dd0506867f8f,80,,,56,Patient,14:05.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_543793,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients receiving either:( Bolus or 48-hr infusion CHOP (cyclophosphamide 750 mg/m^2 IV Day 1, doxorubicin 25 mg/m^2/day IV given as bolus infusion or over 48 hours continuous infusion Days 1-2, vincristine 2 mg IV Day 1, prednisone PO 100 mg * 5 days) OR ( Bolus or 48-hr infusion R-CHOP (Rituximab 375mg/m^2 on Day 1+ CHOP as above).(For patients receiving R-CHOP, CHOP may be administered starting on Day 2 at the discretion of the treating physician Age",ct_inc_543793,AACT,52,NCT00651755,Recent,CHOP
5c74306d8625dd0506867f92,80,,,128,Patient,14:05.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_372257,Clinical Trial Inclusion Criteria,UNKNOWN,Adults treated for diffuse large B-cell lymphoma: - Diagnosed between 2010 and 2015 - Having received immuno-chemotherapy R-CHOP - Supported in the health facilities of the Languedoc-Rousillon,ct_inc_372257,AACT,124,NCT02898870,Recent,CHOP
5c74306d8625dd0506867f94,80,,,138,Patient,14:05.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_318598,Clinical Trial Inclusion Criteria,UNKNOWN,Adults treated for diffuse large B-cell lymphoma: - Diagnosed between 2010 and 2015 - Included in ProLyPhy search - Having received R-CHOP immuno-chemotherapy - Supported in health facilities in Languedoc-Rousillon Exclusion criterion:,ct_inc_318598,AACT,134,NCT03597685,Recent,CHOP
5c74306d8625dd0506867f96,80,,,27,Patient,14:06.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_567818,Clinical Trial Inclusion Criteria,UNKNOWN,"- Recently completed R-CHOP therapy and achieved remission - International Prognostic Index (IPI) score 3,4,5 - At least 18 years of age - Agree to study follow-up schedule",ct_inc_567818,AACT,23,NCT00332202,Recent,CHOP
5c74306e8625dd04f7867f8e,550,,,30,Patient,14:06.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_549060,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - All CHOP primary care,ct_inc_549060,AACT,26,NCT00581711,Recent,CHOP
5c74306e8625dd04f7867f8f,550,,,66,Patient,14:06.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_549060,Clinical Trial Inclusion Criteria,UNKNOWN,"We expect 35,000 patients to receive care for otitis media by CHOP clinicians at these sites during the study period however, they are not the subjects of this research.",ct_inc_549060,AACT,62,NCT00581711,Recent,CHOP
5c74306e8625dd04ec867f86,1130,,,152,Patient,14:06.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_582675,Clinical Trial Inclusion Criteria,UNKNOWN,"allowed provided patient had a remission duration of < 1 year after administration of any established, multi-agent chemotherapy regimen (e.g., CVP, CHOP, or rituximab in combination with CHOP) - Intermediate- or high-grade NHL allowed provided patient is ineligible for autologous SCT according to the criteria listed above - Multiple myeloma - Myelodysplastic syndromes - Paroxysmal nocturnal hemoglobinuria - Chronic myeloproliferative disorders other than CML, including any of the following: - Chronic myelomonocytic leukemia - Agnogenic myeloid metaplasia (or myeloid metaplasia with myelofibrosis), with hemoglobin < 10 g/dL OR WBC",ct_inc_582675,AACT,148,NCT00134004,Recent,CHOP
5c74306e8625dd0518867f85,100,,,79,Patient,14:06.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_363268,Clinical Trial Inclusion Criteria,UNKNOWN,"Men must agree not to father a child during the therapy, - 6 to 8 cycles R-CHOP/like, total of 8 x Rituximab, - CR, CRu",ct_inc_363268,AACT,75,NCT03016000,Recent,CHOP
5c74306e8625dd0518867f87,100,,,42,Patient,14:06.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_562710,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - 4 to 8 cycles R-CHOP/like, total of 8x Rituximab - CR, CRu - ECOG/ 0.1 or 2 - Known IPI at time of diagnosis - Age",ct_inc_562710,AACT,38,NCT00400478,Recent,CHOP
5c74306e8625dd04ec867f87,1130,,,32,Patient,14:06.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_539769,Clinical Trial Inclusion Criteria,UNKNOWN,"This includes 3-6 cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or an equivalent, CHOP-like regimen +/-",ct_inc_539769,AACT,28,NCT00704691,Recent,CHOP
5c74306f8625dd0518867f89,100,,,82,Patient,14:07.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_505427,Clinical Trial Inclusion Criteria,UNKNOWN,- Patients that achieved a complete (CR) or partial response (PR) after 6th R-CHOP chemotherapy - Aged over 18 years - ECOG performance status 0-2.,ct_inc_505427,AACT,78,NCT01157988,Recent,CHOP
5c7430708625dd0532867f84,1310,,,617,Patient,14:08.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_570928,Clinical Trial Inclusion Criteria,UNKNOWN,"- In second or greater CR - No morphologic relapse or persistent disease - Chronic myelogenous leukemia (CML), excluding refractory blast crisis - Advanced myelofibrosis - Advanced myelodysplasia (blasts < 10% [otherwise need AML induction pre-transplant]",ct_inc_570928,AACT,613,NCT00290641,Historical,CHOP
5c7430708625dd0518867f92,100,,,233,Patient,14:08.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_477514,Clinical Trial Inclusion Criteria,UNKNOWN,"Patient age is 18 years Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 2 Patient has a history of DLBCL according to the WHO classification Patient has progressive disease after receiving at least CHOP-R or CHOP-R like first line regimen, standard second line therapy (DHAP, ESHAP, ICE or similar salvage regimens) inclusive ASCT Patient has progressive disease after receiving at least CHOP-R or CHOP-R like first line regimen and is not considered eligible for intensive salvage therapy including ASCT because of age, co-morbidities, impossibility to perform ASCT Patient undergoes at baseline new lymphnode or other pathologic tissue biopsy for confirmation of diagnosis and biologic studies; bone marrow biopsy is not adequate for this purpose and should be performed only for staging.",ct_inc_477514,AACT,229,NCT01523834,Historical,CHOP
5c7430718625dd052e867f84,1300,,,188,Patient,14:09.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_326607,Clinical Trial Inclusion Criteria,DIAGNOSES,"Previously received 1 or more appropriate systemic therapies (eg, non-anthracycline based regimens such as L asparaginase-based therapy) for cohort 1 and combination chemotherapy (eg, CHOP, EPOCH, or similar therapy) for cohort Radiation therapy alone would not be acceptable previous therapy.",ct_inc_326607,AACT,184,NCT03493451,Recent,CHOP
5c7430728625dd0544867f96,280,,,144,Patient,14:10.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_586830,Clinical Trial Inclusion Criteria,UNKNOWN,"No more than 1 prior combination chemotherapy regimen Chemotherapy consisted of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or a CHOP-like regimen, ACVBP, or other similar regimen",ct_inc_586830,AACT,140,NCT00002905,Historical,CHOP
5c7430728625dd052e867f85,1300,,,283,Patient,14:10.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_588816,Clinical Trial Inclusion Criteria,COMMENT,"Biologic therapy - Prior rituximab immediately after the first chemotherapy regimen allowed Chemotherapy - See Disease Characteristics - See Biologic therapy - At least 6 months since prior anthracycline therapy (e.g., cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP]) - More than 2 years since prior fludarabine - More than 2 years since prior nitrosoureas - More than 1 year since prior platinum-based chemotherapy or cytarabine, unless a CR or CR_u was achieved - No prior cumulative dose of cisplatin",ct_inc_588816,AACT,279,NCT00069966,Historical,CHOP
5c7430728625dd0518867f98,100,,,598,Patient,14:10.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_591468,Clinical Trial Inclusion Criteria,UNKNOWN,"- Histologically proven intermediate- or high-grade non-Hodgkin's lymphoma - Ann Arbor classification of bulky stage II, III, or IV - Must be classified as high-intermediate or high-risk according to International Age Adjusted Index - Bidimensionally meas",ct_inc_591468,AACT,594,NCT00004031,Hypothetical,CHOP
5c7430728625dd0518867f9a,100,,,115,Patient,14:10.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_591468,Clinical Trial Inclusion Criteria,PULMONARY_REVIEW,Biologic therapy: - No prior monoclonal antibody therapy for lymphoma except if included in a single course of CHOP/CHOP-R,ct_inc_591468,AACT,111,NCT00004031,Hypothetical,CHOP
5c7430728625dd0518867f9c,100,,,71,Patient,14:10.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_591468,Clinical Trial Inclusion Criteria,CHEMOTHERAPEUTICS,- No prior chemotherapy for lymphoma except for a single course of CHOP/CHOP-R*,ct_inc_591468,AACT,67,NCT00004031,Historical,CHOP
5c7430738625dd0518867fa3,100,,,123,Patient,14:11.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_328750,Clinical Trial Inclusion Criteria,UNKNOWN,Histologically the first large-scaled B-cell lymphoma patient Diagnosis time 65 years old or older Patients planning R-CHOP chemotherapy,ct_inc_328750,AACT,119,NCT03465527,Recent,CHOP
5c7430748625dd052e867f86,1300,,,959,Patient,14:12.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_480780,Clinical Trial Inclusion Criteria,UNKNOWN,"At least one measurable lymph node mass that is > 1.5 cm in two perpendicular dimensions and that has not been previously irradiated or has grown since previous irradiation - Dominant lymph node masses include up to 6 nodal masses that are clearly measurable in 2 perpendicular dimensions and > 1.5 cm in each dimension - Measurement may be by radiographic imaging - If there are lymph node masses in the mediastinum or pelvis larger than 1.5 cm in 2 perpendicular dimensions, they should always be chosen as dominant masses - The dominant masses should be from as disparate regions of the body as possible - Measurable sites of disease are also extra-nodal sites such as splenic nodules and hepatic nodules that are thought to contain lymphoma, and are greater than 1 cm in the longest transverse dimension - Must have received at least two prior treatment lines; there is no maximal limit on the number of prior therapies - Prior treatment must include CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone)-like chemotherapy in combination with rituximab - Rituximab used alone is not considered as a separate regimen - Salvage treatment, mobilization chemotherapy, high-dose chemotherapy, and planned post-transplant therapy should be considered as one regimen - Relapsed or refractory patients who are candidates for high-dose chemotherapy and autologous or allogeneic stem cell transplantation are not eligible - Tumor tissue sample must be available for pathological review - No known CNS involvement - ECOG performance status < 2 (Karnofsky > 60%) - Life expectancy >",ct_inc_480780,AACT,955,NCT01481129,Historical,CHOP
5c7430748625dd052e867f87,1300,,,85,Patient,14:12.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_469672,Clinical Trial Inclusion Criteria,COMMENT,Patients ages 22-24 will only be enrolled if they are currently being treated at CHOP or another pediatric facility/oncologist Expected survival > 12 weeks Creatinine < 2.5 mg/dl and less than 2.5x normal for age 5.,ct_inc_469672,AACT,81,NCT01626495,Hypothetical,CHOP
5c7430768625dd052e867f88,1300,,,174,Patient,14:14.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_502688,Clinical Trial Exclusion Criteria,UNKNOWN,"Participants who have received more than one (1) prior cycle of chemotherapy similar to cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (CHOP) or EPOCH with or without rituximab - Absolute CD4 count of < 50 cells/ mm^3 - Presence of second active tumor, other than non-melanoma skin cancer, carcinoma in situ of the cervix, or Kaposi's sarcoma (KS) that requires systemic therapy - Central nervous system (CNS) involvement by lymphoma including parenchymal brain or spinal cord lymphoma or known presence of leptomeningeal disease prior to registration - Participants with viral hepatitis who do not meet the criteria will not be eligible; all participants who present with acute hepatitis B including those with normal transaminases who are HBsAg+ and IgM + for hepatitis core antigen will not be eligible; participants who are hepatitis B core antibody positive are eligible only if they start or are on prophylactic therapy; a hepatitis B viral load should be confirmed negative on all participants who are hepatitis B core antibody positive, but hepatitis B antigen negative; participants refusing to take any anti-hepatitis B therapy during study will also be excluded; participants diagnosed with hepatitis C are eligible if they meet criteria - Pregnant women or nursing mothers - ECOG performance score >= 3",ct_exc_502688,AACT,170,NCT01193842,Hypothetical,CHOP
5c7430778625dd052e867f89,1300,,,4,Patient,14:15.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_490594,Clinical Trial Inclusion Criteria,UNKNOWN,CHOP:,ct_inc_490594,AACT,0,NCT01352520,Recent,CHOP
5c7430778625dd057f867f84,810,,,196,Patient,14:15.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_538649,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Written informed consent - Age 18 years - Patients with previously untreated diffuse large B-cell lymphoma (DLBCL) who are scheduled to receive rituximab 375 mg/m^2 plus CHOP (cyclophosphamide, hydroxydaunorubicin [also called doxorubicin or adriamycin], Oncovin [vincristine], prednisone or prednisolone) chemotherapy, or previously untreated follicular non-Hodgkin lymphoma (NHL) who are scheduled to receive rituximab 375 mg/m^2 plus CVP (cyclophosphamide, vincristine, prednisolone) chemotherapy - Eastern Cooperative Oncology Group (ECOG) performance status 0-2",ct_inc_538649,AACT,192,NCT00719472,Recent,CHOP
5c7430778625dd0574867f8a,270,,,96,Patient,14:15.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_424770,Clinical Trial Inclusion Criteria,UNKNOWN,"Further, at the investigator's discretion and for patients who are unstable, one cycle of R-CHOP is allowed prior to enrollment but no more than one cycle.",ct_inc_424770,AACT,92,NCT02213913,Historical,CHOP
5c7430778625dd0574867f8c,270,,,625,Patient,14:15.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_511903,Clinical Trial Inclusion Criteria,UNKNOWN,"Able to provide written informed consent - Eastern Cooperative Oncology Group (ECOG) performance status <=2 - Estimated life expectancy >=6 months - Serum creatinine of <=2.0 mg/dL or creatinine clearance >=50 mL/min - Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 2.5* upper limit of normal (ULN), and alkaline phosphatase and total bilirubin within normal limits - Left ventricular ejection fraction (LVEF) >=50% by multiple gated acquisition scan (MUGA) or cardiac echocardiogram (ECHO), prior for any patient to be treated with rituximab/cyclophosphamide/doxorubicin/vincristine/prednisolone (R-CHOP) -",ct_inc_511903,AACT,621,NCT01073163,Historical,CHOP
5c7430778625dd057f867f85,810,,,359,Patient,14:15.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_545546,Clinical Trial Inclusion Criteria,UNKNOWN,Cardiac arrests occurring in the PICU or ED at The Children's Hospital of Philadelphia equipped with the MRx/Q-CPR - Patient experiencing the arrest must be greater than or equal to 8 years old and receive chest compressions with the Q-CPR sensor employed Clinical Staff Inclusion Criteria: - All clinical staff who participate in resuscitation events in CHOP's ICU or ED,ct_inc_545546,AACT,355,NCT00628693,Recent,CHOP
5c7430778625dd0574867f8e,270,,,130,Patient,14:15.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_526716,Clinical Trial Inclusion Criteria,UNKNOWN,">= 50% by multiple gated acquisition scan (MUGA) or cardiac echocardiogram (ECHO), prior for any patient to be treated with R-CHOP - A medically accepted method of contraception to be used by women of childbearing potential (not surgically sterile or at least 12 months naturally postmenopausal) -",ct_inc_526716,AACT,126,NCT00877006,Historical,CHOP
5c7430788625dd052e867f8a,1300,,,229,Patient,14:16.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_586376,Clinical Trial Inclusion Criteria,UNKNOWN,"Non-Hodgkin's Lymphoma may be entered if they are refractory to or have relapsed following conventional chemotherapy regimens such as alkylating agents (e.g.chlorambucil and cyclophosphamide), anthracycline combinations [e.g.CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)], and/or purine analogues (e.g.fludarabine monophosphate and 2-CDA) and are not currently being considered for re-treatment with conventional regimens - Patients with CLL and other leukemic malignancies will be staged according to the modified Rai staging criteria [low-risk, intermediate-risk and high risk].All patients in the high-risk group (Stage III and IV) are eligible.",ct_inc_586376,AACT,225,NCT00088101,Hypothetical,CHOP
5c7430798625dd052e867f8b,1300,,,357,Patient,14:17.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_586061,Clinical Trial Inclusion Criteria,UNKNOWN,"chemotherapy regimen without restriction on dose Emetogenic agents must be given as part of cyclophosphamide-based or carboplatin-based regimen on day 0 and not at another time within the 72 hour period Cyclophosphamide, carboplatin, or doxorubicin must be the first emetogenic agent given No cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen",ct_inc_586061,AACT,353,NCT00005024,Recent,CHOP
5c7430798625dd058e867f84,760,,,195,Patient,14:17.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_502543,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - in inpatient mental health treatment - report a suicide attempt in the past month - have a primary caretaker willing to participate in aftercare - are able to travel to CHOP - have no history of psychosis or low intellectual capacity - speak adequate English.,ct_inc_502543,AACT,191,NCT01195740,Historical,CHOP
5c7430798625dd058a867f84,1100,,,903,Patient,14:17.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_577025,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - WHO performance of 3 or more - Known anti-murine antibody (HAMA) reactivity or known hypersensitivity to murine antibodies - Leukocytes <2.0x 10^9/l or thrombocytes <100x 10^9/l, unless clearly related to mantle cell lymphoma (MCL) bone marrow infiltration - Patients previously treated for lymphoma - Patients without measurable lesions; if, for example only bone marrow infiltration, patients may be included, but can only undergo a second randomization in case of a CR - Patients with stage I disease - Patients with central nervous system involvement - Patients with a history of autoimmune hemolytic anaemia or autoimmune thrombocytopenia - Patients with serious cardiac disease (uncontrolled arrhythmias, unstable angina, severe congestive heart failure) - Patients with serious pulmonary, neurological, endocrinological or other disorder interfering with full dosing of CHOP or FC chemotherapy - Liver enzymes >3x normal or bilirubin >2.5x normal (not due to lymphoma)",ct_exc_577025,AACT,899,NCT00209209,Historical,CHOP
5c7430798625dd058e867f85,760,,,5,Patient,14:17.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_491850,Clinical Trial Inclusion Criteria,UNKNOWN,"(CHOP)operating room (OR), PICU and NICU where hemoglobin measurements are anticipated.",ct_inc_491850,AACT,1,NCT01335919,Recent,CHOP
5c7430798625dd058e867f86,760,,,89,Patient,14:17.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_535492,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: Male and Female patients age 0 to 18 years old Spinal surgery at CHOP between 4/1/07 and 3/31/08 Complete CompuRecord Anesthesia documentation Use of Propofol and Remifentanil infusions as primary anesthetic technique,ct_inc_535492,AACT,85,NCT00761072,Recent,CHOP
5c7430798625dd058e867f87,760,,,153,Patient,14:17.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_550819,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Burkitt lymphoma - Posttransplant lymphoproliferation - Previous treatment (up to one cycle of standard pretreatment with COP, CHOP or steroids permitted and latter mandatory to decrease tumor burden and/or improve performance status) -",ct_exc_550819,AACT,149,NCT00558220,Recent,CHOP
5c7430798625dd058e867f88,760,,,107,Patient,14:18.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_583716,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Age 65 years and older; - Diagnosis of Non-Hodgkin's lymphoma where therapy with CHOP plus rituximab is considered;,ct_inc_583716,AACT,103,NCT00120198,Recent,CHOP
5c74307b8625dd058a867f85,1100,,,80,Patient,14:19.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_590548,Clinical Trial Inclusion Criteria,CHEMOTHERAPEUTICS,"- No prior chemotherapy except 1 course of preinduction chemotherapy (e.g., CHOP [cyclophosphamide, doxorubicin, vincristine, and prednisone] or a related regimen)",ct_inc_590548,AACT,76,NCT00040690,Historical,CHOP
5c74307c8625dd058a867f86,1100,,,36,Patient,14:20.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_588034,Clinical Trial Inclusion Criteria,RENAL_REVIEW,No medical contraindications to CHOP chemotherapy or rituximab No prior malignancy within past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix No AIDS or HIV,ct_inc_588034,AACT,32,NCT00005089,Historical,CHOP
5c74307c8625dd05b6867f89,10,,,234,Patient,14:20.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_478558,Clinical Trial Inclusion Criteria,UNKNOWN,"Patient is 60-years of age or older at time of randomization Histologically confirmed Ann Arbor stage II, III, or IV DLBCL; or FCL Grade 3B according to the REAL/WHO classification (from initial diagnosis made prior to starting R-CHOP therapy).Results from a pre R-CHOP marrow shall be available for review.",ct_inc_478558,AACT,230,NCT01510184,Historical,CHOP
5c74307c8625dd05b6867f8a,10,,,114,Patient,14:20.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_478558,Clinical Trial Inclusion Criteria,UNKNOWN,Patients who received pre-phase therapy for the purpose of improving performance status prior to initiating R-CHOP are eligible.(See CRF Manual for further clarification).,ct_inc_478558,AACT,110,NCT01510184,Historical,CHOP
5c74307c8625dd05b6867f8b,10,,,157,Patient,14:20.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_478558,Clinical Trial Inclusion Criteria,UNKNOWN,"Bone marrow cellularity greater than 15%, no evidence of myelodysplasia morphologically and no evidence of involvement with lymphoma either at the pre R-CHOP marrow or on repeat assessment pre-Zevalin.",ct_inc_478558,AACT,153,NCT01510184,Recent,CHOP
5c74307c8625dd058a867f87,1100,,,671,Patient,14:20.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_485836,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Transformed lymphoma (follicular IIIB) if previously treated with chemotherapy or immunotherapy - Prior therapy for diffuse large B-cell lymphoma except for nodal biopsy or local irradiation - Central nervous system (CNS) lymphoma, primary mediastinal large cell lymphoma, primary cutaneous lymphoma, primary effusion lymphoma - Patients who received cytotoxic drugs or rituximab as part of their treatment for another condition (e.g.rheumatoid arthritis) or prior use of an anti-CD20 antibody - Chemotherapy or other investigational therapy within 28 days prior to the start of Cycle 1 - Contraindication to any of the individual components of CHOP, including prior receipt of anthracyclines - History of severe allergic or anaphylactic reactions to monoclonal antibody therapy - History of other malignancy, except for curatively treated basal or squamous cell carcinoma or melanoma of the skin or in situ carcinoma of the cervix, or malignancy treated with or without curative intent and in remission without treatment for 2 years prior to enrolment - Positive for hepatitis B, hepatitis C, human immunodeficiency virus (HIV) or human T-cell leukemia virus",ct_exc_485836,AACT,667,NCT01414855,Historical,CHOP
5c74307c8625dd055a867f8a,1320,,,57,Patient,14:20.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_319420,Clinical Trial Inclusion Criteria,UNKNOWN,"If given cytotoxic chemotherapy (one cycle only, e.g.CHOP), this cycle of treatment will count toward the 6 cycles of treatment given in the study.7.",ct_inc_319420,AACT,53,NCT03586999,Hypothetical,CHOP
5c74307c8625dd058a867f88,1100,,,99,Patient,14:20.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_480132,Clinical Trial Inclusion Criteria,UNKNOWN,Subjects will be accepted to the study if they have had a positive food challenge conducted at CHOP in the three months prior to the start of the study.,ct_inc_480132,AACT,95,NCT01489553,Hypothetical,CHOP
5c74307d8625dd058a867f89,1100,,,340,Patient,14:21.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_467931,Clinical Trial Exclusion Criteria,UNKNOWN,"Patients positive for HCV antibody are eligible only if polymerase chain reaction testing for HCV ribonucleic acid is negative.- History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products - Contraindication to any of the individual components of CHOP, including prior receipt of anthracyclines - Prior treatment with cytotoxic drugs or rituximab for another condition (e.g.rheumatoid arthritis) or prior use of an anti-CD20 antibody - Pregnant or lactating women",ct_exc_467931,AACT,336,NCT01649856,Hypothetical,CHOP
5c74307d8625dd058a867f8a,1100,,,182,Patient,14:21.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_524811,Clinical Trial Inclusion Criteria,UNKNOWN,"-diffuse large cell de novo or transformed or follicular lymphoma grade IIIb Stage II, III, IV according to Ann Arbor criteria Chemoresistant disease after first line treatment (CHOP-like + Rituximab) or relapsed patients after one or two lines of chemoth",ct_inc_524811,AACT,178,NCT00902525,Recent,CHOP
5c74307d8625dd058a867f8b,1100,,,696,Patient,14:21.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_532719,Clinical Trial Exclusion Criteria,PAST_MEDICAL_HISTORY,"e.g.- Severe, unmanageable complications such as sepsis, pneumonia with oxygen deficiency, - Shock, hemorrhage at the time of diagnosis - Renal insufficiency from leukemia/lymphoma-unrelated causes - Severe cardiac or hepatic insufficiency - Severe obstructive or restrictive lung disease that would compromise patient's treatment with intensified chemotherapy - HIV infection - Secondary lymphoma following prior chemotherapy/ radiotherapy or an active second malignancy - Known severe allergy to foreign proteins - Cytostatic pretreatment for B-ALL/lymphoma (exceptions: short-term administration of steroids = 7 days, single administration of vincristine or cyclophosphamide, one cycle of CHOP, a single administration in an emergency of other cytostatic agents) for another malignant disease within the last 5 years - Pregnancy/ nursing period - Severe psychiatric illness or other circumstances giving ground to the assumption that a patient cannot give his consent to therapy or act co-operatively - Absence of patient's informed consent - Participation in another clinical study that would possibly interfere with study therapy",ct_exc_532719,AACT,692,NCT00797810,Historical,CHOP
5c74307d8625dd055a867f8b,1320,,,577,Patient,14:21.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_477430,Clinical Trial Inclusion Criteria,UNKNOWN,"No concurrent use of drugs or foods that are known strongCYP3A4 inhibitors - No concurrent use of drugs that are known potent CYP3A4 inducers,within 12 days prior to first dose of crizotinib - No concomitant intercurrent illnesses - Effective contraception method (if applicable) Disease-specific inclusion criteria for patients with anaplastic large cell lymphoma - Patient may have received previous systemic treatment, surgery and/or radiotherapy for localized, locally advanced or advanced disease.- Patient must have received previous systemic chemotherapy (usually a CHOP-like multidrug combination, if not medically contraindicated, with or without monoclonal antibodies), and may not qualify for further conventional therapy with curative intent.- No pretreatment limitations (including autologous or allogeneic stem",ct_inc_477430,AACT,573,NCT01524926,Historical,CHOP
5c74307d8625dd058a867f8c,1100,,,103,Patient,14:21.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_467684,Clinical Trial Inclusion Criteria,UNKNOWN,Prior treatment must have included at least 3 cycles of anthracycline containing chemotherapy (e.g.CHOP-like) -,ct_inc_467684,AACT,99,NCT01653067,Historical,CHOP
5c74307e8625dd058a867f8d,1100,,,5,Patient,14:22.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_586603,Clinical Trial Inclusion Criteria,UNKNOWN,(CHOP) chemotherapy,ct_inc_586603,AACT,1,NCT00004192,Recent,CHOP
5c74307e8625dd05b6867f93,10,,,211,Patient,14:22.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_415115,Clinical Trial Inclusion Criteria,UNKNOWN,"With a diagnosis formally established of DLBCL or transformed straightaway follicular lymphoma or 3B grade follicular lymphoma or Burkitt-like lymphoma - Eligible to a treatment by immunochemotherapy like R-CHOP, R-ACVBP or R-CHOP like - First line of treatment - Being able to benefit from standard extension assessment ( Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET) and bone marrow biopsy with a bone marrow aspiration)",ct_inc_415115,AACT,207,NCT02339805,Recent,CHOP
5c74307e8625dd05b6867f97,10,,,67,Patient,14:22.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_583905,Clinical Trial Inclusion Criteria,UNKNOWN,"Chemotherapy combinations may include, but are not limited to: CHOP (Cyclophosphamide, doxorubicin, vincristine, prednisone), R-CHOP (Rituximab, Cyclophosphamide, doxorubicin, vincristine, prednisone), FCM (Fludarabine, cyclophosphamide, mitoxantrone), R-FCM (Rituximab,Fludarabine, cyclophosphamide, mitoxantrone), ICE(Ifosfamide, carboplatin, etoposide), DHAP (Dexamethasone, cisplatin, cytarabine) and hyper-CVAD (Cyclophosphamide, doxorubicin, vincristine, dexamethasone).",ct_inc_583905,AACT,63,NCT00117598,Recent,CHOP
5c74307e8625dd05c1867f85,870,,,209,Patient,14:22.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_374663,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Participation in another interventional clinical trial in the past 3 months.- Known allergic reactions against monoclonal antibody or rituximab.- Contraindication to any component of CHOP regimen.- Previous treatment for DLBCL, including chemotherapy, immunotherapy, partial radiotherapy for lymphoma, or surgical treatment (excluding tumor mass biopsies and surgical resection for non-lymphoma lesions), or prior use of any monoclonal antibody within 3 month.- History of cytotoxic drugs treatment or anti-CD20 monoclonal antibody treatment for other disease",ct_exc_374663,AACT,205,NCT02867566,Historical,CHOP
5c74307e8625dd05c1867f86,870,,,144,Patient,14:23.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_416676,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria Primary Subjects: Any physician or nurse practioner caring for an intervention patient or control patient in the PICU at CHOP Secondary Subjects: - Low acuity patients as determined by Optilink Guidelines - High alarm patients (top 10-20%) - Admission to the PICU,ct_inc_416676,AACT,140,NCT02319421,Recent,CHOP
5c74307f8625dd05c1867f87,870,,,126,Patient,14:23.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_438277,Clinical Trial Inclusion Criteria,UNKNOWN,In 20th week of pregnancy - Plan to receive their child's primary care services from Children's Hospital of Philadelphia (CHOP) Care Network - Own a smartphone with both a data and text plan - Able to use their phone to obtain photographs and videos prior to enrollment,ct_inc_438277,AACT,122,NCT02037490,Historical,CHOP
5c74307f8625dd05b6867f9d,10,,,89,Patient,14:23.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_570297,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients whose therapy was switched to (R)Hyper-CVAD after initial treatment with (R)CHOP, because of aggressive disease will also be eligible for the study.",ct_inc_570297,AACT,85,NCT00299182,Recent,CHOP
5c74307f8625dd05b6867fa1,10,,,446,Patient,14:23.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_362663,Clinical Trial Inclusion Criteria,UNKNOWN,"Subject has provided informed consent prior to initiation of any study-specific activities/procedures - Age 18 at time of informed consent - Subject must have untreated, histologically proven high-risk DLBCL defined by IPI 3 to 5 and/or Double-hit or higher or double protein expression - Eastern Cooperative Oncology Group performance status 2.- Subject meets the criteria per investigator's institution to receive SOC R-chemotherapy (ie, R-CHOP",ct_inc_362663,AACT,442,NCT03023878,Historical,CHOP
5c74307f8625dd05c1867f88,870,,,113,Patient,14:23.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_451245,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - prior radiation, prior biological therapy, or prior chemotherapy other than first-line CHOP - active bilateral obstructive hydronephrosis - New York Heart Association class III or IV heart disease or other serious illness - prior malignancy other than lymphoma (except for adequately treated skin cancer, in situ cervical cancer, or other cancer for which they had been disease-free for >5 years) - human immunodeficiency virus infection - HAMA positive - brain or leptomeningeal metastases at any time since diagnosis - active infection requiring intravenous anti-infectives - pregnant or breastfeeding",ct_exc_451245,AACT,109,NCT01868035,Historical,CHOP
5c74307f8625dd05b6867fa6,10,,,361,Patient,14:23.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_490450,Clinical Trial Inclusion Criteria,UNKNOWN,"Platelet count 100x109/L Absolute Neutrophil count 1.0x109/L; Serum bilirubin 1.5 x ULN AST (SGOT) or ALT 1.5 x ULN Creatinine clearance (Cockcroft-Gault) > 50 ml/min - Relapsed or refractory DLBCL in which all participants must have received at least one potentially curative established immunochemotherapy lymphoma regimen that contained rituximab (e.g.R-CHOP, R-PMitCEBO, R-GCVP, R-CNOP).Participants must also have failed or be ineligible for salvage/high dose therapy.- Relapsed or refractory DLBCL proven by biopsy (within 6 months of enrolment in trial); either de novo DLBCL or transformed follicular lymphoma.-",ct_inc_490450,AACT,357,NCT01354392,Recent,CHOP
5c74307f8625dd05c1867f89,870,,,199,Patient,14:23.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_442898,Clinical Trial Inclusion Criteria,UNKNOWN,"BMI >= 25, calculated using self-reported pre-pregnancy height and weight) - Subjects able to speak, read and write in English - Attend their infant's (up to 1 month old) primary care visit at a CHOP Primary Care Network site - Received prenatal care - Own a smartphone with both a data and text plan - Able to use their phone to obtain photographs and videos prior to enrollment",ct_inc_442898,AACT,195,NCT01977105,Historical,CHOP
5c7430808625dd05b6867fac,10,,,6,Patient,14:24.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_508134,Clinical Trial Inclusion Criteria,LABORATORY_AND_RADIOLOGY_DATA,R-CHOP:,ct_inc_508134,AACT,2,NCT01122472,Recent,CHOP
5c7430808625dd05b6867fad,10,,,428,Patient,14:24.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_508134,Clinical Trial Inclusion Criteria,LABORATORY_AND_RADIOLOGY_DATA,Patients with DLBCL associated with some small cell infiltration in bone marrow may also be included Or CD20+ B-cell lymphoma with intermediate features between DLBCL and Burkitt or with intermediate features between DLBCL and classical Hodgkin lymphoma Or CD20+ Follicular lymphoma grade 3B Or CD20+ Aggressive B-cell lymphoma unclassifiable - Have reached a CR or PR after first line treatment with at least 6 cycles of R-CHOP 14 regimens and up to 8 cycles of R-CHOP21 - Previously untreated with Radiotherapy For all patients: - aged from 60 to 80 years at time of registration - Ann Arbor stages II-IV at time of initial diagnosis - aaIPI> 1 at time of initial diagnosis - ECOG performance status 0-2 - Minimum life expectancy of 3 months - Following laboratory values at,ct_inc_508134,AACT,424,NCT01122472,Recent,CHOP
5c7430808625dd05c1867f8a,870,,,320,Patient,14:24.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_570657,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: Age 12 months through 18 years History of asthma defined as 2 or more prior physician visits at which bronchodilators were prescribed Persistent symptoms identified by an asthma control tool based on the NAEPP Guidelines and developed and validated by a multidisciplinary team of clinicians from CHOP Allergy, Pulmonary Medicine, General Pediatrics and Emergency Medicine.",ct_inc_570657,AACT,316,NCT00294398,Historical,CHOP
5c7430808625dd05c1867f8b,870,,,87,Patient,14:24.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_559696,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria: - Previous antineoplastic treatment other than the 6 cycles of CHOP for the initial treatment of DLBCL - Positive HIV serology - Positive serology of HCV with the presence of HCV RNA of chronic hepatitis - Positive serology of HBV with the presence of HBV RNA of chronic hepatitis - Serum creatinine or bilirubin > 2.5 x upper limit of,ct_exc_559696,AACT,83,NCT00440583,Recent,CHOP
5c7430808625dd05b6867fb1,10,,,141,Patient,14:24.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_486155,Clinical Trial Inclusion Criteria,UNKNOWN,"All patients must have a histologic or cytological diagnosis of de novo DLBCL and be scheduled to receive first line chemotherapy with R-CHOP given every 21 days (R-CHOP-21) within 6 weeks of their enrollment and for 6 cycles.- Patients must be >=18 years of age, but there will be no discrimination based on gender, race, creed, or ethnic background.- Patients must have an ECOG performance status of 0-2.- Patients must sign an informed consent, and be mentally responsible.",ct_inc_486155,AACT,137,NCT01410630,Recent,CHOP
5c7430828625dd05f1867f86,1000,,,36,Patient,14:26.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_327246,Clinical Trial Exclusion Criteria,UNKNOWN,"Contraindicative to any drug in CHOP, or to anthracycline;Patients with diabetes and intolerant to the prednisone in this study.",ct_exc_327246,AACT,32,NCT03485118,Recent,CHOP
5c7430828625dd05f1867f87,1000,,,104,Patient,14:26.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_327246,Clinical Trial Exclusion Criteria,UNKNOWN,Susceptible to allergies or allergic to anyactive ingredients or excipients in the trial (including CHOP) or murine source products ormedication (including CHOP) including active ingredients or excipients or rat source products or heterogeneous proteins.,ct_exc_327246,AACT,100,NCT03485118,Recent,CHOP
5c7430838625dd05f1867f88,1000,,,458,Patient,14:27.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_583876,Clinical Trial Inclusion Criteria,UNKNOWN,Fine needle aspirates are not acceptable.1.1.2 Failure to submit pathology specimens within 60 days of patient registration will result in the patient being declared ineligible.1.2 Institutional flow cytometry or immunohistochemistry must confirm CD20 antigen expression.1.3 Patients classified as high risk according to the Follicular Lymphoma International Prognostic Index (FLIPI) should be considered for CALGB 50102/SWOG S0016 (A Phase III Trial of CHOP vs CHOP + Rituximab vs CHOP + Iodine-131-Labeled Monoclonal Anti-B1 Antibody [Tositumomab],ct_inc_583876,AACT,454,NCT00117975,Recent,CHOP
5c7430868625dd05e2867f97,330,,,105,Patient,14:30.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_571855,Clinical Trial Inclusion Criteria,UNKNOWN,"Recurrent disease - Patients must have received 1 induction regimen containing anthracyclines (e.g., CHOP [with or without rituximab] or R-EPOCH) - Chemosensitive disease at the time of relapse - Patients who responded with a complete or partial remission that lasted at least 8 weeks after their last chemotherapy regimen are considered chemosensitive - Measurable disease, defined as a lymph node or a nodal mass of > 1 cm in its longest transverse diameter on CT scan - Ineligible for, refused, or relapsed after stem cell transplant (for patients with non-mantle cell lymphoma) -",ct_inc_571855,AACT,101,NCT00278382,Recent,CHOP
5c7430878625dd0628867f85,90,,,39,Patient,14:31.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_567818,Clinical Trial Exclusion Criteria,UNKNOWN,"Have received therapy other than R-CHOP for lymphoma - Serious medical condition such as infection,second cancer,heart disease - Received radiation to more than one lesion - Unable to swallow tablets",ct_exc_567818,AACT,35,NCT00332202,Recent,CHOP
5c7430878625dd0628867f88,90,,,121,Patient,14:31.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_453093,Clinical Trial Inclusion Criteria,UNKNOWN,Pre-phase therapy with prednisolone and/or vincristine for < one week duration prior to commencement of cycle 1 of R-CHOP is permissible,ct_inc_453093,AACT,117,NCT01843868,Historical,CHOP
5c7430878625dd0628867f89,90,,,26,Patient,14:31.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_453093,Clinical Trial Inclusion Criteria,UNKNOWN,Intended to receive R-CHOP every 14 or 21 days for minimum 3 cycles with rituximab planned to be given with CHOP on day 1 or fractionated over days 1 and 21.,ct_inc_453093,AACT,22,NCT01843868,Recent,CHOP
5c7430878625dd0628867f8c,90,,,467,Patient,14:31.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_568389,Clinical Trial Inclusion Criteria,UNKNOWN,"Advanced stage disease defined as - patients with stage III or stage IV disease; or patients with stage I or stage II disease with one of the following additional criteria: B-symptoms, or disease that is not radio- encompassable within a single involved field, or not a candidate for brief chemotherapy and irradiation, or the presence of bulky disease (any single mass => 10 cm) - Previously untreated or treated with up to 3 cycles of standard dose 3- weekly R-CHOP chemotherapy prior to enrollment (i.e.patients may be enrolled prior to initiation of the fourth cycle of R-CHOP chemotherapy) - ECOG Performance",ct_inc_568389,AACT,463,NCT00324467,Historical,CHOP
5c7430878625dd0628867f8d,90,,,50,Patient,14:31.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_568389,Clinical Trial Inclusion Criteria,UNKNOWN,No evidence of progressive disease while on R-CHOP chemotherapy -,ct_inc_568389,AACT,46,NCT00324467,Recent,CHOP
5c7430888625dd0628867f90,90,,,74,Patient,14:32.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_372893,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically confirmed diffuse large B cell lymphoma treated with R-CHOP(Rituximab, Cyclophosphamide, Adriamycin, Vincristine, Prednisolone) chemotherapy 2.",ct_inc_372893,AACT,70,NCT02890602,Recent,CHOP
5c7430888625dd0628867f91,90,,,61,Patient,14:32.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_372893,Clinical Trial Inclusion Criteria,UNKNOWN,"< 10.0 g/dL are shown at least 3 cycles after starting R-CHOP(Rituximab, Cyclophosphamide, Adriamycin, Vincristine, Prednisolone)",ct_inc_372893,AACT,57,NCT02890602,Recent,CHOP
5c7430898625dd0628867f99,90,,,637,Patient,14:33.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_367053,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Follicular lymphoma with histology documented by the participating institution (grades 1, 2 or 3a).For subjects with presumptive evidence of transformation based on clinical assessment of factors such as, but not limited to, increasing lactate dehydrogenase (LDH), rapidly worsening disease, or frequent B-symptoms, a pre-treatment biopsy is required to rule out large cell transformation - Completion of a full course of first line immunochemotherapy including rituximab OR completion of 4 cycles of first line immunochemotherapy including rituximab if intolerant (e.g.which include, but are not limited to, R-CHOP, R-CVP,",ct_inc_367053,AACT,633,NCT02966730,Hypothetical,CHOP
5c7430898625dd0628867f9b,90,,,70,Patient,14:33.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_552923,Clinical Trial Inclusion Criteria,UNKNOWN,Stage 3 or 4 and elevated LDH - No more than one prior cycle of R-CHOP chemotherapy - Adequate cardiac function -,ct_inc_552923,AACT,66,NCT00530179,Historical,CHOP
5c7430898625dd0628867f9d,90,,,97,Patient,14:33.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_413963,Clinical Trial Exclusion Criteria,UNKNOWN,"Other subtype of lymphoma except DLBCL - DLBCL patients who are NOT suitable for receiving R-CHOP chemotherapy OR plan to receive other chemotherapy - patients had been treated with antiviral therapy known to have activity against HBV (e.g., alpha-interferon, lamivudine, telbivudine, clevudine, adefovir, entecavir or tenofovir) within the previous 6 months.- evidence of hepatocellular carcinoma.- evidence of decompensated liver disease",ct_exc_413963,AACT,93,NCT02354846,Historical,CHOP
5c7430898625dd0628867f9f,90,,,259,Patient,14:33.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_360281,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - confirmed diagnosis of MCL (hematopathologic examination in the reference centre, with evidence of cyclin D1 or translocation t(11;14) ) - not eligible for high-dose therapy with autologous stem cell transplantation - eligible for R-CHOP or R-COEP-based therapy - signed informed consent form with the study and data processing",ct_inc_360281,AACT,255,NCT03054883,Recent,CHOP
5c74308a8625dd0642867f88,610,,,136,Patient,14:34.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_314105,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - English speaking - Adult caregiver accompanying pediatric patient in the Children's Hospital of Philadelphia (CHOP) emergency department,ct_inc_314105,AACT,132,NCT03656146,Recent,CHOP
5c74308a8625dd0642867f89,610,,,153,Patient,14:34.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_493931,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - History of airway compromise - Undergoing microlaryngoscopy, bronchoscopy, esophagoscopy, and esophageal pH probe placement at CHOP",ct_inc_493931,AACT,149,NCT01308502,Historical,CHOP
5c74308b8625dd063e867f84,1010,,,417,Patient,14:35.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_369948,Clinical Trial Inclusion Criteria,PATIENT_NAME,"Donor must be at least 6 months of age - Donor suitable for bone marrow collection and meets eligibility for donation, including fulfilling infectious disease criteria as per SOP, including HIV, Hepatitis B, Hepatitis C Polymerase chain reaction (PCR) negative.- If subject has confirmed iBMF syndrome, donor must be evaluated for this disorder and testing must be negative - Children's Hospital of Philadelphia (CHOP) bone marrow transplant",ct_inc_369948,AACT,413,NCT02928991,Hypothetical,CHOP
5c74308b8625dd063e867f85,1010,,,205,Patient,14:35.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_369948,Clinical Trial Inclusion Criteria,PATIENT_NAME,"(BMT) procedures apply for determining donor eligibility, including donor screening and testing for relevant communicable disease agents and diseases.- Donor evaluation and collection procedure as per CHOP Standard Operating Procedures (SOP)",ct_inc_369948,AACT,201,NCT02928991,Recent,CHOP
5c74308b8625dd063e867f86,1010,,,4,Patient,14:35.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_546743,Clinical Trial Inclusion Criteria,UNKNOWN,"CHOP).- Mantle zone lymphoma after any progression following initial therapy (>CR1, > PR1).At least one prior therapy of intermediate intensity (e.g.",ct_inc_546743,AACT,0,NCT00612716,Historical,CHOP
5c74308b8625dd063e867f87,1010,,,4,Patient,14:35.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_546743,Clinical Trial Inclusion Criteria,UNKNOWN,"CHOP).- Intermediate grade lymphoma (>PR2).Response duration <1 year from prior therapy.- High-grade Non-Hodgkin's Lymphoma (NHL) (IWF H, I, J) after initial therapy if >stage III at diagnosis; after any progression even if localized (stage I, II) at diagnosis with prior response duration < 1 year.- Recent chemotherapy responsiveness after treatment with > 3 intermediate intensity regimens.- Advanced Hodgkin's disease beyond PR2 (>CR3, >",ct_inc_546743,AACT,0,NCT00612716,Historical,CHOP
5c74308c8625dd065b867f8a,20,,,21,Patient,14:36.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_533302,Clinical Trial Inclusion Criteria,UNKNOWN,"Any variation of CHOP (R-CHOP-14, R-CHOP-21) is acceptable.",ct_inc_533302,AACT,17,NCT00790036,Recent,CHOP
5c74308d8625dd065b867f92,20,,,106,Patient,14:37.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_560048,Clinical Trial Inclusion Criteria,UNKNOWN,"Diagnosis of DLBCL.- Received at least one combination chemotherapy regimen with rituximab, such as R-CHOP, R-ESHAP or equivalent.- Progression or relapse since most recent therapy.-",ct_inc_560048,AACT,102,NCT00435916,Recent,CHOP
5c74308d8625dd065b867f96,20,,,73,Patient,14:37.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_540944,Clinical Trial Inclusion Criteria,UNKNOWN,"Previously treated with chemotherapy regimen containing rituximab: R CHOP or R ACVBP - Chemo-sensitive disease - PET Scan prior transplant - Eligible for autologous stem cell transplantation - With a minimum life expectancy of 3 months.- Negative HIV, HBV and HCV serologies (in the last 4 weeks except after vaccination).- Having previously signed a written informed consent.",ct_inc_540944,AACT,69,NCT00689169,Historical,CHOP
5c74308d8625dd0666867f84,750,,,123,Patient,14:37.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_437337,Clinical Trial Inclusion Criteria,UNKNOWN,Caregiver is English speaking Child is 2-6 years old Caregiver reports that child has a behavior problem Child attends CHOP South Philadelphia Primary Care for primary care Parental/guardian permission is provided (informed consent),ct_inc_437337,AACT,119,NCT02049749,Recent,CHOP
5c74308e8625dd0666867f85,750,,,211,Patient,14:38.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_336564,Clinical Trial Inclusion Criteria,UNKNOWN,"AYA is 15-29 year old with a history of a malignant cancer diagnosis; - Completed cancer treatment and are currently in remission or receiving cancer survivorship care; - Seen for follow-up oncology care at CHOP or Penn; - For AYA less than 18 years old, must have a caregiver to provide informed consent.",ct_inc_336564,AACT,207,NCT03363711,Historical,CHOP
5c74308e8625dd0666867f86,750,,,154,Patient,14:38.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_326400,Clinical Trial Inclusion Criteria,UNKNOWN,Adolescent Criteria: Inclusion Criteria: Teens age 13 to 15 years at the time of their upcoming well-child visit Children's Hospital of Philadelphia (CHOP) primary care patient.,ct_inc_326400,AACT,150,NCT03496155,Recent,CHOP
5c74308e8625dd0666867f87,750,,,5,Patient,14:38.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_317883,Clinical Trial Exclusion Criteria,UNKNOWN,(CHOP study #16-012631).- Inability to understand and speak Spanish - Severe cognitive impairment or severe psychiatric disease which would prohibit the answering of study questions,ct_exc_317883,AACT,1,NCT03606993,Recent,CHOP
5c74308e8625dd0666867f88,750,,,339,Patient,14:38.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_577784,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Serious secondary diseases, including psychiatric conditions, under which the required therapy compliance is not to be expected - HIV infection - Secondary lymphoma following prior chemotherapy/radiotherapy or active second malignancy - Known severe allergy to foreign proteins - Pre-treatment other than 1 cycle CHOP or similar; < 1 week of another chemotherapy.-",ct_exc_577784,AACT,335,NCT00199082,Historical,CHOP
5c74308e8625dd0666867f89,750,,,143,Patient,14:38.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_589978,Clinical Trial Inclusion Criteria,UNKNOWN,#NAME?,ct_inc_589978,AACT,139,NCT00057447,Recent,CHOP
5c74308e8625dd0666867f8a,750,,,45,Patient,14:38.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_504995,Clinical Trial Inclusion Criteria,UNKNOWN,Scheduled to undergo elective surgery at CHOP American Society of Anesthesiologists (ASA) Physical Status,ct_inc_504995,AACT,41,NCT01163656,Recent,CHOP
5c74308f8625dd0666867f8b,750,,,145,Patient,14:39.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_511899,Clinical Trial Inclusion Criteria,UNKNOWN,(BMI) of 28 kg/m2 - Adolescent expresses desire to lose weight - Parent willing to participate - Live within 40 minutes from study clinic at CHOP or 60 minutes at Geisinger,ct_inc_511899,AACT,141,NCT01073215,Recent,CHOP
5c74308f8625dd067c867f84,1110,,,115,Patient,14:39.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_558706,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria: - Previous treatment with chemotherapy or radiation with the exception of up to 1 cycle of CHOP chemotherapy.- Expected survival < 4 months.- ECOG performance status,ct_exc_558706,AACT,111,NCT00453427,Recent,CHOP
5c74308f8625dd0666867f8c,750,,,63,Patient,14:39.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_507142,Clinical Trial Inclusion Criteria,UNKNOWN,Assent of the study subject - Subjects followed within the CHOP Cardiology Division - Operative note(s) available for review in medical record - Have undergone stage,ct_inc_507142,AACT,59,NCT01135485,Recent,CHOP
5c7430908625dd067c867f85,1110,,,72,Patient,14:40.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_559696,Clinical Trial Inclusion Criteria,UNKNOWN,No prior antibody therapy for lymphoma - Chemotherapy : 6 cycles of CHOP - Endocrine therapy : Not specified -,ct_inc_559696,AACT,68,NCT00440583,Historical,CHOP
5c7430908625dd0666867f8d,750,,,89,Patient,14:40.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_524049,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - adult (age 18 and older) who has decision making authority for CHOP patient who has been referred to the Pediatric Advanced Care Team (PACT) for palliative care services, and with a child(ren) age 6-11 years who is a sibling of the patient - any race/ethnicity",ct_inc_524049,AACT,85,NCT00912626,Recent,CHOP
5c7430918625dd065b867fa5,20,,,153,Patient,14:41.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_381550,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - histologically confirmed DLBCL - age 18-72 years - signed informed consent with the study - first-line treatment 6 cycles of R CHOP +2x R or 6 cycles of DA EPOCH R+ 2xR,ct_inc_381550,AACT,149,NCT02777736,Recent,CHOP
5c7430988625dd06c9867f84,1220,,,84,Patient,14:48.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_501783,Clinical Trial Exclusion Criteria,UNKNOWN,"Known allergic reactions against foreign proteins Subjects for whom 8 cycles of CHOP might be problematic, and have the following findings/conditions, should not be enrolled: - Cardiac contra-indication to doxorubicin: Left ventricular ejection fraction (LVEF)",ct_exc_501783,AACT,80,NCT01205737,Recent,CHOP
5c7430998625dd06c9867f85,1220,,,109,Patient,14:49.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_533412,Clinical Trial Exclusion Criteria,UNKNOWN,"Any other serious active disease - General status that does not allow the administration of 8 courses of CHOP according to the investigator - Positive serology for HIV, Hepatitis B or Hepatitis C - Medical or psychiatric conditions that compromise the patient's ability to give informed consent - Bevacuzumab related criteria: - No major surgery, major trauma or open biopsy within 28 days prior to study entry.",ct_exc_533412,AACT,105,NCT00788606,Historical,CHOP
5c7430998625dd06c9867f86,1220,,,181,Patient,14:49.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_584484,Clinical Trial Inclusion Criteria,UNKNOWN,"- Diagnosis of peripheral T-cell non-Hodgkin's lymphoma - Newly diagnosed, relapsed or progressing disease after 1 prior treatment with a non-platinum based chemotherapy (e.g., CHOP) -",ct_inc_584484,AACT,177,NCT00109928,Historical,CHOP
5c74309a8625dd06c9867f87,1220,,,171,Patient,14:50.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_585181,Clinical Trial Inclusion Criteria,UNKNOWN,"Received at least two previous treatment regimens for FL or relapsed, or progressed, while on or following cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or anthracycline-based regimen for DLBCL subjects Solid tumor subjects must have histologically or cytologically confirmed solid tumor that is either measurable or evaluable and refractory to standard treatment or fow which no curative treatment exists.- Eastern Cooperative Oncology Group (ECOG)",ct_inc_585181,AACT,167,NCT00100347,Recent,CHOP
5c74309a8625dd06df867f8c,850,,,76,Patient,14:50.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_563281,Clinical Trial Inclusion Criteria,COMMENT,"- Seven consecutive days of steroids alone or in combination with a non-CHOP regimen necessary for patient stabilization (e.g., cyclophosphamide and steroids steroids for normalization of disease-related hyperbilirubinemia) - One course of CHOP or fractio",ct_inc_563281,AACT,72,NCT00392834,Recent,CHOP
5c74309b8625dd06c9867f88,1220,,,123,Patient,14:51.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_586231,Clinical Trial Inclusion Criteria,UNKNOWN,"First relapse from a complete response or complete response unconfirmed after a front line chemotherapy regimen (e.g., CHOP-like regimen)",ct_inc_586231,AACT,119,NCT00003957,Recent,CHOP
5c74309c8625dd06df867f8d,850,,,119,Patient,14:52.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_485391,Clinical Trial Exclusion Criteria,UNKNOWN,"Patient has: - Precursor T/NK neoplasms - ALCL (ALK+) with IPI score less than 2 at initial diagnosis and CR after CHOP-based therapy - T cell prolymphocytic leukemia - T cell large granular lymphocytic leukemia - Mycosis fungoides, except tMF - Szary syndrome - Primary cutaneous CD30+ disorders: ALCL and lymphomatoid papulosis -",ct_exc_485391,AACT,115,NCT01420679,Recent,CHOP
5c74309c8625dd06df867f8e,850,,,478,Patient,14:52.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_485391,Clinical Trial Exclusion Criteria,UNKNOWN,"Patients with malignancies listed below less than 5 years before study entry may be enrolled if they have received treatment resulting in complete resolution of the cancer and have no clinical, radiologic, or laboratory evidence of active/recurrent disease.- non-melanoma skin cancer - carcinoma in situ of the cervix - localized prostate cancer - localized thyroid cancer - Receipt of prior chemotherapy (CT) or radiation therapy (RT) for PTCL, other than a single allowed CHOP regimen, except: - Patients with nasal NK lymphoma who received local RT less than 4 weeks prior to randomization.- Patients with tMF who received 1 systemic single-agent CT (except methotrexate) prior to transformation.- Prior exposure to pralatrexate.- Receipt of systemic corticosteroids within 3 weeks of study treatment, unless patient has been taking a continuous dose of 10 mg/day or less of oral prednisone or equivalent for at least 4 weeks or as part of a CHOP prednisone taper.- Planned use of any treatment for PTCL during the course of the study.- Patient has: - Human immunodeficiency virus (HIV)-positive diagnosis with a CD4 count of less than 100 mm3 or detectable viral load within past 3 months and receiving anti-retroviral therapy.- Hepatitis B (HBV)-positive serology and is receiving interferon therapy or has liver function test results outside the parameters of study inclusion criteria.",ct_exc_485391,AACT,474,NCT01420679,Historical,CHOP
5c74309d8625dd06df867f8f,850,,,736,Patient,14:53.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_586196,Clinical Trial Inclusion Criteria,UNKNOWN,"- Grade 1, 2, or 3 - Meets 1 of the following criteria for treatment with rituximab: - Treatment nave - Relapsed or refractory disease after prior chemotherapy - Relapsed after a prior documented response (i.e., complete or partial response) to rituximab ",ct_inc_586196,AACT,732,NCT00089115,Historical,CHOP
5c74309d8625dd06df867f90,850,,,5,Patient,14:53.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_586196,Clinical Trial Inclusion Criteria,COMMENT,*CHOP followed by rituximab at time of relapse is considered 2 treatment regimens - No history of CNS lymphoma or meningeal lymphomatosis,ct_inc_586196,AACT,1,NCT00089115,Historical,CHOP
5c74309d8625dd06df867f91,850,,,175,Patient,14:53.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_586196,Clinical Trial Inclusion Criteria,COMMENT,"- At least 4 weeks since prior chemotherapy - More than 9 months since prior fludarabine - More than 2 years since prior chemotherapy/rituximab combination therapy (e.g., CHOP/rituximab or cyclophosphamide, vincristine, and prednisone [CVP]/rituximab) - N",ct_inc_586196,AACT,171,NCT00089115,Historical,CHOP
5c74309d8625dd0700867f85,200,,,114,Patient,14:53.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_498671,Clinical Trial Exclusion Criteria,UNKNOWN,"HIV-positive or infectious hepatitis type A, B or C. Candidates eligible for intensive rescue therapies (ex.R-CHOP plus alemtuzumab, allogenic transplant)",ct_exc_498671,AACT,110,NCT01246557,Recent,CHOP
5c74309d8625dd0700867f87,200,,,74,Patient,14:53.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_544374,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria: - Contraindication to any drug contained in the R-CHOP (Rituximab/Cyclophosphamide/Doxorubicin/Vincristine/Prednisone +/-,ct_exc_544374,AACT,70,NCT00644124,Recent,CHOP
5c74309e8625dd0700867f89,200,,,194,Patient,14:54.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_586213,Clinical Trial Exclusion Criteria,UNKNOWN,The safety of Zevalin in this population has not been tested at this time - Serious coexisting medical condition or active infection which would compromise the ability to deliver standard R-CHOP chemotherapy - Evidence of myelodysplasia on bone marrow aspiration and biopsy,ct_exc_586213,AACT,190,NCT00088881,Recent,CHOP
5c74309e8625dd06f5867f8c,440,,,191,Patient,14:54.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_516131,Clinical Trial Inclusion Criteria,UNKNOWN,"Patient must have evaluable or measurable disease - Have failed prior treatment, as evidenced by 1 of the following: - Aggressive NHL - Failed at least 1 regimen containing rituximab and CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) (unless anthracyclines are contraindicated) in addition to another salvage regimen (unless it is determined by the treating physician that it is to the patient's best interest to receive valproic acid after the first relapse)",ct_inc_516131,AACT,187,NCT01016990,Historical,CHOP
5c74309e8625dd070b867f88,510,,,352,Patient,14:54.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_520262,Clinical Trial Inclusion Criteria,UNKNOWN,"- Histologically confirmed diagnosis of one of the following: - Hodgkin or non-Hodgkin lymphoma (including small lymphocytic lymphoma [SLL]) - Any histology, including B, T, or NK/T cell allowed - Multiple myeloma (MM) - Relapsed or refractory disease - P",ct_inc_520262,AACT,348,NCT00962507,Recent,CHOP
5c7430a08625dd0700867f8f,200,,,77,Patient,14:56.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_462885,Clinical Trial Inclusion Criteria,UNKNOWN,Whatever the IPI score and the performance status - Treated by Rituximab-CHOP or Rituximab-mini-CHOP - CT scan imaging performed one month or less before inclusion - Signed informed consent,ct_inc_462885,AACT,73,NCT01715961,Recent,CHOP
5c7430a08625dd0700867f90,200,,,85,Patient,14:56.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_459251,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - The patients treated by other anti-cancer treatment except CHOP regimen or R (Rituximab)-CHOP regimen at 21 days interval - Pregnant or breast feeding woman, fertile woman without appropriate contraception - Patients with hypersensitivity against study drugs - Patients treated by other study medication or co-treatment with anticancer chemotherapy, hormone therapy, and immunotherapy",ct_exc_459251,AACT,81,NCT01763398,Recent,CHOP
5c7430a18625dd070b867f8f,510,,,89,Patient,14:57.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_411514,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Patients who had received anthracycline-based therapy, such as CHOP or CHOP-like regimens, as the initial treatment.- Patients who do not have pathology slides available for central review.",ct_exc_411514,AACT,85,NCT02386813,Recent,CHOP
5c7430a18625dd070b867f90,510,,,125,Patient,14:57.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_573099,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - mantle cell lymphoma at stage II - IV, previously treated with at least one line of prior therapy (CHOP or CHOP-like), measurable disease, age 19 - 75 years, adequate cardiac, liver and renal function tests, patient's written informed consent",ct_inc_573099,AACT,121,NCT00261612,Historical,CHOP
5c7430a28625dd0716867f88,150,,,394,Patient,14:58.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_444230,Clinical Trial Inclusion Criteria,UNKNOWN,"I to stage IV DLBCL at the time of relapsed/refractory disease to be eligible - Measurable or assessable disease is required; measurable tumor size (at least one node measuring 2.25 cm^2 in bidimensional measurement) per computed tomography (CT) scan, other radiological study, and/or physical exam - Patients must have received at least 1 prior rituximab-based immunochemotherapy (e.g., R-CHOP, R-EPOCH, etc.)- >= 2 weeks since major surgery - Patients must not have any significant toxicity associated with prior surgery, radiation therapy, chemotherapy, or immunotherapy, per principal investigator (PI) discretion - Life expectancy >= 3 months - Karnofsky score (KS)",ct_inc_444230,AACT,390,NCT01959698,Historical,CHOP
5c7430a28625dd0716867f8d,150,,,179,Patient,14:58.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_356406,Clinical Trial Inclusion Criteria,UNKNOWN,"Subject has [follicular lymphoma or marginal zone lymphoma that has progressed after at least 2 lines of treatment with combination chemoimmunotherapy] (e.g.R-bendamustine, R-CHOP).",ct_inc_356406,AACT,175,NCT03105336,Recent,CHOP
5c7430a28625dd0737867f85,180,,,303,Patient,14:58.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_519563,Clinical Trial Inclusion Criteria,UNKNOWN,"- Histologically confirmed CD20-positive diffuse large B-cell non-Hodgkin lymphoma (DLBCL) according to the current WHO classification, including all morphological variants - Newly diagnosed disease - Bulky stage IA-IV disease - No non-bulky stage IA dise",ct_inc_519563,AACT,299,NCT00971763,Recent,CHOP
5c7430a28625dd0716867f8f,150,,,116,Patient,14:59.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_436873,Clinical Trial Inclusion Criteria,LABORATORY_AND_RADIOLOGY_DATA,- Participants must have histologically confirmed B-cell NHL - Participants must have never received previous R-CHOP treatment - Any relapsed/refractory participants that are enrolled during the dose escalation should have received only a single previous ,ct_inc_436873,AACT,112,NCT02055820,Recent,CHOP
5c7430a38625dd0716867f91,150,,,45,Patient,14:59.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_335862,Clinical Trial Inclusion Criteria,PATIENT_NAME,with recurrent or relapsed DLBCL after R-CHOP-like theraphy as the firstline therapy.,ct_inc_335862,AACT,41,NCT03372837,Recent,CHOP
5c7430a38625dd0716867f93,150,,,29,Patient,14:59.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_325663,Clinical Trial Inclusion Criteria,UNKNOWN,"Planned treatment with R-CHOP chemotherapy - Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 3 - Life expectancy of greater than 3 months with chemotherapy - Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately - Ability to understand and the willingness to sign an Institutional Review Board (IRB)-approved informed consent document (either directly or via a legally authorized representative)",ct_inc_325663,AACT,25,NCT03505762,Historical,CHOP
5c7430a38625dd0716867f95,150,,,57,Patient,14:59.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_318392,Clinical Trial Inclusion Criteria,UNKNOWN,"At the initial stage of therapy, received standard R-CHOP regimen and complete remission after the first course of treatment;",ct_inc_318392,AACT,53,NCT03600363,Recent,CHOP
5c7430a98625dd077d867f86,170,,,176,Patient,15:05.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_518382,Clinical Trial Inclusion Criteria,UNKNOWN,"Transformed follicular lymphoma - Follicular lymphoma grade 3B - Meets 1 of the following criteria: - Not eligible for anthracycline-based first-line chemotherapy (e.g., R-CHOP) -",ct_inc_518382,AACT,172,NCT00987493,Recent,CHOP
5c7430a98625dd077d867f87,170,,,100,Patient,15:05.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_518382,Clinical Trial Inclusion Criteria,UNKNOWN,"Refractory disease after at least 2 courses of anthracycline-based immune-chemotherapy (e.g., R-CHOP) and patient is not eligible for intensive salvage regimens including HDT with ASCT - Relapsed disease after at least 1 treatment with curative intention and patient is not eligible for intensive salvage regimens including HDT with ASCT - Relapsed disease after HDT with ASCT - Measurable disease defined as 1 lesion 2 cm in greatest transverse diameter on cross-sectional imaging - Must complete pre-treatment cancer-specific geriatric assessment",ct_inc_518382,AACT,96,NCT00987493,Recent,CHOP
5c7430aa8625dd077d867f89,170,,,89,Patient,15:06.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_493515,Clinical Trial Inclusion Criteria,DIAGNOSES,"In the case of de novo diffuse large B-cell lymphoma, prior treatment must include R-CHOP or R-CHOP-like therapy, as well as second line autologous stem cell transplantation unless the patient is not eligible.",ct_inc_493515,AACT,85,NCT01314014,Historical,CHOP
5c7430aa8625dd077d867f8c,170,,,268,Patient,15:06.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_535176,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients with histological confirmation of diffuse large B cell lymphoma with at least one of the following characteristics: - High or intermediate IPI score (See Appendix 8.0 for IPI scoring criteria) - Patients who are still PET scan positive mid therapy with R-CHOP, but, have turned negative after completion of therapy.- Low risk International prognostic index ie., an IPI score of <3 if age >60 years or <2 if age is less than or equal to 60 with c-myc positive by Fluorescent",ct_inc_535176,AACT,264,NCT00765245,Recent,CHOP
5c7430aa8625dd077d867f8d,170,,,104,Patient,15:06.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_535176,Clinical Trial Inclusion Criteria,UNKNOWN,"No other previous lymphoma therapy, hormonal therapy or surgery, except for standard therapy with R-CHOP with or without radiation and with or without prophylactic Methotrexate therapy.",ct_inc_535176,AACT,100,NCT00765245,Recent,CHOP
5c7430ab8625dd078f867f85,350,,,628,Patient,15:07.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_407687,Clinical Trial Inclusion Criteria,UNKNOWN,"Participating centres must designate a local reference expert pathologist who will confirm the diagnosis for the patients enrolled at that centre.- Patients must be CD20+ in order to be eligible for the study.- Clinically and/or radiologically measurable disease (one site bidimensionally measurable).Measurements/ evaluations must be done within 28 days prior to randomization.- Prior FDG-PET scan, if done at baseline, must be positive (known FDG-avid lymphoma) - Patients with de novo aggressive B-cell lymphoma must have relapsed or progressed, or have biopsy proven refractory disease, after 1 prior line of therapy (R-CHOP chemotherapy or equivalent).Patients with histological transformation from low grade lymphoma may have had up to 3 prior treatment regimens.",ct_inc_407687,AACT,624,NCT02436707,Historical,CHOP
5c7430ab8625dd0779867f86,520,,,54,Patient,15:07.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_383625,Clinical Trial Inclusion Criteria,UNKNOWN,Patients must have relapsed or progressed after R-CHOP chemotherapy or equivalent.,ct_inc_383625,AACT,50,NCT02750670,Recent,CHOP
5c7430ac8625dd079a867f87,380,,,115,Patient,15:08.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_572562,Clinical Trial Exclusion Criteria,UNKNOWN,"General status that, in the opinion of the Investigator does not permit the administration of eight courses of CHOP-R/CPOP-R. Treatment with any other investigational study drug within 30 days before randomization.",ct_exc_572562,AACT,111,NCT00268853,Recent,CHOP
5c7430ac8625dd0779867f88,520,,,596,Patient,15:08.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_388947,Clinical Trial Inclusion Criteria,UNKNOWN,"De novo diffuse large B cell lymphoma that fails to achieve a PET negative complete response to primary rituximab and anthracycline based multi-agent chemotherapy and at least maintains stable disease after salvage chemotherapy or present double/triple hit features defined by overexpression by standard immunohistochemistry of c-MYC plus BCL2 and/or BCL6 or presence of chromosomal translocations as detected by break-apart FISH involving IGH/MYC plus IGH/BCL2 and/or IGH/BCL6 and who only received standard chemoimmunotherapy with rituximab, cyclophosphamide, vincristine and prednisone (R-CHOP) for induction and present at least stable disease after consolidation or salvage chemotherapy.",ct_inc_388947,AACT,592,NCT02681302,Recent,CHOP
5c7430ac8625dd0779867f8a,520,,,418,Patient,15:08.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_434793,Clinical Trial Inclusion Criteria,UNKNOWN,"signed written informed consent - Males and females >=18 years of age (at the time consent is obtained).- Tumor type criteria: relapsed/refractory non-Hodgkin's lymphoma (NHL) that meets one of the following criteria: - Germinal Center B cell Diffuse large B cell lymphoma (GCB-DLBCL) relapsed or refractory to at least one prior regimen (e.g., rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone [R-CHOP]) AND not a candidate for standard salvage regimens or autologous or allogeneic stem cell transplant.",ct_inc_434793,AACT,414,NCT02082977,Historical,CHOP
5c7430ad8625dd077d867f94,170,,,316,Patient,15:09.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_422608,Clinical Trial Inclusion Criteria,COMMENT,"Measurable disease is not required, but will be followed if it exists - Patients must have received 4 or more cycles of one of the following prior systemic induction chemotherapy regimens: - Rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunomycin), vincristine sulfate (Oncovin), prednisone (R-CHOP) (with or without alternating rituximab, dexamethasone, cytarabine [ara-c], cisplatin [platinum] [R-DHAP]) with or without autologous (auto) stem cell transplant (SCT) - Hyper-cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride (adriamycin), dexamethasone (CVAD) with or without auto SCT - Bendamustine + rituximab with or without auto SCT - Please",ct_inc_422608,AACT,312,NCT02242097,Hypothetical,CHOP
5c7430ad8625dd07a5867f88,740,,,210,Patient,15:09.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_359728,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Patients with cancers (colorectal, breast) who treated with curative intents and ones with malignant lymphoma who are expected to achieve complete remission with chemotherapy (mainly, CHOP regimen) - Patients without history of diabetes mellitus - Normal glucose tolerance, as defined in the protocol",ct_inc_359728,AACT,206,NCT03062072,Historical,CHOP
5c7430ad8625dd07a5867f89,740,,,60,Patient,15:09.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_393970,Clinical Trial Inclusion Criteria,UNKNOWN,"Patient receives primary care at one of the three urban CHOP primary care practices (Karabots, South Philadelphia, and Cobbs Creek)",ct_inc_393970,AACT,56,NCT02615743,Recent,CHOP
5c7430ad8625dd077d867f98,170,,,81,Patient,15:09.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_394735,Clinical Trial Exclusion Criteria,UNKNOWN,Received 3 previous anticancer regimens prior to enrollment Received prior R-CHOP therapy,ct_exc_394735,AACT,77,NCT02605694,Historical,CHOP
5c7430ad8625dd077d867f99,170,,,98,Patient,15:09.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_394735,Clinical Trial Exclusion Criteria,UNKNOWN,"Previous receipt of any anthracycline Contraindication to any of the individual components of CHOP (cyclophosphamide, vincristine, doxorubicin and prednisone)",ct_exc_394735,AACT,94,NCT02605694,Recent,CHOP
5c7430ad8625dd07a5867f8a,740,,,65,Patient,15:09.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_395608,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically confirmed, new diagnosis of PTCL Eligible for CHOP regimen Measurable disease based on Cheson 2007 criteria Eastern Cooperative Oncology Group (ECOG) performance status",ct_inc_395608,AACT,61,NCT02594267,Recent,CHOP
5c7430ad8625dd07a5867f8b,740,,,105,Patient,15:09.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_429733,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Males or females 18 years admitted to the Children's Hospital of Philadelphia (CHOP) ED or PICU with a known or suspected traumatic head injury undergoing a head CT scan to evaluate for the presence of an intracranial hematoma.- Head injury occurred <12 hours prior to presentation for the initial CT scan, or the subject had a clinical change prompting repeat CT scanning.",ct_inc_429733,AACT,101,NCT02149082,Historical,CHOP
5c7430ad8625dd07a5867f8c,740,,,16,Patient,15:10.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_425457,Clinical Trial Inclusion Criteria,UNKNOWN,Referred to CHOP for the performance of the clinically indicated VCUG examination.,ct_inc_425457,AACT,12,NCT02204917,Recent,CHOP
5c7430ae8625dd07a5867f8d,740,,,107,Patient,15:10.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_381528,Clinical Trial Inclusion Criteria,UNKNOWN,English speaking Child is 2-6 years old Parent reports that child has a behavior problem Child attends CHOP's South Philadelphia Primary Care Center or Karabots Pediatric Care Center for primary care Parental/guardian permission is provided (informed consent),ct_inc_381528,AACT,103,NCT02778022,Recent,CHOP
5c7430ae8625dd078f867f87,350,,,848,Patient,15:10.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_400525,Clinical Trial Inclusion Criteria,UNKNOWN,"WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissues published in 2008; patients with transform lymphoma are excluded; patients with known primary mediastinal large B-cell lymphoma (PMLBCL) are excluded; patients with known c-v-myc avian myelocytomatosis viral oncogene homolog (c-myc) translocation (by fluorescence in situ hybridization) positive DLBCL are eligible for enrollment; c-myc testing prior to study enrollment is not required; availability of diagnostic biopsy samples in encouraged for the exploratory analysis but not required for enrollment; patients with double-hit or triple-hit lymphoma are eligible for enrollment - Previously completed anthracycline-based induction chemotherapy with standard regimens including rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (R-CHOP), dose adjusted (DA)-etoposide, prednisone, vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide (EPOCH), and rituximab (R), and R-hyper cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone, methotrexate, and cytarabine (CVAD); patients need a minimum of 6 cycles of treatment; initial treatment with pidilizumab must be administered between 30-90 days from last dose of induction chemotherapy - Complete remission (CR) according to the Revised Response Criteria for Malignant Lymphoma after first-line treatment - Diagnostic CT scans with contrast of chest, abdomen, and pelvis must have been performed within 8 weeks from the first day of the last cycle of R-chemotherapy; a neck CT will be required if the patient had involvement of the neck region at initial diagnosis - A negative fludeoxyglucose F 18 (FDG)-positron emission tomography (PET)/CT scan performed within 8 weeks from the first day of the last cycle of R-chemotherapy and confirming CR, with negative defined as a score of 1-3 on the Deauville 5-point scale used to quantify radionucleotide density in PET scans as determined locally; PET positive/indeterminate lesions which are confirmed on biopsy to harbor no active lymphoma will be considered negative for determination of CR status -",ct_inc_400525,AACT,844,NCT02530125,Hypothetical,CHOP
5c7430ae8625dd077d867f9b,170,,,449,Patient,15:10.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_326294,Clinical Trial Inclusion Criteria,UNKNOWN,"All subjects must personally sign and date the consent form before initiating any study specific procedures or activities; All subjects must be able to comply with all the scheduled procedures in the study; Histologically or cytologically confirmed CD19 positive non-Hodgkin lymphoma; Chemotherapy-refractory disease, defined as one or more of the following: Relapsed in 6 months after most recent therapy; Progressive disease in the standard R-CHOP or CHOP chemotherapy; Disease progression or relapsed in 12 months of ASCT (must have biopsy proven recurrence in relapsed subjects); If salvage therapy is given post-ASCT, the subject must have had no response to or relapsed after the last line of therapy.",ct_inc_326294,AACT,445,NCT03497533,Hypothetical,CHOP
5c7430af8625dd078f867f89,350,,,170,Patient,15:11.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_589911,Clinical Trial Inclusion Criteria,COMMENT,At least 4 weeks since prior RBC transfusion - No prior biologic therapy - No other concurrent biologic therapy Chemotherapy - No prior chemotherapy (one course of R-CHOP allowed) -,ct_inc_589911,AACT,166,NCT00058422,Historical,CHOP
5c7430af8625dd07bb867f84,1330,,,117,Patient,15:11.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_538642,Clinical Trial Inclusion Criteria,COMMENT,"Exercise is allowed.- Known brain metastasis or primary CNS malignancy - Chronic systemic steroid use (including CHOP therapy or as part of any regular cancer treatment, however, steroids used as prophylaxis for nausea and vomiting are allowed) to prevent rash with Alimta, low dose dexamethasone will be allowed.- Diabetes Type I or II (defined by being on oral hypoglycemics or insulin).- Psychiatric disorder such as severe depression, manic depressive disorder, obsessive compulsive disorder or schizophrenia.(Defined per medical history).- 4 weeks from major surgery to randomization, including any procedure that requires general anesthetic - Any of the following: - Pregnant women - Nursing women - Women of childbearing potential who are unwilling to employ adequate contraception - Pain requiring opioid pain medication, however, over the counter analgesics such as Tylenol or ibuprofen are allowed.- Use of full dose of anticoagulant therapy (Exception: 1 mg/day of Coumadin for preventing catheter clots is allowed).- Use of MAO inhibitors.- Planning to start or complete any type of cancer therapy during the 8 week, double blind, course of the study, once randomized on the study.",ct_inc_538642,AACT,113,NCT00719563,Historical,CHOP
5c7430b08625dd078f867f8b,350,,,381,Patient,15:12.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_457409,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Newly diagnosed aggressive lymphoma or CLL/small lymphocytic lymphoma (SLL) that meets disease specific criteria below: - Study 1 - Aggressive lymphoma - Newly diagnosed de-novo DLBCL or primary mediastinal B-cell lymphoma that will be treated with an anthracycline-containing regimen (rituximab-cyclophosphamide, doxorubicin hydrochloride, prednisone [R-CHOP] or equivalent)",ct_inc_457409,AACT,377,NCT01787409,Recent,CHOP
5c7430b18625dd07c6867f8e,490,,,4,Patient,15:13.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_326400,Clinical Trial Exclusion Criteria,LABORATORY_AND_RADIOLOGY_DATA,CHOP IRB # 15-011732 and/or CHOP IRB #,ct_exc_326400,AACT,0,NCT03496155,Recent,CHOP
5c7430b18625dd07c6867f8f,490,,,189,Patient,15:13.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_326400,Clinical Trial Exclusion Criteria,LABORATORY_AND_RADIOLOGY_DATA,17-013895 Adolescent has sibling enrolled in (IRB 18- Parent Criteria: Inclusion Criteria: Parent or legal guardian of a teen age 13 to 15 years at their upcoming well-child visit at a CHOP primary care practice Exclusion Criteria:,ct_exc_326400,AACT,185,NCT03496155,Recent,CHOP
5c7430b18625dd07c6867f90,490,,,4,Patient,15:13.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_326400,Clinical Trial Exclusion Criteria,LABORATORY_AND_RADIOLOGY_DATA,CHOP IRB # 15-011732 and/or CHOP IRB # 17-013895,ct_exc_326400,AACT,0,NCT03496155,Recent,CHOP
5c7430b28625dd078f867f8d,350,,,105,Patient,15:14.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_412466,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: 1.18 Age < 65 Relapsed/refractory disease after receiving one line of standard R-CHOP like chemotherapy Diffuse Large B-cell Lymphoma at relapse.,ct_inc_412466,AACT,101,NCT02374424,Recent,CHOP
5c7430b28625dd07b0867f8d,840,,,94,Patient,15:14.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_594611,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria: - Patients who have received prior chemotherapy other than first-line CHOP.Patients,ct_exc_594611,AACT,90,NCT00022932,Historical,CHOP
5c7430b28625dd07b0867f8e,840,,,88,Patient,15:14.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_594611,Clinical Trial Exclusion Criteria,UNKNOWN," must not have been treated with radiation, or biological therapy prior to or after CHOP chemotherapy.- Patients with active bilateral obstructive hydronephrosis.- Patients with New York Heart Association class III or IV heart disease or other serious illness that would preclude evaluation.- Patients with prior malignancy other than lymphoma, except for adequately treated skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for 5 years.",ct_exc_594611,AACT,84,NCT00022932,Historical,CHOP
5c7430b38625dd07b0867f8f,840,,,151,Patient,15:15.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_506848,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Patients with histological or cytological confirmation of lymphoma who are previously untreated and are scheduled to receive CHOP alone.,ct_inc_506848,AACT,147,NCT01139359,Recent,CHOP
5c7430b38625dd07b0867f90,840,,,198,Patient,15:15.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_506848,Clinical Trial Inclusion Criteria,UNKNOWN,"Since the objective of the study is the assessment of safety, eligible subjects may have any type of lymphoma (Hodgkin's or non-Hodgkin's, T-cell or B-cell), as long as the scheduled therapy is CHOP alone.- Men and women of 18 years of age.- ECOG performance score",ct_inc_506848,AACT,194,NCT01139359,Recent,CHOP
5c7430b68625dd07fd867f88,210,,,67,Patient,15:18.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_524159,Clinical Trial Inclusion Criteria,UNKNOWN,> 30 mol/L - Severe comorbidity that would preclude the use of CHOP chemotherapy - Ineligible for standard R-CHOP therapy - No cerebral or meningeal involvement,ct_inc_524159,AACT,63,NCT00911183,Recent,CHOP
5c7430b78625dd07fd867f8b,210,,,252,Patient,15:19.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_568560,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Presence of any other malignancy or history of prior malignancy except non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma - Prior radioimmunotherapy, radiation therapy, or any other NHL therapy except first-line CHOP-R - Presence of gastric, central nervous system (CNS), or testicular lymphoma at first diagnosis - Histological transformation of low-grade NHL - Known seropositivity for hepatitis C virus (HCV) or hepatitis B surface antigen (HbsAg) - Known history of HIV infection - Abnormal liver function: total bilirubin",ct_exc_568560,AACT,248,NCT00322218,Historical,CHOP
5c7430b78625dd07fd867f8c,210,,,172,Patient,15:19.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_568560,Clinical Trial Exclusion Criteria,UNKNOWN,"2.5 x ULN within 1 week of randomization - Abnormal renal function: serum creatinine > 2.0 x ULN within 1 week of randomization - Nonrecovery from the toxic effects of CHOP-R therapy - Known hypersensitivity to murine or chimeric antibodies or proteins - G-CSF or GM-CSF therapy within two weeks (or four weeks if pegylated) prior to screening laboratory sampling - Concurrent severe and/or uncontrolled medical disease (e.g., uncontrolled diabetes,congestive heart failure, myocardial infarction within 6 months of study, unstable and uncontrolled hypertension, chronic renal disease, or active uncontrolled infection) which could compromise participation in the study - Male and female patients of child-bearing potential unwilling to practice effective contraception during the study and unwilling or unable to continue contraception for 12 months after their last dose of study treatment - Female patients who are pregnant or are currently breastfeeding - Treatment with investigational drugs less than 4 weeks before the planned Day 1 or nonrecovery from the toxic effects of such therapy - Surgery less than 4 weeks before the planned Day 1 or nonrecovery from the side effects of such surgery - Concurrent systemic corticosteroid use for any reason except as premedication in case of known or suspected allergies to contrast media or as premedication for potential side effects of rituximab treatment - Unwillingness or inability to comply with the protocol",ct_exc_568560,AACT,168,NCT00322218,Recent,CHOP
5c7430b88625dd07fd867f8f,210,,,57,Patient,15:20.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_537364,Clinical Trial Inclusion Criteria,UNKNOWN,"No prior chemotherapy (with the exception of 1 cycle CHOP-R based on current diagnosis, clinical condition, and availability/feasibility of initiating Genasense), immunotherapy, radiotherapy, or investigational therapies for NHL; steroid therapy is allowed only if required for maintenance of another chronic disease (e.g., rheumatoid arthritis) - Patients aged >= 60 years, or patients with a history of coronary artery disease, congestive heart failure, hypertension, diabetes, or hyperlipidemia must have an estimated ejection fraction >= 0.45 (45%) by MUGA or echocardiography, performed within two months of study entry - Patients must be willing to give written informed consent, and sign an institutionally approved consent form prior to initiating genasense or any study related activities (i.e., Genasense & microarray) - Females of childbearing potential must have a negative serum pregnancy test prior to enrollment in the study - Adequate venous access for 7-day continuous infusion - Patients without evidence of severe organ dysfunction as determined within two weeks of 1st cycle of",ct_inc_537364,AACT,53,NCT00736450,Hypothetical,CHOP
5c7430b88625dd07fd867f90,210,,,4,Patient,15:20.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_537364,Clinical Trial Inclusion Criteria,UNKNOWN,CHOP-R:,ct_inc_537364,AACT,0,NCT00736450,Recent,CHOP
5c7430b88625dd081e867f85,110,,,56,Patient,15:20.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_480552,Clinical Trial Exclusion Criteria,UNKNOWN,This does not include patients who have initiated R-CHOP at an outside institution within 2 weeks of enrollment.- Patients using > or = to 10mg/day of steroids for any chronic medical condition - Pregnant or breast-feeding.,ct_exc_480552,AACT,52,NCT01484093,Recent,CHOP
5c7430b88625dd081e867f87,110,,,156,Patient,15:20.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_479387,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Aged at least 18 years of age.- Patients with relapsed or refractory diffuse large B-cell lymphoma who have previously received R-CHOP (or equivalent) chemo-immunotherapy and high dose chemotherapy with stem cell rescue, or who are ineligible for high dose therapy with stem cell rescue.- Measurable disease as defined by Cheson et al 2007",ct_inc_479387,AACT,152,NCT01499303,Recent,CHOP
5c7430b88625dd081e867f89,110,,,223,Patient,15:20.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_544280,Clinical Trial Inclusion Criteria,UNKNOWN,"CD20 Positive diffuse large B cell lymphoma (LBCL) of any stage, including subtypes mediastinal large B cell, centroblastic, immunoblastic, T cell rich B cell and anaplastic B cell lymphoma, who will receive standard R/CHOP as first line chemotherapy will be included.- Patients must be age 18 or older.-",ct_inc_544280,AACT,219,NCT00645359,Recent,CHOP
5c7430b98625dd07fd867f97,210,,,226,Patient,15:21.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_337151,Clinical Trial Inclusion Criteria,UNKNOWN,"according to the WHO classification 2008: - CD30 positive DLBCL, including EBV positive DLBCL - CD30 positive primary mediastinal B-cell lymphoma - Primary refractory to or in first relapse after first line therapy with R-CHOP or R-CHOP",ct_inc_337151,AACT,222,NCT03356054,Recent,CHOP
5c7430ba8625dd083f867f88,240,,,135,Patient,15:22.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_311621,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - CD20 positive diffuse large b-cell lymphoma undergoing treatment with systemic rituximab in combination with CHOP, CHOEP, or EPOCH and deemed high risk of CNS relapse and eligible for central nervous system prophylaxis with intrathecal therapy.",ct_inc_311621,AACT,131,NCT03688451,Recent,CHOP
5c7430ba8625dd083f867f8a,240,,,100,Patient,15:22.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_368828,Clinical Trial Inclusion Criteria,UNKNOWN,All patients with newly diagnosed NHL - Scheduled to receive anthracycline-based therapy of the CHOP/RCHOP type,ct_inc_368828,AACT,96,NCT02943590,Recent,CHOP
5c7430bc8625dd084a867f85,140,,,121,Patient,15:24.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_456023,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: Age 18-65 Relapsed/refractory disease after receiving one line of standard chemoimmunotherapy (R-CHOP, GA-CHOP, R-CHOP like) Diffuse Large B-cell Lymphoma at relapse.",ct_inc_456023,AACT,117,NCT01805557,Recent,CHOP
5c7430bd8625dd0859867f88,1160,,,966,Patient,15:26.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_420580,Clinical Trial Inclusion Criteria,UNKNOWN,"Clearance should be obtained from the site investigator and sponsor if the patient resides more than 2 hours ground travel from the study center Specific for Part 1 - Age at screening between 1 and 7 months - Must have or agree to have placement of feeding tube for enteral access via nasogastric (NG), nasojejunal (NJ), percutaneous gastrostomy (PEG), or percutaneous jejunostomy (PEJ) tube for administration of branaplam (for patients in whom branaplam cannot be administered orally ; NG tube may be removed between doses).Specific for Part 2 - Age at screening between 30 and 180 days of age - Must have or agree to have placement of feeding tube for enteral access via nasogastric (NG), nasojejunal (NJ), percutaneous gastrostomy (PEG), or percutaneous jejunostomy (PEJ) tube for administration of branaplam (for the first administration only and for patients in whom branaplam cannot be administered orally; NG tube may be removed between doses).- Minimum CHOP INTEND score of 15 at baseline - Must be able to feed orally for all nutritional needs and be greater than the 2nd percentile for weight on the standard growth curves for the country of origin",ct_inc_420580,AACT,962,NCT02268552,Recent,CHOP
5c7430be8625dd0859867f89,1160,,,202,Patient,15:26.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_420580,Clinical Trial Exclusion Criteria,UNKNOWN,"Examples are medical disability other than SMA that would interfere with the assessment of safety or would compromise the ability of the subject to undergo study procedures including be assessed by CHOP INTEND motor scale, changes in hematologic parameters or gastrointestinal dysfunction that would compromise the ability of adequate assessment of safety Specific for Part 1 - Use of other investigational drugs within 14 days.- Intractable seizure disorder (other than inactive febrile seizures).- Persistent (in the opinion of the Investigator) hypoxemia (O2 saturation awake <92% or O2 saturation asleep <91%, without ventilation support) or requiring oral suctioning >2 per day, or presence of a tracheostomy.",ct_exc_420580,AACT,198,NCT02268552,Recent,CHOP
5c7430be8625dd0859867f8a,1160,,,86,Patient,15:26.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_383122,Clinical Trial Inclusion Criteria,UNKNOWN,Patients must have received at least one prior standard cytotoxic regimen such as CHOP or EPOCH OR B),ct_inc_383122,AACT,82,NCT02757248,Historical,CHOP
5c7430be8625dd081e867f95,110,,,197,Patient,15:26.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_343958,Clinical Trial Inclusion Criteria,COMMENT,"For example, a patient who started treatment with rituximab/bendamustine and was then switched to rituximab(R)-cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (CHOP) (due to insufficient response or excessive toxicity) would be counted as having received 2 regimens; however, R-CHOP alternating with R-dexamethasone, high-dose cytarabine, and cisplatin (DHAP) as a planned induction regimen would count as one regimen - Patient does not have any documented history of central nervous system (CNS) involvement by mantle cell lymphoma; this includes no evidence of parenchymal brain, spinal cord, or cerebrospinal fluid involvement; radiculopathy symptoms from nerve root compression by lymphoma do not constitute CNS involvement - Patient must have archived formalin-fixed paraffin-embedded (FFPE) tumor tissue specimen from the original diagnostic biopsy available for submission to Adaptive Biotechnologies for ClonoSEQ ID molecular marker identification of unique clonal immunoglobulin deoxyribonucleic acid (DNA) sequence -",ct_inc_343958,AACT,193,NCT03267433,Historical,CHOP
5c7430be8625dd081e867f99,110,,,104,Patient,15:26.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_343958,Clinical Trial Inclusion Criteria,COMMENT,"For example, a patient who started treatment with rituximab/bendamustine and was then switched to R-CHOP (due to insufficient response or excessive toxicity) would be counted as having received 2 regimens; however, R-CHOP alternating with R-DHAP as a planned induction regimen would count as one regimen - Patients must have achieved a radiologic complete or partial remission as defined by the Lugano criteria - Patients must meet institutional eligibility requirements for stem cell transplant, including cardiac, renal, liver, and pulmonary requirements - Patients have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 - Human immunodeficiency virus (HIV) positive patients are not excluded, but to enroll, must meet all of the below criteria: - HIV is sensitive to antiretroviral therapy - Must be willing to take effective antiretroviral therapy if indicated - CD4 count at screening >",ct_inc_343958,AACT,100,NCT03267433,Hypothetical,CHOP
5c7430be8625dd0859867f8b,1160,,,116,Patient,15:26.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_409024,Clinical Trial Inclusion Criteria,UNKNOWN,"Refractory disease or relapse after at least one prior chemotherapy regimen (typically a minimum of 6 cycles of CHOP); presence of measurable disease by physical examination, CT or CT-PET scan.",ct_inc_409024,AACT,112,NCT02419287,Historical,CHOP
5c7430be8625dd084a867f92,140,,,594,Patient,15:26.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_570923,Clinical Trial Inclusion Criteria,UNKNOWN,"Intermediate histology B-cell NHL, including any of the following: - Diffuse large B-cell lymphoma - Transformed large cell lymphoma - Any T-cell NHL histology - Cutaneous T-cell lymphoma (CTCL) or mycosis fungoides (MF) allowed - Relapsed or refractory disease, defined as disease progressed after prior complete remission (CR), partial remission (PR), or stable disease (SD) to last therapy OR failure to achieve CR, PR, or SD after completion of last therapy - Must have received 1-3 prior therapeutic regimens - Cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (CHOP) AND cyclophosphamide, vincristine, and prednisone (CVP) OR CHOP with rituximab (CHOP-R) AND CVP with rituximab (CVP-R) is considered",ct_inc_570923,AACT,590,NCT00290706,Historical,CHOP
5c7430be8625dd0859867f8c,1160,,,269,Patient,15:26.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_436873,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: General Exclusion Criteria: - History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products - Contraindication to receive any of the individual components of CHOP, rituximab or obinutuzumab",ct_exc_436873,AACT,265,NCT02055820,Historical,CHOP
5c7430be8625dd0859867f8d,1160,,,7,Patient,15:26.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_563269,Clinical Trial Inclusion Criteria,UNKNOWN,"* (CHOP)-like therapy allowed, provided the following doses are not exceeded: - Rituximab 750 mg/m - Cyclophosphamide 1,000 mg/m - Doxorubicin hydrochloride 50 mg/m - Vincristine 2 mg/m -",ct_inc_563269,AACT,3,NCT00392990,Recent,CHOP
5c7430bf8625dd081e867f9c,110,,,88,Patient,15:27.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_328940,Clinical Trial Inclusion Criteria,UNKNOWN,3 at diagnosis - Complete metabolic remission (Deauville 1-3) after 6-8 cycles of R-CHOP according to the Lugano criteria,ct_inc_328940,AACT,84,NCT03463057,Recent,CHOP
5c7430bf8625dd081e867f9e,110,,,62,Patient,15:27.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_328940,Clinical Trial Inclusion Criteria,COMMENT,Only dose reductions for vincristine are allowed during R-CHOP Central nervous system prophylaxis by intrathecal therapy is allowed.,ct_inc_328940,AACT,58,NCT03463057,Recent,CHOP
5c7430bf8625dd084a867f95,140,,,129,Patient,15:27.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_568560,Clinical Trial Inclusion Criteria,UNKNOWN,"Ann Arbor stage II, III, or IV DLBCL according to the REAL/WHO classification (from initial diagnosis made prior to starting CHOP-R therapy) -",ct_inc_568560,AACT,125,NCT00322218,Historical,CHOP
5c7430bf8625dd084a867f96,140,,,194,Patient,15:27.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_568560,Clinical Trial Inclusion Criteria,UNKNOWN,"Central pathology review confirming the DLBCL diagnosis and CD20 positivity, and no evidence of DLBCL in bone marrow - First-line treatment of DLBCL must have been 6 or 8 cycles of standard CHOP chemotherapy (cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2 up to a maximum of 2 mg on day 1, and at least 40 mg/m2/day prednisone on Days 1 to 5 every three weeks, with generally accepted adjustments in dose or frequency due to toxicity, patient scheduling, etc.)in combination with rituximab (375 mg/m2) - Complete remission (CR) or unconfirmed complete remission (CRu) according to the International Workshop Response Criteria for NHL described by Cheson et al and modified for this study after first-line treatment with CHOP-R. CT scans of chest, abdomen, pelvis, and neck (if applicable) must have been performed within 6 weeks after the last dose of the last course of CHOP-R. Applicability of the neck CT means that the patient had involvement of the neck region by palpation / physical examination at first diagnosis (pre-CHOP-R).- Central radiographic review of the CT scans (chest, abdomen, pelvis and if applicable, neck) from before and after first-line treatment with CHOP-R fulfilling the radiological requirements for CR/CRu - Patients 60 years of age or older at time of randomization - WHO performance status (PS) of 0 to 2 within 1 week of randomization - Absolute neutrophil count (ANC)greater than or equal to 1.5 x 10^9/L within 1 week of randomization - Hemoglobin (Hgb) greater than or equal to 10 g/dL within 1 week of randomization - Platelets greater than or equal to 150 x 10^9/L within 1 week of randomization - Life expectancy of 3 months or longer - Written informed consent obtained according to local guidelines",ct_inc_568560,AACT,190,NCT00322218,Recent,CHOP
5c7430bf8625dd081e867fa1,110,,,639,Patient,15:27.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_568389,Clinical Trial Exclusion Criteria,UNKNOWN,"Men and women of childbearing age must be using adequate contraception.- Significant renal insufficiency (serum creatinine > 200 mmol/L), unless due to lymphoma - Significant hepatic insufficiency (serum total bilirubin > 30 mmol/L), unless due to lymphoma - Cardiac contraindication to doxorubicin therapy (e.g.abnormal contractility on echocardiography).If history of cardiac disease, ejection fraction must be within normal limits for age.- Neurologic contraindication to vincristine (e.g.peripheral neuropathy) - Absolute neutrophil count <1.5 x 109/L (unless due to bone marrow involvement with lymphoma or due to initiation of R-CHOP chemotherapy) -",ct_exc_568389,AACT,635,NCT00324467,Historical,CHOP
5c7430bf8625dd081e867fa2,110,,,126,Patient,15:27.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_568389,Clinical Trial Exclusion Criteria,UNKNOWN,"Platelet count < 100 x 109/L (unless due to splenomegaly, bone marrow involvement with lymphoma or due to initiation of R-CHOP chemotherapy) -",ct_exc_568389,AACT,122,NCT00324467,Recent,CHOP
5c7430bf8625dd086b867f86,60,,,166,Patient,15:27.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_544280,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria: - Patients will be excluded if the diagnosis of diffuse large B cell lymphoma cannot be confirmed.- Patients receiving treatment other than R/CHOP or R/CHOP followed by radiotherapy or who have previously been treated for DLBCL will be excluded.- Patients with HIV infection will also be excluded.,ct_exc_544280,AACT,162,NCT00645359,Recent,CHOP
5c7430bf8625dd086b867f87,60,,,154,Patient,15:27.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_544280,Clinical Trial Exclusion Criteria,UNKNOWN,"No selection will be made based on other medical problems or laboratory values, except as they affect the patient's eligibility to receive standard R/CHOP chemotherapy as determined by the treating physician.- Patients who have magnetic metal implants or fragments in their body that are incompatible with MRI will be excluded.",ct_exc_544280,AACT,150,NCT00645359,Recent,CHOP
5c7430c08625dd086b867f8e,60,,,89,Patient,15:28.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_367197,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Histological Diagnosis of NHL- DLBCL.- Eligible for RT after R-CHOP.- ECOG 0-3.- 18 - 65 years.- Stage I-IV.- Patients should receive at least 4 cycles of R-CHOP chemotherapy.- Patients with all extranodal disease except the ones mentioned in the,ct_inc_367197,AACT,85,NCT02964858,Recent,CHOP
5c7430c08625dd086b867f91,60,,,304,Patient,15:28.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_329914,Clinical Trial Inclusion Criteria,UNKNOWN,"ole - Able to understand and voluntarily sign consent prior to any study related assessments or procedures - Performance status of 0-2 on the ECOG scale - Adequate organ function as specified in the protocol.- must have received at least one prior CD20 containing multi-agent chemotherapy regimen (R-CHOP, R-EPOCH).Bendamustine and rituximab can be the prior regimen if used for follicular lymphoma or marginal zone lymphoma and susequently transformed to DLBCL.- A pre-phase treatment with prednisoe at 1mg/kg/day or equivalent, for a maximum of 10 days leading up to the first dose of CC-486 is allowed.",ct_inc_329914,AACT,300,NCT03450343,Hypothetical,CHOP
5c7430c08625dd086b867f97,60,,,21,Patient,15:28.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_480999,Clinical Trial Inclusion Criteria,UNKNOWN,Treatment with R-CHOP or R-CHOP like regimens (+/- transplant).,ct_inc_480999,AACT,17,NCT01478269,Recent,CHOP
5c7430c08625dd086b867f99,60,,,65,Patient,15:28.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_536023,Clinical Trial Inclusion Criteria,UNKNOWN,>18 years.- Patients must have a treatment plan to include R/CHOP or R/CHOP followed by radiotherapy.- Ability to understand and the willingness to sign a written informed consent document.,ct_inc_536023,AACT,61,NCT00754117,Recent,CHOP
5c7430c08625dd086b867f9b,60,,,57,Patient,15:28.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_497130,Clinical Trial Inclusion Criteria,UNKNOWN,"Stage I or II of primary breast DLBCL treated with R-CHOP - Stage I or II of nodal DLBCL treated with R-CHOP Definition of primary breast DLBCL - Isolated breast involvement with or without nodal disease, which include distant nodal disease as well as regional nodal disease Definition of nodal DLBCL -",ct_inc_497130,AACT,53,NCT01266668,Recent,CHOP
5c7430538625dd03c7867f8f,0,,,219,Patient,13:39.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_316883,Clinical Trial Inclusion Criteria,UNKNOWN,Patients with early breast cancer planned to receive 3 weekly or dose-dense anthracycline/cyclophosphamide combination or 3 weekly taxane containing chemotherapy regimen or patients with NHL planned to receive R-CHOP-14 or R-CHOP-21 immunochemotherapy as 1st-line treatment with the indication for G-CSF prophylaxis with pegfilgrastim for the prevention of FN and reduction in CIN duration.,ct_inc_316883,AACT,212,NCT03619993,Recent,CHOP-14
5c7430538625dd03c7867fa0,0,,,411,Patient,13:39.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_486155,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Subjects with significant concurrent medical complications that in the judgment of the Principal Investigator(s) could affect the patient's ability to complete the planned trial, including the multiple imaging studies.- Patients with history of prior lymphoma (e.g., follicular lymphoma) and/or second cancers other than basal cell carcinoma.- Patients planned to be treated with R-CHOP-14 (i.e.:",ct_exc_486155,AACT,404,NCT01410630,Historical,CHOP-14
5c7430548625dd03c7867fa9,0,,,82,Patient,13:40.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_567491,Clinical Trial Inclusion Criteria,UNKNOWN,"B-cell Non-Hodgkins lymphoma (NHL) planned to receive at least 2 cycles of CHOP-14, CHOEP-14, CHOP-DI-14, EPOCH-14 or CHOP-21 +/-",ct_inc_567491,AACT,75,NCT00336609,Recent,CHOP-14
5c74305f8625dd0457867f95,70,,,246,Patient,13:51.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_524716,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Subjects greater than or equal to 18 years old - Subjects diagnosed with any histological type of NHL (including both chemotherapy nave and pre-treated subjects) - Subjects planned to receive a minimum of 3 cycles of CHOP-14 or CHOP-21 with or without Rituximab (for subjects enrolled retrospectively, eligibility should be assessed on the profile at time of planning treatment, where treatment initiates on or after 01 Jan 2005, with specific focus on planned chemotherapy and not outcome or number of delivered cycles) -",ct_inc_524716,AACT,239,NCT00903812,Recent,CHOP-14
5c74308c8625dd065b867f86,20,,,32,Patient,14:36.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_533302,Clinical Trial Inclusion Criteria,UNKNOWN,"Any variation of CHOP (R-CHOP-14, R-CHOP-21) is acceptable.",ct_inc_533302,AACT,25,NCT00790036,Recent,CHOP-14
5c7430538625dd03c7867f90,0,,,232,Patient,13:39.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_316883,Clinical Trial Inclusion Criteria,UNKNOWN,Patients with early breast cancer planned to receive 3 weekly or dose-dense anthracycline/cyclophosphamide combination or 3 weekly taxane containing chemotherapy regimen or patients with NHL planned to receive R-CHOP-14 or R-CHOP-21 immunochemotherapy as 1st-line treatment with the indication for G-CSF prophylaxis with pegfilgrastim for the prevention of FN and reduction in CIN duration.,ct_inc_316883,AACT,225,NCT03619993,Recent,CHOP-21
5c7430538625dd03c7867fa1,0,,,103,Patient,13:39.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_486155,Clinical Trial Exclusion Criteria,UNKNOWN,"R-CHOP given every 14 days) will be excluded (this should be extremely rare, if at all, since R-CHOP-21 is the standard treatment.- Patients who are scheduled to receive Rituxan or any other therapy (e.g., XRT, radioimmunotherapy) as adjuvant therapy after completion of R-CHOP-21.- Pregnant women will be excluded.- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) after study entry and for the duration of study participation.",ct_exc_486155,AACT,96,NCT01410630,Hypothetical,CHOP-21
5c7430548625dd03c7867faa,0,,,125,Patient,13:40.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_567491,Clinical Trial Inclusion Criteria,UNKNOWN,"B-cell Non-Hodgkins lymphoma (NHL) planned to receive at least 2 cycles of CHOP-14, CHOEP-14, CHOP-DI-14, EPOCH-14 or CHOP-21 +/-",ct_inc_567491,AACT,118,NCT00336609,Recent,CHOP-21
5c74305c8625dd043c867f89,50,,,134,Patient,13:48.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_437757,Clinical Trial Inclusion Criteria,UNKNOWN,"Histological documentation of aggressive B cell NHL Planned to receive systemic anticancer therapy with at least 6 cycles of R-CHOP-21, according to local standards 5.",ct_inc_437757,AACT,127,NCT02044276,Recent,CHOP-21
5c74305f8625dd0457867f96,70,,,257,Patient,13:51.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_524716,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Subjects greater than or equal to 18 years old - Subjects diagnosed with any histological type of NHL (including both chemotherapy nave and pre-treated subjects) - Subjects planned to receive a minimum of 3 cycles of CHOP-14 or CHOP-21 with or without Rituximab (for subjects enrolled retrospectively, eligibility should be assessed on the profile at time of planning treatment, where treatment initiates on or after 01 Jan 2005, with specific focus on planned chemotherapy and not outcome or number of delivered cycles) -",ct_inc_524716,AACT,250,NCT00903812,Recent,CHOP-21
5c74306b8625dd04cb867f93,260,,,154,Patient,14:03.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_342748,Clinical Trial Inclusion Criteria,UNKNOWN,T-cell/histiocyte-rich DLBCL Subject is considered an appropriate candidate (per Investigator assessment) for induction therapy with 6 cycles of R-CHOP-21 immunochemotherapy.,ct_inc_342748,AACT,147,NCT03283202,Recent,CHOP-21
5c7430808625dd05b6867faf,10,,,172,Patient,14:24.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_486155,Clinical Trial Inclusion Criteria,UNKNOWN,"All patients must have a histologic or cytological diagnosis of de novo DLBCL and be scheduled to receive first line chemotherapy with R-CHOP given every 21 days (R-CHOP-21) within 6 weeks of their enrollment and for 6 cycles.- Patients must be >=18 years of age, but there will be no discrimination based on gender, race, creed, or ethnic background.- Patients must have an ECOG performance status of 0-2.- Patients must sign an informed consent, and be mentally responsible.",ct_inc_486155,AACT,165,NCT01410630,Recent,CHOP-21
5c74308c8625dd065b867f87,20,,,43,Patient,14:36.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_533302,Clinical Trial Inclusion Criteria,UNKNOWN,"Any variation of CHOP (R-CHOP-14, R-CHOP-21) is acceptable.",ct_inc_533302,AACT,36,NCT00790036,Recent,CHOP-21
5c7430548625dd03c7867fab,0,,,101,Patient,13:40.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_567491,Clinical Trial Inclusion Criteria,UNKNOWN,"B-cell Non-Hodgkins lymphoma (NHL) planned to receive at least 2 cycles of CHOP-14, CHOEP-14, CHOP-DI-14, EPOCH-14 or CHOP-21 +/-",ct_inc_567491,AACT,94,NCT00336609,Recent,CHOP-DI
5c7430548625dd03c7867fa6,0,,,104,Patient,13:40.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_567491,Clinical Trial Inclusion Criteria,UNKNOWN,"B-cell Non-Hodgkins lymphoma (NHL) planned to receive at least 2 cycles of CHOP-14, CHOEP-14, CHOP-DI-14, EPOCH-14 or CHOP-21 +/-",ct_inc_567491,AACT,94,NCT00336609,Recent,CHOP-DI-14
5c7430468625dd0355867f89,160,,,1429,Patient,13:27.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_537364,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Significant medical disease other than cancer including: Any bleeding or coagulation disorder including a history of autoimmune hemolytic anemia or autoimmune thrombocytopenia; Severe pulmonary disease; Uncontrolled congestive heart failure; New York Heart Association class III or IV disease; Uncontrolled seizure disorder; and Active infections - Less than 3 weeks from prior major surgery - Prior organ allograft - Known HIV infection (due to expected frequent occurrence of myelo-suppression and immunosuppression) - Women who are pregnant (confirmed by a serum pregnancy test in females of reproductive potential) or breast-feeding (women of child-bearing potential and sexually active males must be advised to take precautions to prevent pregnancy during treatment or remain abstinent) - Women of child-bearing potential and sexually active males must be advised to take precautions to prevent pregnancy during treatment (unless the subject or subject's partner(s) is sterile, i.e., women who have had a hysterectomy or have been post-menopausal for at least twelve consecutive months) or remain abstinent - Known hypersensitivity to phosphorothiate-containing oligonucleotides - Concurrent investigational, corticosteroid therapy or any other anti-cancer treatments (such as chemotherapy, radiation, biologic or investigational therapies) while receiving protocol therapy; other than one cycle CHOP-R allowed based on current diagnosis, clinical condition, and availability/feasibility of initiating Genasense; other than chronic steroid use for another indication (For stage I/II or as clinically indicated- involved field irradiation as per standard practice is accepted) -",ct_exc_537364,AACT,1423,NCT00736450,Historical,CHOP-R
5c74305c8625dd0431867f90,220,,,47,Patient,13:48.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_570939,Clinical Trial Inclusion Criteria,UNKNOWN,Ages 16 - 60 years (due to the fact that CHOP-R is not studied enough in younger patients and is not considered standard of care).,ct_inc_570939,AACT,41,NCT00290498,Recent,CHOP-R
5c7430708625dd0518867f90,100,,,235,Patient,14:08.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_477514,Clinical Trial Inclusion Criteria,UNKNOWN,"Patient age is 18 years Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 2 Patient has a history of DLBCL according to the WHO classification Patient has progressive disease after receiving at least CHOP-R or CHOP-R like first line regimen, standard second line therapy (DHAP, ESHAP, ICE or similar salvage regimens) inclusive ASCT Patient has progressive disease after receiving at least CHOP-R or CHOP-R like first line regimen and is not considered eligible for intensive salvage therapy including ASCT because of age, co-morbidities, impossibility to perform ASCT Patient undergoes at baseline new lymphnode or other pathologic tissue biopsy for confirmation of diagnosis and biologic studies; bone marrow biopsy is not adequate for this purpose and should be performed only for staging.",ct_inc_477514,AACT,229,NCT01523834,Historical,CHOP-R
5c7430728625dd0518867f97,100,,,639,Patient,14:10.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_591468,Clinical Trial Inclusion Criteria,UNKNOWN,"- Histologically proven intermediate- or high-grade non-Hodgkin's lymphoma - Ann Arbor classification of bulky stage II, III, or IV - Must be classified as high-intermediate or high-risk according to International Age Adjusted Index - Bidimensionally meas",ct_inc_591468,AACT,633,NCT00004031,Hypothetical,CHOP-R
5c7430728625dd0518867f99,100,,,122,Patient,14:10.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_591468,Clinical Trial Inclusion Criteria,PULMONARY_REVIEW,Biologic therapy: - No prior monoclonal antibody therapy for lymphoma except if included in a single course of CHOP/CHOP-R,ct_inc_591468,AACT,116,NCT00004031,Hypothetical,CHOP-R
5c7430728625dd0518867f9b,100,,,78,Patient,14:10.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_591468,Clinical Trial Inclusion Criteria,CHEMOTHERAPEUTICS,- No prior chemotherapy for lymphoma except for a single course of CHOP/CHOP-R*,ct_inc_591468,AACT,72,NCT00004031,Historical,CHOP-R
5c7430ac8625dd079a867f86,380,,,117,Patient,15:08.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_572562,Clinical Trial Exclusion Criteria,UNKNOWN,"General status that, in the opinion of the Investigator does not permit the administration of eight courses of CHOP-R/CPOP-R. Treatment with any other investigational study drug within 30 days before randomization.",ct_exc_572562,AACT,111,NCT00268853,Recent,CHOP-R
5c7430b78625dd07fd867f89,210,,,254,Patient,15:19.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_568560,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Presence of any other malignancy or history of prior malignancy except non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma - Prior radioimmunotherapy, radiation therapy, or any other NHL therapy except first-line CHOP-R - Presence of gastric, central nervous system (CNS), or testicular lymphoma at first diagnosis - Histological transformation of low-grade NHL - Known seropositivity for hepatitis C virus (HCV) or hepatitis B surface antigen (HbsAg) - Known history of HIV infection - Abnormal liver function: total bilirubin",ct_exc_568560,AACT,248,NCT00322218,Historical,CHOP-R
5c7430b78625dd07fd867f8a,210,,,174,Patient,15:19.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_568560,Clinical Trial Exclusion Criteria,UNKNOWN,"2.5 x ULN within 1 week of randomization - Abnormal renal function: serum creatinine > 2.0 x ULN within 1 week of randomization - Nonrecovery from the toxic effects of CHOP-R therapy - Known hypersensitivity to murine or chimeric antibodies or proteins - G-CSF or GM-CSF therapy within two weeks (or four weeks if pegylated) prior to screening laboratory sampling - Concurrent severe and/or uncontrolled medical disease (e.g., uncontrolled diabetes,congestive heart failure, myocardial infarction within 6 months of study, unstable and uncontrolled hypertension, chronic renal disease, or active uncontrolled infection) which could compromise participation in the study - Male and female patients of child-bearing potential unwilling to practice effective contraception during the study and unwilling or unable to continue contraception for 12 months after their last dose of study treatment - Female patients who are pregnant or are currently breastfeeding - Treatment with investigational drugs less than 4 weeks before the planned Day 1 or nonrecovery from the toxic effects of such therapy - Surgery less than 4 weeks before the planned Day 1 or nonrecovery from the side effects of such surgery - Concurrent systemic corticosteroid use for any reason except as premedication in case of known or suspected allergies to contrast media or as premedication for potential side effects of rituximab treatment - Unwillingness or inability to comply with the protocol",ct_exc_568560,AACT,168,NCT00322218,Recent,CHOP-R
5c7430b88625dd07fd867f8d,210,,,59,Patient,15:20.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_537364,Clinical Trial Inclusion Criteria,UNKNOWN,"No prior chemotherapy (with the exception of 1 cycle CHOP-R based on current diagnosis, clinical condition, and availability/feasibility of initiating Genasense), immunotherapy, radiotherapy, or investigational therapies for NHL; steroid therapy is allowed only if required for maintenance of another chronic disease (e.g., rheumatoid arthritis) - Patients aged >= 60 years, or patients with a history of coronary artery disease, congestive heart failure, hypertension, diabetes, or hyperlipidemia must have an estimated ejection fraction >= 0.45 (45%) by MUGA or echocardiography, performed within two months of study entry - Patients must be willing to give written informed consent, and sign an institutionally approved consent form prior to initiating genasense or any study related activities (i.e., Genasense & microarray) - Females of childbearing potential must have a negative serum pregnancy test prior to enrollment in the study - Adequate venous access for 7-day continuous infusion - Patients without evidence of severe organ dysfunction as determined within two weeks of 1st cycle of",ct_inc_537364,AACT,53,NCT00736450,Hypothetical,CHOP-R
5c7430b88625dd07fd867f8e,210,,,6,Patient,15:20.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_537364,Clinical Trial Inclusion Criteria,UNKNOWN,CHOP-R:,ct_inc_537364,AACT,0,NCT00736450,Recent,CHOP-R
5c7430be8625dd084a867f90,140,,,682,Patient,15:26.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_570923,Clinical Trial Inclusion Criteria,UNKNOWN,"Intermediate histology B-cell NHL, including any of the following: - Diffuse large B-cell lymphoma - Transformed large cell lymphoma - Any T-cell NHL histology - Cutaneous T-cell lymphoma (CTCL) or mycosis fungoides (MF) allowed - Relapsed or refractory disease, defined as disease progressed after prior complete remission (CR), partial remission (PR), or stable disease (SD) to last therapy OR failure to achieve CR, PR, or SD after completion of last therapy - Must have received 1-3 prior therapeutic regimens - Cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (CHOP) AND cyclophosphamide, vincristine, and prednisone (CVP) OR CHOP with rituximab (CHOP-R) AND CVP with rituximab (CVP-R) is considered",ct_inc_570923,AACT,676,NCT00290706,Historical,CHOP-R
5c7430bf8625dd084a867f93,140,,,131,Patient,15:27.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_568560,Clinical Trial Inclusion Criteria,UNKNOWN,"Ann Arbor stage II, III, or IV DLBCL according to the REAL/WHO classification (from initial diagnosis made prior to starting CHOP-R therapy) -",ct_inc_568560,AACT,125,NCT00322218,Historical,CHOP-R
5c7430bf8625dd084a867f94,140,,,751,Patient,15:27.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_568560,Clinical Trial Inclusion Criteria,UNKNOWN,"Central pathology review confirming the DLBCL diagnosis and CD20 positivity, and no evidence of DLBCL in bone marrow - First-line treatment of DLBCL must have been 6 or 8 cycles of standard CHOP chemotherapy (cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2 up to a maximum of 2 mg on day 1, and at least 40 mg/m2/day prednisone on Days 1 to 5 every three weeks, with generally accepted adjustments in dose or frequency due to toxicity, patient scheduling, etc.)in combination with rituximab (375 mg/m2) - Complete remission (CR) or unconfirmed complete remission (CRu) according to the International Workshop Response Criteria for NHL described by Cheson et al and modified for this study after first-line treatment with CHOP-R. CT scans of chest, abdomen, pelvis, and neck (if applicable) must have been performed within 6 weeks after the last dose of the last course of CHOP-R. Applicability of the neck CT means that the patient had involvement of the neck region by palpation / physical examination at first diagnosis (pre-CHOP-R).- Central radiographic review of the CT scans (chest, abdomen, pelvis and if applicable, neck) from before and after first-line treatment with CHOP-R fulfilling the radiological requirements for CR/CRu - Patients 60 years of age or older at time of randomization - WHO performance status (PS) of 0 to 2 within 1 week of randomization - Absolute neutrophil count (ANC)greater than or equal to 1.5 x 10^9/L within 1 week of randomization - Hemoglobin (Hgb) greater than or equal to 10 g/dL within 1 week of randomization - Platelets greater than or equal to 150 x 10^9/L within 1 week of randomization - Life expectancy of 3 months or longer - Written informed consent obtained according to local guidelines",ct_inc_568560,AACT,745,NCT00322218,Recent,CHOP-R
5c7430618625dd0452867f92,40,,,66,Patient,13:53.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_447673,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Previously untreated NHL suitable for CHOP/R-CHOP treatment - Age range 18-80 years old - HBsAg positive with high level of HBV DNA - Eastern Cooperative Oncology Group performance status 0-2 - Life expectancy of more than 3 months -,ct_inc_447673,AACT,60,NCT01914744,Recent,CHOP/R
5c7430628625dd0452867f9e,40,,,220,Patient,13:54.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_471737,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients will be eligible if the treatment phase consisting in a Rituximab combined with any anthracycline-containing chemotherapy regimen without consolidation with autologous stem cell support (e.g., 6 cycles of CHOP14-21, DA-EPOCH, Mega-CHOP or 12 weeks of VACOP-B or MACOP-B).-",ct_inc_471737,AACT,214,NCT01599559,Hypothetical,CHOP14
5c74306d8625dd0506867f90,80,,,107,Patient,14:05.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_412771,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Diagnosis of lymphoma - No prior treatment for lymphoma - Scheduled to receive CHOP14 +/-,ct_inc_412771,AACT,101,NCT02370446,Historical,CHOP14
5c74307c8625dd05b6867f85,10,,,84,Patient,14:20.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_478558,Clinical Trial Inclusion Criteria,UNKNOWN,"First-line treatment of DLBCL must have been 6 cycles of standard R-CHOP21, R-CHOP14 or DA-EPOCH-R chemotherapy.",ct_inc_478558,AACT,78,NCT01510184,Recent,CHOP14
5c74305f8625dd045a867f86,1190,,,188,Patient,13:51.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_583227,Clinical Trial Inclusion Criteria,COMMENT,"At least 1 measurable metastasis that has not been previously excised or biopsied - Failed 1 standard chemotherapy or chemoimmunotherapy regimen (e.g., dacarbazine or cisplatin monotherapy) - At least 1 metastatic lesion surgically accessible* for excision or biopsy to obtain tumor material for RNA isolation**",ct_inc_583227,AACT,167,NCT00126685,Recent,cisplatin monotherapy
5c7430608625dd045a867f87,1190,,,226,Patient,13:52.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_588420,Clinical Trial Inclusion Criteria,UNKNOWN,"- Histologically confirmed cutaneous* melanoma - Stage IV - Incurable by surgical resection - Progressive disease after at least 1 standard chemotherapy or chemoimmunotherapy regimen (e.g., dacarbazine or cisplatin monotherapy) -",ct_inc_588420,AACT,205,NCT00074230,Recent,cisplatin monotherapy
5c7430908625dd0680867f8b,480,,,256,Patient,14:40.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_311524,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - squamous cell carcinoma of the head and neck - treatment plan to receive IMRT delivered as single daily fractions of 2.0 to 2.2 Gy with a cumulative radiation dose of 60-72 Gy - Treatment plan to receive standard cisplatin monotherapy - Age 18 years or older - Eastern Cooperative Oncology Group (ECOG) performance status,ct_inc_311524,AACT,235,NCT03689712,Recent,cisplatin monotherapy
5c74309c8625dd06f5867f85,440,,,273,Patient,14:52.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_520482,Clinical Trial Inclusion Criteria,UNKNOWN,"Patient has ovarian, primary peritoneal, or fallopian tube cancer - Patient has first or subsequent relapse - Patient has had at least on prior platinum-based treatment for ovarian cancer - Patient is scheduled to receive treatment with carboplatin or cisplatin monotherapy or combination where one of the drugs is a platinum - Patient is not pregnant",ct_inc_520482,AACT,252,NCT00959582,Historical,cisplatin monotherapy
5c7430a08625dd071a867f84,1060,,,56,Patient,14:56.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_402190,Clinical Trial Inclusion Criteria,COMMENT,Treatment plan to receive standard cisplatin monotherapy administered either every three weeks,ct_inc_402190,AACT,35,NCT02508389,Recent,cisplatin monotherapy
5c7430a08625dd071a867f85,1060,,,95,Patient,14:56.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_324911,Clinical Trial Inclusion Criteria,COMMENT,#3 below are eligible for the trial Treatment planned to include standard cisplatin monotherapy administered either every three weeks (100 mg/m2 for 3 doses) with concomitant radiation delivered as a continuous course of IMRT with single daily fractions of 2.0 to 2.2 Gy with a cumulative radiation dose between 60 Gy and 72 Gy.,ct_inc_324911,AACT,74,NCT03515538,Recent,cisplatin monotherapy
5c7430368625dd02b7867f86,560,,,305,Patient,13:10.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_548096,Clinical Trial Exclusion Criteria,UNKNOWN,"History of other curatively untreated malignancy, except non-melanotic skin cancers.- Patients that have received investigational agents within 1 month of study entry.- History of allergic reaction attributed to compounds of similar chemical or biologic composition to Gleevec or any component of the CLAG regimen.",ct_exc_548096,AACT,301,NCT00594555,Historical,CLAG
5c7430668625dd04b5867f85,860,,,123,Patient,13:59.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_409205,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria: - Acute promyelocytic leukemia (AML with t(15;17)(q22;q11) and variants).- Previous treatment with CLAG or other chemotherapy regimen containing both cladribine and cytarabine.- Colony stimulating factors within 2 weeks of study.- Active graft versus host disease (GVHD) after allogeneic stem cell transplantation.,ct_exc_409205,AACT,119,NCT02416908,Recent,CLAG
5c7430aa8625dd0763867f91,730,,,123,Patient,15:06.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_505157,Clinical Trial Inclusion Criteria,UNKNOWN,"Because no dosing or adverse event data are currently available on the use of midostaurin in combination with ATRA and CLAG in patients <18 years of age, children are excluded from this study but will be eligible for future pediatric phase 2 combination trials.- Patient must be diagnosed with refractory or relapsed",ct_inc_505157,AACT,119,NCT01161550,Recent,CLAG
5c74303c8625dd02f6867f8d,120,,,4,Patient,13:16.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_524716,Clinical Trial Exclusion Criteria,UNKNOWN,"CNOP (Cytoxan, Novantrone, Oncovin (Vincristine),Etoposide, Prednisone) chemotherapy are not eligible for inclusion in this study",ct_exc_524716,AACT,0,NCT00903812,Recent,CNOP
5c7430578625dd03e4867f87,800,,,75,Patient,13:43.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_549583,Clinical Trial Inclusion Criteria,UNKNOWN,"No prior anthracycline/anthracenedione-based chemotherapy (e.g., CHOP, CNOP)",ct_inc_549583,AACT,71,NCT00574730,Historical,CNOP
5c74307f8625dd05b6867fa7,10,,,389,Patient,14:23.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_490450,Clinical Trial Inclusion Criteria,UNKNOWN,"Platelet count 100x109/L Absolute Neutrophil count 1.0x109/L; Serum bilirubin 1.5 x ULN AST (SGOT) or ALT 1.5 x ULN Creatinine clearance (Cockcroft-Gault) > 50 ml/min - Relapsed or refractory DLBCL in which all participants must have received at least one potentially curative established immunochemotherapy lymphoma regimen that contained rituximab (e.g.R-CHOP, R-PMitCEBO, R-GCVP, R-CNOP).Participants must also have failed or be ineligible for salvage/high dose therapy.- Relapsed or refractory DLBCL proven by biopsy (within 6 months of enrolment in trial); either de novo DLBCL or transformed follicular lymphoma.-",ct_inc_490450,AACT,385,NCT01354392,Recent,CNOP
5c74305f8625dd0452867f8a,40,,,319,Patient,13:51.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_344212,Clinical Trial Inclusion Criteria,COMMENT,"Prior Treatment: Previously untreated or has received a maximum of one cycle of any combination chemotherapy (e.g.cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP), CHOEP, DA-EPOCH, doxorubicin, cyclophosphamide, cytarabine, vincristine, methotrexate/Etoposide, ifosfamide, cytarabine, methotrexate (CODOX-M/IVAC), HyperCVAD) within 4 weeks of study entry.",ct_inc_344212,AACT,312,NCT03264131,Historical,CODOX-M
5c74309f8625dd0700867f8d,200,,,94,Patient,14:55.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_519334,Clinical Trial Inclusion Criteria,COMMENT,"that, according to the investigator, does not allow the administration of 2 courses of CODOX-M/IVAC -",ct_inc_519334,AACT,87,NCT00974792,Recent,CODOX-M
5c74305f8625dd0452867f86,40,,,324,Patient,13:51.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_344212,Clinical Trial Inclusion Criteria,COMMENT,"Prior Treatment: Previously untreated or has received a maximum of one cycle of any combination chemotherapy (e.g.cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP), CHOEP, DA-EPOCH, doxorubicin, cyclophosphamide, cytarabine, vincristine, methotrexate/Etoposide, ifosfamide, cytarabine, methotrexate (CODOX-M/IVAC), HyperCVAD) within 4 weeks of study entry.",ct_inc_344212,AACT,312,NCT03264131,Historical,CODOX-M/IVAC
5c74309f8625dd0700867f8c,200,,,99,Patient,14:55.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_519334,Clinical Trial Inclusion Criteria,COMMENT,"that, according to the investigator, does not allow the administration of 2 courses of CODOX-M/IVAC -",ct_inc_519334,AACT,87,NCT00974792,Recent,CODOX-M/IVAC
5c7430628625dd0452867f98,40,,,160,Patient,13:54.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_590819,Clinical Trial Inclusion Criteria,UNKNOWN,"- Histologically confirmed Hodgkin's lymphoma - Early or late first relapse - Complete or partial remission for at least 3 months after completion of prior COPP/ABVD, COPP/ABV/IMEP, MOPP/ABV, ABVD, BEACOPP, or other polychemotherapy regimen with or withou",ct_inc_590819,AACT,156,NCT00025636,Historical,COPP
5c7430888625dd0628867f93,90,,,310,Patient,14:32.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_585900,Clinical Trial Inclusion Criteria,UNKNOWN,"No evidence of disease - Prior treatment on 1 of the following protocols during the years 1987-2001: - Children's Cancer Group (CCG) CCG-5942, CCG-59704 - Pediatric Oncology Group (POG) POG-8625, POG-8725, POG-9425, POG-9426 - Pediatric Hodgkin's Consortium: VAMP, VEPA, VAMP/COP - Institutional protocols COPP/ABV, MOPP/ABVD, ABVD - Childhood Cancer Survivor Study (CCSS)",ct_inc_585900,AACT,306,NCT00091091,Historical,COPP
5c7430468625dd0334867f90,400,,,417,Patient,13:26.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_430820,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients must have histologically or cytologically proven primary non-squamous non-small cell lung cancer (adenocarcinoma, large cell carcinoma, adenocarcinoma in situ, mixed histology with < 50% squamous or unspecified); patients with tumors having squamous cell components >= 50% are not eligible; disease must be stage IV - Patients must have documented ALK positivity at the time of initial crizotinib monotherapy using the Vysis Break-Apart FISH assay (or other Food and Drug Administration [FDA]-approved diagnostic test); samples are deemed to be FISH-positive if greater than or equal to 15% of scored tumor cells",ct_inc_430820,AACT,395,NCT02134912,Hypothetical,crizotinib monotherapy
5c7430468625dd0334867f91,400,,,344,Patient,13:26.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_430820,Clinical Trial Inclusion Criteria,UNKNOWN,"had split ALK 5' and 3' probe signals or had isolated 3' signal; FISH status must be documented on the Onstudy Form and a copy of the pathology report from the Vysis Break-Apart FISH assay (or other FDA-approved diagnostic test) must be submitted - Prior to registration, patients must have achieved clinical benefit with crizotinib monotherapy and subsequently have systemically progressed; clinical benefit is defined as having stable disease on crizotinib monotherapy for at least 90 days or achieving a confirmed partial or complete response; systemic progression is defined as progressive disease based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, excluding progression based on brain/CNS metastases alone - Patients must have received crizotinib monotherapy at 250 mg BID on a continuous dosing schedule for at least 90 days; patients must be planning to start treatment at least three days, but no more than 30 days after discontinuing crizotinib monotherapy; patients who were not able to tolerate 250 mg BID of crizotinib are not eligible for this study - Patients must be pemetrexed-nave; patients may have received any number of prior chemotherapy or molecularly targeted agents; if crizotinib was used in the 1st line setting then chemotherapy naive patients are also eligible; if patient received crizotinib in combination with chemotherapy, prior chemotherapy must have been discontinued at least 14 days prior to registration and all adverse events must have resolved to =< grade 1 - Patients must have measurable disease per RECIST documented by computed tomography (CT) or magnetic resonance imaging (MRI); the CT from a combined positron emission tomography (PET)/CT may be used to document only non-measurable disease unless it is of diagnostic quality; measurable disease must be assessed within 28 days prior to registration; pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease; non-measurable disease must be assessed within 42 days prior to registration; all disease must be assessed and documented on the Baseline Tumor Assessment Form RECIST 1.1 - Patients must have a CT or MRI scan of the brain to evaluate for CNS disease within 42 days prior to registration; patient must not have brain metastases unless: (1) metastases have been treated and have remained controlled for at least 14 days following treatment or was not treated, but is asymptomatic, AND (2) patient has no residual neurological dysfunction off corticosteroids or anti-convulsants for at least 14 days - Patients may have received palliative radiotherapy to non-target lesions within 14 days prior to registration provided all radiotherapy related toxicities have resolved to =< grade 1 prior to registration; patients must not have received any major surgery within 28 days prior to registration - Patients must not have had any prior exposure to heat shock protein (HSP)90 inhibitors (such as IPI-504 or ganetespib) or non-crizotinib ALK inhibitors (such as AP26113 or LDK378) - Patients must be offered participation in the translational medicine studies; additionally if patient has biopsy accessible disease they must be offered participation in the translational medicine studies - Absolute neutrophil count (ANC) >= 1,500/ul - Platelet count >= 100,000/ul - Hemoglobin >= 9 g/dL - Serum bilirubin =< 2 X institutional upper limit of normal (IULN) - Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) or serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =",ct_inc_430820,AACT,322,NCT02134912,Historical,crizotinib monotherapy
5c7430be8625dd084a867f91,140,,,713,Patient,15:26.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_570923,Clinical Trial Inclusion Criteria,UNKNOWN,"Intermediate histology B-cell NHL, including any of the following: - Diffuse large B-cell lymphoma - Transformed large cell lymphoma - Any T-cell NHL histology - Cutaneous T-cell lymphoma (CTCL) or mycosis fungoides (MF) allowed - Relapsed or refractory disease, defined as disease progressed after prior complete remission (CR), partial remission (PR), or stable disease (SD) to last therapy OR failure to achieve CR, PR, or SD after completion of last therapy - Must have received 1-3 prior therapeutic regimens - Cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (CHOP) AND cyclophosphamide, vincristine, and prednisone (CVP) OR CHOP with rituximab (CHOP-R) AND CVP with rituximab (CVP-R) is considered",ct_inc_570923,AACT,708,NCT00290706,Historical,CVP-R
5c7430478625dd0355867f8d,160,,,46,Patient,13:27.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_480284,Clinical Trial Inclusion Criteria,UNIT,"Examples include but are not limited to Cy/TBI, BuCy 200, etc.- Patients 16 years old must have a Karnofsky score 70%, and patients < 16 years old must have a Lansky score 70%.-",ct_inc_480284,AACT,40,NCT01487577,Recent,Cy/TBI
5c74304e8625dd03a2867f88,130,,,285,Patient,13:35.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_591483,Clinical Trial Inclusion Criteria,UNKNOWN,"Best medical judgment and further imaging studies can be used to clarify the diagnosis and determine confounding causes of liver dysfunction.- Severity of VOD defined by: - For patients addressed by the Bearman model (i.e.within 16 days of SCT and conditioned with either BU/CY, CY/TBI or CBV), there must be a 30% or greater risk of severe VOD (see Appendix B).-",ct_inc_591483,AACT,279,NCT00003966,Recent,CY/TBI
5c74304e8625dd03a2867f89,130,,,142,Patient,13:35.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_591483,Clinical Trial Inclusion Criteria,UNKNOWN,"For all other patients who are not addressed by the Bearman model (ie.beyond 16 days of SCT and/or not conditioned with either BU/CY, - CY/TBI or CBV), there must be concomitant multi-organ failure defined as presence of one or more of the following : - renal dysfunction: a) creatinine 2x value on the date of admission day to the BMT unit for conditioning or 2x lowest value during conditioning (use the lowest value for calculation), or b) creatinine clearance or GFR 50% of admission value, or c) dialysis dependence - pulmonary dysfunction: documentation of oxygenation saturation 90% on room air; requirement for positive pressure/ventilator dependence pulmonary dysfunction must not be attributable to another cause (e.g.documented infectious pneumonia) - central nervous dysfunction: documentation of confusion, lethargy, and/or delirium central nervous dysfunction must not be attributable to another cause (e.g.documented cyclosporin toxicity) - Patients or their parents/guardians or designated proxy must have the ability to give voluntary informed consent to the protocol.",ct_inc_591483,AACT,136,NCT00003966,Recent,CY/TBI
5c7430a48625dd0737867f8d,180,,,153,Patient,15:00.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_531374,Clinical Trial Inclusion Criteria,UNKNOWN,"old.- ECOG performance status 0-2.- Patients with AML or MDS with intermediate/unfavorable cytogenetics.- Patients with ALL and CML ineligible for Cy/TBI conditioning.- Patients with NHL or HD eligible to myeloablative HCT.- Patients receiving unrelated BMT for AML, MDS, ALL, CML, NHL or HD.- Consent form signed and dated prior to study specific procedures.- Subject able to comply with the scheduled follow-up and with the management of toxicities.",ct_inc_531374,AACT,147,NCT00815568,Historical,Cy/TBI
5c7430ae8625dd079a867f8a,380,,,120,Patient,15:10.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_354846,Clinical Trial Inclusion Criteria,NEURO_PSYCH_EXAM,Patients with a history of CNS involvement by lymphoma or with relapsed primary CNS lymphoma will be eligible for Cy/TBI arm.,ct_inc_354846,AACT,114,NCT03125642,Historical,Cy/TBI
5c7430508625dd03a2867f8b,130,,,594,Patient,13:36.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_345097,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Biopsy-proven histochemical diagnosis of amyloid light-chain (AL) amyloidosis based on tissue specimens with Congo red staining or other histologic stain; thioflavin T or S, or crystal violet; tandem mass spec or immunohistochemistry (IHC) confirmation of immunoglobulin-derived amyloidosis is encouraged; cases in which histochemical confirmation is lacking need to be discussed with one of the Multiple Myeloma Research Foundation (MMRF) protocol chair/co-chairs - One prior line of therapy (defined as either one non-transplant regimen such as MelDex, Vel-Dex or CyBorD, one autologous stem cell transplant, or one regimen of non-transplant induction therapy followed by a single autologous stem cell transplant (without hematologic progression between induction and autologous stem cell transplant [ASCT]) -",ct_inc_345097,AACT,588,NCT03252600,Historical,CyBorD
5c7430508625dd03a2867f8c,130,,,594,Patient,13:36.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_345097,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Biopsy-proven histochemical diagnosis of amyloid light-chain (AL) amyloidosis based on tissue specimens with Congo red staining or other histologic stain; thioflavin T or S, or crystal violet; tandem mass spec or immunohistochemistry (IHC) confirmation of immunoglobulin-derived amyloidosis is encouraged; cases in which histochemical confirmation is lacking need to be discussed with one of the Multiple Myeloma Research Foundation (MMRF) protocol chair/co-chairs - One prior line of therapy (defined as either one non-transplant regimen such as MelDex, Vel-Dex or CyBorD, one autologous stem cell transplant, or one regimen of non-transplant induction therapy followed by a single autologous stem cell transplant (without hematologic progression between induction and autologous stem cell transplant [ASCT]) -",ct_inc_345097,AACT,588,NCT03252600,Historical,CyBorD
5c7430878625dd060e867f88,470,,,248,Patient,14:31.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_387451,Clinical Trial Inclusion Criteria,UNKNOWN,"- Have > 1 cytogenetic abnormality - Are hypodiploid - Have failed adequate initial therapy (lenalidomide, bortezomib, dexamethasone [RVD], thalidomide, bortezomib, and dexamethasone [TVD], or cyclophosphamide, bortezomib, and dexamethasone [CyBorD]) - Ha",ct_inc_387451,AACT,242,NCT02700841,Recent,CyBorD
5c7430878625dd060e867f89,470,,,248,Patient,14:31.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_387451,Clinical Trial Inclusion Criteria,UNKNOWN,"- Have > 1 cytogenetic abnormality - Are hypodiploid - Have failed adequate initial therapy (lenalidomide, bortezomib, dexamethasone [RVD], thalidomide, bortezomib, and dexamethasone [TVD], or cyclophosphamide, bortezomib, and dexamethasone [CyBorD]) - Ha",ct_inc_387451,AACT,242,NCT02700841,Recent,CyBorD
5c74308e8625dd063a867f8f,390,,,123,Patient,14:38.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_417529,Clinical Trial Inclusion Criteria,UNKNOWN,"; Patients 50 years, regardless of cytogenetics or ISS stage - Having received a Bortezomib-containing regimen (VTD, CyBorD, VRD or PAD [in patients with PCL]) for a minimum of 4 cycles with PR.- Received high-dose Melphalan 140 mg/m2 followed by autologous stem cell transplantation.- Available HLA-identical sibling donor or 8/8 allele matched (HLA-A, -B, -C, -DR) matched unrelated donor",ct_inc_417529,AACT,117,NCT02308280,Recent,CyBorD
5c74308e8625dd063a867f90,390,,,123,Patient,14:38.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_417529,Clinical Trial Inclusion Criteria,UNKNOWN,"; Patients 50 years, regardless of cytogenetics or ISS stage - Having received a Bortezomib-containing regimen (VTD, CyBorD, VRD or PAD [in patients with PCL]) for a minimum of 4 cycles with PR.- Received high-dose Melphalan 140 mg/m2 followed by autologous stem cell transplantation.- Available HLA-identical sibling donor or 8/8 allele matched (HLA-A, -B, -C, -DR) matched unrelated donor",ct_inc_417529,AACT,117,NCT02308280,Recent,CyBorD
5c7430cc8625dd0855867f8e,1070,,,1877,Patient,15:40.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_361091,Clinical Trial Inclusion Criteria,UNKNOWN,"Definite histochemical identification of amyloid by Congo red staining and green birefringence in crossed polarised light in cardiac or other tissue biopsy and identification of TTR as the amyloid fibril protein either by immunohistochemistry or proteomic analysis OR Scintigraphy 99m^Technetium-dicarboxypropane diphosphonate (99m^Tc-DPD) with Grade 2 cardiac uptake or 99m^ Technetium-pyrophosphate (99m^Tc-PYP) with Grade 2 or 3 cardiac uptake.- Clinically stable in New York heart association (NYHA) class 2 or 3 for the 3 months preceding screening Inclusion Criteria for Group 2 - Subject medically diagnosed with AL amyloidosis that has required chemotherapy or an autologous stem cell transplant based upon: AL amyloidosis confirmed by biopsy with immunohistochemical staining or proteomic identification of AL amyloid fibril type, in subjects with definite monoclonal gammopathy in whom causative mutations of all known relevant amyloidogenic genes have been excluded - Clinically stable in NYHA class 2 or 3 for the 3 months preceding screening - >=6 months after completing any line of chemotherapy, or after autologous stem cell transplantation, and having attained either a very good partial response (VGPR) or a complete response (CR), and without the need for haematological maintenance therapies Inclusion Criteria for Group 3 - Newly diagnosed AL amyloidosis based upon: AL amyloidosis confirmed by biopsy with immunohistochemical staining or proteomic identification of AL amyloid fibril type in subjects with definite monoclonal gammopathy in whom causative mutations of all known relevant amyloidogenic genes have been excluded - Mayo stage II or IIIa - Confirmed free light chain complete response (CR) during the first three cycles of first-line chemotherapy where at least the first cycle has been with cyclophosphamide, bortezomib, dexamethasone (CyBorD).",ct_inc_361091,AACT,1871,NCT03044353,Recent,CyBorD
5c7430cc8625dd0855867f8f,1070,,,1877,Patient,15:40.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_361091,Clinical Trial Inclusion Criteria,UNKNOWN,"Definite histochemical identification of amyloid by Congo red staining and green birefringence in crossed polarised light in cardiac or other tissue biopsy and identification of TTR as the amyloid fibril protein either by immunohistochemistry or proteomic analysis OR Scintigraphy 99m^Technetium-dicarboxypropane diphosphonate (99m^Tc-DPD) with Grade 2 cardiac uptake or 99m^ Technetium-pyrophosphate (99m^Tc-PYP) with Grade 2 or 3 cardiac uptake.- Clinically stable in New York heart association (NYHA) class 2 or 3 for the 3 months preceding screening Inclusion Criteria for Group 2 - Subject medically diagnosed with AL amyloidosis that has required chemotherapy or an autologous stem cell transplant based upon: AL amyloidosis confirmed by biopsy with immunohistochemical staining or proteomic identification of AL amyloid fibril type, in subjects with definite monoclonal gammopathy in whom causative mutations of all known relevant amyloidogenic genes have been excluded - Clinically stable in NYHA class 2 or 3 for the 3 months preceding screening - >=6 months after completing any line of chemotherapy, or after autologous stem cell transplantation, and having attained either a very good partial response (VGPR) or a complete response (CR), and without the need for haematological maintenance therapies Inclusion Criteria for Group 3 - Newly diagnosed AL amyloidosis based upon: AL amyloidosis confirmed by biopsy with immunohistochemical staining or proteomic identification of AL amyloid fibril type in subjects with definite monoclonal gammopathy in whom causative mutations of all known relevant amyloidogenic genes have been excluded - Mayo stage II or IIIa - Confirmed free light chain complete response (CR) during the first three cycles of first-line chemotherapy where at least the first cycle has been with cyclophosphamide, bortezomib, dexamethasone (CyBorD).",ct_inc_361091,AACT,1871,NCT03044353,Recent,CyBorD
5c7430588625dd03fe867f99,290,,,91,Patient,13:44.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_441799,Clinical Trial Inclusion Criteria,UNKNOWN,"If younger than 40, there must be comorbidities which preclude the patient to undergo CyTBI conditioning regimen.-",ct_inc_441799,AACT,86,NCT01991457,Recent,CyTBI
5c74305f8625dd0452867f89,40,,,192,Patient,13:51.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_344212,Clinical Trial Inclusion Criteria,COMMENT,"Prior Treatment: Previously untreated or has received a maximum of one cycle of any combination chemotherapy (e.g.cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP), CHOEP, DA-EPOCH, doxorubicin, cyclophosphamide, cytarabine, vincristine, methotrexate/Etoposide, ifosfamide, cytarabine, methotrexate (CODOX-M/IVAC), HyperCVAD) within 4 weeks of study entry.",ct_inc_344212,AACT,184,NCT03264131,Historical,DA-EPOCH
5c7430608625dd043c867f94,50,,,660,Patient,13:52.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_472146,Clinical Trial Exclusion Criteria,UNKNOWN,"The subject must have received first line therapy with Rituximab-Cyclophosphamide, Hydroxydaunomycin, Vincristine (Oncovin), Prednisone (R-CHOP) [or a similar standard rituximab-containing front-line chemoimmunotherapy regimen including, but not limited to Etoposide, Prednisone, Vincristine (Oncovin), Cyclophosphamide, Doxorubicin (Hydrochloride) + Rituximab (EPOCH + R); Rituximab, Cyclophosphamide, Etoposide, Procarbazine, Prednisone (RCEPP); Rituximab, Cyclophosphamide, Mitoxantrone (Novantrone), Vincristine (Oncovin), Prednisone (RCNOP); Dose-adjusted-Etoposide, Prednisone, Vincristine(Oncovin), Cyclophosphamide, Doxorubicin (Hydrocloride) (DA-EPOCH); and Rituximab, Cyclophosphamide, Etoposide, Vincristine (Oncovin), Prednisone (RCEOP)].- Subject must have adequate coagulation, renal, and hepatic function, per laboratory reference range at Screening.",ct_exc_472146,AACT,652,NCT01594229,Recent,DA-EPOCH
5c7430628625dd0452867f9c,40,,,233,Patient,13:54.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_471737,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients will be eligible if the treatment phase consisting in a Rituximab combined with any anthracycline-containing chemotherapy regimen without consolidation with autologous stem cell support (e.g., 6 cycles of CHOP14-21, DA-EPOCH, Mega-CHOP or 12 weeks of VACOP-B or MACOP-B).-",ct_inc_471737,AACT,225,NCT01599559,Hypothetical,DA-EPOCH
5c7430698625dd04cb867f89,260,,,417,Patient,14:01.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_407198,Clinical Trial Inclusion Criteria,UNKNOWN,"< 3 x upper limit of normal (ULN) - Creatinine =< 2.0 mg/dL OR creatinine clearance (calculated clearance permitted) >= 40 mL/min by Cockcroft-Gault formula - Prothrombin time (PT)/ international normalized ration (INR) < 1.5 x ULN and partial thromboplastin time (PTT) (activated [a]PTT) < 1.5 x ULN - Patient must have progressed or be refractory to prior anthracycline-containing chemotherapy (e.g.R-CHOP, DA-EPOCH-R, etc) -",ct_inc_407198,AACT,409,NCT02443077,Historical,DA-EPOCH
5c74306f8625dd0518867f8d,100,,,8,Patient,14:07.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_596409,Clinical Trial Exclusion Criteria,UNKNOWN,DA-Epoch-R chemotherapy.,ct_exc_596409,AACT,0,NCT00001379,Recent,DA-Epoch
5c74306f8625dd0518867f8e,100,,,217,Patient,14:07.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_596409,Clinical Trial Exclusion Criteria,UNKNOWN,Patients with significant renal (Cr.greater than 1.5 mg/dl or creatinine less than 40 cc/min) or hepatic (bilirubin greater than 2.5 u) dysfunction not due to tumor involvement will not be eligible to receive DA-EPOCH-R chemotherapy.,ct_exc_596409,AACT,209,NCT00001379,Recent,DA-EPOCH
5c74306f8625dd0518867f8f,100,,,182,Patient,14:07.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_596409,Clinical Trial Exclusion Criteria,UNKNOWN,Patients who received > 450 mg/m2 doxorubicin and have a cardiac ejection fraction on echocardiogram less than or equal to 40% on protocol entry are not eligible to received DA-EPOCH-R.,ct_exc_596409,AACT,174,NCT00001379,Recent,DA-EPOCH
5c74307c8625dd05b6867f84,10,,,96,Patient,14:20.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_478558,Clinical Trial Inclusion Criteria,UNKNOWN,"First-line treatment of DLBCL must have been 6 cycles of standard R-CHOP21, R-CHOP14 or DA-EPOCH-R chemotherapy.",ct_inc_478558,AACT,88,NCT01510184,Recent,DA-EPOCH
5c74307f8625dd05b6867f9e,10,,,24,Patient,14:23.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_362663,Clinical Trial Inclusion Criteria,UNKNOWN,[14 or 21] or R-DA-EPOCH or R-CHOEP) of 6 cycles.,ct_inc_362663,AACT,16,NCT03023878,Recent,DA-EPOCH
5c7430818625dd05e2867f84,330,,,1011,Patient,14:25.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_399851,Clinical Trial Inclusion Criteria,COMMENT,"Patients with liver test abnormalities attributable to hepatic involvement by ALL will be permitted if the total bilirubin is =< 3.0 x ULN and ALT/AST are =< 5.0 x ULN - Creatinine =< 1.5 mg/dL; however, patients with a creatinine > 1.5 mg/dL but with a calculated creatinine clearance of > 60 ml/min, as measured by the Modification of Diet in Renal Disease (MDRD) equation, will be eligible - Measurement of left ventricular ejection fraction (LVEF) should be performed in patients with prior anthracycline exposure or known history of arrhythmia or structural heart disease; in these cases, LVEF must be >= 40% - As patients with ALL frequently have cytopenias, no hematologic parameters will be required for enrollment or to receive the first cycle of treatment; however, adequate recovery of blood counts will be required to receive subsequent cycles - Per good clinical practice, any toxicity related to prior therapies that, in the opinion of the investigator, would potentially be worsened with DA-EPOCH-A +/-",ct_inc_399851,AACT,1003,NCT02538926,Hypothetical,DA-EPOCH
5c7430828625dd05e2867f85,330,,,67,Patient,14:26.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_483498,Clinical Trial Inclusion Criteria,LABORATORY_DATA,"Not pregnant or nursing, because of the unknown effects of DA-EPOCH-R or siplizumab on the developing fetus and infant.",ct_inc_483498,AACT,59,NCT01445535,Recent,DA-EPOCH
5c7430548625dd03c7867fb4,0,,,369,Patient,13:40.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_389834,Clinical Trial Inclusion Criteria,UNKNOWN,"These patients include: - Acute myeloid leukemia patients receiving induction and consolidation (first line and relapsed/refractory) - Acute lymphoid leukemia patients receiving HyperCVAD/R (cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, rituximab) - Lymphoma patients receiving ICE (ifosfamide, carboplatin, etoposide), DA-R-EPOCH (dose-adjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin), and other inpatient lymphoma regimens - Patients receiving other inpatient chemotherapy regimens that are given on a monthly basis - Patients who have received an allogeneic stem cell transplant - Have given informed consent - May have previously received inhaled or IV pentamidine",ct_inc_389834,AACT,359,NCT02669706,Recent,DA-R-EPOCH
5c7430b78625dd07eb867f89,930,,,22,Patient,15:19.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_491797,Clinical Trial Exclusion Criteria,UNKNOWN,"Dabrafenib monotherapy within 14 days prior to starting combination therapy is allowed for crossover subjects in Cohort A); - Use of any investigational anti-cancer drug within 14 days or 5-half-lives (minimum 14 days), prior to start of study medication (Note:",ct_exc_491797,AACT,0,NCT01336634,Historical,Dabrafenib monotherapy
5c7430b78625dd07eb867f8a,930,,,22,Patient,15:19.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_491797,Clinical Trial Exclusion Criteria,UNKNOWN,"Dabrafenib monotherapy within 14 days prior to starting combination therapy is allowed for crossover subjects in Cohort A); - Current use of a prohibited medication or expected to require any of these medications during treatment with study treatment.- Unresolved toxicity of National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 (NCI CTCAE v4.",ct_exc_491797,AACT,0,NCT01336634,Historical,Dabrafenib monotherapy
5c74303f8625dd0329867f84,1210,,,160,Patient,13:19.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_383580,Clinical Trial Exclusion Criteria,UNKNOWN,"Subject has received daratumumab or other anti-CD38 therapies, within 6 months before start of treatment (however, patients treated with daratumumab monotherapy in compassionate use program or after European Medicines Agency (EMA) approval, and have progressive disease during daratumumab after previous response, or unresponsive disease to daratumumab [progressive disease after cycle 1, less than minimal response after cycle 2, or less than partial response after cycle 3], may be included in Part B) Non-secretory myeloma Systemic amyloid light-chain (AL) amyloidosis or plasma cell leukemia (>2.0x109/L circulating plasma cells by standard differential) or",ct_exc_383580,AACT,137,NCT02751255,Recent,daratumumab monotherapy
5c7430618625dd0473867f8b,570,,,823,Patient,13:53.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_435329,Clinical Trial Exclusion Criteria,UNKNOWN,"Has received any of the following therapies: daratumumab or other anti-CD38 therapies - Has received anti-myeloma treatment within 2 weeks or 5 pharmacokinetic half-lives of the treatment - Disease shows evidence of refractoriness or intolerance to lenalidomide or if previously treated with a lenalidomide-containing regimen the participant is excluded if he or she discontinued due to any adverse event related to prior lenalidomide treatment - Has received autologous stem cell transplantation within 12 weeks before the date of randomization, or previously received an allogenic stem cell transplant (regardless of timing), or planning to undergo a stem cell transplant prior to progression of disease - History of malignancy (other than multiple myeloma) within 5 years before the first dose of daratumumab monotherapy (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or breast, or other non-invasive lesion, that in the opinion of the investigator, with concurrence with the sponsor's medical monitor, is considered cured with minimal risk of recurrence within 5 years)",ct_exc_435329,AACT,800,NCT02076009,Hypothetical,daratumumab monotherapy
5c7430b78625dd0808867f89,320,,,728,Patient,15:19.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_435329,Clinical Trial Inclusion Criteria,UNKNOWN,"Must have documented multiple myeloma and measurable disease - Must have received at least 1 prior line of therapy for multiple myeloma and achieved a response (partial response or better) to at least one prior regimen - Must have documented evidence of progressive disease as defined by the International Myeloma Working Group criteria on or after their last regimen - Must have an Eastern Cooperative Oncology Group Performance Status score of 0, 1, or 2 - If a participant has received subsequent anticancer therapy (salvage therapy), the participant must have a wash-out period defined as 2 weeks or 5 pharmacokinetic half-lives of the treatment, whichever is longer, before the planned start date of daratumumab monotherapy.",ct_inc_435329,AACT,705,NCT02076009,Historical,daratumumab monotherapy
5c7430b78625dd0808867f8a,320,,,182,Patient,15:19.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_435329,Clinical Trial Inclusion Criteria,UNKNOWN,The only exception is the emergency use of a short course of corticosteroids (equivalent of dexamethasone 40 milligram per day for a maximum of 4 days) before Daratumumab monotherapy,ct_inc_435329,AACT,159,NCT02076009,Recent,Daratumumab monotherapy
5c7430668625dd049f867f88,960,,,150,Patient,13:58.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_465876,Clinical Trial Inclusion Criteria,UNKNOWN,"This may include a combination regimen including lenalidomide; these regimens will include dexamethasone, cyclophosphamide, etoposide, cisplatin (DCEP), Velcade with Doxil, Cytoxan and/or lenalidomide; patients who have thrombocytopenia (CIT) from lenalidomide or from radiation therapy alone will not be allowed - Calculated or measured creatinine clearance >= 30 mL/min",ct_inc_465876,AACT,146,NCT01676961,Recent,DCEP
5c74303b8625dd02f6867f88,120,,,74,Patient,13:15.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_366993,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Patients who have undergone or will undergo DEB-TACE for HCC delivered by the Surefire Precision Infusion System - Patients aged 18 years or older - Diagnosis of HCC -,ct_inc_366993,AACT,66,NCT02967523,Recent,DEB-TACE
5c7430518625dd03a2867f92,130,,,302,Patient,13:37.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_340115,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: Diagnosed as primary HCC, primary ICC or secondary liver cancer confirmed by pathological findings, clinical features or radiographic examinations according to American Association for the Study of the Liver Diseases (AASLD) guidelines; Age above 18 years; About to receive DEB-TACE treatment with CalliSpheres according to clinical needs and patients' willing.",ct_inc_340115,AACT,294,NCT03317483,Recent,DEB-TACE
5c74305b8625dd0431867f8a,220,,,368,Patient,13:47.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_353492,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Age 18 and over at the time of consent - Histology and/or cytology confirmed HCC per the enrolling institution - Measurable disease per RECIST v1.1 - Disease not amenable to curative or transplant surgery (BCLC Stage B); disease must be reviewed by members of disease management team at the local enrolling institution and be amenable to deb-TACE to treat all sites of disease in one session - ECOG Performance status 0 or 1 - Child-,ct_inc_353492,AACT,360,NCT03143270,Recent,deb-TACE
5c74305b8625dd0431867f8b,220,,,85,Patient,13:47.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_389802,Clinical Trial Exclusion Criteria,UNKNOWN,"Any other condition that according to investigator criteria, contraindicates DEB-TACE.",ct_exc_389802,AACT,77,NCT02670122,Recent,DEB-TACE
5c74305b8625dd0431867f8c,220,,,175,Patient,13:47.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_337227,Clinical Trial Inclusion Criteria,PAST_SURGICAL_HISTORY,"whichever is shortest Other locoregional therapy [e.g., radiofrequency ablation (RFA), TACE (transarterial chemoembolization), TARE (transarterial radioembolization), DEB-TACE (drug eluting bead transarterial chemoembolization)]:",ct_inc_337227,AACT,167,NCT03355066,Recent,DEB-TACE
5c74305c8625dd0411867f92,300,,,90,Patient,13:48.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_491770,Clinical Trial Inclusion Criteria,UNKNOWN,"Anti-VEGF agents (eg, Avastin) may not be administered less than 4 weeks prior to DEB-TACE treatment.- Patients are not to receive conventional chemotherapy or therapeutic monoclonal antibodies while receiving protocol treatment -",ct_inc_491770,AACT,82,NCT01336985,Historical,DEB-TACE
5c74305f8625dd0447867f93,250,,,164,Patient,13:51.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_456589,Clinical Trial Exclusion Criteria,UNKNOWN,"Any co-morbid disease or condition or event that, in the investigator's judgment, would place the patient at undue risk that would preclude the safe use of DEB-TACE.",ct_exc_456589,AACT,156,NCT01798134,Recent,DEB-TACE
5c7430a08625dd0716867f84,150,,,202,Patient,14:56.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_351373,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Patients aged 18 years or older with the diagnosis of HCC currently being evaluated for liver transplantation and considered for downstaging.- Patients undergoing Surefire DEB-TACE procedure as clinically determined - Single tumor that is >5 cm and less than 8 cm, OR 1 to 3 tumors with combined diameter greater than 15 cm and less than 24 cm - No portal invasion or extrahepatic spread - No previous chemotherapy, radiotherapy or transarterial embolization (with or without chemotherapy) -",ct_inc_351373,AACT,194,NCT03170869,Recent,DEB-TACE
5c7430a18625dd0716867f85,150,,,183,Patient,14:57.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_315489,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Signed informed consent form - Age 18-75 years - Newly diagnosed with hepatocellular carcinoma - Have measurable disease - Have disease that responds to DEB-TACE - Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 - Body weight,ct_inc_315489,AACT,175,NCT03638141,Recent,DEB-TACE
5c7430ad8625dd077d867f96,170,,,8,Patient,15:09.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_389802,Clinical Trial Inclusion Criteria,UNKNOWN,DEB-TACE with 100 microspheres according to usual clinical practice.,ct_inc_389802,AACT,0,NCT02670122,Recent,DEB-TACE
5c7430bf8625dd084a867f97,140,,,146,Patient,15:27.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_429870,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: Liver-directed therapy (chemoembolization, radioembolization, bland embolization, ablative therapy) within 4 weeks of DEB-TACE.",ct_exc_429870,AACT,138,NCT02147301,Recent,DEB-TACE
5c7430bf8625dd084a867f98,140,,,124,Patient,15:27.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_429870,Clinical Trial Exclusion Criteria,UNKNOWN,Systemic therapy with sorafenib or other systemic chemotherapeutic agent(s) less than 1 week prior to first planned DEB-TACE.,ct_exc_429870,AACT,116,NCT02147301,Historical,DEB-TACE
5c7430bf8625dd084a867f99,140,,,135,Patient,15:27.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_429870,Clinical Trial Exclusion Criteria,UNKNOWN,"Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with DEB-TACE, breastfeeding must be discontinued for eligibility.",ct_exc_429870,AACT,127,NCT02147301,Recent,DEB-TACE
5c7430718625dd0544867f84,280,,,36,Patient,14:09.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_516146,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria: - Prior DexaBEAM or miniBEAM therapy and prior bone marrow or PBPC transplant - Any history of seasonal or recurrent asthma within the preceding 10 years.-,ct_exc_516146,AACT,28,NCT01016795,Historical,DexaBEAM
5c74304f8625dd0397867f88,1090,,,110,Patient,13:35.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_361940,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: Types of Multiple Myeloma previously shown to be irresponsive to dexamethasone monotherapy during the last 6 months Plasma cell leukemia Subject with positive hepatitis panel (including hepatitis B surface antigen [HBsAg], and / or anti-hepatitis B core antibodies, and / or hepatitis C virus antibody [anti-HCV]), and / or a positive HIV antibody screen Severe abnormal organ function function or laboratory results at the time of the Screening Visit:",ct_exc_361940,AACT,85,NCT03033316,Recent,dexamethasone monotherapy
5c7430388625dd02b7867f8c,560,,,228,Patient,13:12.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_585991,Clinical Trial Inclusion Criteria,UNKNOWN,"cell Diffuse large cell Large cell, immunoblastic Lymphoblastic Small noncleaved cell Disease has relapsed following or is resistant to primary anthracycline-containing combination chemotherapy Objective response to salvage DHAP chemotherapy required Ineligible for bone marrow transplantation",ct_inc_585991,AACT,224,NCT00002488,Recent,DHAP
5c7430388625dd02b7867f8d,560,,,83,Patient,13:12.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_585991,Clinical Trial Inclusion Criteria,CHEMOTHERAPEUTICS,Prior anthracycline-containing combination chemotherapy required Prior salvage DHAP chemotherapy required Endocrine therapy:,ct_inc_585991,AACT,79,NCT00002488,Historical,DHAP
5c7430408625dd0329867f86,1210,,,256,Patient,13:20.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_436865,Clinical Trial Exclusion Criteria,UNKNOWN,"Serum total bilirubin > 2.0 mg/dL (34 mol/L), except in patients with hemolytic anemia or with Gilbert syndrome, Calculated creatinine clearance of < 50 mL /min (for patients who will have DHAOx chemotherapy) or < 70 mL/min (for patients who will have DHAP chemotherapy)",ct_exc_436865,AACT,252,NCT02055924,Recent,DHAP
5c74304b8625dd0381867f94,230,,,1028,Patient,13:31.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_363654,Clinical Trial Inclusion Criteria,COMMENT,"Has EITHER histologically confirmed B-cell lymphomas including but not limited to diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), primary mediastinal B-cell lymphoma (PMBCL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), or Hodgkin lymphoma (HL) and has relapsed or refractory disease following at least two lines of prior standard therapy, including alkylator/anthracycline (unless anthracycline-based chemotherapy is contraindicated)/anti-CD20-based therapy (R-CHOP, rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisolone or dexamethasone, or equivalent for non-Hodgkin lymphoma), AND must be considered unable to benefit from intensification treatment with autologous hematopoietic stem cell transplantation (ASCT) , as defined by meeting at least one of the following criteria: - Relapsed following, or refractory to, previous ASCT - Did not achieve at least a partial response to a standard salvage regimen (e.g., R-ICE, rituximab, ifosfamide, carboplatin, etoposide, or R-DHAP, rituximab, dexamethasone, cytarabine, cisplatin) -",ct_inc_363654,AACT,1024,NCT03010982,Historical,DHAP
5c74304c8625dd0381867f99,230,,,163,Patient,13:32.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_362341,Clinical Trial Inclusion Criteria,UNKNOWN,"previous ASCT Did not achieve at least a partial response (PR) to a standard salvage regimen (e.g., R-ICE; rituximab, ifosfamide, carboplatin, etoposide, or R-DHAP; rituximab, dexamethasone, cytarabine, cisplatin)",ct_inc_362341,AACT,159,NCT03028103,Recent,DHAP
5c7430578625dd03fe867f8e,290,,,906,Patient,13:43.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_448981,Clinical Trial Exclusion Criteria,COMMENT,"Subjects must satisfy all of the following criteria: Have histologically confirmed DLBCL (including primary mediastinal B-cell lymphoma), with relapsed or refractory disease following at least 2 lines of prior standard therapy, including alkylator/anthracycline (unless anthracycline-based chemotherapy is contraindicated)/anti-CD20-based therapy (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP] or equivalent) AND must be considered unable to benefit from intensification treatment with autologous hematopoietic stem cell transplantation (ASCT) as defined by meeting at least 1 of the following criteria: - Relapsed following, or refractory to, previous ASCT - Did not achieve at least a partial response to a standard salvage regimen (eg, rituximab, ifosfamide, carboplatin, and etoposide phosphate [R-ICE] or rituximab, dexamethasone, cytarabine, and cisplatin [R-DHAP]) -",ct_exc_448981,AACT,902,NCT01897571,Historical,DHAP
5c7430588625dd03fe867f95,290,,,113,Patient,13:44.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_586600,Clinical Trial Inclusion Criteria,UNKNOWN,"No more than 1 prior salvage chemotherapy regimen, e.g.: Dexamethasone, high dose cytarabine, and cisplatin (DHAP) Etoposide, methylprednisolone, high dose cytarabine, and cisplatin",ct_inc_586600,AACT,109,NCT00005613,Historical,DHAP
5c7430588625dd03fe867f96,290,,,10,Patient,13:44.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_586600,Clinical Trial Inclusion Criteria,UNKNOWN,ESHAP DHAP OR,ct_inc_586600,AACT,6,NCT00005613,Recent,DHAP
5c74305b8625dd0431867f8f,220,,,126,Patient,13:47.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_571475,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically confirmed Hodgkin's lymphoma or Non-Hodgkin's lymphoma receiving Q14, Q21, or Q28 day CHOP, ICE, ESHAP, or DHAP chemotherapy; with or without Rituximab - Has adequate bone marrow function; platelet count > 100 x 10^9/L on the day of initiation of the on study chemotherapy of the next treatment cycle and absolute neutrophil count, ANC > or = 1 x 10^9/L, and hemoglobin > or = 9.5 g/dL - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - Has adequate liver function - must be able to receive the same chemotherapy regimen during the first treatment cycle as was received during the prior qualifying cycle - must experience Common Terminology Criteria (CTC) grade 3 or 4 thrombocytopenia (",ct_inc_571475,AACT,122,NCT00283439,Historical,DHAP
5c7430708625dd0518867f93,100,,,305,Patient,14:08.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_477514,Clinical Trial Inclusion Criteria,UNKNOWN,"Patient age is 18 years Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 2 Patient has a history of DLBCL according to the WHO classification Patient has progressive disease after receiving at least CHOP-R or CHOP-R like first line regimen, standard second line therapy (DHAP, ESHAP, ICE or similar salvage regimens) inclusive ASCT Patient has progressive disease after receiving at least CHOP-R or CHOP-R like first line regimen and is not considered eligible for intensive salvage therapy including ASCT because of age, co-morbidities, impossibility to perform ASCT Patient undergoes at baseline new lymphnode or other pathologic tissue biopsy for confirmation of diagnosis and biologic studies; bone marrow biopsy is not adequate for this purpose and should be performed only for staging.",ct_inc_477514,AACT,301,NCT01523834,Historical,DHAP
5c7430738625dd0518867fa1,100,,,258,Patient,14:11.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_329307,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients eligible for ASCT who failed to achieve a Complete Response (CR) after at least one salvage therapy (eg, Rituximab-Etoposide- Methylprednisolone - Cytarabine - Cisplatin (R-ESHAP) or Rituximab- Dexamethasone- High-dose Cytarabine - Cisplatin (R-DHAP), patients who were previously refractory to Rituximab-Ifosfamide-Cytarabine-Etoposide (R-ICE) (stable disease or progressive disease) are not eligible to the study) Or patients in first relapse after Autologous Stem Cell Transplant (ASCT) Or patients not eligible for ASCT who failed to achieve a CR after at least one prior treatment (and no more than 4 previous lines) or in relapse after at least one prior treatment (and no more than 4 previous lines).",ct_inc_329307,AACT,254,NCT03458260,Historical,DHAP
5c74307e8625dd05b6867f98,10,,,361,Patient,14:22.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_583905,Clinical Trial Inclusion Criteria,UNKNOWN,"Chemotherapy combinations may include, but are not limited to: CHOP (Cyclophosphamide, doxorubicin, vincristine, prednisone), R-CHOP (Rituximab, Cyclophosphamide, doxorubicin, vincristine, prednisone), FCM (Fludarabine, cyclophosphamide, mitoxantrone), R-FCM (Rituximab,Fludarabine, cyclophosphamide, mitoxantrone), ICE(Ifosfamide, carboplatin, etoposide), DHAP (Dexamethasone, cisplatin, cytarabine) and hyper-CVAD (Cyclophosphamide, doxorubicin, vincristine, dexamethasone).",ct_inc_583905,AACT,357,NCT00117598,Recent,DHAP
5c74307f8625dd05d0867f86,410,,,80,Patient,14:23.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_373846,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria: - Pregnancy (first trimester only) - Known allergies to DHAP - Known chronic cardiac disease,ct_exc_373846,AACT,76,NCT02878200,Recent,DHAP
5c74308e8625dd065b867f9d,20,,,5,Patient,14:38.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_509078,Clinical Trial Inclusion Criteria,UNKNOWN,[DHAP];,ct_inc_509078,AACT,1,NCT01110135,Recent,DHAP
5c7430918625dd065b867fa2,20,,,930,Patient,14:41.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_509078,Clinical Trial Exclusion Criteria,UNKNOWN,- Fludarabine or other nucleoside analog (except gemcitabine or cytarabine) therapy within 24 months of registration; patients with limited exposure to fludarabine/other nucleoside analog therapy within 24 months may be considered eligible with review and,ct_exc_509078,AACT,926,NCT01110135,Historical,DHAP
5c7430968625dd069d867f8c,880,,,515,Patient,14:46.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_467684,Clinical Trial Exclusion Criteria,UNKNOWN,"Brain MRI is required only if clinically indicated - Pregnancy or breast feeding women - Lymphoma other than DLBCL - Severe concomitant disease (e.g.uncontrolled arterial hypertension, heart failure (NYHA III-IV), uncontrolled diabetes mellitus, pulmonary fibrosis, uncontrolled hyperlipoproteinemia) - Active uncontrolled infections including HIV-positivity, active Hep B or C - Mental status precluding patient's compliance - Prior treatment with Temsirolimus - Known CD20 negativity - Patients refractory to DHAP in a prior treatment line - Prior autologous or allogeneic stem cell or bone marrow transplantation - Peripheral neuropathy or neuropathic pain of Grade 2 or worse - Diagnosed or treated for a malignancy other than NHL except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, DCIS of the breast, or other solid tumors curatively treated with no evidence of disease for >5 years - Concurrent treatment with another investigational agent during the conduct of the trial.- Concurrent participation in non-treatment studies is not excluded - Known intolerance to Sirolimus or derivates, Cytarabine, Cisplatine or Rituximab.",ct_exc_467684,AACT,511,NCT01653067,Historical,DHAP
5c74309d8625dd06f5867f88,440,,,122,Patient,14:53.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_373846,Clinical Trial Inclusion Criteria,UNKNOWN,Resident in the study area for at least two weeks - Informed consent to participate in the trial - willing to receive DHAP (intervention villages) - Age 6 months and weight 5kg*,ct_inc_373846,AACT,118,NCT02878200,Recent,DHAP
5c74309d8625dd06f5867f89,440,,,191,Patient,14:53.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_592716,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients must have recurrent or refractory intermediate-grade or high-grade non-Burkitt's, non-Hodgkin's lymphoma (NHL) or Hodgkin's disease and be scheduled for a minimum of 2 cycles of DHAP (Dexamethasone, high-dose Cytarabine and Cisplatin) chemotherapy",ct_inc_592716,AACT,187,NCT00039910,Recent,DHAP
5c7430aa8625dd077d867f90,170,,,71,Patient,15:06.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_399410,Clinical Trial Inclusion Criteria,DIAGNOSES,"18 years Eligible for intensive salvage chemotherapy with R-ICE, R-DHAP Patient received first line of chemotherapy when DLBCL was initially diagnosed and did not receive any further chemotherapy until enrollment in this study All treatment-related toxicities from prior chemotherapy resolved to grade 1or resolved to grade 2 only if deemed clinically not significant and approved by the Sponsor 7.",ct_inc_399410,AACT,67,NCT02544724,Hypothetical,DHAP
5c7430ad8625dd077d867f95,170,,,421,Patient,15:09.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_422608,Clinical Trial Inclusion Criteria,COMMENT,"Measurable disease is not required, but will be followed if it exists - Patients must have received 4 or more cycles of one of the following prior systemic induction chemotherapy regimens: - Rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunomycin), vincristine sulfate (Oncovin), prednisone (R-CHOP) (with or without alternating rituximab, dexamethasone, cytarabine [ara-c], cisplatin [platinum] [R-DHAP]) with or without autologous (auto) stem cell transplant (SCT) - Hyper-cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride (adriamycin), dexamethasone (CVAD) with or without auto SCT - Bendamustine + rituximab with or without auto SCT - Please",ct_inc_422608,AACT,417,NCT02242097,Hypothetical,DHAP
5c7430bb8625dd083f867f96,240,,,134,Patient,15:23.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_591782,Clinical Trial Inclusion Criteria,DIAGNOSES,"In PR or CR after 1-2 other salvage chemotherapy regimens (e.g., 3 courses of dexamethasone, high-dose cytarabine, and cisplatin (DHAP); 2 courses of cyclophosphamide, mechlorethamine, vincristine, procarbazine, and prednisone (C-MOPP)) -",ct_inc_591782,AACT,130,NCT00002697,Recent,DHAP
5c7430be8625dd081e867f96,110,,,391,Patient,15:26.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_343958,Clinical Trial Inclusion Criteria,COMMENT,"For example, a patient who started treatment with rituximab/bendamustine and was then switched to rituximab(R)-cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (CHOP) (due to insufficient response or excessive toxicity) would be counted as having received 2 regimens; however, R-CHOP alternating with R-dexamethasone, high-dose cytarabine, and cisplatin (DHAP) as a planned induction regimen would count as one regimen - Patient does not have any documented history of central nervous system (CNS) involvement by mantle cell lymphoma; this includes no evidence of parenchymal brain, spinal cord, or cerebrospinal fluid involvement; radiculopathy symptoms from nerve root compression by lymphoma do not constitute CNS involvement - Patient must have archived formalin-fixed paraffin-embedded (FFPE) tumor tissue specimen from the original diagnostic biopsy available for submission to Adaptive Biotechnologies for ClonoSEQ ID molecular marker identification of unique clonal immunoglobulin deoxyribonucleic acid (DNA) sequence -",ct_inc_343958,AACT,387,NCT03267433,Historical,DHAP
5c7430be8625dd081e867f9a,110,,,245,Patient,15:26.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_343958,Clinical Trial Inclusion Criteria,COMMENT,"For example, a patient who started treatment with rituximab/bendamustine and was then switched to R-CHOP (due to insufficient response or excessive toxicity) would be counted as having received 2 regimens; however, R-CHOP alternating with R-DHAP as a planned induction regimen would count as one regimen - Patients must have achieved a radiologic complete or partial remission as defined by the Lugano criteria - Patients must meet institutional eligibility requirements for stem cell transplant, including cardiac, renal, liver, and pulmonary requirements - Patients have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 - Human immunodeficiency virus (HIV) positive patients are not excluded, but to enroll, must meet all of the below criteria: - HIV is sensitive to antiretroviral therapy - Must be willing to take effective antiretroviral therapy if indicated - CD4 count at screening >",ct_inc_343958,AACT,241,NCT03267433,Hypothetical,DHAP
5c7430c08625dd084a867f9c,140,,,315,Patient,15:28.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_436865,Clinical Trial Inclusion Criteria,UNKNOWN,Each patient (or their legally acceptable representative) must sign an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the study and are willing to participate in the study Patients eligible for autologous stem cell transplantation (ASCT) for whom R-DHAP or R-DHAOx is an acceptable therapy regarding the investigator's opinion Measurable disease defined by at least one single node or tumor lesion > 1.5 cm Patients who received prior therapy with at least one but no more than two lines therapies for B-Cell Lymphoma (except for patients included in group C during the expansion part of the study),ct_inc_436865,AACT,311,NCT02055924,Historical,DHAP
5c7430448625dd033f867f8c,310,,,1087,Patient,13:24.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_477019,Clinical Trial Inclusion Criteria,UNKNOWN,- Provision of informed consent prior to any study specific procedures.- Histologically or cytologically confirmed NSCLC with an activating sensitising EGFR TK mutation as it was determined before starting the first gefitinib treatment by using a well-val,ct_inc_477019,AACT,1066,NCT01530334,Historical,docetaxel monotherapy
5c7430448625dd033f867f8e,310,,,242,Patient,13:24.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_439216,Clinical Trial Inclusion Criteria,UNKNOWN,">12 weeks as the best response to their 1st EGFR-TKI treatment and who have received any subsequent anti-cancer therapy (excluding EGFR-TKIs) treatment, including but not limited to doublet platinum based chemotherapy or docetaxel monotherapy or pemetrexed monotherapy, on which they progressed.- Measurable disease defined as at least one lesion, not previously irradiated, that can be accurately measured at baseline as 10 mm in the longest diameter (except lymph nodes which must have short axis 15 mm) with spiral CT or MRI and which is suitable for accurate repeated measurements.- WHO / ECOG / Zubrod performance status 0-2.- Possibility of obtaining tumour material before the start of the study treatment.",ct_inc_439216,AACT,221,NCT02025218,Recent,docetaxel monotherapy
5c7430458625dd033f867f93,310,,,57,Patient,13:25.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_552478,Clinical Trial Inclusion Criteria,UNKNOWN,"AC, doxorubicin and vinorelbine, or docetaxel monotherapy) in the presence of 1 patient risk factor (>65 yrs, extensive bone marrow involvement or prior extensive radiotherapy on bone tissue - Prior chemotherapy - ECOG performance status of 2 or more, grade 2 or higher liver function abnormalities).- That is, patients starting with docetaxel as second part of FEC-D are eligible for the last 3 docetaxel cycles, if there is an increased risk of febrile neutropenia, e.g.by elderly age.-",ct_inc_552478,AACT,36,NCT00536081,Historical,docetaxel monotherapy
5c7430488625dd0360867f8d,780,,,64,Patient,13:28.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_379657,Clinical Trial Exclusion Criteria,UNKNOWN,"Patients with following treatment prior to Docetaxel monotherapy: chemotherapy, immunotherapy, or biologic systemic anticancer therapy within 21 days of study entry (42 days for mitomycin and nitrosoureas); prior taxanes; radiation therapy within 28 days (3 months for bone marrow exposure 20%); hormonal therapy within 4 weeks.",ct_exc_379657,AACT,43,NCT02802423,Historical,Docetaxel monotherapy
5c7430528625dd03ad867f88,590,,,314,Patient,13:38.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_522660,Clinical Trial Inclusion Criteria,UNKNOWN,Study participants - Has provided written informed consent - Is at least 18 years of age - Has histologically or cytologically confirmed non-small cell lung (NSCLC) or breast cancer (BC) that is locally advanced or metastatic - Has at least two planned consecutive 21-day cycles with 75 mg/m2 docetaxel monotherapy,ct_inc_522660,AACT,293,NCT00931008,Recent,docetaxel monotherapy
5c74306b8625dd04d6867f88,890,,,205,Patient,14:03.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_367327,Clinical Trial Inclusion Criteria,UNKNOWN,Histologically or cytologically confirmed solid tumor that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective Docetaxel monotherapy is a reasonable treatment in the judgement of the Investigator Measurable disease as per RECIST v1.1 criteria Able to swallow oral medication as an intact dosage form,ct_inc_367327,AACT,184,NCT02963168,Recent,Docetaxel monotherapy
5c74306b8625dd04d6867f89,890,,,41,Patient,14:03.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_379657,Clinical Trial Inclusion Criteria,UNKNOWN,Planning to receive Docetaxel monotherapy.,ct_inc_379657,AACT,20,NCT02802423,Recent,Docetaxel monotherapy
5c7430af8625dd079a867f92,380,,,133,Patient,15:11.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_467677,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Age greater than 18 years - Documented advanced-stage non-hematologic malignancy for whom docetaxel monotherapy is a reasonable treatment option - Eastern Cooperative Oncology Group [ECOG] performance status 0,ct_inc_467677,AACT,112,NCT01653158,Recent,docetaxel monotherapy
5c74307d8625dd0599867f8c,1180,,,321,Patient,14:21.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_435282,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients with histologically or cytologically confirmed advanced solid cancer deemed suitable for combination therapy of L19TNF and doxorubicin.- Patients aged 18 years old with advanced or metastatic solid tumor in whom standard anticancer therapies have been exhausted and who are amenable for a doxorubicin monotherapy according to the discretion of the Principal Investigators and previously treated with a cumulative dose of anthracyclines ( 300 mg/m2).- Eastern cooperative oncology group (ECOG) performance status 2.- Patients may have received previous chemotherapy (>4 weeks prior therapy) or radiation therapy (>6 weeks prior therapy), but they must be amenable for doxorubicin treatment according to the discretion of the Principal Investigator.- Patients must have at least one unidimensionally measurable lesion by computed tomography as defined by RECIST criteria version 1.",ct_inc_435282,AACT,298,NCT02076620,Historical,doxorubicin monotherapy
5c7430aa8625dd0763867f92,730,,,54,Patient,15:06.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_584188,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients must be able to receive full doses of DT-PACE, in the opinion of the treating investigator, with the exception of cisplatin.- Patients must have a performance status of 0-2 based on SWOG criteria unless the patient's status is due to active myeloma - All patients must be informed of the investigational nature of the study and have signed an IRB-approved informed consent in accordance with institutional and federal guidelines.",ct_inc_584188,AACT,47,NCT00113919,Recent,DT-PACE
5c7430398625dd02e7867f84,580,,,80,Patient,13:13.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_561359,Clinical Trial Inclusion Criteria,UNKNOWN,"Excluded prior therapies include prior high dose aldesleukin, sorafenib and DTIC/",ct_inc_561359,AACT,76,NCT00418496,Historical,DTIC
5c7430398625dd02e7867f85,580,,,378,Patient,13:13.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_551937,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Chronic intravascular coagulopathy confirmed by the presence of fibrinogen degradation products, metastases to the liver, or exudative ascites - Prior organ allograft - Requirement for concomitant anticoagulant therapy (with the exception of 1 mg/day of warfarin for central line prophylaxis) while receiving protocol therapy - Known hypersensitive to DTIC - Prior treatment with Genasense",ct_exc_551937,AACT,374,NCT00543205,Historical,DTIC
5c7430398625dd02e7867f86,580,,,333,Patient,13:14.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_551961,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Less than 3 weeks of recovery from prior major surgery or other therapy, including radiation therapy, chemotherapy, or immunotherapy, or cytokine, biologic, or vaccine therapy - Significant medical disease - Known hypersensitivity to phosphorothioate-containing oligonucleotides - Known hypersensitivity to DTIC - Pregnancy/Lactation",ct_exc_551961,AACT,329,NCT00542893,Historical,DTIC
5c74303a8625dd02e7867f87,580,,,114,Patient,13:14.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_583298,Clinical Trial Inclusion Criteria,UNKNOWN,"Stage M1a, M1b, M1c biopsy proven metastatic melanoma - Failure of at least one prior chemotherapy regimen of DTIC and/or temozolomide with/without interleukin-2 (IL-2).- Karnofsky performance status greater than/equal to 80%.-",ct_inc_583298,AACT,110,NCT00125749,Historical,DTIC
5c74303b8625dd02e7867f8b,580,,,103,Patient,13:15.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_541204,Clinical Trial Inclusion Criteria,UNKNOWN,"AND The patient is a candidate for one of the following treatments: - First-line chemotherapy with DTIC or TMZ as monotherapy [group ME1],",ct_inc_541204,AACT,99,NCT00685750,Recent,DTIC
5c74303b8625dd02e7867f8c,580,,,55,Patient,13:15.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_541204,Clinical Trial Inclusion Criteria,UNKNOWN,"- First-line chemotherapy with an agent other than DTIC/TMZ as monotherapy or a combination (that may, but need not, include DTIC, TMZ, IL-2 or IFN) [group ME2], - Second- or higherline chemotherapy with any agent or combination of agents (that may, but n",ct_inc_541204,AACT,51,NCT00685750,Recent,DTIC
5c7430428625dd0310867f8b,970,,,611,Patient,13:23.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_370712,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Subject with dark brown or black spots, such as large freckles, birth marks, moles or warts on the area to be treated.- Subject with eczema, psoriasis, lesions, open wounds or active infections, such as cold sore in the area to be treated.- Subject with a history of kelodial scar formation, a known sensitivity to light (photosensitivity) or is taking medication that makes the skin more sensitive to light, including non-steroidal anti-inflammatory agents, (e.g., aspirins, ibuprofens, acetaminophen), tetracyclines, phenothiazines, thiazide, diuretics, sulfonyluraes, sulfonamides, DTIC, fluorouracil, vinblastine, griseofulvin, Alpha-Hydroxi Acids (AHAs), Beta-Hydroxi Acids (BHAs), Retin-A, Accutane and/or topical retinoids.- Subject with abnormal skin conditions caused by diabetes, for example, or other systemic or metabolic diseases.- Subject currently or has recently been treated with Alpha-Hydroxi Acids (AHAs), Beta-Hydroxi Acids (BHAs), Retin-A, topical retinoids or azelaic acid.- Subject has been treated with Accutane (isotretinoin) within the past 6 months.- Subject has been on a steroid regimen within the past 3 months.- Subject has a history of herpes outbreaks in the area of treatment.- Subject suffers from epilepsy.- Subject with an active implant, such as a pacemaker, incontinence device, insulin pump, etc.- Subject with a disease related to photosensitivity, such as porphyria, polymorphic light eruption, solar urticaria, lupus, etc.- Subject with a history of skin cancer or areas of potential skin malignancies.- Subject received radiation therapy or chemotherapy treatments within the past 3 months.- Subject is pregnant or nursing",ct_exc_370712,AACT,607,NCT02919007,Historical,DTIC
5c7430448625dd0308867f8f,680,,,117,Patient,13:24.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_377457,Clinical Trial Exclusion Criteria,UNKNOWN,"Prior chemotherapy with combination of capecitabine (or 5-flourouracil [5-FU]) and temozolomide (or dacarbazine [DTIC]) will be excluded; patients can have had prior therapies up to 3 prior chemotherapy regimens such as streptozocin, anthracyclines, irinotecan, etoposide, or a platinum agent including single agent capecitabine (or 5FU) or temozolomide (or DTIC).- History of severe hypersensitivity reaction to capecitabine, 5-FU, temozolomide or DTIC will be excluded (i.e.anaphylaxis or anaphylactoid reactions)",ct_exc_377457,AACT,113,NCT02831179,Historical,DTIC
5c7430448625dd0308867f90,680,,,220,Patient,13:24.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_435280,Clinical Trial Exclusion Criteria,UNKNOWN,"Pregnant or breastfeeding female Primary ocular melanoma Primary mucosal melanoma Use of any investigational or other anti-cancer drug within 28 days or 5 half-lives, whichever is longer, preceding the first dose of DTIC and L19-IL2 Prior radiation to a target lesion, unless there has been clear progression of the lesion since radiotherapy 6.",ct_exc_435280,AACT,216,NCT02076646,Historical,DTIC
5c7430448625dd0308867f91,680,,,450,Patient,13:24.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_435280,Clinical Trial Exclusion Criteria,UNKNOWN,"A history of known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection History or clinical evidence of brain metastases or leptomeningeal disease Any other malignancy from which the patient has been disease-free for less than 5 years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix Treatment with DTIC within 6 months before start of study Treatment with Ipilimumab within 6 months before start of study Hypersensitivity to DTIC Concomitant use of drugs known to alter cardiac conduction Chronic use of corticosteroids used in the management of cancer or non-cancer-related illness",ct_exc_435280,AACT,446,NCT02076646,Historical,DTIC
5c7430478625dd034a867f8d,650,,,81,Patient,13:27.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_527319,Clinical Trial Exclusion Criteria,UNKNOWN,"Patients previously treated with continuous infusion 5-FU or any schedule of DTIC (dacarbazine), which are similar to capecitabine and temozolomide, respectively, will be excluded.",ct_exc_527319,AACT,77,NCT00869050,Recent,DTIC
5c7430478625dd034a867f8e,650,,,103,Patient,13:27.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_527319,Clinical Trial Exclusion Criteria,UNKNOWN,"Patients with a history of severe hypersensitivity reaction to capecitabine, 5-FU, temozolomide or DTIC will be excluded (i.e.anaphylaxis or anaphylactoid reactions) -",ct_exc_527319,AACT,99,NCT00869050,Historical,DTIC
5c7430568625dd03fe867f89,290,,,95,Patient,13:42.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_495692,Clinical Trial Exclusion Criteria,UNKNOWN,Have a history of hypersensitivity reaction or intolerance to temozolomide or dacarbazine (DTIC),ct_exc_495692,AACT,91,NCT01285414,Historical,DTIC
5c7430598625dd03fb867f91,620,,,177,Patient,13:45.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_521233,Clinical Trial Inclusion Criteria,UNKNOWN,"/=18 years of age - histologically confirmed metastatic melanoma (Stage IV, AJCC) - patients must have completed and failed at least one prior standard of care regimen (e.g.DTIC, temozolomide, etc.)- BRAF V600E positive mutation (by Roche CoDx BRAF mutation assay) - measurable disease by RECIST criteria - negative pregnancy test and, for fertile men and women, effective contraception during treatment and for 6 months after completion",ct_inc_521233,AACT,173,NCT00949702,Historical,DTIC
5c7430598625dd0414867f84,690,,,943,Patient,13:45.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_506539,Clinical Trial Inclusion Criteria,COMMENT,"< 5 X institutional ULN for patients with concurrent liver metastases - Creatinine =< 1.5 mg/dL - Tumor Gnaq and Gna11 status must be determined on all patients using a Clinical Laboratory Improvement Act (CLIA) approved assay; if initial CLIA testing is performed locally, patients must consent to provide a tumor block or unstained slides to MSKCC for central review of Gnaq and Gna11 status; this central review may be performed retrospectively and will not delay patient treatment on study - Patients must agree to provide all imaging studies for central radiology review; this central radiology review may be performed retrospectively and will not be utilized for decision making for patients on study - Ability to understand and the willingness to sign a written informed consent document - Eligibility for enrollment in each cohort is dependent upon tumor Gnaq/Gna11 status and prior therapy as follows: - Cohort 1: no prior TMZ or DTIC; mutant",ct_inc_506539,AACT,939,NCT01143402,Historical,DTIC
5c7430598625dd0414867f85,690,,,50,Patient,13:45.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_506539,Clinical Trial Inclusion Criteria,COMMENT,Gnaq/Gna11 status - Cohort 2: no prior TMZ or DTIC; wild-type Gnaq/Gna11 status - Cohort 3: received prior TMZ or DTIC; mutant or wild-type Gnaq/Gna11 status -,ct_inc_506539,AACT,46,NCT01143402,Historical,DTIC
5c74305b8625dd0411867f90,300,,,304,Patient,13:47.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_564768,Clinical Trial Exclusion Criteria,UNKNOWN,"Foscarnet, Cidofovir (HPMPC), Acyclovir, Valaciclovir, Famciclovir/Penciclovir, Lobucavir, Antisense compound - Antimetabolites: Fluorouracil, Mercaptopurine, Methotrexate, Thioguanine, Hydroxurea - Alkylating substances: Busulfan, Carmustine, Chlorambucil, Cisplatin, Cyclophosphamide, Dacarbazine (DTIC), Lomustine, Mechlormethamine, Melphalan, Streptozotocin, Tiothepa, Uracil mustard - anti CMV immunoglobulins (except in the case of signs of CMV infection) such as anti CMV hyperimmunoglobulins and immunoglobulins - Known hypersensitivity to ganciclovir - Patients with active CMV infection or positive viraemia at randomization - Severe gastro-intestinal diseases which may interfere with the oral resorption of ganciclovir - Conversion of immunosuppression (Replacement of MMF) - Participation in another clinical drug trial",ct_exc_564768,AACT,300,NCT00373165,Recent,DTIC
5c7430678625dd0489867f8b,1260,,,607,Patient,13:59.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_414827,Clinical Trial Exclusion Criteria,UNKNOWN,"3 times the upper limit of normal - Total bilirubin> 2 times the upper limit of normal - Significant renal impairment (serum creatinine> 1.7 mg/dL) - Implanted pacemaker, programmable shunts, defibrillator, deep brain stimulator, other implanted electronic devices in the brain, or documented clinically significant arrhythmias.- Infra-tentorial tumor - Evidence of increased intracranial pressure (midline shift > 5mm, clinically significant papilledema, vomiting and nausea, or reduced level of consciousness) - History of hypersensitivity reaction to temozolomide or a history of hypersensitivity to DTIC or hydrogel - Inability to adequately cover treatment area with TTFields (Tumor Treating Fields) - Inability to wear NovoTTF-100A System for an average of 18 hours per 24 hours -",ct_exc_414827,AACT,603,NCT02343549,Historical,DTIC
5c7430688625dd0489867f8c,1260,,,76,Patient,14:00.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_326417,Clinical Trial Exclusion Criteria,UNKNOWN,Known hypersensitivity to any temozolomide component or to dacarbazine (DTIC).,ct_exc_326417,AACT,72,NCT03495921,Recent,DTIC
5c74306b8625dd04d6867f8a,890,,,4,Patient,14:04.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_331453,Clinical Trial Exclusion Criteria,UNKNOWN,DTIC:,ct_exc_331453,AACT,0,NCT03430297,Recent,DTIC
5c74306b8625dd04d6867f8b,890,,,121,Patient,14:04.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_331453,Clinical Trial Exclusion Criteria,UNKNOWN,"According to investigators' evaluation, the subjects must have documented radiological progression of disease during DTIC treatment; - Previous anticancer therapy, including DTIC and palliative radiotherapy, must be completed at least three weeks prior to the dose of JS001; - Adverse events related with DTIC or palliative radiotherapy must have been relieved to grade 1 or baseline at randomization; - Any major surgery must be completed at least 28 days prior to the first dose of JS001; - No previous treatment with anti-PD-1 or anti-PD-L1 therapy; - The laboratory data on the eligibility for cross-over therapy must meet the following criteria and should be acquired within 14 days prior to the start of JS001 treatment: - Peripheral hemogram: white blood cell (WBC) 3.0109/L, neutrophil (ANC) 1.5109/L, platelet (PLT) 100109/L, hemoglobin (Hgb) 90g/L; - Renal function: serum creatinine1.5 x ULN or calculated creatinine clearance (CrCl)",ct_exc_331453,AACT,117,NCT03430297,Historical,DTIC
5c74306c8625dd0489867f8d,1260,,,775,Patient,14:04.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_506539,Clinical Trial Exclusion Criteria,UNKNOWN,"Patients may have had any number of prior therapies, but cannot have previously been treated with a mitogen-activated protein kinase kinase (MEK) inhibitor; at least 3 weeks must have elapsed since the last dose of systemic therapy; at least 6 weeks must have elapsed if the last regimen included carmustine (BCNU), mitomycin C or an anti-CTLA4 antibody; patients must have experienced disease progression on their prior therapy in the opinion of the treating investigator - Patients may not be receiving any other investigational agents - Patients with active or untreated brain metastases; treated brain metastases must have been stable for at least 2 months - History of allergic reactions attributed to compounds of similar chemical or biologic composition to TMZ or DTIC or AZD6244 - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or bleeding, symptomatic congestive heart failure, unstable angina pectoris, unstable cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements - Pregnant women are excluded from this study; breast-feeding should be discontinued if the mother is treated with AZD6244 - Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; women of child-bearing potential must have a negative pregnancy test prior to entry; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately; please note that the AZD6244 manufacturer recommends that adequate contraception for male patients should be used for 16 weeks post-last dose due to sperm life cycle - Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; patients with compensated HIV, with adequate cluster of differentiation (CD)4+ T-cell counts, and not requiring antiretroviral medication will be allowed - Patients taking vitamin E supplements while on study - No concomitant anti-cancer chemotherapy or other systemic drugs; palliative radiation therapy will be allowed as long as the patient meets all other eligibility criteria - Refractory nausea and vomiting, chronic gastrointestinal diseases (e.g.inflammatory bowel disease), or significant bowel resection that would preclude adequate absorption - Patients with corrected QT (QTc) interval >",ct_exc_506539,AACT,771,NCT01143402,Hypothetical,DTIC
5c7430708625dd0523867f8c,830,,,339,Patient,14:08.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_398465,Clinical Trial Inclusion Criteria,UNKNOWN,"Previous biological or hormonal therapy will be permitted.- Scheduled to receive first course of one of the following reference HEC, alone or in combination with other chemotherapeutic agents on Day 1: - cisplatin administered as a single IV dose of 70 mg/m2 - cyclophosphamide 1500 mg/m2 - carmustine (BCNU) >250 mg/m2 - dacarbazine (DTIC) - mechloretamine (nitrogen mustard) - Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2 .- If a patient is female, she shall be of non-childbearing potential or of childbearing potential using reliable contraceptive measures and having a negative urine pregnancy test.- Hematologic and metabolic status adequate for receiving an highly emetogenic regimen based on laboratory criteria (Total Neutrophils,Platelets, Bilirubin, Liver enzymes, Serum Creatinine or Creatinine Clearance) -",ct_inc_398465,AACT,335,NCT02557035,Recent,DTIC
5c7430708625dd0523867f8d,830,,,118,Patient,14:09.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_427587,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients receiving planned standard treatment of one or more of the following: - Chemotherapy regimens containing DTIC, TMZ and/or cisplatin - Immunotherapy (for example ipilimumab and/or anti-PD-L1/PD-1 therapies) - BRAF and/or MEK inhibitors Patients were FFPE and fresh frozen tissue is available (both mandatory).",ct_inc_427587,AACT,114,NCT02177110,Recent,DTIC
5c7430758625dd055a867f85,1320,,,1675,Patient,14:13.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_589149,Clinical Trial Inclusion Criteria,UNKNOWN,"Exclusion Patients must have none of the following at the time of randomization: - Pregnancy or nursing; - Prior therapy for metastatic melanoma including chemotherapy, radiotherapy, hormonal therapy, or biologics; - Any concurrent chemotherapy, radiotherapy, immunotherapy, biologic or hormonal therapy for treatment of cancer; - Current or planned participation (from the day of randomization through 30 days after the last dose of MEDI-522) in a research protocol in which an investigational agent or therapy may be administered; - Received an investigational agent within 4 weeks prior to randomization; - Known brain metastases or primary brain tumors, ocular melanoma, symptomatic pleural effusion or ascites requiring paracentesis; - History of prior malignancies within the past 5 years other than non-melanomatous skin cancers that have been controlled, carcinoma in situ of the cervix, T1a or b prostate cancer noted incidentally during a transurethral resection of prostate (TURP) with prostate-specific antigen (PSA) values within normal limits since TURP, or superficial bladder cancer; - History of pulmonary embolus.- Any history or evidence of pulmonary embolism or thrombophlebitis (including deep vein thrombosis) requiring anticoagulant therapy (i.e., warfarin or heparin).- Currently requiring therapeutic anticoagulation.- Any evidence of hematemesis, melena, hematochezia, or gross hematuria; - History or presence of bleeding diatheses; - Elective surgery planned during the study period through 30 days after the last dose of MEDI-522.- History of hypersensitivity to a previously administered monoclonal antibody.- History of hypersensitivity to DTIC; - History of immunodeficiency; - Known human immunodeficiency virus (HIV) or known active viral hepatic infections; - A prior myocardial infarction or angina, or uncontrolled/refractory hypertension within 6 months prior to randomization; - A prior stroke or transient ischemic attack within the past 6 months; - An active infection requiring systemic antiinfective therapy; - Prior treatment with MEDI-522 or MEDI-523; - A general medical or psychological condition or behavior, including substance dependence or abuse that, in the opinion of the investigator, might not permit the patient to complete the study or sign the informed consent.",ct_inc_589149,AACT,1671,NCT00066196,Recent,DTIC
5c74307a8625dd0599867f84,1180,,,532,Patient,14:18.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_555490,Clinical Trial Exclusion Criteria,UNKNOWN,"The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate.- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the subject inappropriate for entry into this study.- Patients may not have had previous treatment with a DTIC or temozolomide based chemotherapy regimen.",ct_exc_555490,AACT,528,NCT00496223,Recent,DTIC
5c74307a8625dd0599867f85,1180,,,58,Patient,14:18.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_551193,Clinical Trial Exclusion Criteria,UNKNOWN,Any history of allergy or intolerance to dacarbazine (DTIC) - Significant traumatic injury within the past 21 days - Severe allergy to sulfa medications - Inability to tolerate levofloxacin with dapsone or pentamidine (inhaled or IV),ct_exc_551193,AACT,54,NCT00553150,Historical,DTIC
5c74307a8625dd0599867f86,1180,,,209,Patient,14:18.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_371247,Clinical Trial Exclusion Criteria,UNKNOWN,"Subject is taking medication known to induce photosensitivity, including non-steroidal anti-inflammatory agents, tetracyclines, phenothiazines, thiazide diuretics, sulfonylureas, sulfonamides, Dacarbazine(DTIC), fluorouracil, vinblastine, and griseofulvin within 4 weeks of therapy.",ct_exc_371247,AACT,205,NCT02912013,Recent,DTIC
5c74307a8625dd0599867f87,1180,,,94,Patient,14:18.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_436133,Clinical Trial Inclusion Criteria,UNKNOWN,"Prior therapy allowed but no prior therapy with nab-paclitaxel, paclitaxel, temozolomide, DTIC or bevacizumab.- Bevacizumab may not be initiated until 4 weeks after surgical resection or radiation therapy completion.- Age 18 or older.- Pre-existing peripheral neuropathy must have < Grade 2 (per CTCAE 4.0) at the time of registration.- Negative serum or urine -hCG pregnancy test at screening for patients of childbearing potential.- Women of childbearing potential and sexually active males must use an effective contraception method during treatment and for three months after completing treatment.- ECOG Performance status 0-1.- Estimated life expectancy of greater than 2 months.- Patients must have adequate organ function as defined below (these must be evaluated within 14 days prior to registration): - leukocytes",ct_inc_436133,AACT,90,NCT02065466,Historical,DTIC
5c74307b8625dd0599867f88,1180,,,284,Patient,14:19.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_475501,Clinical Trial Exclusion Criteria,UNKNOWN,"Patients who have received such compounds for other indications, eg, valproic acid for epilepsy, may enroll after a 30-day washout period.- History of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide; vorinostat; dacarbazine (DTIC-Dome, DIC, imidazole carboxamide) - History of gastrointestinal disease or significant bowel resection that could interfere with drug absorption or inability to swallow tablets.- Uncontrolled intercurrent illness (as defined by the investigators) including, but not limited to, ongoing or active infection (HIV, Hepatitis B or Hepatitis C), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.- Prior allogeneic stem cell transplantation within 2 months of trial enrollment or prior radiation up to more than 25% of bone marrow.- Currently active 2nd malignancy, other than nonmelanoma skin cancer and carcinoma in situ of the cervix (completed therapy for a prior malignancy, and disease-free from prior malignancies for >5 years or are considered by their physician to be at less than 30% risk of relapse is not considered to be an currently active malignancy) -",ct_exc_475501,AACT,280,NCT01550224,Recent,DTIC
5c74307b8625dd0599867f89,1180,,,256,Patient,14:19.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_487692,Clinical Trial Inclusion Criteria,UNKNOWN,"- No gastrointestinal disorders likely to interfere with absorption of the study medication - No known hypersensitivity to any of the components of olaparib - No known hypersensitivity to temozolomide (TMZ) or any of its components, or to dacarbazine (DTI",ct_inc_487692,AACT,252,NCT01390571,Recent,DTIC
5c74307c8625dd0599867f8a,1180,,,2014,Patient,14:20.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_490878,Clinical Trial Exclusion Criteria,UNKNOWN,"Recently tanned in the area to be treated and/or unable or unlikely to refrain from tanning during the study.- Subject has disease related to photosensitivity, such as porphyria, polymorphic light eruption, solar urticaria, lupus, etc - Subject has a history of herpes outbreak in the area of treatment, unless receiving preventative treatment from physician - Pregnant, planning to become pregnant, hormone fluctuations and/or breast feeding during the experiment.- Subjects with Diabetes (Type I or II) or other systemic or metabolic condition - Subject has an active electrical implant anywhere in the body, such as a pacemaker, an internal defibrillator, insulin pump, incontinence device, etc.- Subject suffers from epilepsy.- Subject has active cancer, or has a history of skin cancer or any other cancer in the area to be treated, including presence of malignant or pre-malignant pigmented lesions.- Subject received radiation therapy or chemotherapy treatments with the past 3 months.- Subject has known anticoagulative or thromboembolic condition or is on any form of anticoagulation treatment.- Subject has a history of immunosuppressant/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications.- Subject has any other condition which in the physician's opinion would make it unsafe for the subject to be treated.- Subject had rotating type tweezer epilator treatment, or waxing within the last 3 months - Subject had electrolysis treatment within the last 6 months over the treatment area.- Subject had any type of professional intense pulsed light (IPL), laser or RF hair removal in the treatment site within the last 6 months.- Participation in a study of another device or drug within 1 month prior to enrollment or during this study.- Subject is taking medication known to induce photosensitivity, including non-steroidal anti-inflammatory agents, tetracyclines, phenothiazines, thiazide diuretics, sulfonylureas, sulfonamides, Dacarbazine (DTIC), fluorouracil, vinblastine, and griseofulvin within 4 weeks of therapy.- Subject has been taking Accutane within 6 months of therapy.- Subject has been on steroid regimen during the last three months.- Subject is on Gold therapy (for arthritis treatment).",ct_exc_490878,AACT,2010,NCT01348789,Historical,DTIC
5c74307c8625dd0599867f8b,1180,,,209,Patient,14:20.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_490879,Clinical Trial Exclusion Criteria,UNKNOWN,"Subject is taking medication known to induce photosensitivity, including non-steroidal anti-inflammatory agents, tetracyclines, phenothiazines, thiazide diuretics, sulfonylureas, sulfonamides, Dacarbazine(DTIC), fluorouracil, vinblastine, and griseofulvin within 4 weeks of therapy.",ct_exc_490879,AACT,205,NCT01348776,Recent,DTIC
5c74308c8625dd063e867f8d,1010,,,17,Patient,14:36.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_554233,Clinical Trial Exclusion Criteria,UNKNOWN,Prior TMZ or DTIC is only allowed in those patients enrolled into the prior chemotherapy cohort - All patients must have ECOG 0-1.-,ct_exc_554233,AACT,13,NCT00512798,Historical,DTIC
5c74308c8625dd063e867f8e,1010,,,17,Patient,14:36.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_554233,Clinical Trial Exclusion Criteria,UNKNOWN,Prior TMZ or DTIC is only allowed in those patients enrolled into the prior chemotherapy cohort - Patients must be 18 years of age or above and competent to sign an institutionally IRB approved informed consent.,ct_exc_554233,AACT,13,NCT00512798,Historical,DTIC
5c7430948625dd06be867f85,700,,,134,Patient,14:44.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_569347,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria: - refusal of the patients to take part in the study - previous radiotherapy of the brain or chemotherapy with DTIC or TMZ - known allergy against extrinsical proteins - previous chemotherapy or therapy with an EGFR-inhibitor - Previous antibody therapy - Patients who have not yet recovered from acute toxicities of prior therapies - Acute infections requiring systemic application of antibiotics - Frequent vomiting or a medical condition preventing the oral application of TMZ - Clinically active,ct_exc_569347,AACT,130,NCT00311857,Historical,DTIC
5c7430948625dd06be867f86,700,,,358,Patient,14:44.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_538930,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Any evidence of renal dysfunction (proteinuria, estimated creatinine clearance from serum creatinine test of <60 ml/min).- Impaired hepatic function (liver enzymes greater than twice the upper limit of normal or bilirubin > 2.0 except in patients with Gilbert's syndrome).- Prior treatment with alkylating agents (including TMZ and DTIC).- Active brain metastases (metastatic lesions to the brain that have been adequately treated with surgery and/or appropriate radiation therapy and that have documented stability for >4 weeks remain eligible).- Active infections or serious general medical conditions.- Female patients of child-bearing age who are not on adequate contraception, or are pregnant or breast-feeding.",ct_exc_538930,AACT,354,NCT00715793,Historical,DTIC
5c7430948625dd06be867f87,700,,,173,Patient,14:44.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_532179,Clinical Trial Exclusion Criteria,UNKNOWN,"2 x Upper Limit of Normal (ULN).- Ocular malignant melanoma.- History of central nervous system metastases or leptomeningeal disease.- Prior treatment with Dacarbazine (DTIC) or Temozolomide (TMZ).- Prior DNA damaging agents or cytotoxic chemotherapy.- Prior Whole Brain Radiation Therapy (with exceptions).- Received an investigational agent within 28 days of study.- History of seizure disorder and/or taking medication for seizure disorder.- Active malignancy within the past 5 years, except cervical cancer in situ, in situ carcinoma of the bladder or non-melanoma carcinoma of the skin.- Medical condition that would cause a high risk for toxicities.",ct_exc_532179,AACT,169,NCT00804908,Historical,DTIC
5c7430948625dd06be867f88,700,,,139,Patient,14:44.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_585209,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Prior treatment with M200 or a5b1 inhibitors and murine or chimeric monoclonal antibodies.- Prior treatment with DTIC, temozolomide, or other chemotherapeutic regimens.- Known sensitivity to murine proteins or chimeric antibodies or other components of the product.- Use of any investigational drug within 4 weeks prior to screening or 5 half-lives of the prior investigational drug (whichever is longer).- Systemic biologic, immunotherapy, and/or radiation therapy within 4 weeks of the first dose of M200.- Documented central nervous system (CNS) tumor or CNS metastasis.- History of thromboembolic events and bleeding disorders within the past year.- Medical conditions that may be exacerbated by bleeding.",ct_exc_585209,AACT,135,NCT00099970,Historical,DTIC
5c7430958625dd069d867f88,880,,,642,Patient,14:45.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_471306,Clinical Trial Exclusion Criteria,LABORATORY_AND_RADIOLOGY_DATA,"Subjects with melanoma of intraocular origin Leptomeningeal metastasis or brain metastasis except as for inclusion criteria number 8 Subjects taking medications which are either strong CYP inhibitors or inducers Subjects with active malignancies except for wt BRAF Stage IV and unresectable Stage III melanoma, basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, adequately treated Stage I or II cancer from which the subject is currently in complete remission, or any other cancer from which the subject has been disease-free for 5 years Prior treatment with a PARP inhibitor Prior treatment with dacarbazine (DTIC) or TMZ containing regimens Subjects with known allergy, hypersensitivity, or other contraindication to E7016, TMZ, or DTIC or any of the other components of the formulations Subjects with known human immunodeficiency virus infection (HIV), active hepatitis B or C Subjects with active infections requiring specific anti-infective therapy Subjects who have had a major surgical procedure (including tumor resection) within 4 weeks prior to initiating E7016 treatment Subjects scheduled for surgery during the projected course of the study Chemotherapy, radiation therapy, or immunotherapy within 4 weeks prior to initiating E7016 treatment (6 weeks for mitomycin C or nitrosoureas) or any investigational agent within 30 days prior to the first dose of study drug or who have not recovered (Grade 0 or 1) from any acute toxicity related to previous anticancer treatment Prolongation of QT corrected, the QT interval corrected for heart rate (QTc) interval (greater than 480 ms) Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA)",ct_exc_471306,AACT,638,NCT01605162,Historical,DTIC
5c7430a28625dd072c867f84,1270,,,657,Patient,14:58.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_454543,Clinical Trial Inclusion Criteria,UNKNOWN,"Patient must have histologically or pathologically confirmed locally unresectable or metastatic low or intermediate grade pancreatic neuroendocrine tumor, excluding small cell carcinoma - Patient must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; baseline measurements and evaluations of all sites of disease must be obtained =< 4 weeks prior to randomization and must be acquired by multiphasic CT or contrast magnetic resonance imaging (MRI) - Date of last documented disease progression must be =< 12 months from date of randomization - Patient must not have received prior temozolomide, dacarbazine (DTIC), or capecitabine, or 5-FU (fluorouracil) therapy - Prior everolimus",ct_inc_454543,AACT,653,NCT01824875,Historical,DTIC
5c7430a28625dd071a867f8b,1060,,,572,Patient,14:58.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_415088,Clinical Trial Exclusion Criteria,UNKNOWN,"Any condition that prevents compliance with the protocol or adherence to therapy.- Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.- Treated with antibiotics for infection within one week prior to study entry.- Fever (> 38.1C) - Have diastolic blood pressure of > 90 mm Hg resting at baseline despite medication.- Serious nonmalignant disease - Enrollment in a concomitant clinical study - Have a history of hypersensitivity reaction to any of the components of Temozolomide - Have a history of hypersensitivity to dacarbazine (DTIC)",ct_exc_415088,AACT,568,NCT02340156,Historical,DTIC
5c7430a28625dd071a867f8c,1060,,,43,Patient,14:58.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_432498,Clinical Trial Exclusion Criteria,UNKNOWN,Known hypersensitivity to dacarbazine (DTIC).,ct_exc_432498,AACT,39,NCT02113007,Recent,DTIC
5c7430a28625dd072c867f85,1270,,,232,Patient,14:58.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_534900,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Prior CT-322 therapy or prior therapy with another VEGF-modulating agent (marketed or investigational) for malignant glioma - History of hypersensitivity to TMZ or any of its excipients, or to Dacarbazine (DTIC) -",ct_exc_534900,AACT,228,NCT00768911,Historical,DTIC
5c7430a28625dd071a867f8d,1060,,,67,Patient,14:59.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_363872,Clinical Trial Exclusion Criteria,HISTORY_PRESENT_ILLNESS,"Known hypersensitivity reactions to Temozolomide, dacarbazine (DTIC), hydroxychloroquine, 4-aminoquinoline, rapamune, sirolimus, rapamycin, or their analogs.",ct_exc_363872,AACT,63,NCT03008148,Recent,DTIC
5c7430a38625dd071a867f8e,1060,,,41,Patient,14:59.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_561816,Clinical Trial Exclusion Criteria,MEDICATIONS,"cisplatin, vinblastine, Dacarbazine (DTIC), interferon and interleukin-2 -",ct_exc_561816,AACT,37,NCT00412425,Recent,DTIC
5c7430a38625dd071a867f8f,1060,,,231,Patient,14:59.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_513249,Clinical Trial Exclusion Criteria,UNKNOWN,female.- Anti-tumor therapy within 4 weeks of the administration of study treatment.- Previous in vivo exposure to monoclonal antibodies for biological therapy in the 6 weeks before administration of study treatment.- Previous DTIC treatment in the last 6 months prior to study entry - Growth factors or immunomodulatory agents within 7 days of the administration of study treatment.- Patient requires or is taking corticosteroids or other immunosuppressant drugs on a long-term basis.,ct_exc_513249,AACT,227,NCT01055522,Historical,DTIC
5c7430a58625dd074d867f84,990,,,205,Patient,15:01.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_448945,Clinical Trial Inclusion Criteria,UNKNOWN,"Metastatic melanoma AJCC stage IV, completely resected. Non-resectable metastatic melanoma of low burden disease and normal LDH who have undergone at least two treatment lines, including chemotherapy (DTIC, temodal, taxanes, platinum compounds), anti-CTLA-4 (ipilimumab) and B-RAF inhibitor if harboring the V600E BRAF mutation in their tumor.",ct_inc_448945,AACT,201,NCT01898039,Recent,DTIC
5c7430a58625dd074d867f85,990,,,853,Patient,15:01.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_526368,Clinical Trial Exclusion Criteria,UNKNOWN,"Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with these agents, breastfeeding should be discontinued if the mother is treated.- HIV-positive patients are ineligible because these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy and the potential pharmacokinetic interaction between antiretroviral therapy and the investigational agents.- All herbal and/or alternative medications should be discontinued while on study, these include but are not limited to: Hydrastis canadensis (goldenseal), Uncaria tomentosa (cat's claw) or Echinacea angustifolia.- Requirement for treatment with immunosuppressive agents or chronic steroids.- A history of a hypersensitivity reaction to any of temozolomide's components or to Dacarbazine(DTIC).",ct_exc_526368,AACT,849,NCT00881595,Historical,DTIC
5c7430a68625dd074d867f86,990,,,43,Patient,15:02.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_516727,Clinical Trial Inclusion Criteria,UNKNOWN,Patients who had no prior therapy with DTIC.,ct_inc_516727,AACT,39,NCT01009177,Historical,DTIC
5c7430a68625dd074d867f87,990,,,445,Patient,15:02.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_516727,Clinical Trial Exclusion Criteria,UNKNOWN,CNS metastases or carcinomatous meningitis Ocular melanoma Known hypersensitivity to any excipients of Tracleer Prior therapy with bosentan Use of therapy with another investigational drug within 4 weeks of the start of dosing with bosentan or plan to receive such treatment during the study Known drug or alcohol dependence or any other factor that will interfere with the conduct of the study Any standard contraindications for the use of DTIC as per Australian package insert,ct_exc_516727,AACT,441,NCT01009177,Historical,DTIC
5c7430a68625dd074d867f88,990,,,93,Patient,15:02.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_523760,Clinical Trial Exclusion Criteria,UNKNOWN,History of hypersensitivity reaction to Temozolomide or a history of hypersensitivity to DTIC.,ct_exc_523760,AACT,89,NCT00916409,Historical,DTIC
5c7430a68625dd074d867f89,990,,,200,Patient,15:02.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_492412,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Histologic/cytologic proof of stage IV malignant melanoma not amenable to surgery - Any number of previous chemotherapy regimens (except those containing TMZ or dacarbazine [DTIC]) in the metastatic setting are allowed as long as >= 4 weeks have elapsed from last treatment - Measurable disease defined as at least one lesion whose longest diameter can be accurately measured as >= 1.0 cm with spiral CT scan, or 2 cm with computed tomography (CT) component of a positron emission tomography (PET)/CT;",ct_inc_492412,AACT,196,NCT01328535,Recent,DTIC
5c7430a68625dd074d867f8a,990,,,835,Patient,15:02.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_492412,Clinical Trial Exclusion Criteria,UNKNOWN,"Pregnant or breast feeding women, or women of child-bearing potential (and/or their partners) who are unwilling to utilize an approved method of birth control during the study and for 1 month afterward - History of other malignancy < 5 years with the exception of basal cell or squamous cell carcinoma of the skin treated with local resection only, limited stage prostate cancer treated with surgery or radiation therapy with currently undetectable prostate-specific antigen (PSA), or carcinoma in situ of the cervix - Known standard therapy for the patient's disease that is potentially curative or proven capable of extending life expectancy - Known immunosuppression (i.e.chronic steroid use) or autoimmune disorder - Human immunodeficiency virus (HIV) positive - Current or known history of hepatitis - Previous treatment with DTIC or TMZ - Previous immunotherapy treatment for metastatic disease in the preceding 2 months;",ct_exc_492412,AACT,831,NCT01328535,Recent,DTIC
5c7430a78625dd074d867f8b,990,,,21,Patient,15:03.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_571880,Clinical Trial Inclusion Criteria,ONCOLOGY_FAMILY_HISTORY,#NAME?,ct_inc_571880,AACT,17,NCT00278018,Recent,DTIC
5c7430a78625dd074d867f8c,990,,,113,Patient,15:03.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_571804,Clinical Trial Inclusion Criteria,UNKNOWN,"All patients will be HLA-A2 positive - Patient must have received accepted standard treatmnet for melanoma - DTIC -containing protocol ,unless unwilling.- Patients who failed previous treatment with IL-2 will be included on a compassionate basis in the IL-2 plus vaccination scheme without being included in the analysis.2.",ct_inc_571804,AACT,109,NCT00279058,Recent,DTIC
5c7430a78625dd074d867f8d,990,,,471,Patient,15:03.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_572295,Clinical Trial Exclusion Criteria,UNKNOWN,"Women of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to administration of each cycle of the study drug regimen.- Subjects of childbearing potential who are not willing or able to use an effective method of contraception, consisting of at least one-barrier method (e.g., condom and diaphragm), for the duration of the study and for at least 3 months after completing the treatment.- Subjects previously treated with DTIC or TMZ - Symptomatic central nervous metastases - Concurrent severe and/or uncontrolled medical disease that could compromise participation in the study.-",ct_exc_572295,AACT,467,NCT00272415,Historical,DTIC
5c7430ac8625dd0779867f8b,520,,,209,Patient,15:08.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_588765,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria: - Prior treatment with anti-neoplastic biologic or chemotherapy for recurrent or metastatic disease (except one course of adjuvant immunotherapy and/or adjuvant chemotherapy other than DTIC).- Suspected or known CNS metastases.,ct_exc_588765,AACT,205,NCT00070642,Historical,DTIC
5c7430af8625dd07b0867f84,840,,,305,Patient,15:11.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_313522,Clinical Trial Exclusion Criteria,UNKNOWN,"Planned use of tumor-treating electric fields - Planned use of Carmustine implants - Prior malignancy in the last 5 years before inclusion or concomitant - Severe myelosuppression - Known hypersensitivity to any of the study drugs, study drug classes, excipients in the formulation or to dacarbazine (DTIC) -",ct_exc_313522,AACT,301,NCT03663725,Historical,DTIC
5c7430af8625dd07b0867f85,840,,,30,Patient,15:11.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_595229,Clinical Trial Inclusion Criteria,LABORATORY_DATA,2.- No prior therapy with DTIC or thalidomide - No other history of malignancy other than curatively resected basal cell carcinoma of the skin or carcinoma in situ of the cervix.-,ct_inc_595229,AACT,26,NCT00006200,Historical,DTIC
5c7430b08625dd07b0867f86,840,,,38,Patient,15:12.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_463694,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria: - No previous DTIC -,ct_exc_463694,AACT,34,NCT01705392,Recent,DTIC
5c7430b08625dd07b0867f87,840,,,121,Patient,15:12.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_546856,Clinical Trial Exclusion Criteria,UNKNOWN,History of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide or DTIC History of gastrointestinal disease or significant bowel resection that could interfere with drug absorption.,ct_exc_546856,AACT,117,NCT00611247,Historical,DTIC
5c7430b08625dd07c6867f87,490,,,140,Patient,15:12.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_561810,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Hypersensibility to Topotecan and/or Temozolomide or to one of their compounds - Hypersensibility to Dacarbazine (DTIC) - Galactosaemia, Glucose and galactose malabsorption syndrom, deficiency in lactase",ct_exc_561810,AACT,136,NCT00412503,Recent,DTIC
5c7430b18625dd07bb867f85,1330,,,44,Patient,15:13.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_470311,Clinical Trial Inclusion Criteria,UNKNOWN,No previous treatment with dacarbazine (DTIC) or TMZ containing regimens For the Phase 2 Cohort 4 (mTNBC) only: Histologically confirmed metastatic triple-negative breast cancer.,ct_inc_470311,AACT,40,NCT01618136,Recent,DTIC
5c7430b38625dd07dc867f84,630,,,270,Patient,15:15.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_584401,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Subjects who have a life expectancy of at least 12 weeks - Subjects with histologically or cytologically confirmed unresectable (Stage III) or metastatic (Stage IV) melanoma - Subjects must have progressed after receiving at least one cycle of DTIC or TMZ containing regimen - Subjects who have an ECOG PS of 0 or 1 - Measurable disease defined as at least one lesion that can be accurately and serially measured per the modified RECIST criteria,ct_inc_584401,AACT,266,NCT00111007,Recent,DTIC
5c7430b58625dd07e7867f8c,770,,,56,Patient,15:17.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_553196,Clinical Trial Exclusion Criteria,UNKNOWN,"Prior therapy with regimens containing dacarbazine (DTIC) or TMZ is not permitted.- Anti-cancer therapy is not permitted during the treatment portion of the study.- Hormone therapy, bisphosphonates or LHRH-agonists for prostate cancer are permitted prior to and during the study.- Significant adverse event or toxicity due to previous anti-cancer treatment that has not recovered to within one grade level (not to exceed Grade 2) of baseline.",ct_exc_553196,AACT,52,NCT00526617,Historical,DTIC
5c7430b58625dd07e7867f8d,770,,,162,Patient,15:17.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_553196,Clinical Trial Exclusion Criteria,UNKNOWN,"- MM Only: Prior treatment with DNA damaging agents or cytotoxic chemotherapy including carboplatin, cisplatin, fotemustine, paclitaxel, vincristine, TMZ and DTIC.- Prior therapy with biologic agents (including IL-2, interferon, bevacizumab, vaccines and ",ct_exc_553196,AACT,158,NCT00526617,Historical,DTIC
5c7430b98625dd0834867f84,980,,,259,Patient,15:21.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_437769,Clinical Trial Exclusion Criteria,UNKNOWN,"480 msec.- Inability to swallow capsules.- Known hypersensitivity to any of the components of niraparib or prior hypersensitivity reactions to that class of drugs.- Known hypersensitivity reaction to temozolomide or any of its components, or dacarbazine (DTIC) if enrolled on ARM 1 or irinotecan or any of its components if enrolled on ARM 2 - Concomitant use of any other investigational or anticancer agent(s).-",ct_exc_437769,AACT,255,NCT02044120,Hypothetical,DTIC
5c7430ba8625dd0834867f85,980,,,147,Patient,15:22.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_337391,Clinical Trial Inclusion Criteria,UNKNOWN,No curative option available - Progressive disease within 9 months after prior first line chemotherapy (platinum based chemotherapy or STZ/TEM/DTIC based chemotherapy in NET G3),ct_inc_337391,AACT,143,NCT03352934,Historical,DTIC
5c7430ba8625dd0834867f86,980,,,54,Patient,15:22.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_346648,Clinical Trial Exclusion Criteria,UNKNOWN,Past hypersensitivity reaction to temozolomide or DTIC.,ct_exc_346648,AACT,50,NCT03232424,Recent,DTIC
5c7430ba8625dd0834867f87,980,,,81,Patient,15:22.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_348138,Clinical Trial Exclusion Criteria,UNKNOWN,"Patients previously treated with continuous infusion 5-FU or any schedule of DTIC, which are similar to capecitabine and temozolomide, respectively, will be excluded.",ct_exc_348138,AACT,77,NCT03213002,Recent,DTIC
5c7430ba8625dd0834867f88,980,,,449,Patient,15:22.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_343279,Clinical Trial Exclusion Criteria,UNKNOWN,"Subject is currently being treated with Optune.- Subject is currently being treated with other investigational agents.- Subject has not sufficiently recovered from prior surgery in the opinion of the investigator.- Subject has significant co-morbidities at baseline which would prevent radiotherapy and/or temozolomide treatment.- Subject has history of hypersensitivity reaction to temozolomide or a history of hypersensitivity to dacarbazine (DTIC).- Subject has a clinically significant electrolyte abnormality.- Subject has an active implantable (e.g., neurostimulator, pacemaker) or other electromagnetic device that is incompatible with MRI.Subjects",ct_exc_343279,AACT,445,NCT03276286,Historical,DTIC
5c7430ba8625dd0834867f89,980,,,67,Patient,15:22.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_352909,Clinical Trial Exclusion Criteria,UNKNOWN,Known hypersensitivity to any component of TMZ or decarbazine (DTIC).[Subjects in Arms B and C only.],ct_exc_352909,AACT,63,NCT03150862,Recent,DTIC
5c7430ba8625dd0834867f8a,980,,,322,Patient,15:22.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_563148,Clinical Trial Exclusion Criteria,UNKNOWN,less than the institutional lower limit of normal.- Prior investigational therapy within the past 28 days.- Prior AQ4N therapy.- Hypersensitivity to AQ4N or to any ingredients contained in the drug formulation.- Hypersensitivity to temozolomide or to any ingredients contained in the drug formulation and dacarbazine (DTIC).- Pregnant or lactating women.,ct_exc_563148,AACT,318,NCT00394628,Historical,DTIC
5c7430bb8625dd0834867f8b,980,,,44,Patient,15:23.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_512418,Clinical Trial Inclusion Criteria,UNKNOWN,Having failed first line treatment with DTIC based chemotherapy Full recovery from all prior therapies.,ct_inc_512418,AACT,40,NCT01066390,Historical,DTIC
5c7430bb8625dd0834867f8c,980,,,4,Patient,15:23.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_513249,Clinical Trial Inclusion Criteria,UNKNOWN,DTIC:,ct_inc_513249,AACT,0,NCT01055522,Recent,DTIC
5c7430bb8625dd0834867f8d,980,,,205,Patient,15:23.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_510969,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - A subject with cord compression or a history of uncontrolled central nervous system (CNS) metastases or leptomeningeal disease.- Subject has had prior therapies with Dacarbazine (DTIC) or TMZ containing regimens.- The subject has received an investigational agent within 28 days prior to study drug administration.- Subject with a history of seizure disorder and currently receiving medications for seizure disorders (e.g., steroid or anticonvulsant drugs).- The subject has had another active malignancy within the past 1 year with the exception of definitely treated carcinomas in situ, superficial bladder cancer, and non-melanoma carcinoma of the skin.",ct_exc_510969,AACT,201,NCT01085422,Historical,DTIC
5c7430bc8625dd0855867f84,1070,,,46,Patient,15:24.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_500946,Clinical Trial Inclusion Criteria,UNKNOWN,The previous treatment must have included DTIC alone or in combination - Performance status of 0 to 2 on the ECOG scale - Life expectancy,ct_inc_500946,AACT,42,NCT01216657,Recent,DTIC
5c7430bc8625dd0855867f85,1070,,,536,Patient,15:24.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_547911,Clinical Trial Exclusion Criteria,UNKNOWN,"The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate.- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the subject inappropriate for entry into this study.- May not have had previous treatment with a Dacarbazine (DTIC) or temozolomide based chemotherapy regimen.",ct_exc_547911,AACT,532,NCT00597038,Recent,DTIC
5c7430448625dd0308867f8b,680,,,350,Patient,13:24.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_354452,Clinical Trial Inclusion Criteria,UNKNOWN,"For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and 6 months after completion of durvalumab + tremelimumab administration or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time period.",ct_inc_354452,AACT,328,NCT03130764,Historical,durvalumab monotherapy
5c7430448625dd0308867f8c,680,,,278,Patient,13:24.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_354452,Clinical Trial Inclusion Criteria,UNKNOWN,"Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of durvalumab + tremelimumab administration or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time period.- Ability to understand and the willingness to sign a written informed consent document.- Female subjects must either be of non-reproductive potential (ie, post-menopausal by",ct_inc_354452,AACT,256,NCT03130764,Historical,durvalumab monotherapy
5c7430448625dd0308867f8d,680,,,429,Patient,13:24.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_358009,Clinical Trial Inclusion Criteria,UNKNOWN,"Female patients of childbearing potential (i.e., not surgically sterile or post-menopausal) who are sexually active with a non-sterilized male partner must use at least one highly effective method of contraception from the time of screening and must agree to continue using such precautions for 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy.",ct_inc_358009,AACT,407,NCT03084471,Recent,durvalumab monotherapy
5c7430448625dd0308867f8e,680,,,321,Patient,13:24.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_358009,Clinical Trial Inclusion Criteria,UNKNOWN,Non-sterilized male patients who are sexually active with a female partner of childbearing potential must use a male condom plus spermicide from screening through 180 days after receipt of the final dose of durvalumab + tremelimumab combination therapy or 90 days after receipt of the final dose of durvalumab monotherapy.,ct_inc_358009,AACT,299,NCT03084471,Recent,durvalumab monotherapy
5c74304c8625dd0397867f84,1090,,,36,Patient,13:32.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_340140,Clinical Trial Inclusion Criteria,LABORATORY_AND_RADIOLOGY_DATA,cross-over to durvalumab monotherapy.- Subjects with BCG-unresponsive disease defined by any of the following: - Prior treatment with 2 or more adequate courses of BCG (at least 5 of 6 induction installations and at least 2 of 3 maintenance installations for subjects on maintenance therapy).- Persistent T1 high-grade disease at the initial 3-month cystoscopy/TURBT assessment in subjects who received 5 of 6 inductions BCG installations.- Relapsed NMIBC within 6 months of last exposure to BCG - Prostatic urethra involvement of NMIBC Primary,ct_inc_340140,AACT,14,NCT03317158,Historical,durvalumab monotherapy
5c74304d8625dd0397867f85,1090,,,1484,Patient,13:33.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_362769,Clinical Trial Exclusion Criteria,UNKNOWN,"Current or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab or tremelimumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid Receipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other investigational agent) 21 days prior to the first dose of study drug History of allogeneic organ transplant Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses including any subject known to have evidence of acute or chronic hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time period",ct_exc_362769,AACT,1462,NCT03022500,Historical,durvalumab monotherapy
5c74304f8625dd0376867f8f,940,,,1056,Patient,13:35.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_356702,Clinical Trial Inclusion Criteria,UNKNOWN,"The following age-specific requirements apply: - Women <50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).- Women 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).- Patients of childbearing / reproductive potential should use adequate birth control measures, as defined by the investigator, during the study treatment period and for from screening to 90 days after the last dose of durvalumab monotherapy or 180 days after the last dose of durvalumab + tremelimumab combination therapy.",ct_inc_356702,AACT,1034,NCT03101475,Hypothetical,durvalumab monotherapy
5c74304f8625dd0376867f90,940,,,347,Patient,13:35.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_356702,Clinical Trial Inclusion Criteria,UNKNOWN,A highly effective method of birth control is defined as those which result in low failure rate (i.e.less than 1% per year) when used consistently and correctly.- Female subjects who are breast feeding should discontinue nursing prior to the first dose of study treatment and from screening to 90 days after the last dose of durvalumab monotherapy or 180 days after the last dose of durvalumab + tremelimumab combination therapy.- Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.-,ct_inc_356702,AACT,325,NCT03101475,Historical,durvalumab monotherapy
5c7430508625dd0376867f91,940,,,349,Patient,13:36.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_331733,Clinical Trial Exclusion Criteria,COMMENT,"Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to 30 days after the last dose of IP.- Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy or180 days after the last dose of durvalumab + tremelimumab combination therapy.- Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.- Prior randomisation or treatment in a previous durvalumab and/or tremelimumab clinical study regardless of treatment arm assignment.- Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.- Judgment by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions and requirements.- Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time period - Known allergy or hypersensitivity to durvalumab, tremelimumab, cisplatin/carboplatin, docetaxel or any excipient - Cisplatin/carboplatin induced polyneuropathy or hearing disorder",ct_exc_331733,AACT,327,NCT03426657,Historical,durvalumab monotherapy
5c7430528625dd0376867f92,940,,,228,Patient,13:39.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_342717,Clinical Trial Exclusion Criteria,COMMENT,Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy or180 days after the last dose of durvalumab + tremelimumab combination therapy.,ct_exc_342717,AACT,206,NCT03283605,Recent,durvalumab monotherapy
5c7430528625dd0376867f93,940,,,309,Patient,13:39.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_342717,Clinical Trial Exclusion Criteria,COMMENT,"Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time period.",ct_exc_342717,AACT,287,NCT03283605,Recent,durvalumab monotherapy
5c7430538625dd03d9867f84,1080,,,473,Patient,13:39.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_354452,Clinical Trial Exclusion Criteria,COMMENT,"- Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results - Female patients who are pregnant or breastfeeding or male or female patients of reproductiv",ct_exc_354452,AACT,451,NCT03130764,Recent,durvalumab monotherapy
5c7430538625dd03d9867f85,1080,,,291,Patient,13:40.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_358009,Clinical Trial Exclusion Criteria,UNKNOWN,Pregnant or breastfeeding women or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy.,ct_exc_358009,AACT,269,NCT03084471,Recent,durvalumab monotherapy
5c7430548625dd03d9867f86,1080,,,471,Patient,13:40.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_355087,Clinical Trial Exclusion Criteria,COMMENT,"Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results.- Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time period.- QT interval corrected for heart rate (QTc) 470ms calculated from 1 electrocardiogram (ECG) using Fridericia's Correction.- History of primary immunodeficiency.- Known history of previous clinical diagnosis of tuberculosis.- Subjects with uncontrolled seizures.",ct_exc_355087,AACT,449,NCT03122509,Historical,durvalumab monotherapy
5c7430548625dd03d9867f87,1080,,,595,Patient,13:40.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_356702,Clinical Trial Exclusion Criteria,COMMENT,C - Active bleeding diatheses - History of primary immunodeficiency - Psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent - Mean QT interval corrected for heart rate (QTc) 470 ms calculated from 3 electrocardiograms (ECGs) using Frediricia's Correction - Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy or 180 days after the last dose of durvalumab + tremelimumab combination,ct_exc_356702,AACT,573,NCT03101475,Historical,durvalumab monotherapy
5c7430558625dd03d9867f88,1080,,,1837,Patient,13:41.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_364114,Clinical Trial Exclusion Criteria,COMMENT,"Subjects with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded - Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis) - History of primary immunodeficiency - History of allogeneic organ transplant - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses including any subject known to have evidence of acute or chronic hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent - Known history of previous clinical diagnosis of tuberculosis - History of leptomeningeal carcinomatosis - Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab - Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results - Symptomatic or uncontrolled brain metastases requiring concurrent treatment, inclusive of but not limited to surgery, radiation and/or corticosteroids - Subjects with uncontrolled seizures - Patients with symptomatic extrahepatic metastases - Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time period - Known allergy or hypersensitivity to investigational product (IP) or any excipient",ct_exc_364114,AACT,1815,NCT03005002,Historical,durvalumab monotherapy
5c7430568625dd03d9867f89,1080,,,435,Patient,13:42.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_330205,Clinical Trial Exclusion Criteria,UNKNOWN,(HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA - Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab - Female subjects who are pregnant or breastfeeding or male or female subjects of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy.-,ct_exc_330205,AACT,413,NCT03446547,Historical,durvalumab monotherapy
5c7430568625dd03d9867f8a,1080,,,301,Patient,13:42.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_317026,Clinical Trial Inclusion Criteria,UNKNOWN,"min.- Female patients with reproductive potential (e.g., females menopausal for less than 1 year and not surgically sterilized) must agree to practice two highly effective contraceptive measures for the duration of study drug therapy and for at least 90 days after completion of durvalumab monotherapy or for at least 180 days after completion of durvalumab/tremelimumab combination therapy.",ct_inc_317026,AACT,279,NCT03618134,Recent,durvalumab monotherapy
5c7430578625dd03d9867f8b,1080,,,500,Patient,13:43.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_316557,Clinical Trial Exclusion Criteria,UNKNOWN,"Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results - Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control as described in the protocol from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time period - Distant metastasis - Patients who are institutionalised by official order - Mean QT interval corrected for heart rate (QTc) 470 ms calculated from 3 electrocardiograms (ECGs) using Fredericia's Correction - Receipt of live attenuated vaccination within 30 days prior to study entry step 2 or within 30 days of receiving durvalumab or tremelimumab",ct_exc_316557,AACT,478,NCT03624231,Historical,durvalumab monotherapy
5c7430588625dd03d9867f8c,1080,,,736,Patient,13:44.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_348179,Clinical Trial Inclusion Criteria,UNKNOWN,"I12.Female patients must either be of non-reproductive potential (ie, postmenopausal 12 months with no menses without an alternative medical cause OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry (within 72 hours before study drug start) I13.Fertile men with a female partner of childbearing potential must agree to use male codom plus spermicide and childbearing potential women must have agreed to use at least one highly effective contraceptive method during treatment on this trial and for up to 180 days after the last of dose of Durvalumab + Tremelimumab or 90 days after the last dose of Durvalumab monotherapy, whichever is the longer period I14.Patient should understand, sign, and date the written voluntary informed consent form prior to any protocol-specific procedures performed.",ct_inc_348179,AACT,714,NCT03212469,Historical,Durvalumab monotherapy
5c7430588625dd03fb867f8d,620,,,703,Patient,13:44.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_358205,Clinical Trial Exclusion Criteria,UNKNOWN,"Any concurrent chemotherapy, biologic, or hormonal therapy for cancer treatment.- History of allogenic organ transplantation that requires use of immunosuppressive agents.- Active or prior documented autoimmune or inflammatory disorders.- Active infection including active tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).- Current or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab or tremelimumab.- Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy or 180 days after the last dose of durvalumab + tremelimumab combination therapy.",ct_exc_358205,AACT,681,NCT03081923,Historical,durvalumab monotherapy
5c7430588625dd03fb867f8e,620,,,455,Patient,13:44.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_355547,Clinical Trial Inclusion Criteria,HISTORY_PRESENT_ILLNESS,"entry.- Females of childbearing potential who are sexually active with a non-sterilized male partner and non-sterilized male subjects who are sexually active with a female partner of childbearing potential must be willing to use 2 methods of effective contraception from time of screening through 180 days after receipt of the final dose of Durvalumab + Tremelimumab combination therapy or 90 days after receipt of the final dose of Durvalumab Monotherapy, whichever is the longer time period.",ct_inc_355547,AACT,433,NCT03116529,Recent,Durvalumab Monotherapy
5c7430638625dd047e867f8b,910,,,318,Patient,13:55.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_353376,Clinical Trial Inclusion Criteria,UNKNOWN,"x 0.85 / 72 x serum creatinine (mg/dL) Patients with reproductive potential (e.g., females menopausal for less than 1 year and not surgically sterilized) must practice two highly effective contraceptive measures for the duration of study drug therapy and for at least 90 days after completion of durvalumab monotherapy or for at least 180 days after completion of durvalumab/tremelimumab combination therapy.",ct_inc_353376,AACT,296,NCT03144778,Recent,durvalumab monotherapy
5c7430638625dd047e867f8c,910,,,79,Patient,13:56.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_320543,Clinical Trial Inclusion Criteria,CHEMOTHERAPEUTICS,-nave for their pancreatic cancer Body weight >30kg (for durvalumab monotherapy or durvalumab + novel),ct_inc_320543,AACT,57,NCT03572400,Recent,durvalumab monotherapy
5c7430848625dd05e6867f88,1230,,,781,Patient,14:28.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_355547,Clinical Trial Exclusion Criteria,COMMENT,"Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results - Previously enrolled in the present study - Participation in another clinical study with an investigational product during the last 6 months - Previously enrolled in the present study - Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site) - Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time period",ct_exc_355547,AACT,759,NCT03116529,Recent,durvalumab monotherapy
5c7430848625dd05e6867f89,1230,,,228,Patient,14:28.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_371790,Clinical Trial Exclusion Criteria,HISTORY_PRESENT_ILLNESS,Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy.,ct_exc_371790,AACT,206,NCT02904954,Recent,durvalumab monotherapy
5c7430878625dd0619867f84,1250,,,666,Patient,14:31.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_345363,Clinical Trial Exclusion Criteria,UNKNOWN,"E-28 Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment related complications.E-29 Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential (< 2 years after last menstruation and not surgically sterile) who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time period.",ct_exc_345363,AACT,644,NCT03249142,Recent,durvalumab monotherapy
5c7430888625dd0619867f85,1250,,,363,Patient,14:32.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_348669,Clinical Trial Inclusion Criteria,UNKNOWN,"For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and up to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time period.",ct_inc_348669,AACT,341,NCT03206073,Historical,durvalumab monotherapy
5c7430898625dd0619867f86,1250,,,576,Patient,14:33.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_343187,Clinical Trial Exclusion Criteria,UNKNOWN,"Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with durvalumab, tremelimumab and radiation, breastfeeding should be discontinued if the mother is treated with durvalumab, tremelimumab and radiation.- Female patients who are pregnant or breastfeeding or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time period - HIV-positive patients are ineligible due to the risks associated with immune checkpoint blockade.- Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab and tremelimumab.",ct_exc_343187,AACT,554,NCT03277482,Historical,durvalumab monotherapy
5c7430898625dd0619867f87,1250,,,1075,Patient,14:33.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_343332,Clinical Trial Exclusion Criteria,COMMENT,"Patients, if enrolled, should not receive live vaccine during the study and up to 30 days after the last dose of IP.- Any condition or uncontrolled intercurrent illness that, in the opinion of the Investigator, would interfere with the evaluation of IP or interpretation of patient safety or study results, including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs from durvalumab or tremelimumab, or compromise the ability of the patient to give written informed consent - Subjects with uncontrolled seizures.- Female patients who are pregnant or breast-feeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab and tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy.- History of hypersensitivity to IP or comparator agents - History of medically diagnosed pneumonitis or interstitial lung disease",ct_exc_343332,AACT,1053,NCT03275597,Historical,durvalumab monotherapy
5c74308a8625dd0619867f88,1250,,,246,Patient,14:34.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_348765,Clinical Trial Exclusion Criteria,COMMENT,"Male patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time period.",ct_exc_348765,AACT,224,NCT03204812,Recent,durvalumab monotherapy
5c74308b8625dd0619867f89,1250,,,309,Patient,14:35.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_352911,Clinical Trial Exclusion Criteria,HISTORY_PRESENT_ILLNESS,"Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time period",ct_exc_352911,AACT,287,NCT03150836,Recent,durvalumab monotherapy
5c74308c8625dd05e6867f8a,1230,,,2275,Patient,14:36.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_373036,Clinical Trial Exclusion Criteria,UNKNOWN,"> grade 1) - Patients who are receiving any other investigational agents - Patients with untreated brain metastases, spinal cord compression, or leptomeningeal carcinomatosis should be excluded from this clinical trial; patients whose brain metastases have been treated may participate provided they show radiographic stability (defined as 2 brain images, both of which are obtained after treatment to the brain metastases; these imaging scans should both be obtained at least four weeks apart and show no evidence of intracranial progression); in addition, any neurologic symptoms that developed either as a result of the brain metastases or their treatment must have resolved or be stable either, without the use of steroids, or are stable on a steroid dose of =< 10 mg/day of prednisone or its equivalent (and anti-convulsants) for at least 14 days prior to the start of treatment - History of allergic reactions attributed to compounds of similar chemical or biologic composition to tremelimumab and MEDI4736 or previous toxicity attributed to MEDI4736 or other PD-1 or PD-L1 directed therapy that led to drug discontinuation - Prior exposure to immune-mediated therapy, including durvalumab and tremelimumab, except for anti-PD-1 or anti-PD-L1 therapy (including durvalumab) in NSCLC patients; this includes anti-CTLA-4 agents (prior treatment with these agents is NOT allowed in either cohort) and, excludes therapeutic anticancer vaccines, excluding therapeutic anticancer vaccines; exposure to other investigational agents may be permitted after discussion with the study principal investigator (PI) - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements - Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MEDI4736 (durvalumab), tremelimumab and radiation - Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy or 180 days after the last dose of durvalumab + tremelimumab combination therapy, whichever is later - Human immunodeficiency virus (HIV)-positive patients are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated - Any concurrent chemotherapy, immune therapy, biologic, hormonal therapy for cancer treatment - Current or prior use of immunosuppressive medication within 14 days before the first dose of their assigned IP; the following are exceptions to this criterion: - Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra-articular injection) -",ct_exc_373036,AACT,2253,NCT02888743,Hypothetical,durvalumab monotherapy
5c74308c8625dd05e6867f8b,1230,,,316,Patient,14:36.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_357179,Clinical Trial Exclusion Criteria,COMMENT,"Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ highly effective birth control from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time period.",ct_exc_357179,AACT,294,NCT03095274,Recent,durvalumab monotherapy
5c74308d8625dd05e6867f8c,1230,,,2078,Patient,14:37.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_387408,Clinical Trial Exclusion Criteria,COMMENT,"subjects with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded - Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis) - History of primary immunodeficiency - History of allogeneic organ transplant - History of hypersensitivity to durvalumab or any excipient - History of hypersensitivity to the combination or comparator agent - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses including any subject known to have evidence of acute or chronic hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent - Known history of previous clinical diagnosis of tuberculosis - History of leptomeningeal carcinomatosis - Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab - Female subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control - Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results - Symptomatic or uncontrolled brain metastases requiring concurrent treatment, inclusive of but not limited to surgery, radiation and/or corticosteroids - Subjects with uncontrolled seizures - Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time period - Patients receiving any other investigational agents for any reason or non-investigational agents administered for the purpose of controlling cancer growth (use of conventional external beam radiation therapy will be allowed during protocol therapy solely for palliation of localized painful lesions or bone lesions at risk of fracture provided the radiation field does not encompass any selected target lesions required for assessment)",ct_exc_387408,AACT,2056,NCT02701400,Historical,durvalumab monotherapy
5c74308d8625dd0619867f8a,1250,,,640,Patient,14:37.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_363335,Clinical Trial Exclusion Criteria,COMMENT,"Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results - Symptomatic or uncontrolled brain metastases requiring concurrent treatment, inclusive of but not limited to surgery, radiation and/or corticosteroids.- Subjects with uncontrolled seizures.- Patients who are pregnant or breastfeeding or patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time period - History of small or large bowel obstruction within 3 months of registration, including subjects with palliative gastric drainage catheters.",ct_exc_363335,AACT,618,NCT03015129,Historical,durvalumab monotherapy
5c74308d8625dd05e6867f8d,1230,,,165,Patient,14:37.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_367064,Clinical Trial Exclusion Criteria,COMMENT,"male patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy, whichever is the longer time period -",ct_exc_367064,AACT,143,NCT02966587,Recent,durvalumab monotherapy
5c74308d8625dd0619867f8b,1250,,,335,Patient,14:38.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_362496,Clinical Trial Exclusion Criteria,COMMENT,"Subjects who are pregnant, breast-feeding or of reproductive potential who are not employing an effective method of birth control or are not willing to employ effective birth control from screening to 180 days after the last dose of Durvalumab + Tremelimumab combination therapy or 90 days after the last dose of Durvalumab monotherapy, whichever is the longer time period.",ct_exc_362496,AACT,313,NCT03026062,Recent,Durvalumab monotherapy
5c7430928625dd06a8867f84,1240,,,283,Patient,14:42.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_324675,Clinical Trial Exclusion Criteria,COMMENT,Male or female patients of reproductive potential who are not willing to employ highly effective methods of contraception from screening to 180 days after receipt of the final dose of durvalumab and tremelimumab in combination or 90 days after the last dose of durvalumab monotherapy or vinorelbine.,ct_exc_324675,AACT,261,NCT03518606,Recent,durvalumab monotherapy
5c7430938625dd06a8867f85,1240,,,269,Patient,14:43.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_329763,Clinical Trial Exclusion Criteria,UNKNOWN,"Previous enrollment in the present study Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy or180 days after the last dose of durvalumab + tremelimumab combination therapy Received more than 2 prior systemic chemotherapy regimens, including adjuvant systemic chemotherapy following definitive chemoradiation (OUTBACK chemotherapy).Concurrent chemotherapy with prior radiation treatment is not to be counted Prior treatment with an anti-CTLA-4, including tremelimumab PD-1 or PD-L1 inhibitor, including durvalumab.",ct_exc_329763,AACT,247,NCT03452332,Historical,durvalumab monotherapy
5c7430948625dd06a8867f86,1240,,,1081,Patient,14:44.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_335221,Clinical Trial Exclusion Criteria,COMMENT,"use of antibiotics to treat superficial infection or contamination of tumor shall not, by itself, be considered evidence of infection).- Clinically significant gastritis or peptic ulcer disease.- Stroke or other symptoms of cerebral vascular insufficiency within the last 3 months.- Allergy to ciprofloxacin (or other quinolones).- Previous diagnosis of invasive cancer from which the individual is not disease-free AND that has required treatment within the past 3 years, except for superficial skin, cervical cancer in-situ, or early stage prostate or bladder cancer (i.e.treatment with curative intent and long term disease-free expectations).- History of leptomeningeal carcinomatosis - Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.- Females who are pregnant or breastfeeding; males or females of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy or 1 year after last dose of cyclophosphamide, whichever is the longer time period.- Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.- Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) 470 ms calculated from 3 ECGs (within 15 minutes at 5 minutes apart).- History of active primary immunodeficiency - Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis (TB) testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies).Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible.",ct_exc_335221,AACT,1059,NCT03381183,Recent,durvalumab monotherapy
5c7430968625dd06a8867f87,1240,,,2359,Patient,14:46.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_317026,Clinical Trial Exclusion Criteria,UNKNOWN,"Mean QT interval corrected for heart rate (QTc) >= 470 ms calculated from a baseline electrocardiogram using Fredericia?s correction.- Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab or tremelimumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid.- Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]).The following are exceptions to this criterion: - Patients with vitiligo or alopecia - Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement - Any chronic skin condition that does not require systemic therapy - Patients without active disease in the last 5 years may be included but only after consultation with the study physician - Patients with celiac disease controlled by diet alone.- History of allogeneic organ transplant.- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, seizures, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, active peptic ulcer disease or gastritis, serious chronic gastrointestinal (GI) conditions associated with diarrhea, active bleeding diatheses including any subject known to have evidence of acute or chronic hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent.- Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab.- Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ two highly effective birth control methods from screening to 90 days after the last dose of durvalumab monotherapy or 180 days after the last dose of durvalumab + tremelimumab combination therapy.- Major surgical procedure (",ct_exc_317026,AACT,2337,NCT03618134,Historical,durvalumab monotherapy
5c7430968625dd06a8867f88,1240,,,235,Patient,14:46.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_315718,Clinical Trial Exclusion Criteria,COMMENT,Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ highly effective birth control from screening to 90 days after the last dose of durvalumab monotherapy.,ct_exc_315718,AACT,213,NCT03635164,Recent,durvalumab monotherapy
5c7430978625dd06a8867f89,1240,,,531,Patient,14:47.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_317739,Clinical Trial Exclusion Criteria,COMMENT,"Asymptomatic central nervous system metastases are eligible if the subject has no abnormal findings on neurologic examination and is not receiving corticosteroid therapy to control symptoms - Subjects with uncontrolled seizures - Female patients who are pregnant or breastfeeding or female subjects of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time period",ct_exc_317739,AACT,509,NCT03608865,Hypothetical,durvalumab monotherapy
5c7430978625dd06a8867f8a,1240,,,376,Patient,14:47.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_316602,Clinical Trial Exclusion Criteria,COMMENT,"Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to 30 days after the last dose of IP Vaccination for yellow fever Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy or 180 days after the last dose of cisplatin",ct_exc_316602,AACT,354,NCT03623646,Hypothetical,durvalumab monotherapy
5c7430988625dd06a8867f8b,1240,,,266,Patient,14:48.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_323844,Clinical Trial Exclusion Criteria,LABORATORY_AND_RADIOLOGY_DATA,"breast milk cannot be stored for future use while the mother is being treated on study) or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy or 180 days after the last dose of durvalumab + tremelimumab combination therapy.- History of another primary malignancy except for.- Malignancy treated with curative intent and with no known active disease 5 years before the first dose of investigational product (IP) and of low potential risk for recurrence - Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease - Adequately treated carcinoma in situ without evidence of disease - History of leptomeningeal carcinomatosis.- Has an active autoimmune disease (or inflammatory disorders) requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents.",ct_exc_323844,AACT,244,NCT03529422,Historical,durvalumab monotherapy
5c7430988625dd06a8867f8c,1240,,,532,Patient,14:48.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_318308,Clinical Trial Exclusion Criteria,COMMENT,"Following radiotherapy and/or surgery, patients with suspected brain metastases at screening should have a magnetic resonance imaging (MRI)(preferred)/CT, preferably with IV contrast.- Subjects with uncontrolled seizures.- Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time period.",ct_exc_318308,AACT,510,NCT03601455,Recent,durvalumab monotherapy
5c74309a8625dd06a8867f8d,1240,,,378,Patient,14:50.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_322286,Clinical Trial Exclusion Criteria,COMMENT,"Patients, if enrolled, should not receive live vaccine whilst receiving study treatment and for up to 30 days after the last dose of study treatment Female patients who are pregnant or breastfeeding, or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy or180 days after the last dose of durvalumab + tremelimumab combination therapy Known allergy or hypersensitivity to chimeric or humanized antibodies or fusion proteins, or to any of the study drugs or study drug excipients Prior randomisation or treatment in a previous durvalumab and/or tremelimumab clinical study regardless of treatment arm assignment Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that, in the opinion of the Investigator, makes the patient unsuitable for participation in the study.",ct_exc_322286,AACT,356,NCT03549715,Hypothetical,durvalumab monotherapy
5c7430ae8625dd0779867f8c,520,,,334,Patient,15:10.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_323844,Clinical Trial Inclusion Criteria,COMMENT,"Documentation of postmenopausal status must be provided.- WOCBP must be willing to abstain from heterosexual activity or to use at least 1 highly effective method of contraception from the time of informed consent until 180 days after durvalumab and tremelimumab combination therapy is stopped; or 90 days after durvalumab monotherapy treatment is discontinued (whichever is longer).- Male patients with female partners must have had a prior vasectomy or agree to use an adequate method of contraception (i.e., double barrier method: condom plus spermicidal agent) starting with the first dose of study therapy through 6 months (180 days) after the last dose of durvalumab and tremelimumab combination therapy; or 90 days after durvalumab monotherapy is discontinued (whichever is longer).- Subjects are willing and able to comply with study procedures based on the judgment of the investigator or protocol designee.",ct_inc_323844,AACT,312,NCT03529422,Historical,durvalumab monotherapy
5c7430cb8625dd0855867f89,1070,,,1482,Patient,15:39.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_373036,Clinical Trial Inclusion Criteria,UNKNOWN,"the lesion to be irradiated must be in the liver - Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients is required; women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause; the following age-specific requirements apply: - Women < 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy) - Women >= 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced oophorectomy with last menses > 1 year ago, had chemotherapy-induced menopause with > 1 year interval since last menses, or underwent surgical sterilization (bilateral oophorectomy or hysterectomy) - Females of childbearing potential who are sexually active with a non sterilized male partner must use at least 1 highly effective method of contraception from the time of screening and must agree to continue using such precautions for 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy; non-sterilized male partners of a female patient must use male condom plus spermicide throughout this period; cessation of birth control after this point should be discussed with a responsible physician; not engaging in sexual activity for the total duration of the drug treatment and the drug washout period is an acceptable practice; however, periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control; female patients should also refrain from breastfeeding throughout this period - Non-sterilized males who are sexually active with a female partner of childbearing potential must use a male condom plus spermicide from screening through 180 days after receipt of the final dose of durvalumab + tremelimumab combination therapy or 90 days after receipt of the final dose of durvalumab monotherapy; not engaging in sexual activity is an acceptable practice; however, occasional abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception; male patients should refrain from sperm donation throughout this period - Female partners (of childbearing potential) of male patients must also use a highly effective method of contraception throughout this period - Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately - Ability of a patient or a Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document - Body weight > 30 kg - Must have a life expectancy of at least 12 weeks - Cohort 1 (NSCLC cohort) - Ability to undergo a fresh tumor biopsy for the purpose of screening for this clinical trial (including able and willing to give valid written consent) to ability or to provide an available archival tumor sample taken less than 3 months prior to study enrollment (and not obtained prior to progression on a PD-1/PD-L1 inhibitor) if a fresh tumor biopsy is not feasible with an acceptable clinical risk; tumor lesions used for fresh biopsies should be the same lesions to be irradiated when possible and should not be the same lesions used as Response Evaluation Criteria in Solid Tumors (RECIST) target lesions, unless there are no other lesions accessible; additional, optional archival tumor tissue is also requested from before the prior PD-1 directed therapy - Cohort 2 (colorectal cohort) - Ability to undergo a fresh tumor biopsy for the purpose of screening for this clinical trial (including able and willing to give valid written consent) to ability or to provide an available archival tumor sample taken less than 3 months prior to study enrollment if a fresh tumor biopsy is not feasible with an acceptable clinical risk; tumor lesions used for fresh biopsies should be the same lesions to be irradiated when possible and should not be the same lesions used as RECIST target lesions, unless there are no other lesions accessible - Microsatellite stable (MSS) tumor as documented by either: - Immunohistochemistry (IHC) testing that does not suggest loss of MLH-1, MSH-2, PMS2 or MSH6 - Polymerase chain reaction (PCR) testing that does not suggest microsatellite instability (MSI)",ct_inc_373036,AACT,1460,NCT02888743,Hypothetical,durvalumab monotherapy
5c7430cc8625dd0855867f8a,1070,,,811,Patient,15:40.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_352356,Clinical Trial Inclusion Criteria,COMMENT,"A pelvic US does not need to be repeated with each cycle unless the treating physician thinks it is necessary to do so.- Female patients of reproductive potential, defined as not surgical sterile (i.e., bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or post-menopausal (see above for definition) and non-sterilized males who are sexually active with a female partner of reproductive potential must be willing to adhere to the following restrictions: - Females of childbearing potential who are sexually active with a non-sterilized male partner must agree to use at least 1 highly effective method of contraception from the time of screening until 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy.",ct_inc_352356,AACT,789,NCT03158064,Recent,durvalumab monotherapy
5c7430cc8625dd0855867f8b,1070,,,587,Patient,15:40.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_352356,Clinical Trial Inclusion Criteria,COMMENT,It is strongly recommended that non-sterilized male partners of a female patient must use male condom plus spermicide throughout this period Not engaging in sexual activity for the total duration of the drug treatment and the drug washout period is an acceptable practice.- Non-sterilized males who are sexually active with a female partner of childbearing potential must use a male condom plus spermicide from screening through 180 days after receipt of the final dose of durvalumab + tremelimumab combination therapy or 90 days after receipt of the final dose of durvalumab monotherapy.,ct_inc_352356,AACT,565,NCT03158064,Recent,durvalumab monotherapy
5c7430cc8625dd0855867f8c,1070,,,173,Patient,15:40.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_320543,Clinical Trial Exclusion Criteria,COMMENT,Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) 470 ms calculated from 3 ECGs (within 15 minutes at 5 minutes apart) <<for durvalumab monotherapy and durvalumab + tremelimumab combination studies this criterion can be removed.,ct_exc_320543,AACT,151,NCT03572400,Recent,durvalumab monotherapy
5c7430cc8625dd0855867f8d,1070,,,228,Patient,15:40.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_320543,Clinical Trial Exclusion Criteria,COMMENT,Female subjects who are pregnant or breastfeeding or male or female subjects of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy.,ct_exc_320543,AACT,206,NCT03572400,Recent,durvalumab monotherapy
5c7430728625dd054f867f87,340,,,102,Patient,14:10.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_386606,Clinical Trial Inclusion Criteria,UNKNOWN,"Have participated in a previous study of duvelisib, and: - Be actively receiving duvelisib monotherapy on the previous study (within 14 days of study entry) and demonstrating clinical benefit (complete response [CR]/ partial response [PR]/ stable disease [SD]) of continued use, or - Be in the survival follow-up phase of a previous duvelisib study - Have completed the required components of the previous study and be appropriate for enrollment into this long-term continued treatment and follow-up study, as determined by the Sponsor",ct_inc_386606,AACT,81,NCT02711852,Recent,duvelisib monotherapy
5c7430758625dd0569867f84,1050,,,706,Patient,14:13.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_466937,Clinical Trial Exclusion Criteria,UNKNOWN,"- Any contraindication listed in the local labeling of LMWH, UFH, or warfarin - Chronic treatment with non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) including both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX- 2) inhibitors for > or = 4",ct_exc_466937,AACT,686,NCT01662908,Hypothetical,edoxaban monotherapy
5c74304e8625dd02f2867f87,1290,,,181,Patient,13:34.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_521594,Clinical Trial Inclusion Criteria,UNKNOWN,"(Cardiac function does not need to be assessed in patients who will not receive doxorubicin as part of their initial therapy on this study [i.e., patients who start on regimen EE-4A]) -",ct_inc_521594,AACT,176,NCT00945009,Recent,EE-4A
5c7430808625dd05d0867f88,410,,,253,Patient,14:24.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_507333,Clinical Trial Inclusion Criteria,UNKNOWN,- Outpatients who will be treated with enoxaparin + VKA in combination are permitted to receive initial treatment other than enoxaparin for a maximum of 48 hours or 2 treatment doses preceding entry into the study - Outpatients on enoxaparin monotherapy a,ct_inc_507333,AACT,231,NCT01133002,Recent,enoxaparin monotherapy
5c7430548625dd03c7867fa8,0,,,114,Patient,13:40.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_567491,Clinical Trial Inclusion Criteria,UNKNOWN,"B-cell Non-Hodgkins lymphoma (NHL) planned to receive at least 2 cycles of CHOP-14, CHOEP-14, CHOP-DI-14, EPOCH-14 or CHOP-21 +/-",ct_inc_567491,AACT,106,NCT00336609,Recent,EPOCH-14
5c7430418625dd030d867f8d,1150,,,112,Patient,13:21.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_498541,Clinical Trial Exclusion Criteria,UNKNOWN,Drug Specific Eligibility Criteria based on Treatment Arms- Subjects are excluded from the erlotinib monotherapy arm if they have progressed on prior EGFR TKI therapy; from the AKT inhibitor arm(s) if they have received prior AKT inhibitor therapy; from the MEK inhibitor arm if they have received prior MEK inhibitor therapy; and from Sorafenib arm if they have previously received the drug or have prior history of clinically significant hemoptysis or bleeding diathesis as per principal investigator judgment.,ct_exc_498541,AACT,91,NCT01248247,Hypothetical,erlotinib monotherapy
5c7430608625dd0473867f85,570,,,490,Patient,13:52.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_548289,Clinical Trial Exclusion Criteria,UNKNOWN,"Pregnant or breast-feeding women will not be entered on this study - Patients who are currently receiving another investigational drugs - Patients who are currently receiving other anti-cancer agents.- Hormone replacement therapy will not be allowed and have to be stopped 1 month prior to entry into the study - Patients who have an uncontrolled infection.- Patients receiving less than 100mg/day of erlotinib - Patients with evidence of progression after 2 months of erlotinib monotherapy.- Patients with a history of bleeding diathesis (i.e., disseminated intravascular coagulation [DIC], clotting factor deficiency) or long-term anticoagulant therapy (other than antiplatelet therapy).- Patients with a history of hypersensitivity to active or inactive excipients of fulvestrant (i.e.castor oil or Mannitol).- Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study.",ct_exc_548289,AACT,469,NCT00592007,Historical,erlotinib monotherapy
5c7430808625dd05c1867f8c,870,,,472,Patient,14:24.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_543103,Clinical Trial Inclusion Criteria,UNKNOWN,INCLUSION CRITERIA - Pathologic diagnosis of stage IIIB (with pleural effusion) or IV non-small cell lung cancer - Progression following at least twelve weeks of treatment with single-agent erlotinib (or in combination with other experimental agents) during which time the patients experienced a clinical benefit as assessed by his/her treating physician and corroborated by radiographic assessment (at least one CT scan following at least 4 weeks of erlotinib monotherapy demonstrating stable disease or response on erlotinib therapy).-,ct_inc_543103,AACT,451,NCT00660816,Recent,erlotinib monotherapy
5c7430898625dd0624867f8c,420,,,59,Patient,14:33.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_371798,Clinical Trial Inclusion Criteria,UNKNOWN,All patients receiving treatment with erlotinib monotherapy for locally advanced or metastatic NSCLC either first line in patients with an activating mutation of the receptor EGF-R or patients with stable disease after 4 cycles of standard first-line chemotherapy with platinum or after failure of at least one prior chemotherapy regimen - Age> 18 years - Subject has signed an informed consent - Treatment initiated for at least 7 days or dosage changed for at least 7 days,ct_inc_371798,AACT,38,NCT02904850,Historical,erlotinib monotherapy
5c7430898625dd0624867f8d,420,,,153,Patient,14:33.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_548289,Clinical Trial Inclusion Criteria,UNKNOWN,Estrogen or progesterone receptor positive stage IIIb/IV non-small cell lung cancer - Eligible patients will have stable disease on erlotinib monotherapy at FDA- approved doses after a minimum duration of erlotinib therapy of 2 months - 18 years or older - ECOG Performance,ct_inc_548289,AACT,132,NCT00592007,Recent,erlotinib monotherapy
5c7430918625dd0680867f8c,480,,,166,Patient,2/25/19 18:14,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_448747,Clinical Trial Inclusion Criteria,UNKNOWN,"NSCLC - At least 1 measurable extra-central nervous system (CNS) lesion - Documented radiographic progression while on continuous treatment with erlotinib monotherapy - Objective clinical benefit from erlotinib treatment as defined by either documented partial or complete response or stable disease 6 months or, if most recent erlotinib treatment has been initiated based on documented epidermal growth factor receptor mutation (EGFRmt) status, at least 12 weeks stable disease - Determined to be MET diagnostic positive (+",ct_inc_448747,AACT,145,NCT01900652,Hypothetical,erlotinib monotherapy
5c7430918625dd0680867f8d,480,,,179,Patient,14:41.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_546744,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents within four weeks of first dose (patients currently on erlotinib monotherapy may be enrolled into the study without a washout) -",ct_exc_546744,AACT,158,NCT00612703,Recent,erlotinib monotherapy
5c7430428625dd0329867f89,1210,,,182,Patient,13:22.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_415028,Clinical Trial Exclusion Criteria,UNKNOWN,"Presence of abnormal or clinically significant cardiac disease, such as acute myocardial infarction or unstable angina within 6 months prior to initiation of treatment with LR- ESHAP , grade III or IV heart failure, uncontrolled hypertension or history of poor compliance with antihypertensive treatment , uncontrolled treated arrhythmias, except , with the exception of extra systoles or minor conduction abnormalities.",ct_exc_415028,AACT,177,NCT02340936,Historical,ESHAP
5c7430558625dd03c7867fc0,0,,,261,Patient,13:41.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_544174,Clinical Trial Inclusion Criteria,UNKNOWN,"- Obtain no partial response after first-line chemotherapy including anthracyclines + rituximab (R-CHOP, R-MegaCHOP, R-EPOCH or the like), or else - Absence of partial response after having received salvage (post-induction) chemotherapy including R-IFE, R",ct_inc_544174,AACT,256,NCT00646750,Recent,ESHAP
5c7430588625dd03fe867f93,290,,,6,Patient,13:44.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_586600,Clinical Trial Inclusion Criteria,UNKNOWN,(ESHAP) Low grade,ct_inc_586600,AACT,1,NCT00005613,Recent,ESHAP
5c7430588625dd03fe867f94,290,,,5,Patient,13:44.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_586600,Clinical Trial Inclusion Criteria,UNKNOWN,ESHAP DHAP OR,ct_inc_586600,AACT,0,NCT00005613,Recent,ESHAP
5c74305b8625dd0431867f8d,220,,,117,Patient,13:47.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_571475,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically confirmed Hodgkin's lymphoma or Non-Hodgkin's lymphoma receiving Q14, Q21, or Q28 day CHOP, ICE, ESHAP, or DHAP chemotherapy; with or without Rituximab - Has adequate bone marrow function; platelet count > 100 x 10^9/L on the day of initiation of the on study chemotherapy of the next treatment cycle and absolute neutrophil count, ANC > or = 1 x 10^9/L, and hemoglobin > or = 9.5 g/dL - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - Has adequate liver function - must be able to receive the same chemotherapy regimen during the first treatment cycle as was received during the prior qualifying cycle - must experience Common Terminology Criteria (CTC) grade 3 or 4 thrombocytopenia (",ct_inc_571475,AACT,112,NCT00283439,Historical,ESHAP
5c7430618625dd043c867f9a,50,,,6,Patient,13:53.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_587871,Clinical Trial Inclusion Criteria,UNKNOWN,(ESHAP),ct_inc_587871,AACT,1,NCT00005595,Recent,ESHAP
5c7430648625dd047e867f8d,910,,,92,Patient,13:56.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_408095,Clinical Trial Inclusion Criteria,UNKNOWN,Paraffin block of the lesions available for immunohistochemical analysis Candidate for ESHAP salvage therapy Evidence of at least one lesion with a diameter of 1.5 cm Age of over 20 years Eastern cooperative oncology group performance status (ECOG) less than or equal to 2.,ct_inc_408095,AACT,87,NCT02431403,Recent,ESHAP
5c7430648625dd047e867f8e,910,,,161,Patient,13:56.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_586947,Clinical Trial Inclusion Criteria,UNKNOWN,Failure to achieve CR within 6 months in newly diagnosed patients with intensive doxorubicin treatment Relapse patients who are sensitive to doxorubicin or ESHAP chemotherapies,ct_inc_586947,AACT,156,NCT00002829,Recent,ESHAP
5c74306c8625dd04ec867f84,1130,,,262,Patient,14:04.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_422505,Clinical Trial Inclusion Criteria,UNKNOWN,Patient >65 years old with ECOG 1 and absence of comorbidities will be included in the study - ECOG 2 - Karnofsky performance status 60 - No major organ dysfunction - Biopsy at HL relapse or when refractoriness disease is diagnosed must be done prior to BV-ESHAP.If,ct_inc_422505,AACT,257,NCT02243436,Historical,ESHAP
5c7430708625dd0518867f91,100,,,312,Patient,14:08.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_477514,Clinical Trial Inclusion Criteria,UNKNOWN,"Patient age is 18 years Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 2 Patient has a history of DLBCL according to the WHO classification Patient has progressive disease after receiving at least CHOP-R or CHOP-R like first line regimen, standard second line therapy (DHAP, ESHAP, ICE or similar salvage regimens) inclusive ASCT Patient has progressive disease after receiving at least CHOP-R or CHOP-R like first line regimen and is not considered eligible for intensive salvage therapy including ASCT because of age, co-morbidities, impossibility to perform ASCT Patient undergoes at baseline new lymphnode or other pathologic tissue biopsy for confirmation of diagnosis and biologic studies; bone marrow biopsy is not adequate for this purpose and should be performed only for staging.",ct_inc_477514,AACT,307,NCT01523834,Historical,ESHAP
5c7430728625dd054f867f86,340,,,129,Patient,14:10.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_532010,Clinical Trial Inclusion Criteria,UNKNOWN,"Disease relapsed after, refractory or failing to achieve a PR after two or more cycles of intensive salvage chemotherapy (R-ESHAP or other) or disease relapsed after autologous stem cell transplantation.",ct_inc_532010,AACT,124,NCT00807196,Recent,ESHAP
5c7430738625dd0518867f9f,100,,,187,Patient,14:11.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_329307,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients eligible for ASCT who failed to achieve a Complete Response (CR) after at least one salvage therapy (eg, Rituximab-Etoposide- Methylprednisolone - Cytarabine - Cisplatin (R-ESHAP) or Rituximab- Dexamethasone- High-dose Cytarabine - Cisplatin (R-DHAP), patients who were previously refractory to Rituximab-Ifosfamide-Cytarabine-Etoposide (R-ICE) (stable disease or progressive disease) are not eligible to the study) Or patients in first relapse after Autologous Stem Cell Transplant (ASCT) Or patients not eligible for ASCT who failed to achieve a CR after at least one prior treatment (and no more than 4 previous lines) or in relapse after at least one prior treatment (and no more than 4 previous lines).",ct_inc_329307,AACT,182,NCT03458260,Historical,ESHAP
5c74308d8625dd065b867f91,20,,,115,Patient,14:37.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_560048,Clinical Trial Inclusion Criteria,UNKNOWN,"Diagnosis of DLBCL.- Received at least one combination chemotherapy regimen with rituximab, such as R-CHOP, R-ESHAP or equivalent.- Progression or relapse since most recent therapy.-",ct_inc_560048,AACT,110,NCT00435916,Recent,ESHAP
5c7430908625dd0680867f86,480,,,37,Patient,14:40.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_408095,Clinical Trial Exclusion Criteria,UNKNOWN,until the initiation of round 2 ESHAP.Exceptions,ct_exc_408095,AACT,32,NCT02431403,Recent,ESHAP
5c7430908625dd0680867f87,480,,,211,Patient,14:40.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_408095,Clinical Trial Exclusion Criteria,UNKNOWN," are itraconazole and fluconazole for treatment or prevention of fungal infection, hydrocortisone and dexamethasone for treatment of nausea/vomiting/fluid retention, and methylprednisolone as a part of the ESHAP regimen.",ct_exc_408095,AACT,206,NCT02431403,Recent,ESHAP
5c7430908625dd0680867f88,480,,,229,Patient,14:40.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_408095,Clinical Trial Exclusion Criteria,UNKNOWN,"Serious or uncontrolled medical condition, such as presence of abnormal or clinically significant cardiac disease, such as acute myocardial infarction or unstable angina within 6 months prior to initiation of treatment with ESHAP-imatinib, serious neurological or psychological conditions such as dementia or epilepsy, or uncontrolled active infection.",ct_exc_408095,AACT,224,NCT02431403,Historical,ESHAP
5c74309e8625dd070b867f86,510,,,403,Patient,14:54.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_520262,Clinical Trial Inclusion Criteria,UNKNOWN,"- Histologically confirmed diagnosis of one of the following: - Hodgkin or non-Hodgkin lymphoma (including small lymphocytic lymphoma [SLL]) - Any histology, including B, T, or NK/T cell allowed - Multiple myeloma (MM) - Relapsed or refractory disease - P",ct_inc_520262,AACT,398,NCT00962507,Recent,ESHAP
5c7430a18625dd070b867f91,510,,,193,Patient,14:57.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_565424,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - patients diagnosed as malignant lymphoma - patients who were refractory to anthracycline or anthraquinone containing chemotherapy - patients who are going to receive ESHAP or CHASE treatment regimen - ECOG performance status =< 2 - patients who have appropriate bone marrow, hepatic and renal functions - written informed consent",ct_inc_565424,AACT,188,NCT00364468,Recent,ESHAP
5c7430b68625dd07dc867f92,630,,,172,Patient,15:18.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_494566,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria: - Previous high dose chemotherapy with autologous stem cell transplantation or allogeneic stem cell transplantation - Previous chemotherapies with ESHAP regimen -,ct_exc_494566,AACT,167,NCT01300156,Recent,ESHAP
5c7430358625dd02b4867f84,1020,,,956,Patient,13:09.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_469730,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - B-cell Chronic Lymphocytic Leukemia defined by standard NCI criteria in first line or in relapse - > 18 years-old - Presence of Minimal Residual Disease (MRD positivity) by Flow Cytometry criteria in these two clinical situations : Patients in Complete Remission (defined by standard criteria including Bone Marrow examination) after rituximab-containing immunochemotherapy (ICT), who show persisting MRD either in the Peripheral Blood at least 6 months after the last dose of rituximab-containing immunochemotherapy or in the Bone Marrow at least 3 months after the last dose of rituximab-containing ICT Patients in continuous CR who show MRD relapse in PB or BM without clinical progression (as defined by NCI) at any time after ICT - ICT should have comprised: Rituximab combined with fludarabine, with or without an alkylating drug, with or without an anthracycline (ex: Fludarabine-Rituximab, Fluda-Cyclophsphamide-Rituximab, FCR-Mitoxantrone, R-bendamustine)",ct_inc_469730,AACT,953,NCT01625741,Recent,FCR
5c7430358625dd02b4867f85,1020,,,501,Patient,13:10.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_544262,Clinical Trial Exclusion Criteria,UNKNOWN,Any coexisting medical or psychological condition that would preclude participation to the required study procedures - Patient with mental deficiency preventing proper understanding of the requirements of treatment Inclusion criteria at randomization - Patients having received the full induction phase with 4 FC and 6 rituximab courses (with/without dose adjustments as per protocol) - Complete or partial response according to NCI and iwCLL criteria at the end of induction phase - Recovery from FCR toxicities - Patient willingness to continue on protocol,ct_exc_544262,AACT,498,NCT00645606,Recent,FCR
5c7430368625dd02bd867f86,1140,,,76,Patient,13:10.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_416603,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria: Detected del(17p) or TP53 mutation Refractoriness to FCR / BR Transformation of CLL to aggressive NHL (Richter's transformation),ct_exc_416603,AACT,73,NCT02320383,Recent,FCR
5c7430368625dd02bd867f87,1140,,,111,Patient,13:10.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_356987,Clinical Trial Inclusion Criteria,UNKNOWN,"Not eligible or appropriate for conventional allogeneic SCT Patients who achieve only a partial response to FCR(fludarabine, cyclophosphamide and Rituxan) as initial therapy will be eligible.",ct_inc_356987,AACT,108,NCT03097770,Recent,FCR
5c7430368625dd02bd867f88,1140,,,113,Patient,13:10.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_461384,Clinical Trial Inclusion Criteria,UNKNOWN,"Not eligible or appropriate for conventional allogeneic SCT - Patients who achieve only a partial response to FCR as initial therapy will be eligible.- Mantle cell lymphoma: - Beyond 1st CR with relapsed or persistent disease and not eligible or appropriate for conventional allogeneic or autologous SCT - Disease responding or stable after most recent therapy (chemotherapy, MoAb, etc...) - Relapsed after prior autologous SCT - B-cell prolymphocytic leukemia (PLL) with relapsed or residual disease after at least 1 prior therapy and not eligible for allogeneic SCT - Diffuse large cell lymphoma, previously identified as CD20+: - Residual disease after primary therapy and not eligible for autologous SCT - Relapsed after prior autologous SCT - Beyond 1st CR with relapsed or persistent disease and not eligible or appropriate of conventional allogeneic or autologous SCT - Expected survival",ct_inc_461384,AACT,110,NCT01735604,Recent,FCR
5c7430378625dd02bd867f89,1140,,,139,Patient,13:11.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_477769,Clinical Trial Inclusion Criteria,UNKNOWN,"Any CLL and SLL patient who has a short remission duration of less than 3 years after prior first-line chemo-immunotherapy, such as the FCR regimen, also fulfills criteria of high-risk CLL/SLL, regardless of the presence or absence of cytogenetic abnormalities.2.2.",ct_inc_477769,AACT,136,NCT01520519,Historical,FCR
5c7430388625dd02bd867f8a,1140,,,113,Patient,13:12.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_451486,Clinical Trial Inclusion Criteria,UNKNOWN,"Not eligible or appropriate for conventional allogeneic SCT - Patients who achieve only a partial response to FCR(fludarabine, cyclophosphamide and Rituxan) as initial therapy will be eligible.- Mantle cell lymphoma: - Beyond 1st CR (complete remission) with relapsed or persistent disease and not eligible or appropriate for conventional allogeneic or autologous SCT - Disease responding or stable after most recent therapy (chemotherapy, MoAb, etc...)",ct_inc_451486,AACT,110,NCT01864889,Recent,FCR
5c7430448625dd034a867f84,650,,,357,Patient,13:24.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_462854,Clinical Trial Inclusion Criteria,UNKNOWN,"All of the following must apply: - Patient must either have newly diagnosed AML/high-risk MDS with a poor prognosis or relapsed/refractory AML/high-risk MDS - Patient has previously proven LewisY expression on the myeloblasts prior to study entry in an analysis as defined in study criteria - Patient is planned to receive fludarabine containing regime (FCR) chemotherapy (after apheresis of PBMC) which is planned to be the last cycle of FCR chemotherapy, no further FCR chemotherapy should be planned within 3 months after this cycle of FCR Definition of poor prognosis in AML/high-risk MDS A patient with AML has a poor prognosis if any of the following is satisfied: - Age > 65 years - Age 56 - 65 years with any of the following single cytogenetic abnormalities:",ct_inc_462854,AACT,354,NCT01716364,Hypothetical,FCR
5c7430478625dd0360867f86,780,,,55,Patient,13:27.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_338667,Clinical Trial Inclusion Criteria,UNKNOWN,All subjects Unsuitable for chemoimmunotherapy with FCR in the opinion of the investigator.,ct_inc_338667,AACT,52,NCT03336333,Recent,FCR
5c7430478625dd0360867f87,780,,,21,Patient,13:27.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_439985,Clinical Trial Exclusion Criteria,UNKNOWN,Fit for full-dose FCR as initial treatment.,ct_exc_439985,AACT,18,NCT02015208,Recent,FCR
5c7430488625dd0360867f88,780,,,253,Patient,13:28.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_527368,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Must have relapsed or refractory Chronic Lymphocytic Leukemia (CLL), received no more than 5 prior myelosuppressive/chemotherapy regimens and must be a candidate for treatment with either Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR); - Subject has an Eastern Cooperative Oncology Group (ECOG) performance score of </=1; - Must have adequate bone marrow independent of growth factor support (with the exception of subjects with bone marrow heavily infiltrated with underlying disease [80% or more] who may use growth factor support to achieve Absolute Neutrophil Count (ANC) eligibility criteria), per local laboratory reference range at Screening as follows:",ct_inc_527368,AACT,250,NCT00868413,Historical,FCR
5c74304b8625dd038c867f89,640,,,158,Patient,13:31.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_351663,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria: - Gross cognitive impairment - Active suicidal ideation or severe depression - Previous attendance in the active treatment groups (any FCR classes ever taken or CBT in the past 3 years) -,ct_exc_351663,AACT,155,NCT03167086,Recent,FCR
5c74304b8625dd038c867f8a,640,,,23,Patient,13:31.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_439985,Clinical Trial Inclusion Criteria,UNKNOWN,Unfit for full dose FCR chemotherapy.,ct_inc_439985,AACT,20,NCT02015208,Recent,FCR
5c74304b8625dd038c867f8b,640,,,3,Patient,13:31.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_466347,Clinical Trial Inclusion Criteria,UNKNOWN,"FCR, FR, PCR, BR etc) (3) fludarabine-refractory Understand and voluntarily sign an informed consent form, able to adhere to the study visit schedule and other protocol requirements",ct_inc_466347,AACT,0,NCT01670812,Recent,FCR
5c74304b8625dd038c867f8c,640,,,127,Patient,13:31.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_492405,Clinical Trial Inclusion Criteria,UNKNOWN,"Subject must have relapsed following or be refractory to standard treatments such as fludarabine based regimens (F, FC, FR, FCR) or alkylator (chlorambucil, bendamustine) based regimens.",ct_inc_492405,AACT,124,NCT01328626,Recent,FCR
5c7430508625dd03b8867f84,430,,,56,Patient,13:36.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_429148,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria: - patients treated with low dose FCR within prospective clinical trials,ct_exc_429148,AACT,53,NCT02156726,Recent,FCR
5c74305e8625dd0457867f94,70,,,344,Patient,13:51.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_392045,Clinical Trial Inclusion Criteria,UNKNOWN,"Subject must have either Relapsed or refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (for Waves 2 or 3) - Subject has evaluable disease and requires treatment in the opinion of the investigator.- Subject must have relapsed following or be refractory to 1 standard treatments such as fludarabine based regimens (F, FC, FR, FCR), alkylator (chlorambucil, bendamustine) based regimens, or Bruton's Tyrosine Kinase inhibitor (Ibrutinib).Or Relapsed or refractory indolent Non-Hodgkin Lymphoma or aggressive Non-Hodgkin Lymphoma (for Waves 1, 2, or 3, unless otherwise indicated) - Subject must have histologically documented diagnosis of a Follicular Lymphoma or Marginal Zone Lymphoma.- Subject must have histologically documented diagnosis of a Diffuse Large B-cell Lymphoma (excluding Richter's Transformation), Non-cutaneous T-Cell Lymphoma, or Mantle Cell Lymphoma (MCL)",ct_inc_392045,AACT,341,NCT02640833,Recent,FCR
5c7430618625dd0473867f8c,570,,,145,Patient,13:53.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_411860,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Men and women diagnosed with cancer (stages I-III), - English-speaking, - 18 years of age or older, - clinical level of FCR as indicated by a score of 13 or greater on the severity subscale of the FCRI (range 0-36), - clinical distress score as indicated by a score of at least 24 on the IES (range 0-75), - completion of cancer treatment, - current or previous patients of the Ottawa Hospital Cancer Centre.",ct_inc_411860,AACT,142,NCT02382315,Recent,FCR
5c7430618625dd0473867f8d,570,,,63,Patient,13:53.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_437553,Clinical Trial Inclusion Criteria,UNKNOWN,Not a candidate for fludarabine/cyclophosphamide/rituximab (FCR) or has preference to not receive chemotherapy.-,ct_inc_437553,AACT,60,NCT02046928,Recent,FCR
5c7430728625dd0532867f87,1310,,,170,Patient,14:10.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_345535,Clinical Trial Inclusion Criteria,UNKNOWN,"disease relapse within 12 months after completing therapy with a regimen containing FLU (or another nucleoside analog); 2) failed FLU-cyclophosphamide (CY)-rituximab (FCR) combination chemotherapy at any time point; or 3) have 17p deletion cytogenetic abnormality; patients should have received induction chemotherapy but could be transplanted in 1st CR; or 4) patients with a diagnosis of CLL (or small lymphocytic lymphoma) or diagnosis of CLL that progresses to prolymphocytic leukemia (PLL), or T-cell CLL or PLL; 5) patients failing to achieve a response to ibrutinib as first-line therapy; 6) patients not responding to ibrutinib, idelalisib, or venetoclax as salvage therapy or intolerant of these agents as salvage therapy due to side effects; all CLL patients must have received prior myelosuppressive chemotherapy - Hodgkin lymphoma - must have received and failed frontline therapy - Multiple myeloma - must have received prior chemotherapy; consolidation of chemotherapy by autografting prior to nonmyeloablative HCT is permitted - Acute myeloid leukemia (AML) - must have < 5% marrow blasts at the time of transplant - Acute lymphocytic leukemia (ALL) - must have < 5% marrow blasts at the time of transplant - Chronic myeloid leukemia (CML) - patients in CP1 must have failed or be intolerant of tyrosine kinase inhibitors (TKIs); patients beyond CP1 will be accepted if they have < 5% marrow blasts at time of transplant - Myelodysplasia (MDS)/myeloproliferative syndrome (MPS)/chronic myelomonocytic leukemia (CMML) - patients",ct_inc_345535,AACT,167,NCT03246906,Hypothetical,FCR
5c7430748625dd0532867f88,1310,,,1024,Patient,14:12.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_477270,Clinical Trial Exclusion Criteria,UNKNOWN,"the following diseases will be permitted although other diagnoses can be considered if approved by Patient Care Conference (PCC) and the principal investigator: - Aggressive non-Hodgkin lymphomas (NHL) and other histologies such as diffuse large B-cell NHL - not eligible for autologous HCT, not eligible for high-dose allogeneic HCT, or after failed autologous HCT - Mantle-cell NHL - may be treated in first complete remission (CR); (diagnostic lumbar puncture [LP] required pre-transplant) - Low grade NHL - with < 6 month duration of CR between courses of conventional therapy - Chronic lymphocytic leukemia (CLL) - must have either: - Failed to meet National Cancer Institute (NCI) Working Group criteria for complete or partial response after therapy with a regimen containing fludarabine phosphate (FLU) (or another nucleoside analog) or experience disease relapse within 12 months after completing therapy with a regimen containing FLU (or another nucleoside analog) - Failed FLU-cyclophosphamide (CY)-Rituximab (FCR) combination chemotherapy at any time point; or - Have 17p deletion cytogenetic abnormality; patients should have received induction chemotherapy but could be transplanted in 1st CR - Patients with a diagnosis of CLL (or small lymphocytic lymphoma) that progresses to prolymphocytic leukemia (PLL); or - Patients with T-cell CLL or PLL - Hodgkin lymphoma - must have received and failed frontline therapy - Multiple myeloma - must have received prior chemotherapy; consolidation of chemotherapy by autografting prior to nonmyeloablative HCT is permitted - Acute myeloid leukemia (AML) - must have < 5% marrow blasts at the time of transplant - Acute lymphocytic leukemia (ALL) - must have < 5% marrow blasts at the time of transplant - Chronic myeloid leukemia (CML) - Patients will be accepted if they have shown intolerance to tyrosine kinase inhibitors or are beyond first chronic phase (CP1) and if they have received previous myelosuppressive chemotherapy or HCT, and have < 5% marrow blasts at time of transplant - Myelodysplasia (MDS)/myeloproliferative syndrome (MPS) -",ct_exc_477270,AACT,1021,NCT01527045,Hypothetical,FCR
5c7430758625dd0532867f89,1310,,,412,Patient,14:13.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_499823,Clinical Trial Inclusion Criteria,UNKNOWN,"- Failed to meet National Cancer Institute (NCI) Working Group criteria for complete or partial response after therapy with a regimen containing FLU (or another nucleoside analog, e.g.2-Chlorodeoxyadenosine [2-CDA], pentostatin) or experience disease rela",ct_inc_499823,AACT,409,NCT01231412,Historical,FCR
5c7430768625dd0532867f8a,1310,,,170,Patient,14:14.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_498289,Clinical Trial Inclusion Criteria,UNKNOWN,disease relapse within 12 months after completing therapy with a regimen containing FLU (or another nucleoside analog); 2) failed FLU-cyclophosphamide (CY)-Rituximab (FCR) combination chemotherapy at any time point; or 3) have 17p deletion cytogenetic abnormality; patients should have received induction chemotherapy but could be transplanted in first (1st) CR;,ct_inc_498289,AACT,167,NCT01251575,Recent,FCR
5c7430778625dd0532867f8b,1310,,,150,Patient,14:15.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_584840,Clinical Trial Inclusion Criteria,UNKNOWN,disease relapse within 12 months after completing therapy with a regimen containing FLU (or another nucleoside analog); - Failed FLU-CY-Rituximab (FCR) combination chemotherapy at any time point; or - Have 17p deletion cytogenetic abnormality; patients should have received induction chemotherapy but could be transplanted in 1st CR - Hodgkin Lymphoma must have received and failed frontline therapy -,ct_inc_584840,AACT,147,NCT00105001,Recent,FCR
5c74307a8625dd055a867f89,1320,,,639,Patient,14:18.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_437409,Clinical Trial Inclusion Criteria,UNKNOWN,"Symptomatic or progressive lymphadenopathy, splenomegaly, or hepatomegaly - One or more of the following disease-related symptoms: - Weight loss >= 10% within the previous 6 months - Grade 2 or 3 fatigue attributed to CLL - Fevers > 100.5 Fahrenheit (F) for 2 weeks without evidence of infection - Clinically significant night sweats without evidence of infection - Progressive lymphocytosis (not due to the effects of corticosteroids) with an increase of > 50% over a two-month period or an anticipated doubling time of less than six months - ECOG performance status between 0-2 - Life expectancy of >= 12 months - Ability to tolerate FCR based therapy -",ct_inc_437409,AACT,636,NCT02048813,Recent,FCR
5c7430818625dd05e6867f84,1230,,,1106,Patient,14:25.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_533322,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients with the following hematologic malignancies will be permitted although other diagnoses can be considered if approved by Patient Care Conference (PCC) and the principal investigators: - Aggressive non-Hodgkin lymphomas (NHL) and other histologies such as diffuse large B cell (DLBC) NHL - a) not eligible for autologous HCT, b) not eligible for high-dose HCT, c) after failed autologous HCT, or d) be part of a tandem auto-allo approach for high risk patients - Mantle cell NHL must be beyond first complete response (CR) - Low-grade NHL with < 6 month duration of CR between courses of conventional therapy - Chronic lymphocytic leukemia (CLL) must have either - Failed to meet National Cancer Institute (NCI) Working Group criteria for complete or partial response after therapy with a regimen containing FLU (fludarabine phosphate) (or another nucleoside analog, e.g.2-chlorodeoxyadenosine [2-CDA], pentostatin) or experience disease relapse within 12 months after completing therapy with a regimen containing FLU (or another nucleoside analog) - Failed FLU- CY (cyclophosphamide)-rituximab (FCR) combination chemotherapy at any time point; or - Have 17p deletion cytogenetic abnormality and relapsed at any time point after any initial chemotherapy - Hodgkin lymphoma - must have received and a) failed frontline therapy, b) not be eligible for autologous HCT, or c) or be part of a tandem auto-allo approach for high risk patients - Multiple myeloma or plasma cell leukemia must have received more than one line of prior chemotherapy; consolidation of chemotherapy by autografting prior to nonmyeloablative HCT is permitted - Acute myeloid leukemia (AML) must have < 5% marrow blasts at the time of HCT - Acute lymphocytic leukemia (ALL) must have < 5% marrow blasts at the time of HCT - Chronic myeloid leukemia (CML) accepted if they are beyond chronic phase (",ct_inc_533322,AACT,1103,NCT00789776,Historical,FCR
5c7430828625dd05e6867f85,1230,,,1271,Patient,14:26.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_586204,Clinical Trial Inclusion Criteria,UNKNOWN,"Patient must be not eligible for conventional allogeneic hematopoietic cell transplantation (HCT) and must have disease expected to be stable for at least 100 days without chemotherapy; patients with hematologic malignancies treatable with HCT or with a B cell malignancy except those curable with autologous transplant will be included; patients not eligible for active disease specific protocols may be enrolled in this protocol; patients will include the following - Diffuse large B cell non-Hodgkin lymphoma (NHL) and other aggressive lymphomas - not eligible for conventional myeloablative HCT or after autologous HCT - Low grade NHL- with < 6 months duration of complete response (CR) between courses of conventional therapy - Mantle cell NHL- may be treated in first CR - Chronic lymphocytic leukemia (CLL) - must have either 1) failed to meet National Cancer Institute (NCI) Working Group criteria for complete or partial response after therapy with a regimen containing fludarabine phosphate (FLU) (or another nucleoside analog, e.g.2-chlorodeoxyadenosine [2-CDA], pentostatin) or experience disease relapse within 12 months after completing therapy with a regimen containing FLU (or another nucleoside analog); 2) failed FLU-cyclophosphamide (CY)-Rituximab (FCR) combination chemotherapy at any time point; or 3) have 17p deletion cytogenetic abnormality; patients should have received induction chemotherapy but could be transplanted in 1st CR; 4) patients with a diagnosis of CLL (or small lymphocytic lymphoma) or a diagnosis of CLL that progresses to prolymphocytic leukemia (PLL), or T-cell CLL or PLL - Hodgkin lymphoma (HL) - must have received and failed frontline therapy; patients must have failed or were not eligible for autologous transplant - Multiple myeloma (MM) - following a planned autologous transplant or equivalent high-dose therapy without a graft, or following a failed prior autograft - Acute myeloid leukemia (AML) - must have < 5% marrow blasts at the time of transplant - Acute lymphoblastic leukemia (ALL) - must have < 5% marrow blasts at the time of transplant - Chronic myelogenous leukemia (CML) - patients will be accepted beyond first chronic phase (CP1) if they have received previous myelosuppressive chemotherapy or HCT, and have < 5% marrow blasts at time of transplant - Myelodysplastic syndromes/myeloproliferative disorders (MDS/MPD) - must have received previous myelosuppressive chemotherapy or HCT, and have < 5% marrow blasts at time of transplant - Waldenstrom's macroglobulinemia - must have failed 2 courses of therapy - Myelosuppressive chemotherapy must be discontinued three weeks prior to conditioning with the exception of hydroxyurea or imatinib - Patients < 12 years old must be approved by both the participating institutions' patient review committee such as the Patient Care Conference (PCC) at the Fred Hutchinson Cancer Research Center (FHCRC) and the FHCRC principal investigator - Patient who refused to be treated on a conventional HCT protocol; for this inclusion criterion, transplants must be approved by both the participating institution's patient review committee such as the Patient Care Conference (PCC) at the FHCRC and the FHCRC principal investigators - Patients with human leukocyte antigen (",ct_inc_586204,AACT,1268,NCT00089011,Historical,FCR
5c7430838625dd05e6867f86,1230,,,556,Patient,14:27.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_584851,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Patients with a diagnosis of CLL (or SLL) or diagnosis of CLL that progresses to prolymphocytic leukemia (PLL) - Patients with B-Cell CLL or PLL who: - Failed to meet National Cancer Institute (NCI) Working Group criteria 2 for complete or partial response after 2 cycles of therapy with regimen containing fludarabine (or another nucleoside analog, e.g.cladribine [2-CDA], pentostatin) or with disease relapse within 12 months after completing therapy with a fludarabine (or another nucleoside analog) containing regimen - Failed FCR or pentostatin/cyclophosphamide/rituximab (PCR) combination chemotherapy at any time point - Patients with novo or acquired 17p deletion cytogenetic abnormality; patients should have received induction treatment but could be transplanted in 1st CR - Patients who have suitable human leukocyte antigen (HLA)-matched related or unrelated donors willing to receive filgrastim (G-CSF), undergo leukapheresis to collect peripheral blood mononuclear cell (PBMC), and to donate stem cells -",ct_inc_584851,AACT,553,NCT00104858,Recent,FCR
5c7430838625dd05e6867f87,1230,,,49,Patient,14:27.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_588293,Clinical Trial Inclusion Criteria,UNKNOWN,- Failed FLU-cyclophosphamide [CY]-rituximab (FCR) combination chemotherapy at any time point,ct_inc_588293,AACT,46,NCT00075478,Recent,FCR
5c7430888625dd060e867f8c,470,,,87,Patient,14:32.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_545079,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion criteria: - Presence of bulky lymph nodes (> 5 cm) after second-line F/FC/FCR/B/BR - Clinically apparent autoimmune cytopenia (i.e., autoimmune hemolytic anemia, autoimmune thrombocytopenia, or pure red cell aplasia) - CNS involvement with",ct_exc_545079,AACT,84,NCT00634881,Recent,FCR
5c7430888625dd060e867f8d,470,,,166,Patient,14:32.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_545079,Clinical Trial Exclusion Criteria,UNKNOWN,"normal - Not pregnant or nursing - Fertile patients must use effective contraception Exclusion criteria: - Severe infection during second-line treatment with F/FC/FCR/B/BR, meeting any 1 of the following criteria: - Any episode of NCI grade 4 infection - More than 1 episode of NCI grade 3 infection - Medical condition requiring long-term use of oral corticosteroids for more than 1 month - Active bacterial, viral, or fungal infection - HIV, hepatitis B virus, and/or hepatitis C virus-positive serum status - Concurrent severe diseases that exclude the administration of protocol therapy, including any of the following: - NYHA class III-IV heart insufficiency - Severe chronic obstructive lung disease with hypoxemia - Severe ischemic cardiac disease - Active secondary malignancy other than B-CLL prior to the study - Known hypersensitivity or anaphylactic reaction against murine proteins or one of the drug components",ct_exc_545079,AACT,163,NCT00634881,Historical,FCR
5c7430888625dd060e867f8e,470,,,55,Patient,14:32.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_545079,Clinical Trial Exclusion Criteria,UNKNOWN,"No more than 2 prior chemotherapies, including F/FC/FCR/B/BR therapy - No more than 1 pretreatment (before second-line therapy) with chlorambucil or F/FC/FCR/B",ct_exc_545079,AACT,52,NCT00634881,Historical,FCR
5c74308c8625dd063e867f8f,1010,,,3,Patient,14:36.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_357955,Clinical Trial Inclusion Criteria,UNKNOWN,"FCR, BR) requiring further treatment - Refactory to or relapsed after at least 1 prior biologic agent (e.g.",ct_inc_357955,AACT,0,NCT03085173,Historical,FCR
5c7430918625dd0680867f8e,480,,,92,Patient,14:41.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_429148,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - confirmed diagnosis of CLL or SLL - previously treated by low dose FCR for active disease requiring treatment per IWCLL criteria - dose reduction of fludarabine and cyclophosphamide due to age, comorbid conditions, or reduce creatinine clearance",ct_inc_429148,AACT,89,NCT02156726,Recent,FCR
5c7430918625dd0680867f90,480,,,614,Patient,14:41.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_523604,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - >= 18 yrs of age, have B-cell CLL, failed at least 1 prior fludarabine-containing regimen.- Refractory to 1 fludarabine-containing regimen is defined as failure to achieve at least PR to the last fludarabine-containing regimen received, or disease progression while receiving the last fludarabine-containing regimen, or disease progression in responders (i.e., achieved a PR or CR) within 6 mos of the last cycle of the last fludarabine-containing regimen received (e.g., fludarabine monotherapy, FR, or FC) or in responders (i.e., achieved a PR or CR ) within 24 mos of the last cycle of FCR.- Intolerant to fludarabine is defined as discontinuation of therapy within 2 cycles due to side effects/toxicity from the last fludarabine-containing regimen.- ECOG score of <=1.- Adequate coagulation, renal, & hepatic function at Screening as follows: - Serum creatinine <= 2.0 mg/dL or calculated creatinine clearance >= 50 mL/min; - AST & ALT <= 3.0 x ULN; - Bilirubin <= 1.5 x ULN.- Gilbert's Syndrome may have a Bilirubin > 1.5 x ULN; aPTT, PT, not to exceed 1.2 x ULN.- Adequate bone marrow (BM) independent of any growth factor support (with the exception of subjects with BM heavily infiltrated with underlying disease [80% or more] who may use growth factor support to achieve adequate BM) at Screening as follows: -",ct_inc_523604,AACT,611,NCT00918450,Historical,FCR
5c74309b8625dd06c9867f89,1220,,,113,Patient,14:52.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_515190,Clinical Trial Inclusion Criteria,UNKNOWN,"Not eligible or appropriate for conventional allogeneic SCT - Patients who achieve only a partial response to FCR as initial therapy will be eligible.- Mantle cell lymphoma: - Beyond 1st CR with relapsed or persistent disease and not eligible or appropriate for conventional allogeneic or autologous SCT - Disease responding or stable after most recent therapy (chemotherapy, MoAb, etc...) - Relapsed after prior autologous SCT - B-cell prolymphocytic leukemia (PLL) with relapsed or residual disease after at least 1 prior therapy and not eligible for allogeneic SCT - Diffuse large cell lymphoma, previously identified as CD19+: - Residual disease after primary therapy and not eligible for autologous SCT - Relapsed after prior autologous SCT - Beyond 1st CR with relapsed or persistent disease and not eligible or appropriate of conventional allogeneic or autologous SCT - Expected survival",ct_inc_515190,AACT,110,NCT01029366,Recent,FCR
5c74309c8625dd06c9867f8a,1220,,,3,Patient,14:52.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_499032,Clinical Trial Inclusion Criteria,UNKNOWN,"FCR, FR, PCR, Fludarabine) or alemtuzumab-based regimen or bendamustine-based regimen prior to study enrollment.",ct_inc_499032,AACT,0,NCT01241786,Historical,FCR
5c74309c8625dd06c9867f8b,1220,,,332,Patient,14:52.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_489270,Clinical Trial Exclusion Criteria,UNKNOWN,"More than 2 previous alkylating agent based-therapy (i.e.cyclophosphamide, chlorambucil) - More than 3 total prior lines of therapy for CLL - Primary refractory disease as defined by progression while receiving or within 6 months of completion of a chemoimmunotherapy regimen such as fludarabine, cyclophosphamide and rituximab (FCR) or pentostatin, cyclophosphamide and rituximab (PCR) -",ct_exc_489270,AACT,329,NCT01369849,Historical,FCR
5c74309c8625dd06c9867f8c,1220,,,750,Patient,14:52.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_516781,Clinical Trial Inclusion Criteria,UNKNOWN,"- Patients with either a: - Diagnosis of T-cell CLL or T-cell prolymphocytic leukemia (PLL) who have failed initial chemotherapy, patients with T cell CLL or PLL or - Diagnosis of B-cell CLL, B-cell small lymphocytic lymphoma, or B-cell CLL that progresse",ct_inc_516781,AACT,747,NCT01008462,Recent,FCR
5c7430ae8625dd0779867f8f,520,,,149,Patient,15:10.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_394292,Clinical Trial Inclusion Criteria,UNKNOWN,"have completed curative treatment for breast cancer, 4. have not experienced a cancer recurrence, and 5. report a clinically significant level of FCR (as assessed with the Fear of Cancer Recurrence Inventory-Short Form 13)",ct_inc_394292,AACT,146,NCT02611544,Recent,FCR
5c7430b18625dd07c6867f8b,490,,,65,Patient,15:13.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_545079,Clinical Trial Inclusion Criteria,UNKNOWN,"FC) - Fludarabine phosphate, cyclophosphamide, and rituximab (FCR) - Bendamustine hydrochloride alone (B) - Bendamustine hydrochloride and rituximab chemotherapy (BR) - Complete minimal residual disease response defined by the following: - At least negativity of 4-color-cytometry and/or even PCR-amplifiable clonal CDR III rearrangement of the IgV_H -",ct_inc_545079,AACT,62,NCT00634881,Recent,FCR
5c7430b18625dd07c6867f8c,490,,,204,Patient,15:13.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_545079,Clinical Trial Inclusion Criteria,UNKNOWN,"For PCR analysis, blood sample need to be taken at beginning or during second-line cytoreductive therapy before achievement of a clinical complete remission - Disease not refractory to first-line F/FC/FCR/B/BR if received such therapy",ct_inc_545079,AACT,201,NCT00634881,Hypothetical,FCR
5c7430b88625dd07eb867f8b,930,,,139,Patient,15:20.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_589724,Clinical Trial Inclusion Criteria,UNKNOWN,disease relapse within 12 months after completing therapy with a regimen containing fludarabine (or another nucleoside analog) - Failed FCR combination chemotherapy at any time point - Had de novo of acquired 17p deletion cytogenetic abnormality; patients should have received induction chemotherapy but could be transplanted in first (1st) complete response (CR),ct_inc_589724,AACT,136,NCT00060424,Recent,FCR
5c7430b88625dd07eb867f8c,930,,,397,Patient,15:20.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_434873,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Male and female with CD19+ relapsed or refractory MCL, and with no available curative treatment options (such as autologous or allogeneic SCT) who have limited prognosis (several months to < 2 year survival) with currently available therapies will be enrolled.- Not eligible or appropriate for conventional allogeneic SCT - Patients who achieve only a partial response to FCR(fludarabine, cyclophosphamide and Rituxan) as initial therapy will be eligible.- Beyond 1st CR (complete remission) with relapsed or persistent disease and not eligible or appropriate for conventional allogeneic or autologous SCT - Disease responding or stable after most recent therapy (chemotherapy, MoAb, etc...) - Relapsed after prior autologous SCT - Residual disease after primary therapy and not eligible for autologous SCT - Relapsed after prior autologous SCT - Beyond 1st CR with relapsed or persistent disease and not eligible or appropriate of conventional allogeneic or autologous SCT - Expected survival",ct_inc_434873,AACT,394,NCT02081937,Recent,FCR
5c7430b88625dd07eb867f8d,930,,,3,Patient,15:20.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_487478,Clinical Trial Exclusion Criteria,UNKNOWN,FCR:,ct_exc_487478,AACT,0,NCT01393366,Recent,FCR
5c7430b88625dd07eb867f8e,930,,,63,Patient,15:20.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_584945,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Subjects who did not respond to prior FCR therapy (relapsed within 6 months of the last dose).- Cancer radiotherapy, radioimmunotherapy, biological therapy, chemotherapy, or other investigational therapy within 4 weeks prior to Study Day 1 - Previous exposure to lumiliximab or other anti-CD23 antibodies - Subjects who have had a prior allogenic bone marrow transplant (BMT) or autologous BMT or peripheral stem-cell transplant (PBSCT) -",ct_exc_584945,AACT,60,NCT00103558,Historical,FCR
5c74306f8625dd0518867f8a,100,,,65,Patient,14:07.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_392688,Clinical Trial Inclusion Criteria,UNKNOWN,"- Planned to start trastuzumab based neo/adjuvant therapy: FEC-DH or AC-DH, or; dose-dense AC-TH, or docetaxel/cyclophosphamide/trastuzumab or docetaxel/carboplatin/trastuzumab, or weekly paclitaxel with trastuzumab.- 19 years of age - Able to provide ver",ct_inc_392688,AACT,59,NCT02632435,Recent,FEC-DH
5c74306c8625dd04e1867f8a,500,,,68,Patient,14:04.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_404979,Clinical Trial Inclusion Criteria,UNKNOWN,Coronary vasculopathy grade 1 or 2 (CAV 1 or 2) associated with FELV (FEVG) dysfunction <45% or abnormality of completion of restrictive type.,ct_inc_404979,AACT,64,NCT02472002,Recent,FELV
5c7430bb8625dd081e867f92,110,,,40,Patient,15:23.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_362416,Clinical Trial Inclusion Criteria,UNKNOWN,Patients in remission following FLAG-Ida induction therapy who are receiving consolidation treatment.,ct_inc_362416,AACT,32,NCT03027102,Recent,FLAG-Ida
5c7430bb8625dd081e867f93,110,,,40,Patient,15:23.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_362416,Clinical Trial Inclusion Criteria,UNKNOWN,Patients in remission following FLAG-Ida induction therapy who are receiving consolidation treatment.,ct_inc_362416,AACT,32,NCT03027102,Recent,FLAG-Ida
5c7430548625dd03b8867f8e,430,,,215,Patient,13:41.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_390264,Clinical Trial Inclusion Criteria,UNKNOWN,"The patient must be able to swallow oral medication.- The patient must have completed at least 4 months of adjuvant chemotherapy (i.e., FOLFOX, CapeOx, or other, such as 5-fluorouracil, leucovorin, oxaliplatin (FLOX), 5-fluorouracil/leucovorin (5FU/LV), capecitabine).- The interval between completion of standard adjuvant chemotherapy and randomization must be less than or equal to 60 days.- Blood counts performed within 28 days prior to randomization must meet the following criteria: - Absolute neutrophil count (ANC) must be greater than or equal to 1500/mm3; - platelet count must be greater than or equal to 100,000/mm3; and - hemoglobin must be greater than or equal to 9 g/dL.-",ct_inc_390264,AACT,211,NCT02664077,Historical,FLOX
5c74307f8625dd05d0867f85,410,,,507,Patient,14:23.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_334682,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Patient has histologically verified CRC adenocarcinoma (also comprising the mucinous adenocarcinoma and signet-ring cell carcinoma entities).- Patient is ambulatory with Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.- Patient has radiologically measurable metastatic disease.- Patient has an intra-abdominal metastatic lesion that can be biopsied.- Patient has not had previous systemic therapy for the metastatic disease.- Patient is eligible for the Nordic FLOX regimen.-,ct_inc_334682,AACT,503,NCT03388190,Recent,FLOX
5c7430af8625dd079a867f8e,380,,,375,Patient,15:11.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_567473,Clinical Trial Inclusion Criteria,UNKNOWN,"There must be histologic confirmation of adenocarcinoma of the colon or rectum.- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 - Estimated life expectancy of at least 12 weeks.- One prior therapy for metastatic disease is permitted.- Recurrence within 12 months of adjuvant therapy with FOLFOX or a similar regimen (i.e FLOX, CapOX) is considered one regimen and allowed for study - There must be evidence of adequate organ function - Patients with a history of prior non-colorectal malignancies are eligible if they have been disease-free for 5 years prior to study entry and are deemed by the physician to be at low risk for recurrence.- Age > 18 yrs.",ct_inc_567473,AACT,371,NCT00336856,Hypothetical,FLOX
5c7430558625dd03b8867f8f,430,,,231,Patient,13:41.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_479486,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - patient with acute myeloid or lymphoblastic leukemia in 1st or second remission - age 18-55 years - with inform consent - no contraindication for allogeneic transplantation: active infection, allergy to FLu/Bu/CTX, liver and renal function damage - HLA matched related (6/6) or unrelated donors (at least 8/10)",ct_inc_479486,AACT,225,NCT01498016,Recent,FLu/Bu
5c7430558625dd03b8867f90,430,,,211,Patient,13:41.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_484264,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - adult acute lymphocytic leukemia in 1st or second remission - age 18-60 years - with inform consent - no contraindication for allogeneic transplantation: active infection, allergy to FLu/Bu/CTX, liver and renal function damage - HLA matched related (6/6), unrelated donors (at least 8/10) or mismatched related donor (haplo)",ct_inc_484264,AACT,205,NCT01435447,Recent,FLu/Bu
5c7430588625dd03fb867f87,620,,,223,Patient,13:44.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_384652,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients 18 years of age with a hematologic malignancy other than aplastic anemia or primary myelofibrosis, scheduled to undergo RIC allogeneic SCT with a peripheral blood stem cell graft, using Fludarabine/Busulfan (Flu/Bu) conditioning and Tacrolimus/ Methotrexate (Tac/MTX)",ct_inc_384652,AACT,217,NCT02737306,Recent,Flu/Bu
5c7430588625dd03fb867f89,620,,,223,Patient,13:44.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_384652,Clinical Trial Inclusion Criteria,COMMENT,"Patients 18 years of age with a hematologic malignancy other than aplastic anemia or primary myelofibrosis, scheduled to undergo RIC allogeneic SCT with a peripheral blood stem cell graft, using Fludarabine/Busulfan (Flu/Bu) conditioning and Tacrolimus/ Methotrexate (Tac/MTX)",ct_inc_384652,AACT,217,NCT02737306,Recent,Flu/Bu
5c7430868625dd060e867f84,470,,,247,Patient,14:30.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_457531,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Patients 18 years of age with a hematologic malignancy other than aplastic anemia or primary myelofibrosis, scheduled to undergo RIC allogeneic SCT with a peripheral blood stem cell graft from an unrelated donor, using Flu/Bu conditioning and Tac/MTX GVHD prophylaxis.",ct_inc_457531,AACT,241,NCT01785810,Recent,Flu/Bu
5c74308f8625dd0680867f84,480,,,404,Patient,14:39.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_382384,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - adult patients with refractory or relapse acute lymphoblastic leukemia not in remission after 2 cycles of induction chemotherapy early relapse (1st remission less than 6 months) not in remission after 1 cycle of re-induction chemotherapy multiple relapse - age 16-60 years with inform consent - no contraindication for allogeneic transplantation: active infection, allergy to FLu/Bu/CTX, liver and renal function damage - HLA matched related (6/6), unrelated donors (8 10/10) or haplo",ct_inc_382384,AACT,398,NCT02766868,Recent,FLu/Bu
5c74308f8625dd0680867f85,480,,,212,Patient,14:39.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_521306,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Patients not expected to be available for follow-up in our institution for at least 100 days after the transplant - Patients who are not undergoing standard non-myeloablative SCT with Flu/Bu conditioning and Tax/MTX GVHD prophylaxis - Patients with uncontrolled bacterial, viral or fungal infections - Patients who take strong inducers or inhibitors of the CYP450A4 - Patients receiving other investigational drugs for GVHD - Women who are pregnant, plan to become pregnant or are breastfeeding",ct_exc_521306,AACT,206,NCT00948753,Recent,Flu/Bu
5c74309c8625dd06f5867f84,440,,,227,Patient,14:52.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_479204,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - adult patient undergoing allogeneic hematopoietic stem cell transplantation - age 18-55 years - with inform consent - no contraindication for allogeneic transplantation: active infection, allergy to FLu/Bu/CTX, liver and renal function damage - HLA mismatched related (3 5/6) or unrelated donors (at least 8/10)",ct_inc_479204,AACT,221,NCT01501708,Recent,FLu/Bu
5c7430a48625dd0737867f89,180,,,6,Patient,15:00.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_343977,Clinical Trial Inclusion Criteria,UNKNOWN,FLU/BU:,ct_inc_343977,AACT,0,NCT03267186,Recent,FLU/BU
5c7430a48625dd0737867f88,180,,,7,Patient,15:00.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_343977,Clinical Trial Inclusion Criteria,UNKNOWN,FLU/MEL:,ct_inc_343977,AACT,0,NCT03267186,Recent,FLU/MEL
5c7430b88625dd07fd867f94,210,,,233,Patient,15:20.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_325340,Clinical Trial Exclusion Criteria,UNKNOWN,"inotuzumab-treated patients are eligible for the observational arm (HCT center standard of care).- Patients receiving non-myeloablative conditioning are not allowed on the observational arm (reduced toxicity conditioning with Flu/Mel/Thio is allowed on the observational arm).- Pregnant or lactating females are ineligible as many of the medications used in this protocol could be harmful to unborn children and infants.- Patients with HIV or uncontrolled fungal, bacterial or viral infections are excluded.",ct_exc_325340,AACT,226,NCT03509961,Recent,Flu/Mel
5c7430538625dd03c7867f93,0,,,150,Patient,13:39.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_392418,Clinical Trial Inclusion Criteria,UNKNOWN,- ABVD - ICE R - 7+3 - Conditioning therapy for stem cell transplantation: - BEAM - Bu/Cy ATG - Bu/Flu ATG - FluCy ATG - FluCy + TBI - BuMel - FluBuCy - Melphalan - Etoposide + TBI - Cyclophosphamide + TBI,ct_inc_392418,AACT,143,NCT02635984,Recent,FluBuCy
5c7430928625dd0692867f86,790,,,137,Patient,14:42.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_586537,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria: - Previously treated with >1 prior regimen for B-CLL.- Previously treated with a fludarabine plus alemtuzumab (FluCAM) regimen for B-CLL.- Positive Coombs test and actively hemolyzing.- Absolute neutrophil count (ANC),ct_exc_586537,AACT,131,NCT00086580,Historical,FluCAM
5c74305e8625dd043c867f8c,50,,,246,Patient,13:50.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_523788,Clinical Trial Exclusion Criteria,UNKNOWN,psychiatric/ psychological disorders Absence of /inability to provide informed consent Serious diseases that prevent treatments with chemotherapy Myelofibrosis Inclusion criteria: reduced-intensity conditioning regimen (For both FluMel & FluCyTBI regimens): Age under 70 years and older than 18 years Absence of HLA compatible related donor.,ct_exc_523788,AACT,238,NCT00916045,Recent,FluCyTBI
5c74305e8625dd043c867f8d,50,,,86,Patient,13:50.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_523788,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria: reduced-intensity conditioning regimen (For both FluMel & FluCyTBI regimens):,ct_exc_523788,AACT,78,NCT00916045,Recent,FluCyTBI
5c7430918625dd0680867f8f,480,,,517,Patient,14:41.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_523604,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - >= 18 yrs of age, have B-cell CLL, failed at least 1 prior fludarabine-containing regimen.- Refractory to 1 fludarabine-containing regimen is defined as failure to achieve at least PR to the last fludarabine-containing regimen received, or disease progression while receiving the last fludarabine-containing regimen, or disease progression in responders (i.e., achieved a PR or CR) within 6 mos of the last cycle of the last fludarabine-containing regimen received (e.g., fludarabine monotherapy, FR, or FC) or in responders (i.e., achieved a PR or CR ) within 24 mos of the last cycle of FCR.- Intolerant to fludarabine is defined as discontinuation of therapy within 2 cycles due to side effects/toxicity from the last fludarabine-containing regimen.- ECOG score of <=1.- Adequate coagulation, renal, & hepatic function at Screening as follows: - Serum creatinine <= 2.0 mg/dL or calculated creatinine clearance >= 50 mL/min; - AST & ALT <= 3.0 x ULN; - Bilirubin <= 1.5 x ULN.- Gilbert's Syndrome may have a Bilirubin > 1.5 x ULN; aPTT, PT, not to exceed 1.2 x ULN.- Adequate bone marrow (BM) independent of any growth factor support (with the exception of subjects with BM heavily infiltrated with underlying disease [80% or more] who may use growth factor support to achieve adequate BM) at Screening as follows: -",ct_inc_523604,AACT,494,NCT00918450,Historical,fludarabine monotherapy
5c74305e8625dd043c867f8e,50,,,235,Patient,13:50.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_523788,Clinical Trial Exclusion Criteria,UNKNOWN,psychiatric/ psychological disorders Absence of /inability to provide informed consent Serious diseases that prevent treatments with chemotherapy Myelofibrosis Inclusion criteria: reduced-intensity conditioning regimen (For both FluMel & FluCyTBI regimens): Age under 70 years and older than 18 years Absence of HLA compatible related donor.,ct_exc_523788,AACT,229,NCT00916045,Recent,FluMel
5c74305e8625dd043c867f8f,50,,,75,Patient,13:50.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_523788,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria: reduced-intensity conditioning regimen (For both FluMel & FluCyTBI regimens):,ct_exc_523788,AACT,69,NCT00916045,Recent,FluMel
5c74303c8625dd02f6867f8e,120,,,203,Patient,13:16.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_438902,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients with histologically confirmed metastatic colorectal cancer - Cetuximab-based chemotherapy (monotherapy, combination therapy with cytotoxic chemotherapy such as FOLFOX, XELOX, irinotecan, FOLFIRI, XELIRI, first-line, second-line or third-line are all eligible)",ct_inc_438902,AACT,196,NCT02029326,Recent,FOLFIRI
5c7430418625dd0334867f84,400,,,471,Patient,13:21.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_340555,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically proven adenocarcinoma of the colon and/or rectum, - Metastatic disease confirmed clinically/radiologically, - Patients with Formalin-Fixed, Paraffin-Embedded tissue RAS wild type colorectal cancer at diagnosis, who had initial clinical benefit [complete response, partial response or stable disease] during first line irinotecan-based or oxaliplatin-based chemotherapy in combination with cetuximab or panitumumab, - First- line treatment duration (FOLFIRI, FOLFOX with anti-EGFR monoclonal antibody, of whom at least 2/3 of cases will have involved panitumumab) of at least 3 months, - Second line therapy consisting of any chemotherapy (with or without Bevacizumab) definitely without anti-EGFR therapy of at least 2 months, followed by disease progression, - Eligible third line regimens include FOLFIRI or Irinotecan or FOLFOX, according to standard practice and approved indications.",ct_inc_340555,AACT,464,NCT03311750,Recent,FOLFIRI
5c7430448625dd033f867f8f,310,,,398,Patient,13:24.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_438969,Clinical Trial Exclusion Criteria,UNKNOWN,"Any other medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent Phase II Specific Exclusion Criteria: - Progression on first line therapy - A complete response on first line therapy - Use of first line therapy for longer than 4 months - Use of any first line treatment with a chemotherapy regimen other than FOLFOX, FOLFIRI or CAPOX (each with or without bevacizumab) - More than 6 weeks since the last administration of 5 FU, capecitabine, oxaliplatin or irinotecan",ct_exc_438969,AACT,391,NCT02028442,Recent,FOLFIRI
5c7430458625dd033f867f98,310,,,61,Patient,13:25.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_374714,Clinical Trial Inclusion Criteria,UNKNOWN,"Systemic chemotherapy indication, compatible with the FOLFIRI + bevacizumab combination - Satisfactory haematological evaluation: PNN rate greater than 1500 / mm3, platelet count greater than 100 G / l; - Satisfactory renal and hepatic function : serum creatinine 1.5 times the normal lower values or creatinine clearance 50 ml / min, bilirubin 1.25 times lower normal values, AST / ALT 1.5 times the lower normal values (5 times the lower normal values for patients with liver metastases) -",ct_inc_374714,AACT,54,NCT02866903,Recent,FOLFIRI
5c7430458625dd0355867f87,160,,,58,Patient,13:25.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_356855,Clinical Trial Inclusion Criteria,UNKNOWN,"Prior regimens may include FOLFOX -/+ bevacizumab, FOLFIRI -/+ bevacizumab or -/+ cetuximab (if KRAS wild-type) or panitumumab (if KRAS wilt-type).Other prior regimens may include 5-FU or capecitabine -/+ bevacizumab, irinotecan -/+ cetuximab or panitumumab, FOLFIRI -/+ ziv-aflibercept or ramucirumab.",ct_inc_356855,AACT,51,NCT03099486,Historical,FOLFIRI
5c7430468625dd0360867f84,780,,,564,Patient,13:26.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_446462,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion criteria: - Treatment with chemotherapy, hormonal therapy, radiotherapy, surgery, or an investigational agent within 28 days - Eastern Cooperative Oncology Group (ECOG) >1 - Need for a major surgical procedure or radiation therapy during the study - Diagnosis of squamous-cell lung cancer - Cumulative radiation therapy to > 25% of the total bone marrow - History of brain metastases - Inadequate organ and bone marrow function - Uncontrolled hypertension - Evidence of clinically significant bleeding diathesis or underlying coagulopathy - Prior FOLFIRI treatment but have not been appropriate for safety reasons - Patients with known Gilbert's syndrome",ct_exc_446462,AACT,557,NCT01930552,Historical,FOLFIRI
5c7430478625dd0360867f85,780,,,111,Patient,13:27.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_531936,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Histologically or cytologically proven solid tumour for which CPT-11 given by the Folfiri regimen is indicated and prescribed by the attending physician.- Age above 21 years.- Measurable or evaluable disease - Karnofsky performance status,ct_inc_531936,AACT,104,NCT00808184,Recent,Folfiri
5c7430478625dd036b867f84,190,,,22,Patient,13:27.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_374899,Clinical Trial Inclusion Criteria,UNKNOWN,bevacizumab or FOLFIRI +/-,ct_inc_374899,AACT,15,NCT02864485,Recent,FOLFIRI
5c7430488625dd036b867f86,190,,,343,Patient,13:28.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_461817,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically confirmed colorectal cancer - Evaluable or measurable radiographic evidence of colorectal cancer - Patients with unresected metastases from colorectal cancer; patients may be either untreated with chemotherapy or currently receiving first-line 5-FU based chemotherapy (folinic acid-fluorouracil-irinotecan hydrochloride [FOLFIRI], capecitabine-irinotecan hydrochloride [CAPIRI], fluorouracil-leucovorin calcium-oxaliplatin [FOLFOX], or capecitabine-oxaliplatin [CAPOX] with or without bevacizumab) within 10 months of beginning ADAPT therapy with at least stable disease radiographically; patients who received prior adjuvant chemotherapy with 5-FU, capecitabine, or FOLFOX are eligible if adjuvant therapy was completed greater than 6 months ago - History of histological confirmation for recurrent disease, or if recurrent disease is not readily accessible to biopsy, must have two consecutive carcinoembryonic antigen (CEA) or cancer antigen (CA) 19-9 increases, or positron emission tomography (PET) avidity - Men and women from all ethnic and racial groups - Eastern Cooperative Oncology Group (ECOG) performance status =< 2 - Total bilirubin",ct_inc_461817,AACT,336,NCT01729923,Hypothetical,FOLFIRI
5c7430498625dd0355867f92,160,,,334,Patient,13:29.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_430536,Clinical Trial Exclusion Criteria,UNKNOWN,"UGT1A1 genotype other than *1/*1, *1/*28, or *28/*28 Known dihydropyrimidine dehydrogenase (DPD) deficiency Prior treatment with irinotecan and/or bevacizumab Unable or unwilling to discontinue (and substitute if necessary) use of prohibited drugs for at least 14 days (fruits and juices for at least 7 days) prior to Day 1 of FOLFIRI + bevacizumab initiation (see section 11.2,",ct_exc_430536,AACT,327,NCT02138617,Hypothetical,FOLFIRI
5c7430498625dd0355867f93,160,,,387,Patient,13:29.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_430536,Clinical Trial Exclusion Criteria,UNKNOWN,"Prior history of hypertensive encephalopathy Active cardiac disease including any of the following: - New York Heart Association (NYHA) Grade II or greater congestive heart failure (see section 11.3, Appendix C) - History of myocardial infarction or unstable angina within 6 months prior to Day 1 - History of stroke or transient ischemic attack within 6 months prior to Day 1 of FOLFIRI + bevacizumab initiation Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Day 1 of FOLFIRI + bevacizumab initiation History of hemoptysis ( 1/2 teaspoon of bright red blood per episode) within 1 month prior to Day 1 of FOLFIRI + bevacizumab initiation Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)",ct_exc_430536,AACT,380,NCT02138617,Historical,FOLFIRI
5c7430498625dd0355867f94,160,,,111,Patient,13:29.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_430536,Clinical Trial Exclusion Criteria,UNKNOWN,"Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 of FOLFIRI + bevacizumab initiation or anticipation of need for major surgical procedure during the course of the study Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to Day 1 of FOLFIRI + bevacizumab initiation History of abdominal fistula or gastrointestinal perforation within 6 months prior to Day 1 of FOLFIRI + bevacizumab initiation Serious, non-healing wound, active ulcer, or untreated bone fracture Proteinuria as demonstrated by:",ct_exc_430536,AACT,104,NCT02138617,Historical,FOLFIRI
5c7430498625dd036b867f8a,190,,,202,Patient,13:29.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_454730,Clinical Trial Inclusion Criteria,UNKNOWN,"Planned combination bevacizumab (bvz) treatment with either: - leucovorin, fluorouracil and oxaliplatin (FOLFOX) - capecitabine and oxaliplatin (XELOX) - leucovorin, fluorouracil and irinotecan (FOLFIRI) - capecitabine and irinotecan (XELIRI) Naive for bvz",ct_inc_454730,AACT,195,NCT01822444,Recent,FOLFIRI
5c7430498625dd0355867f95,160,,,75,Patient,13:29.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_518643,Clinical Trial Inclusion Criteria,UNKNOWN,Scheduled to receive first-line chemotherapy (FOLFOX/bevacizumab or FOLFIRI/bevacizumab) for metastatic disease.,ct_inc_518643,AACT,68,NCT00984048,Recent,FOLFIRI
5c7430498625dd0355867f97,160,,,161,Patient,13:29.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_511552,Clinical Trial Inclusion Criteria,UNKNOWN,/=18 years of age - metastatic colorectal cancer - at least 1 measurable lesion according to RECIST v. 1.1 - patients with disease progression with prior FOLFIRI + Avastin therapy who are not candidates for primary metastasectomy - disease progression <,ct_inc_511552,AACT,154,NCT01077739,Historical,FOLFIRI
5c7430498625dd0355867f98,160,,,62,Patient,13:29.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_511552,Clinical Trial Inclusion Criteria,UNKNOWN,- No more than 8 weeks between 1st-line treatment with FOLFIRI + Avastin and 2nd-line treatment with XELOX or FOLFOX + Avastin,ct_inc_511552,AACT,55,NCT01077739,Recent,FOLFIRI
5c7430498625dd036b867f8e,190,,,15,Patient,13:29.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_527450,Clinical Trial Inclusion Criteria,UNKNOWN,"FOLFOX, FOLFIRI, XELOX, or XELIRI.- Documentation of wild type k-Ras expression in the liver",ct_inc_527450,AACT,8,NCT00867334,Recent,FOLFIRI
5c74304a8625dd0376867f85,940,,,156,Patient,13:30.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_407659,Clinical Trial Inclusion Criteria,UNKNOWN,"Such therapies should include regimens containing oxaliplatin and irinotecan in combination with a fluoropyrimidine if appropriate (e.g., FOLFOX and FOLFIRI or their variants).-",ct_inc_407659,AACT,149,NCT02437071,Recent,FOLFIRI
5c74304a8625dd0381867f8a,230,,,51,Patient,13:30.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_556746,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Patients eligible for FOLFIRI or FOLFOX therapy - ECOG performance status score 0-1,ct_inc_556746,AACT,44,NCT00479583,Recent,FOLFIRI
5c74304a8625dd0381867f8b,230,,,85,Patient,13:30.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_556746,Clinical Trial Inclusion Criteria,UNKNOWN,No maximum age for Study Arm A (FOLFOX) - 18-65 years of age for Study Arm B (FOLFIRI),ct_inc_556746,AACT,78,NCT00479583,Recent,FOLFIRI
5c74304a8625dd0381867f8e,230,,,90,Patient,13:30.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_393267,Clinical Trial Inclusion Criteria,UNKNOWN,RAS wild-type metastatic colorectal cancer patients candidate to receive FOLFOX or FOLFIRI plus panitumumab or FOLFOX or FOLFIRI plus cetuximab as upfront treatment as per clinical practice - Willingness and ability to comply with the protocol - Written informed consent to study procedures -,ct_inc_393267,AACT,83,NCT02624895,Recent,FOLFIRI
5c74304a8625dd0376867f87,940,,,102,Patient,13:30.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_423126,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically confirmed stage IV colorectal adenocarcinoma previously treated with FOLFOX and FOLFIRI and bevacizumab, receipt of cetuximab or panitumumab is not required, and has shown progression or intolerant of both oxaliplatin and irinotecanbased regimens; baseline tumor assessments must be done within 28 days of starting treatment - Patients must have lesions that can be easily biopsied - Representative tumor tissue specimens (paraffin block preferred) - Signed informed consent prior to initiation of any studyspecific procedure or treatment, including agreement to two biopsies during the study - Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 - Able to comply with the protocol, including tissue and blood sampling - Leukocytes >= 3,000 per mm^3 - Absolute neutrophil count >",ct_inc_423126,AACT,95,NCT02235324,Historical,FOLFIRI
5c74304b8625dd0376867f8a,940,,,56,Patient,13:31.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_437699,Clinical Trial Exclusion Criteria,REGISTRATION,"Contraindication to any of the components of the FOLFIRI chemotherapy regimen, as per investigators' judgement.",ct_exc_437699,AACT,49,NCT02045030,Recent,FOLFIRI
5c74304c8625dd0376867f8b,940,,,835,Patient,13:32.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_554890,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Histologically or cytologically confirmed colorectal cancer - Metastatic disease - Not curable by surgical resection - Archival tumor tissue available - Measurable disease, defined as at least one unidimensionally measurable lesion 20 mm by conventional techniques or 10 mm by spiral CT scan - Measurable disease must be outside of a prior radiation port - Documented disease progression either during or after prior chemotherapy treatment - No more than 2 prior chemotherapy regimens in the adjuvant or metastatic setting - Prior chemotherapy regimens must have contained a fluoropyrimidine (e.g., fluorouracil or capecitabine), oxaliplatin, and irinotecan - Patients who received no prior adjuvant therapy must have received 2 prior chemotherapy regimens for metastatic disease (e.g., FOLFOX followed by FOLFIRI) - Patients who received prior adjuvant therapy with a fluoropyrimidine plus oxaliplatin must have received no more than 1 chemotherapy regimen for metastatic disease that must have contained irinotecan - VEGF or EGFR inhibitors with prior chemotherapy allowed - No known brain metastases - Life expectancy > 3 months - ECOG performance status (PS) 0-2 or Karnofsky PS 60% - WBC",ct_inc_554890,AACT,828,NCT00504153,Historical,FOLFIRI
5c74304c8625dd0381867f9a,230,,,104,Patient,13:33.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_505499,Clinical Trial Inclusion Criteria,UNKNOWN,Patients must hvae metastatic colorectal cancer (stage IV) - Patients who have been treated with FOLFIRI regimen for metastatic setting may be eligible for this trial - Patients must be 18 years - Patients must have an Eastern Cooperative Oncology Group (EGOC) performance status 0 to 2.- Patients must have adequate renal function of creatinine < 1.5mg/dL and a creatinine clearance,ct_inc_505499,AACT,97,NCT01157039,Recent,FOLFIRI
5c7430528625dd03a2867f95,130,,,222,Patient,13:38.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_439263,Clinical Trial Inclusion Criteria,UNKNOWN,"A histologically confirmed solid tumor of the gastrointestinal tract including Advanced unresectable, metastatic or recurrent colorectal carcinoma (CRC) for which treatment with FOLFOX6 with or without bevacizumab, FOLFIRI with or without bevacizumab, CAPOX, or regorafenib would be acceptable as determined by the Investigator.",ct_inc_439263,AACT,215,NCT02024607,Recent,FOLFIRI
5c7430528625dd03a2867f96,130,,,7,Patient,13:38.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_439263,Clinical Trial Inclusion Criteria,UNKNOWN,FOLFIRI-refractory patients with CRC enrolling on the FOLFIRI study arm must have failed treatment with one FOLFIRI with or without bevacizumab regimen for unresectable or metastatic disease.,ct_inc_439263,AACT,0,NCT02024607,Recent,FOLFIRI
5c7430528625dd03a2867f97,130,,,109,Patient,13:38.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_439263,Clinical Trial Inclusion Criteria,UNKNOWN,Treatment failure is defined as progression of disease (clinical or radiologic) during treatment with FOLFIRI with or without bevacizumab or < 3 months after the last dose of treatment with FOLFIRI with or without bevacizumab.,ct_inc_439263,AACT,102,NCT02024607,Recent,FOLFIRI
5c7430528625dd03a2867f98,130,,,74,Patient,13:38.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_439263,Clinical Trial Inclusion Criteria,UNKNOWN,"Pancreatic adenocarcinoma for which treatment with FOLFOX6, CAPOX, FOLFIRI, or irinotecan would be acceptable as determined by the Investigator.",ct_inc_439263,AACT,67,NCT02024607,Recent,FOLFIRI
5c7430528625dd03a2867f99,130,,,90,Patient,13:38.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_439263,Clinical Trial Inclusion Criteria,UNKNOWN,"Gastric, GEJ or esophageal adenocarcinoma for which treatment with FOLFOX6, CAPOX, FOLFIRI, or irinotecan would be acceptable as determined by the Investigator.",ct_inc_439263,AACT,83,NCT02024607,Recent,FOLFIRI
5c7430548625dd03c7867fac,0,,,111,Patient,13:40.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_567491,Clinical Trial Inclusion Criteria,UNKNOWN,Histologically proven adenocarcinoma of the colon or rectum planned to receive a minimum of 2 cycles of FOLFIRI +/-,ct_inc_567491,AACT,104,NCT00336609,Recent,FOLFIRI
5c7430548625dd03c7867fad,0,,,56,Patient,13:40.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_567491,Clinical Trial Inclusion Criteria,UNKNOWN,Avastin or Erbitux.1 cycle defined as 2 doses of FOLFIRI.,ct_inc_567491,AACT,49,NCT00336609,Recent,FOLFIRI
5c7430598625dd03fe867f9b,290,,,127,Patient,13:45.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_369523,Clinical Trial Inclusion Criteria,UNKNOWN,"Additional inclusion criteria solely for Part 2: - Former first-line treatment of the metastatic colorectal cancer with FOLFIRI and cetuximab; data available for the duration of treatment and the response within the context of first-line treatment - Former second-line treatment of the colorectal cancer without FOLFIRI, irinotecan or an anti-EGFR substance with data available for the substances administered, duration of treatment and response within the context of the second-line treatment - Proof of a RAS wild-type tumour (KRAS and NRAS exons 2-4) in a tumour biopsy (metastasis) within 4 weeks before randomisation - CT examinations with evidence of a partial response (PR) or complete response (CR) or stable disease (SD) 6 months according to RECIST Version 1.1 criteria as best response within the context of the first-line treatment with FOLFIRI and cetuximab",ct_inc_369523,AACT,120,NCT02934529,Recent,FOLFIRI
5c74305a8625dd0411867f88,300,,,251,Patient,13:46.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_441653,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically proven solid organ cancer - Eastern Cooperative Oncology Group Performance status 0-2 - More than 3 months for life expectancy - Patients scheduled to receive the first line, first cycle FOLFOX (5-FU, Oxaliplatin, Leucovorin) or FOLFIRI (5-FU, Irinotecan, Leucovorin)",ct_inc_441653,AACT,244,NCT01993381,Recent,FOLFIRI
5c74305a8625dd0411867f8a,300,,,406,Patient,13:46.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_495161,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Patients aged under 18 - Patients taking immunosuppressive therapy - Patient having a severe skin disease - No measurable metastasis - Patients with a contra-indication of cetuximab: hypersensitivity to cetuximab or to any excipients - Severe alteration of respiratory or cardiac function or severe coronary disease - Patients with contra-indication to chemotherapy FOLFOX and FOLFIRI - Participation in another research protocol - Patients not affiliated to the Social Security - Hospitalized patients without consent - Pregnant or nursing women, women of childbearing age with no effective contraception",ct_exc_495161,AACT,399,NCT01292356,Recent,FOLFIRI
5c74305d8625dd0414867f90,690,,,28,Patient,13:49.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_471292,Clinical Trial Exclusion Criteria,UNKNOWN,Prior treatment with FOLFIRI or single agent irinotecan is prohibited within six weeks of enrollment.,ct_exc_471292,AACT,21,NCT01605344,Historical,FOLFIRI
5c74305d8625dd0414867f91,690,,,129,Patient,13:49.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_471292,Clinical Trial Exclusion Criteria,UNKNOWN,"Women of childbearing potential must have a pregnancy test performed a maximum of 7 days before start of atorvastatin and FOLFIRI treatment, and a negative result must be documented before start of treatment with atorvastatin or FOLFIRI (whichever is received first by patient).",ct_exc_471292,AACT,122,NCT01605344,Recent,FOLFIRI
5c74305d8625dd0414867f92,690,,,188,Patient,13:49.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_471292,Clinical Trial Exclusion Criteria,UNKNOWN,"Known Dihydropyrimidine dehydrogenase (DPD) deficiency Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of Day 1 of treatment with FOLFIRI",ct_exc_471292,AACT,181,NCT01605344,Recent,FOLFIRI
5c74305d8625dd0414867f93,690,,,166,Patient,13:49.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_471292,Clinical Trial Exclusion Criteria,UNKNOWN,"Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months).Myocardial infarction less than 6 months before start of Day 1 of FOLFIRI Cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted)",ct_exc_471292,AACT,159,NCT01605344,Recent,FOLFIRI
5c74305d8625dd0414867f94,690,,,437,Patient,13:49.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_471292,Clinical Trial Exclusion Criteria,UNKNOWN,"Grade 2 according to NCI Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v. 4.0) Known history of human immunodeficiency virus (HIV) infection Presence of acute or chronic liver disease, renal disease or pancreatitis Known history of chronic hepatitis B or C Symptomatic metastatic brain or meningeal tumors unless the patient is >6 months from definitive therapy, has a negative imaging study within 4 weeks of FOLFIRI initiation, and is clinically stable with respect to the tumor at the time of study entry.",ct_exc_471292,AACT,430,NCT01605344,Historical,FOLFIRI
5c74305d8625dd0414867f95,690,,,77,Patient,13:49.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_471292,Clinical Trial Exclusion Criteria,UNKNOWN,Any hemorrhage or bleeding event > Grade 4 within 4 weeks of start of FOLFIRI Patients with diarrhea CTCAE v4 grade 2,ct_exc_471292,AACT,70,NCT01605344,Recent,FOLFIRI
5c74305d8625dd0447867f87,250,,,388,Patient,13:49.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_493009,Clinical Trial Inclusion Criteria,UNKNOWN,Patients must have a Karnofsky performance status of >= 60% - Patients must have histological confirmation of colorectal carcinoma - Patients must have colorectal tumors that produce carcinoembryonic antigen (CEA) as documented by either immunohistochemistry or by an elevated serum CEA - Patients will be enrolled on this trial after resection of hepatic metastases combined with FOLFIRI or FOLFOX [+/-,ct_inc_493009,AACT,381,NCT01320683,Recent,FOLFIRI
5c74305d8625dd0447867f88,250,,,84,Patient,13:49.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_493009,Clinical Trial Inclusion Criteria,UNKNOWN,"Bevacizumab], or XELOX; patients may have received a maximum of 12 cycles of FOLFIRI or FOLFOX [+/-",ct_inc_493009,AACT,77,NCT01320683,Recent,FOLFIRI
5c74305f8625dd043c867f90,50,,,79,Patient,13:51.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_416899,Clinical Trial Inclusion Criteria,UNKNOWN,First line chemotherapy regimen with a fluoropyrimidine and Irinotecan (FOLFIRI) + cetuximab with initial partial or complete response and progressive disease (PD) with PD 6 weeks after the last administration of cetuximab - Other line(s) of therapy(ies) including the following,ct_inc_416899,AACT,72,NCT02316496,Recent,FOLFIRI
5c74305f8625dd0457867f9b,70,,,337,Patient,13:51.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_472547,Clinical Trial Inclusion Criteria,UNKNOWN,"For resected primary tumor participants, and patients with primary tumor in situ: - Previously untreated metastatic colorectal cancer and not a candidate for curative resection - World Health Organization (WHO) performance status of 0-1 - Life expectancy of greater than or equal to (>/=) 3 months - Eligible for XELOX, mFOLFOX6, FOLFIRI and bevacizumab treatment in accordance with local standards of care and pharmaceutical benefits scheme Additional inclusion criteria for participants with primary tumor in situ: - Intact primary tumor of the colon or the rectum not requiring surgical intervention prior to study start - Minimal or asymptomatic primary tumor",ct_inc_472547,AACT,330,NCT01588990,Historical,FOLFIRI
5c7430608625dd0457867f9e,70,,,286,Patient,13:52.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_522368,Clinical Trial Exclusion Criteria,UNKNOWN,"Adjuvant chemotherapy for Colorectal Cancer (Stage I, II, II) is permitted, if the adjuvant therapy ended >6 month before screening.- Previous FOLFOX treatment for patients who will be included in the mFOLFOX6 cohort apart from FOLFOX treatment in an adjuvant setting.- Previous FOLFIRI treatment for patients who will be included in the FOLFIRI cohort.",ct_exc_522368,AACT,279,NCT00934882,Recent,FOLFIRI
5c7430608625dd0473867f86,570,,,84,Patient,13:52.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_558382,Clinical Trial Inclusion Criteria,UNKNOWN,Not received previous therapy for metastatic colorectal disease but for whom FOLFIRI treatment is clinically indicated.- Adequate organ function defined by blood test.,ct_inc_558382,AACT,77,NCT00457691,Recent,FOLFIRI
5c7430608625dd0473867f87,570,,,57,Patient,13:52.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_514467,Clinical Trial Inclusion Criteria,UNKNOWN,"UGT1A1 genotyped patients - Patients to receiving FOLFIRI, CPT-11+S-1 and CPT-11 alone therapy (with or without molecular targeted agents)",ct_inc_514467,AACT,50,NCT01039506,Recent,FOLFIRI
5c7430608625dd0473867f88,570,,,150,Patient,13:52.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_489737,Clinical Trial Inclusion Criteria,UNKNOWN,Histologically confirmed colorectal adenocarcinoma; - Measurable metastatic disease according to RECIST criteria; - Patients receiving BV plus FOLFIRI as first-line treatment; - Written informed consent; - Availability of blood samples for genetic analysis.-,ct_inc_489737,AACT,143,NCT01363739,Recent,FOLFIRI
5c7430608625dd045a867f89,1190,,,427,Patient,13:52.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_402213,Clinical Trial Inclusion Criteria,UNKNOWN,Histologically confirmed colon or rectal cancer with metastatic disease - Extended RAS and BRAF wild type status documented on archival tumor tissue or on fresh biopsy if no archival tissue present - Measurable disease defined by at least 1 lesion >= 1 cm - Documented objective response or stable disease lasting for 6 months or more to last prior anti-EGFR (cetuximab or panitumumab) in combination with irinotecan or FOLFIRI - Progression within 6 weeks following their last dose of anti-EGFR therapy - Treatment with a non-EGFR targeting regimen following progression on anti-EGFR plus irinotecan-based therapy -,ct_inc_402213,AACT,420,NCT02508077,Hypothetical,FOLFIRI
5c7430618625dd045a867f8a,1190,,,88,Patient,13:53.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_519880,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - First-line treatment with an irinotecan-based regimen (eg, FOLFIRI).- Anticipation of need for a major surgical procedure or radiation therapy (RT) during the study.- Treatment with chemotherapy, other TZDs, RT, surgery, immunotherapy, biological therapy, or any investigational anticancer agent within 4 weeks before start of study treatment.- History of any of the following conditions within 6 months before initiating study treatment: - Diabetes mellitus requiring treatment with insulin or TZD agents - Myocardial infarction with significant impairment of cardiac function (e.g., ejection fraction = 50%) - Severe/unstable angina pectoris - Coronary/peripheral artery bypass graft - New York Heart Association (NYHA) class III or IV congestive heart failure - Malabsorption syndrome, chronic diarrhea (lasting > 4 weeks), inflammatory bowel disease, or partial bowel obstruction.- Subjects with clinically active brain metastases (defined as untreated, symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms); uncontrolled seizure disorder; spinal cord compression; or carcinomatous meningitis.",ct_exc_519880,AACT,81,NCT00967616,Historical,FOLFIRI
5c7430628625dd0452867f9b,40,,,210,Patient,13:54.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_493366,Clinical Trial Inclusion Criteria,UNKNOWN,- Confirmation of KRAS wildtype status - Confirmation of EGFR-Expression in the tumor - Stadium IV - Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 - Qualified for an application of FOLFIRI + Cetuximab treatment - Signed patient infor,ct_inc_493366,AACT,203,NCT01315990,Recent,FOLFIRI
5c7430638625dd047e867f87,910,,,7,Patient,13:55.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_572785,Clinical Trial Inclusion Criteria,UNKNOWN,FOLFIRI:,ct_inc_572785,AACT,0,NCT00265850,Recent,FOLFIRI
5c7430638625dd047e867f88,910,,,92,Patient,13:55.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_572785,Clinical Trial Inclusion Criteria,UNKNOWN,"However, patients known to be homozygous for the UGT1A1*28 allele are not to receive FOLFIRI for this study.",ct_inc_572785,AACT,85,NCT00265850,Recent,FOLFIRI
5c7430638625dd048d867f84,1200,,,58,Patient,13:55.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_503037,Clinical Trial Inclusion Criteria,COMMENT,(patients with grade 2 neuropathy who will receive FOLFIRI are eligible) -,ct_inc_503037,AACT,51,NCT01189227,Recent,FOLFIRI
5c7430638625dd048d867f85,1200,,,865,Patient,13:55.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_503037,Clinical Trial Inclusion Criteria,COMMENT,- Documented history of congestive heart failure requiring chronic medical therapy - No active inflammatory bowel disease - No active infection or chronic infection requiring chronic suppressive antibiotics - No known bleeding diathesis or coagulopathy - ,ct_inc_503037,AACT,858,NCT01189227,Historical,FOLFIRI
5c7430648625dd045a867f8d,1190,,,18,Patient,13:56.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_466354,Clinical Trial Exclusion Criteria,UNKNOWN,"Related to FOLFIRI - Known dihydropyrimidine dehydrogenase deficiency.- Predisposing colonic or small bowel disorders in which the symptoms were uncontrolled as indicated by baseline of >3 loose stools daily.- Prior history of chronic enteropathy, inflammatory enteropathy, chronic diarrhea, unresolved bowel obstruction/sub-obstruction, more than hemicolectomy, extensive small intestine resection with chronic diarrhea.-",ct_exc_466354,AACT,11,NCT01670721,Historical,FOLFIRI
5c7430648625dd045a867f8e,1190,,,152,Patient,13:56.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_466354,Clinical Trial Exclusion Criteria,UNKNOWN,History of anaphylaxis or known intolerance to atropine sulphate or loperamide or appropriate antiemetics to be administered in conjunction with FOLFIRI.- Treatment with concomitant anticonvulsivant agents that are cytochrome P450 3A4,ct_exc_466354,AACT,145,NCT01670721,Historical,FOLFIRI
5c7430648625dd04aa867f85,530,,,111,Patient,13:56.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_446462,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically or cytologically confirmed solid malignancy that is metastatic or unresectable for which FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) treatment is appropriate",ct_inc_446462,AACT,104,NCT01930552,Recent,FOLFIRI
5c7430688625dd04cb867f85,260,,,63,Patient,14:00.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_466511,Clinical Trial Inclusion Criteria,GENDER,Previous treatment for metastatic disease is limited to FOLFIRI+ bevacizumab.,ct_inc_466511,AACT,56,NCT01668680,Recent,FOLFIRI
5c7430688625dd04c0867f94,30,,,133,Patient,14:00.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_418456,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically proven diagnosis of colorectal adenocarcinoma; - RAS and BRAF wild-type status; - First-line irinotecan-based (FOLFIRI or FOLFOXIRI) cetuximab-containing therapy producing at least a partial response; - First-line progression-free survival in response to cetuximab-containing therapy 6 months; - Documentation of progression to first-line cetuximab within 4 weeks after last cetuximab administration; - Time between the end of first-line therapy and the start of third-line treatment with cetuximab plus irinotecan 4 months; - Second-line oxaliplatin-based (FOLFOXIRI, FOLFOX or XELOX) bevacizumab-containing therapy; - Documentation of progression to second-line treatment; - Measurable disease according to RECIST criteria v1.1; - Have tumor tissue (of primary tumor and metastases or at least one of the two) available for biomarker analysis; - Male or female patients > 18 years of age; - ECOG Performance Status 2; - Life expectancy of at least 3 months; - Adequate bone marrow, liver and renal function assessed within 14 days before starting study treatment; - Women of childbearing potential must have a negative blood pregnancy test at the baseline visit.",ct_inc_418456,AACT,126,NCT02296203,Recent,FOLFIRI
5c7430688625dd04cb867f86,260,,,156,Patient,14:00.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_564110,Clinical Trial Inclusion Criteria,UNKNOWN,"- Scheduled to receive 1 of the following chemotherapy regimens*: - FOLFOX 4 (oxaliplatin, fluorouracil, leucovorin calcium) - FOLFOX 6 - FOLFOX 7 - FOLFIRI (irinotecan hydrochloride, fluorouracil, leucovorin calcium)",ct_inc_564110,AACT,149,NCT00381862,Recent,FOLFIRI
5c7430698625dd04cb867f8c,260,,,84,Patient,14:01.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_546753,Clinical Trial Inclusion Criteria,UNKNOWN,"Received 6 cycles (3 months [12 weeks]) of first-line therapy with FOLFOX or FOLFIRI, plus bevacizumab for metastatic CRC.Patients",ct_inc_546753,AACT,77,NCT00612586,Recent,FOLFIRI
5c7430698625dd04cb867f8d,260,,,75,Patient,14:01.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_546753,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients who received 6 cycles of first-line therapy with FOLFOX or FOLFIRI, plus bevacizumab for recurrent CRC that has relapsed at least 12 months after completion of adjuvant therapy will also be included.",ct_inc_546753,AACT,68,NCT00612586,Recent,FOLFIRI
5c7430698625dd04cb867f8e,260,,,32,Patient,14:01.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_546753,Clinical Trial Inclusion Criteria,UNKNOWN,"All standard FOLFOX ( or FOLFIRI) regimens given on a biweekly schedule will be permitted; however, 21-day regimens will not be allowed.-",ct_inc_546753,AACT,25,NCT00612586,Recent,FOLFIRI
5c74306a8625dd04d6867f84,890,,,107,Patient,14:02.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_318606,Clinical Trial Exclusion Criteria,UNKNOWN,"The following exclusion criteria are relevant for patients who will be treated with RGX-202-01 plus FOLFIRI, per protocol, on both Dose Escalation and Dose Expansion Cohorts: The patient has known dihydropyrimidine dehydrogenase (DPD) deficiency or is on treatment with DPD inhibitors, including sorivudine or its chemically related analogues such as brivudine, within 4 weeks prior to the start of FOLFIRI treatment.",ct_exc_318606,AACT,100,NCT03597581,Historical,FOLFIRI
5c74306a8625dd04d6867f85,890,,,144,Patient,14:02.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_318606,Clinical Trial Exclusion Criteria,UNKNOWN,"The patient has gastric/gastroesophageal junction, biliary, pancreatic, small bowel or colorectal cancer and has previously received the FOLFIRI regimen at any point in the past with evidence of disease progression within 8 weeks.",ct_exc_318606,AACT,137,NCT03597581,Recent,FOLFIRI
5c74306d8625dd04f7867f86,550,,,74,Patient,14:05.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_423369,Clinical Trial Inclusion Criteria,UNKNOWN,"that is not resectable - Have failed or have not tolerated FOLFOX, FOLFIRI and, if KRAS wild type, then a EGFR inhibitor-based regimen - Eastern Cooperative Oncology Group (ECOG) performance status being 0-2 - Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use accepted contraceptive methods (abstinence, intrauterine device [IUD], oral contraceptive or double barrier device) during the study, and must have a negative serum or urine pregnancy test within 1 week prior to treatment initiation - Fertile men must practice effective contraceptive methods during the study, unless documentation of infertility exists - At least 2 weeks must have elapsed from any prior surgery - Granulocyte count >= 1500/mm^3 - White blood cell (WBC) >= 3500 cells/mm^3 or >= 3.5 bil/L - Platelet count >",ct_inc_423369,AACT,67,NCT02232152,Hypothetical,FOLFIRI
5c74306d8625dd04f7867f88,550,,,374,Patient,14:05.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_460966,Clinical Trial Inclusion Criteria,UNKNOWN,"At least one liver lesion able to be visualized by ultrasound and determined to be safely assessable for percutaneous cryoablation Previous treatment failure of at 2 previous lines of active systemic chemotherapy for metastatic disease: - Previous chemotherapy must have included one line with oxaliplatin (e.g.FOLFOX) and a previous second line with irinotecan (e.g.FOLFIRI) with or without bevacizumab - If KRAS wild type, at least one anti-EGFR therapy in first or second line - Treatment failure can be due to disease progression or toxicity - Disease progression on 2nd line therapy must be documented radiologically and have occurred during or within 30 days following the last administration of 2nd line chemotherapy 7.",ct_inc_460966,AACT,367,NCT01741038,Hypothetical,FOLFIRI
5c74306d8625dd04f7867f8a,550,,,70,Patient,14:05.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_538670,Clinical Trial Inclusion Criteria,LABORATORY_AND_RADIOLOGY_DATA,Preferred patients are those who have progressed on first line FOLFIRI or FOLFOX with or without bevacizumab.,ct_inc_538670,AACT,63,NCT00719199,Recent,FOLFIRI
5c7430718625dd0518867f95,100,,,491,Patient,14:09.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_318198,Clinical Trial Inclusion Criteria,UNKNOWN,"Patient Inclusion Criteria: - Self-identify as Hispanic/Latino - Has been diagnosed with metastatic colorectal cancer (mCRC) OR locally advanced pancreatic cancer (LAPC) OR metastatic pancreatic cancer (mPC) AND is making a decision regarding treatment with 1st line palliative chemotherapy - Treating oncologist has recommended consideration of one or more of the regimens for which we have developed chemotherapy educational (CEI) toolkits - For mCRC: FOLFOX, FOLFOX + bevacizumab, FOLFIRI, FOLFIRI + bevacizumab - For LAPC or mPC: FOLFIRINOX, Gemcitabine, or Gemcitabine + nab-paclitaxel - Patients who are also considering treatment on a clinical trial of one of these regimens +/-",ct_inc_318198,AACT,484,NCT03602885,Recent,FOLFIRI
5c7430718625dd0544867f87,280,,,200,Patient,14:09.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_495161,Clinical Trial Inclusion Criteria,UNKNOWN,Patients older than 18 years - Patient with histologically proven metastatic colorectal cancer with KRAS wild-type - Treatment with cetuximab in first line chemotherapy combined with FOLFOX or FOLFIRI - Patient has signed informed consent - Patient affiliated to the Social Security - Prescription of cetuximab in agreement with the Summary of Product Characteristics,ct_inc_495161,AACT,193,NCT01292356,Recent,FOLFIRI
5c7430728625dd0544867f93,280,,,184,Patient,14:10.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_476020,Clinical Trial Inclusion Criteria,UNKNOWN,Written informed consent; Male or female patient 18 years of age; Confirmed diagnosis of colorectal cancer; Chemotherapy nave patient; Patient scheduled to receive a FOLFOX4 or FOLFIRI chemotherapy regimen according to the following scheme and dosage (1st cycle): AGENT DOSE ROUTE/DURATION DAYS Oxaliplatin or Irinotecan 85/180 mg m2 i.v.infusion/2h 1 FolinicAcid (leucovorin),ct_inc_476020,AACT,177,NCT01543451,Recent,FOLFIRI
5c7430768625dd055a867f86,1320,,,298,Patient,14:14.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_358263,Clinical Trial Exclusion Criteria,UNKNOWN,"Patients curatively treated and disease-free for at least 5 years will be discussed with the sponsor before inclusion Squamous gastric cancer Concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy not indicated in the study protocol Previous therapy with paclitaxel or FOLFIRI Current treatment with any anti-cancer therapy 2 weeks prior to study treatment start unless rapidly progressing disease is measured Concurrent treatment with any other anti-cancer therapy Previous exposure to a VEGF or VEGFR inhibitor or any antiangiogenic agent, or prior enrolment in this study Patient has undergone major surgery within 28 days prior to first dose of protocol therapy, or minor surgery/subcutaneous venous access device placement within 7 days prior to first dose of protocol therapy.",ct_exc_358263,AACT,291,NCT03081143,Historical,FOLFIRI
5c7430778625dd0574867f87,270,,,261,Patient,14:15.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_411745,Clinical Trial Inclusion Criteria,UNKNOWN,Written informed consent Male or female > 18 years of age; Histologically or cytologically confirmed diagnosis of colorectal cancer - Inclusion in the Target Population: Scheduled to receive at least 3 consecutive cycles of the same regimen of FOLFOX or FOLFIRI without monoclonal antibody; - Inclusion in the Additional Population: Scheduled to receive at least 3 consecutive cycles of the same regimen of FOLFOX or FOLFIRI in combination with monoclonal antibody; 4.,ct_inc_411745,AACT,254,NCT02383810,Recent,FOLFIRI
5c7430788625dd0574867f8f,270,,,123,Patient,14:16.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_344540,Clinical Trial Inclusion Criteria,UNKNOWN,"If mCRC, they should have received at least one regimen of 5-fluouracil based systemic chemotherapy such as FOLFOX, FOLFIRI, CAPOX, or XELOX, with or without a VEGF or EGFR receptor inhibitor.",ct_inc_344540,AACT,116,NCT03259867,Hypothetical,FOLFIRI
5c7430798625dd0574867f98,270,,,38,Patient,14:17.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_423402,Clinical Trial Inclusion Criteria,UNKNOWN,Patients enrolling onto Arm C (FOLFIRI) or Arm D (MM-398 with 5-FU and leucovorin) must have failed one prior line of gemcitabine-based therapy with or without BBI608 in the metastatic setting.,ct_inc_423402,AACT,31,NCT02231723,Historical,FOLFIRI
5c74307b8625dd058e867f8a,760,,,187,Patient,14:19.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_455338,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Patients with advanced adenocarcinoma of the colon or rectum not curable with surgery or radiotherapy and have been previously treated for their disease with FOLFIRI plus bevacizumab in the first line metastatic setting,ct_inc_455338,AACT,180,NCT01814501,Recent,FOLFIRI
5c74307b8625dd058e867f8b,760,,,108,Patient,14:19.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_455338,Clinical Trial Inclusion Criteria,UNKNOWN,"; patients will only be eligible if their last line of therapy prior to enrolling onto the study was FOLFIRI and bevacizumab received no more than 6 months prior to enrolling in this study; they should have been treated with FOLFIRI plus bevacizumab until disease progression is radiographically documented - Patients' tumors will need to tested for the K-RAS and N-RAS mutation status; only those patients with wild-type or unmutated K-RAS and N-RAS oncogene are eligible to participate in this study - Provide written informed consent prior to study-specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time, without prejudice - Prior cetuximab is allowed in the adjuvant but not in the metastatic setting, but must have been completed at least 6 months before starting this trial - Eastern Cooperative Oncology Group (ECOG) performance status =< 1 - Life expectancy greater than 12 weeks - No active brain metastasis; previously surgically treated or irradiated lesions are allowed if not clinically active - Has a negative serum pregnancy test within 7 days prior to registration (female patients of childbearing potential) - Ability to understand and willingness to sign a written informed consent - No history of severe reactions to fluorouracil (5-FU), irinotecan (irinotecan hydrochloride), or a monoclonal antibody - Leukocytes >= 3000/uL - Absolute neutrophil count >= 1500/uL - Platelets >= 100,000/uL",ct_inc_455338,AACT,101,NCT01814501,Hypothetical,FOLFIRI
5c74307b8625dd058e867f8c,760,,,245,Patient,14:19.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_445650,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients with metastatic colorectal cancer are eligible for this study; colorectal cancer should have been previously confirmed by pathology or cytology; to be eligible for this protocol, patients should be receiving ziv-aflibercept plus FOLFIRI as a standard treatment prior to enrolling on this trial; the number and type of therapy administered prior to enrollment will not affect the ability to enroll on this study - Patients should have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 - Patients should have an expected life expectancy of 12 weeks or longer - Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial,",ct_inc_445650,AACT,238,NCT01941173,Historical,FOLFIRI
5c74307b8625dd058e867f8d,760,,,160,Patient,14:19.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_445650,Clinical Trial Inclusion Criteria,UNKNOWN,"To be eligible for this study, patients should already be receiving a standard dose of ziv-aflibercept intravenously over 60 minutes in combination with FOLFIRI chemotherapy every 2 weeks without evidence of progressive disease; treatment on this study can start as early as two weeks from last off protocol ziv-aflibercept plus FOLFIRI cycle, granted treatment parameters have been met - Total bilirubin < 1.5 upper limit of normal (ULN) - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)",ct_inc_445650,AACT,153,NCT01941173,Recent,FOLFIRI
5c74307d8625dd05ab867f8c,720,,,155,Patient,14:21.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_423713,Clinical Trial Inclusion Criteria,UNKNOWN,"At a minimum, such therapies should include regimens containing oxaliplatin and irinotecan in combination with a fluoropyrimidine (e.g., FOLFOX and FOLFIRI or their variants).- Age 18 years at time of study entry.- Eastern Cooperative Oncology Group (ECOG) status of 0 or 1 - Adequate organ and marrow function as defined below: - Absolute neutrophil count 1,500/mm3.- Platelet count 90,000/mm3.- AST and ALT 3 institutional upper limit of normal (ULN) or 5 ULN for subjects with liver metastases.- Bilirubin 1.5 ULN or 3 ULN for subjects with documented/suspected Gilbert's disease.- Serum",ct_inc_423713,AACT,148,NCT02227667,Recent,FOLFIRI
5c74307e8625dd05ab867f8e,720,,,157,Patient,14:22.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_325514,Clinical Trial Inclusion Criteria,UNKNOWN,"Such therapies should include regimens containing oxaliplatin and irinotecan in combination with a fluoropyrimidine, if appropriate (e.g., FOLFOX and FOLFIRI, or their variants).Subjects that are unable to receive oxaliplatin and/or irinotecan due to allergy or hypersensitivity, or due to concerns regarding the side effects of oxaliplatin and/or irinotecan, will be allowed to receive less than two lines of standard therapies prior to enrollment to this study.- Patients must have at least two liver metastases, separated by 2 cm, and measured in at least one dimension (longest diameter) as 2 cm by CT/MRI.One",ct_inc_325514,AACT,150,NCT03507699,Historical,FOLFIRI
5c74307f8625dd05ab867f90,720,,,16,Patient,14:23.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_495233,Clinical Trial Inclusion Criteria,UNKNOWN,"(FOLFOX, FOLFIRI) Patient Characteristics - Prior treatments: Patients must have received at least one prior chemotherapeutic regimen and must be more than 1 month past the last treatment.-",ct_inc_495233,AACT,9,NCT01291420,Historical,FOLFIRI
5c7430808625dd05ab867f92,720,,,115,Patient,14:24.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_532048,Clinical Trial Exclusion Criteria,UNKNOWN,< 6 months prior to treatment on study or any previous palliative chemotherapy.. - Any contraindication for FOLFIRI chemotherapy regimen.- Any investigational drug within the 30 days before inclusion.- Prior use of sunitinib or other multitarget tyrosine kinase inhibitors or VEGF pathway,ct_exc_532048,AACT,108,NCT00806663,Historical,FOLFIRI
5c7430808625dd05c1867f8d,870,,,271,Patient,14:24.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_427248,Clinical Trial Inclusion Criteria,UNKNOWN,3 months - Metastatic adenocarcinoma of the rectum or of the colon histologically proven on the primary tumor or a metastasis - Unresectable metastasis (metastases) and/or inoperable patient - Patient eligible for a 1st line treatment associating 5 FU-Irinotecan (FOLFIRI) and aflibercept - At least one measurable target lesion according to RECIST criteria v1.1 not previously irradiated - Absence of prior treatment of the metastatic disease.,ct_inc_427248,AACT,264,NCT02181556,Historical,FOLFIRI
5c7430808625dd05ab867f94,720,,,214,Patient,14:24.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_439361,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Age 18 years.- Life expectancy of at least 12 weeks (3 months).- Untreated for metastatic colorectal cancer, or progression on any first line 5-FU containing regimen (such as FOLFOX or FOLFIRI)",ct_inc_439361,AACT,207,NCT02023333,Recent,FOLFIRI
5c7430828625dd05e2867f87,330,,,301,Patient,14:26.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_414344,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Adenocarcinoma of the pancreas - Prior therapy with 1 prior systemic therapy over a period of at least 2 months (eg, at least two 4-week cycles of a regimen such as gemcitabine and nab-paclitaxel; or at least four 2-week cycles of a regimen such as FOLFOX, FOLFIRINOX, or FOLFIRI) -Candidate for additional therapy consisting of radiation with gemcitabine- radiosensitization.- Able to initiate study treatment no later than 6 weeks from last dose of any antineoplastic component of prior therapy",ct_inc_414344,AACT,294,NCT02349867,Historical,FOLFIRI
5c7430838625dd05e2867f8a,330,,,88,Patient,14:27.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_438969,Clinical Trial Inclusion Criteria,LABORATORY_AND_RADIOLOGY_DATA,"mCRC - Have received 3 - 4 months of first line chemotherapy with either FOLFOX, FOLFIRI or CAPOX, with or without bevacizumab - At least one measurable lesion according to RECIST 1.1 criteria - Documented partial response or stable disease - Eligible to receive chemotherapy with FOLFOX or CAPOX after a short chemotherapy interruption (3 to 4 weeks)",ct_inc_438969,AACT,81,NCT02028442,Recent,FOLFIRI
5c7430888625dd060e867f8a,470,,,153,Patient,14:32.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_342476,Clinical Trial Inclusion Criteria,UNKNOWN,"Adult patients at least 19 years of age with metastatic colorectal cancer who are planned to receive Bevacizumab or Cetuximab in combination with FOLFIRI regimen as first-line treatment Patients who will receive irinotecan, a component of FOLFIRI regimen, using Camtop Injection",ct_inc_342476,AACT,146,NCT03286738,Recent,FOLFIRI
5c74308b8625dd063e867f88,1010,,,703,Patient,14:35.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_397621,Clinical Trial Inclusion Criteria,UNKNOWN,"Failed* treatment for locally advanced or metastatic disease with first-line combination therapy of oxaliplatin and a fluoropyrimidine, with or without bevacizumab, during treatment or < 3 months after the last dose of first-line therapy and within < 3 months of C1/D1.Patients who discontinued first-line therapy due to toxicity may be enrolled provided progression occurred < 6 months after the last dose of the first-line therapy regimen.or Failed* adjuvant therapy with combination therapy of oxaliplatin and a fluoropyrimidine during treatment or within < 6 months after the last dose of oxaliplatin and within < 6 months of C1/D1.- Failure is defined as radiologic progression Eligible for FOLFIRI Measurable disease according to RECIST v1.1 Main",ct_inc_397621,AACT,696,NCT02568046,Recent,FOLFIRI
5c74308b8625dd063e867f89,1010,,,117,Patient,14:35.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_430536,Clinical Trial Inclusion Criteria,LABORATORY_AND_RADIOLOGY_DATA,"Willing to undergo UGT1A1 genotyping Negative pregnancy test (urine or serum), within 7 day prior to Day 1 of FOLFIRI in women of childbearing potential Women of childbearing potential and male subjects must agree to use adequate contraception for the duration of study participation.",ct_inc_430536,AACT,110,NCT02138617,Historical,FOLFIRI
5c74308b8625dd063e867f8a,1010,,,258,Patient,14:35.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_347824,Clinical Trial Inclusion Criteria,UNKNOWN,"Previous treatments such as surgery, radiofrequency ablation, transarterial liver embolization, somatostatin analogs, interferon, everolimus or other targeted therapy, peptide receptor radionuclide treatment (PRRT) and chemotherapy (platin-etoposide, folfiri, paclitaxel or docetaxel) are allowed.",ct_inc_347824,AACT,251,NCT03217097,Recent,folfiri
5c74308c8625dd063e867f8b,1010,,,214,Patient,14:36.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_445273,Clinical Trial Inclusion Criteria,UNKNOWN,"Women of childbearing potential and men must agree to use adequate contraception.- Subjects in the combination therapy cohorts must meet the above inclusion criteria and be eligible to receive paclitaxel or FOLFIRI per most current prescribing information, or at the discretion of the Investigator.",ct_inc_445273,AACT,207,NCT01946074,Recent,FOLFIRI
5c74308c8625dd063e867f8c,1010,,,163,Patient,14:36.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_445273,Clinical Trial Exclusion Criteria,UNKNOWN,"less than 50%.- Subjects enrolled on the combination therapy phase must not meet the above exclusion criteria and must be eligible to receive paclitaxel or FOLFIRI per most current prescribing information, or at the discretion of the Investigator.",ct_exc_445273,AACT,156,NCT01946074,Recent,FOLFIRI
5c74308c8625dd065b867f8d,20,,,554,Patient,14:36.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_481478,Clinical Trial Exclusion Criteria,UNKNOWN,"Subjects with brain metastases are eligible provided they have shown clinical and radiographic stable disease after definitive therapy and have not used steroids for at least 1 month prior to first dose of ABT-700.- Subject has unresolved adverse events > Grade 1 from prior anticancer therapy except for alopecia or anemia.- Subject has had major surgery within 21 days prior to the first dose of ABT-700.- Subjects enrolled on the combination therapy phase must not meet the above exclusion criteria and must be eligible to receive docetaxel or FOLFIRI/cetuximab or erlotinib per most current prescribing information, or at the discretion of the Investigator.",ct_exc_481478,AACT,547,NCT01472016,Historical,FOLFIRI
5c74308c8625dd065b867f8e,20,,,95,Patient,14:36.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_481478,Clinical Trial Exclusion Criteria,UNKNOWN,Subjects with K-Ras mutation-positive colorectal cancer will be excluded from receiving FOLFIRI/cetuximab.,ct_exc_481478,AACT,88,NCT01472016,Recent,FOLFIRI
5c74308d8625dd065b867f98,20,,,590,Patient,14:37.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_481478,Clinical Trial Inclusion Criteria,UNKNOWN,"Subject must have disease: a) that is not amenable to surgical resection, or b) that has progressed or recurred despite standard therapy, or c) that has failed to respond to standard therapy, or d) for which no effective therapy exists.- Subject cannot tolerate or must not be eligible for other approved therapeutic options with known survival advantage.- Subjects enrolled on the combination therapy phase must satisfy the above inclusion criteria and also the following: Subjects must have inoperable, locally advanced or metastatic cancer and be eligible to receive docetaxel or FOLFIRI/cetuximab or erlotinib in combination with ABT-700.",ct_inc_481478,AACT,583,NCT01472016,Recent,FOLFIRI
5c74308e8625dd063a867f8c,390,,,443,Patient,14:38.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_476020,Clinical Trial Exclusion Criteria,UNKNOWN,"and/or cooperate with the study Investigator; Any investigational drugs within 30 days before enrollment in the study or foreseen use of investigational agents during the study; Patient with any type of ostomy; Any previous radiotherapy to the abdomen or pelvis; Scheduled to receive radiotherapy to abdomen or pelvis during the study (Day 1 to Day 14); Scheduled to receive any concomitant chemotherapeutic agent other than FOLFOX4 or FOLFIRI agents (Oxaliplatin, Irinotecan, Folinic acid, 5-FU) from Day 1 to Day 14; Previous use or scheduled to receive monoclonal antibodies (e.g.bevacizumab, cetuximab, etc) during the study (From Day 1 to Day 14); Major surgery within the previous 3 weeks; Any type of condition leading to chronic diarrhea, including but not limited to inflammatory bowel diseases (e.g.ulcerative colitis and Crohn's disease), chronic diarrhea of presumed or confirmed infectious origin and irritable bowel syndrome; Any diarrhea in the 48 hours preceding study drug administration; Use of anti-diarrheal agents within the 48 hours prior to study drug administration; Use of laxatives within 7 days prior to study drug administration; Use of antibiotics within 7 days prior to study drug administration; History of chronic ( 30 consecutive days) use of laxatives; Active and ongoing systemic infection; Lactating woman; History of hypersensitivity or allergies to drugs or compounds potentially related to this investigational drug class; Previous exposure to GLP-2 or other compounds in this investigational drug class; Abnormal laboratory values, including - Aspartate aminotransferase (AST)",ct_exc_476020,AACT,436,NCT01543451,Historical,FOLFIRI
5c7430908625dd0671867f87,950,,,156,Patient,14:40.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_383438,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria: Anti-cancer chemotherapy or biologic therapy if administered prior to the first planned dose of study medication (napabucasin or FOLFIRI) within period of time equivalent to the usual cycle length of the regimen.,ct_exc_383438,AACT,149,NCT02753127,Hypothetical,FOLFIRI
5c7430908625dd0671867f88,950,,,75,Patient,14:40.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_383438,Clinical Trial Exclusion Criteria,UNKNOWN,"Standard dose of bevacizumab (5 mg/kg) may be administered prior to FOLFIRI infusion, per Investigator decision, for as long as permanent decision to include or exclude bevacizumab is made prior to patient randomization.",ct_exc_383438,AACT,68,NCT02753127,Historical,FOLFIRI
5c7430908625dd0671867f89,950,,,150,Patient,14:40.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_383438,Clinical Trial Exclusion Criteria,UNKNOWN,Women should not breastfeed while taking study treatment and for 4 weeks after the last dose of napabucasin or while undergoing treatment with FOLFIRI and for 180 days after the last dose of FOLFIRI.,ct_exc_383438,AACT,143,NCT02753127,Recent,FOLFIRI
5c7430928625dd069d867f84,880,,,53,Patient,14:42.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_477529,Clinical Trial Inclusion Criteria,UNKNOWN,- Subjects scheduled to receive cetuximab and FOLFIRI - ECOG performance status of 0 - 1 at study entry - Leukocytes >= 3.0 x 10^9/L and neutrophils >= 1.5 x 10^,ct_inc_477529,AACT,46,NCT01523639,Recent,FOLFIRI
5c7430928625dd069d867f85,880,,,197,Patient,14:42.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_496752,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically confirmed colorectal or gastric cancer patients who are chemonaive or failed to 1st line chemotherapy - Subjects who are expected to receive toxicity test at least once after FOLFIRI treatment.- Aged 18 years or older.- ECOG performance status of 2.- Anticipated life expectancy of 3 months.- Clinically acceptable function of bone marrow, kidney and liver function as below.1.",ct_inc_496752,AACT,190,NCT01271582,Recent,FOLFIRI
5c7430928625dd069d867f86,880,,,175,Patient,14:42.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_491128,Clinical Trial Inclusion Criteria,UNKNOWN,Histologically proven and measurable metastatic adenocarcinoma of the colon or rectum (according to modified RECIST criteria v.1.1) - Patients eligible for Erbitux and FOLFIRI treatment K-Ras wild type tumour - Metastatic disease - Life expectancy of at least 12 weeks - WHO performance status of 0 or 1 - Effective contraception for both male and female patients if the risk of conception exists -,ct_inc_491128,AACT,168,NCT01345526,Recent,FOLFIRI
5c7430928625dd067c867f89,1110,,,773,Other,14:42.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_396082,Clinical Trial Exclusion Criteria,UNKNOWN,"If your liver and kidney aren't working normally - If your heart isn't working normally or you have a strong family history of certain heart diseases - Other cancers within the past 3 years, except for certain types of cervical and skin cancers - Sickness and vomiting, digestive diseases or previous significant bowel removal - Patients with uncontrolled fitting - Infections requiring treatment - Other severe and/or uncontrolled medical conditions in addition to your cancer - A blockage in your digestive system or severe bleeding from the stomach within 4 weeks before your take medication on the stuy - Patients with acute leukaemia or certain bone marrow diseases - Patients with a known sensitivity to olaparib or its components (Module 1), or components of FOLFIRI (Module 2) -",ct_exc_396082,AACT,766,NCT02588105,Hypothetical,FOLFIRI
5c7430938625dd0692867f88,790,,,7,Patient,14:43.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_347146,Clinical Trial Exclusion Criteria,LABORATORY_AND_RADIOLOGY_DATA,"FOLFIRI after progression to adjuvant FOLFOX, occurred on treatment or within 6 months after treatment completion.",ct_exc_347146,AACT,0,NCT03225937,Recent,FOLFIRI
5c7430938625dd067c867f8a,1110,,,180,Patient,14:43.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_505498,Clinical Trial Inclusion Criteria,UNKNOWN,Patients must have Metastatic Colorectal Cancer (stage IV) - Patients who were treated with 5FU and leucovorin in the adjuvant setting or with 5FU and leucovorin (LV)or/and FOLFIRI regimen for metastatic setting may be eligible for this trial.- Patients must be 18 years - Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 - Patients must have adequate renal function of creatinine < 1.5mg/dl and a creatinine clearance >,ct_inc_505498,AACT,173,NCT01157052,Recent,FOLFIRI
5c7430938625dd067c867f8b,1110,,,370,Patient,14:43.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_496518,Clinical Trial Inclusion Criteria,UNKNOWN,- Have histologically confirmed cancer of the colon or rectum with radiologically documented and measurable metastases (high CEA alone is insufficient for study entry).- Have received an oxaliplatin-based chemotherapy regimen in the metastatic setting or ,ct_inc_496518,AACT,363,NCT01274624,Historical,FOLFIRI
5c74309d8625dd06ea867f8b,820,,,202,Patient,14:53.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_484369,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically proven metastatic/unresectable gastrointestinal malignancies (colon, small bowel, pancreas, gastric and esophageal cancer, etc.)not amenable to curative surgical therapy, for whom FOLFIRI can be considered a standard treatment - Have had at least 1 prior treatment for all GI tumors except for small bowel adenocarcinoma as FOLFIRI can be considered standard first line therapy for that particular tumor.- Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) criteria - 4 weeks since any major surgery, completion of radiation, or completion of all prior systemic anticancer therapy (adequately recovered from the acute toxicities of any prior therapy) - Eastern Cooperative Oncology Group (ECOG) performance status 2 - Adequate bone marrow function as shown by: absolute neutrophil count (ANC) 1.5 x 10^9/L,",ct_inc_484369,AACT,195,NCT01434069,Historical,FOLFIRI
5c74309d8625dd06ea867f8c,820,,,122,Patient,14:53.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_471292,Clinical Trial Inclusion Criteria,UNKNOWN,"Histological or cytological documentation of adenocarcinoma of the colon or rectum, and patient scheduled to begin FOLFIRI for treatment of their metastatic disease Patients taking statins at the time of enrollment are permitted.",ct_inc_471292,AACT,115,NCT01605344,Recent,FOLFIRI
5c74309d8625dd06ea867f8d,820,,,92,Patient,14:53.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_471292,Clinical Trial Inclusion Criteria,UNKNOWN,Medical oncologist agrees that two week window is appropriate/safe prior to start of FOLFIRI for trial candidate.,ct_inc_471292,AACT,85,NCT01605344,Historical,FOLFIRI
5c74309e8625dd06ea867f8e,820,,,156,Patient,14:54.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_496518,Clinical Trial Exclusion Criteria,UNKNOWN,No patient may: - Receive concurrent therapy with any other investigational anticancer agent while on study.- Have previously received irinotecan or FOLFIRI in the metastatic setting (patient is eligible if he/she had received irinotecan or FOLFIRI as adjuvant therapy more than 6 months before entry into the study),ct_exc_496518,AACT,149,NCT01274624,Recent,FOLFIRI
5c74309e8625dd06ea867f8f,820,,,77,Patient,14:54.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_497610,Clinical Trial Inclusion Criteria,UNKNOWN,"> 90 g/L total bilirubin < 2 x upper limit of normal (< 1.5 x ULN for FOLFIRI), AST(SGOT) and ALT(SGPT)",ct_inc_497610,AACT,70,NCT01260415,Recent,FOLFIRI
5c74309e8625dd06ea867f90,820,,,50,Patient,14:54.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_497610,Clinical Trial Inclusion Criteria,UNKNOWN,< 5 x upper limit of normal (< 3 x ULN for FOLFIRI);creatinine within normal institutional limits OR- creatinine clearance,ct_inc_497610,AACT,43,NCT01260415,Recent,FOLFIRI
5c7430a18625dd0700867f94,200,,,49,Patient,14:58.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_572594,Clinical Trial Inclusion Criteria,UNKNOWN,- At least 1 year since prior FOLFOX 4 or FOLFIRI regimen in the adjuvant setting - No concurrent participation in another clinical trial - Recovered from prior therapy,ct_inc_572594,AACT,42,NCT00268398,Historical,FOLFIRI
5c7430a28625dd071a867f88,1060,,,7,Patient,14:58.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_383438,Clinical Trial Inclusion Criteria,UNKNOWN,FOLFIRI therapy is appropriate for the patient and is recommended by the Investigator.,ct_inc_383438,AACT,0,NCT02753127,Recent,FOLFIRI
5c7430a28625dd071a867f89,1060,,,209,Patient,14:58.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_383438,Clinical Trial Inclusion Criteria,UNKNOWN,"For male or female patient of child producing potential: Must agree to use contraception or take measures to avoid pregnancy during the study and for 180 days for female and male patients, of the final FOLFIRI dose.",ct_inc_383438,AACT,202,NCT02753127,Recent,FOLFIRI
5c7430a28625dd071a867f8a,1060,,,61,Patient,14:58.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_383438,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients who receive single agent napabucasin without FOLFIRI must agree to use contraception or take measures to avoid pregnancy during the study and for 30 days for female patients and 90 days for male patients, of the final napabucasin dose.",ct_inc_383438,AACT,54,NCT02753127,Recent,FOLFIRI
5c7430a48625dd0737867f8f,180,,,180,Patient,15:00.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_368896,Clinical Trial Exclusion Criteria,UNKNOWN,"At randomisation: Inclusion criteria: - WHO performance status 0-1 (Karnofsky PS > 70%); - Disease evaluation with proven SD, PR or CR according to RECIST after 8 cycles of FOLFIRI or mFOLFOX6; - Laboratory values obtained 2 weeks prior to randomisation: adequate bone marrow function (Hb > 8.0 mmol/L, absolute neutrophil count > 1.5 x 109/L, platelets > 100 x 109/L), renal function (serum creatinine 1.5x ULN and creatinine clearance, Cockroft formula, > 30 ml/min), liver function (serum bilirubin 2 x ULN, serum transaminases 3 x ULN without presence of liver metastases or 5x ULN with presence of liver metastases); - Life expectancy > 24 weeks; -",ct_exc_368896,AACT,173,NCT02942706,Historical,FOLFIRI
5c7430a48625dd0737867f91,180,,,75,Patient,15:00.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_366164,Clinical Trial Inclusion Criteria,UNKNOWN,- Ongoing or planned first line treatment with 6 cycles of mFOLFOX6/FOLFIRI plus Cetuximab.,ct_inc_366164,AACT,68,NCT02978313,Recent,FOLFIRI
5c7430a58625dd0737867f92,180,,,95,Patient,15:01.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_521738,Clinical Trial Inclusion Criteria,UNKNOWN,"21 years to 80 years - Histologically proven advanced stage carcinoma where De Gramont, FOLFIRI or mFOLFOX-6 regimen is indicated.-",ct_inc_521738,AACT,88,NCT00943137,Recent,FOLFIRI
5c7430a58625dd0737867f94,180,,,219,Patient,15:01.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_559447,Clinical Trial Inclusion Criteria,UNKNOWN,"- Tissue diagnosis of adenocarcinoma of the colon or rectum - Documented metastatic disease with at least one measurable lesion by RECIST criteria - Previously treated with 5-FU-based chemotherapy in the form of FOLFIRI, FOLFOX, or XELOX plus bevacizumab ",ct_inc_559447,AACT,212,NCT00443573,Recent,FOLFIRI
5c7430a58625dd0737867f95,180,,,50,Patient,15:01.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_559447,Clinical Trial Inclusion Criteria,UNKNOWN,No contraindication to modified FOLFOX6 or FOLFIRI combination chemotherapy - No receipt of any investigational compound within 28 days of enrollment,ct_inc_559447,AACT,43,NCT00443573,Recent,FOLFIRI
5c7430a78625dd072c867f88,1270,,,1131,Patient,15:03.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_473893,Clinical Trial Exclusion Criteria,UNKNOWN,"Any of the following within 3 months prior study inclusion: severe gastrointestinal bleeding/hemorrhage, treatment resistant peptic ulcer disease, erosive oesophagitis or gastritis, infectious or inflammatory bowel disease, diverticulitis, pulmonary embolism or other uncontrolled thromboembolic event.- Occurrence of deep vein thrombosis within 4 weeks, prior to study inclusion.- Known acquired immunodeficiency syndrome (AIDS-related illnesses) or known HIV disease requiring antiretroviral treatment.- Known dihydropyrimidine dehydrogenase deficiency.- Predisposing colonic or small bowel disorders in which the symptoms were uncontrolled.- Prior history of chronic enteropathy, inflammatory enteropathy, chronic diarrhea, unresolved bowel obstruction/sub-obstruction, more than hemicolectomy, extensive small intestine resection with chronic diarrhea.- Known Gilbert's syndrome.- Unresolved or unstable toxicity from any prior anti cancer therapy at the time of inclusion.- History of anaphylaxis or known intolerance to atropine sulphate or loperamide or appropriate antiemetics to be administered in conjunction with FOLFIRI (irinotecan, 5-Fluorouracil, leucovorin).- Severe acute or chronic medical condition, which could impair the ability of the participants to participate to the study.- Urine protein-creatinine ratio (UPCR)",ct_exc_473893,AACT,1124,NCT01571284,Historical,FOLFIRI
5c7430a78625dd0758867f85,460,,,503,Patient,15:03.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_419923,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically or cytologically confirmed refractory colorectal cancer - Measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as >10 mm with CT scan, as >20 mm by chest x-ray, or >10 mm with calipers by clinical exam.- Refractory to or intolerant of standard systemic therapy, including having received two or more standard available therapies known to prolong survival for which s/he was eligible, including FOLFOX or FOLFIRI with or without bevacizumab, aflibercept, cetuximab, or panitumumab",ct_inc_419923,AACT,496,NCT02277093,Recent,FOLFIRI
5c7430a78625dd072c867f89,1270,,,588,Patient,15:03.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_484369,Clinical Trial Exclusion Criteria,COMMENT,"- Presence of active or suspected acute or chronic uncontrolled infection or with a history of immunocompromise, including a positive HIV test result - Any severe and/or uncontrolled medical conditions or other conditions that could affect their participa",ct_exc_484369,AACT,581,NCT01434069,Historical,FOLFIRI
5c7430a88625dd072c867f8a,1270,,,271,Patient,15:04.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_508027,Clinical Trial Inclusion Criteria,UNKNOWN,* Subjects with histologically or cytologically confirmed malignancy that is meta static or unresectable and for which standard curative measures or other therapy that may provide clinical benefit do not exist or are no longer effective or for whom treatment with FOLFIRI is a viable option.,ct_inc_508027,AACT,264,NCT01123876,Recent,FOLFIRI
5c7430a88625dd0763867f84,730,,,105,Patient,15:04.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_585585,Clinical Trial Inclusion Criteria,UNKNOWN,"However, if subject received prior therapy with oxaliplatin, they will be eligible to receive the FOLFIRI regimen.",ct_inc_585585,AACT,98,NCT00094809,Hypothetical,FOLFIRI
5c7430a88625dd0767867f86,670,,,362,Patient,15:04.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_394785,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Patient with non-resectable metastatic colorectal cancer - Metastatic disease not amenable to surgical resection - Patient in second line treatment after progression according to RECIST criteria - Patient with measurable lesions according to RECIST criteria (version 1.1) - Patient eligible for a standard second line treatment with FOLFIRI - Patient with ECOG 2 - Patient with adequate organ function - Patient with life expectancy > 3 months - Female or male patient 18 - Patient weight > 40 kg and BMI > 18,ct_inc_394785,AACT,355,NCT02605044,Recent,FOLFIRI
5c7430a88625dd0758867f87,460,,,108,Patient,15:04.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_312710,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Diagnosed by pathology as gastrointestinal carcinoma and no previous FOLFOX or FOLFIRI,ct_inc_312710,AACT,101,NCT03674294,Recent,FOLFIRI
5c7430a88625dd072c867f8b,1270,,,347,Patient,15:04.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_525779,Clinical Trial Exclusion Criteria,UNKNOWN,- Patients with seizure disorder requiring medication (such as steroids or anti-epileptics) - History of organ allograft - Patients with evidence or history of bleeding diathesis - Patients undergoing renal dialysis - Known deficit in Dihydropyrimidine De,ct_exc_525779,AACT,340,NCT00889343,Historical,FOLFIRI
5c7430a88625dd0767867f87,670,,,138,Patient,15:04.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_347824,Clinical Trial Exclusion Criteria,UNKNOWN,"Previous chemotherapy using Oxaliplatin or ALKY (streptozotocin, dacarbazin or temozolomide).Other chemotherapy (platin-etoposide, folfiri, paclitaxel or docetaxel) are allowed; - Pregnant or breastfeeding; - Men and women of childbearing age potential not using medically accepted contraceptive measures, as judged by the investigator; - Contraindication to any drug contained in the chemotherapy regimen; - Any significant disease which, in the investigator's opinion, excludes the patient from the study; - Under any administrative or legal supervision.",ct_exc_347824,AACT,131,NCT03217097,Recent,folfiri
5c7430a88625dd072c867f8c,1270,,,522,Patient,15:04.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_496304,Clinical Trial Exclusion Criteria,UNKNOWN,"- Histologically or cytologically confirmed advanced stage colorectal carcinoma - Documented progression after precedent treatment according to RECIST criteria - K-ras mutation (which contraindicates EGFR inhibitor therapy, results from local pathology wi",ct_exc_496304,AACT,515,NCT01277406,Historical,FOLFIRI
5c7430a88625dd0758867f89,460,,,140,Patient,15:04.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_461598,Clinical Trial Inclusion Criteria,LABORATORY_AND_RADIOLOGY_DATA,"first-line in combination with FOLFOX (folinic acid, leucovorin, fluorouracil [5FU], oxaliplatin) or second-line in combination with FOLFIRI (folinic acid, leucovorin, 5FU, irinotecan) in subjects who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan) for treatment of wild-type RAS mCRC per approved prescribing information - Subject or subject's legally acceptable representative has provided informed consent (for countries where required per local regulations) - Subjects treated with Vectibix in accordance with the current version of the Summary of Product Characteristics (SmPC)",ct_inc_461598,AACT,133,NCT01732783,Recent,FOLFIRI
5c7430a98625dd072c867f8d,1270,,,365,Patient,15:05.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_467062,Clinical Trial Exclusion Criteria,UNKNOWN,"Prior history of chronic enteropathy, inflammatory enteropathy, chronic diarrhea, unresolved bowel obstruction/sub-obstruction, more than hemicolectomy, extensive small intestine resection with chronic diarrhea.- History of anaphylaxis or known intolerance to atropine sulphate or loperamide or appropriate antiemetics to be administered in conjunction with FOLFIRI.- Treatment with concomitant anticonvulsant agents that were cytochrome P450 3A4 (CYP3A4) inducers (phenytoin, phenobarbital, carbamazepine), unless discontinued > 7 days.- Participants with known Gilbert's syndrome.",ct_exc_467062,AACT,358,NCT01661270,Historical,FOLFIRI
5c7430a98625dd0758867f8b,460,,,64,Patient,15:05.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_504063,Clinical Trial Inclusion Criteria,COMMENT,Continuous 5-FU-containing regimens (such as FOLFOX6 and FOLFIRI) are allowed as both the 5-FU bolus as well as the oxaliplatin and irinotecan administration is completed on day 1 of chemotherapy - Life expectancy of >= 168 days (6 months) - Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 - Body mass index (BMI) > 21 kg/m^2 - Weight loss < 5% of body weight in the last 168 days (6 months) -,ct_inc_504063,AACT,57,NCT01175837,Recent,FOLFIRI
5c7430a98625dd0763867f87,730,,,65,Patient,15:05.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_423402,Clinical Trial Exclusion Criteria,UNKNOWN,"For patients enrolling onto Arm B (mFOLFIRINOX) or Arm C (FOLFIRI) Known hypersensitivity to 5-fluorouracil/leucovorin Known dihydropyrimidine dehydrogenase (DPD) deficiency Known hypersensitivity to oxaliplatin or other platinum containing compounds Known hypersensitivity to irinotecan Uncontrolled seizure disorder, active neurological disease, or known CNS disease.",ct_exc_423402,AACT,58,NCT02231723,Recent,FOLFIRI
5c7430a98625dd0758867f8c,460,,,327,Patient,15:05.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_492846,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Prior chemotherapy other than that listed in inclusion criteria - Receiving any other investigational agent - Known brain metastases, uncontrolled seizure disorders, encephalitis, or multiple sclerosis - History of known hypersensitivity to S. cerevisiae, bevacizumab or any component of FOLFOX or FOLFIRI - Concurrent and chronic therapy with corticosteroids or any other immunosuppressive drugs - Uncontrolled hypertension, unstable angina, congestive heart failure, peripheral vascular disease, serious cardiac arrythmias requiring medication - History of heart attack or stroke within 6 months before enrollment - History of intra-abdominal abscess, abdominal fistula, gastrointestinal perforation, or active peptic ulcer disease - Bleeding disorder or coagulopathy - Serious non-healing wound, ulcer or bone fracture - Major surgical procedure, open biopsy, or traumatic injury within 4 weeks prior to enrollment or anticipation of need for surgery during the study - Known active infection with HIV, hepatitis B or C - History of splenectomy - History of Crohn's disease or ulcerative colitis - History of organ transplantation - Evidence of immunodeficiency or immune suppression - Any Autoimmune disease - Active infection - Concurrent malignancy - Pregnant or nursing",ct_exc_492846,AACT,320,NCT01322815,Historical,FOLFIRI
5c7430a98625dd0758867f8e,460,,,22,Patient,15:05.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_549959,Clinical Trial Inclusion Criteria,UNKNOWN,Treatment with FOLFIRI and FOLFOX is not indicated.,ct_inc_549959,AACT,15,NCT00569699,Recent,FOLFIRI
5c7430ac8625dd067c867f8e,1110,,,1541,Patient,15:08.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_372912,Clinical Trial Inclusion Criteria,UNKNOWN,"(MRI)s used to assess measurable disease must have been completed within 28 days prior to registration; CT scans or MRIs used to assess non-measurable disease must have been completed within 42 days prior to registration; all disease must be assessed and documented on the Baseline Tumor Assessment Form - Patients must not have history of brain metastases - Patients must have had one and only one prior regimen of systemic therapy for metastatic disease unless the patient meets the criteria below - Prior systemic therapy and chemoradiotherapy for treatment of resectable, borderline resectable or locally advanced unresectable disease is allowed and does not count toward prior therapy for metastatic disease - Patients who received systemic therapy with gemcitabine/nab-paclitaxel for resectable or borderline/locally advanced unresectable disease and progressed with metastatic disease within 3 months of the past dose of systemic therapy are eligible - Patients must have completed systemic therapy at least 14 days prior to registration, any surgical procedure must have been performed at least 14 days prior to registration, and radiation therapy must be completed at least 7 days prior to registration; patients must have recovered from major side effects of prior therapies or procedures in the opinion of the local site investigator prior to registration - Patients must not have received prior irinotecan-based chemotherapy (e.g.irinotecan hydrochloride, leucovorin calcium, fluorouracil, and oxaliplatin [FOLFIRINOX] or FOLFIRI) -",ct_inc_372912,AACT,1534,NCT02890355,Historical,FOLFIRI
5c7430b28625dd07c6867f91,490,,,731,Patient,15:14.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_411745,Clinical Trial Exclusion Criteria,UNKNOWN,"Any investigational drugs within 30 days before enrollment or foreseen use of investigational agents during the study; Treatment with chemotherapy of any type within 12 months before enrollment; Patient with any type of ostomy (temporary ostomy should be closed at least 6 months prior to enrollment); Patient who underwent total colectomy; Patient who had abdominal-perineal resection or surgery leaving the patient without a functioning rectum; Any radiotherapy to the abdomen or pelvis in the 6 months prior to enrollment; Scheduled to receive radiotherapy to abdomen or pelvis during the study; 8. a) Exclusion from the Target population Scheduled to receive any concomitant chemotherapeutic agent, other than FOLFOX or FOLFIRI agents; any type of monoclonal antibodies; 8",ct_exc_411745,AACT,724,NCT02383810,Historical,FOLFIRI
5c7430b28625dd07c6867f92,490,,,135,Patient,15:14.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_411745,Clinical Trial Exclusion Criteria,UNKNOWN,". b) Exclusion from the Additional population Scheduled to receive any concomitant chemotherapeutic agent, other than FOLFOX or FOLFIRI agents;",ct_exc_411745,AACT,128,NCT02383810,Recent,FOLFIRI
5c7430b38625dd078f867f90,350,,,144,Patient,15:15.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_455338,Clinical Trial Exclusion Criteria,UNKNOWN,< 1 year - Bevacizumab within the last 4 weeks before starting treatment on trial - Patient is more than 6 months since the last dose of FOLFIRI - Patients who have required toxicity related dose reductions of no less than 50% of the original dose of infusional 5-FU and/or irinotecan during the administration of FOLFIRI + bevacizumab - Prior exposure to panitumumab in any setting - Prior exposure to cetuximab in the metastatic (stage IV) setting - Radiotherapy =,ct_exc_455338,AACT,137,NCT01814501,Historical,FOLFIRI
5c7430b48625dd07dc867f89,630,,,156,Patient,15:16.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_513909,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Histological/cytological confirmed diagnosis of Gastrointestinal malignancy, except pancreatic cancer - Eligible for 5FU/LV or FOLFIRI chemotherapy - ECOG 0-1 - Able to swallow and tolerate tablets - Life expectancy of 3 months",ct_inc_513909,AACT,149,NCT01046864,Recent,FOLFIRI
5c7430b48625dd07dc867f8a,630,,,168,Patient,15:16.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_496304,Clinical Trial Inclusion Criteria,UNKNOWN,- Patients must have previously received treatment with 5-FU alone or in combination with other anti-tumor medications - Patients foreseen for chemotherapy with FOLFIRI in second or further line treatment,ct_inc_496304,AACT,161,NCT01277406,Recent,FOLFIRI
5c7430b68625dd07fd867f85,210,,,37,Patient,15:18.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_354259,Clinical Trial Inclusion Criteria,UNKNOWN,"polychemotherapy type FOLFOX, FOLFIRI, FOLFIRINOX, associated or not with targeted therapies Adapted to the expression of BRAF and RAS, whatever the route of administration of the proposed, oral or intravenous therapies) - Metastatic CRC diagnosed preoperatively on imaging or per-operative on macroscopic findings and proved by histological analysis (biopsy or surgical excision and if possible biopsies or excrescence on the metastatic sites)",ct_inc_354259,AACT,30,NCT03133273,Hypothetical,FOLFIRI
5c7430b68625dd07eb867f86,930,,,688,Patient,15:18.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_378246,Clinical Trial Exclusion Criteria,UNKNOWN,"Well differentiated gastroentero-pancreatic (GEP) neuroendocrine tumor (NET) (G1 and G2 according to the WHO 2010), - Mixed tumor, - First-line chemotherapy other than cisplatin (or carboplatin) and etoposide, - All malignant disease in the three years before randomization, with the exception of basal cell carcinoma or in situ cancer treated for curative purposes, - A pregnant or breastfeeding woman, - Lack of efficient contraception (for men or women of reproductive age), - All medical, geographical, social, and psychological conditions or a legal situation that will not allow the patient to finish the study or sign an informed consent form, Relating to the chemotherapy (Folfiri):",ct_exc_378246,AACT,681,NCT02820857,Recent,Folfiri
5c7430b68625dd07eb867f87,930,,,321,Patient,15:18.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_378246,Clinical Trial Exclusion Criteria,UNKNOWN,"5x ULN; TP <50%; - Neutrophils <1.5x109/l, platelets <100x109/l, hemoglobin <10 g/dl, - Chronic uncontrolled diarrhea, unresolved intestinal occlusion or subocclusion, - History of anaphylactic reaction or known intolerance to atropine (sulfate) or to loperamide or to antiemetics administered in association with Folfiri, - All treatment with concomitant anticonvulsive agents, CYP3A4 inducers (phenytoin, phenobarbital, carbamazepine), discontinued for at least 7 days, Relating to bevacizumab: - Uncontrolled brain metastases (by local treatment), - All uncontrolled progressive disease within 1 month prior to randomization: grade 3-4 gastrointestinal bleeding (peptic ulcer, erosive esophagitis or gastritis), infectious disease or intestinal inflammation, diverticulitis, pulmonary embolism or other uncontrolled thromboembolic event, - Uncontrolled high blood pressure defined as a systolic blood pressure >140 mmHg or diastolic pressure >",ct_exc_378246,AACT,314,NCT02820857,Historical,Folfiri
5c7430b68625dd07e7867f8e,770,,,56,Patient,15:18.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_394785,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Patient who cannot receive FOLFIRI - More than 1 prior chemotherapy regimens for metastatic colorectal cancer - Pregnant, intent to be pregnant, or nursing female patient - Patient with any chronic inflammatory bowel disease - Patient treated for a cancer other than colorectal cancer within five years before enrollment - Patient with an hepatic involvement >",ct_exc_394785,AACT,49,NCT02605044,Historical,FOLFIRI
5c7430b78625dd0813867f84,370,,,231,Patient,15:19.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_387041,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Male or female adults - patients with gastric or colorectal cancer (stages III or IV), where a treatment with 5-Fluoruracil in combination with other chemotherapeutic remedies (FLO, FOLFOX, FOLFOX-Bev, FOLFIRI) is planned - life expectancy of at least the trial duration - the first administering of the product under investigation must be able to take place 72 hours before or after the beginning of the chemotherapeutical treatment, ideally at the same time - an inclusion into the study is only possible at the beginning of the first chemotherapeutic cycle - fertile female patients (aged 49 years or minor, the last menstruation occured in less than two years) have to be either surgically sterilized or use the same highly effective method of contraception for at least three months - willingness to refrain from other probiotics or probiotic yoghurts, a systematic change of eating behavior should not be planned - sufficient knowledge of german language and sufficient psychological state for being able to answer questionnaires and assessment scales - informed written consent",ct_inc_387041,AACT,224,NCT02706184,Recent,FOLFIRI
5c7430b78625dd0813867f86,370,,,286,Patient,15:19.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_330038,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically confirmed adenocarcinoma of the colon or rectum in patients with initially unresectable metastatic (M1) disease - Wild-type RAS tumour status confirmed before study inclusion at local institution - Patients who have a treatment plan based on FOLFOX + anti-EGFR or FOLFIRI + anti-EGFR, as first-line treatment of mCRC - Eastern Cooperative Oncology Group (ECOG) performance status 2 - Adequate bone marrow function: neutrophils 1.5 x109/L; platelets 100 x109/L; haemoglobin 9 g/dL - Hepatic, renal and metabolic function as follows:",ct_inc_330038,AACT,279,NCT03448731,Recent,FOLFIRI
5c7430b78625dd07e7867f8f,770,,,357,Patient,15:19.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_515855,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Signed and dated informed consent before the start of specific protocol procedures - Histological proven gastric adenocarcinoma including adenocarcinoma of the esophagogastric junction or lower esophagus - Failure of any prior chemotherapy (docetaxel and/or platinum-based chemotherapy); but patient has not previously received FOLFIRI treatment - Measurable metastatic disease according to the RECIST criteria patients aged 18 years and older - karnofsky index 100 - 70 % - Life expectancy > 12 weeks - Adequate hematological, hepatic and renal functions - At least 3 weeks from previous docetaxel- and/or platinum-based chemotherapy - Recovery from hematological side effects (CTC grade <1) and non-hematological side effects (CTC grade=<1) of any prior therapy (except oxaliplatine induced neuropathy CTC grade =<2)",ct_inc_515855,AACT,350,NCT01020630,Historical,FOLFIRI
5c7430b78625dd0813867f88,370,,,82,Patient,15:19.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_492846,Clinical Trial Inclusion Criteria,UNKNOWN,those patients who enroll just after completing bevacizumab plus FOLFOX or FOLFIRI - Anticipated survival of at least 6 months - Ambulatory with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - Ability to maintain weight - Normal organ and marrow function - Women of child-bearing potential and men must agree to avoid pregnancy or fathering a child for the duration of study participation and for 6 months after the final scheduled study visit.- Ability to understand and willingness to sign a written informed consent document,ct_inc_492846,AACT,75,NCT01322815,Recent,FOLFIRI
5c7430b78625dd0808867f8e,320,,,68,Patient,15:19.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_376081,Clinical Trial Inclusion Criteria,UNKNOWN,Indication for treatment with a combination including FOLFOX/FOLFIRI associated to an anti VEGF drug (Avastin),ct_inc_376081,AACT,61,NCT02849106,Recent,FOLFIRI
5c7430b78625dd0808867f90,320,,,320,Patient,15:19.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_367547,Clinical Trial Inclusion Criteria,UNKNOWN,"Must be willing and able to provide fecal samples according to protocol schedule - COHORT A - Diagnosis of metastatic colorectal cancer, where the metastatic disease has not been previously treated - Scheduled to begin fluorouracil/leucovorin calcium/oxaliplatin (FOLFOX) or folinic acid-fluorouracil-irinotecan (FOLFIRI) based chemotherapy for the advanced disease - Must have radiologic evidence of disease - COHORT B - Diagnosis of metastatic cancer",ct_inc_367547,AACT,313,NCT02960282,Recent,FOLFIRI
5c7430b78625dd0808867f92,320,,,213,Patient,15:20.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_336494,Clinical Trial Inclusion Criteria,UNKNOWN,Patients must have histologically confirmed CRC with isolated liver metastasis Patients must be planned for a hepatic metastasectomy Patients must have received at least 3 cycles of chemotherapy (FOLFOX or FOLFIRI with or without Bevacizumab) prior to the planned hepatic metastasectomy Primary tumor must be considered resectable with a plan for this to either occur concurrently with the liver resection or subsequent to this.,ct_inc_336494,AACT,206,NCT03364621,Historical,FOLFIRI
5c7430b88625dd0813867f8a,370,,,136,Patient,15:20.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_559717,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Patients with recurrent metastatic liver lesions from colorectal cancer who progressed on either FOLFOX or FOLFIRI - Biopsy proven evidence of colorectal cancer -,ct_inc_559717,AACT,129,NCT00440310,Recent,FOLFIRI
5c7430b88625dd07fd867f95,210,,,129,Patient,15:20.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_443963,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Colorectal cancer histologically or cytologically proven - Indication of treatment according to the FOLFIRI + / - bevacizumab or cetuximab or panitumumab - Age,ct_inc_443963,AACT,122,NCT01963182,Recent,FOLFIRI
5c7430b98625dd081e867f8a,110,,,753,Patient,15:21.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_468526,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Cytological or histological proven diagnosis of colorectal cancer, metastatic or inoperable advanced disease, not amenable to curative therapy - Measurable disease, defined as at least one lesion (outside of irradiated areas) that can be measured in at least one dimension as 10 mm ( 15 mm in case of lymph nodes) according to RECIST v1.1 - Tumor either wild-type KRAS or KRAS-mutated - Indication for the therapeutic use of continuous intravenous 5FU over 48 hours (deGramont regimen) or oral Cp, either alone or in combination with other anticancer drugs (including monoclonal antibodies or other molecularly-targeted drugs) - Eligible treatment regimens include: FOLFOX (FOLFOX 4, FOLFOX 6, modified FOLFOX 6, FOLFOX 7), FOLFIRI, 5FU or Cp mono-chemotherapy (deGramont regimen), XELOX, XELIRI,",ct_inc_468526,AACT,746,NCT01641458,Recent,FOLFIRI
5c7430ba8625dd0813867f8c,370,,,13,Patient,15:22.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_494688,Clinical Trial Exclusion Criteria,UNKNOWN,Prior FOLFIRI or single agent irinotecan is prohibited.,ct_exc_494688,AACT,6,NCT01298570,Historical,FOLFIRI
5c7430ba8625dd0813867f8d,370,,,112,Patient,15:22.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_494688,Clinical Trial Exclusion Criteria,UNKNOWN,"Women of childbearing potential must have a pregnancy test performed a maximum of 7 days before start of FOLFIRI treatment, and a negative result must be documented before start of treatment.",ct_exc_494688,AACT,105,NCT01298570,Recent,FOLFIRI
5c7430ba8625dd0813867f8e,370,,,133,Patient,15:22.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_494688,Clinical Trial Exclusion Criteria,UNKNOWN,"Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of Day 1 of treatment with FOLFIRI Radiotherapy within 4 weeks prior to first dose of FOLFIRI Active cardiac disease including any of the following: - Congestive heart failure (New York Heart Association (NYHA))",ct_exc_494688,AACT,126,NCT01298570,Historical,FOLFIRI
5c7430ba8625dd0813867f8f,370,,,193,Patient,15:22.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_494688,Clinical Trial Exclusion Criteria,UNKNOWN,"Class 2 (see Appendix D) - Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months).Myocardial infarction less than 6 months before start of Day 1 of FOLFIRI - Cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted) - Uncontrolled hypertension.(Systolic blood pressure",ct_exc_494688,AACT,186,NCT01298570,Recent,FOLFIRI
5c7430ba8625dd0813867f90,370,,,207,Patient,15:22.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_494688,Clinical Trial Exclusion Criteria,UNKNOWN,"Patients with pheochromocytoma Arterial thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), or pulmonary embolism within the 6 months before start of FOLFIRI Ongoing infection",ct_exc_494688,AACT,200,NCT01298570,Recent,FOLFIRI
5c7430ba8625dd0813867f91,370,,,415,Patient,15:22.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_494688,Clinical Trial Exclusion Criteria,UNKNOWN,"Grade 2 according to NCI Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v. 4.0) Known history of human immunodeficiency virus (HIV) infection Known history of chronic hepatitis B or C Patients with seizure disorder requiring medication Symptomatic metastatic brain or meningeal tumors unless the patient is >6 months from definitive therapy, has a negative imaging study within 4 weeks of FOLFIRI initiation, and is clinically stable with respect to the tumor at the time of study entry.",ct_exc_494688,AACT,408,NCT01298570,Historical,FOLFIRI
5c7430ba8625dd0813867f92,370,,,77,Patient,15:22.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_494688,Clinical Trial Exclusion Criteria,UNKNOWN,"Any hemorrhage or bleeding event > Grade 4 within 4 weeks of start of FOLFIRI Non-healing wound, ulcer, or bone fracture 21.",ct_exc_494688,AACT,70,NCT01298570,Recent,FOLFIRI
5c7430ba8625dd0813867f94,370,,,836,Patient,15:22.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_494688,Clinical Trial Exclusion Criteria,RENAL_REVIEW,"failure requiring hemo- or peritoneal dialysis Dehydration according to NCI-CTC v 4.0 Grade >1 Substance abuse, medical, psychological, or social conditions that may interfere with the patient's participation in the study or evaluation of the study results Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation Interstitial lung disease with ongoing signs and symptoms at the time of informed consent Inability to swallow oral medications Any malabsorption condition Unresolved toxicity higher than CTCAE v. 4.0 Grade 1 attributed to any prior therapy/procedure excluding alopecia and oxaliplatin-induced neurotoxicity (which must be Grade 2) Patients unable or unwilling to discontinue (and substitute if necessary) use of prohibited drugs for at least 30 days prior to Day 1 of FOLFIRI initiation (see Appendix B for list of prohibited drugs)",ct_exc_494688,AACT,829,NCT01298570,Historical,FOLFIRI
5c7430bb8625dd081e867f91,110,,,594,Patient,2/25/19 18:15,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_368896,Clinical Trial Inclusion Criteria,UNKNOWN,"Before the start of induction therapy: Inclusion Criteria: - Histological proof of colorectal cancer (in case of a single metastasis, histological or cytological proof of this lesion should be obtained); - Distant metastases which are either technically unresectable or no chance to reach NED (patients with only local recurrence are not eligible); - Measurable disease (> 1 cm on spiral CT scan or > 2 cm on chest X-ray; liver ultrasound is not allowed).Serum CEA may not be used as a parameter for disease evaluation; - Ongoing or planned first line induction therapy with 8 cycles of FOLFIRI or mFOLFOX6.",ct_inc_368896,AACT,587,NCT02942706,Recent,FOLFIRI
5c7430bb8625dd083f867f98,240,,,174,Patient,15:23.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_376081,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria: Elevation of Carcinoembryonic antigen (CEA) without measurable metastatic disease Medical contraindication to chemotherapy or biotherapy as FOLFOX/FOLFIRI or Avastin.,ct_exc_376081,AACT,167,NCT02849106,Recent,FOLFIRI
5c7430bb8625dd083f867f99,240,,,29,Patient,15:23.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_376081,Clinical Trial Exclusion Criteria,UNKNOWN,Treatment with FOLFOX/FOLFIRI and biotherapy anti-EGFR (epidermal growth factor receptor)(Erbitux) planned Patient already enrolled in an other clinical trial with another first line of chemotherapy.,ct_exc_376081,AACT,22,NCT02849106,Recent,FOLFIRI
5c7430bd8625dd084a867f89,140,,,42,Patient,15:25.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_490966,Clinical Trial Inclusion Criteria,UNKNOWN,Prior treatment with irinotecan or FOLFIRI is not allowed for Phase II).For Phase,ct_inc_490966,AACT,35,NCT01347645,Historical,FOLFIRI
5c7430598625dd03fe867f9a,290,,,141,Patient,13:45.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_369523,Clinical Trial Inclusion Criteria,UNKNOWN,"Additional inclusion criteria solely for Part 2: - Former first-line treatment of the metastatic colorectal cancer with FOLFIRI and cetuximab; data available for the duration of treatment and the response within the context of first-line treatment - Former second-line treatment of the colorectal cancer without FOLFIRI, irinotecan or an anti-EGFR substance with data available for the substances administered, duration of treatment and response within the context of the second-line treatment - Proof of a RAS wild-type tumour (KRAS and NRAS exons 2-4) in a tumour biopsy (metastasis) within 4 weeks before randomisation - CT examinations with evidence of a partial response (PR) or complete response (CR) or stable disease (SD) 6 months according to RECIST Version 1.1 criteria as best response within the context of the first-line treatment with FOLFIRI and cetuximab",ct_inc_369523,AACT,120,NCT02934529,Recent,FOLFIRI and cetuximab
5c74308c8625dd065b867f8b,20,,,564,Patient,14:36.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_481478,Clinical Trial Exclusion Criteria,UNKNOWN,"Subjects with brain metastases are eligible provided they have shown clinical and radiographic stable disease after definitive therapy and have not used steroids for at least 1 month prior to first dose of ABT-700.- Subject has unresolved adverse events > Grade 1 from prior anticancer therapy except for alopecia or anemia.- Subject has had major surgery within 21 days prior to the first dose of ABT-700.- Subjects enrolled on the combination therapy phase must not meet the above exclusion criteria and must be eligible to receive docetaxel or FOLFIRI/cetuximab or erlotinib per most current prescribing information, or at the discretion of the Investigator.",ct_exc_481478,AACT,547,NCT01472016,Historical,FOLFIRI/cetuximab
5c74308c8625dd065b867f8c,20,,,105,Patient,14:36.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_481478,Clinical Trial Exclusion Criteria,UNKNOWN,Subjects with K-Ras mutation-positive colorectal cancer will be excluded from receiving FOLFIRI/cetuximab.,ct_exc_481478,AACT,88,NCT01472016,Recent,FOLFIRI/cetuximab
5c74308d8625dd065b867f97,20,,,600,Patient,14:37.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_481478,Clinical Trial Inclusion Criteria,UNKNOWN,"Subject must have disease: a) that is not amenable to surgical resection, or b) that has progressed or recurred despite standard therapy, or c) that has failed to respond to standard therapy, or d) for which no effective therapy exists.- Subject cannot tolerate or must not be eligible for other approved therapeutic options with known survival advantage.- Subjects enrolled on the combination therapy phase must satisfy the above inclusion criteria and also the following: Subjects must have inoperable, locally advanced or metastatic cancer and be eligible to receive docetaxel or FOLFIRI/cetuximab or erlotinib in combination with ABT-700.",ct_inc_481478,AACT,583,NCT01472016,Recent,FOLFIRI/cetuximab
5c7430358625dd02b7867f84,560,,,139,Patient,13:09.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_370509,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Pancreatic metastatic cancer - Patient older than 18 years - Initiation of a first line of chemotherapy by Folfirinox, or Gemcitabine or in combination with Nab-Paclitaxel.-",ct_inc_370509,AACT,129,NCT02921646,Recent,Folfirinox
5c7430368625dd02b7867f85,560,,,183,Patient,13:10.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_333635,Clinical Trial Inclusion Criteria,UNKNOWN,Pathologically confirmed pancreatic adenocarcinoma Patients with locally advanced or distant metastasis status Patients who had undergone primary chemotherapy with previous FOLFIRINOX and whose disease progress was confirmed Patients whose consent was obtained (non-insurance agreement) 2.,ct_inc_333635,AACT,173,NCT03401827,Recent,FOLFIRINOX
5c7430408625dd030d867f88,1150,,,166,Patient,13:20.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_415091,Clinical Trial Exclusion Criteria,UNKNOWN,Patient has received any prior cytotoxic chemotherapy for pancreatic cancer with the exception of patients who progressed on or were intolerant of 1st line FOLFIRINOX.Prior,ct_exc_415091,AACT,156,NCT02340117,Historical,FOLFIRINOX
5c7430408625dd030d867f89,1150,,,74,Patient,13:20.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_354785,Clinical Trial Exclusion Criteria,UNKNOWN,Clinically significant ascites Any anti-tumor treatment (except FOLFIRINOX as the first-line therapy) for pancreatic adenocarcinoma before enrollment.,ct_exc_354785,AACT,64,NCT03126435,Recent,FOLFIRINOX
5c7430408625dd030d867f8a,1150,,,223,Patient,13:20.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_325766,Clinical Trial Exclusion Criteria,UNKNOWN,Prior treatment with any chemotherapy for metastatic adenocarcinoma of the pancreas.- Completion of a gemcitabine-based adjuvant chemotherapy regimen within less than 6 months.- Receipt of neoadjuvant or adjuvant FOLFIRINOX therapy.-,ct_exc_325766,AACT,213,NCT03504423,Historical,FOLFIRINOX
5c7430408625dd030d867f8b,1150,,,77,Patient,13:20.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_453662,Clinical Trial Exclusion Criteria,UNKNOWN,Subjects may receive steroids as prophylactic anti-emetics per the FOLFIRINOX or gemcitabine/nab-paclitaxel regimen.,ct_exc_453662,AACT,67,NCT01836432,Recent,FOLFIRINOX
5c7430408625dd030d867f8c,1150,,,119,Patient,13:20.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_465004,Clinical Trial Exclusion Criteria,UNKNOWN,> grade 2).- Any other hemorrhage/bleeding event > CTCAE Grade 3 within the 12 weeks prior to the first dose FOLFIRINOX.- Evidence or history of bleeding diathesis or coagulopathy.,ct_exc_465004,AACT,109,NCT01688336,Historical,FOLFIRINOX
5c7430468625dd0334867f93,400,,,121,Patient,13:26.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_319168,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria: - diagnosis of other neoplasia than pancreatic carcinoma - treatment with drugs other than FOLFIRINOX - treatment with experimental drugs in combination with FOLFIRINOX - unavailability of clinical and pathological data,ct_exc_319168,AACT,111,NCT03590275,Recent,FOLFIRINOX
5c7430528625dd03b8867f8a,430,,,123,Patient,13:39.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_442320,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Patients suffering from locally advanced pancreatic cancer and have started treatment with Folfirinox but must stop because of side effects or who declined the Folfirinox treatment.- Minimum age of 18 years old and be capable of understanding the information and giving informed consent, - Minimum height of 155 cm, - Expected survival time (life expectancy) of over 6 months, - Adequate performance status 2 (see below*),",ct_inc_442320,AACT,113,NCT01984658,Recent,Folfirinox
5c7430548625dd03ad867f95,590,,,99,Patient,13:40.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_361893,Clinical Trial Inclusion Criteria,UNKNOWN,"AJCC stage IV disease at time of enrollment.- Patient planning to receive treatment with FOLFIRINOX or gem/nab-P chemotherapy, with or without investigational agents.- Prior surgery, chemotherapy and/or radiation therapy for AJCC Stage I-III pancreatic adenocarcinoma is permitted.- ECOG performance status 0",ct_inc_361893,AACT,89,NCT03033927,Historical,FOLFIRINOX
5c7430598625dd0426867f8b,660,,,59,Patient,13:46.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_372408,Clinical Trial Exclusion Criteria,UNKNOWN,Resectable pancreatic cancer - Prior neoadjuvant FOLFIRINOX - Pregnant or lactating females -,ct_exc_372408,AACT,49,NCT02896907,Historical,FOLFIRINOX
5c74305a8625dd0431867f87,220,,,308,Patient,13:46.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_383626,Clinical Trial Inclusion Criteria,UNKNOWN,Patients must be fit enough to safely undergo a tumor biopsy.- Age 18 years or older.- Eastern Cooperative Group (ECOG) performance status of 1 or less.- Life expectancy of greater than 90 days.- Patients must have normal organ and marrow function - Patients must undergo systemic treatment with m-FOLFIRINOX or nab-paclitaxel as a first line standard systemic palliative treatment or combination treatment with m-FOLFIRINOX or nab-paclitaxel with or without other investigational agents within a clinical trial as a first line palliative treatment.- Ability to understand and willing to sign a written informed consent document.,ct_inc_383626,AACT,298,NCT02750657,Recent,FOLFIRINOX
5c74305e8625dd0447867f92,250,,,137,Patient,13:50.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_467105,Clinical Trial Exclusion Criteria,UNKNOWN,"Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with FOLFIRINOX, breastfeeding should be discontinued if the mother is treated with these agents.",ct_exc_467105,AACT,127,NCT01660711,Hypothetical,FOLFIRINOX
5c7430648625dd049f867f84,960,,,492,Patient,13:56.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_485376,Clinical Trial Inclusion Criteria,UNKNOWN,- Must have metastatic colorectal cancer or pancreatic cancer with stable disease after first line chemotherapy or patients with colorectal or pancreatic cancer who have progressed with standard chemotherapy options* - Standard chemotherapy for metastatic,ct_inc_485376,AACT,482,NCT01420874,Recent,FOLFIRINOX
5c7430648625dd04aa867f86,530,,,162,Patient,13:56.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_350185,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Patient immediately eligible for a curative therapy (surgical and/or percutaneous) after discussion in CPR - Patient treated with FOLFIRINOX or FOLFOXIRI in 1st line - Cerebral metastasis - Previous treatment with anti-PD1 or anti-PDL1 - Autoimmune disease that might be aggravated during treatment with an immuno-stimulating agent (patients with type I diabetes, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible) -",ct_exc_350185,AACT,152,NCT03186326,Recent,FOLFIRINOX
5c7430648625dd0489867f85,1260,,,57,Patient,13:56.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_361543,Clinical Trial Inclusion Criteria,HISTORY_PRESENT_ILLNESS,Have received at least one treatment of either FOLFIRINOX or gemcitabine/abraxane based regimens in both neoadjuvant and adjuvant setting.,ct_inc_361543,AACT,47,NCT03038477,Recent,FOLFIRINOX
5c7430658625dd049f867f85,960,,,52,Patient,13:57.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_446636,Clinical Trial Inclusion Criteria,UNKNOWN,Patients already receiving treatment with FOLFIRINOX +/-,ct_inc_446636,AACT,42,NCT01928290,Recent,FOLFIRINOX
5c7430658625dd049f867f86,960,,,210,Patient,13:57.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_459168,Clinical Trial Inclusion Criteria,UNKNOWN,Patients with measurable or evaluable disease according to the response evaluation criteria in solid tumors Patients eligible for second-line therapy after failing first-line therapy with the regimen FOLFIRINOX.,ct_inc_459168,AACT,200,NCT01764477,Recent,FOLFIRINOX
5c7430658625dd0489867f86,1260,,,514,Patient,13:57.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_500484,Clinical Trial Inclusion Criteria,UNKNOWN,"The following represent acceptable examples meeting the definition of one prior line of therapy: - Gemcitabine as a single agent or in combination with other agents; patients receiving (a) gemcitabine initially alone, with the eventual addition of a second agent; or (b) gemcitabine as part of a combination regimen, followed by gemcitabine alone; are eligible - A non-gemcitabine-based regimen, including (but not limited to) leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin (FOLFIRINOX) or any combination of components therein - Treatment as part of a clinical trial involving cytotoxic agents, small molecule inhibitors, monoclonal antibodies, and/or immunomodulatory agents -",ct_inc_500484,AACT,504,NCT01222689,Historical,FOLFIRINOX
5c74306a8625dd04e1867f84,500,,,50,Patient,14:02.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_478974,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Patient receiving FOLFIRINOX chemotherapy - Southwest Oncology Group (SWOG) Performance status 0 or 1 - Ability of patient or guardian to understand and to provide voluntary written informed consent,ct_inc_478974,AACT,40,NCT01504711,Recent,FOLFIRINOX
5c74306b8625dd04e1867f85,500,,,174,Patient,14:03.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_469226,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - History of islet cell, acinar cell, or cystadenocarcinomas - Prior cytotoxic chemotherapy for metastatic disease, except prior gemcitabine or FOLFIRINOX (5FU + leucovorin + irinotecan + oxaliplatin) - Radiation therapy, immunotherapy or biologic therapy",ct_exc_469226,AACT,164,NCT01632306,Historical,FOLFIRINOX
5c74306e8625dd04f7867f91,550,,,88,Patient,14:06.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_398564,Clinical Trial Inclusion Criteria,UNKNOWN,Patient is treatment-nave or currently receiving front-line chemotherapy with FOLFIRINOX or GEMCITABINE-ABRAXANE and has stable disease.- ECOG performance status 0,ct_inc_398564,AACT,78,NCT02555735,Recent,FOLFIRINOX
5c74306e8625dd04f7867f92,550,,,56,Patient,14:06.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_395752,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Prior chemotherapy with FOLFIRINOX; - Prior history of pancreatic electroporation; - Untreatable contrast allergy; - History of allergy or hypersensitivity to gemcitabine, nab-paclitaxel, or any of the excipients; - Presence of metal biliary stent; - Psychosis or seizures; - Evidence of serious gastrointestinal bleeding or bowel obstruction; - Pregnant or lactating women",ct_exc_395752,AACT,46,NCT02592395,Historical,FOLFIRINOX
5c7430718625dd0518867f94,100,,,544,Patient,14:09.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_318198,Clinical Trial Inclusion Criteria,UNKNOWN,"Patient Inclusion Criteria: - Self-identify as Hispanic/Latino - Has been diagnosed with metastatic colorectal cancer (mCRC) OR locally advanced pancreatic cancer (LAPC) OR metastatic pancreatic cancer (mPC) AND is making a decision regarding treatment with 1st line palliative chemotherapy - Treating oncologist has recommended consideration of one or more of the regimens for which we have developed chemotherapy educational (CEI) toolkits - For mCRC: FOLFOX, FOLFOX + bevacizumab, FOLFIRI, FOLFIRI + bevacizumab - For LAPC or mPC: FOLFIRINOX, Gemcitabine, or Gemcitabine + nab-paclitaxel - Patients who are also considering treatment on a clinical trial of one of these regimens +/-",ct_inc_318198,AACT,534,NCT03602885,Recent,FOLFIRINOX
5c7430828625dd05e2867f86,330,,,289,Patient,14:26.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_414344,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Adenocarcinoma of the pancreas - Prior therapy with 1 prior systemic therapy over a period of at least 2 months (eg, at least two 4-week cycles of a regimen such as gemcitabine and nab-paclitaxel; or at least four 2-week cycles of a regimen such as FOLFOX, FOLFIRINOX, or FOLFIRI) -Candidate for additional therapy consisting of radiation with gemcitabine- radiosensitization.- Able to initiate study treatment no later than 6 weeks from last dose of any antineoplastic component of prior therapy",ct_inc_414344,AACT,279,NCT02349867,Historical,FOLFIRINOX
5c7430828625dd0603867f84,600,,,155,Patient,14:26.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_313623,Clinical Trial Inclusion Criteria,CHEMOTHERAPEUTICS,"patients who had previously received treatment with gemcitabine-based chemotherapy failed, and received fluorouracil based chemotherapy (such as FOLFIRINOX) and had received or not received radiotherapy and failed treatment.2.",ct_inc_313623,AACT,145,NCT03662412,Recent,FOLFIRINOX
5c7430838625dd0603867f85,600,,,66,Patient,14:27.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_449035,Clinical Trial Inclusion Criteria,UNKNOWN,Stable metastatic pancreatic cancer after 8-12 doses of FOLFIRINOX 3.,ct_inc_449035,AACT,56,NCT01896869,Recent,FOLFIRINOX
5c7430908625dd0680867f89,480,,,63,Patient,14:40.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_386203,Clinical Trial Exclusion Criteria,UNKNOWN,"other severe medical conditions; contraindication of FOLFIRINOX, paclitaxel and gemcitabine 3.",ct_exc_386203,AACT,53,NCT02717091,Recent,FOLFIRINOX
5c7430918625dd0671867f8b,950,,,55,Patient,14:41.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_374491,Clinical Trial Inclusion Criteria,UNKNOWN,"Planned for first-line systemic therapy with FOLFIRINOX or GP, either in routine care or in combination with an investigational agent(s) within a clinical trial.-",ct_inc_374491,AACT,45,NCT02869802,Recent,FOLFIRINOX
5c7430918625dd0671867f8c,950,,,132,Patient,14:41.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_374199,Clinical Trial Inclusion Criteria,UNKNOWN,"Completion of at least 3 months, but no more than 6 months of standard induction chemotherapy for LAPC, which may include FOLFIRINOX or gemcitabine and nab-paclitaxel, preferably within 2-4 weeks but no longer than 8 weeks.",ct_inc_374199,AACT,122,NCT02873598,Recent,FOLFIRINOX
5c7430918625dd0671867f8d,950,,,125,Patient,14:41.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_415091,Clinical Trial Inclusion Criteria,URINALYSIS,"However, this study may be used as 2nd line treatment of patients who progressed on or were intolerant of 1st line FOLFIRINOX.Prior",ct_inc_415091,AACT,115,NCT02340117,Recent,FOLFIRINOX
5c7430918625dd0671867f8e,950,,,400,Patient,14:41.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_366074,Clinical Trial Inclusion Criteria,UNKNOWN,"Pathologically confirmed or highly suspected aPDAC defined as a pancreatic mass on imaging, suspected distant metastases, no features suggestive of a neuroendocrine tumor, and/or clinico-biological abnormalities compatible with the diagnosis of aPDAC, Age 18 years, Patients with ECOG PS 2 and clinico-biological features precluding initial therapeutic clinical trial and/or treatment with FOLFIRINOX or gemcitabine + nab-paclitaxel, No prior history of cancer, except: in situ breast, cervix cancer, or basal cell carcinoma and/or complete remission for more than 3 years from another cancer.",ct_inc_366074,AACT,390,NCT02979483,Historical,FOLFIRINOX
5c7430928625dd0671867f8f,950,,,43,Patient,14:42.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_314391,Clinical Trial Exclusion Criteria,UNKNOWN,"No prior chemotherapy except for FOLFIRINOX, Gem-Abrax, or Gem-Cap.",ct_exc_314391,AACT,33,NCT03652428,Historical,FOLFIRINOX
5c7430938625dd0692867f8a,790,,,128,Patient,14:43.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_376478,Clinical Trial Inclusion Criteria,UNKNOWN,"Induction chemotherapy was administered with any combination of the following agents: - Gemcitabine + nb-paclitaxel - FOLFIRINOX - Neoadjuvant Chemordiation was administered as IMRT or 3DCRT wPreoperative External beam dose (NCCN) - 50.4 Gy (1.8 Gy per fraction) with concurrent gemcitabine, capecitabine, or infusional 5-fluorouracil",ct_inc_376478,AACT,118,NCT02843945,Recent,FOLFIRINOX
5c7430938625dd0692867f8b,790,,,282,Patient,14:43.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_354785,Clinical Trial Inclusion Criteria,UNKNOWN,Written informed consent Histologically or cytologically confirmed adenocarcinoma of the pancreas Metastatic or locally advanced disease that is considered unresectable Measurable / assessable disease according to RECIST v.1.1 Documented disease progression on first line FOLFIRINOX Negative pregnancy test,ct_inc_354785,AACT,272,NCT03126435,Recent,FOLFIRINOX
5c7430938625dd0692867f8c,790,,,142,Patient,14:43.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_352301,Clinical Trial Inclusion Criteria,UNKNOWN,Status of 70.- Lesions cannot exceed 5 cm in maximum diameter.- Absence of lymph-nodal metastases - Patients received 4-6 months of FOLFIRINOX or Gemcitabine-Abraxane before SBRT was administered.-,ct_inc_352301,AACT,132,NCT03158779,Recent,FOLFIRINOX
5c7430938625dd0692867f8d,790,,,403,Patient,14:43.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_430183,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Other than ductal pancreatic carcinoma: namely endocrin tumors, acinar cells carcinoma, cystadenocarcinoma or adenocarcinoma of the ampulla of vater - Non-metastatic but locally advanced pancreatic adenocarcinoma - Complete DPD deficiency - History of Cardiac failure or symptomatic coronary artery disease - Autonomy Daily Living score by Katz <4 - Prior treatment with FOLFIRINOX (adjuvant) -",ct_exc_430183,AACT,393,NCT02143219,Historical,FOLFIRINOX
5c7430938625dd0692867f8e,790,,,135,Patient,14:43.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_372408,Clinical Trial Inclusion Criteria,UNKNOWN,"performance status (PS) 0-1 - No prior treatment for metastatic disease (prior neo-adjuvant or adjuvant chemotherapy, except FOLFIRINOX, chemoradiation or radiation allowed) -",ct_inc_372408,AACT,125,NCT02896907,Historical,FOLFIRINOX
5c7430938625dd0692867f8f,790,,,484,Patient,14:43.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_372416,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Patients with pancreatic adenocarcinoma, confirmed by biopsy and histological material available for review - Unresectable primary tumor considered by the team assistant or metastatic disease - Aged between 18 and 75 at the time of study entry - Nave patients of palliative chemotherapy, admitted for treatment at the Institute of the So Paulo State Cancer (ICESP) - Patients with performance status 0 or 1, not candidates to receive chemotherapy with FOLFIRINOX or performance status 2.-",ct_inc_372416,AACT,474,NCT02896803,Recent,FOLFIRINOX
5c7430a58625dd0742867f86,1120,,,358,Patient,15:01.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_318272,Clinical Trial Inclusion Criteria,UNKNOWN,"The somatic mutational testing can be performed on tissue samples taken from any time in the patient's pancreatic cancer history.- Patients must have received at least one line of treatment for their cancer prior to enrolling on the trial.- Patients who had investigator assessed progression on an oxaliplatin-containing regimen (such as FOLFOX or FOLFIRINOX) are not eligible for the trial.- Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as 20 mm with conventional techniques or as 10 mm with spiral CT scan, MRI, or calipers by clinical exam.",ct_inc_318272,AACT,348,NCT03601923,Historical,FOLFIRINOX
5c7430a98625dd0763867f88,730,,,178,Patient,15:05.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_453829,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria - Subjects with recurrent, locally advanced unresectable or metastatic adenocarcinoma of the pancreas who have progressed after primary therapy with FOLFIRINOX or FOLFIRINOX-like regimen or were intolerant of it.- IHC greater than or equal to 20 percent of tumor on tissue sections must stain with NPC-1C.- 18 years of age or older.- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.-",ct_inc_453829,AACT,168,NCT01834235,Recent,FOLFIRINOX
5c7430ac8625dd067c867f8d,1110,,,1529,Patient,15:08.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_372912,Clinical Trial Inclusion Criteria,UNKNOWN,"(MRI)s used to assess measurable disease must have been completed within 28 days prior to registration; CT scans or MRIs used to assess non-measurable disease must have been completed within 42 days prior to registration; all disease must be assessed and documented on the Baseline Tumor Assessment Form - Patients must not have history of brain metastases - Patients must have had one and only one prior regimen of systemic therapy for metastatic disease unless the patient meets the criteria below - Prior systemic therapy and chemoradiotherapy for treatment of resectable, borderline resectable or locally advanced unresectable disease is allowed and does not count toward prior therapy for metastatic disease - Patients who received systemic therapy with gemcitabine/nab-paclitaxel for resectable or borderline/locally advanced unresectable disease and progressed with metastatic disease within 3 months of the past dose of systemic therapy are eligible - Patients must have completed systemic therapy at least 14 days prior to registration, any surgical procedure must have been performed at least 14 days prior to registration, and radiation therapy must be completed at least 7 days prior to registration; patients must have recovered from major side effects of prior therapies or procedures in the opinion of the local site investigator prior to registration - Patients must not have received prior irinotecan-based chemotherapy (e.g.irinotecan hydrochloride, leucovorin calcium, fluorouracil, and oxaliplatin [FOLFIRINOX] or FOLFIRI) -",ct_inc_372912,AACT,1519,NCT02890355,Historical,FOLFIRINOX
5c7430b08625dd07d1867f84,1040,,,160,Patient,15:13.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_407466,Clinical Trial Inclusion Criteria,AGE,"No evidence of any distant metastasis Patients with microscopic peritoneal carcinomatosis, detected on laparoscopy following 4 cycles on neo-adjuvant FOLFIRINOX would be included.",ct_inc_407466,AACT,150,NCT02439593,Recent,FOLFIRINOX
5c7430b28625dd07d1867f85,1040,,,160,Patient,15:14.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_427465,Clinical Trial Inclusion Criteria,UNKNOWN,Women of childbearing potential definition (WOCBP) must have a negative serum or urine pregnancy test performed within 14 days prior to initiation of FOLFIRINOX.Any,ct_inc_427465,AACT,150,NCT02178709,Historical,FOLFIRINOX
5c7430b28625dd07d1867f86,1040,,,171,Patient,15:14.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_384894,Clinical Trial Inclusion Criteria,UNKNOWN,"Participants who have received prior neoadjuvant therapy and who now have metastatic disease must have received 1 of the following for their metastatic disease: FOLFIRINOX, nanoparticle albumin-bound paclitaxel/gemcitabine, TS-1",ct_inc_384894,AACT,161,NCT02734160,Historical,FOLFIRINOX
5c7430b28625dd07d1867f87,1040,,,145,Patient,15:14.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_338311,Clinical Trial Inclusion Criteria,UNKNOWN,"Completion of at least 3 months, but no more than 7 months of standard induction chemotherapy for LAPC, which should consist of either FOLFIRINOX or gemcitabine and nab-paclitaxel, preferably with a washout period no longer than 8 weeks.",ct_inc_338311,AACT,135,NCT03340974,Recent,FOLFIRINOX
5c7430b38625dd07d1867f88,1040,,,126,Patient,15:15.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_453829,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria - Have received a second line chemotherapy after progressing on or not tolerating treatment with FOLFIRINOX as a first line.,ct_exc_453829,AACT,116,NCT01834235,Recent,FOLFIRINOX
5c7430b48625dd07d1867f89,1040,,,73,Patient,15:16.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_494824,Clinical Trial Inclusion Criteria,UNKNOWN,"Gemzar, Tarceva, and 5-FU or Xeloda, Oxaliplatin Taxotere, and FOLFIRINOX are permitted.",ct_inc_494824,AACT,63,NCT01296763,Recent,FOLFIRINOX
5c7430b48625dd07d1867f8a,1040,,,309,Patient,15:16.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_467548,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Patient 18 years of age - Biopsy proven adenocarcinoma of the pancreas - Evidence of metastatic disease - Received at least 1 prior chemotherapy treatment regimen with disease progression - May have had any prior chemotherapy regimen including any gemcitabine based regimen or FOLFIRINOX - May have participated in a prior study protocol - May have had prior treatment with HDIVC - Anticipated survival of at least 3 months - Eastern Cooperative Oncology Group (ECOG) performance status = 0,1, or 2 - The patient must have screening",ct_inc_467548,AACT,299,NCT01654861,Historical,FOLFIRINOX
5c7430b58625dd07dc867f8d,630,,,14,Patient,15:17.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_449035,Clinical Trial Exclusion Criteria,UNKNOWN,Off FOLFIRINOX treatment for more than 70 days prior to treatment on study Prior chemotherapy for metastatic pancreatic cancer (other than FOLFIRINOX or adjuvant therapy).,ct_exc_449035,AACT,4,NCT01896869,Historical,FOLFIRINOX
5c7430b58625dd07dc867f8e,630,,,110,Patient,15:17.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_464605,Clinical Trial Inclusion Criteria,UNKNOWN,Patients with a pathological or clinical diagnosis of pancreatic cancer and beginning or continuing FOLFIRINOX or gemcitabine-based chemotherapy.,ct_inc_464605,AACT,100,NCT01693523,Recent,FOLFIRINOX
5c7430b58625dd07dc867f8f,630,,,110,Patient,15:17.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_464605,Clinical Trial Inclusion Criteria,UNKNOWN,Patients with a pathological or clinical diagnosis of pancreatic cancer and beginning or continuing FOLFIRINOX chemotherapy.,ct_inc_464605,AACT,100,NCT01693523,Recent,FOLFIRINOX
5c7430b68625dd07fd867f84,210,,,49,Patient,15:18.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_354259,Clinical Trial Inclusion Criteria,UNKNOWN,"polychemotherapy type FOLFOX, FOLFIRI, FOLFIRINOX, associated or not with targeted therapies Adapted to the expression of BRAF and RAS, whatever the route of administration of the proposed, oral or intravenous therapies) - Metastatic CRC diagnosed preoperatively on imaging or per-operative on macroscopic findings and proved by histological analysis (biopsy or surgical excision and if possible biopsies or excrescence on the metastatic sites)",ct_inc_354259,AACT,39,NCT03133273,Hypothetical,FOLFIRINOX
5c7430b68625dd07dc867f90,630,,,95,Patient,15:18.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_465004,Clinical Trial Inclusion Criteria,UNKNOWN,Baseline CT abdomen and chest (or MRI abdomen) within 28 days prior to initiation of FOLFIRINOX is required.- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.- No prior chemotherapy or chemoradiotherapy for pancreatic cancer.- Age 18 years of age.- Laboratory requirements at study entry: - Hemoglobin 10 g/dL (transfusions are acceptable) - absolute neutrophil count (ANC),ct_inc_465004,AACT,85,NCT01688336,Historical,FOLFIRINOX
5c7430b68625dd07dc867f91,630,,,196,Patient,15:18.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_465004,Clinical Trial Inclusion Criteria,UNKNOWN,"x ULN - Life expectancy of at least 6 months.- Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test performed within 14 days prior to initiation of FOLFIRINOX.- WOCBP and men must agree to use adequate contraception prior to study entry, for the duration of study participation, and 8 weeks after the end of treatment.- Before patient registration, written informed consent must be given.",ct_inc_465004,AACT,186,NCT01688336,Historical,FOLFIRINOX
5c7430358625dd02ba867f84,900,,,82,Patient,13:09.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_384545,Clinical Trial Exclusion Criteria,UNKNOWN,"Previous or current malignant tumor beyond HCC; Allergy to any agent of the FOLFOX regimen; History of organ transplantation; Previously receiving other treatments for HCC; Pregnant or breastfeeding women, and women of childbearing potential without adequate contraception; Neurological or mental abnormalities that may affect cognitive assessment and inform consent; Concomitant anti-tumor therapy or participating in other interventional clinical trials; Other psychological, family or social reason, which would affect compliance with the study protocol.",ct_exc_384545,AACT,76,NCT02738697,Historical,FOLFOX
5c7430368625dd02ba867f85,900,,,75,Patient,13:10.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_480022,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria: - Main exclusion criteria - Contraindications to FOLFOX,ct_exc_480022,AACT,69,NCT01490996,Recent,FOLFOX
5c7430378625dd02ba867f86,900,,,332,Patient,13:11.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_507100,Clinical Trial Inclusion Criteria,UNKNOWN,"A patient who is able to walk and should have ECOG performance status of 0-1.- Histologically confirmed adenocarcinoma of the stomach - Unresectable locally advanced or initially metastatic or recurrent after curative resection - Prior one regimen chemotherapy including fluoropyrimidine and platinum.(FP, XP, TS-1+cisplatin, FOLFOX) - A patient with at least one measurable primary lesion of which the diameter is confirmed to be 10mm in Spiral CT or multidetector CT (MD CT), or 20 mm or longer in conventional CT",ct_inc_507100,AACT,326,NCT01136031,Historical,FOLFOX
5c7430388625dd02ba867f87,900,,,285,Patient,13:12.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_535946,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically confirmed locally advanced or metastatic colorectal cancer - Measurable or evaluable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) - ECOG performance status 2 - Age 18 - 72 years - Patients who progress after 1st line therapy with FOLFOX/AVASTIN - Adequate liver (Bilirubin 1.5 upper normal limit, SGOT/SGPT 4 upper normal limit, ALP 2.5 upper normal limit),renal (Creatinine 1.5 upper normal limit) and bone marrow (ANC 1,500/mm3, PLT 100,000/mm3)",ct_inc_535946,AACT,279,NCT00755118,Recent,FOLFOX
5c7430388625dd02b4867f8a,1020,,,300,Patient,13:12.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_530519,Clinical Trial Inclusion Criteria,COMMENT,"Pathological confirmation of adenocarcinoma or poorly differentiated carcinoma as the primary histology.- CT or MRI scans (done within 30 days of registration) of the Chest, Abdomen and Pelvis all without clear evidence of distant metastatic (M1) disease.- Candidates for systemic therapy with FOLFOX and bevacizumab based on the opinion of the primary treating medical oncologist.- Candidates for complete surgical resection prior to administration of any therapy.- Performance status of ECOG 0 or 1.- Patients must be of age 18 years.- ANC 1.5 cells/mm3, PLT >",ct_inc_530519,AACT,294,NCT00826800,Historical,FOLFOX
5c7430388625dd02ba867f88,900,,,291,Patient,13:12.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_531003,Clinical Trial Exclusion Criteria,UNKNOWN,"Patients must not have severe congestive heart failure (defined as New York Heart Association Class II or greater); - For Arm A only: Any other major medical illness that, in the investigator's opinion, would: (1) prevent administration or completion of institution's standard of care FOLFOX/bevacizumab therapy; (2) prevent administration or completion of protocol-specified imaging; and/or (3) interfere with follow-up.",ct_exc_531003,AACT,285,NCT00820456,Recent,FOLFOX
5c7430388625dd02ba867f89,900,,,443,Patient,13:12.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_536814,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Resectable liver metastasis - Extrahepatic metastases, regardless of their resectability - Chronic active hepatitis or cirrhosis - Prior therapy for metastatic disease - Pregnant or lactating women - Uncontrolled medical illnesses including medically uncontrolled infection, uncontrolled hypertension, unstable angina, symptomatic congestive heart failure, myocardial infarction within 6 months - Previous adjuvant FOLFOX chemotherapy - Prior adjuvant chemotherapy, if administered within 6 months before study entry - Known hypersensitivity reaction to any of the components of study treatment - Prior agents directed against EGFR - Prior allergic reaction (known sensitivity) to chimerized or murine monoclonal antibody therapy - Known alcohol or drug abuse - Participation in another clinical study within the 30 days before registration - Peripheral neuropathy > grade 1 - Other previous malignancy with exception of a history of a previous curatively treated basal cell carcinoma of the skin of pre-invasive carcinoma of the cervix.",ct_exc_536814,AACT,437,NCT00743678,Hypothetical,FOLFOX
5c7430388625dd02b4867f8b,1020,,,65,Patient,13:12.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_371705,Clinical Trial Inclusion Criteria,UNKNOWN,Patients relapsing within 12 months of completing adjuvant FOLFOX will also be considered eligible.- Eastern Cooperative Oncology Group (ECOG) Performance Status 0 - 1,ct_inc_371705,AACT,59,NCT02906059,Recent,FOLFOX
5c7430388625dd02ba867f8a,900,,,186,Patient,13:12.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_439460,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Patients with serious medical risk factors involving any of the major organ systems such that the investigator considers it unsafe for the patient to receive FOLFOX-A - Prior hypersensitivity to Oxaliplatin or Abraxane that in the investigators opinion would put the patient at risk if re-exposed - Patients with islet cell (neuroendocrine) tumors, cystadenomas, cystadenocarcinomas, carcinoid tumors, duodenal carcinomas, distal bile duct, and ampullary carcinomas.- Prior systemic chemotherapy for pancreas cancer; note that prior chemotherapy for a different cancer is allowable.",ct_exc_439460,AACT,180,NCT02022033,Hypothetical,FOLFOX
5c7430398625dd02b4867f8c,1020,,,299,Patient,13:13.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_396800,Clinical Trial Exclusion Criteria,UNKNOWN,that in the investigators opinion would put the patient at risk if re-exposed - Preexisting neuropathy is not allowed from any cause.- Patients with serious medical risk factors involving any of the major organ systems such that the investigator considers it unsafe for the patient to receive FOLFOX-A - Patients with unstable biliary stents or with plastic stents.,ct_exc_396800,AACT,293,NCT02578732,Recent,FOLFOX
5c7430398625dd02b4867f8d,1020,,,269,Patient,13:13.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_437583,Clinical Trial Inclusion Criteria,UNKNOWN,"In patients with rectal cancer, primary tumor that is clinically T3-4 or N + (evaluation by colorectal surgery is required as part of multidisciplinary approach).- No prior chemotherapy for metastatic disease is allowed for patients with CRC-liver mets.(adjuvant FOLFOX is permitted) - No prior chemotherapy for proximal rectal cancer is allowed - ECOG Performance",ct_inc_437583,AACT,263,NCT02046538,Historical,FOLFOX
5c74303c8625dd02f6867f8f,120,,,175,Patient,13:16.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_438902,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients with histologically confirmed metastatic colorectal cancer - Cetuximab-based chemotherapy (monotherapy, combination therapy with cytotoxic chemotherapy such as FOLFOX, XELOX, irinotecan, FOLFIRI, XELIRI, first-line, second-line or third-line are all eligible)",ct_inc_438902,AACT,169,NCT02029326,Recent,FOLFOX
5c7430418625dd0334867f85,400,,,479,Patient,13:21.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_340555,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically proven adenocarcinoma of the colon and/or rectum, - Metastatic disease confirmed clinically/radiologically, - Patients with Formalin-Fixed, Paraffin-Embedded tissue RAS wild type colorectal cancer at diagnosis, who had initial clinical benefit [complete response, partial response or stable disease] during first line irinotecan-based or oxaliplatin-based chemotherapy in combination with cetuximab or panitumumab, - First- line treatment duration (FOLFIRI, FOLFOX with anti-EGFR monoclonal antibody, of whom at least 2/3 of cases will have involved panitumumab) of at least 3 months, - Second line therapy consisting of any chemotherapy (with or without Bevacizumab) definitely without anti-EGFR therapy of at least 2 months, followed by disease progression, - Eligible third line regimens include FOLFIRI or Irinotecan or FOLFOX, according to standard practice and approved indications.",ct_inc_340555,AACT,473,NCT03311750,Recent,FOLFOX
5c7430438625dd0308867f89,680,,,347,Patient,13:23.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_555252,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients must have metastatic colorectal cancer that has been histologically or cytologically confirmed; confirmation may be from either the primary tumor or a metastasis; patients must have wild type KRAS - Patients must be registered within 28 days of documented disease progression on first line chemotherapy with bevacizumab plus either FOLFOX, OPTIMOX, or XELOX; this progression must have occurred within 90 days after the last dose of bevacizumab; patients who discontinued oxaliplatin, continued with 5-FU/LV or capecitabine and bevacizumab and then had subsequent progression while on fluoropyrimidine and bevacizumab are eligible; patients who discontinued bevacizumab due to adverse events in the first-line setting are not eligible - Measurable or nonmeasurable disease - At least 14 days must have elapsed since the last dose of first line chemotherapy and bevacizumab - Patients must not have received prior treatment with irinotecan (either as adjuvant or metastatic treatment) - Patients must have no history of prior treatment with cetuximab or other agents targeting VEGF or EGFR (except for bevacizumab) - Prior radiotherapy is allowed, provided at least 28 days have elapsed since the last treatment; all adverse events related to radiation therapy must be resolved - Prior surgery is allowed, provided at least 28 days have elapsed since any major surgery and patient has recovered from all effects - Zubrod performance status 0-2 - Absolute neutrophil count (ANC) >= 1,500/mm^3 - Platelet count >= 100,000/mm^3 - Hemoglobin >",ct_inc_555252,AACT,341,NCT00499369,Historical,FOLFOX
5c7430438625dd033f867f87,310,,,338,Patient,13:24.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_568959,Clinical Trial Inclusion Criteria,UNKNOWN,- Histologically confirmed adenocarcinoma of the colon or rectum - Stage II disease - Stage III disease - Stage IV disease (completely resected with no evidence of residual tumor) - Must have undergone curative resection for stage II or III disease - Sche,ct_inc_568959,AACT,332,NCT00316914,Recent,FOLFOX
5c7430438625dd033f867f88,310,,,179,Patient,13:24.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_568959,Clinical Trial Inclusion Criteria,UNKNOWN,"No prior treatment with neurotoxic chemotherapy such as oxaliplatin, cisplatin, taxanes, or vinca alkaloids - Concurrent use of bevacizumab or cetuximab in combination with FOLFOX as part of a clinical trial or clinical practice are allowed -",ct_inc_568959,AACT,173,NCT00316914,Historical,FOLFOX
5c7430448625dd033f867f89,310,,,49,Patient,13:24.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_442902,Clinical Trial Inclusion Criteria,UNKNOWN,5-fluorouracil/leucovorin with oxaliplatin(FOLFOX) or XELOX.A treatment with trastuzumab is allowed in association.-,ct_inc_442902,AACT,43,NCT01977053,Recent,FOLFOX
5c7430448625dd033f867f90,310,,,389,Patient,13:24.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_438969,Clinical Trial Exclusion Criteria,UNKNOWN,"Any other medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent Phase II Specific Exclusion Criteria: - Progression on first line therapy - A complete response on first line therapy - Use of first line therapy for longer than 4 months - Use of any first line treatment with a chemotherapy regimen other than FOLFOX, FOLFIRI or CAPOX (each with or without bevacizumab) - More than 6 weeks since the last administration of 5 FU, capecitabine, oxaliplatin or irinotecan",ct_exc_438969,AACT,383,NCT02028442,Recent,FOLFOX
5c7430458625dd033f867f92,310,,,134,Patient,13:25.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_458326,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - - Patients affected by gastrointestinal cancer, without cytotoxic neurotoxic chemotherapy, had to receive FOLFOX 4 chemotherapy (folinic acid + 5-FU + oxaliplatin) in the adjuvant, neoadjuvant or palliative situation with an expected period of 8 cures of treatment or 4 months.- Patients having given their written, free and informed consent - Patient's members of a social security scheme - Patients not having participated in another clinical trial within 15 days before its baseline (possibility of participating and / or participate in an observational trial) -",ct_inc_458326,AACT,128,NCT01775449,Recent,FOLFOX
5c7430458625dd0355867f88,160,,,33,Patient,13:25.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_356855,Clinical Trial Inclusion Criteria,UNKNOWN,"Prior regimens may include FOLFOX -/+ bevacizumab, FOLFIRI -/+ bevacizumab or -/+ cetuximab (if KRAS wild-type) or panitumumab (if KRAS wilt-type).Other prior regimens may include 5-FU or capecitabine -/+ bevacizumab, irinotecan -/+ cetuximab or panitumumab, FOLFIRI -/+ ziv-aflibercept or ramucirumab.",ct_inc_356855,AACT,27,NCT03099486,Historical,FOLFOX
5c7430478625dd036b867f85,190,,,6,Patient,13:27.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_374899,Clinical Trial Inclusion Criteria,UNKNOWN,FOLFOX +/-,ct_inc_374899,AACT,0,NCT02864485,Recent,FOLFOX
5c7430488625dd034a867f8f,650,,,23,Patient,13:28.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_422753,Clinical Trial Inclusion Criteria,COMMENT,"prior XELOX, XP, FOLFOX, or SP (S-1+cisplatin)) treatment could be eligible, but prior-taxane are ineligible.",ct_inc_422753,AACT,17,NCT02240212,Historical,FOLFOX
5c7430488625dd034a867f91,650,,,47,Patient,13:28.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_398662,Clinical Trial Inclusion Criteria,AGE,Will receive neoadjuvant treatment using Folfox or chemoradiotherapy .,ct_inc_398662,AACT,41,NCT02554448,Recent,Folfox
5c7430488625dd036b867f88,190,,,445,Patient,13:28.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_461817,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically confirmed colorectal cancer - Evaluable or measurable radiographic evidence of colorectal cancer - Patients with unresected metastases from colorectal cancer; patients may be either untreated with chemotherapy or currently receiving first-line 5-FU based chemotherapy (folinic acid-fluorouracil-irinotecan hydrochloride [FOLFIRI], capecitabine-irinotecan hydrochloride [CAPIRI], fluorouracil-leucovorin calcium-oxaliplatin [FOLFOX], or capecitabine-oxaliplatin [CAPOX] with or without bevacizumab) within 10 months of beginning ADAPT therapy with at least stable disease radiographically; patients who received prior adjuvant chemotherapy with 5-FU, capecitabine, or FOLFOX are eligible if adjuvant therapy was completed greater than 6 months ago - History of histological confirmation for recurrent disease, or if recurrent disease is not readily accessible to biopsy, must have two consecutive carcinoembryonic antigen (CEA) or cancer antigen (CA) 19-9 increases, or positron emission tomography (PET) avidity - Men and women from all ethnic and racial groups - Eastern Cooperative Oncology Group (ECOG) performance status =< 2 - Total bilirubin",ct_inc_461817,AACT,439,NCT01729923,Hypothetical,FOLFOX
5c7430498625dd036b867f8b,190,,,111,Patient,13:29.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_454730,Clinical Trial Inclusion Criteria,UNKNOWN,"Planned combination bevacizumab (bvz) treatment with either: - leucovorin, fluorouracil and oxaliplatin (FOLFOX) - capecitabine and oxaliplatin (XELOX) - leucovorin, fluorouracil and irinotecan (FOLFIRI) - capecitabine and irinotecan (XELIRI) Naive for bvz",ct_inc_454730,AACT,105,NCT01822444,Recent,FOLFOX
5c7430498625dd0355867f96,160,,,52,Patient,13:29.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_518643,Clinical Trial Inclusion Criteria,UNKNOWN,Scheduled to receive first-line chemotherapy (FOLFOX/bevacizumab or FOLFIRI/bevacizumab) for metastatic disease.,ct_inc_518643,AACT,46,NCT00984048,Recent,FOLFOX
5c7430498625dd0355867f99,160,,,116,Patient,13:29.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_511552,Clinical Trial Inclusion Criteria,UNKNOWN,- No more than 8 weeks between 1st-line treatment with FOLFIRI + Avastin and 2nd-line treatment with XELOX or FOLFOX + Avastin,ct_inc_511552,AACT,110,NCT01077739,Recent,FOLFOX
5c7430498625dd036b867f8f,190,,,6,Patient,13:29.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_527450,Clinical Trial Inclusion Criteria,UNKNOWN,"FOLFOX, FOLFIRI, XELOX, or XELIRI.- Documentation of wild type k-Ras expression in the liver",ct_inc_527450,AACT,0,NCT00867334,Recent,FOLFOX
5c74304a8625dd0376867f86,940,,,144,Patient,13:30.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_407659,Clinical Trial Inclusion Criteria,UNKNOWN,"Such therapies should include regimens containing oxaliplatin and irinotecan in combination with a fluoropyrimidine if appropriate (e.g., FOLFOX and FOLFIRI or their variants).-",ct_inc_407659,AACT,138,NCT02437071,Recent,FOLFOX
5c74304a8625dd0381867f8c,230,,,61,Patient,13:30.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_556746,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Patients eligible for FOLFIRI or FOLFOX therapy - ECOG performance status score 0-1,ct_inc_556746,AACT,55,NCT00479583,Recent,FOLFOX
5c74304a8625dd0381867f8d,230,,,38,Patient,13:30.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_556746,Clinical Trial Inclusion Criteria,UNKNOWN,No maximum age for Study Arm A (FOLFOX) - 18-65 years of age for Study Arm B (FOLFIRI),ct_inc_556746,AACT,32,NCT00479583,Recent,FOLFOX
5c74304a8625dd0381867f8f,230,,,79,Patient,13:30.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_393267,Clinical Trial Inclusion Criteria,UNKNOWN,RAS wild-type metastatic colorectal cancer patients candidate to receive FOLFOX or FOLFIRI plus panitumumab or FOLFOX or FOLFIRI plus cetuximab as upfront treatment as per clinical practice - Willingness and ability to comply with the protocol - Written informed consent to study procedures -,ct_inc_393267,AACT,73,NCT02624895,Recent,FOLFOX
5c74304a8625dd0376867f88,940,,,90,Patient,13:30.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_423126,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically confirmed stage IV colorectal adenocarcinoma previously treated with FOLFOX and FOLFIRI and bevacizumab, receipt of cetuximab or panitumumab is not required, and has shown progression or intolerant of both oxaliplatin and irinotecanbased regimens; baseline tumor assessments must be done within 28 days of starting treatment - Patients must have lesions that can be easily biopsied - Representative tumor tissue specimens (paraffin block preferred) - Signed informed consent prior to initiation of any studyspecific procedure or treatment, including agreement to two biopsies during the study - Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 - Able to comply with the protocol, including tissue and blood sampling - Leukocytes >= 3,000 per mm^3 - Absolute neutrophil count >",ct_inc_423126,AACT,84,NCT02235324,Historical,FOLFOX
5c74304b8625dd0376867f89,940,,,24,Patient,13:31.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_437699,Clinical Trial Exclusion Criteria,UNKNOWN,Previous adjuvant FOLFOX based chemotherapy is allowed.,ct_exc_437699,AACT,18,NCT02045030,Recent,FOLFOX
5c74304c8625dd0376867f8c,940,,,815,Patient,13:32.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_554890,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Histologically or cytologically confirmed colorectal cancer - Metastatic disease - Not curable by surgical resection - Archival tumor tissue available - Measurable disease, defined as at least one unidimensionally measurable lesion 20 mm by conventional techniques or 10 mm by spiral CT scan - Measurable disease must be outside of a prior radiation port - Documented disease progression either during or after prior chemotherapy treatment - No more than 2 prior chemotherapy regimens in the adjuvant or metastatic setting - Prior chemotherapy regimens must have contained a fluoropyrimidine (e.g., fluorouracil or capecitabine), oxaliplatin, and irinotecan - Patients who received no prior adjuvant therapy must have received 2 prior chemotherapy regimens for metastatic disease (e.g., FOLFOX followed by FOLFIRI) - Patients who received prior adjuvant therapy with a fluoropyrimidine plus oxaliplatin must have received no more than 1 chemotherapy regimen for metastatic disease that must have contained irinotecan - VEGF or EGFR inhibitors with prior chemotherapy allowed - No known brain metastases - Life expectancy > 3 months - ECOG performance status (PS) 0-2 or Karnofsky PS 60% - WBC",ct_inc_554890,AACT,809,NCT00504153,Historical,FOLFOX
5c74304e8625dd0397867f86,1090,,,271,Patient,13:34.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_408532,Clinical Trial Inclusion Criteria,UNKNOWN,"A signed informed consent form must be appropriately obtained prior to the conduct of any trial-specific procedure.- Age 18 years.- Stage IIIC colorectal cancer (T4a, N2a, M0) or (T3-4a, N2b, M0), or (T4b, N1- N2, M0) (per AJCC 7th ed).- Must have started adjuvant FOLFOX chemotherapy within 8 weeks of resection for colorectal carcinoma - CT scan that demonstrates no evidence of disease (NED) after completion of adjuvant therapy",ct_inc_408532,AACT,265,NCT02425683,Historical,FOLFOX
5c74304e8625dd0397867f87,1090,,,69,Patient,13:34.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_408532,Clinical Trial Inclusion Criteria,COMMENT,"This CT scan will also be used for Texture analysis.- Received FOLFOX within 6 weeks before starting regorafenib - Eastern Cooperative Oncology Group (ECOG) performance status 0-1 - Life expectancy of at least 12 weeks (3 months).- Complete Metabolic Profile (CMP) within normal limits - Adequate bone marrow, liver, and renal function as assessed by the following laboratory requirements:",ct_inc_408532,AACT,63,NCT02425683,Recent,FOLFOX
5c7430518625dd03ad867f85,590,,,77,Patient,13:37.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_336681,Clinical Trial Inclusion Criteria,UNKNOWN,"Tumor stage will not affect eligibility.- Subjects must be receiving a FOLFOX-based chemotherapy regimen, containing 5-fluorouracil and oxaliplatin, on a 14-day schedule.",ct_inc_336681,AACT,71,NCT03362177,Recent,FOLFOX
5c7430518625dd03ad867f87,590,,,15,Patient,13:37.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_336681,Clinical Trial Inclusion Criteria,COMMENT,Use of a FOLFOX-based combination regimen is permitted with (1) anti-angiogenic agents (such as bevacizumab) or (2) targeted therapy (such as anti-epidermal growth factor receptor agents).FOLFOXIRI-based regimens will not be allowed.- Subjects must have a platelet count < 75 x 109/L on study day,ct_inc_336681,AACT,9,NCT03362177,Recent,FOLFOX
5c7430548625dd03c7867fae,0,,,110,Patient,13:40.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_567491,Clinical Trial Inclusion Criteria,UNKNOWN,Histologically proven adenocarcinoma of the colon or rectum planned to receive a minimum of 2 cycles of FOLFOX +/-,ct_inc_567491,AACT,104,NCT00336609,Recent,FOLFOX
5c7430548625dd03c7867faf,0,,,55,Patient,13:40.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_567491,Clinical Trial Inclusion Criteria,UNKNOWN,Avastin or Erbitux.1 cycle defined as 2 doses of FOLFOX.,ct_inc_567491,AACT,49,NCT00336609,Recent,FOLFOX
5c7430548625dd03b8867f8d,430,,,142,Patient,13:41.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_390264,Clinical Trial Inclusion Criteria,UNKNOWN,"The patient must be able to swallow oral medication.- The patient must have completed at least 4 months of adjuvant chemotherapy (i.e., FOLFOX, CapeOx, or other, such as 5-fluorouracil, leucovorin, oxaliplatin (FLOX), 5-fluorouracil/leucovorin (5FU/LV), capecitabine).- The interval between completion of standard adjuvant chemotherapy and randomization must be less than or equal to 60 days.- Blood counts performed within 28 days prior to randomization must meet the following criteria: - Absolute neutrophil count (ANC) must be greater than or equal to 1500/mm3; - platelet count must be greater than or equal to 100,000/mm3; and - hemoglobin must be greater than or equal to 9 g/dL.-",ct_inc_390264,AACT,136,NCT02664077,Historical,FOLFOX
5c7430598625dd0426867f84,660,,,95,Patient,13:45.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_324925,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Diagnosed stage II to IV colorectal cancer; - Scheduled to receive FOLFOX; - Receiving care at the UM Multidisciplinary Colorectal Cancer Clinic in Ann Arbor or SJ in Ann Arbor;,ct_inc_324925,AACT,89,NCT03515356,Recent,FOLFOX
5c7430598625dd0426867f85,660,,,166,Patient,13:45.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_578318,Clinical Trial Inclusion Criteria,UNKNOWN,Radiation must be completed at least 4 weeks prior to study enrollment.- Performance status 0 to 2 - Patient must have received 1 prior course of chemotherapy (Folfox regimen) for metastatic disease,ct_inc_578318,AACT,160,NCT00191984,Historical,Folfox
5c7430598625dd0426867f86,660,,,166,Patient,13:45.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_508608,Clinical Trial Inclusion Criteria,UNKNOWN,Current failure of 1st line anti-cancer therapy with an oxaliplatin and bevacizumab based regimen or patients relapsing within 12 months of completing adjuvant FOLFOX .,ct_inc_508608,AACT,160,NCT01116271,Recent,FOLFOX
5c74305a8625dd0411867f89,300,,,208,Patient,13:46.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_441653,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically proven solid organ cancer - Eastern Cooperative Oncology Group Performance status 0-2 - More than 3 months for life expectancy - Patients scheduled to receive the first line, first cycle FOLFOX (5-FU, Oxaliplatin, Leucovorin) or FOLFIRI (5-FU, Irinotecan, Leucovorin)",ct_inc_441653,AACT,202,NCT01993381,Recent,FOLFOX
5c74305a8625dd0411867f8b,300,,,394,Patient,13:46.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_495161,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Patients aged under 18 - Patients taking immunosuppressive therapy - Patient having a severe skin disease - No measurable metastasis - Patients with a contra-indication of cetuximab: hypersensitivity to cetuximab or to any excipients - Severe alteration of respiratory or cardiac function or severe coronary disease - Patients with contra-indication to chemotherapy FOLFOX and FOLFIRI - Participation in another research protocol - Patients not affiliated to the Social Security - Hospitalized patients without consent - Pregnant or nursing women, women of childbearing age with no effective contraception",ct_exc_495161,AACT,388,NCT01292356,Recent,FOLFOX
5c74305b8625dd0411867f8e,300,,,95,Patient,13:47.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_411196,Clinical Trial Inclusion Criteria,COMMENT,"A.When adjuvant therapy including oxaliplatin was previously used, at least 9 courses of FOLFOX (2 weeks regimens), 6 courses of CapeOX (3 week regimen), or 750mg/m^2 cumulative consumption of oxaliplatin, are required.",ct_inc_411196,AACT,89,NCT02390947,Recent,FOLFOX
5c74305d8625dd0447867f89,250,,,398,Patient,13:49.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_493009,Clinical Trial Inclusion Criteria,UNKNOWN,Patients must have a Karnofsky performance status of >= 60% - Patients must have histological confirmation of colorectal carcinoma - Patients must have colorectal tumors that produce carcinoembryonic antigen (CEA) as documented by either immunohistochemistry or by an elevated serum CEA - Patients will be enrolled on this trial after resection of hepatic metastases combined with FOLFIRI or FOLFOX [+/-,ct_inc_493009,AACT,392,NCT01320683,Recent,FOLFOX
5c74305d8625dd0447867f8a,250,,,94,Patient,13:49.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_493009,Clinical Trial Inclusion Criteria,UNKNOWN,"Bevacizumab], or XELOX; patients may have received a maximum of 12 cycles of FOLFIRI or FOLFOX [+/-",ct_inc_493009,AACT,88,NCT01320683,Recent,FOLFOX
5c7430608625dd0457867f9f,70,,,149,Patient,13:52.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_522368,Clinical Trial Exclusion Criteria,UNKNOWN,"Adjuvant chemotherapy for Colorectal Cancer (Stage I, II, II) is permitted, if the adjuvant therapy ended >6 month before screening.- Previous FOLFOX treatment for patients who will be included in the mFOLFOX6 cohort apart from FOLFOX treatment in an adjuvant setting.- Previous FOLFIRI treatment for patients who will be included in the FOLFIRI cohort.",ct_exc_522368,AACT,143,NCT00934882,Recent,FOLFOX
5c7430638625dd047e867f89,910,,,112,Patient,13:55.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_572785,Clinical Trial Inclusion Criteria,UNKNOWN,Patients with Gilbert's Syndrome or who are found to be homozygous for the UGT1A1 allele who will receive FOLFOX are eligible.,ct_inc_572785,AACT,106,NCT00265850,Recent,FOLFOX
5c7430638625dd047e867f8a,910,,,94,Patient,13:55.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_572785,Clinical Trial Inclusion Criteria,UNKNOWN,No sensory peripheral neuropathy of grade 2 at baseline for patients who are to receive FOLFOX.,ct_inc_572785,AACT,88,NCT00265850,Recent,FOLFOX
5c7430648625dd048d867f89,1200,,,6,Patient,13:57.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_389185,Clinical Trial Inclusion Criteria,UNKNOWN,"FOLFOX they should have received 8 cycles.- Disease which, following first-line chemotherapy, remains inoperable and unsuitable for definitive chemoradiotherapy.- Able to proceed with maintenance treatment within 28 days of the last day of the last cycle of chemotherapy.- Formalin fixed paraffin embedded (FFPE) blocks of diagnostic tissue available for biomarker analysis.-",ct_inc_389185,AACT,0,NCT02678182,Recent,FOLFOX
5c7430658625dd048d867f8c,1200,,,23,Patient,13:57.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_324880,Clinical Trial Inclusion Criteria,PAST_SURGICAL_HISTORY,Either CAPEOX or FOLFOX is allowed.,ct_inc_324880,AACT,17,NCT03515941,Recent,FOLFOX
5c7430658625dd048d867f8d,1200,,,522,Patient,13:57.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_558025,Clinical Trial Inclusion Criteria,UNKNOWN,"No bulky N2 disease by either ERUS or MRI - No primary fixed or unresectable (clinical stage T4) rectal cancer or recurrent colorectal cancer limited to the pelvis - Primary unresectable rectal cancer is defined as a primary rectal tumor which on the basis of either physical exam, ERUS or pelvic MRI is deemed to be adherent or fixed to adjacent pelvic structures - Must be a candidate for all of the following: - Neoadjuvant chemoradiotherapy - Systemic therapy with fluorouracil, leucovorin calcium, oxaliplatin (FOLFOX), and bevacizumab - Complete surgical resection via low anterior resection prior to administration of any therapy - No low-lying tumors deemed to require an abdominal perineal resection - No large or bulky tumors that require a diverting colostomy or placement of an endorectal stent prior to treatment initiation - No clinical evidence of metastatic disease",ct_inc_558025,AACT,516,NCT00462501,Historical,FOLFOX
5c7430688625dd04c0867f95,30,,,590,Patient,14:00.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_418456,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically proven diagnosis of colorectal adenocarcinoma; - RAS and BRAF wild-type status; - First-line irinotecan-based (FOLFIRI or FOLFOXIRI) cetuximab-containing therapy producing at least a partial response; - First-line progression-free survival in response to cetuximab-containing therapy 6 months; - Documentation of progression to first-line cetuximab within 4 weeks after last cetuximab administration; - Time between the end of first-line therapy and the start of third-line treatment with cetuximab plus irinotecan 4 months; - Second-line oxaliplatin-based (FOLFOXIRI, FOLFOX or XELOX) bevacizumab-containing therapy; - Documentation of progression to second-line treatment; - Measurable disease according to RECIST criteria v1.1; - Have tumor tissue (of primary tumor and metastases or at least one of the two) available for biomarker analysis; - Male or female patients > 18 years of age; - ECOG Performance Status 2; - Life expectancy of at least 3 months; - Adequate bone marrow, liver and renal function assessed within 14 days before starting study treatment; - Women of childbearing potential must have a negative blood pregnancy test at the baseline visit.",ct_inc_418456,AACT,584,NCT02296203,Recent,FOLFOX
5c7430688625dd04cb867f87,260,,,74,Patient,14:00.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_564110,Clinical Trial Inclusion Criteria,UNKNOWN,"- Scheduled to receive 1 of the following chemotherapy regimens*: - FOLFOX 4 (oxaliplatin, fluorouracil, leucovorin calcium) - FOLFOX 6 - FOLFOX 7 - FOLFIRI (irinotecan hydrochloride, fluorouracil, leucovorin calcium)",ct_inc_564110,AACT,68,NCT00381862,Recent,FOLFOX
5c7430688625dd049f867f8a,960,,,51,Patient,14:00.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_494395,Clinical Trial Exclusion Criteria,UNKNOWN,"In Phase 1b, patients with a history of poor FOLFOX tolerability as manifested by inability to tolerate standard therapeutic doses (i.e., at minimum patients must have tolerated an oxaliplatin dose of 85 mg/m2 and a 5FU dose of 2400 mg/m2).",ct_exc_494395,AACT,45,NCT01302405,Historical,FOLFOX
5c7430688625dd049f867f8b,960,,,67,Patient,14:00.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_494395,Clinical Trial Exclusion Criteria,COMMENT,"Patients are eligible for this trial if, during the previous FOLFOX administration, they underwent one dose reduction of oxaliplatin due to sensory neuropathy (provided the neuropathy has now resolved to Grade 1 or less),",ct_exc_494395,AACT,61,NCT01302405,Hypothetical,FOLFOX
5c7430698625dd04cb867f8f,260,,,73,Patient,14:01.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_546753,Clinical Trial Inclusion Criteria,UNKNOWN,"Received 6 cycles (3 months [12 weeks]) of first-line therapy with FOLFOX or FOLFIRI, plus bevacizumab for metastatic CRC.Patients",ct_inc_546753,AACT,67,NCT00612586,Recent,FOLFOX
5c7430698625dd04cb867f90,260,,,64,Patient,14:01.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_546753,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients who received 6 cycles of first-line therapy with FOLFOX or FOLFIRI, plus bevacizumab for recurrent CRC that has relapsed at least 12 months after completion of adjuvant therapy will also be included.",ct_inc_546753,AACT,58,NCT00612586,Recent,FOLFOX
5c7430698625dd04cb867f91,260,,,19,Patient,14:01.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_546753,Clinical Trial Inclusion Criteria,UNKNOWN,"All standard FOLFOX ( or FOLFIRI) regimens given on a biweekly schedule will be permitted; however, 21-day regimens will not be allowed.-",ct_inc_546753,AACT,13,NCT00612586,Recent,FOLFOX
5c7430698625dd04c0867f9f,30,,,101,Patient,14:01.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_441288,Clinical Trial Inclusion Criteria,UNKNOWN,"IV colorectal cancer - Scheduled for treatment with first line chemotherapy, either CAPOX(-B), FOLFOX(-B) or capecitabine(-B) -",ct_inc_441288,AACT,95,NCT01998152,Recent,FOLFOX
5c74306c8625dd04d6867f8d,890,,,567,Patient,14:04.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_542250,Clinical Trial Exclusion Criteria,UNKNOWN,"Other tumour types than colon adenocarcinomas Current severe neutropenia, leucopenia or thrombocytopenia Severely reduced liver or renal function Unresolved bowel obstruction or sub-obstruction, uncontrolled Crohn's disease or ulcerative colitis Current chronic diarrhoea Contraindication for corticosteroid administration History of prior serious allergic or pseudo-allergic reaction Any other serious illness or medical condition Symptomatic peripheral neuropathy grade 2 Received mangafodipir 5 weeks before planned start of chemotherapy Received any of the FOLFOX drugs 5 weeks before planned start of chemotherapy Any plans of administered other anti-cancer therapy (including radiotherapy) concurrent with this study Fertile females Males with reproductive potential not implementing adequate contraception measures Phaeochromocytoma",ct_exc_542250,AACT,561,NCT00671996,Historical,FOLFOX
5c74306d8625dd04d6867f8e,890,,,189,Patient,14:05.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_552346,Clinical Trial Exclusion Criteria,UNKNOWN,Near-obstructing or obstructing colon lesions in patients in whom combined resection is planned (as delay for preoperative chemotherapy would be medially impossible) - Treatment with FOLFOX or cetuximab within 12 months - Treatment with irinotecan within 12 months -,ct_exc_552346,AACT,183,NCT00537823,Recent,FOLFOX
5c74306d8625dd04d6867f8f,890,,,51,Patient,14:05.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_411665,Clinical Trial Inclusion Criteria,UNKNOWN,Patients who are feasible for treatment with FOLFOX (prior adjuvant or palliative treatment is allowed),ct_inc_411665,AACT,45,NCT02384850,Recent,FOLFOX
5c74306d8625dd04f7867f87,550,,,65,Patient,14:05.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_423369,Clinical Trial Inclusion Criteria,UNKNOWN,"that is not resectable - Have failed or have not tolerated FOLFOX, FOLFIRI and, if KRAS wild type, then a EGFR inhibitor-based regimen - Eastern Cooperative Oncology Group (ECOG) performance status being 0-2 - Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use accepted contraceptive methods (abstinence, intrauterine device [IUD], oral contraceptive or double barrier device) during the study, and must have a negative serum or urine pregnancy test within 1 week prior to treatment initiation - Fertile men must practice effective contraceptive methods during the study, unless documentation of infertility exists - At least 2 weeks must have elapsed from any prior surgery - Granulocyte count >= 1500/mm^3 - White blood cell (WBC) >= 3500 cells/mm^3 or >= 3.5 bil/L - Platelet count >",ct_inc_423369,AACT,59,NCT02232152,Hypothetical,FOLFOX
5c74306d8625dd04f7867f89,550,,,317,Patient,14:05.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_460966,Clinical Trial Inclusion Criteria,UNKNOWN,"At least one liver lesion able to be visualized by ultrasound and determined to be safely assessable for percutaneous cryoablation Previous treatment failure of at 2 previous lines of active systemic chemotherapy for metastatic disease: - Previous chemotherapy must have included one line with oxaliplatin (e.g.FOLFOX) and a previous second line with irinotecan (e.g.FOLFIRI) with or without bevacizumab - If KRAS wild type, at least one anti-EGFR therapy in first or second line - Treatment failure can be due to disease progression or toxicity - Disease progression on 2nd line therapy must be documented radiologically and have occurred during or within 30 days following the last administration of 2nd line chemotherapy 7.",ct_inc_460966,AACT,311,NCT01741038,Hypothetical,FOLFOX
5c74306d8625dd04d6867f90,890,,,27,Patient,14:05.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_430746,Clinical Trial Exclusion Criteria,UNKNOWN,Contraindications to FOLFOX,ct_exc_430746,AACT,21,NCT02135887,Recent,FOLFOX
5c74306d8625dd04f7867f8b,550,,,80,Patient,14:05.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_538670,Clinical Trial Inclusion Criteria,LABORATORY_AND_RADIOLOGY_DATA,Preferred patients are those who have progressed on first line FOLFIRI or FOLFOX with or without bevacizumab.,ct_inc_538670,AACT,74,NCT00719199,Recent,FOLFOX
5c74306d8625dd04fb867f84,1030,,,265,Patient,14:05.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_435005,Clinical Trial Exclusion Criteria,UNKNOWN,that in the investigators opinion would put the patient at risk if re-exposed Preexisting neuropathy Patients with serious medical risk factors involving any of the major organ systems such that the investigator considers it unsafe for the patient to receive FOLFOX-A Patients with unstable biliary stents or with plastic stents.,ct_exc_435005,AACT,259,NCT02080221,Hypothetical,FOLFOX
5c74306e8625dd04fb867f85,1030,,,257,Patient,14:06.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_334382,Clinical Trial Inclusion Criteria,AGE,"18-70 years old, sex is not restricted; Pathologically diagnosed as gastric adenocarcinoma or gastroesophageal junction adenocarcinoma; did not receive neoadjuvant chemotherapy or radiotherapy before surgery;received the 2-3 cycles of chemotherapy of FOLFOX regimens or 1-2 cycles of XeLOX or SOX regimens after operation;",ct_inc_334382,AACT,251,NCT03392103,Recent,FOLFOX
5c74306e8625dd04fb867f87,1030,,,64,Patient,14:06.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_322344,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria: Patients with contraindication to use FOLFOX chemotherapy and pelvic radiation.,ct_exc_322344,AACT,58,NCT03548961,Recent,FOLFOX
5c74306e8625dd04fb867f88,1030,,,290,Patient,14:06.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_561345,Clinical Trial Inclusion Criteria,UNKNOWN,Patients must be receiving moderately emetogenic chemotherapy for the first time with one of the following neoplasms/regimens: - Non-small cell lung cancer receiving paclitaxel and carboplatin - Breast cancer receiving cyclophosphamide and doxorubicin - Colorectal cancer receiving a FOLFOX regimen .,ct_inc_561345,AACT,284,NCT00418678,Recent,FOLFOX
5c74306e8625dd04fb867f89,1030,,,286,Patient,14:06.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_473128,Clinical Trial Exclusion Criteria,UNKNOWN,"Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with TheraSpheres, breastfeeding should be discontinued if the mother is treated with TheraSpheres.- Initiation of second-line chemotherapy not consisting of FOLFOX - Patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy.",ct_exc_473128,AACT,280,NCT01581307,Recent,FOLFOX
5c74306e8625dd04fb867f8a,1030,,,249,Patient,14:06.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_460711,Clinical Trial Inclusion Criteria,UNKNOWN,Laparoscopy and central venous catheter placement are not considered major surgery.- Patients with serious medical risk factors involving any of the major organ systems such that the investigator considers it unsafe for the patient to receive FOLFOX-A - Preexisting neuropathy > grade 1.- No prior invasive malignancy within the prior two years.,ct_inc_460711,AACT,243,NCT01744353,Historical,FOLFOX
5c74306e8625dd04fb867f8b,1030,,,103,Patient,14:06.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_526127,Clinical Trial Inclusion Criteria,UNKNOWN,- Histologically confirmed colorectal cancer - Requires treatment with oxaliplatin (as part of a FOLFOX regimen) -,ct_inc_526127,AACT,97,NCT00884767,Recent,FOLFOX
5c74306e8625dd04fb867f8c,1030,,,169,Patient,14:07.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_475479,Clinical Trial Inclusion Criteria,UNKNOWN,IV disease).- Patients must have progressed on one or more prior chemotherapy treatment regimens including at least one trial of a 5-FU/oxaliplatin based therapy (FOLFOX) in combination with bevacizumab.,ct_inc_475479,AACT,163,NCT01550510,Historical,FOLFOX
5c7430718625dd0518867f96,100,,,460,Patient,14:09.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_318198,Clinical Trial Inclusion Criteria,UNKNOWN,"Patient Inclusion Criteria: - Self-identify as Hispanic/Latino - Has been diagnosed with metastatic colorectal cancer (mCRC) OR locally advanced pancreatic cancer (LAPC) OR metastatic pancreatic cancer (mPC) AND is making a decision regarding treatment with 1st line palliative chemotherapy - Treating oncologist has recommended consideration of one or more of the regimens for which we have developed chemotherapy educational (CEI) toolkits - For mCRC: FOLFOX, FOLFOX + bevacizumab, FOLFIRI, FOLFIRI + bevacizumab - For LAPC or mPC: FOLFIRINOX, Gemcitabine, or Gemcitabine + nab-paclitaxel - Patients who are also considering treatment on a clinical trial of one of these regimens +/-",ct_inc_318198,AACT,454,NCT03602885,Recent,FOLFOX
5c7430718625dd0544867f88,280,,,189,Patient,14:09.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_495161,Clinical Trial Inclusion Criteria,UNKNOWN,Patients older than 18 years - Patient with histologically proven metastatic colorectal cancer with KRAS wild-type - Treatment with cetuximab in first line chemotherapy combined with FOLFOX or FOLFIRI - Patient has signed informed consent - Patient affiliated to the Social Security - Prescription of cetuximab in agreement with the Summary of Product Characteristics,ct_inc_495161,AACT,183,NCT01292356,Recent,FOLFOX
5c7430718625dd0544867f89,280,,,158,Patient,14:09.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_556815,Clinical Trial Inclusion Criteria,UNKNOWN, of CRC diagnosis by histological or cytological specimen from original resection of primary tumor.- Patients who progressed despite prior therapy with FOLFOX (5FU and oxaliplatin) plus bevacizumab or XELOX (capecitabine and oxaliplatin) plus bevacizumab.- Patients with at least one measurable lesion by RECIST as determined by Computer Tomography,ct_inc_556815,AACT,152,NCT00478634,Historical,FOLFOX
5c7430718625dd0544867f8b,280,,,119,Patient,14:09.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_371902,Clinical Trial Inclusion Criteria,UNKNOWN,"-2 - At least one measurable or evaluable lesion in the first-line chemotherapy (5-FU based regimen: ECF/EOF/EOX/FOLFOX/XELOX) with the efficacy evaluation of non-PD - Adequate hepatic,renal,heart, and hematologic functions (platelets 75109/L, neutrophil1",ct_inc_371902,AACT,113,NCT02903498,Recent,FOLFOX
5c7430718625dd0544867f8d,280,,,332,Patient,14:09.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_369428,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - aged 18-70 years with histologically or cytologically confirmed advanced colorectal adenocarcinoma - Eastern Cooperative Oncology Group performance status of 0 to 2 - life expectancy of 3 months - patients who had failed first-line treatment with either XELOX (capecitabine combined with oxaliplatin) or FOLFOX (5-fluorouracil/leucovorin with oxaliplatin) - at least one measurable disease lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria -,ct_inc_369428,AACT,326,NCT02935764,Recent,FOLFOX
5c7430718625dd0544867f8f,280,,,76,Patient,14:10.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_491220,Clinical Trial Inclusion Criteria,GENDER,"Not specified - Patients with colon/rectal cancer who first underwent FOLFOX, XELOX or SOX regimen including oxaliplatin at 85 mg/m2 (naive patient), or those who had already started chemotherapy and had nausea of Grade 2 or higher in the last course or an earlier course (non-naive patient).- Stage: not specified (neoadjuvant/adjuvant chemotherapy, advanced or recurrent type are allowed) - Combination of molecular targeted therapy: allowable - Written informed consent for participation in the study.",ct_inc_491220,AACT,70,NCT01344304,Recent,FOLFOX
5c7430728625dd0544867f91,280,,,332,Patient,14:10.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_412310,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - aged 18-70 years with histologically or cytologically confirmed advanced colorectal adenocarcinoma - Eastern Cooperative Oncology Group performance status of 0 to 1 - life expectancy of 3 months - patients who had failed first-line treatment with either XELOX (capecitabine combined with oxaliplatin) or FOLFOX (5-fluorouracil/leucovorin with oxaliplatin) - at least one measurable disease lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria -,ct_inc_412310,AACT,326,NCT02376452,Recent,FOLFOX
5c7430758625dd054f867f8f,340,,,77,Patient,14:13.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_444456,Clinical Trial Inclusion Criteria,UNKNOWN,"first line palliative treatment with cytotoxic agents will be started (Folfox, Xelox, capecitabine, paclitaxel or docetaxel)",ct_inc_444456,AACT,71,NCT01956747,Recent,Folfox
5c7430768625dd0574867f84,270,,,256,Patient,14:14.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_377562,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Patients with Colorectal cancer with a resected minimal synchronous peritoneal carcinomatosis, or ovarian metastases, tumour rupture in the abdominal cavity.- Patients received six months of systemic chemotherapy (currently the Folfox-4 regimen which could be modified if the standard is modified)",ct_inc_377562,AACT,250,NCT02829788,Hypothetical,Folfox
5c7430778625dd0574867f86,270,,,59,Patient,14:15.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_546902,Clinical Trial Inclusion Criteria,UNKNOWN,Secondary resectable hepatic metastasis converted by FOLFOX-4 regimen.2.,ct_inc_546902,AACT,53,NCT00610636,Recent,FOLFOX
5c7430778625dd0574867f88,270,,,250,Patient,14:15.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_411745,Clinical Trial Inclusion Criteria,UNKNOWN,Written informed consent Male or female > 18 years of age; Histologically or cytologically confirmed diagnosis of colorectal cancer - Inclusion in the Target Population: Scheduled to receive at least 3 consecutive cycles of the same regimen of FOLFOX or FOLFIRI without monoclonal antibody; - Inclusion in the Additional Population: Scheduled to receive at least 3 consecutive cycles of the same regimen of FOLFOX or FOLFIRI in combination with monoclonal antibody; 4.,ct_inc_411745,AACT,244,NCT02383810,Recent,FOLFOX
5c7430778625dd055a867f87,1320,,,498,Patient,14:15.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_348922,Clinical Trial Exclusion Criteria,UNKNOWN,"Mean QT interval corrected for heart rate (QTc) 470 ms calculated from 3 electrocardiograms (ECGs) using Frediricia's Correction Current or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid Any history of hypersensitivity to durvalumab or tremelimumab, FOLFOX or their excipients Any unresolved toxicity (CTCAE grade >1) from previous anti-cancer therapy.",ct_exc_348922,AACT,492,NCT03202758,Historical,FOLFOX
5c7430788625dd0574867f90,270,,,114,Patient,14:16.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_344540,Clinical Trial Inclusion Criteria,UNKNOWN,"If mCRC, they should have received at least one regimen of 5-fluouracil based systemic chemotherapy such as FOLFOX, FOLFIRI, CAPOX, or XELOX, with or without a VEGF or EGFR receptor inhibitor.",ct_inc_344540,AACT,108,NCT03259867,Hypothetical,FOLFOX
5c7430788625dd057f867f87,810,,,86,Patient,14:16.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_371442,Clinical Trial Inclusion Criteria,UNKNOWN,"Diagnosis of colorectal cancer - No prior chemotherapy and scheduled to receive FOLFOX chemotherapy (oxaliplatin,leucovorin and 5-fluorouracil) - Age 18 years - Eastern Cooperative Oncology Group (",ct_inc_371442,AACT,80,NCT02909478,Historical,FOLFOX
5c7430788625dd057f867f88,810,,,182,Patient,14:16.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_377789,Clinical Trial Inclusion Criteria,UNKNOWN,"cytologically confirmed measurable and/or evaluable advanced (stage III/IV) colorectal cancer that can be accurately assessed by CT/MRI scan (RECIST v1.1) for which regimen of FOLFOX + Bevacizumab/Cetuximab is arranged by the investigator Subjects may be treatment nave, or may have received therapy for colorectal cancer.4.",ct_inc_377789,AACT,176,NCT02826837,Recent,FOLFOX
5c7430788625dd057f867f89,810,,,81,Patient,14:16.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_322303,Clinical Trial Exclusion Criteria,UNKNOWN,Patients with known hypersensitivity to any component of the Chemotherapy (FOLFOX).,ct_exc_322303,AACT,75,NCT03549494,Recent,FOLFOX
5c7430788625dd057f867f8a,810,,,294,Patient,14:16.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_340689,Clinical Trial Inclusion Criteria,UNKNOWN,"Men or women 18 years old at the time of signing the ICF Patients with histologically proven colorectal adenocarcinoma with potentially resectable liver metastases, No previous chemotherapy for metastatic CRC, The patient is due to receive first-line metastatic chemotherapy regimen with FOLFOX as a neoadjuvant The patient must have an ECOG performance status 0 or 1 The patient must have sufficient bone marrow reserve, hepatic and renal functions Detailed disease specific criteria exist and can be discussed with contacts listed below",ct_inc_340689,AACT,288,NCT03310008,Recent,FOLFOX
5c7430788625dd057f867f8b,810,,,71,Patient,14:16.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_525705,Clinical Trial Inclusion Criteria,UNKNOWN,Patients with metastatic disease who are eligible for first line FOLFOX chemotherapy.,ct_inc_525705,AACT,65,NCT00890305,Recent,FOLFOX
5c7430788625dd057f867f8c,810,,,248,Patient,14:16.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_496933,Clinical Trial Exclusion Criteria,UNKNOWN,"Chronic active hepatitis or cirrhosis - History of treatment for colorectal cancer - Subject pregnant or breast feeding - Uncontrolled disease (eg.infection, hypertension, heart failure, Myocardial Infarction within 6months) - Have been used FOLFOX as an adjuvant therapy -",ct_exc_496933,AACT,242,NCT01269229,Historical,FOLFOX
5c7430788625dd057f867f8d,810,,,276,Patient,14:16.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_538762,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically confirmed locally advanced or metastatic colorectal cancer - Measurable or evaluable disease according to the Response Evaluation Criteria in Solid Tumors - ECOG performance status 2 - Age 18 - 72 years - Patients who progress after 1st line therapy with FOLFOX/AVASTIN - Adequate liver (Bilirubin 1.5 upper normal limit, SGOT/SGPT 4 upper normal limit, ALP 2.5 upper normal limit) renal (Creatinine 1.5 upper normal limit) and bone marrow (ANC 1,500/mm3, PLT 100,000/mm3)",ct_inc_538762,AACT,270,NCT00717990,Recent,FOLFOX
5c74307d8625dd05ab867f8d,720,,,143,Patient,14:21.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_423713,Clinical Trial Inclusion Criteria,UNKNOWN,"At a minimum, such therapies should include regimens containing oxaliplatin and irinotecan in combination with a fluoropyrimidine (e.g., FOLFOX and FOLFIRI or their variants).- Age 18 years at time of study entry.- Eastern Cooperative Oncology Group (ECOG) status of 0 or 1 - Adequate organ and marrow function as defined below: - Absolute neutrophil count 1,500/mm3.- Platelet count 90,000/mm3.- AST and ALT 3 institutional upper limit of normal (ULN) or 5 ULN for subjects with liver metastases.- Bilirubin 1.5 ULN or 3 ULN for subjects with documented/suspected Gilbert's disease.- Serum",ct_inc_423713,AACT,137,NCT02227667,Recent,FOLFOX
5c74307e8625dd05ab867f8f,720,,,145,Patient,14:22.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_325514,Clinical Trial Inclusion Criteria,UNKNOWN,"Such therapies should include regimens containing oxaliplatin and irinotecan in combination with a fluoropyrimidine, if appropriate (e.g., FOLFOX and FOLFIRI, or their variants).Subjects that are unable to receive oxaliplatin and/or irinotecan due to allergy or hypersensitivity, or due to concerns regarding the side effects of oxaliplatin and/or irinotecan, will be allowed to receive less than two lines of standard therapies prior to enrollment to this study.- Patients must have at least two liver metastases, separated by 2 cm, and measured in at least one dimension (longest diameter) as 2 cm by CT/MRI.One",ct_inc_325514,AACT,139,NCT03507699,Historical,FOLFOX
5c74307f8625dd05ab867f91,720,,,7,Patient,14:23.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_495233,Clinical Trial Inclusion Criteria,UNKNOWN,"(FOLFOX, FOLFIRI) Patient Characteristics - Prior treatments: Patients must have received at least one prior chemotherapeutic regimen and must be more than 1 month past the last treatment.-",ct_inc_495233,AACT,1,NCT01291420,Historical,FOLFOX
5c7430808625dd05ab867f93,720,,,28,Patient,14:24.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_532048,Clinical Trial Exclusion Criteria,UNKNOWN,Adjuvant therapy with FOLFOX or 5-FU / Capecitabine =,ct_exc_532048,AACT,22,NCT00806663,Recent,FOLFOX
5c7430808625dd05ab867f95,720,,,203,Patient,14:24.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_439361,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Age 18 years.- Life expectancy of at least 12 weeks (3 months).- Untreated for metastatic colorectal cancer, or progression on any first line 5-FU containing regimen (such as FOLFOX or FOLFIRI)",ct_inc_439361,AACT,197,NCT02023333,Recent,FOLFOX
5c7430818625dd05d0867f8a,410,,,72,Patient,14:25.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_509896,Clinical Trial Inclusion Criteria,UNKNOWN,#NAME?,ct_inc_509896,AACT,66,NCT01099449,Recent,FOLFOX
5c7430818625dd05cc867f85,1280,,,299,Patient,14:25.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_419106,Clinical Trial Inclusion Criteria,UNKNOWN,"[AJCC] 7th edition) that was treated with the following treatment with curative intent: - Curative surgical resection - Pre- or post-operative chemoradiation; and at least 3 months of adjuvant systemic chemotherapy (equivalent to 6 cycles of leucovorin calcium, fluorouracil, and oxaliplatin [FOLFOX] or infusional fluorouracil [5FU]) -",ct_inc_419106,AACT,293,NCT02287727,Recent,FOLFOX
5c7430818625dd05d0867f8c,410,,,244,Patient,14:25.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_377593,Clinical Trial Inclusion Criteria,UNKNOWN,"Unresectable colorectal cancer confirmed by histological means with measurable indicationa minimum size of 10mm by spiral CT scanwhich meets the criteria of RECIST 1.1.- Time interval traced back to the latest administration of xelox and folfox combination must be no less than 1 year.- age range: 18 and 75.- ECOG PS scale 0 or 1expected survival time 12 weeks.- Sufficient blood functionabsolute neutrophil count (ANC) 1.5109/L, platelet count 80109/L and hemoglobin9g/dL.- Sufficient",ct_inc_377593,AACT,238,NCT02829385,Recent,folfox
5c7430818625dd05d0867f8e,410,,,93,Patient,14:25.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_321323,Clinical Trial Inclusion Criteria,UNKNOWN,"operative chemotherapy planned using Oxaliplatin-based chemotherapy regimen (including FOLFOX, XELOX and OXCAP regimens Age greater than or equal to 18 years 4.",ct_inc_321323,AACT,87,NCT03562234,Recent,FOLFOX
5c7430818625dd05d0867f90,410,,,6,Patient,14:25.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_533673,Clinical Trial Inclusion Criteria,UNKNOWN,FOLFOX or XELOX) administered at the following minimum dosages over this 12 week period:,ct_inc_533673,AACT,0,NCT00785122,Recent,FOLFOX
5c7430828625dd05cc867f86,1280,,,15,Patient,14:26.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_385495,Clinical Trial Inclusion Criteria,UNKNOWN,Adjuvant FOLFOX within the last 6 months is considered a line of therapy.,ct_inc_385495,AACT,9,NCT02726334,Recent,FOLFOX
5c7430828625dd05e2867f88,330,,,277,Patient,14:26.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_414344,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Adenocarcinoma of the pancreas - Prior therapy with 1 prior systemic therapy over a period of at least 2 months (eg, at least two 4-week cycles of a regimen such as gemcitabine and nab-paclitaxel; or at least four 2-week cycles of a regimen such as FOLFOX, FOLFIRINOX, or FOLFIRI) -Candidate for additional therapy consisting of radiation with gemcitabine- radiosensitization.- Able to initiate study treatment no later than 6 weeks from last dose of any antineoplastic component of prior therapy",ct_inc_414344,AACT,271,NCT02349867,Historical,FOLFOX
5c7430828625dd05cc867f87,1280,,,159,Patient,14:26.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_330748,Clinical Trial Inclusion Criteria,UNKNOWN,"Minimum of 4 weeks since any major surgery, completion of radiation, or completion of all prior systemic anticancer therapy, and 6 months since adjuvant FOLFOX therapy (adequately recovered from the acute toxicities of any prior therapy, including neuropathy should be grade 1).",ct_inc_330748,AACT,153,NCT03439462,Historical,FOLFOX
5c7430838625dd05cc867f88,1280,,,116,Patient,14:27.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_330748,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: History of severe and uncontrolled allergic reactions to bevacizumab Prior treatment with FOLFOX or bevacizumab within the preceding 4 weeks Patients currently receiving or have received anticancer therapies within 4 weeks of the start of study treatment (including chemotherapy, radiation therapy, antibody based therapy, etc.)",ct_exc_330748,AACT,110,NCT03439462,Historical,FOLFOX
5c7430838625dd05e2867f8b,330,,,79,Patient,14:27.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_438969,Clinical Trial Inclusion Criteria,LABORATORY_AND_RADIOLOGY_DATA,"mCRC - Have received 3 - 4 months of first line chemotherapy with either FOLFOX, FOLFIRI or CAPOX, with or without bevacizumab - At least one measurable lesion according to RECIST 1.1 criteria - Documented partial response or stable disease - Eligible to receive chemotherapy with FOLFOX or CAPOX after a short chemotherapy interruption (3 to 4 weeks)",ct_inc_438969,AACT,73,NCT02028442,Recent,FOLFOX
5c7430838625dd0603867f86,600,,,145,Patient,14:27.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_350877,Clinical Trial Inclusion Criteria,UNKNOWN,"-2 - Provision of signed, written and dated informed consent prior to any study specific procedures - Receiving adjuvant chemotherapy with FOLFOX (5-FU, leucovorin, oxaliplatin) regimen",ct_inc_350877,AACT,139,NCT03177317,Historical,FOLFOX
5c7430838625dd0603867f87,600,,,64,Patient,14:27.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_472385,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - patients who received chemotherapy (FOLFOX) including bevacizumab.,ct_inc_472385,AACT,58,NCT01591109,Recent,FOLFOX
5c7430838625dd0603867f88,600,,,209,Patient,14:27.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_519113,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - aged 18 or older - curatively resected colon adenocarcinoma - pathologically staged III - adequate performance status - adequate major organ functions - to be treated with adjuvant FOLFOX chemotherapy - written informed consent,ct_inc_519113,AACT,203,NCT00977717,Recent,FOLFOX
5c7430838625dd05cc867f89,1280,,,131,Patient,14:27.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_566997,Clinical Trial Inclusion Criteria,UNKNOWN,"Advanced and/or metastatic disease - Suitable for first-line therapy with oxaliplatin, leucovorin calcium, and fluorouracil (FOLFOX-6) - Clinically or radiologically documented disease - No tumor marker elevation as sole evidence of disease - No necrotic/hemorrhagic metastases or tumor - No untreated brain or meningeal metastases",ct_inc_566997,AACT,125,NCT00343408,Recent,FOLFOX
5c7430838625dd05e2867f91,330,,,285,Patient,14:28.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_342075,Clinical Trial Inclusion Criteria,UNKNOWN,"Men and women 18 years - Newly diagnosed with histologically confirmed stage II-Ill colon cancer - Completed curative-intent surgical resection - Currently prescribed one of the following adjuvant chemotherapy regimens: (IV 5-fluorouracil [5-FU] / leucovorin [LV], capecitabine, FOLFOX [5-FU, LV, oxaliplatin], CAPOX [capecitabine and oxaliplatin] - Patients must have started chemotherapy or plan to start within 4 weeks of planned receipt of the first exercise visit.",ct_inc_342075,AACT,279,NCT03291951,Recent,FOLFOX
5c7430838625dd05e2867f92,330,,,78,Patient,14:28.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_342075,Clinical Trial Inclusion Criteria,UNKNOWN,Patients enrolled at the Dana-Farber Cancer Institute must be receiving FOLFOX chemotherapy to be eligible since they will be enrolled in the pharmacokinetics sub-study.-,ct_inc_342075,AACT,72,NCT03291951,Recent,FOLFOX
5c7430858625dd05cc867f8a,1280,,,308,Patient,14:29.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_531003,Clinical Trial Inclusion Criteria,UNKNOWN,Participants must be >18 years old; - Participants must have an ECOG performance status of 0-1; - Participants must not be pregnant or breastfeeding; - Participants must have prior histological documentation of adenocarcinoma of the colon or rectum; - Participants must be commencing chemotherapy with FOLFOX plus bevacizumab; - Participants must not have had prior exposure to bevacizumab.,ct_inc_531003,AACT,302,NCT00820456,Historical,FOLFOX
5c7430858625dd05cc867f8b,1280,,,163,Patient,14:29.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_433336,Clinical Trial Inclusion Criteria,UNKNOWN,Contraceptive use must be continued until at least 30 days after the last administration of ADI-PEG 20 and at least 90 days after the last administration of FOLFOX.For,ct_inc_433336,AACT,157,NCT02102022,Recent,FOLFOX
5c7430878625dd0624867f87,420,,,260,Patient,14:31.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_344879,Clinical Trial Inclusion Criteria,AGE,"Histologically confirmed adenocarcinoma of the colon.- Has undergone a curative resection for stage III colon cancer.- Scheduled to receive 6 months of Oxaliplatin-based adjuvant chemotherapy at a dose of 85 mg/m of Oxaliplatin every 2 weeks (simplified FOLFOX 4 regimen).- The following laboratory values obtained 28 days prior to inclusion: WBC 3000/mm3; ANC 1500/mm3; PLT 100,000/mm3; HgB 10.0g/dl; Total bilirubin 1.5 x upper normal limit (UNL); Serum creatinine 1.5 x UNL; Serum calcium 1.2 x UNL; Serum magnesium 1.2 x UNL.- Central venous access line present or patient scheduled to have a central line placed prior to starting chemotherapy or the treatment protocol.- Negative pregnancy test (serum or urine) done 7 days prior to registration, for women of childbearing potential only.- Ability to complete questionnaire(s) by themselves or with assistance.- ECOG Performance Status (PS) of 0, 1 for patients until 70 years old included and ECOG PS of 0 for patients between 70 to 75 years old included.-",ct_inc_344879,AACT,254,NCT03255434,Historical,FOLFOX
5c7430888625dd0624867f88,420,,,59,Patient,14:32.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_458326,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - - Patient which cannot receive FOLFOX 4 whatever the reason - Patients < 18 years old and > 70 years old - Malnourished patient (French National Authority for Health, 2003) -",ct_exc_458326,AACT,53,NCT01775449,Recent,FOLFOX
5c7430888625dd0624867f89,420,,,30,Patient,14:32.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_500205,Clinical Trial Inclusion Criteria,HISTORY_PRESENT_ILLNESS,"- Chemotherapy with the Folfox 4 regimen (the current standard treatment ; it can be modified in the future in the two groups,",ct_inc_500205,AACT,24,NCT01226394,Recent,Folfox
5c7430938625dd0692867f89,790,,,44,Patient,14:43.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_347146,Clinical Trial Exclusion Criteria,LABORATORY_AND_RADIOLOGY_DATA,"FOLFIRI after progression to adjuvant FOLFOX, occurred on treatment or within 6 months after treatment completion.",ct_exc_347146,AACT,38,NCT03225937,Recent,FOLFOX
5c74309b8625dd06ea867f84,820,,,342,Patient,14:51.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_541497,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically confirmed locally advanced or metastatic colorectal cancer.- Measurable or evaluable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) - ECOG performance status 2 - Age 18 - 72 years - Patients with de novo refractory disease (progression of disease as best response at 1st line therapy with FOLFOX/Avastin) - Adequate liver (Bilirubin 1.5 UNL, SGOT/SGPT 4 UNL, ALP 2.5 UNL),renal (Creatinine 1.5 UNL) and bone marrow (ANC 1,500/mm3, PLT 100,000/mm3)",ct_inc_541497,AACT,336,NCT00681876,Recent,FOLFOX
5c74309d8625dd06ea867f87,820,,,111,Patient,14:53.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_377789,Clinical Trial Exclusion Criteria,COMMENT,"CNS = central nervous system Ascertained hypersensitivity to any component of investigational product or FOLFOX + Bevacizumab/Cetuximab that the subject will be treated Any of the following hematologic abnormalities: Hemoglobin < 10.0 g/dL, 2.",ct_exc_377789,AACT,105,NCT02826837,Recent,FOLFOX
5c74309d8625dd06ea867f88,820,,,330,Patient,14:53.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_377789,Clinical Trial Exclusion Criteria,COMMENT,"HIV = human immunodeficiency virus Uncontrolled psychiatric disorder or altered mental status precluding informed consent or necessary testing Consumption of herbal preparations/supplements (except for a daily multivitamin/mineral supplement not containing herbal components) within 2 weeks prior to the start of Cycle 1 of FOLFOX + Bevacizumab/Cetuximab administration Significant cardiovascular disease, including: Active clinically symptomatic left ventricular failure Active hypertension",ct_exc_377789,AACT,324,NCT02826837,Historical,FOLFOX
5c74309d8625dd06ea867f89,820,,,157,Patient,14:53.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_377789,Clinical Trial Exclusion Criteria,COMMENT,> 100 mmHg).Subjects with a history of hypertension must have been on stable doses of anti-hypertensive drugs for 4 weeks prior to start of Cycle 1 of FOLFOX + Bevacizumab/Cetuximab administration Uncontrolled hypertension: Blood pressure >,ct_exc_377789,AACT,151,NCT02826837,Historical,FOLFOX
5c74309d8625dd06ea867f8a,820,,,164,Patient,14:53.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_377789,Clinical Trial Exclusion Criteria,COMMENT,"140/90 mmHg on more than 2 antihypertensive medications Myocardial infarction, severe angina, or unstable angina within 12 weeks prior to start of Cycle 1 of FOLFOX + Bevacizumab/Cetuximab administration History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation)",ct_exc_377789,AACT,158,NCT02826837,Historical,FOLFOX
5c74309f8625dd06ea867f92,820,,,111,Patient,14:55.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_467887,Clinical Trial Inclusion Criteria,UNKNOWN,"- General condition considered suitable for radical pelvic surgery - Candidate for systemic therapy with FOLFOX/FOLFOXIRI plus bevacizumab - Adequate bone marrow, hepatic and renal function: - Haemoglobin 80 g/L - ANC 2 x 109/L - Platelet count 100 x 109/",ct_inc_467887,AACT,105,NCT01650428,Recent,FOLFOX
5c7430a18625dd0700867f95,200,,,36,Patient,14:58.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_572594,Clinical Trial Inclusion Criteria,UNKNOWN,- At least 1 year since prior FOLFOX 4 or FOLFIRI regimen in the adjuvant setting - No concurrent participation in another clinical trial - Recovered from prior therapy,ct_inc_572594,AACT,30,NCT00268398,Historical,FOLFOX
5c7430a28625dd0716867f8a,150,,,49,Patient,14:58.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_470846,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Scheduled to receive FOLFOX chemotherapy with individual oxaliplatin doses of 85 mg/m^2 per cycle given in 2 week cycles (e.g.modified [m],ct_inc_470846,AACT,43,NCT01611155,Recent,FOLFOX
5c7430a58625dd0737867f96,180,,,227,Patient,15:01.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_559447,Clinical Trial Inclusion Criteria,UNKNOWN,"- Tissue diagnosis of adenocarcinoma of the colon or rectum - Documented metastatic disease with at least one measurable lesion by RECIST criteria - Previously treated with 5-FU-based chemotherapy in the form of FOLFIRI, FOLFOX, or XELOX plus bevacizumab ",ct_inc_559447,AACT,221,NCT00443573,Recent,FOLFOX
5c7430a58625dd0742867f87,1120,,,344,Patient,15:01.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_318272,Clinical Trial Inclusion Criteria,UNKNOWN,"The somatic mutational testing can be performed on tissue samples taken from any time in the patient's pancreatic cancer history.- Patients must have received at least one line of treatment for their cancer prior to enrolling on the trial.- Patients who had investigator assessed progression on an oxaliplatin-containing regimen (such as FOLFOX or FOLFIRINOX) are not eligible for the trial.- Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as 20 mm with conventional techniques or as 10 mm with spiral CT scan, MRI, or calipers by clinical exam.",ct_inc_318272,AACT,338,NCT03601923,Historical,FOLFOX
5c7430a68625dd0742867f88,1120,,,221,Patient,15:02.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_416707,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients must have histologically confirmed gastrointestinal malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective, or for whom FOLFOX would be an appropriate therapy - Patients are required to have evaluable disease - Any number of prior treatment regimens is allowed - Eastern Cooperative Oncology Group (ECOG) performance status =",ct_inc_416707,AACT,215,NCT02319018,Historical,FOLFOX
5c7430a68625dd0742867f89,1120,,,198,Patient,15:02.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_397493,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically or cytologically confirmed locally advanced or metastatic colon or rectal adenocarcinoma - Intent to treat the patient with a leucovorin calcium, fluorouracil, and oxaliplatin (FOLFOX) chemotherapy regimen containing fluorouracil (5-FU), leucovorin, and oxaliplatin according to clinical standard practice; the intent should be to dose oxaliplatin at 85 mg/m^2 on an every 2 week basis - Treatment with any additional Food and Drug Administration (FDA)-approved biologic agent (i.e.bevacizumab, cetuximab, or panitumumab) is allowed according to standard practice - Prior radiation or surgery is allowed, but should be finished at least 2 weeks prior to study enrollment; if a participant has prior radiation therapy, at least one measurable lesion outside of the radiation field should be available for the evaluation of response to chemotherapy -",ct_inc_397493,AACT,192,NCT02569723,Historical,FOLFOX
5c7430a68625dd0742867f8a,1120,,,105,Patient,15:02.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_341409,Clinical Trial Inclusion Criteria,UNKNOWN,No prior systemic chemotherapy for metastatic disease; subjects who received adjuvant therapy with FOLFOX and at the time of recurrence are at least 6 months away from last chemotherapy are eligible for this study -,ct_inc_341409,AACT,99,NCT03300609,Historical,FOLFOX
5c7430a68625dd0742867f8b,1120,,,168,Patient,15:02.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_454105,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Anti-cancer chemotherapy or biologic therapy within the lesser of i) 21 days, or ii) the usual cycle length of the regimen (e.g.14 days for FOLFOX), prior to the first planned dose of BBI608/placebo.",ct_exc_454105,AACT,162,NCT01830621,Historical,FOLFOX
5c7430a78625dd0742867f8c,1120,,,158,Patient,15:03.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_470792,Clinical Trial Inclusion Criteria,UNKNOWN,ONLY Patients must have histologically confirmed solid tumor malignancy that is metastatic or unresectable and for which standard therapy would include FOLFOX or for which standard curative or palliative measures do not exist or are no longer effective.,ct_inc_470792,AACT,152,NCT01611857,Recent,FOLFOX
5c7430a78625dd0758867f86,460,,,492,Patient,15:03.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_419923,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically or cytologically confirmed refractory colorectal cancer - Measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as >10 mm with CT scan, as >20 mm by chest x-ray, or >10 mm with calipers by clinical exam.- Refractory to or intolerant of standard systemic therapy, including having received two or more standard available therapies known to prolong survival for which s/he was eligible, including FOLFOX or FOLFIRI with or without bevacizumab, aflibercept, cetuximab, or panitumumab",ct_inc_419923,AACT,486,NCT02277093,Recent,FOLFOX
5c7430a88625dd0763867f85,730,,,94,Patient,15:04.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_585585,Clinical Trial Inclusion Criteria,UNKNOWN,"If subject received prior therapy with irinotecan, they will be eligible to receive the FOLFOX regimen.-",ct_inc_585585,AACT,88,NCT00094809,Hypothetical,FOLFOX
5c7430a88625dd0758867f88,460,,,97,Patient,15:04.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_312710,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Diagnosed by pathology as gastrointestinal carcinoma and no previous FOLFOX or FOLFIRI,ct_inc_312710,AACT,91,NCT03674294,Recent,FOLFOX
5c7430a88625dd0758867f8a,460,,,37,Patient,15:05.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_461598,Clinical Trial Inclusion Criteria,LABORATORY_AND_RADIOLOGY_DATA,"first-line in combination with FOLFOX (folinic acid, leucovorin, fluorouracil [5FU], oxaliplatin) or second-line in combination with FOLFIRI (folinic acid, leucovorin, 5FU, irinotecan) in subjects who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan) for treatment of wild-type RAS mCRC per approved prescribing information - Subject or subject's legally acceptable representative has provided informed consent (for countries where required per local regulations) - Subjects treated with Vectibix in accordance with the current version of the Summary of Product Characteristics (SmPC)",ct_inc_461598,AACT,31,NCT01732783,Recent,FOLFOX
5c7430a98625dd0758867f8d,460,,,316,Patient,15:05.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_492846,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Prior chemotherapy other than that listed in inclusion criteria - Receiving any other investigational agent - Known brain metastases, uncontrolled seizure disorders, encephalitis, or multiple sclerosis - History of known hypersensitivity to S. cerevisiae, bevacizumab or any component of FOLFOX or FOLFIRI - Concurrent and chronic therapy with corticosteroids or any other immunosuppressive drugs - Uncontrolled hypertension, unstable angina, congestive heart failure, peripheral vascular disease, serious cardiac arrythmias requiring medication - History of heart attack or stroke within 6 months before enrollment - History of intra-abdominal abscess, abdominal fistula, gastrointestinal perforation, or active peptic ulcer disease - Bleeding disorder or coagulopathy - Serious non-healing wound, ulcer or bone fracture - Major surgical procedure, open biopsy, or traumatic injury within 4 weeks prior to enrollment or anticipation of need for surgery during the study - Known active infection with HIV, hepatitis B or C - History of splenectomy - History of Crohn's disease or ulcerative colitis - History of organ transplantation - Evidence of immunodeficiency or immune suppression - Any Autoimmune disease - Active infection - Concurrent malignancy - Pregnant or nursing",ct_exc_492846,AACT,310,NCT01322815,Historical,FOLFOX
5c7430a98625dd0758867f8f,460,,,33,Patient,15:05.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_549959,Clinical Trial Inclusion Criteria,UNKNOWN,Treatment with FOLFIRI and FOLFOX is not indicated.,ct_inc_549959,AACT,27,NCT00569699,Recent,FOLFOX
5c7430ae8625dd0779867f8d,520,,,108,Patient,15:10.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_398995,Clinical Trial Inclusion Criteria,UNKNOWN,"5-fluorouracil; these include combinations such as fluorouracil, oxaliplatin, and leucovorin calcium (FOLFOX), FOLFOX + bevacizumab, FOLFOX + cetuximab - Standard antiemetic therapy with initial treatment must include the dolasetron and dexamethasone; the minimum adequate doses include either: - Dolasetron (Anzemet) 100mg PO/IV or 1.8mg/kg IV AND - Dexamethasone (Decadron)",ct_inc_398995,AACT,102,NCT02550119,Recent,FOLFOX
5c7430af8625dd079a867f8c,380,,,344,Patient,15:11.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_567473,Clinical Trial Inclusion Criteria,UNKNOWN,"There must be histologic confirmation of adenocarcinoma of the colon or rectum.- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 - Estimated life expectancy of at least 12 weeks.- One prior therapy for metastatic disease is permitted.- Recurrence within 12 months of adjuvant therapy with FOLFOX or a similar regimen (i.e FLOX, CapOX) is considered one regimen and allowed for study - There must be evidence of adequate organ function - Patients with a history of prior non-colorectal malignancies are eligible if they have been disease-free for 5 years prior to study entry and are deemed by the physician to be at low risk for recurrence.- Age > 18 yrs.",ct_inc_567473,AACT,338,NCT00336856,Hypothetical,FOLFOX
5c7430b28625dd07c6867f93,490,,,720,Patient,15:14.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_411745,Clinical Trial Exclusion Criteria,UNKNOWN,"Any investigational drugs within 30 days before enrollment or foreseen use of investigational agents during the study; Treatment with chemotherapy of any type within 12 months before enrollment; Patient with any type of ostomy (temporary ostomy should be closed at least 6 months prior to enrollment); Patient who underwent total colectomy; Patient who had abdominal-perineal resection or surgery leaving the patient without a functioning rectum; Any radiotherapy to the abdomen or pelvis in the 6 months prior to enrollment; Scheduled to receive radiotherapy to abdomen or pelvis during the study; 8. a) Exclusion from the Target population Scheduled to receive any concomitant chemotherapeutic agent, other than FOLFOX or FOLFIRI agents; any type of monoclonal antibodies; 8",ct_exc_411745,AACT,714,NCT02383810,Historical,FOLFOX
5c7430b28625dd07c6867f94,490,,,124,Patient,15:14.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_411745,Clinical Trial Exclusion Criteria,UNKNOWN,". b) Exclusion from the Additional population Scheduled to receive any concomitant chemotherapeutic agent, other than FOLFOX or FOLFIRI agents;",ct_exc_411745,AACT,118,NCT02383810,Recent,FOLFOX
5c7430b38625dd07dc867f85,630,,,72,Patient,15:15.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_442235,Clinical Trial Inclusion Criteria,UNKNOWN,(stage IV) disease - Have a plan by treating physician to receive FOLFOX or FOLFOX-Avastin,ct_inc_442235,AACT,66,NCT01985763,Recent,FOLFOX
5c7430b48625dd07dc867f86,630,,,71,Patient,15:16.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_529621,Clinical Trial Inclusion Criteria,UNKNOWN,Have recurred or progressed within 6 months of the last cycle of FOLFOX +/-,ct_inc_529621,AACT,65,NCT00838578,Recent,FOLFOX
5c7430b48625dd07dc867f87,630,,,30,Patient,15:16.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_529621,Clinical Trial Inclusion Criteria,COMMENT,"Those who had initiated FOLFOX/CapOx but stopped oxaliplatin because of intolerable toxicity are also eligible.- At least 4 weeks have elapsed since the last chemotherapy, radiotherapy, immunotherapy, or biologic therapy prior to enrollment (except at least 6 weeks in the case of nitrosourea and mitomycin).- Have not received any other investigational agents within 4 weeks of study entry and have fully recovered from any adverse event due to prior therapy.-",ct_inc_529621,AACT,24,NCT00838578,Historical,FOLFOX
5c7430b58625dd07e7867f89,770,,,177,Patient,15:17.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_322303,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: Patients with cyto-histological diagnosis of stomach adenocarcinoma and gastric esophageal junction in stages III and IV, which are tributaries of the FOLFOX chemotherapy scheme.",ct_inc_322303,AACT,171,NCT03549494,Recent,FOLFOX
5c7430b58625dd07e7867f8a,770,,,45,Patient,15:17.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_322303,Clinical Trial Inclusion Criteria,UNKNOWN,Clinically fit patients to receive the FOLFOX chemotherapy scheme.,ct_inc_322303,AACT,39,NCT03549494,Recent,FOLFOX
5c7430b58625dd07e7867f8b,770,,,166,Patient,15:17.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_559947,Clinical Trial Inclusion Criteria,UNKNOWN,"Have had documented disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST; Therasse et al.2000) within 3 months after receiving FOLFOX plus bevacizumab as first-line therapy for locally advanced or metastatic disease, or within 6 months after receiving FOLFOX with or without bevacizumab in the adjuvant setting.",ct_inc_559947,AACT,160,NCT00437268,Recent,FOLFOX
5c7430b68625dd07fd867f86,210,,,28,Patient,15:18.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_354259,Clinical Trial Inclusion Criteria,UNKNOWN,"polychemotherapy type FOLFOX, FOLFIRI, FOLFIRINOX, associated or not with targeted therapies Adapted to the expression of BRAF and RAS, whatever the route of administration of the proposed, oral or intravenous therapies) - Metastatic CRC diagnosed preoperatively on imaging or per-operative on macroscopic findings and proved by histological analysis (biopsy or surgical excision and if possible biopsies or excrescence on the metastatic sites)",ct_inc_354259,AACT,22,NCT03133273,Hypothetical,FOLFOX
5c7430b78625dd0813867f85,370,,,210,Patient,15:19.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_387041,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Male or female adults - patients with gastric or colorectal cancer (stages III or IV), where a treatment with 5-Fluoruracil in combination with other chemotherapeutic remedies (FLO, FOLFOX, FOLFOX-Bev, FOLFIRI) is planned - life expectancy of at least the trial duration - the first administering of the product under investigation must be able to take place 72 hours before or after the beginning of the chemotherapeutical treatment, ideally at the same time - an inclusion into the study is only possible at the beginning of the first chemotherapeutic cycle - fertile female patients (aged 49 years or minor, the last menstruation occured in less than two years) have to be either surgically sterilized or use the same highly effective method of contraception for at least three months - willingness to refrain from other probiotics or probiotic yoghurts, a systematic change of eating behavior should not be planned - sufficient knowledge of german language and sufficient psychological state for being able to answer questionnaires and assessment scales - informed written consent",ct_inc_387041,AACT,204,NCT02706184,Recent,FOLFOX
5c7430b78625dd0813867f87,370,,,263,Patient,15:19.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_330038,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically confirmed adenocarcinoma of the colon or rectum in patients with initially unresectable metastatic (M1) disease - Wild-type RAS tumour status confirmed before study inclusion at local institution - Patients who have a treatment plan based on FOLFOX + anti-EGFR or FOLFIRI + anti-EGFR, as first-line treatment of mCRC - Eastern Cooperative Oncology Group (ECOG) performance status 2 - Adequate bone marrow function: neutrophils 1.5 x109/L; platelets 100 x109/L; haemoglobin 9 g/dL - Hepatic, renal and metabolic function as follows:",ct_inc_330038,AACT,257,NCT03448731,Recent,FOLFOX
5c7430b78625dd0813867f89,370,,,71,Patient,15:19.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_492846,Clinical Trial Inclusion Criteria,UNKNOWN,those patients who enroll just after completing bevacizumab plus FOLFOX or FOLFIRI - Anticipated survival of at least 6 months - Ambulatory with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - Ability to maintain weight - Normal organ and marrow function - Women of child-bearing potential and men must agree to avoid pregnancy or fathering a child for the duration of study participation and for 6 months after the final scheduled study visit.- Ability to understand and willingness to sign a written informed consent document,ct_inc_492846,AACT,65,NCT01322815,Recent,FOLFOX
5c7430b78625dd0808867f8f,320,,,60,Patient,15:19.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_376081,Clinical Trial Inclusion Criteria,UNKNOWN,Indication for treatment with a combination including FOLFOX/FOLFIRI associated to an anti VEGF drug (Avastin),ct_inc_376081,AACT,54,NCT02849106,Recent,FOLFOX
5c7430b78625dd0808867f91,320,,,270,Patient,15:19.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_367547,Clinical Trial Inclusion Criteria,UNKNOWN,"Must be willing and able to provide fecal samples according to protocol schedule - COHORT A - Diagnosis of metastatic colorectal cancer, where the metastatic disease has not been previously treated - Scheduled to begin fluorouracil/leucovorin calcium/oxaliplatin (FOLFOX) or folinic acid-fluorouracil-irinotecan (FOLFIRI) based chemotherapy for the advanced disease - Must have radiologic evidence of disease - COHORT B - Diagnosis of metastatic cancer",ct_inc_367547,AACT,264,NCT02960282,Recent,FOLFOX
5c7430b78625dd0808867f93,320,,,202,Patient,15:20.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_336494,Clinical Trial Inclusion Criteria,UNKNOWN,Patients must have histologically confirmed CRC with isolated liver metastasis Patients must be planned for a hepatic metastasectomy Patients must have received at least 3 cycles of chemotherapy (FOLFOX or FOLFIRI with or without Bevacizumab) prior to the planned hepatic metastasectomy Primary tumor must be considered resectable with a plan for this to either occur concurrently with the liver resection or subsequent to this.,ct_inc_336494,AACT,196,NCT03364621,Historical,FOLFOX
5c7430b88625dd0808867f94,320,,,174,Patient,15:20.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_387169,Clinical Trial Exclusion Criteria,UNKNOWN,"Are contraindicated for chemoradiotherapy (CRT) Hypersensitivity or contraindication to the drug(s) associated with the planned choice of systemic chemotherapy (CAPOX, FOLFOX or single agent 5-FU or capecitabine) as stated in the SmPC for each of the drugs.",ct_exc_387169,AACT,168,NCT02704520,Recent,FOLFOX
5c7430b88625dd0813867f8b,370,,,125,Patient,15:20.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_559717,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Patients with recurrent metastatic liver lesions from colorectal cancer who progressed on either FOLFOX or FOLFIRI - Biopsy proven evidence of colorectal cancer -,ct_inc_559717,AACT,119,NCT00440310,Recent,FOLFOX
5c7430b98625dd081e867f8b,110,,,694,Patient,15:21.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_468526,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Cytological or histological proven diagnosis of colorectal cancer, metastatic or inoperable advanced disease, not amenable to curative therapy - Measurable disease, defined as at least one lesion (outside of irradiated areas) that can be measured in at least one dimension as 10 mm ( 15 mm in case of lymph nodes) according to RECIST v1.1 - Tumor either wild-type KRAS or KRAS-mutated - Indication for the therapeutic use of continuous intravenous 5FU over 48 hours (deGramont regimen) or oral Cp, either alone or in combination with other anticancer drugs (including monoclonal antibodies or other molecularly-targeted drugs) - Eligible treatment regimens include: FOLFOX (FOLFOX 4, FOLFOX 6, modified FOLFOX 6, FOLFOX 7), FOLFIRI, 5FU or Cp mono-chemotherapy (deGramont regimen), XELOX, XELIRI,",ct_inc_468526,AACT,688,NCT01641458,Recent,FOLFOX
5c7430ba8625dd0813867f93,370,,,24,Patient,15:22.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_494688,Clinical Trial Exclusion Criteria,UNKNOWN,Previous adjuvant FOLFOX based chemotherapy is allowed.,ct_exc_494688,AACT,18,NCT01298570,Recent,FOLFOX
5c7430bb8625dd083f867f92,240,,,28,Patient,15:23.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_494688,Clinical Trial Inclusion Criteria,COMMENT,"In patients receiving FOLFOX, oxaliplatin is sometimes discontinued due to toxicity or as part of maintenance therapy strategy.",ct_inc_494688,AACT,22,NCT01298570,Recent,FOLFOX
5c7430bb8625dd083f867f93,240,,,47,Patient,15:23.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_494688,Clinical Trial Inclusion Criteria,COMMENT,"As an example, a patient who is begun on FOLFOX or CapeOx (capecitabine with oxaliplatin, with or without bevacizumab), whose oxaliplatin is held for neurotoxicity and who is switched to capecitabine monotherapy or capecitabine with bevacizumab, would be considered to have had one prior therapy.",ct_inc_494688,AACT,41,NCT01298570,Historical,FOLFOX
5c7430bb8625dd083f867f94,240,,,77,Patient,15:23.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_494688,Clinical Trial Inclusion Criteria,COMMENT,"OR Patients who develop metastatic disease within 9 months of adjuvant FOLFOX for stage II or III colon cancer Measurable disease, defined as at least 1 unidimensionally measurable lesion on a CT scan as defined by RECIST 1.1.",ct_inc_494688,AACT,71,NCT01298570,Recent,FOLFOX
5c7430bb8625dd083f867f9a,240,,,166,Patient,15:23.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_376081,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria: Elevation of Carcinoembryonic antigen (CEA) without measurable metastatic disease Medical contraindication to chemotherapy or biotherapy as FOLFOX/FOLFIRI or Avastin.,ct_exc_376081,AACT,160,NCT02849106,Recent,FOLFOX
5c7430bb8625dd083f867f9b,240,,,21,Patient,15:23.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_376081,Clinical Trial Exclusion Criteria,UNKNOWN,Treatment with FOLFOX/FOLFIRI and biotherapy anti-EGFR (epidermal growth factor receptor)(Erbitux) planned Patient already enrolled in an other clinical trial with another first line of chemotherapy.,ct_exc_376081,AACT,15,NCT02849106,Recent,FOLFOX
5c7430bd8625dd084a867f8c,140,,,437,Patient,15:25.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_490966,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients may be entered in the study only if they meet all of the following criteria: Male or female patient greater than or equal to 18 years of age; Histologically or cytologically confirmed nonresectable locally advanced or metastatic colorectal adenocarcinoma; Patients must have failed a first-line chemotherapy regimen for nonresectable locally advanced or mCRC (first-line 5-FU-based therapies, including but not limited to FOLFOX, FOLFOX 4, mFOLFOX6, CapeOX, single-agent capecitabine, infusional 5-FU, or other chemotherapies.",ct_inc_490966,AACT,431,NCT01347645,Hypothetical,FOLFOX
5c7430438625dd033f867f86,310,,,9,Patient,13:24.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_568959,Clinical Trial Inclusion Criteria,UNKNOWN,"- FOLFOX4, comprising leucovorin calcium, fluorouracil, and oxaliplatin (2-week course) - Modified FOLFOX6, comprising high-dose leucovorin calcium, high-dose fluorouracil, and oxaliplatin (2-week course)",ct_inc_568959,AACT,2,NCT00316914,Recent,FOLFOX4
5c74305a8625dd0431867f88,220,,,136,Patient,13:46.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_378840,Clinical Trial Exclusion Criteria,UNKNOWN,Child-pugh C is not capable to tolerate chemotherapy - patients undergo postoperative adjuvant treatments except chemotherapy of Folfox4,ct_exc_378840,AACT,129,NCT02813096,Recent,Folfox4
5c74305a8625dd0431867f89,220,,,89,Patient,13:46.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_378840,Clinical Trial Exclusion Criteria,UNKNOWN,regimen - patients with badly chemotherapy complications who can finish the whole Folfox4 treatment course,ct_exc_378840,AACT,82,NCT02813096,Recent,Folfox4
5c7430728625dd0544867f94,280,,,173,Patient,14:10.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_476020,Clinical Trial Inclusion Criteria,UNKNOWN,Written informed consent; Male or female patient 18 years of age; Confirmed diagnosis of colorectal cancer; Chemotherapy nave patient; Patient scheduled to receive a FOLFOX4 or FOLFIRI chemotherapy regimen according to the following scheme and dosage (1st cycle): AGENT DOSE ROUTE/DURATION DAYS Oxaliplatin or Irinotecan 85/180 mg m2 i.v.infusion/2h 1 FolinicAcid (leucovorin),ct_inc_476020,AACT,166,NCT01543451,Recent,FOLFOX4
5c7430768625dd0574867f85,270,,,157,Patient,14:14.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_378840,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - patients undergo curative resection - HCC with PVTT is confirmed by pathological examination - patients undergo chemotherapy of Folfox4,ct_inc_378840,AACT,150,NCT02813096,Recent,Folfox4
5c7430818625dd05d0867f89,410,,,378,Patient,14:25.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_509896,Clinical Trial Inclusion Criteria,UNKNOWN,- Histologically confirmed adenocarcinoma of the colon or rectum - Has undergone curative resection and is considered to have stage II or III disease or completely resected stage IV disease with no evidence of residual tumor - Scheduled to receive 6 month,ct_inc_509896,AACT,371,NCT01099449,Recent,FOLFOX4
5c74308e8625dd063a867f8d,390,,,432,Patient,14:38.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_476020,Clinical Trial Exclusion Criteria,UNKNOWN,"and/or cooperate with the study Investigator; Any investigational drugs within 30 days before enrollment in the study or foreseen use of investigational agents during the study; Patient with any type of ostomy; Any previous radiotherapy to the abdomen or pelvis; Scheduled to receive radiotherapy to abdomen or pelvis during the study (Day 1 to Day 14); Scheduled to receive any concomitant chemotherapeutic agent other than FOLFOX4 or FOLFIRI agents (Oxaliplatin, Irinotecan, Folinic acid, 5-FU) from Day 1 to Day 14; Previous use or scheduled to receive monoclonal antibodies (e.g.bevacizumab, cetuximab, etc) during the study (From Day 1 to Day 14); Major surgery within the previous 3 weeks; Any type of condition leading to chronic diarrhea, including but not limited to inflammatory bowel diseases (e.g.ulcerative colitis and Crohn's disease), chronic diarrhea of presumed or confirmed infectious origin and irritable bowel syndrome; Any diarrhea in the 48 hours preceding study drug administration; Use of anti-diarrheal agents within the 48 hours prior to study drug administration; Use of laxatives within 7 days prior to study drug administration; Use of antibiotics within 7 days prior to study drug administration; History of chronic ( 30 consecutive days) use of laxatives; Active and ongoing systemic infection; Lactating woman; History of hypersensitivity or allergies to drugs or compounds potentially related to this investigational drug class; Previous exposure to GLP-2 or other compounds in this investigational drug class; Abnormal laboratory values, including - Aspartate aminotransferase (AST)",ct_exc_476020,AACT,425,NCT01543451,Historical,FOLFOX4
5c7430a28625dd0716867f89,150,,,10,Patient,14:58.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_470846,Clinical Trial Inclusion Criteria,UNKNOWN,or FOLFOX4),ct_inc_470846,AACT,3,NCT01611155,Recent,FOLFOX4
5c7430a38625dd0737867f86,180,,,165,Patient,14:59.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_395908,Clinical Trial Inclusion Criteria,UNKNOWN,"All cases have been diagnosed with colorectal cancer by pathology; Patients who received no chemotherapy before should receive oxaliplatin-based chemotherapy(FOLFOX4,FOLFOX6,XELOX) ; Patients of 18-70 years old have no serious heart,liver,kidney and hematopoietic disfunction,life expectancy of over 3 months and KPS more than 60; Patients with no positive sign in neurological examination,and no drug allergy history or diabetes; Volunteered to participate and signed informed consent,patients can not receive radiotherapy,acupuncture and moxibustion or other treatment during the experiment.",ct_inc_395908,AACT,158,NCT02590367,Historical,FOLFOX4
5c7430be8625dd084a867f8d,140,,,91,Patient,15:26.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_436291,Clinical Trial Inclusion Criteria,UNKNOWN,Aged 18 or above Diagnosed with AEGC and were prescribed with either XELOX-based or FOLFOX4- based chemotherapy treatment,ct_inc_436291,AACT,84,NCT02063412,Recent,FOLFOX4
5c7430c08625dd086b867f93,60,,,25,Patient,15:28.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_427406,Clinical Trial Inclusion Criteria,HISTORY_PRESENT_ILLNESS,"Chemotherapy with FOLFOX4, mFOLFOX6, CapeOx or Capecitabine(the current standard treatment; it can be modified in the future in the two groups, if the standard is modified)",ct_inc_427406,AACT,18,NCT02179489,Hypothetical,FOLFOX4
5c7430518625dd03ad867f86,590,,,197,Patient,13:37.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_336681,Clinical Trial Inclusion Criteria,COMMENT,Use of a FOLFOX-based combination regimen is permitted with (1) anti-angiogenic agents (such as bevacizumab) or (2) targeted therapy (such as anti-epidermal growth factor receptor agents).FOLFOXIRI-based regimens will not be allowed.- Subjects must have a platelet count < 75 x 109/L on study day,ct_inc_336681,AACT,188,NCT03362177,Recent,FOLFOXIRI
5c7430608625dd0473867f89,570,,,167,Patient,13:52.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_427697,Clinical Trial Inclusion Criteria,UNKNOWN,"To have received first_line treatment with bevacizumab in combination with chemotherapy with the three drugs 5FU/leucovorin (LV), irinotecan and oxaliplatin (FOLFOXIRI), and - have had radiological progression of the disease during the first_line treatment, or - have had radiological progression of the disease within a period of 6 months after the last dose of first-line treatment, or - have discontinued part or all of the first_line treatment due to toxicity and have had radiological progression of the disease within a period of 6 months after the last dose of first-line treatment.",ct_inc_427697,AACT,158,NCT02175654,Recent,FOLFOXIRI
5c7430608625dd0473867f8a,570,,,102,Patient,13:52.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_427697,Clinical Trial Inclusion Criteria,UNKNOWN,The patient will have to have received at least one cycle of bevacizumab in combination with FOLFOXIRI + bevacizumab as part of the first_line treatment.,ct_inc_427697,AACT,93,NCT02175654,Recent,FOLFOXIRI
5c7430648625dd04aa867f87,530,,,175,Patient,13:56.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_350185,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Patient immediately eligible for a curative therapy (surgical and/or percutaneous) after discussion in CPR - Patient treated with FOLFIRINOX or FOLFOXIRI in 1st line - Cerebral metastasis - Previous treatment with anti-PD1 or anti-PDL1 - Autoimmune disease that might be aggravated during treatment with an immuno-stimulating agent (patients with type I diabetes, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible) -",ct_exc_350185,AACT,166,NCT03186326,Recent,FOLFOXIRI
5c7430688625dd04c0867f93,30,,,146,Patient,14:00.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_418456,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically proven diagnosis of colorectal adenocarcinoma; - RAS and BRAF wild-type status; - First-line irinotecan-based (FOLFIRI or FOLFOXIRI) cetuximab-containing therapy producing at least a partial response; - First-line progression-free survival in response to cetuximab-containing therapy 6 months; - Documentation of progression to first-line cetuximab within 4 weeks after last cetuximab administration; - Time between the end of first-line therapy and the start of third-line treatment with cetuximab plus irinotecan 4 months; - Second-line oxaliplatin-based (FOLFOXIRI, FOLFOX or XELOX) bevacizumab-containing therapy; - Documentation of progression to second-line treatment; - Measurable disease according to RECIST criteria v1.1; - Have tumor tissue (of primary tumor and metastases or at least one of the two) available for biomarker analysis; - Male or female patients > 18 years of age; - ECOG Performance Status 2; - Life expectancy of at least 3 months; - Adequate bone marrow, liver and renal function assessed within 14 days before starting study treatment; - Women of childbearing potential must have a negative blood pregnancy test at the baseline visit.",ct_inc_418456,AACT,137,NCT02296203,Recent,FOLFOXIRI
5c7430768625dd0569867f8d,1050,,,657,Patient,14:14.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_538571,Clinical Trial Inclusion Criteria,UNKNOWN,"- Histologically confirmed colorectal adenocarcinoma - Metastatic or unresectable disease - Progressive disease based on the following criteria: - Progression during or after first-line chemotherapy for metastatic disease, including any of the following: ",ct_inc_538571,AACT,648,NCT00720512,Recent,FOLFOXIRI
5c7430938625dd0692867f87,790,,,9,Patient,14:43.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_347146,Clinical Trial Exclusion Criteria,LABORATORY_AND_RADIOLOGY_DATA,FOLFOXIRI; 10.,ct_exc_347146,AACT,0,NCT03225937,Recent,FOLFOXIRI
5c74309f8625dd06ea867f91,820,,,121,Patient,14:55.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_467887,Clinical Trial Inclusion Criteria,UNKNOWN,"- General condition considered suitable for radical pelvic surgery - Candidate for systemic therapy with FOLFOX/FOLFOXIRI plus bevacizumab - Adequate bone marrow, hepatic and renal function: - Haemoglobin 80 g/L - ANC 2 x 109/L - Platelet count 100 x 109/",ct_inc_467887,AACT,112,NCT01650428,Recent,FOLFOXIRI
5c7430b68625dd07eb867f88,930,,,77,Patient,15:18.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_521850,Clinical Trial Exclusion Criteria,UNKNOWN,"Prior treatment with 5-FU, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) (treatment with any of the components as separate regimens is allowable).",ct_exc_521850,AACT,68,NCT00941655,Historical,FOLFOXIRI
5c7430bb8625dd0813867f96,370,,,12,Patient,15:23.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_383509,Clinical Trial Inclusion Criteria,UNKNOWN,"RCHOP, GCHOP, RGCVP).High grade transformation from low grade lymphoma (e.g.follicular lymphoma, lymphoplasmacytic lymphoma, chronic lymphocytic leukaemia) is permitted.",ct_inc_383509,AACT,7,NCT02752204,Recent,GCHOP
5c74307f8625dd05b6867fa8,10,,,381,Patient,14:23.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_490450,Clinical Trial Inclusion Criteria,UNKNOWN,"Platelet count 100x109/L Absolute Neutrophil count 1.0x109/L; Serum bilirubin 1.5 x ULN AST (SGOT) or ALT 1.5 x ULN Creatinine clearance (Cockcroft-Gault) > 50 ml/min - Relapsed or refractory DLBCL in which all participants must have received at least one potentially curative established immunochemotherapy lymphoma regimen that contained rituximab (e.g.R-CHOP, R-PMitCEBO, R-GCVP, R-CNOP).Participants must also have failed or be ineligible for salvage/high dose therapy.- Relapsed or refractory DLBCL proven by biopsy (within 6 months of enrolment in trial); either de novo DLBCL or transformed follicular lymphoma.-",ct_inc_490450,AACT,377,NCT01354392,Recent,GCVP
5c7430828625dd05f1867f84,1000,,,613,Patient,14:26.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_539252,Clinical Trial Inclusion Criteria,UNKNOWN,"After the above chemotherapies, patients who once got clinical benefits (i.e.complete response, partial response or stable disease) but progressed following at least 12 weeks of treatment with erlotinib (Tarceva) or gefitinib (Iressa) as the most recent treatment.(Clinical benefit and progression should be confirmed by computed tomography (CT) or magnetic resonance imaging (MRI).In addition, at least 12 weeks of treatment should be 9 weeks or more as the actual treatment period except for treatment pause due to adverse events and other reasons.)As long as the treatment is erlotinib or gefitinib monotherapy, patients can receive multiple regimens of either or both treatments, but one of the regimens should be for at least 12 weeks",ct_inc_539252,AACT,592,NCT00711594,Recent,gefitinib monotherapy
5c7430948625dd06be867f84,700,,,558,Patient,14:44.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_514433,Clinical Trial Inclusion Criteria,UNKNOWN,"Never smoker or light ex-smoker.- Available tumor tissue for determination of EGFR mutational status and immunohistochemistry analysis - Adequate hematologic, hepatic, renal and coagulation function - No active central nervous system metastases - Prior radiotherapy is allowed if 14 days from first dose of study drug and toxicity is resolved; additionally in Phase 2 only, 1 target lesion not irradiated or with definitive progression after prior radiation therapy.- Agreement to use effective contraception.- Phase 2 only: Subjects on Gefitinib monotherapy arm must have documented CR, PR, or SD for 12 weeks prior to disease progression in order to cross over to combination therapy arm.",ct_inc_514433,AACT,537,NCT01039948,Hypothetical,Gefitinib monotherapy
5c7430998625dd06df867f85,850,,,138,Patient,14:49.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_590545,Clinical Trial Inclusion Criteria,UNKNOWN,No more than 1 prior chemotherapy regimen - Two prior chemotherapy regimens allowed provided 1 of the 2 regimens was gefitinib monotherapy as second-line therapy -,ct_inc_590545,AACT,117,NCT00040768,Historical,gefitinib monotherapy
5c7430448625dd0334867f8f,400,,,79,Patient,13:24.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_423558,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - mismatch the inclusion criteria, - got non-CR after GELOX chemotherapy before IMRT, - systematic central nervous system involvement, previous or concomitant malignancies and any coexisting medical problems that could cause poor compliance with the study protocol, - primary lesion not from the upper aerodigestive tract",ct_exc_423558,AACT,74,NCT02229682,Recent,GELOX
5c7430898625dd060e867f8f,470,,,131,Patient,14:33.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_423558,Clinical Trial Inclusion Criteria,AGE,"18-75years - Ann Arbor stage IE,or stage IIE with cervical lymph node involvement - at lease one measurable lesion - received GELOX chemotherapy and got CR before radiotherapy - Eastern CooperativeOncology Group performance status of 0 to 2 - Adequate hematologic function (eg, white blood cell 310e9/l:",ct_inc_423558,AACT,126,NCT02229682,Recent,GELOX
5c74303a8625dd02e7867f88,580,,,143,Patient,13:15.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_421105,Clinical Trial Inclusion Criteria,UNKNOWN,Successful surgical resection - Complete resection (R0) or with microscopic residual disease (R1) - Expected to receive gemcitabine monotherapy as adjuvant chemotherapy 4.,ct_inc_421105,AACT,120,NCT02261714,Recent,gemcitabine monotherapy
5c74303b8625dd02e7867f89,580,,,395,Patient,13:15.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_383626,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Patients with one or more contraindications to tumor biopsy.- Patients who have prior systemic treatment (chemotherapy or any other anti-cancer agent) in advanced setting.- Patients who are currently on anti-cancer treatment including chemotherapy.- Patients with known brain metastases.- Patients with advanced PDAC who are going to be treated with gemcitabine monotherapy in advanced setting.- Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.- Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures.",ct_exc_383626,AACT,372,NCT02750657,Recent,gemcitabine monotherapy
5c74303b8625dd02e7867f8a,580,,,124,Patient,13:15.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_372416,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Use of prior chemotherapy with other agents, except adjuvant chemotherapy with gemcitabine monotherapy since completed more than 6 months - Absence of histological material available to local review (eg diagnostic fine needle aspiration (FNA) or cytology) -",ct_exc_372416,AACT,101,NCT02896803,Historical,gemcitabine monotherapy
5c7430b28625dd07b0867f8b,840,,,43,Patient,15:14.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_341317,Clinical Trial Exclusion Criteria,UNKNOWN,Planning to receive Gemcitabine monotherapy.,ct_exc_341317,AACT,20,NCT03301805,Recent,Gemcitabine monotherapy
5c7430b28625dd07b0867f8c,840,,,86,Patient,15:14.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_341317,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: Patients with following treatment prior to Gemcitabine monotherapy: chemotherapy, immunotherapy, or biologic systemic anticancer therapy within 28 days of study entry.",ct_exc_341317,AACT,63,NCT03301805,Historical,Gemcitabine monotherapy
5c7430bd8625dd0859867f86,1160,,,282,Patient,15:25.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_492736,Clinical Trial Inclusion Criteria,UNKNOWN,"Eligible are the cancers for which gemcitabine has been approved in 4-week schedule;1,000mg/m2 weekly for 3weeks followed by 1 week rest at the 4th week, including non-small cell lung cancer, pancreatic cancer, biliary cancer, and urothelial cancer, to which gemcitabine monotherapy is considered to be appropriate - Adequate organ system functions as defined below;",ct_inc_492736,AACT,259,NCT01324258,Recent,gemcitabine monotherapy
5c7430578625dd03fe867f91,290,,,303,Patient,13:43.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_580019,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Burkitt's, mantle cell, T-cell lymphomas - CD 20-negative lymphoma - HIV or HBV related disease - Central nervous system or meningeal involvement by the lymphoma - Not previously treated with anthracycline-containing regimens - Contraindication to any drug contained in the R-GEMOX chemotherapy regimen -",ct_exc_580019,AACT,298,NCT00169195,Recent,GEMOX
5c7430578625dd03fe867f92,290,,,303,Patient,13:43.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_580019,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Burkitt's, mantle cell, T-cell lymphomas - CD 20-negative lymphoma - HIV or HBV related disease - Central nervous system or meningeal involvement by the lymphoma - Not previously treated with anthracycline-containing regimens - Contraindication to any drug contained in the R-GEMOX chemotherapy regimen -",ct_exc_580019,AACT,298,NCT00169195,Recent,GEMOX
5c7430838625dd05e2867f8f,330,,,185,Patient,14:27.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_474526,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Burkitt, mantle cell and T-cell lymphomas.- Central nervous system or meningeal involvement by the lymphoma.- Contraindication to any drug contained in the R-GEMOX combination chemotherapy.- Treatment with any investigational drug within 30 days before the first planned cycle of chemotherapy and during the study.- Nitrosurea or mitomycin C administration within 6 weeks",ct_exc_474526,AACT,180,NCT01562990,Recent,GEMOX
5c7430838625dd05e2867f90,330,,,185,Patient,14:27.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_474526,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Burkitt, mantle cell and T-cell lymphomas.- Central nervous system or meningeal involvement by the lymphoma.- Contraindication to any drug contained in the R-GEMOX combination chemotherapy.- Treatment with any investigational drug within 30 days before the first planned cycle of chemotherapy and during the study.- Nitrosurea or mitomycin C administration within 6 weeks",ct_exc_474526,AACT,180,NCT01562990,Recent,GEMOX
5c7430b48625dd07e7867f84,770,,,108,Patient,15:16.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_543110,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Patients with advanced incurable solid malignancy who are likely to benefit from GEMOX,ct_inc_543110,AACT,103,NCT00660725,Recent,GEMOX
5c7430b48625dd07e7867f85,770,,,108,Patient,15:16.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_543110,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Patients with advanced incurable solid malignancy who are likely to benefit from GEMOX,ct_inc_543110,AACT,103,NCT00660725,Recent,GEMOX
5c7430368625dd02c0867f84,540,,,65,Patient,13:10.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_590313,Clinical Trial Inclusion Criteria,UNKNOWN,- No prior polifeprosan 20 with carmustine implant (Gliadel wafer) -,ct_inc_590313,AACT,52,NCT00052715,Historical,Gliadel wafer
5c7430368625dd02c0867f85,540,,,77,Patient,13:10.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_591031,Clinical Trial Inclusion Criteria,CHEMOTHERAPEUTICS,No prior or concurrent polifeprosan 20 with carmustine implant (Gliadel wafer) -,ct_inc_591031,AACT,64,NCT00017264,Historical,Gliadel wafer
5c7430368625dd02c0867f86,540,,,106,Patient,13:10.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_591183,Clinical Trial Inclusion Criteria,CHEMOTHERAPEUTICS,- At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin including Gliadel wafer therapy) and recovered Endocrine therapy: - Not specified Radiotherapy: - See Disease Characteristics,ct_inc_591183,AACT,93,NCT00006656,Historical,Gliadel wafer
5c7430398625dd02c0867f87,540,,,63,Patient,13:13.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_591298,Clinical Trial Inclusion Criteria,CHEMOTHERAPEUTICS,No prior polifeprosan 20 with carmustine implant (Gliadel wafer) -,ct_inc_591298,AACT,50,NCT00005976,Historical,Gliadel wafer
5c7430398625dd02c0867f88,540,,,26,Patient,13:13.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_514111,Clinical Trial Exclusion Criteria,UNKNOWN,Placement of Gliadel wafer at surgery.,ct_exc_514111,AACT,13,NCT01044225,Recent,Gliadel wafer
5c7430398625dd02c0867f89,540,,,255,Patient,13:13.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_509597,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients must have recovered from the toxicity of prior therapy; specifically, there must be at least a 3 month interval from the completion of the most recent course of radiation therapy, at least a 3 month interval from the implantation of Gliadel wafer(s), at least a 3 week interval from the completion of a non-nitrosourea-containing chemotherapy regimen, and at least a 6 week interval from the completion of a nitrosourea-containing chemo-regimen",ct_inc_509597,AACT,242,NCT01103375,Historical,Gliadel wafer
5c74303a8625dd02c0867f8a,540,,,61,Patient,13:14.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_519134,Clinical Trial Exclusion Criteria,UNKNOWN,Planned surgery for other diseases Placement of Gliadel wafer at surgery.,ct_exc_519134,AACT,48,NCT00977431,Recent,Gliadel wafer
5c74303b8625dd02c0867f8b,540,,,1882,Patient,13:15.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_517575,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - peripheral neuropathy grade 2 - Myocardial infarction within the past 6 months - NYHA class III or IV heart failure - Uncontrolled angina - Severe uncontrolled ventricular arrhythmias - Electrocardiographic evidence of acute ischemia or active conduction system abnormalities - hypersensitivity to bortezomib, boron, or mannitol - serious medical or psychiatric illness that would interfere with study participation including, but not limited to, any of the following: - Ongoing or active infection requiring IV antibiotics - Psychiatric illness and/or social situations that would limit compliance with study requirements - Disorders associated with a significant immunocompromised state (e.g., HIV, systemic lupus erythematosus) - history of stroke within the past 6 months - other malignancy within the past 3 years except completely resected basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy (i.e., cervical cancer), or low-risk prostate cancer after curative therapy - significant medical illness that, in the investigator's opinion, cannot be adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate this therapy - disease that will obscure toxicity or dangerously alter drug metabolism - viral hepatitis (HBV surface antigen positive) or active hepatitis C infection - Prior or concurrent corticosteroids, automated external defibrillator, analgesics, and other drugs to treat symptoms or prevent complications allowed - concurrent investigational drugs that must be stopped at least 4 months prior to therapy.- prior radiotherapy to the brain - prior cytotoxic or noncytotoxic drug therapy or experimental drug therapy (including chemotherapy, hormonal therapy, or immunotherapy) directed against the brain tumor - prior polifeprosan 20 with carmustine implant (Gliadel wafer) - concurrent stereotactic radiosurgery or brachytherapy - concurrent sargramostim - concurrent inducers of CYP450 3A4 (e.g., enzyme-inducing anti-epileptic drugs [EIAED])",ct_exc_517575,AACT,1869,NCT00998010,Historical,Gliadel wafer
5c74303b8625dd02bd867f8c,1140,,,237,Patient,13:15.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_366212,Clinical Trial Exclusion Criteria,UNKNOWN,"Prior treatment with any cytotoxic chemotherapy, including but not limited to temozolomide, lomustine, Nimustine Hydrochloride (ACNU), bis(chloroethyl) nitrosourea (BCNU), procarbazine, vincristine, carboplatin, irinotecan, Gliadel wafer, cyclophosphamide, etoposide, etc.",ct_exc_366212,AACT,224,NCT02977689,Historical,Gliadel wafer
5c74303b8625dd02c0867f8c,540,,,57,Patient,13:15.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_531448,Clinical Trial Inclusion Criteria,UNKNOWN,"No polifeprosan 20 with carmustine implant (Gliadel wafer) at the time of prior surgery for GBM - No prior treatment for progressive disease - No other concurrent anticancer therapy (e.g., continuation of hormonal therapy for breast or prostate cancer that was diagnosed > 5 years ago)",ct_inc_531448,AACT,44,NCT00814593,Historical,Gliadel wafer
5c74303b8625dd02c0867f8d,540,,,442,Patient,13:15.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_543118,Clinical Trial Exclusion Criteria,UNKNOWN,"Subjects who have had a diagnostic stereotactic biopsy are eligible.- Subjects with more than one focus of tumor or tumor crossing the midline as assessed by coronal cranial MRI scan.- Concomitant significant life-threatening disease from which the subject could reasonably be expected to die within the first 12 months of the study.- Known hypersensitivity reactions to temozolomide, nitrosoureas or any other components of the Gliadel wafer.-",ct_exc_543118,AACT,429,NCT00660621,Recent,Gliadel wafer
5c74303c8625dd02bd867f8d,1140,,,67,Patient,13:16.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_485327,Clinical Trial Inclusion Criteria,UNKNOWN,"No prior therapy with Avastin - No prior or scheduled Gliadel wafer implant unless area of assessment and planned resection is outside the region previously implanted.- No prior interstitial brachytherapy or stereotactic radiosurgery unless area of assessment and planned resection is outside the region previously treated.- No enzyme-inducing anti-epileptic drugs (EIAED) such as carbamazepine, phenytoin, phenobarbital, or primidone within 14 days before Day 1.- Able to undergo repeated magnetic resonance imaging (magnetic resonance imaging (MRI),",ct_inc_485327,AACT,54,NCT01421524,Historical,Gliadel wafer
5c74303d8625dd030d867f84,1150,,,131,Patient,13:17.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_515410,Clinical Trial Inclusion Criteria,COMMENT,"- See Disease Characteristics - Recovered from the toxic effects of prior therapy - Prior interstitial brachytherapy, Gliadel wafer, or stereotactic radiosurgery allowed provided there is confirmation of progressive disease by positron emission tomography",ct_inc_515410,AACT,118,NCT01026493,Historical,Gliadel wafer
5c74303d8625dd030d867f85,1150,,,468,Patient,13:17.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_444623,Clinical Trial Inclusion Criteria,UNKNOWN,Patients will be eligible if the original histology was low-grade glioma and a subsequent histological diagnosis of GBM is made.- Received radiotherapy of at least 45 Gy and temozolomide chemotherapy as initial treatment for GBM.- Unequivocal evidence of recurrent or progressive GBM before or after bevacizumab treatment first based on radiographic appearances then confirmed by histologic confirmation through biopsy or resection.- Prior treatment with Gliadel wafer is allowed if it has been at least 3 months from placement.- There must be an interval of at least 12 weeks from the completion of radiotherapy to start of device treatment.,ct_inc_444623,AACT,455,NCT01954576,Historical,Gliadel wafer
5c74303f8625dd030d867f86,1150,,,548,Patient,13:19.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_584679,Clinical Trial Inclusion Criteria,COMMENT,"Biologic therapy - More than 2 weeks since prior hematopoietic colony-stimulating factors (e.g., filgrastim [G-CSF] or sargramostim [GM-CSF]) except epoetin alfa - More than 2 weeks since prior immunotherapy and recovered - No concurrent biologic therapy - No concurrent prophylactic hematopoietic growth factors (e.g., G-CSF or GM-CSF) unless approved by the study sponsor Chemotherapy - More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered - Prior polifeprosan 20 with carmustine implant (Gliadel wafer) allowed - No other concurrent chemotherapy Endocrine therapy - Must be on stable or deceasing doses of steroids for at least 7 days before baseline Gd-MRI of the brain and before starting study drug -",ct_inc_584679,AACT,535,NCT00107237,Historical,Gliadel wafer
5c74303f8625dd030d867f87,1150,,,640,Patient,13:20.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_560242,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically confirmed intracranial glioblastoma multiforme (GBM) or gliosarcoma - Original histology of low-grade glioma with subsequent histological diagnosis of GBM or gliosarcoma allowed - Recurrent or refractory disease, meeting all of the following criteria: - Must have received prior temozolomide - Pathologic or imaging confirmation of tumor progression or regrowth required - Confirmation of true progressive disease (rather than radiation necrosis) by positron emission tomography, thallium scanning, MRI spectroscopy, or surgical documentation required for patients who received prior interstitial brachytherapy, Gliadel wafer, or stereotactic radiosurgery - Unequivocal radiographic evidence of tumor progression by MRI within the past 14 days (while on a stable dose of steroids for ?",ct_inc_560242,AACT,627,NCT00433381,Historical,Gliadel wafer
5c7430548625dd03c3867f8b,920,,,60,Patient,13:40.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_563652,Clinical Trial Inclusion Criteria,COMMENT,Prior polifeprosan 20 with carmustine implant (Gliadel wafer) allowed at discretion of principal investigator,ct_inc_563652,AACT,47,NCT00387933,Historical,Gliadel wafer
5c7430558625dd03c3867f8c,920,,,322,Patient,13:41.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_591136,Clinical Trial Inclusion Criteria,CHEMOTHERAPEUTICS,- Recovered from prior chemotherapy - At least 4 weeks since prior cytotoxic therapy - At least 2 weeks since prior vincristine - At least 6 weeks since prior nitrosoureas - At least 4 weeks since prior temozolomide - At least 3 weeks since prior procarba,ct_inc_591136,AACT,309,NCT00010049,Historical,Gliadel wafer
5c7430558625dd03c3867f8d,920,,,29,Patient,13:41.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_515940,Clinical Trial Inclusion Criteria,UNKNOWN,No placement of Gliadel wafer during prior surgery,ct_inc_515940,AACT,16,NCT01019434,Historical,Gliadel wafer
5c7430568625dd03fe867f88,290,,,46,Patient,13:42.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_495692,Clinical Trial Exclusion Criteria,UNKNOWN,"Have a carmustine implant (e.g., Gliadel Wafer) Have uncontrolled hypertension (SBP > 140 mmHg or DBP > 90 mmHg for more than 1 week)",ct_exc_495692,AACT,33,NCT01285414,Recent,Gliadel Wafer
5c7430598625dd0411867f85,300,,,154,Patient,13:45.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_388675,Clinical Trial Exclusion Criteria,UNKNOWN,"The patient is enrolled in an interventional clinical trial, in which treatment for CNS tumor(s) is managed through a protocol that excludes Gliadel Wafer treatment.",ct_exc_388675,AACT,141,NCT02684838,Recent,Gliadel Wafer
5c7430598625dd0411867f86,300,,,138,Patient,13:45.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_434616,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - single enhancing lesion of the brain with MRI appearance consistent with GBM - Must be appropriate for Gliadel wafer implant - Pathologic confirmation of GBM - no gross residual tumor found on the immediate postoperative MRI scan - Volumetric measurements of the resection cavity margin being < 50 cc - Karnofsky performance status (KPS) 80% or better - Must be able to undergo MRI imaging with gadolinium - Willingness to have follow up visits at Barrow Neurological Institute(BNI),ct_inc_434616,AACT,125,NCT02085304,Recent,Gliadel wafer
5c74305e8625dd0447867f8f,250,,,101,Patient,13:50.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_586956,Clinical Trial Exclusion Criteria,UNKNOWN,Patients with other cancers excluding nonmelanomatous skin cancers or carcinoma in situ Gliadel wafer placement at the time of surgery <TAB><TAB>,ct_exc_586956,AACT,88,NCT00083512,Recent,Gliadel wafer
5c7430678625dd04aa867f91,530,,,1038,Patient,13:59.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_553038,Clinical Trial Exclusion Criteria,UNKNOWN,"women who are breastfeeding - Patients with unstable or serious concurrent medical or psychiatric conditions that would interfere with study treatment or follow-up - Patients with more than one discrete enhancing lesion on MRI, or radiographic evidence of satellite lesions or leptomeningeal disease not obviously contiguous by FLAIR imaging - Patients who may require further neurosurgery within 4 weeks after REOLYSIN treatment - Patients with a prior history of encephalitis, multiple sclerosis or other significant chronic CNS disease - Patients who have evidence of a current CNS infection, meningeal gliomatosis or gliomatosis cerebri - Patients with tumor that to be treated would require needle or catheter passage through a ventricle, the posterior fossa or basal ganglia; or patients with tumors invading the ventricle - Patients who have previously participated in experimental viral therapy protocols - Patients who have had prior intratumoral gene therapy or other intratumoral therapies - Patients who have had Gliadel wafer therapy less than 6 months prior to enrollment - Patients who have a history of bleeding disorders including congenital or acquired coagulopathies - Patients who have a known history of hepatitis or tuberculosis - Patients who have a known history of hereditary or acquired immunodeficiency including HIV infection - Patients who have impaired non-neurological organ function (>Grade 1) - Patients who have used systemic antiviral (or potentially antiviral) therapies within 28 days of enrollment - Patients who have had brachytherapy or radiosurgery to the brain at any time - Patients with previous or concurrent malignancies at other sites (except surgically-cured carcinoma in situ of the cervix and non-melanoma skin cancer) - Prior or current medical history indicating that a patient may be significantly immunosuppressed",ct_exc_553038,AACT,1025,NCT00528684,Historical,Gliadel wafer
5c7430678625dd04aa867f92,530,,,26,Patient,13:59.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_360600,Clinical Trial Exclusion Criteria,UNKNOWN,Placement of Gliadel wafer at surgery.,ct_exc_360600,AACT,13,NCT03050736,Recent,Gliadel wafer
5c74306c8625dd04f7867f84,550,,,107,Patient,14:04.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_543144,Clinical Trial Exclusion Criteria,UNKNOWN,"Known hypersensitivity reactions to temozolomide, nitrosoureas or any other components of the Gliadel wafer.",ct_exc_543144,AACT,94,NCT00660283,Recent,Gliadel wafer
5c7430718625dd0544867f86,280,,,307,Patient,14:09.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_571467,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - prior cytoreductive surgery for moderate or high grade glioma - prior CNS radiotherapy - prior chemo for this glioma - more than one focus of tumor or tumor crossing the midline per MRI - life expectancy less than 12 months - sensitivity to temozolomide, nitrosoureas, or Gliadel wafer",ct_exc_571467,AACT,294,NCT00283543,Historical,Gliadel wafer
5c74307a8625dd05ab867f84,720,,,168,Patient,14:18.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_588413,Clinical Trial Inclusion Criteria,COMMENT,At least 8 weeks since prior hematopoietic stem cell transplantation Chemotherapy - At least 6 months since prior polifeprosan 20 with carmustine implant (Gliadel wafer) - At least 4 weeks since prior cytotoxic chemotherapy (6 weeks for nitrosoureas and 2 weeks for vincristine) - At least 2 weeks since prior non-cytotoxic chemotherapy - No other prior intracerebral chemotherapy - No concurrent chemotherapy Endocrine therapy - Concurrent steroids allowed Radiotherapy - See Disease Characteristics -,ct_inc_588413,AACT,155,NCT00074334,Historical,Gliadel wafer
5c74308d8625dd063a867f89,390,,,87,Patient,14:37.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_396959,Clinical Trial Exclusion Criteria,UNKNOWN,"For patients with rHGG, the patient intends to undergo treatment with the Gliadel wafer at the time of planned resection (ie, on-study surgery) or has received the Gliadel wafer < 30 days from the date of planned resection.",ct_exc_396959,AACT,74,NCT02576665,Recent,Gliadel wafer
5c74308d8625dd063a867f8a,390,,,188,Patient,14:37.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_514054,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients must not have received more than one other systemic or ITV adjuvant chemotherapy regimen in addition to temozolomide prior to enrollment, not including intracavitary Gliadel wafer placement.",ct_inc_514054,AACT,175,NCT01044966,Historical,Gliadel wafer
5c74308d8625dd063a867f8b,390,,,19,Patient,14:37.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_514054,Clinical Trial Inclusion Criteria,UNKNOWN,"Prior Gliadel wafer placement is not a contradiction to patient enrollment in this trial.- Performance Status Patients must have Karnofsky performance status (KPS) of 60%.- Recovery from Prior Therapy Patients must have recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy, prior to entering this study and must be without significant systemic illness (e.g.infection unresponsive to treatment after 7 days).Such that they are healthy enough to safely undergo tumor biopsy and Ommaya reservoir placement.",ct_inc_514054,AACT,6,NCT01044966,Historical,Gliadel wafer
5c7430938625dd06ac867f84,360,,,279,Patient,14:43.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_316092,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Subject, if female, is pregnant or is breast feeding.- Subject has initiated chemotherapy or radiation treatment for diagnosis of or GBM.- Subject intends to participate in another clinical trial.- Subject intends to undergo treatment with the Gliadel wafer at the time of this surgery.- Subject has an active infection requiring treatment.- Subject has radiographic evidence of multi-focal disease or leptomeningeal dissemination.- Subject has a history of other malignancy, unless the patient has been disease-free for at least 5 years.",ct_exc_316092,AACT,266,NCT03630289,Historical,Gliadel wafer
5c7430938625dd06ac867f85,360,,,26,Patient,14:43.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_351523,Clinical Trial Exclusion Criteria,UNKNOWN,Placement of GLIADEL wafer in the resection cavity; Significant amount of hemorrhage within the resection cavity (seen on immediate post-operative scan); 4.,ct_exc_351523,AACT,13,NCT03168919,Recent,GLIADEL wafer
5c7430938625dd06ac867f86,360,,,158,Patient,14:43.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_505534,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - cytotoxic therapy within the past 4 weeks (6 weeks for BCNU/CCNU) - more than 2 recurrences including present recurrence - Gliadel wafer or wafers implanted within the past 8 weeks - taking more than 8 mg of dexamethasone per day - for intratumoral cohorts, injection of tumor would require violation of ventricular system - any infection requiring antibiotic, anticoagulant, or antiplatelet agents within the past 4 weeks - for intratumoral cohort, bleeding diathesis or use of anticoagulants/antiplatelet agents that cannot be stopped - allergy or intolerance to 5-FC - HIV positive - g.i.condition that would prevent ingestion or absorption of 5-FC - any investigational treatment within the past 30 days - pregnant or breast feeding - received Avastin - history of prior malignancy, excluding basal or squamous cell carcinoma of the skin, with an expected survival of less than 5 years.",ct_exc_505534,AACT,145,NCT01156584,Historical,Gliadel wafer
5c7430938625dd06ac867f87,360,,,182,Patient,14:43.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_503254,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients must have a MRI consistent with a WHO grade IV primary malignant glioma (glioblastoma multiforme or gliosarcoma), and be candidates for surgical resection with Gliadel wafer placement.",ct_inc_503254,AACT,169,NCT01186406,Recent,Gliadel wafer
5c7430938625dd06ac867f88,360,,,134,Patient,14:43.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_496062,Clinical Trial Exclusion Criteria,UNKNOWN,"Recurrent disease Radiosurgery including Gamma Knife, linear accelerator based radiosurgery, CyberKnife and placement of Gliadel wafer Presence of any other active malignancy or prior history of malignancy (except for basal cell carcinoma of the skin)",ct_exc_496062,AACT,121,NCT01280552,Historical,Gliadel wafer
5c7430938625dd06ac867f89,360,,,37,Patient,14:43.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_544278,Clinical Trial Exclusion Criteria,UNKNOWN,"other components of the Gliadel wafer, such as polifeprosan polymer.- Multifocal CNS disease - Diagnosis of prior CNS tumor - Women who are pregnant or lactating.- Posterior Fossa or Brain stem tumor - Open communication of the resection cavity with the ventricular system and tumors that cross the midline.- Concurrent severe medical (e.g., active infection, acute hepatitis, cardiac arrhythmia, unstable angina, congestive heart failure, uncontrolled diabetes mellitus, uncontrolled seizures, pulmonary insufficiency, pulmonary fibrosis, pulmonary embolus, etc) or psychiatric illness, or abnormal laboratory values that preclude surgical candidacy or limits expected survival to less than 12 weeks.",ct_exc_544278,AACT,24,NCT00645385,Historical,Gliadel wafer
5c7430948625dd06ac867f8a,360,,,118,Patient,14:44.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_573697,Clinical Trial Inclusion Criteria,UNKNOWN,Chemotherapy - No prior chemotherapy for the brain tumor except polifeprosan 20 with carmustine implant (Gliadel wafer),ct_inc_573697,AACT,105,NCT00253669,Historical,Gliadel wafer
5c7430948625dd06ac867f8b,360,,,703,Patient,14:44.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_554461,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Have a prior malignancy (other than glioblastoma, or adequately treated carcinoma in situ of the cervix, or nonmelanoma skin cancer), unless that prior malignancy was diagnosed and definitively treated at least 5 years previously with no subsequent evidence of recurrence - Unable to undergo Gd MRI - Prior chemotherapy within the last 5 years - Prior chemotherapy for a brain tumor - Prior radiotherapy of the head - Are unable to discontinue use of carbamazepine, phenobarbital, and phenytoin - History of coagulation disorder associated with bleeding, or recurrent thrombotic events - Are receiving concurrent administration of anticoagulant therapy - Placement of Gliadel wafer at surgery - Have a serious concomitant systemic disorder (for example, active infection including HIV, or cardiac disease) - patients who are pregnant, anticipate becoming pregnant within 6 months after study participation, or are currently breast-feeding - Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry",ct_exc_554461,AACT,690,NCT00509821,Historical,Gliadel wafer
5c7430958625dd06be867f89,700,,,241,Patient,14:45.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_382397,Clinical Trial Exclusion Criteria,UNKNOWN,"Receipt of therapies or procedures prior to first dose including: - Radiation therapy (within 12 weeks of Study Day 1 or has not recovered from the toxic effects of such therapy).- Bevacizumab or other anti-angiogenic therapy.- Gliadel Wafer (within 6 months of Study Day 1, or has not recovered from the toxic effects of such therapy).- Immunotherapeutic agents, vaccines, or monoclonal antibody therapy (within 4 weeks of Study Day 1 or has not recovered from the toxic effects of such cancer therapy).- Temozolomide or other chemotherapy (within 4 weeks of Study Day 1 or 6 weeks for nitrogen mustards, or has not recovered from the toxic effects of such cancer therapy).- Anticoagulation therapy (within 7 days of Study Day 1), except low molecular weight heparins or low dose aspirin.- Other investigational therapy (within 30 days of Study Day 1).- Medications known to cause QTc interval prolongation (within 7 days OR five half-lives prior to Study Day 1, whichever is longer).- Surgical resection of brain tumor (within 4 weeks of Study Day 1 or has not recovered from acute side effects of such therapy except for neurological effects).- Any major surgery (within 4 weeks of Study Day 1, or has not recovered from the effects of such surgery).",ct_exc_382397,AACT,228,NCT02766699,Historical,Gliadel Wafer
5c7430958625dd06be867f8a,700,,,63,Patient,14:45.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_395320,Clinical Trial Exclusion Criteria,UNKNOWN,"The subject intends to undergo treatment with the Gliadel wafer at the time of this surgery Prior intracranial gamma knife, stereotactic radiosurgery, or other focal high-dose radiotherapy is not allowed Severe pulmonary, cardiac or other systemic disease, specifically: - New York Heart Association > Grade 2 congestive heart failure within 6 months prior to study entry, unless asymptomatic and well controlled with medication",ct_exc_395320,AACT,50,NCT02598011,Historical,Gliadel wafer
5c7430958625dd06be867f8b,700,,,136,Patient,14:46.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_437357,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: Radiosurgery including Gamma Knife, linear accelerator based radiosurgery, CyberKnife and placement of Gliadel wafer Presence of any other active malignancy or prior history of malignancy, except for: basal cell carcinoma of the skin, cervical carcinoma in situ, early stage prostate carcinoma not requiring active treatment New York Heart Association >",ct_exc_437357,AACT,123,NCT02049489,Historical,Gliadel wafer
5c7430968625dd06be867f8c,700,,,89,Patient,14:47.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_564383,Clinical Trial Inclusion Criteria,HEMATOLOGY_REVIEW,Must have recovered from toxicity of prior therapy: at least 6 months after Gliadel wafer; at least 8 weeks after hematopoietic stem cell transplant; at least 4 weeks after any cytotoxic chemotherapy or any systemic investigational agent; at least 6 weeks after nitrosoureas; at least 2 weeks after vincristine or non-cytotoxic chemotherapy.,ct_inc_564383,AACT,76,NCT00378235,Historical,Gliadel wafer
5c7430988625dd06d4867f84,450,,,34,Patient,14:48.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_553181,Clinical Trial Inclusion Criteria,UNKNOWN,Previously implanted Gliadel wafer may be eligible.- Karnofsky Performance Status (KPS) of 60.- Laboratory parameters:,ct_inc_553181,AACT,21,NCT00526812,Recent,Gliadel wafer
5c7430988625dd06d4867f85,450,,,81,Patient,14:48.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_474856,Clinical Trial Exclusion Criteria,UNKNOWN,"Gross total resection/partial resection (GBM surgery), placement of Gliadel wafer - Receiving concurrent investigational agents or receipt of an investigational agent within the past 30 days prior to the first day of intensified imaging (W1D1) -",ct_exc_474856,AACT,68,NCT01558687,Historical,Gliadel wafer
5c7430988625dd06d4867f86,450,,,50,Patient,14:48.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_481987,Clinical Trial Inclusion Criteria,UNKNOWN,"No prior RT, chemotherapy (including Gliadel wafer), immunotherapy or therapy with a biologic agent, or hormonal therapy.",ct_inc_481987,AACT,37,NCT01465347,Historical,Gliadel wafer
5c7430998625dd06d4867f87,450,,,172,Patient,14:49.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_514054,Clinical Trial Exclusion Criteria,UNKNOWN,"< 60%.- Patients that have received more than one other systemic or ITV adjuvant chemotherapy regimen in addition to temozolomide, not including intracavitary Gliadel wafer placement.- Patients concurrently receiving other therapies (either brachytherapy or systemic) designed specifically to treat the recurrent GBM.- Patients within 8 weeks of receiving stereotactic or external beam irradiation.- Patients with a platelet count < 75,000/mm3 and ANC",ct_exc_514054,AACT,159,NCT01044966,Recent,Gliadel wafer
5c74309a8625dd06d4867f88,450,,,1008,Patient,14:50.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_471504,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Concurrent psoriasis unless the disease is well controlled and patient is under the care of a specialist for the disorder who agrees to monitor for exacerbations - Prior macular degeneration or diabetic retinopathy - Concurrent serious infection or medical illness that would preclude study therapy - Another malignancy within the past 5 years except for curatively treated carcinoma in situ or basal cell carcinoma of the skin - Porphyria - Glucose- 6 phosphate dehydrogenase (G6PD) deficiency - Alcoholic liver disease - Any other concurrent severe/uncontrolled medical conditions - Currently taking amiodarone - Prior radiotherapy, chemotherapy, immunotherapy, biologic agents (e.g., immunotoxins, immunoconjugates, antisense agents, peptide receptor antagonists, interferons, interleukins, tumour-infiltrating lymphocytes, lymphokine-activated killer cell therapy, or gene therapy), or hormonal therapy for brain tumour - Prior polifeprosan 20 with carmustine implant (Gliadel wafer) or GliaSite brachytherapy - Concurrent cytochrome P450 enzyme-inducing anticonvulsant drugs (e.g., phenytoin, carbamazepine, phenobarbital, primidone, or oxcarbazepine) -",ct_exc_471504,AACT,995,NCT01602588,Recent,Gliadel wafer
5c74309a8625dd06d4867f89,450,,,101,Patient,14:50.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_517452,Clinical Trial Inclusion Criteria,UNKNOWN,- No prior chemotherapy for brain tumor except polifeprosan 20 with carmustine implant (Gliadel wafer) -,ct_inc_517452,AACT,88,NCT00999622,Historical,Gliadel wafer
5c74309a8625dd06d4867f8a,450,,,13,Patient,14:50.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_530954,Clinical Trial Inclusion Criteria,UNKNOWN,Gliadel wafer therapy is not counted as a regimen.,ct_inc_530954,AACT,0,NCT00821080,Recent,Gliadel wafer
5c74309b8625dd06d4867f8b,450,,,277,Patient,14:51.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_540940,Clinical Trial Exclusion Criteria,UNKNOWN,Prior chemotherapy within the last 5 years Prior RTX of the head Receiving concurrent investigational agents or has received an investigational agent within the past 30 days prior to the first dose of cilengitide Prior systemic antiangiogenic therapy Placement of Gliadel wafer at surgery Inability to undergo Gd-MRI.,ct_exc_540940,AACT,264,NCT00689221,Historical,Gliadel wafer
5c74309b8625dd06d4867f8c,450,,,26,Patient,14:51.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_458137,Clinical Trial Exclusion Criteria,UNKNOWN,"Placement of Gliadel wafer No severe, active comorbidity, including any of the following: - Unstable angina",ct_exc_458137,AACT,13,NCT01777919,Recent,Gliadel wafer
5c74309b8625dd06d4867f8d,450,,,81,Patient,14:51.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_584671,Clinical Trial Inclusion Criteria,UNKNOWN,- No prior temozolomide or polifeprosan 20 with carmustine implant (Gliadel wafer) for brain metastasis Endocrine therapy -,ct_inc_584671,AACT,68,NCT00107367,Historical,Gliadel wafer
5c74309e8625dd06f5867f8d,440,,,377,Patient,14:54.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_556215,Clinical Trial Inclusion Criteria,UNKNOWN,"- No prior radiotherapy, chemotherapy, immunotherapy, biologic agents (e.g., immunotoxins, immunoconjugates, antisense agents, peptide receptor antagonists, interferons, interleukins, tumor-infiltrating lymphocytes, lymphokine-activated killer cell therap",ct_inc_556215,AACT,364,NCT00486603,Historical,Gliadel wafer
5c74309f8625dd06f5867f8e,440,,,532,Patient,14:55.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_551511,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Patients who have had prior cytoreductive surgery for high-grade glioma (patients who have had a diagnostic stereotactic biopsy are eligible) - Patients with more than one focus of tumor or tumor crossing the midline as assessed by coronal cranial MRI scan - Concomitant significant life-threatening disease from which the patient could reasonably be expected to die within the first 12 months of the study - Known hypersensitivity reactions to temozolomide, nitrosoureas or any components of the Gliadel wafer - Prior CNS radiotherapy - Patients who have received any prior chemotherapy for malignant glioma prior to the baseline evaluation or patients who are currently being treated with chemotherapeutic agents - Patients with fewer than 100,000 platelets per mm3 or fewer than 3,500 leukocytes per mm3 - Liver function tests greater than or equal to 2.5 times the upper limit of normal (transaminases (SGOT, SGPT), total bilirubin, alkaline phosphatase) -",ct_exc_551511,AACT,519,NCT00548938,Historical,Gliadel wafer
5c7430b18625dd07c6867f88,490,,,105,Patient,15:13.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_409416,Clinical Trial Exclusion Criteria,UNKNOWN,The subject is pregnant or breast feeding The subject intends to undergo treatment with the Gliadel wafer at the time of this surgery or has received the Gliadel wafer < 30 days from W1D1 (surgery),ct_exc_409416,AACT,92,NCT02414165,Recent,Gliadel wafer
5c7430b38625dd078f867f91,350,,,74,Patient,15:15.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_334313,Clinical Trial Exclusion Criteria,UNKNOWN,"Subjects must not have had prior RT, chemotherapy (including Gliadel wafer), immunotherapy or therapy with a biologic agent, or hormonal therapy.",ct_exc_334313,AACT,61,NCT03393000,Historical,Gliadel wafer
5c7430b48625dd07eb867f84,930,,,869,Patient,15:16.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_549566,Clinical Trial Inclusion Criteria,UNKNOWN,"Karnofsky Performance Status greater than or equal to 60.- Life expectancy of at least 12 weeks.- Subjects must have normal organ and marrow function as defined below: - WBC greater than or equal 2,000/mm3 - Absolute neutrophil count greater than or equal to 1,500/mm3 - Platelets greater than or equal to 125,000/mm3 - Total bilirubin less than or equal to 2.0 mg/dl - AST(SGOT)/ALT(SGPT) less than or equal to 2.5 X upper limit of normal - PT / PTT within 1.5 X upper limit of normal - Creatinine less than or equal to 1.7 mg/dl - BUN less than or equal to 40 mg/dl - Hemoglobin > 10 g/dL - Clinical evaluation of cardiac and pulmonary functions consistent with adequate tolerance of surgical procedure.- Negative pregnancy test (beta HCG) if a female of childbearing age and not surgically sterilized.- The effects of BCNU (the active ingredient in the Gliadel wafer) with concomitant Temozolomide on the developing human fetus are unknown.",ct_inc_549566,AACT,856,NCT00574964,Hypothetical,Gliadel wafer
5c7430b58625dd07eb867f85,930,,,184,Patient,15:17.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_542973,Clinical Trial Inclusion Criteria,UNKNOWN,"No prior chemotherapy, radiotherapy, or any experimental therapy for this disease - No prior IV bevacizumab for any other medical condition - No prior carmustine implant (Gliadel Wafer) -",ct_inc_542973,AACT,171,NCT00662506,Historical,Gliadel Wafer
5c7430b78625dd0808867f8b,320,,,670,Patient,15:19.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_589929,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Patients with serious concurrent infection or medical illness which would jeopardize the ability of the patient to receive the chemotherapy outlined in this protocol with reasonable safety - Patients who are pregnant or breast-feeding - Patients who have received prior radiation therapy, chemotherapy, hormonal therapy (except glucocorticoids), immunotherapy or therapy with biologic agents (including immunotoxins, immunoconjugates, antisense, peptide receptor antagonists, interferons, interleukins, TIL, LAK or gene therapy) for their brain tumor - Patients receiving concurrent investigational agents - Patients who have received Gliadel wafer therapy may not participate in this study",ct_exc_589929,AACT,657,NCT00058097,Historical,Gliadel wafer
5c7430b78625dd0808867f8c,320,,,288,Patient,15:19.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_505534,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - at least 18 years of age - for intratumoral cohorts, supratentorial HGG (WHO grade III or IV) - technically unresectable HGG - initial definitive therapy such as surgery with or without adjuvant radiation - subject elected not to undergo treatment with Gliadel wafer - if receiving corticosteroids, dose",ct_inc_505534,AACT,275,NCT01156584,Hypothetical,Gliadel wafer
5c7430b78625dd0808867f8d,320,,,228,Patient,15:19.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_572652,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients must be 18 years of age - Patients must have histologically confirmed supratentorial Grade IV astrocytoma (glioblastoma multiforme) - Patients must not have prior radiation therapy, chemotherapy (including Gliadel wafer), immunotherapy or therapy with a biologic agent, or hormonal therapy.",ct_inc_572652,AACT,215,NCT00267592,Historical,Gliadel wafer
5c7430b88625dd0829867f84,710,,,96,Patient,15:20.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_569801,Clinical Trial Inclusion Criteria,UNKNOWN,"No prior systemic chemotherapy, including polifeprosan 20 with carmustine implant (Gliadel wafer), for the current GBM - Prior chemotherapy for a different cancer allowed -",ct_inc_569801,AACT,83,NCT00305864,Historical,Gliadel wafer
5c7430ba8625dd0829867f85,710,,,141,Patient,15:22.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_590452,Clinical Trial Inclusion Criteria,UNKNOWN,- At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas) - No concurrent polifeprosan 20 with carmustine implant (Gliadel wafer),ct_inc_590452,AACT,128,NCT00045474,Historical,Gliadel wafer
5c7430ba8625dd0829867f86,710,,,71,Patient,15:22.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_481571,Clinical Trial Inclusion Criteria,UNKNOWN,Has the patient elected not to undergo treatment with the Gliadel wafer?- Does the patient have a Karnofsky performance status 70?-,ct_inc_481571,AACT,58,NCT01470794,Recent,Gliadel wafer
5c7430ba8625dd0829867f87,710,,,26,Patient,15:22.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_507999,Clinical Trial Exclusion Criteria,UNKNOWN,Placement of Gliadel wafer at surgery.,ct_exc_507999,AACT,13,NCT01124240,Recent,Gliadel wafer
5c7430bb8625dd083f867f9c,240,,,42,Patient,15:24.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_388675,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients planning to receive Gliadel Wafer, or having already received Gliadel Wafer and having signed consent to enroll in the registry within 14 calendar days after surgery for treatment of central nervous system (CNS) tumor(s), or are currently enrolled in another study where they received Gliadel Wafer.",ct_inc_388675,AACT,29,NCT02684838,Recent,Gliadel Wafer
5c7430bb8625dd0829867f88,710,,,71,Patient,15:24.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_442274,Clinical Trial Inclusion Criteria,UNKNOWN,Has the subject elected not to undergo treatment with the Gliadel wafer?-,ct_inc_442274,AACT,58,NCT01985256,Recent,Gliadel wafer
5c7430bc8625dd083f867f9d,240,,,330,Patient,15:24.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_588122,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Patients with contrast-enhancing tumor component crossing the midline, multi-focal tumor not amenable to gross total resection, or tumor dissemination (subependymal or leptomeningeal).- Expected communication between ventricle and resection cavity that cannot be repaired in order to safely use GLIADEL Wafer.- Patients with clinically significant increased intracranial pressure (e.g., impending herniation), uncontrolled seizures, or requirement for immediate palliative treatment.- Patients who have received any type of stereotactic radiosurgery or brachytherapy, with the exception of the stereotactic radiosurgery boost part of the initial fractionated external beam radiation therapy.-",ct_exc_588122,AACT,317,NCT00076986,Recent,GLIADEL Wafer
5c7430bc8625dd083f867f9e,240,,,86,Patient,15:24.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_588122,Clinical Trial Exclusion Criteria,UNKNOWN,"Patients who have received: 1) prior treatment with IL13-PE38QQR, or, 2) GLIADEL Wafer, or, 3) any intracerebral investigational agent - Patients who have demonstrated a previous hypersensitivity to BCNU or any other component of the GLIADEL Wafer.- Patients unwilling or unable to follow protocol requirements.",ct_exc_588122,AACT,73,NCT00076986,Historical,GLIADEL Wafer
5c7430bc8625dd0829867f89,710,,,322,Patient,15:24.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_531498,Clinical Trial Exclusion Criteria,UNKNOWN,"Prior chemotherapy within the last 5 years Prior RTX of the head (except for low dose RTX for tinea capitis) Receiving concurrent investigational agents or has received an investigational agent within the past 30 days prior to the first dose of cilengitide Prior systemic anti-angiogenic therapy Placement of Gliadel wafer at surgery Planned surgery for other diseases History of recent peptic ulcer disease (endoscopically proven gastric ulcer, duodenal ulcer, or esophageal ulcer) within 6 months of enrollment History of malignancy.",ct_exc_531498,AACT,309,NCT00813943,Historical,Gliadel wafer
5c7430bd8625dd0829867f8a,710,,,37,Patient,15:25.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_549566,Clinical Trial Exclusion Criteria,UNKNOWN,"other components of the Gliadel wafer such as polifeprosan polymer.- Known hypersensitivity to temozolomide.- Subjects may not be receiving any other investigational agents.- If the surgeon determines that placement of Gliadel wafers is inappropriate, or if the final diagnosis is other than anaplastic astrocytoma or glioblastoma, the subject will leave the study and not be further analyzed.- Subjects who have had chemotherapy or radiotherapy at any time for this diagnosis.- A subject will be considered unresectable preoperatively if, in the opinion of the neurosurgeon, the subject is not a candidate for maximal cytoreductive surgery, (i.e., crosses the midline, continuous with the ventricular space).Such subjects will not be eligible for treatment on this protocol.- Diagnosis of prior central nervous system tumor.- Diagnosis of systemic cancer requiring treatment within the past five years (except for non-melanotic carcinoma of the skin or carcinoma in situ of the cervix).- Open communication of the resection cavity with the ventricular system that prevents insertion of Gliadel or tumors that cross the midline.- Posterior fossa or brain stem tumor.- Concurrent severe medical illness (e.g., active infection, acute hepatitis, cardiac arrhythmia, unstable angina, congestive heart failure, uncontrolled diabetes mellitus, uncontrolled seizures, pulmonary insufficiency, pulmonary fibrosis, pulmonary embolus, etc) or psychiatric illness, or abnormal laboratory values that preclude surgical candidacy or limits expected survival to less than 12 weeks.- Pregnant women are excluded from this study because BCNU and/or Temozolomide are pregnancy risk D pharmaceutical agents with the potential for teratogenic or abortifacient effects.",ct_exc_549566,AACT,24,NCT00574964,Hypothetical,Gliadel wafer
5c7430be8625dd0829867f8b,710,,,185,Patient,15:26.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_585649,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically proven GBM, which is recurrent or progressive following surgery or biopsy, external beam radiation therapy, and 1 previous regimen of systemic chemotherapy (Gliadel wafer therapy is not considered systemic chemotherapy).Malignancy is to be documented with a previous histopathological report.- Subjects initially diagnosed with other conditions similar to GBM (such as anaplastic astrocytoma [AA] or low grade glioma) that subsequently progressed to histologically proven GBM and have had surgery or biopsy, external beam radiation therapy, and 1 previous regimen of systemic chemotherapy for the original diagnosis are eligible if they meet all inclusion",ct_inc_585649,AACT,172,NCT00093964,Recent,Gliadel wafer
5c7430bf8625dd0829867f8c,710,,,139,Patient,15:27.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_586227,Clinical Trial Inclusion Criteria,CHEMOTHERAPEUTICS,At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered No prior interstitial chemotherapy such as Gliadel wafer implantation for present brain tumor No concurrent chemotherapy Endocrine therapy: At least 3 weeks since prior hormonal therapy and recovered No concurrent hormonal therapy Radiotherapy: See Disease Characteristics,ct_inc_586227,AACT,126,NCT00004080,Historical,Gliadel wafer
5c7430bf8625dd0829867f8d,710,,,155,Patient,15:27.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_583082,Clinical Trial Inclusion Criteria,UNKNOWN,At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) - At least 3 months since prior polifeprosan 20 with carmustine implant (Gliadel wafer^ ) Endocrine therapy - Must be maintained on a stable corticosteroid dose (approximately 4 mg) for 2 weeks before study entry Radiotherapy - See Disease Characteristics -,ct_inc_583082,AACT,142,NCT00128635,Historical,Gliadel wafer
5c74304f8625dd0397867f89,1090,,,222,Patient,13:35.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_485960,Clinical Trial Inclusion Criteria,UNKNOWN,10 mm with spiral CT scan; bone lesions are not considered measurable - One prior systemic chemotherapy and any number of immunotherapies or vaccine therapies are allowed; prior treatment with hepatic arterial chemotherapy infusion or perfusion or chemoembolization of liver metastasis is allowed; prior treatment with radiation therapy is allowed but not more than 3000 cGy to fields including substantial marrow; patients are not required to have had prior therapy -,ct_inc_485960,AACT,193,NCT01413191,Historical,hepatic arterial chemotherapy
5c7430508625dd0397867f8a,1090,,,287,Patient,13:36.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_584482,Clinical Trial Inclusion Criteria,COMMENT,Biologic therapy - Not specified Chemotherapy - No more than 1 prior systemic chemotherapy for HCC - More than 4 weeks since prior IV chemotherapy and recovered - More than 1 year since prior hepatic arterial cisplatin - More than 4 months since other prior hepatic arterial chemotherapy Endocrine therapy - Not specified Radiotherapy - No prior external hepatic radiotherapy for HCC Surgery - Not specified Other - No other concurrent therapy for HCC -,ct_inc_584482,AACT,258,NCT00109954,Historical,hepatic arterial chemotherapy
5c7430a88625dd0767867f85,670,,,86,Patient,15:04.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_574862,Clinical Trial Inclusion Criteria,UNKNOWN,Biologic therapy - Not specified Chemotherapy - No prior hepatic arterial chemotherapy -,ct_inc_574862,AACT,57,NCT00238160,Historical,hepatic arterial chemotherapy
5c7430458625dd034a867f85,650,,,681,Patient,13:25.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_382237,Clinical Trial Inclusion Criteria,UNKNOWN,PT)- 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants or patient has disseminated intravascular coagulation deemed by investigator to be due to leukemia Activated Partial Thromboplastin Time (aPTT) 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants or patient has disseminated intravascular coagulation deemed by investigator to be due to leukemia Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of HiDAC treatment and again prior to D1 of pembrolizumab treatment.,ct_inc_382237,AACT,676,NCT02768792,Historical,HiDAC
5c7430458625dd034a867f86,650,,,93,Patient,13:25.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_382237,Clinical Trial Inclusion Criteria,COMMENT,Male subjects must agree to use an adequate method of contraception starting with D1 of HiDAC through 120 days after the last dose of study therapy.,ct_inc_382237,AACT,88,NCT02768792,Recent,HiDAC
5c7430458625dd034a867f87,650,,,281,Patient,13:25.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_325767,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Patients age 60 years must have histologically documented AML that is relapsed from, or refractory to, prior standard therapies.- Refractory is defined as failure to achieve CR or CRi following: 1.2 standard dose cytarabine based induction cycles or one HiDAC based cycle, or Failure to respond to one cycle of either standard dose or HiDAC (defined as no decrease in marrow blast percentage from diagnosis on day 14 marrow), or No response after at least 3 cycles of a hypomethylating agent (azacytidine or decitabine).- Relapse is defined as development of recurrent AML (as described by Dhner et al, 2010) after CR or CRi has been achieved with a prior chemotherapy or after progression on a hypomethylating agent.- ECOG PS (performance score) 0",ct_inc_325767,AACT,276,NCT03504410,Historical,HiDAC
5c7430458625dd034a867f88,650,,,44,Patient,13:25.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_514349,Clinical Trial Exclusion Criteria,UNKNOWN,The dose of Ara-C in cycles containing HiDAC should be reduced in the following cases: The hematopoietic recovery in the previous cycle has been longer than 28 days.,ct_exc_514349,AACT,39,NCT01041040,Recent,HiDAC
5c7430458625dd034a867f89,650,,,20,Patient,13:25.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_514349,Clinical Trial Exclusion Criteria,UNKNOWN,"Treatment with HiDAC will be definitively suspended (even that included in the BEA conditioning) when previous toxicity include severe cerebellar ataxia, confusion or another sign of central nervous toxicity that has not another clear explanation.",ct_exc_514349,AACT,15,NCT01041040,Recent,HiDAC
5c7430628625dd047e867f84,910,,,170,Patient,13:54.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_382237,Clinical Trial Exclusion Criteria,UNKNOWN,Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of HiDAC treatment.,ct_exc_382237,AACT,165,NCT02768792,Historical,HiDAC
5c7430628625dd047e867f85,910,,,54,Patient,13:54.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_382237,Clinical Trial Exclusion Criteria,COMMENT,use of steroid eye drops starting at the time of HiDAC administration is allowed.,ct_exc_382237,AACT,49,NCT02768792,Recent,HiDAC
5c7430758625dd054f867f8c,340,,,189,Patient,14:13.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_453448,Clinical Trial Exclusion Criteria,UNKNOWN,"< 20,000/uL; hydroxyurea can be overlapped with 5-azacytidine in selected cases, after consultation with the study chair; hydroxyurea must be discontinued before the initiation of the HiDAC/mitoxantrone chemotherapy) -",ct_exc_453448,AACT,184,NCT01839240,Recent,HiDAC
5c7430758625dd054f867f8d,340,,,64,Patient,14:13.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_453448,Clinical Trial Exclusion Criteria,UNKNOWN,Prior treatment with 5-azacytidine followed immediately by HiDAC and mitoxantrone as proposed in this study (note:,ct_exc_453448,AACT,59,NCT01839240,Historical,HiDAC
5c7430758625dd054f867f8e,340,,,55,Patient,14:13.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_453448,Clinical Trial Exclusion Criteria,UNKNOWN,prior therapy with 5-azacytidine or decitabine or HiDAC or mitoxantrone would be allowed-in patients with relapsed/refractory disease- unless the prior therapy was identical to the schema/schedule proposed in this study) -,ct_exc_453448,AACT,50,NCT01839240,Historical,HiDAC
5c74307b8625dd05ab867f86,720,,,233,Patient,14:19.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_502843,Clinical Trial Exclusion Criteria,UNKNOWN,"AML - Had completed a single cycle of treatment containing a total dose of 5 g/m2 or more of cytarabine within 90 days before randomization - Refractory to or relapsed within the previous 3 months after therapy with an IDAC- or HIDAC-containing regimen - Had received a hematopoietic stem cell transplant (HSCT) within the previous 90 days - Had received active immunosuppressive therapy for graft-versus-host disease (GVHD) within 2 weeks before study start - Had any other severe concurrent disease, or have a history of serious disease involving the heart, kidney, liver, or other organ system - Had evidence of central nervous system involvement of active AML - Had other active malignancies (including other hematologic malignancies) or been diagnosed with other malignancies within the last 12 months, except nonmelanoma skin cancer or cervical intraepithelial neoplasia - Had an active, uncontrolled infection - Had received any other investigational therapy within 14 days or not recovered from acute affects of the other investigational therapy - Had received prior or current hydroxyurea or medications to reduce blast count within 24 hours before randomization - Had received previous treatment with vosaroxin - Pregnant or lactating - Had any other medical, psychological, or social condition that may interfere with consent, study participation, or follow-up - Had known HIV seropositivity",ct_exc_502843,AACT,228,NCT01191801,Historical,HIDAC
5c7430818625dd05d0867f8b,410,,,90,Patient,14:25.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_383144,Clinical Trial Inclusion Criteria,UNKNOWN,"document.- Willing to comply with the treatment assignment: - Intent to proceed with HiDAC consolidation for LAM VAF <2.5% - Intent to proceed with either HiDAC consolidation or allogeneic stem cell transplantation, at the discretion of the treating physician, for LAM 2.5%",ct_inc_383144,AACT,85,NCT02756962,Recent,HiDAC
5c74308e8625dd063a867f8e,390,,,77,Patient,14:38.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_433339,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: Inclusion Criteria for Outpatient Administration of HiDAC - Unequivocal diagnosis of AML (>20% blasts in the bone marrow based on the WHO classification), excluding M3 (acute promyelocytic leukemia).- Documented complete remission (CR) following induction chemotherapy as defined as (18): - Bone marrow with <5% blasts; absence of blasts with Auer rods - Absolute neutrophil count",ct_inc_433339,AACT,72,NCT02101983,Recent,HiDAC
5c74308e8625dd065b867f9c,20,,,46,Patient,14:38.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_509078,Clinical Trial Inclusion Criteria,UNKNOWN,"methotrexate [MTX]/high-dose cytarabine [HiDAC]; cyclophosphamide, vincristine, doxorubicin, and dexamethasone [hyperCVAD]; bortezomib, thalidomide, dexamethasone and 4-day continuous infusions of cisplatin, doxorubicin, cyclophosphamide, and etoposide [VTD-PACE])",ct_inc_509078,AACT,41,NCT01110135,Recent,HiDAC
5c7430918625dd065b867fa1,20,,,941,Patient,14:41.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_509078,Clinical Trial Exclusion Criteria,UNKNOWN,- Fludarabine or other nucleoside analog (except gemcitabine or cytarabine) therapy within 24 months of registration; patients with limited exposure to fludarabine/other nucleoside analog therapy within 24 months may be considered eligible with review and,ct_exc_509078,AACT,936,NCT01110135,Historical,HiDAC
5c7430a58625dd0737867f9b,180,,,36,Patient,15:01.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_500526,Clinical Trial Inclusion Criteria,UNKNOWN,(These patients are given NOVE-HiDAC as frontline therapy at Princess Margaret Hospital).- Positivity for c-kit (CD117) in at least 30% of blasts as measured by flow cytometry.,ct_inc_500526,AACT,31,NCT01222143,Recent,HiDAC
5c7430bf8625dd086b867f8a,60,,,51,Patient,15:27.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_565645,Clinical Trial Inclusion Criteria,UNKNOWN,Patients on consolidation chemo regimens like HIDAC and HyperCVAD type B with expected duration of neutropenia (ANC < 500/ml) of at least 10 days,ct_inc_565645,AACT,46,NCT00361517,Recent,HIDAC
5c7430468625dd0334867f94,400,,,317,Patient,13:26.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_593979,Clinical Trial Exclusion Criteria,MEDICATIONS,"Excluded: - The following nucleoside analogs: - IV ganciclovir, IV acyclovir for more than 2 weeks total duration, oral acyclovir at doses > 1000 mg/day, vidarabine, amantadine hydrochloride, cytarabine, idoxuridine.- FIAU, FIAC, foscarnet, CMV hyperimmune globulin, IV immune globulin, CMV monoclonal antibody, HPMPC.- Imipenem-cilastatin (Primaxin).Patients with the following prior condition are excluded: History of hypersensitivity to acyclovir.",ct_exc_593979,AACT,312,NCT00002095,Historical,HPMPC
5c7430468625dd0334867f95,400,,,129,Patient,13:26.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_593979,Clinical Trial Exclusion Criteria,MEDICATIONS,"Excluded within the past 60 days: Ganciclovir, foscarnet, FIAC, FIAU, CMV hyperimmune globulin, CMV monoclonal antibody, or HPMPC.",ct_exc_593979,AACT,124,NCT00002095,Recent,HPMPC
5c74305b8625dd0411867f8f,300,,,27,Patient,13:47.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_564768,Clinical Trial Exclusion Criteria,UNKNOWN,"Foscarnet, Cidofovir (HPMPC), Acyclovir, Valaciclovir, Famciclovir/Penciclovir, Lobucavir, Antisense compound - Antimetabolites: Fluorouracil, Mercaptopurine, Methotrexate, Thioguanine, Hydroxurea - Alkylating substances: Busulfan, Carmustine, Chlorambucil, Cisplatin, Cyclophosphamide, Dacarbazine (DTIC), Lomustine, Mechlormethamine, Melphalan, Streptozotocin, Tiothepa, Uracil mustard - anti CMV immunoglobulins (except in the case of signs of CMV infection) such as anti CMV hyperimmunoglobulins and immunoglobulins - Known hypersensitivity to ganciclovir - Patients with active CMV infection or positive viraemia at randomization - Severe gastro-intestinal diseases which may interfere with the oral resorption of ganciclovir - Conversion of immunosuppression (Replacement of MMF) - Participation in another clinical drug trial",ct_exc_564768,AACT,22,NCT00373165,Recent,HPMPC
5c74306c8625dd04e1867f89,500,,,168,Patient,14:04.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_593930,Clinical Trial Exclusion Criteria,MEDICATIONS,"Excluded: - Intravenous foscarnet for current episode of HSV.- Acyclovir, interferon, or any investigational drug that might have anti-HSV activity (e.g., 256U87, HPMPC, BVDaraU, trifluridine).Patients with the following prior condition are excluded: Previous participation in the study.",ct_exc_593930,AACT,163,NCT00002144,Historical,HPMPC
5c7430848625dd0603867f89,600,,,36,Patient,14:28.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_593932,Clinical Trial Exclusion Criteria,TIME,Prior systemic or intravitreal HPMPC.Drug,ct_exc_593932,AACT,31,NCT00002142,Historical,HPMPC
5c74309c8625dd06f5867f86,440,,,237,Patient,14:52.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_522834,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Written Informed Consent.- Age 18 years.- Confirmed diagnosis of Polycythemia Vera according to the revised WHO criteria.- JAK2V617F positivity.- Non-response to the maximum tolerated dose of hydroxyurea monotherapy for at least 3 months.- ECOG performance status <3.- Use of an effective means of contraception for women of childbearing potential and men with partners of childbearing potential.- Willingness and capability to comply with the requirements of the study.,ct_inc_522834,AACT,214,NCT00928707,Recent,hydroxyurea monotherapy
5c7430678625dd04c0867f89,30,,,119,Patient,13:59.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_509915,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: Patients with a diagnosis of ALL, LL, or Burkitt's receiving induction chemotherapy with Hyper-CVAD, any variant of Hyper-CVAD or augmented BFM at MD Anderson Cancer Center.",ct_inc_509915,AACT,109,NCT01099202,Recent,Hyper-CVAD
5c7430678625dd04c0867f8a,30,,,117,Patient,13:59.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_558778,Clinical Trial Inclusion Criteria,UNKNOWN,"Age greater than or equal to 18 years Newly diagnosed ALL or LL receiving chemotherapy with augmented BFM, Hyper-CVAD or any variant of hyper-CVAD.",ct_inc_558778,AACT,107,NCT00452439,Recent,Hyper-CVAD
5c74307e8625dd05b6867f94,10,,,415,Patient,14:22.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_583905,Clinical Trial Inclusion Criteria,UNKNOWN,"Chemotherapy combinations may include, but are not limited to: CHOP (Cyclophosphamide, doxorubicin, vincristine, prednisone), R-CHOP (Rituximab, Cyclophosphamide, doxorubicin, vincristine, prednisone), FCM (Fludarabine, cyclophosphamide, mitoxantrone), R-FCM (Rituximab,Fludarabine, cyclophosphamide, mitoxantrone), ICE(Ifosfamide, carboplatin, etoposide), DHAP (Dexamethasone, cisplatin, cytarabine) and hyper-CVAD (Cyclophosphamide, doxorubicin, vincristine, dexamethasone).",ct_inc_583905,AACT,405,NCT00117598,Recent,hyper-CVAD
5c74307f8625dd05b6867f9a,10,,,52,Patient,14:23.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_570297,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients whose therapy was switched to (R)Hyper-CVAD after initial treatment with (R)CHOP, because of aggressive disease will also be eligible for the study.",ct_inc_570297,AACT,42,NCT00299182,Recent,Hyper-CVAD
5c7430898625dd0628867f96,90,,,83,Patient,14:33.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_485061,Clinical Trial Inclusion Criteria,UNKNOWN,and/or bcr-abl positive) (includes patients initiated on first course of hyper-CVAD before cytogenetics known),ct_inc_485061,AACT,73,NCT01424982,Recent,hyper-CVAD
5c7430918625dd065b867fa3,20,,,120,Patient,14:41.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_555186,Clinical Trial Inclusion Criteria,UNKNOWN,"Previously untreated ALL, Burkitt's lymphoma, or lymphoblastic leukemia receiving induction chemotherapy with hyper-CVAD or variants of the hyper-CVAD regimen.",ct_inc_555186,AACT,110,NCT00500240,Recent,hyper-CVAD
5c7430ae8625dd079a867f8b,380,,,85,Patient,15:10.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_533080,Clinical Trial Inclusion Criteria,COMMENT,"If the patient has been initiated on the protocol defined regimen (i.e.the hyper-CVAD regimen without a tyrosine kinase inhibitor) before the Philadelphia chromosome (Ph)/BCR-ABL status was known, the patient may be registered on the protocol and start dasatinib; in this first course, dasatinib will be administered up to day 14 (i.e.if the patient is registered on day 5 and starts therapy on day 6, only 8 days of dasatinib will be administered and dasatinib will be completed on day 14) -",ct_inc_533080,AACT,75,NCT00792948,Recent,hyper-CVAD
5c7430c08625dd086b867f8b,60,,,83,Patient,15:28.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_563436,Clinical Trial Inclusion Criteria,UNKNOWN,and/or BCR-ABL positive) (includes patients initiated on first course of hyper-CVAD before cytogenetics known).These groups will be analyzed separately.,ct_inc_563436,AACT,73,NCT00390793,Recent,hyper-CVAD
5c7430c08625dd086b867f8c,60,,,63,Patient,15:28.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_493063,Clinical Trial Inclusion Criteria,UNKNOWN,Allow previous administration of up to one course of Hyper-CVAD and/or FDA approved TKI.,ct_inc_493063,AACT,53,NCT01319981,Recent,Hyper-CVAD
5c74303c8625dd02f6867f89,120,,,342,Patient,13:16.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_553965,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion criteria: - Presence or history of CNS disease (either CNS lymphoma or lymphomatous meningosis) - Newly diagnosed mantle cell lymphoma - Patients suitable for intensive treatment (e.g., hyperfractionated cyclophosphamide, vincristine, doxorubicin hydrochloride and dexamethasone with high-dose methotrexate and cytarabine [HyperCVAD])",ct_exc_553965,AACT,333,NCT00516412,Historical,HyperCVAD
5c74303c8625dd02f6867f8a,120,,,342,Patient,13:16.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_553965,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion criteria: - Presence or history of CNS disease (either CNS lymphoma or lymphomatous meningosis) - Newly diagnosed mantle cell lymphoma - Patients suitable for intensive treatment (e.g., hyperfractionated cyclophosphamide, vincristine, doxorubicin hydrochloride and dexamethasone with high-dose methotrexate and cytarabine [HyperCVAD])",ct_exc_553965,AACT,333,NCT00516412,Historical,HyperCVAD
5c7430538625dd03c7867f97,0,,,210,Patient,13:39.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_411113,Clinical Trial Inclusion Criteria,UNKNOWN,"Planned to receive chemotherapy for 6 cycles which the treating physician plans to utilize for pegfilgrastim to minimize risk for neutropenic fever, including but not limited to R-CHOP, R-EPOCH, and R-HyperCVAD, CHOP, and SMILE.",ct_inc_411113,AACT,201,NCT02392039,Recent,HyperCVAD
5c7430538625dd03c7867f98,0,,,210,Patient,13:39.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_411113,Clinical Trial Inclusion Criteria,UNKNOWN,"Planned to receive chemotherapy for 6 cycles which the treating physician plans to utilize for pegfilgrastim to minimize risk for neutropenic fever, including but not limited to R-CHOP, R-EPOCH, and R-HyperCVAD, CHOP, and SMILE.",ct_inc_411113,AACT,201,NCT02392039,Recent,HyperCVAD
5c7430548625dd03c7867fb5,0,,,187,Patient,13:40.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_389834,Clinical Trial Inclusion Criteria,UNKNOWN,"These patients include: - Acute myeloid leukemia patients receiving induction and consolidation (first line and relapsed/refractory) - Acute lymphoid leukemia patients receiving HyperCVAD/R (cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, rituximab) - Lymphoma patients receiving ICE (ifosfamide, carboplatin, etoposide), DA-R-EPOCH (dose-adjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin), and other inpatient lymphoma regimens - Patients receiving other inpatient chemotherapy regimens that are given on a monthly basis - Patients who have received an allogeneic stem cell transplant - Have given informed consent - May have previously received inhaled or IV pentamidine",ct_inc_389834,AACT,178,NCT02669706,Recent,HyperCVAD
5c7430548625dd03c7867fb6,0,,,187,Patient,13:40.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_389834,Clinical Trial Inclusion Criteria,UNKNOWN,"These patients include: - Acute myeloid leukemia patients receiving induction and consolidation (first line and relapsed/refractory) - Acute lymphoid leukemia patients receiving HyperCVAD/R (cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, rituximab) - Lymphoma patients receiving ICE (ifosfamide, carboplatin, etoposide), DA-R-EPOCH (dose-adjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin), and other inpatient lymphoma regimens - Patients receiving other inpatient chemotherapy regimens that are given on a monthly basis - Patients who have received an allogeneic stem cell transplant - Have given informed consent - May have previously received inhaled or IV pentamidine",ct_inc_389834,AACT,178,NCT02669706,Recent,HyperCVAD
5c74305b8625dd043c867f84,50,,,137,Patient,13:48.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_482519,Clinical Trial Inclusion Criteria,UNKNOWN,Subjects must have received at least 3 cycles of RCHOP-like or any anthracycline base chemotherapy or at least 2 full cycles of HyperCVAD-like chemotherapy.- Persistent lymphoma and stable disease after at least 2 cycles of RCHOP-like or any anthracycline base chemotherapy or at least 1 full cycle of HyperCVAD-like chemotherapy (part A and B).- Progressive disease despite at least 1 cycle of RCHOP-like or any anthracycline base chemotherapy or at least 1 cycle (part A or A and B) of HyperCVAD-like chemotherapy.,ct_inc_482519,AACT,128,NCT01458366,Recent,HyperCVAD
5c74305b8625dd043c867f85,50,,,137,Patient,13:48.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_482519,Clinical Trial Inclusion Criteria,UNKNOWN,Subjects must have received at least 3 cycles of RCHOP-like or any anthracycline base chemotherapy or at least 2 full cycles of HyperCVAD-like chemotherapy.- Persistent lymphoma and stable disease after at least 2 cycles of RCHOP-like or any anthracycline base chemotherapy or at least 1 full cycle of HyperCVAD-like chemotherapy (part A and B).- Progressive disease despite at least 1 cycle of RCHOP-like or any anthracycline base chemotherapy or at least 1 cycle (part A or A and B) of HyperCVAD-like chemotherapy.,ct_inc_482519,AACT,128,NCT01458366,Recent,HyperCVAD
5c74305e8625dd0452867f84,40,,,105,Patient,13:50.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_410550,Clinical Trial Inclusion Criteria,UNKNOWN,"de Buenos Aires infusion of high-dose cyclophosphamide for conducting MSCH prior BMT, GATLA and HyperCVAD in the period 2015-2017.",ct_inc_410550,AACT,96,NCT02399358,Historical,HyperCVAD
5c74305e8625dd0452867f85,40,,,105,Patient,13:50.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_410550,Clinical Trial Inclusion Criteria,UNKNOWN,"de Buenos Aires infusion of high-dose cyclophosphamide for conducting MSCH prior BMT, GATLA and HyperCVAD in the period 2015-2017.",ct_inc_410550,AACT,96,NCT02399358,Historical,HyperCVAD
5c74305f8625dd0452867f87,40,,,336,Patient,13:51.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_344212,Clinical Trial Inclusion Criteria,COMMENT,"Prior Treatment: Previously untreated or has received a maximum of one cycle of any combination chemotherapy (e.g.cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP), CHOEP, DA-EPOCH, doxorubicin, cyclophosphamide, cytarabine, vincristine, methotrexate/Etoposide, ifosfamide, cytarabine, methotrexate (CODOX-M/IVAC), HyperCVAD) within 4 weeks of study entry.",ct_inc_344212,AACT,327,NCT03264131,Historical,HyperCVAD
5c74305f8625dd0452867f88,40,,,336,Patient,13:51.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_344212,Clinical Trial Inclusion Criteria,COMMENT,"Prior Treatment: Previously untreated or has received a maximum of one cycle of any combination chemotherapy (e.g.cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP), CHOEP, DA-EPOCH, doxorubicin, cyclophosphamide, cytarabine, vincristine, methotrexate/Etoposide, ifosfamide, cytarabine, methotrexate (CODOX-M/IVAC), HyperCVAD) within 4 weeks of study entry.",ct_inc_344212,AACT,327,NCT03264131,Historical,HyperCVAD
5c7430638625dd0452867fa2,40,,,398,Patient,13:55.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_359513,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Histological confirmation of relapsed/refractory diffuse large B-cell lymphoma after prior rituximab and anthracycline-containing systemic treatment regimen such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), R-EPOCH (rituximab, etoposide phosphate, prednisone, vincristine sulfate, cyclophosphamide, doxorubicin hydrochloride), R-HyperCVAD (rituximab, cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone) etc.",ct_inc_359513,AACT,389,NCT03064867,Historical,HyperCVAD
5c7430638625dd0452867fa3,40,,,398,Patient,13:55.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_359513,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Histological confirmation of relapsed/refractory diffuse large B-cell lymphoma after prior rituximab and anthracycline-containing systemic treatment regimen such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), R-EPOCH (rituximab, etoposide phosphate, prednisone, vincristine sulfate, cyclophosphamide, doxorubicin hydrochloride), R-HyperCVAD (rituximab, cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone) etc.",ct_inc_359513,AACT,389,NCT03064867,Historical,HyperCVAD
5c7430698625dd04c0867f9a,30,,,336,Patient,14:01.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_387514,Clinical Trial Inclusion Criteria,UNKNOWN," may enroll in the study based on the local laboratory evaluation, but these should be confirmed by the UNC Hematopathology Laboratory retrospectively - Positive for CD20 via immunophenotyping - Prior Treatment: Previously untreated or who received a maximum of one cycle of combination chemotherapy (i.e.R-CHOP, R-EPOCH, or R-hyperCVAD) within 4 weeks of study entry except patients who require dose reduction after the first cycle of off-study R-EPOCH.- Measurable disease as assessed by 2 dimensional measurements by CT ( 1.5 cm).- Adequate organ function as demonstrated by: - Bone marrow function (without platelet transfusion or myeloid growth factor support within two weeks of screening) as demonstrated by: - Hemoglobin 8 g/dL - Absolute neutrophil count (ANC) 1,000 cells/mm3 - Platelet count 75,000/mm3 - And hepatic and renal function as demonstrated by: - Aspartate aminotransferase (AST) and Alanine Aminotransferase (ALT)",ct_inc_387514,AACT,327,NCT02700022,Historical,hyperCVAD
5c7430698625dd04c0867f9b,30,,,336,Patient,14:01.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_387514,Clinical Trial Inclusion Criteria,UNKNOWN," may enroll in the study based on the local laboratory evaluation, but these should be confirmed by the UNC Hematopathology Laboratory retrospectively - Positive for CD20 via immunophenotyping - Prior Treatment: Previously untreated or who received a maximum of one cycle of combination chemotherapy (i.e.R-CHOP, R-EPOCH, or R-hyperCVAD) within 4 weeks of study entry except patients who require dose reduction after the first cycle of off-study R-EPOCH.- Measurable disease as assessed by 2 dimensional measurements by CT ( 1.5 cm).- Adequate organ function as demonstrated by: - Bone marrow function (without platelet transfusion or myeloid growth factor support within two weeks of screening) as demonstrated by: - Hemoglobin 8 g/dL - Absolute neutrophil count (ANC) 1,000 cells/mm3 - Platelet count 75,000/mm3 - And hepatic and renal function as demonstrated by: - Aspartate aminotransferase (AST) and Alanine Aminotransferase (ALT)",ct_inc_387514,AACT,327,NCT02700022,Historical,hyperCVAD
5c74307d8625dd05b6867f8c,10,,,272,Patient,14:21.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_407421,Clinical Trial Inclusion Criteria,UNKNOWN,"patients with newly diagnosed acute lymphoid leukemia who approve to get induction chemotherapy with VPDL (vincristine + prednisolone + daunorubicin + L-asparaginase), C-VPDL (cyclophosphamide + vincristine + prednisolone + daunorubicin + L-asparaginase), or (R)-hyperCVAD ((Rituximab) + cyclophosphamide + vincristine + Adriamycin + dexamethasone)",ct_inc_407421,AACT,263,NCT02440178,Recent,hyperCVAD
5c74307d8625dd05b6867f8d,10,,,272,Patient,14:21.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_407421,Clinical Trial Inclusion Criteria,UNKNOWN,"patients with newly diagnosed acute lymphoid leukemia who approve to get induction chemotherapy with VPDL (vincristine + prednisolone + daunorubicin + L-asparaginase), C-VPDL (cyclophosphamide + vincristine + prednisolone + daunorubicin + L-asparaginase), or (R)-hyperCVAD ((Rituximab) + cyclophosphamide + vincristine + Adriamycin + dexamethasone)",ct_inc_407421,AACT,263,NCT02440178,Recent,hyperCVAD
5c74307f8625dd05b6867f9b,10,,,206,Patient,14:23.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_570297,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: Patients with a diagnosis of previously untreated aggressive non-Hodgkin's lymphoma, including patients with mantle cell lymphoma, who will be or are receiving treatment with R-HyperCVAD and R-Ara-C/MTX.Patients",ct_inc_570297,AACT,197,NCT00299182,Recent,HyperCVAD
5c74307f8625dd05b6867f9c,10,,,206,Patient,14:23.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_570297,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: Patients with a diagnosis of previously untreated aggressive non-Hodgkin's lymphoma, including patients with mantle cell lymphoma, who will be or are receiving treatment with R-HyperCVAD and R-Ara-C/MTX.Patients",ct_inc_570297,AACT,197,NCT00299182,Recent,HyperCVAD
5c74308e8625dd065b867f99,20,,,121,Patient,14:38.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_509078,Clinical Trial Inclusion Criteria,UNKNOWN,"methotrexate [MTX]/high-dose cytarabine [HiDAC]; cyclophosphamide, vincristine, doxorubicin, and dexamethasone [hyperCVAD]; bortezomib, thalidomide, dexamethasone and 4-day continuous infusions of cisplatin, doxorubicin, cyclophosphamide, and etoposide [VTD-PACE])",ct_inc_509078,AACT,112,NCT01110135,Recent,hyperCVAD
5c74308e8625dd065b867f9a,20,,,121,Patient,14:38.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_509078,Clinical Trial Inclusion Criteria,UNKNOWN,"methotrexate [MTX]/high-dose cytarabine [HiDAC]; cyclophosphamide, vincristine, doxorubicin, and dexamethasone [hyperCVAD]; bortezomib, thalidomide, dexamethasone and 4-day continuous infusions of cisplatin, doxorubicin, cyclophosphamide, and etoposide [VTD-PACE])",ct_inc_509078,AACT,112,NCT01110135,Recent,hyperCVAD
5c7430918625dd065b867f9e,20,,,952,Patient,14:41.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_509078,Clinical Trial Exclusion Criteria,UNKNOWN,- Fludarabine or other nucleoside analog (except gemcitabine or cytarabine) therapy within 24 months of registration; patients with limited exposure to fludarabine/other nucleoside analog therapy within 24 months may be considered eligible with review and,ct_exc_509078,AACT,943,NCT01110135,Historical,hyperCVAD
5c7430918625dd065b867f9f,20,,,952,Patient,14:41.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_509078,Clinical Trial Exclusion Criteria,UNKNOWN,- Fludarabine or other nucleoside analog (except gemcitabine or cytarabine) therapy within 24 months of registration; patients with limited exposure to fludarabine/other nucleoside analog therapy within 24 months may be considered eligible with review and,ct_exc_509078,AACT,943,NCT01110135,Historical,hyperCVAD
5c7430bf8625dd086b867f88,60,,,65,Patient,15:27.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_565645,Clinical Trial Inclusion Criteria,UNKNOWN,Patients on consolidation chemo regimens like HIDAC and HyperCVAD type B with expected duration of neutropenia (ANC < 500/ml) of at least 10 days,ct_inc_565645,AACT,56,NCT00361517,Recent,HyperCVAD
5c7430bf8625dd086b867f89,60,,,65,Patient,15:27.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_565645,Clinical Trial Inclusion Criteria,UNKNOWN,Patients on consolidation chemo regimens like HIDAC and HyperCVAD type B with expected duration of neutropenia (ANC < 500/ml) of at least 10 days,ct_inc_565645,AACT,56,NCT00361517,Recent,HyperCVAD
5c7430548625dd03c7867fb3,0,,,189,Patient,13:40.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_389834,Clinical Trial Inclusion Criteria,UNKNOWN,"These patients include: - Acute myeloid leukemia patients receiving induction and consolidation (first line and relapsed/refractory) - Acute lymphoid leukemia patients receiving HyperCVAD/R (cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, rituximab) - Lymphoma patients receiving ICE (ifosfamide, carboplatin, etoposide), DA-R-EPOCH (dose-adjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin), and other inpatient lymphoma regimens - Patients receiving other inpatient chemotherapy regimens that are given on a monthly basis - Patients who have received an allogeneic stem cell transplant - Have given informed consent - May have previously received inhaled or IV pentamidine",ct_inc_389834,AACT,178,NCT02669706,Recent,HyperCVAD/R
5c74308e8625dd0619867f8d,1250,,,67,Patient,14:38.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_431267,Clinical Trial Exclusion Criteria,UNKNOWN,(this may not be a necessary exclusion for an ibrutinib monotherapy protocol),ct_exc_431267,AACT,46,NCT02129062,Recent,ibrutinib monotherapy
5c7430b88625dd07fd867f93,210,,,89,Patient,15:20.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_311832,Clinical Trial Inclusion Criteria,UNKNOWN,Treatment naive CLL patients - Cohort 2: Subjects must be receiving ibrutinib monotherapy for at least 6 months prior to administration of the first vaccine dose - Cohort 3: Subjects must be receiving acalabrutinib monotherapy for at least 6 months prior to administration of the first vaccine dose - Age greater than or equal to 18 years.- ECOG performance status of 0-1 - Able to comprehend the investigational nature of the protocol and provide informed consent.,ct_inc_311832,AACT,68,NCT03685708,Historical,ibrutinib monotherapy
5c74306f8625dd04ec867f88,1130,,,297,Patient,14:07.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_409245,Clinical Trial Exclusion Criteria,UNKNOWN,"Inclusion criteria Patients enrolled in the BIG-1 trial at diagnosis Patients achieving first CR/CRp/CRi after induction or salvage therapy (within 15 days before R4-VOS) Favorable or intermediate risk AML patients, as stratified with BIG-1 prognostic classification Patients randomized to R2-IDAC arm (intermediate dose cytarabine) 5.",ct_exc_409245,AACT,293,NCT02416388,Recent,IDAC
5c74307b8625dd05ab867f87,720,,,223,Patient,14:19.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_502843,Clinical Trial Exclusion Criteria,UNKNOWN,"AML - Had completed a single cycle of treatment containing a total dose of 5 g/m2 or more of cytarabine within 90 days before randomization - Refractory to or relapsed within the previous 3 months after therapy with an IDAC- or HIDAC-containing regimen - Had received a hematopoietic stem cell transplant (HSCT) within the previous 90 days - Had received active immunosuppressive therapy for graft-versus-host disease (GVHD) within 2 weeks before study start - Had any other severe concurrent disease, or have a history of serious disease involving the heart, kidney, liver, or other organ system - Had evidence of central nervous system involvement of active AML - Had other active malignancies (including other hematologic malignancies) or been diagnosed with other malignancies within the last 12 months, except nonmelanoma skin cancer or cervical intraepithelial neoplasia - Had an active, uncontrolled infection - Had received any other investigational therapy within 14 days or not recovered from acute affects of the other investigational therapy - Had received prior or current hydroxyurea or medications to reduce blast count within 24 hours before randomization - Had received previous treatment with vosaroxin - Pregnant or lactating - Had any other medical, psychological, or social condition that may interfere with consent, study participation, or follow-up - Had known HIV seropositivity",ct_exc_502843,AACT,219,NCT01191801,Historical,IDAC
5c7430b18625dd07c6867f8d,490,,,604,Patient,15:13.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_482528,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically or cytologically confirmed soft tissue sarcoma of high or intermediate grade - Documented evidence of advanced or metastatic soft tissue sarcoma, not amenable to surgery or radiotherapy - Within 6 months from the radiographic evidence of disease progression by RECIST criteria in the last chemotherapy regimen for advanced or metastatic soft tissue sarcoma - Presence of measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 - Subjects who received at least one standard chemotherapy for advanced soft tissue sarcoma (an anthracycline or an ifosfamide monotherapy, or a combination therapy) - Subjects aged 20 years at the time of informed consent - Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 - Adequate organ function - Voluntary agreement to provide written informed consent",ct_inc_482528,AACT,582,NCT01458249,Recent,ifosfamide monotherapy
5c7430a18625dd070b867f8d,510,,,43,Patient,14:57.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_422460,Clinical Trial Inclusion Criteria,UNKNOWN,FDG-PET positivity after two cycles of IGEV treatment 5.,ct_inc_422460,AACT,39,NCT02244021,Recent,IGEV
5c7430a18625dd070b867f8e,510,,,67,Patient,14:57.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_422460,Clinical Trial Inclusion Criteria,UNKNOWN,PBPCs should have been collected after the first or the second IGEV cycle Age 18 years 7.,ct_inc_422460,AACT,63,NCT02244021,Recent,IGEV
5c7430b48625dd07e7867f86,770,,,457,Patient,15:16.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_544970,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Previous treatment with velcade - Nitrosoureas within 6 weeks or any other chemotherapy within 3 weeks before enrollment - Immunotherapy or antibody therapy within 4 weeks before enrollment - Experimental drug or medical device within 4 weeks before start of treatment - Major surgery within 4 weeks before enrollment - History of allergic reaction attributable to compounds containing boron or mannitol or any of the drugs in the IGEV regimen - Peripheral neuropathy of NCI CTCAE Grade 2 or higher - Myocardial infarction within 6 months of enrollment or NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities - History of clinically relevant liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic, hematologic, psychiatric, or metabolic disturbances including diabetes mellitus - Need for therapy with concomitant CYP 3A4 inhibitors or inducers - HIV-positive, if known - Hepatitis B surface antigen-positive or active hepatitis C infection, if known - Active systemic infection requiring treatment - If female, pregnancy or breast-feeding.",ct_exc_544970,AACT,453,NCT00636311,Hypothetical,IGEV
5c7430b68625dd0808867f84,320,,,100,Patient,15:18.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_481005,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Patient with a history of classical HL relapsed/refractory which received IGEV regimen as induction therapy before high dose chemotherapy with AHSCT - Age >18 years - Patients with relapsed/refractory disease after standard treatments (chemotherapy +/-,ct_inc_481005,AACT,96,NCT01478191,Historical,IGEV
5c7430b68625dd0808867f85,320,,,25,Patient,15:18.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_481005,Clinical Trial Inclusion Criteria,UNKNOWN,radiotherapy) before IGEV induction regimen.(Relapsed = disease relapse after CR.Refractory,ct_inc_481005,AACT,21,NCT01478191,Recent,IGEV
5c7430b68625dd0808867f86,320,,,344,Patient,15:18.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_481005,Clinical Trial Inclusion Criteria,UNKNOWN,"= non CR with last chemotherapy line, or progression during last treatment, or disease progression within three months from previous treatment completion).- Availability of clinical data, laboratory values and CT scan results of patients enrolled, perform",ct_inc_481005,AACT,340,NCT01478191,Recent,IGEV
5c7430b68625dd0808867f87,320,,,10,Patient,15:18.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_481005,Clinical Trial Inclusion Criteria,UNKNOWN,First IGEV course started before December 31st 2007 - Assessment of tumor response by Cheson 1999 criteria 11,ct_inc_481005,AACT,6,NCT01478191,Recent,IGEV
5c74306e8625dd04f7867f90,550,,,182,Patient,14:06.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_491992,Clinical Trial Inclusion Criteria,UNKNOWN,"Philadelphia chromosome positive CML in chronic phase, in complete cytogenetic response (CCyR) but with detectable BCR-ABL transcripts and maintained the CCyR on imatinib monotherapy for a minimum of 24 months AML patients: WT1+ AML in CR or morphologic CR with incomplete blood count recovery (CRi); All patients: - 18 years of age, written informed consent - Performance status of 0 or 1.- for vaccination groups: HLA-A0201 positive in at least one allele - for control groups: HLA A2 negative in both alleles - renal function and liver function (Creatinine <1.5 x upper limit of normal, liver function tests < 1.5 x upper limit of normal); Lymphocyte count > 1.0 x109/l; normal clotting - HB>100 g/l - Adequate venous access for repeated blood sampling according to protocol schedule.-",ct_inc_491992,AACT,162,NCT01334060,Recent,imatinib monotherapy
5c7430888625dd060e867f8b,470,,,57,Patient,14:32.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_503110,Clinical Trial Inclusion Criteria,UNKNOWN,">18 years old - Prior treatment with imatinib monotherapy as first line treatment, to which the patient is deemed resistant or intolerant.",ct_inc_503110,AACT,37,NCT01188278,Historical,imatinib monotherapy
5c7430a98625dd0763867f89,730,,,239,Patient,15:05.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_472221,Clinical Trial Inclusion Criteria,UNKNOWN,400mg treatment.(Imatinib transient dose adjustments due to Adverse Event (AEs) are allowed with a maximum of 2 weeks interruption of treatment with imatinib (cumulative) within the 3 month period before randomization).Imatinib monotherapy must have been started within 6 months of CP-CML diagnosis (Ph + /BCR-ABL detection) -,ct_inc_472221,AACT,219,NCT01593254,Recent,Imatinib monotherapy
5c7430628625dd0452867f99,40,,,180,Patient,13:54.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_590819,Clinical Trial Inclusion Criteria,UNKNOWN,"- Histologically confirmed Hodgkin's lymphoma - Early or late first relapse - Complete or partial remission for at least 3 months after completion of prior COPP/ABVD, COPP/ABV/IMEP, MOPP/ABV, ABVD, BEACOPP, or other polychemotherapy regimen with or withou",ct_inc_590819,AACT,176,NCT00025636,Historical,IMEP
5c74305a8625dd0414867f86,690,,,752,Patient,13:46.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_515582,Clinical Trial Exclusion Criteria,UNKNOWN,"For subjects enrolled in Cohorts 1-5, prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137 or anti-CTLA-4 antibody - For subjects enrolled in Cohorts 6-7, prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CD137 antibodies - Any non-oncology vaccine therapy used for prevention of infectious disease - Concomitant therapy with any other anti-cancer therapy, concurrent medical conditions requiring use of immunosuppressive medications or use of other investigational drugs - Positive tests for human immunodeficiency virus (HIV), acquired immunodeficiency syndrome (AIDS), hepatitis B, hepatitis C - Subjects weighing 125 kg are excluded from Cohort 5 - Subjects in Cohorts 6 and 7 must have received Ipilimumab monotherapy immediately prior to study entry, but must not have received that Ipilimumab as part of a clinical trial - Subjects with ocular melanoma are excluded from Cohort 8",ct_exc_515582,AACT,730,NCT01024231,Historical,Ipilimumab monotherapy
5c7430988625dd06df867f84,850,,,273,Patient,14:49.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_545914,Clinical Trial Inclusion Criteria,UNKNOWN,and/or 2 measurable lesions >0.3 cm visible on contrast magnetic resonance - Index brain lesion must have resolved consequences of prior therapy that could have confounded attribution of tumor response including edema and hemorrhage - Participants in ipilimumab monotherapy arm (including the first 21 who were enrolled in Stage 1) were to be free of neurologic symptoms related to metastatic brain lesions and must not have required or received systemic corticosteroid therapy in the 10 days prior to beginning ipilimumab therapy - Eastern Cooperative Oncology Group performance status of 0 or 1 - Required values for initial,ct_inc_545914,AACT,251,NCT00623766,Historical,ipilimumab monotherapy
5c7430bd8625dd0859867f87,1160,,,281,Patient,15:25.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_447013,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Eligibility for dose escalation cohort: Histologically or cytologically confirmed metastatic or unresectable solid tumor for which standard curative or palliative measures do not exist or are no longer effective OR solid tumor for which irinotecan monotherapy is considered standard - Eligibility for the expansion cohort: Histologically or cytologically confirmed colon or rectal adenocarcinoma for which curative treatment does not exist,ct_inc_447013,AACT,259,NCT01923337,Recent,irinotecan monotherapy
5c74309d8625dd06f5867f87,440,,,162,Patient,14:53.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_370308,Clinical Trial Inclusion Criteria,UNKNOWN,"Participants will be eligible to enter the rollover study when: The parent study is closed or planned to be closed; and The participant is on ixazomib monotherapy or on a drug combination with another medication, established while in his/her parent study; and In the opinion of the investigator and confirmed by the Millennium medical monitor, the participant may continue to benefit from treatment with ixazomib (eg, response to therapy or stable disease without evidence of disease progression).",ct_inc_370308,AACT,142,NCT02924272,Recent,ixazomib monotherapy
5c74304b8625dd038c867f8d,640,,,49,Patient,13:31.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_462432,Clinical Trial Inclusion Criteria,UNKNOWN,Patient is eligible for Low-Dose Cytarabine (LDAC) treatment.,ct_inc_462432,AACT,45,NCT01721876,Recent,LDAC
5c7430628625dd045a867f8b,1190,,,553,Patient,13:54.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_359168,Clinical Trial Exclusion Criteria,COMMENT,"Class 4 is defined as cardiac disease which subjects have an inability to carry on any physical activity without discomfort, symptoms of heart failure at rest, and if any physical activity is undertaken then discomfort increases.- Participant has chronic respiratory disease that requires continuous oxygen, or significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular disease, any other medical condition or known hypersensitivity to any of the study medications including excipients of LDAC that in the opinion of the investigator would adversely affect his/her participating in this study.- Participant has a malabsorption syndrome or other condition that precludes enteral route of administration.- Participant exhibits evidence of other clinically significant uncontrolled systemic infection requiring therapy (viral, bacterial or fungal).- Participant has a history of other malignancies prior to study entry, with the exception of: Adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast; Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin; Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent.- Participant has a white blood cell count",ct_exc_359168,AACT,549,NCT03069352,Hypothetical,LDAC
5c7430878625dd0624867f84,420,,,414,Patient,14:31.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_505349,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria Serious intercurrent medical illnesses which would interfere with the ability of the patient to carry out the treatment program Pregnant or breastfeeding women Patients who have uncontrolled active infection Patients who have received another investigational product within the longer of 14 days or 5 half-lives of the previous product Any history of adverse reaction or hypersensitivity to LDAC Part,ct_exc_505349,AACT,410,NCT01159028,Historical,LDAC
5c7430878625dd0624867f85,420,,,27,Patient,14:31.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_505349,Clinical Trial Exclusion Criteria,UNKNOWN,BP1001 with Concurrent LDAC Dose-Expansion Cohorts Enrollment in the dose-expansion cohorts,ct_exc_505349,AACT,23,NCT01159028,Recent,LDAC
5c74308f8625dd0671867f84,950,,,275,Patient,14:39.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_371605,Clinical Trial Inclusion Criteria,UNKNOWN,"Women of childbearing potential and men with female partners of childbearing potential must agree to practice 2 highly effective contraceptive measures of birth control and must agree not to become pregnant or father a child while receiving treatment with guadecitabine, LDAC, or IC and for at least 3 months after completing treatment.",ct_inc_371605,AACT,271,NCT02907359,Recent,LDAC
5c74308f8625dd0671867f85,950,,,419,Patient,14:39.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_370635,Clinical Trial Inclusion Criteria,UNKNOWN,"Women of child-bearing potential and men with female partners of child-bearing potential must agree to practice 2 highly effective contraceptive measures of birth control and must agree not to become pregnant or father a child (a) while receiving treatment of guadecitabine, decitabine, or azacitidine and for at least 3 months after completing treatment and (b) while receiving treatment with high-intensity TC or LDAC and for at least 6 months after completing treatment.",ct_inc_370635,AACT,415,NCT02920008,Recent,LDAC
5c74309d8625dd06f5867f8a,440,,,225,Patient,14:53.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_564055,Clinical Trial Exclusion Criteria,UNKNOWN,"Must not have the cytogenetic abnormalities inv (16), t (16;16) t (8;21), or t (15;17).The relatively good prognoses of patients with these findings do not warrant use of 5 azacytidine, + valproic acid or low-dose ara-C (LDAC).",ct_exc_564055,AACT,221,NCT00382590,Recent,LDAC
5c7430b08625dd07c6867f84,490,,,298,Patient,15:12.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_521011,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Participation in another clinical study in which an investigational product was received within 14 days before the first dose in this study, or at any time if the patient has not recovered from side-effects associated with that investigational product - Administration of LDAC is",ct_exc_521011,AACT,294,NCT00952588,Recent,LDAC
5c7430bd8625dd0855867f86,1070,,,352,Patient,15:25.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_462432,Clinical Trial Exclusion Criteria,UNKNOWN,"Severe illness or organ dysfunction involving the heart, kidney, liver or other organ system (e.g.active infection, clinically relevant impairment of cardiac function, severe heart failure/cardiac insufficiency, unstable angina pectoris or history of recent myocardial infarction), which in the opinion of the investigator precludes treatment with LDAC.",ct_exc_462432,AACT,348,NCT01721876,Historical,LDAC
5c7430bd8625dd0855867f87,1070,,,123,Patient,15:25.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_505349,Clinical Trial Inclusion Criteria,COMMENT,"Have not received anti-cancer therapy for at least 2 weeks prior to study entry, with the exception of low dose ara-C (LDAC) given as subcutaneous injections (no less than 15 days prior), hydroxyurea or anagrelide (no less than 24 hours prior), TKI (no less than 5 days prior), and interferon (no less than 2 weeks prior) Have an ECOG Performance of 0-2",ct_inc_505349,AACT,119,NCT01159028,Historical,LDAC
5c7430ab8625dd079a867f85,380,,,265,Patient,15:07.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_391106,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Patients suffering and diagnosed for: - painful shoulder syndrome (periarthritis humeroscapularis) - painful elbow syndrome (Epicondylopathia humeri) - benign achillodynia - benign calcaneodynia - Planned local low dose radiation therapy (LDRT) at the Department of Radiation Oncology, Universittsklinikum Erlangen.- Age at least 18 years",ct_inc_391106,AACT,261,NCT02653079,Recent,LDRT
5c7430798625dd0532867f8c,1310,,,2160,Patient,14:17.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_529223,Clinical Trial Inclusion Criteria,COMMENT,"Within 56 days prior to randomization: Serum creatinine =< 1.5 times upper limit of normal (ULN) - Within 56 days prior to randomization: Serum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST) or serum glutamate pyruvate transaminase (SGPT)/alanine aminotransferase (ALT) =< 2.0 x ULN - Within 56 days prior to randomization: Serum total bilirubin < 3.0 mg/dL - Prior thalidomide is allowed, however, patients must not have prior >= grade-3 allergic reactions to thalidomide - Patients must not have prior history of desquamating rash from thalidomide at time of study entry - Patients must not have clinically significant anemia resulting from iron, B12 or folate deficiencies, autoimmune or hereditary hemolysis, or gastrointestinal bleeding - Patients must not have used cytotoxic chemotherapeutic agents or experimental agents (agents that are not commercially available) for the treatment of MDS within 8 weeks of randomization - Patients must not have prior history of malignancy other than MDS (except basal cell or squamous skin cell carcinoma or carcinoma in situ of the cervix or breast) unless the subject has been confirmed free of disease for >= 3 years - Patients must not have any serious medical condition or any other unstable medical co-morbidity, or psychiatric illness that will prevent the subject from signing the informed consent form or will place the subject at unacceptable risk if he/she participates in the study - Patients must not have a history of thrombo-embolic events within 3 years prior to study randomization - Patients must not have known human immunodeficiency virus (HIV)-1 seropositivity - Patients must not have a known allergic reaction to epoetin alfa (Procrit) or human serum albumin - Eligibility for crossover registration from Arm A (lenalidomide alone) to Arm B (lenalidomide and epoetin alfa): - Patients must have completed 16 weeks of monotherapy with lenalidomide - Patients must show failure to achieve MER (major erythroid response) or have achieved MER but relapsed on Arm A - Patients must not have a limiting unresolved grade 3 or greater toxicity from lenalidomide monotherapy or drug intolerance preventing continuation of lenalidomide treatment",ct_inc_529223,AACT,2136,NCT00843882,Hypothetical,lenalidomide monotherapy
5c7430978625dd06ac867f8d,360,,,39,Patient,14:47.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_315106,Clinical Trial Inclusion Criteria,UNKNOWN,Methotrexate-Etoposide-Ifosfamide (M-EI regimen) for patients 25 years Doxorubicin-Cisplatin-Ifosfamide (API-AI regimen) for patients 26-50 years,ct_inc_315106,AACT,35,NCT03643133,Recent,M-EI
5c7430978625dd06ac867f8e,360,,,72,Patient,14:47.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_315106,Clinical Trial Inclusion Criteria,RISK_FACTORS,operative chemotherapy combining Methotrexate-Etoposide-Ifosfamide (M-EI regimen) for patients 25 years Doxorubicin-Cisplatin-Ifosfamide (API-AI regimen) for patients,ct_inc_315106,AACT,68,NCT03643133,Recent,M-EI
5c7430628625dd0452867f9d,40,,,278,Patient,13:54.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_471737,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients will be eligible if the treatment phase consisting in a Rituximab combined with any anthracycline-containing chemotherapy regimen without consolidation with autologous stem cell support (e.g., 6 cycles of CHOP14-21, DA-EPOCH, Mega-CHOP or 12 weeks of VACOP-B or MACOP-B).-",ct_inc_471737,AACT,271,NCT01599559,Hypothetical,MACOP-B
5c7430448625dd0334867f8e,400,,,233,Patient,13:24.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_358699,Clinical Trial Inclusion Criteria,UNKNOWN,"Able to read, speak and understand English.- Willing to provide informed consent for study participation, authorize the release of their previous 12-month medical records from their PCP for review and de-identified data entry by Mapi into an electronic study database.",ct_inc_358699,AACT,229,NCT03075449,Recent,Mapi
5c7430528625dd03ad867f89,590,,,214,Patient,13:38.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_324622,Clinical Trial Inclusion Criteria,UNKNOWN,"1, Histologically proven and unresectable locally advanced recurrent or metastatic squamous cell anal carcinoma, Presence of a target lesion on CT-scan assessed by RECIST v1.1 criteria, Patient eligible to the mDCF regimen, 6.",ct_inc_324622,AACT,210,NCT03519295,Recent,mDCF
5c7430658625dd04aa867f8f,530,,,80,Patient,13:57.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_554040,Clinical Trial Exclusion Criteria,UNKNOWN,"For patients who are Her2 positive and will be treated on the trastuzumab + mDCF cohort, prior trastuzumab treatment is not allowed.-",ct_exc_554040,AACT,76,NCT00515411,Historical,mDCF
5c7430658625dd04aa867f90,530,,,78,Patient,13:57.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_554040,Clinical Trial Exclusion Criteria,UNKNOWN,"For patients who are Her2 positive and will be treated on the trastuzumab+mDCF cohort, left ventricular function <50%",ct_exc_554040,AACT,74,NCT00515411,Recent,mDCF
5c7430508625dd03a2867f8d,130,,,575,Patient,13:36.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_345097,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Biopsy-proven histochemical diagnosis of amyloid light-chain (AL) amyloidosis based on tissue specimens with Congo red staining or other histologic stain; thioflavin T or S, or crystal violet; tandem mass spec or immunohistochemistry (IHC) confirmation of immunoglobulin-derived amyloidosis is encouraged; cases in which histochemical confirmation is lacking need to be discussed with one of the Multiple Myeloma Research Foundation (MMRF) protocol chair/co-chairs - One prior line of therapy (defined as either one non-transplant regimen such as MelDex, Vel-Dex or CyBorD, one autologous stem cell transplant, or one regimen of non-transplant induction therapy followed by a single autologous stem cell transplant (without hematologic progression between induction and autologous stem cell transplant [ASCT]) -",ct_inc_345097,AACT,569,NCT03252600,Historical,MelDex
5c74303f8625dd0329867f85,1210,,,165,Patient,13:19.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_460142,Clinical Trial Inclusion Criteria,UNKNOWN,Age >= 18 and <= 70 years Patients classified as having RA according to the 1987 ACR Classification Criteria Inadequate clinical response to methotrexate monotherapy defined as moderate/high active disease after oral or s.c.,ct_inc_460142,AACT,141,NCT01751776,Recent,methotrexate monotherapy
5c7430488625dd0360867f8e,780,,,443,Patient,13:28.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_580544,Clinical Trial Inclusion Criteria,UNKNOWN,"All other Disease Modifying Anti-Rheumatic Drugs (DMARDs) (except Methotrexate) have been withdrawn at least 28 days prior to treatment - Oral corticosteroid treatment has been reduced to the equivalent of 10 mg or less prednisone daily and stabilized for at least 28 days prior to enrollment Eligibility of subjects for the study is based on their disease activity and anti-rheumatic treatment at the initial visit: - Methotrexate monotherapy: Subject is receiving only Methotrexate, steroids, Non-steroidal anti-inflammatory drugs (NSAIDs) and will not require washout - Combination therapy: Subject is receiving Methotrexate in combination with another DMARD(s) and will require washout At entry, Methotrexate monotherapy must have a disease",ct_inc_580544,AACT,419,NCT00162266,Historical,Methotrexate monotherapy
5c7430958625dd069d867f89,880,,,148,Patient,14:45.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_434433,Clinical Trial Inclusion Criteria,UNKNOWN,"In women of childbearing potential the pregnancy test must be negative at the screening visit and at baseline.- Patients on methotrexate monotherapy or combined treatment with a biological agent, or patients on biological treatment monotherapy, who show or have ever shown intolerance or poor compliance or safety issues with methotrexate.- Patients judge to be candidates to biological monotherapy by the researcher, without excluding previous use of other disease-modifying antirheumatic drug (DMARDs) different to methotrexate.",ct_inc_434433,AACT,124,NCT02087696,Recent,methotrexate monotherapy
5c74305e8625dd0447867f90,250,,,770,Patient,13:50.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_467105,Clinical Trial Exclusion Criteria,UNKNOWN,"are not eligible.- Patients who are receiving any investigational agents.- Patients with borderline resectable, locally advanced or metastatic disease.- History of allergic reactions attributed to 5FU, leucovorin, irinotecan or oxaliplatin or to compounds of similar chemical or biologic composition.- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, active liver disease including viral or non-viral hepatitis and cirrhosis, chronic diarrhea or inflammatory disease of the colon or rectum, or psychiatric illness/social situations that would limit compliance with study requirements.- Pregnant women are excluded from this study.mFOLFIRINOX is a regimen containing more than one chemotherapy agent with the potential for teratogenic or abortifacient effects.",ct_exc_467105,AACT,759,NCT01660711,Historical,mFOLFIRINOX
5c74305e8625dd0447867f91,250,,,223,Patient,13:50.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_467105,Clinical Trial Exclusion Criteria,UNKNOWN,These potential risks may also apply to other agents used in this study.- HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with mFOLFIRINOX.In,ct_exc_467105,AACT,212,NCT01660711,Recent,mFOLFIRINOX
5c74305f8625dd0447867f95,250,,,82,Patient,13:51.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_391473,Clinical Trial Inclusion Criteria,UNKNOWN,locally advanced pancreatic adenocarcinoma Patients must have received mFOLFIRINOX or Gemcitabine/,ct_inc_391473,AACT,71,NCT02648282,Recent,mFOLFIRINOX
5c7430798625dd0574867f94,270,,,84,Patient,14:17.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_423402,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients enrolling onto Arm A (Gemcitabine and nab-Paclitaxel) or Arm B (mFOLFIRINOX) are allowed to have up to two prior lines of systemic therapy, with adjuvant therapy counted as one line of therapy as long as disease recurrence occurred > 6 months of last dose of therapy.",ct_inc_423402,AACT,73,NCT02231723,Historical,mFOLFIRINOX
5c7430798625dd0574867f95,270,,,176,Patient,14:17.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_423402,Clinical Trial Inclusion Criteria,UNKNOWN,Prior systemic therapy in the metastatic setting is allowed for as long as the therapy contained BBI608 in combination with either Gemcitabine and nab-Paclitaxel or mFOLFIRINOX.Toxicities,ct_inc_423402,AACT,165,NCT02231723,Historical,mFOLFIRINOX
5c7430798625dd0574867f96,270,,,101,Patient,14:17.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_423402,Clinical Trial Inclusion Criteria,UNKNOWN,Patients enrolling onto Arm A (Gemcitabine with nab-Paclitaxel) are allowed to have prior mFOLFIRINOX in combination with BBI608 in the metastatic setting.,ct_inc_423402,AACT,90,NCT02231723,Historical,mFOLFIRINOX
5c7430798625dd0574867f97,270,,,42,Patient,14:17.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_423402,Clinical Trial Inclusion Criteria,UNKNOWN,Patients enrolling onto Arm B (mFOLFIRINOX) are allowed to have prior Gemcitabine with nab-Paclitaxel in combination with BBI608 in the metastatic setting.,ct_inc_423402,AACT,31,NCT02231723,Historical,mFOLFIRINOX
5c7430808625dd05d0867f87,410,,,61,Patient,14:24.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_391473,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: Patients who have been off of mFOLFIRINOX or gemcitabine/abraxane therapy for more than 49 days Patients who have had more than one line of chemotherapy Patients with uncontrolled intercurrent illness, including but not limited to ongoing or active infection, systematic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or psychiatric condition that would limit compliance with study requirements Patient who have had prior treatment with IL-2, interferon, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-OX-40, anti-CD40, or anti-CTLA-4 antibodies Patients receiving active immunosuppressive agents or chronic use of systemic corticosteroids within 14 days prior to first dose of study drug Patients who have received growth factors, including but not limited to granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), erythropoietin,",ct_exc_391473,AACT,50,NCT02648282,Historical,mFOLFIRINOX
5c7430a18625dd070b867f92,510,,,400,Patient,14:57.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_468370,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically or cytologically confirmed locally advanced or metastatic pancreatic adenocarcinoma, colorectal adenocarcinoma, gastric adenocarcinoma, cholangiocarcinoma, gall bladder adenocarcinoma, ampullary carcinoma, adenocarcinoma of unclear primary (with a gastrointestinal primary suspected), or other primary gastrointestinal malignancy for which the treating physician feels that mFOLFIRINOX is a reasonable therapeutic option.- Amendment (January 2014): only subjects with the following histologies will be eligible Cohort # 1 (pancreatic cohort): locally advanced or metastatic pancreatic adenocarcinoma (19 subjects evaluable for the primary endpoint after the amendment)",ct_inc_468370,AACT,389,NCT01643499,Recent,mFOLFIRINOX
5c7430a98625dd0763867f86,730,,,46,Patient,15:05.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_423402,Clinical Trial Exclusion Criteria,UNKNOWN,"For patients enrolling onto Arm B (mFOLFIRINOX) or Arm C (FOLFIRI) Known hypersensitivity to 5-fluorouracil/leucovorin Known dihydropyrimidine dehydrogenase (DPD) deficiency Known hypersensitivity to oxaliplatin or other platinum containing compounds Known hypersensitivity to irinotecan Uncontrolled seizure disorder, active neurological disease, or known CNS disease.",ct_exc_423402,AACT,35,NCT02231723,Recent,mFOLFIRINOX
5c7430aa8625dd0779867f84,520,,,26,Patient,15:06.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_467105,Clinical Trial Inclusion Criteria,UNKNOWN,The effects of mFOLFIRINOX on the developing human fetus are unknown.,ct_inc_467105,AACT,15,NCT01660711,Recent,mFOLFIRINOX
5c7430b28625dd078f867f8e,350,,,79,Patient,15:14.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_446795,Clinical Trial Inclusion Criteria,UNKNOWN,Histologically confirmed adenocarcinoma of the pancreas.- Induction mFolfirinox up to 4 cycles.,ct_inc_446795,AACT,68,NCT01926197,Recent,mFolfirinox
5c7430b38625dd078f867f8f,350,,,216,Patient,15:15.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_446795,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Metastatic disease - Patients who have had prior radiotherapy to the upper abdomen/liver.- Patients who have received chemotherapy for pancreatic cancer, other than up to 4 cycles of mFolfirinox.-",ct_exc_446795,AACT,205,NCT01926197,Historical,mFolfirinox
5c7430b88625dd07fd867f91,210,,,126,Patient,15:20.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_328454,Clinical Trial Inclusion Criteria,UNKNOWN,The patients are defined as locally advanced pancreatic cancer according to NCCN guideline The patients prescribed mFOLFIRINOX-based neoadjuvant therapy,ct_inc_328454,AACT,115,NCT03469375,Recent,mFOLFIRINOX
5c74304c8625dd0381867f9b,230,,,175,Patient,13:33.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_505499,Clinical Trial Inclusion Criteria,UNKNOWN,The target population is patients with metastatic colorectal adenocarcinoma who are sufficiently robust to undergo at least 3 cycles of oxaliplatin based chemotherapy (mFOLFOX or XELOX),ct_inc_505499,AACT,168,NCT01157039,Recent,mFOLFOX
5c74309e8625dd0700867f8a,200,,,299,Patient,14:54.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_438112,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - 20 years and older - Person who agreed to participate in this study and signed voluntarily on the written informed consent form - Person who is confirmed as colorectal cancer through histological and image diagnosis and scheduled for adjuvant or palliative therapy with mFOLFOX-6 regimen - Fertile patients with negative pregnancy test confirmed and who has agreed to use effective contraception - Person who is able to fully communicate with the physician about his/her fatigue status and is able to completely fill out the questionnaires - Life expectancy more than 6 months - Performance status of ECOG grade 0,ct_inc_438112,AACT,292,NCT02039635,Recent,mFOLFOX
5c7430a58625dd0737867f93,180,,,106,Patient,15:01.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_521738,Clinical Trial Inclusion Criteria,UNKNOWN,"21 years to 80 years - Histologically proven advanced stage carcinoma where De Gramont, FOLFIRI or mFOLFOX-6 regimen is indicated.-",ct_inc_521738,AACT,99,NCT00943137,Recent,mFOLFOX
5c7430bd8625dd084a867f87,140,,,67,Patient,15:25.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_439295,Clinical Trial Inclusion Criteria,UNKNOWN,"operated colorectal cancer patients - Patient administering mFOLFOX 6 ( Folinic acid 400 mg/m2 1 day, oxaliplatin 85 mg/m2 1 day, 5-fluorouracil 400 mg/m2 bolus 2400 mg/m2 continuous infusion 48 hours)",ct_inc_439295,AACT,60,NCT02024191,Recent,mFOLFOX
5c74303c8625dd02f6867f92,120,,,91,Patient,13:16.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_420559,Clinical Trial Inclusion Criteria,UNKNOWN,Patients with any locally advanced or metastatic gastrointestinal malignancy which mFOLFOX6 is indicated for treatment - Safety expansion:,ct_inc_420559,AACT,83,NCT02268825,Recent,mFOLFOX6
5c74303c8625dd02f6867f93,120,,,570,Patient,13:16.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_420559,Clinical Trial Inclusion Criteria,COMMENT,"Fine Needle Aspiration's (FNA), frozen samples, plastic embedded samples, cell blocks, clots, bone, bone marrow, or cytologic specimens are exclusionary - Patients must have measurable disease based on irRECIST (Safety expansion only) - Patients must be 18 years of age on day of signing informed consent - Have a performance status of 0 or 1 on the ECOG Performance Scale - Patients must demonstrate adequate organ function as based on screening labs performed within 14 days of treatment initiation - Patients are allowed to have received prior treatment with mFOLFOX6.If patients are currently receiving treatment with mFOLFOX6, the subject must have documented disease progression.",ct_inc_420559,AACT,562,NCT02268825,Recent,mFOLFOX6
5c74303c8625dd02f6867f94,120,,,56,Patient,13:16.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_420559,Clinical Trial Inclusion Criteria,COMMENT,Patients must also be able to tolerate standard mFOLFOX6.Reduced dosing of mFOLFOX6 at enrollment is exclusionary.- Patients must be able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines - Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication.,ct_inc_420559,AACT,48,NCT02268825,Historical,mFOLFOX6
5c74303d8625dd02f6867f99,120,,,47,Patient,13:17.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_344959,Clinical Trial Inclusion Criteria,UNKNOWN,Scheduled for oxaliplatin treatment in mFOLFOX6-based chemotherapy regimen.-,ct_inc_344959,AACT,39,NCT03254394,Recent,mFOLFOX6
5c7430478625dd0355867f8f,160,,,115,Patient,13:27.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_405244,Clinical Trial Inclusion Criteria,UNKNOWN,Received one prior line of chemotherapy for metastatic pancreatic ductal adenocarcinoma (Arm: idelalisib + mFOLFOX6 only) -,ct_inc_405244,AACT,107,NCT02468557,Historical,mFOLFOX6
5c7430478625dd0355867f90,160,,,66,Patient,13:27.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_405244,Clinical Trial Inclusion Criteria,UNKNOWN,"x ULN (Arm: single agent idelalisib and Arm: idelalisib + mFOLFOX6); aspartate transaminase (AST) (SGOT), alanine transaminase (ALT) (SGPT)",ct_inc_405244,AACT,58,NCT02468557,Recent,mFOLFOX6
5c7430488625dd0355867f91,160,,,272,Patient,13:28.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_405244,Clinical Trial Exclusion Criteria,UNKNOWN,"adenocarcinoma originating from the biliary tree or cystadenocarcinoma - History of serious allergic reaction, including anaphylaxis and toxic epidermal necrolysis - Presence of peripheral neuropathy Grade 2 (Arm: idelalisib + nab-paclitaxel and Arm: idelalisib + mFOLFOX6) - Documented myocardial infarction or unstable/uncontrolled cardiac disease (eg, unstable angina, congestive heart failure [New York Heart Association > Class III]) within 6 months or enrollment - Known hypersensitivity to idelalisib, its metabolites, or formulation excipients - Known hypersensitivity to nab-paclitaxel (Arm: idelalisib + nab-paclitaxel), their metabolites, or formulation excipients - Known hypersensitivity to 5-fluorouracil, leucovorin, or oxaliplatin (Arm: idelalisib + mFOLFOX6), their metabolites, or formulation excipients",ct_exc_405244,AACT,264,NCT02468557,Historical,mFOLFOX6
5c7430518625dd03b8867f85,430,,,90,Patient,13:37.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_424817,Clinical Trial Inclusion Criteria,UNKNOWN,No prior treatment with any targeted agent - Patients who have started first line mFOLFOX6 therapy (+/-trastuzumab for HER2 amplified tumors) may be considered for trial participation if they have received no more than 4 doses of therapy at the time of consent and screening.,ct_inc_424817,AACT,82,NCT02213289,Hypothetical,mFOLFOX6
5c7430518625dd03a2867f93,130,,,35,Patient,13:37.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_450279,Clinical Trial Inclusion Criteria,AGE,"Adjuvant chemotherapy with mFOLFOX6 or XELOX for more than four months 5.15 days prior recruit, meet the following criteria: - Hematopoietic - Absolute neutrophil count",ct_inc_450279,AACT,27,NCT01880658,Historical,mFOLFOX6
5c7430518625dd03b8867f86,430,,,731,Patient,13:37.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_325768,Clinical Trial Exclusion Criteria,UNKNOWN,"Subjects using a physiologic replacement dose of hydrocortisone or its equivalent (defined as up to 30 mg per day of hydrocortisone or up to 10 mg per day of prednisone) or a single dose of systemic corticosteroids are allowed.- Subject has received other investigational agents or devices within 28 days prior to first dose of study treatment.- Subject has prior severe allergic reaction or intolerance to known ingredients of zolbetuximab or other monoclonal antibodies, including humanized or chimeric antibodies.- Subject has known immediate or delayed hypersensitivity, intolerance or contraindication to any component of study treatment.- Subject has prior severe allergic reaction or intolerance to any component of mFOLFOX6.- Subject has known dihydropyrimidine dehydrogenase deficiency.- Subject has gastric outlet syndrome or persistent/recurrent vomiting.- Subject with recent gastric bleeding or symptomatic subjects with proven gastric ulcers that would exclude the subject from participation.- Subject has a known history of a positive test for human immunodeficiency virus (HIV) infection or known active hepatitis B (positive hepatitis B surface antigen (HBs Ag)) or hepatitis C infection.",ct_exc_325768,AACT,723,NCT03504397,Historical,mFOLFOX6
5c7430528625dd03a2867f9f,130,,,156,Patient,13:38.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_537879,Clinical Trial Inclusion Criteria,UNKNOWN,- Diagnosis of colorectal cancer - Currently receiving OR scheduled to receive the first course of either of the following chemotherapy regimens: - mFOLFOX6 - FOLFOX7 - No clinical or imaging evidence of brain metastasis,ct_inc_537879,AACT,148,NCT00729677,Recent,mFOLFOX6
5c74305d8625dd0447867f86,250,,,211,Patient,13:49.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_404263,Clinical Trial Inclusion Criteria,UNKNOWN,"I IV for ovarian cancer, stage II IV endometrial cancer or stage III & high risk stage II for colorectal cancer Scheduled to receive adjuvant Paclitaxel/Carboplatin for ovarian or endometrial cancer, or mFOLFOX6 for colorectal cancer Age 20 years old 5.",ct_inc_404263,AACT,203,NCT02481336,Recent,mFOLFOX6
5c74305f8625dd0457867f9a,70,,,328,Patient,13:51.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_472547,Clinical Trial Inclusion Criteria,UNKNOWN,"For resected primary tumor participants, and patients with primary tumor in situ: - Previously untreated metastatic colorectal cancer and not a candidate for curative resection - World Health Organization (WHO) performance status of 0-1 - Life expectancy of greater than or equal to (>/=) 3 months - Eligible for XELOX, mFOLFOX6, FOLFIRI and bevacizumab treatment in accordance with local standards of care and pharmaceutical benefits scheme Additional inclusion criteria for participants with primary tumor in situ: - Intact primary tumor of the colon or the rectum not requiring surgical intervention prior to study start - Minimal or asymptomatic primary tumor",ct_inc_472547,AACT,320,NCT01588990,Historical,mFOLFOX6
5c7430608625dd0457867f9d,70,,,209,Patient,13:52.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_522368,Clinical Trial Exclusion Criteria,UNKNOWN,"Adjuvant chemotherapy for Colorectal Cancer (Stage I, II, II) is permitted, if the adjuvant therapy ended >6 month before screening.- Previous FOLFOX treatment for patients who will be included in the mFOLFOX6 cohort apart from FOLFOX treatment in an adjuvant setting.- Previous FOLFIRI treatment for patients who will be included in the FOLFIRI cohort.",ct_exc_522368,AACT,201,NCT00934882,Recent,mFOLFOX6
5c7430688625dd04cb867f84,260,,,61,Patient,14:00.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_391440,Clinical Trial Inclusion Criteria,UNKNOWN,"For Schedule 3: advanced/metastatic tumors for which mFOLFOX6 is appropriate, or advanced/metastatic tumors that may be sensitive to each component of mFOLFOX6 or sensitive to topoisomerase 1 inhibitors including pancreatic, colorectal, esophageal, gastric, bladder or ovarian cancer, triple-negative breast cancer, small cell lung cancer (SCLC), cholangiocarcinoma, among others -",ct_inc_391440,AACT,53,NCT02648711,Recent,mFOLFOX6
5c7430738625dd054f867f88,340,,,233,Patient,14:11.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_420559,Clinical Trial Exclusion Criteria,COMMENT,"If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy - History of greater than or equal to grade 3 allergic reaction to mFOLFOX6 (patients successfully desensitized to oxaliplatin are eligible or those willing to undergo desensitization during the first two cycles of mFOLFOX6 per institutional guidelines) -",ct_exc_420559,AACT,225,NCT02268825,Hypothetical,mFOLFOX6
5c7430748625dd054f867f89,340,,,872,Patient,14:12.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_371206,Clinical Trial Inclusion Criteria,COMMENT,"(vs.) rectal primary - Based upon the operative report and other source documentation, the location of the primary tumor will be categorized as proximal or distal to the splenic flexure (distal includes), and further categorization will be as follows: cecum/ascending, descending, sigmoid colon, or rectosigmoid colon - No evidence of residual involved lymph node disease or metastatic disease at the time of registration based on clinician assessment of imaging; the treating physician will determine if incidental lesions on imaging require workup to exclude metastatic disease; if based on review of images, the treating physician determines the patient to be stage III, then the patient is eligible - No prior medical therapy (chemotherapy, immunotherapy, biologic or targeted therapy) or radiation therapy for the current colon cancer except for one cycle of mFOLFOX6 - Eastern Cooperative Oncology Group (ECOG) performance status =< 2 - For women of childbearing potential only, a negative pregnancy test done =< 7 days prior to registration is required; a female of childbearing potential is a sexually mature female who: - Has not undergone a hysterectomy or bilateral oophorectomy; or - Has not been naturally postmenopausal for at least 12 consecutive months (i.e.has had menses at any time in the preceding 12 consecutive months) -",ct_inc_371206,AACT,864,NCT02912559,Historical,mFOLFOX6
5c7430748625dd054f867f8a,340,,,88,Patient,14:12.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_371206,Clinical Trial Inclusion Criteria,COMMENT,"100,000 mm^3; platelets >= 75,000 required for patients who received cycle 1 of mFOLFOX6 prior to registration - Creatinine =< 1.5 x upper limit of normal (ULN) or - Calculated creatinine clearance >= 45 mL/min by Cockcroft-Gault equation - Total bilirubin =< 1.5 x upper limit of normal (ULN) except in the case of Gilbert disease - Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =",ct_inc_371206,AACT,80,NCT02912559,Historical,mFOLFOX6
5c7430758625dd054f867f8b,340,,,1830,Patient,14:13.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_364712,Clinical Trial Inclusion Criteria,COMMENT,"< 2.5 x ULN for the lab with the following exception: patients with documented liver metastases or bone involvement - alkaline phosphatase must be =< 5 x ULN; and - Obtained within 28 days prior randomization: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be =< 3 x ULN for the lab with the following exception: for patients with documented liver metastases, AST and ALT must be =< 5 x ULN - Obtained within 28 days prior randomization: serum creatinine =< 1.5 x ULN for the lab or measured or calculated creatinine clearance >= 30 mL/min - A urine sample tested for proteinuria by the dipstick method must indicate 0 -1+ protein; if dipstick reading is >= 2+, a 24-hour urine specimen must demonstrate < 1.0 g of protein per 24 hours - International normalized ratio of prothrombin time (INR) and prothrombin time (PT) must be =< 1.5 x ULN for the lab within 28 days before randomization; patients who are therapeutically treated with an agent such as warfarin may participate if they are on a stable dose and no underlying abnormality in coagulation parameters exists per medical history - Pregnancy test done within 14 days prior randomization must be negative (for women of childbearing potential only); pregnancy testing should be performed according to institutional standards; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately - Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 5 months (150 days) after the last dose of atezolizumab, 6 months after the last dose of bevacizumab, and 6 months after the last dose of mFOLFOX6; Men with female partners of child-bearing potential must agree to use adequate contraception prior to the study, for the duration of study participation, and for 6 months after the last dose of bevacizumab and 6 months after the last dose of mFOLFOX6",ct_inc_364712,AACT,1822,NCT02997228,Historical,mFOLFOX6
5c7430788625dd0574867f93,270,,,59,Patient,14:16.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_314214,Clinical Trial Exclusion Criteria,UNKNOWN,Known hypersensitivity to any of the components of mFOLFOX6,ct_exc_314214,AACT,51,NCT03654729,Recent,mFOLFOX6
5c7430848625dd05e2867f94,330,,,389,Patient,14:28.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_415257,Clinical Trial Inclusion Criteria,UNKNOWN,Serum creatinine 1.5 mg/dL Patients who are assessed at Eastern Cooperative Oncology Group (ECOG) performance status (P.S.)of 0 or 1 Life expectancy of 6 months after enrollment Patients who have given written consent to take part in the study after detailed explanation of the study prior to enrollment Inclusion criteria for randomization: Patients who have received 6 cycles of mFOLFOX6 + panitumumab combination therapy Patients who are assessed at ECOG P.S.of 0-1 in the 6th cycle.,ct_inc_415257,AACT,381,NCT02337946,Historical,mFOLFOX6
5c7430858625dd05e2867f95,330,,,54,Patient,14:29.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_348863,Clinical Trial Inclusion Criteria,UNKNOWN,"For patients who are enrolled into the arm of mFOLFOX6 plus Bevacizumab, they must have metastatic colorectal cancer with predominant hepatic metastases.",ct_inc_348863,AACT,46,NCT03203525,Recent,mFOLFOX6
5c7430968625dd06ac867f8c,360,,,1490,Patient,14:46.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_498640,Clinical Trial Exclusion Criteria,UNKNOWN,"Subcutaneous venous access device placement within 7 days prior to randomization - Clinically significant peripheral neuropathy at the time of registration - Known central nervous system metastases that are symptomatic or untreated - New York Heart Association (NYHA) classification III-IV congestive heart failure - Greater than normal risk of bleeding or coagulopathy in the absence of therapeutic anticoagulation; Grade 3/4 gastrointestinal bleeding within 3 months prior to registration; active bleeding (that is, within 14 days prior to first dose of study therapy); or pathological condition present that carries a high risk of bleeding (for example, tumor involving major vessels or known varices) - Participant has experienced any arterial thromboembolic events, including but not limited to myocardial infarction, stroke, transient ischemic attack (TIA), cerebrovascular accident, or unstable angina, less than or equal to 6 months prior to registration - Clinically significant vascular disease (for example, aortic aneurysm, aortic dissection) for which more than minimal intervention is being administered or planned - History of hypertensive crisis or hypertensive encephalopathy or current poorly-controlled hypertension despite standard medical management - History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess less than 6 months prior to registration - Known hypersensitivity to any of the treatment components of modified FOLFOX6 (mFOLFOX6) (oxaliplatin, 5-FU, and leucovorin) or ramucirumab DP",ct_exc_498640,AACT,1482,NCT01246960,Historical,mFOLFOX6
5c7430988625dd069d867f8d,880,,,921,Patient,14:48.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_414732,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients must have a life expectancy >= 12 weeks - Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 - Women must not be pregnant or breast-feeding; all females of childbearing potential must have a blood test or urine study within 48 hours prior to randomization to rule out pregnancy; a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months) - Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study therapy and for 3 months after the last dose of AMG 337 plus mFOLFOX6 chemotherapy; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately; should a man impregnate or suspect that he has impregnated a woman while participating in this study, he should inform his treating physician immediately - Patients must NOT have a known immediate or delayed hypersensitivity reaction to drugs chemically related to fluorouracil, platins or their excipients nor have a known history of dihydropyrimidine dehydrogenase (DPD) deficiency - Patients must be able to swallow tablets whole - Leukocytes >= 3,000/mcL - Absolute neutrophil count >=",ct_inc_414732,AACT,913,NCT02344810,Historical,mFOLFOX6
5c74309f8625dd0700867f8b,200,,,80,Patient,14:55.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_489842,Clinical Trial Inclusion Criteria,UNKNOWN,Histologically proven colorectal adenocarcinoma Intended treatment with mFOLFOX6 after one prior palliative chemotherapy for metastatic CRC Age > 18 years Metastatic disease not suitable for curative-intent surgery Measurable,ct_inc_489842,AACT,72,NCT01362361,Historical,mFOLFOX6
5c7430a28625dd0716867f8b,150,,,175,Patient,14:58.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_495356,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Male or female subjects aged 18 years - Histological or cytological documentation of adenocarcinoma of the colon or rectum - Suitable to receive mFOLFOX6 regimen as first line metastatic treatment -,ct_inc_495356,AACT,167,NCT01289821,Recent,mFOLFOX6
5c7430a48625dd0737867f8e,180,,,192,Patient,15:00.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_368896,Clinical Trial Exclusion Criteria,UNKNOWN,"At randomisation: Inclusion criteria: - WHO performance status 0-1 (Karnofsky PS > 70%); - Disease evaluation with proven SD, PR or CR according to RECIST after 8 cycles of FOLFIRI or mFOLFOX6; - Laboratory values obtained 2 weeks prior to randomisation: adequate bone marrow function (Hb > 8.0 mmol/L, absolute neutrophil count > 1.5 x 109/L, platelets > 100 x 109/L), renal function (serum creatinine 1.5x ULN and creatinine clearance, Cockroft formula, > 30 ml/min), liver function (serum bilirubin 2 x ULN, serum transaminases 3 x ULN without presence of liver metastases or 5x ULN with presence of liver metastases); - Life expectancy > 24 weeks; -",ct_exc_368896,AACT,184,NCT02942706,Historical,mFOLFOX6
5c7430a48625dd0737867f90,180,,,67,Patient,15:00.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_366164,Clinical Trial Inclusion Criteria,UNKNOWN,- Ongoing or planned first line treatment with 6 cycles of mFOLFOX6/FOLFIRI plus Cetuximab.,ct_inc_366164,AACT,59,NCT02978313,Recent,mFOLFOX6
5c7430ab8625dd077d867f91,170,,,306,Patient,15:07.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_381631,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion criteria: - Males and females aged >=18 years (for Japan only: Age >=20 years at time of signing Informed Consent Form) with histologically confirmed metastatic colorectal cancer (mCRC).- Metastatic disease not amenable to surgical curative treatment and eligible to receive therapy with mFOLFOX6 (Leucovorin/5-Fluorouracil/Oxaliplatin) + bevacizumab.- At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST),ct_inc_381631,AACT,298,NCT02776683,Recent,mFOLFOX6
5c7430b98625dd07fd867f98,210,,,79,Patient,15:21.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_338132,Clinical Trial Inclusion Criteria,UNKNOWN,"v1.1 Histologically or cytologically confirmed GI malignancy for which mFOLFOX6 is considered an appropriate treatment (e.g., gastric cancer [GC], colorectal carcinoma, pancreatic adenocarcinoma)",ct_inc_338132,AACT,71,NCT03343301,Recent,mFOLFOX6
5c7430b98625dd07fd867f99,210,,,67,Patient,15:21.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_338132,Clinical Trial Inclusion Criteria,UNKNOWN,Patient must be a candidate to receive at least 2 doses of mFOLFOX6 chemotherapy,ct_inc_338132,AACT,59,NCT03343301,Recent,mFOLFOX6
5c7430bb8625dd081e867f90,110,,,606,Patient,2/25/19 18:15,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_368896,Clinical Trial Inclusion Criteria,UNKNOWN,"Before the start of induction therapy: Inclusion Criteria: - Histological proof of colorectal cancer (in case of a single metastasis, histological or cytological proof of this lesion should be obtained); - Distant metastases which are either technically unresectable or no chance to reach NED (patients with only local recurrence are not eligible); - Measurable disease (> 1 cm on spiral CT scan or > 2 cm on chest X-ray; liver ultrasound is not allowed).Serum CEA may not be used as a parameter for disease evaluation; - Ongoing or planned first line induction therapy with 8 cycles of FOLFIRI or mFOLFOX6.",ct_inc_368896,AACT,598,NCT02942706,Recent,mFOLFOX6
5c7430bc8625dd084a867f86,140,,,99,Patient,15:24.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_345079,Clinical Trial Inclusion Criteria,UNKNOWN,"Scheduled to receive adjuvant Paclitaxel/Carboplatin for ovarian or endometrial cancer, or mFOLFOX6 for colorectal cancer.- Patient willing to provide blood sample for research purposes.- Ability of the patient to provide informed consent.",ct_inc_345079,AACT,91,NCT03252834,Recent,mFOLFOX6
5c7430bd8625dd084a867f88,140,,,457,Patient,15:25.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_490966,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients may be entered in the study only if they meet all of the following criteria: Male or female patient greater than or equal to 18 years of age; Histologically or cytologically confirmed nonresectable locally advanced or metastatic colorectal adenocarcinoma; Patients must have failed a first-line chemotherapy regimen for nonresectable locally advanced or mCRC (first-line 5-FU-based therapies, including but not limited to FOLFOX, FOLFOX 4, mFOLFOX6, CapeOX, single-agent capecitabine, infusional 5-FU, or other chemotherapies.",ct_inc_490966,AACT,449,NCT01347645,Hypothetical,mFOLFOX6
5c7430c08625dd086b867f92,60,,,35,Patient,15:28.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_427406,Clinical Trial Inclusion Criteria,HISTORY_PRESENT_ILLNESS,"Chemotherapy with FOLFOX4, mFOLFOX6, CapeOx or Capecitabine(the current standard treatment; it can be modified in the future in the two groups, if the standard is modified)",ct_inc_427406,AACT,27,NCT02179489,Hypothetical,mFOLFOX6
5c7430718625dd0544867f85,280,,,48,Patient,14:09.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_516146,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria: - Prior DexaBEAM or miniBEAM therapy and prior bone marrow or PBPC transplant - Any history of seasonal or recurrent asthma within the preceding 10 years.-,ct_exc_516146,AACT,40,NCT01016795,Historical,miniBEAM
5c7430528625dd03b8867f89,430,,,69,Patient,13:38.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_486591,Clinical Trial Exclusion Criteria,UNKNOWN,No prior therapy with Mustargen Oncovin Procarbazine Prednisone (MOPP).,ct_exc_486591,AACT,65,NCT01404936,Historical,MOPP
5c7430618625dd043c867f9c,50,,,207,Patient,13:53.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_587871,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically confirmed relapsed or refractory Hodgkin's disease Relapsed after prior first line treatment with at least 2 regimens, such as: Mechlorethamine, vincristine, procarbazine, and prednisone (MOPP)",ct_inc_587871,AACT,203,NCT00005595,Historical,MOPP
5c7430618625dd043c867f9d,50,,,64,Patient,13:53.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_587871,Clinical Trial Inclusion Criteria,UNKNOWN,"Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) MOPP/ABV Stanford 5 OR Refractory to a second line regimen, such as: Mesna, ifosfamide, mitoxantrone, and etoposide (MINE) Etoposide, methylprednisolone, high dose cytarabine, and cisplatin",ct_inc_587871,AACT,60,NCT00005595,Recent,MOPP
5c7430628625dd0452867f9a,40,,,186,Patient,13:54.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_590819,Clinical Trial Inclusion Criteria,UNKNOWN,"- Histologically confirmed Hodgkin's lymphoma - Early or late first relapse - Complete or partial remission for at least 3 months after completion of prior COPP/ABVD, COPP/ABV/IMEP, MOPP/ABV, ABVD, BEACOPP, or other polychemotherapy regimen with or withou",ct_inc_590819,AACT,182,NCT00025636,Historical,MOPP
5c74306c8625dd04d6867f8c,890,,,73,Patient,14:04.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_587366,Clinical Trial Inclusion Criteria,CHEMOTHERAPEUTICS,"No prior mechlorethamine, vincristine, procarbazine, and prednisone (MOPP)",ct_inc_587366,AACT,69,NCT00002463,Historical,MOPP
5c7430888625dd0628867f94,90,,,320,Patient,14:32.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_585900,Clinical Trial Inclusion Criteria,UNKNOWN,"No evidence of disease - Prior treatment on 1 of the following protocols during the years 1987-2001: - Children's Cancer Group (CCG) CCG-5942, CCG-59704 - Pediatric Oncology Group (POG) POG-8625, POG-8725, POG-9425, POG-9426 - Pediatric Hodgkin's Consortium: VAMP, VEPA, VAMP/COP - Institutional protocols COPP/ABV, MOPP/ABVD, ABVD - Childhood Cancer Survivor Study (CCSS)",ct_inc_585900,AACT,316,NCT00091091,Historical,MOPP
5c7430898625dd0624867f8b,420,,,88,Patient,14:33.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_544970,Clinical Trial Inclusion Criteria,UNKNOWN,"Diagnosis of Hodgkin's lymphoma failing or relapsing after first-line chemotherapy (MOPP/AVBD , MOPP/",ct_inc_544970,AACT,84,NCT00636311,Recent,MOPP
5c74308b8625dd0642867f8b,610,,,67,Patient,14:35.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_587010,Clinical Trial Inclusion Criteria,UNKNOWN,(CR) Relapsed within 1 year following completion of front-line MOPP or ABVD Relapsed at any time following front-line MOPP/ABVD or other hybrid Eligible,ct_inc_587010,AACT,63,NCT00002552,Recent,MOPP
5c74308b8625dd063a867f85,390,,,124,Patient,14:35.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_586346,Clinical Trial Inclusion Criteria,UNKNOWN,"Measurable disease Must have failed the following regimens: Mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) AND Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)",ct_inc_586346,AACT,120,NCT00003936,Recent,MOPP
5c7430928625dd065b867fa8,20,,,77,Patient,14:42.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_593368,Clinical Trial Inclusion Criteria,UNKNOWN,Prior enrollment on the clinical trial of ProMACE-CytaBOM versus ProMACE-MOPP (81-C-0166) or Short Course ProMACE-CytaBOM (87-C-0180) for the treatment of previously untreated aggressive lymphomas.,ct_inc_593368,AACT,73,NCT00026910,Historical,MOPP
5c7430a18625dd0700867f93,200,,,515,Patient,14:57.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_591291,Clinical Trial Inclusion Criteria,UNKNOWN,"In second or greater complete or partial response if treated at diagnosis without clinical symptoms necessitating treatment - T-cell lymphoma (nonlymphoblastic, intermediate, or high grade lymphomas) after initial therapy whether or not complete response is achieved - Hodgkin's lymphoma - Stage I and II disease treated with primary radiotherapy and failure of at least one combination chemotherapy regimen - Stage III and IV disease with failure on mechlorethamine, vincristine, procarbazine, and prednisone (MOPP)-like regimen, alternative noncross resistant regimen (e.g., doxorubicin, bleomycin, vinblastine, and dacarbazine [ABVD]), or a combination (e.g., MOPP-ABV) - High risk features allowed including: - Failure to achieve initial complete remission with MOPP and/or ABVD and crossover or hybrid therapy - Relapse within 6 months after initial therapy - Relapse after initial radiotherapy with complete response longer than 1 year since initial therapy and subsequent failure on MOPP and/or ABVD or hybrid - Bulky mediastinal disease after initial therapy and residual mass of at least 5 cm with other features of persisting disease (e.g., Gallium scan positive, high LDH, enlarging on serial x-rays, or positive biopsy) - No HIV or HTLV-1 associated lymphomas -",ct_inc_591291,AACT,511,NCT00005985,Hypothetical,MOPP
5c7430a98625dd0758867f91,460,,,89,Patient,15:05.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_592784,Clinical Trial Inclusion Criteria,UNKNOWN,Patients with Hodgkin's disease will be eligible only if they have failed at least a MOPP-like and ABVD-like regimen.,ct_inc_592784,AACT,85,NCT00038376,Hypothetical,MOPP
5c7430ae8625dd079a867f89,380,,,166,Patient,15:10.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_354846,Clinical Trial Inclusion Criteria,UNKNOWN,"For advanced (stage III/IV) Hodgkin disease, patients must have failed an Adriamycin containing regimen (ABVD) or an alternative non-cross resistant regimen (e.g.MOPP) - Patients with any high-risk features will also be eligible, including those who: 1. fail to achieve complete remission with initial combination chemotherapy 2. have bulky disease after initial therapy (chemotherapy or radiation) defined as residual mediastinal mass 5 cm or other residual mass 10 cm accompanied by other features of persisting disease (e.g., PET scan positive; high LDH; enlarging on serial x-rays or biopsy positive) will be eligible - if feasible, persistent disease should be proven by biopsy - Patients should receive chemotherapy to attempt to achieve CR or minimal disease state for all patients pre-transplantation.",ct_inc_354846,AACT,162,NCT03125642,Recent,MOPP
5c7430bb8625dd083f867f97,240,,,234,Patient,15:23.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_591782,Clinical Trial Inclusion Criteria,DIAGNOSES,"In PR or CR after 1-2 other salvage chemotherapy regimens (e.g., 3 courses of dexamethasone, high-dose cytarabine, and cisplatin (DHAP); 2 courses of cyclophosphamide, mechlorethamine, vincristine, procarbazine, and prednisone (C-MOPP)) -",ct_inc_591782,AACT,230,NCT00002697,Recent,MOPP
5c7430a18625dd0700867f91,200,,,671,Patient,14:57.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_591291,Clinical Trial Inclusion Criteria,UNKNOWN,"In second or greater complete or partial response if treated at diagnosis without clinical symptoms necessitating treatment - T-cell lymphoma (nonlymphoblastic, intermediate, or high grade lymphomas) after initial therapy whether or not complete response is achieved - Hodgkin's lymphoma - Stage I and II disease treated with primary radiotherapy and failure of at least one combination chemotherapy regimen - Stage III and IV disease with failure on mechlorethamine, vincristine, procarbazine, and prednisone (MOPP)-like regimen, alternative noncross resistant regimen (e.g., doxorubicin, bleomycin, vinblastine, and dacarbazine [ABVD]), or a combination (e.g., MOPP-ABV) - High risk features allowed including: - Failure to achieve initial complete remission with MOPP and/or ABVD and crossover or hybrid therapy - Relapse within 6 months after initial therapy - Relapse after initial radiotherapy with complete response longer than 1 year since initial therapy and subsequent failure on MOPP and/or ABVD or hybrid - Bulky mediastinal disease after initial therapy and residual mass of at least 5 cm with other features of persisting disease (e.g., Gallium scan positive, high LDH, enlarging on serial x-rays, or positive biopsy) - No HIV or HTLV-1 associated lymphomas -",ct_inc_591291,AACT,663,NCT00005985,Recent,MOPP-ABV
5c7430618625dd043c867f99,50,,,68,Patient,13:53.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_587871,Clinical Trial Inclusion Criteria,UNKNOWN,"Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) MOPP/ABV Stanford 5 OR Refractory to a second line regimen, such as: Mesna, ifosfamide, mitoxantrone, and etoposide (MINE) Etoposide, methylprednisolone, high dose cytarabine, and cisplatin",ct_inc_587871,AACT,60,NCT00005595,Recent,MOPP/ABV
5c7430628625dd0452867f95,40,,,190,Patient,13:54.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_590819,Clinical Trial Inclusion Criteria,UNKNOWN,"- Histologically confirmed Hodgkin's lymphoma - Early or late first relapse - Complete or partial remission for at least 3 months after completion of prior COPP/ABVD, COPP/ABV/IMEP, MOPP/ABV, ABVD, BEACOPP, or other polychemotherapy regimen with or withou",ct_inc_590819,AACT,182,NCT00025636,Historical,MOPP/ABV
5c74304d8625dd0376867f8e,940,,,110,Patient,13:34.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_591349,Clinical Trial Inclusion Criteria,CHEMOTHERAPEUTICS,"At least 6 months since prior adjuvant/neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) or cisplatin, methotrexate, and vinblastine (CMV), or cisplatin as a radiosensitizer Endocrine therapy: - Not specified Radiotherapy: - At least 4 weeks since prior radiotherapy - No concurrent radiotherapy",ct_inc_591349,AACT,106,NCT00005644,Historical,MVAC
5c74304f8625dd02f2867f88,1290,,,1057,Patient,13:35.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_360871,Clinical Trial Inclusion Criteria,UNKNOWN,"(RECIST) version 1.1 - Must have a histologically confirmed transitional cell carcinoma (TCC, also known as urothelial carcinoma), locally advanced or metastatic - Patient must have TCCs tumors harboring a TSC1 or TSC2 mutation identified by a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory - Unless the pre-screening was performed at Yale Clinical Molecular Pathology Lab (YCMPL), patients must have TCC tumor tissue available for submission in a form of at least 10 unstained slides or formalin-fixed paraffin-embedded (FFPE) block (FFPE block highly recommended and preferred) along with a buccal swab; if the number of slides is less than 10, a biopsy should be considered; if a biopsy is deemed unsafe, the case may be discussed with the study principal investigator (PI) and approval must be given for eligibility - Patient must have developed disease progression during or following treatment with at least one platinum-containing regimen (e.g., gemcitabine/cisplatin [GC], methotrexate-vinblastine-doxorubicin-cisplatin [MVAC], carboplatin, gemcitabine [CarboGem]) for inoperable locally advanced or metastatic urothelial carcinoma or disease recurrence, or must be unfit or ineligible for cisplatin-based chemotherapy; there is no restriction on the number of prior lines of chemotherapeutics agents received - Patients who progressed within 12 months of treatment with a platinum-containing neoadjuvant or adjuvant regimen are considered second-line patients; therefore, these patients may be also eligible - Patients who are unfit or ineligible for cisplatin-based chemotherapy as defined by any one of the following criteria are eligible for this trial:",ct_inc_360871,AACT,1053,NCT03047213,Historical,MVAC
5c7430608625dd045a867f88,1190,,,295,Patient,13:52.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_407636,Clinical Trial Inclusion Criteria,UNKNOWN,"Be previously chemotherapy-treated; all patients may have received up to two prior lines of chemotherapy (excludes systemic therapy) for recurrent/advanced disease, as long as one of those regimens was platinum-based; (it is anticipated that patients would have been previously treated with MVAC or GC, or variations of these standard frontline regimens) - Be willing and able to provide written informed consent for the trial - Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST)",ct_inc_407636,AACT,291,NCT02437370,Historical,MVAC
5c74306b8625dd04e1867f86,500,,,126,Patient,14:03.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_349612,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients who were administered 4-6 cycles of cisplatin-based first line chemotherapy [GP (gemcitabine/cisplatin), classic MVAC (methotrexate/vinblastine/doxorubicin/cisplatin), or dose-dense MVAC] and were planned to undergo regular surveillance 4.",ct_inc_349612,AACT,122,NCT03193788,Recent,MVAC
5c7430958625dd069d867f8a,880,,,238,Patient,14:45.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_591384,Clinical Trial Inclusion Criteria,UNKNOWN,"No metastatic disease by physical exam and chest x-ray or CT scan of the chest - Eligible for randomization if: - p53 gene alteration present - Randomization occurs within 10 weeks after surgery - Those who are randomized to receive (MVAC) methotrexate, vinblastine, doxorubicin, and cisplatin begin MVAC within 12 weeks after cystectomy - No metastatic disease by physical exam and chest x-ray or CT scan of the chest - No prohibitive medical risk for chemotherapy",ct_inc_591384,AACT,234,NCT00005047,Hypothetical,MVAC
5c7430a18625dd071a867f87,1060,,,125,Patient,14:58.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_316213,Clinical Trial Inclusion Criteria,UNKNOWN,"For Cohort 2: Disease progression during or following treatment with at least one platinum-containing regimen (e.g., GC, MVAC, CarboGem, carboplatin-paclitaxel) for inoperable locally advanced or metastatic urothelial carcinoma or disease recurrence, as defined by: Regimen is defined as patients receiving at least one cycle of a platinum-containing regimen with response assessment.",ct_inc_316213,AACT,121,NCT03628716,Recent,MVAC
5c7430b08625dd07b0867f88,840,,,355,Patient,15:12.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_395958,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically or cytologically documented locally advanced or metastatic urothelial carcinoma (including renal pelvis, ureters, urinary bladder, and urethra) - Disease progression during or following treatment with at least one platinum-containing regimen (e.g., gemcitabine and cisplatin [GC], methotrexate, vinblastine, doxorubicin, and cisplatin [MVAC], carboplatin and gemcitabine [CarboGem], etc.)for inoperable locally advanced or metastatic urothelial carcinoma or disease recurrence - Eastern Cooperative Oncology Group (ECOG)",ct_inc_395958,AACT,351,NCT02589717,Recent,MVAC
5c7430b18625dd07b0867f89,840,,,111,Patient,15:13.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_593072,Clinical Trial Inclusion Criteria,UNKNOWN,- Failure of first line systemic chemotherapy with a platinum-containing combination regimen consisting of MVAC or cisplatin/gemcitabine with cisplatin dosed at 60 mg/m2 or higher per cycle - Adult (18 years of age or older) patients - Adequate hematologi,ct_inc_593072,AACT,107,NCT00034177,Recent,MVAC
5c7430b18625dd07b0867f8a,840,,,721,Patient,15:13.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_432830,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Histologically or cytologically documented locally advanced or metastatic transitional cell carcinoma of the urothelium (including renal pelvis, ureters, urinary bladder, urethra) - Representative tumor specimens as specified by the protocol - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - Life expectancy greater than or equal to (>=) 12 weeks - Measurable disease, as defined by RECIST v1.1 - Adequate hematologic and end organ function Cohort 2-Specific Inclusion Criteria - Disease progression during or following treatment with at least one platinum-containing regimen (e.g., gemcitabine and cisplatin [GC], methotrexate, vinblastine, doxorubicin, and cisplatin [MVAC], CarboGem, etc.)for inoperable locally advanced or metastatic urothelial carcinoma or disease recurrence.-",ct_inc_432830,AACT,717,NCT02108652,Recent,MVAC
5c7430538625dd03ad867f8a,590,,,348,Patient,13:39.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_332531,Clinical Trial Exclusion Criteria,UNKNOWN,"Any condition or comorbidity that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results, including but not limited to: Major surgery 28 days prior first dose of study treatment Anticancer treatment during the last 30 days prior to start of Nivolumab monotherapy treatment, including systemic therapy or major surgery [palliative radiotherapy has to be completed at least 2 weeks prior to start of study treatment]",ct_exc_332531,AACT,327,NCT03416244,Historical,Nivolumab monotherapy
5c7430538625dd03ad867f8b,590,,,331,Patient,13:39.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_332531,Clinical Trial Exclusion Criteria,UNKNOWN,"Any other active infection (viral, fungal or bacterial) requiring systemic therapy History of allogeneic tissue/solid organ transplant Diagnosis of immunodeficiency or patient is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of Nivolumab monotherapy treatment.",ct_exc_332531,AACT,310,NCT03416244,Historical,Nivolumab monotherapy
5c7430538625dd03ad867f8c,590,,,76,Patient,13:39.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_332531,Clinical Trial Exclusion Criteria,UNKNOWN,Live vaccine within 30 days prior to the first dose of Nivolumab monotherapy treatment or during study treatment.,ct_exc_332531,AACT,55,NCT03416244,Historical,Nivolumab monotherapy
5c7430538625dd03ad867f8d,590,,,249,Patient,13:39.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_332531,Clinical Trial Exclusion Criteria,HISTORY_PRESENT_ILLNESS,or clinical evidence of CNS metastases Exceptions are: Subjects who have completed local therapy and who meet both of the following criteria: i. are asymptomatic AND ii.have no requirement for steroids 6 weeks prior to start of Nivolumab monotherapy treatment.,ct_exc_332531,AACT,228,NCT03416244,Historical,Nivolumab monotherapy
5c7430a38625dd0742867f84,1120,,,418,Patient,14:59.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_355487,Clinical Trial Exclusion Criteria,UNKNOWN,Part B - Must meet eligibility criteria for initiation of Part A with the exception of being allowed to have prior nivolumab in Part A of this protocol - Must have evidence of either RECIST 1.1 defined Disease Progression or Stable Disease 1 year after initiating nivolumab therapy - Must undergo repeat tumor biopsy for acquisition of resistant tumor tissue - Must not have had a Grade 3 irAE on nivolumab monotherapy - Must not have untreated brain metastases - Must not have had major surgery or radiation therapy within 14 days of starting study treatment - Must not have active autoimmune disease - Must not have a concurrent medical condition requiring use of systemic corticosteroids with prednisone >,ct_exc_355487,AACT,397,NCT03117309,Historical,nivolumab monotherapy
5c7430a48625dd072c867f86,1270,,,93,Patient,15:00.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_332651,Clinical Trial Inclusion Criteria,UNKNOWN,"For patients randomized to carboplatin alone who decide to crossover to nivolumab monotherapy at time of progression, a mandatory biopsy will be required if tumor is safely accessible prior to initiating nivolumab; participants must also agree to undergo this biopsy, if applicable.- Prior",ct_inc_332651,AACT,72,NCT03414684,Hypothetical,nivolumab monotherapy
5c7430a48625dd0742867f85,1120,,,309,Patient,15:00.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_350883,Clinical Trial Exclusion Criteria,UNKNOWN,"Prior treatment with nivolumab, ipilimumab, or with any other anti-PD-1, anti-PD-L1, Anti-PD-L2, anti-CTLA-4 antibody or any other antibody or drug specifically targeting T cell co-stimulation or immune checkpoint pathways (NB Participant is eligible for Part 2 of the study if they took nivolumab monotherapy in Part 1 of the study).",ct_exc_350883,AACT,288,NCT03177239,Hypothetical,nivolumab monotherapy
5c7430a88625dd0767867f88,670,,,52,Patient,15:04.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_360816,Clinical Trial Inclusion Criteria,UNKNOWN,The patient is a candidate for Nivolumab monotherapy,ct_inc_360816,AACT,31,NCT03047928,Recent,Nivolumab monotherapy
5c7430af8625dd079a867f8f,380,,,44,Patient,15:11.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_348696,Clinical Trial Inclusion Criteria,UNKNOWN,- Newly initiated with nivolumab monotherapy as their first-line therapy for previously untreated advanced melanoma between June 2015 and June 2016 -,ct_inc_348696,AACT,23,NCT03205722,Recent,nivolumab monotherapy
5c7430b58625dd07e7867f87,770,,,182,Patient,15:17.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_322081,Clinical Trial Inclusion Criteria,COMMENT,Patients who have completed at least one dose of ipilimumab + nivolumab and progress or have completed the 4 doses of ipilimumab + nivolumab and progress during nivolumab monotherapy maintenance are eligible unless they have received additional treatment(s) for their renal cell carcinoma prior to registration.,ct_inc_322081,AACT,161,NCT03552380,Historical,nivolumab monotherapy
5c7430b58625dd07e7867f88,770,,,78,Patient,15:17.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_322081,Clinical Trial Inclusion Criteria,COMMENT,Patients who discontinue prior ipilimumab + nivolumab or nivolumab monotherapy for toxicity are excluded.,ct_inc_322081,AACT,57,NCT03552380,Historical,nivolumab monotherapy
5c74307f8625dd05d0867f84,410,,,507,Patient,14:23.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_334682,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Patient has histologically verified CRC adenocarcinoma (also comprising the mucinous adenocarcinoma and signet-ring cell carcinoma entities).- Patient is ambulatory with Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.- Patient has radiologically measurable metastatic disease.- Patient has an intra-abdominal metastatic lesion that can be biopsied.- Patient has not had previous systemic therapy for the metastatic disease.- Patient is eligible for the Nordic FLOX regimen.-,ct_inc_334682,AACT,496,NCT03388190,Recent,Nordic FLOX
5c7430a58625dd0737867f9a,180,,,36,Patient,15:01.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_500526,Clinical Trial Inclusion Criteria,UNKNOWN,(These patients are given NOVE-HiDAC as frontline therapy at Princess Margaret Hospital).- Positivity for c-kit (CD117) in at least 30% of blasts as measured by flow cytometry.,ct_inc_500526,AACT,26,NCT01222143,Recent,NOVE-HiDAC
5c7430b08625dd079a867f93,380,,,186,Patient,15:12.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_418762,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Richter's transformation or prolymphocytic leukemia - Refractory to obinutuzumab (defined as progression or relapse <12 months of receiving obinutuzumab monotherapy or <24 months of receiving an obinutuzumab-containing regimen) - Progressive disease while previously receiving a PI3K inhibitor (e.g.GS-1101 [idelalisib], duvelisib) or a serious/severe AE related to PI3K inhibitor treatment - History of severe reaction to prior monoclonal antibody therapy (defined as a Grade 4 event and/or requiring permanent discontinuation) - Human immunodeficiency virus (HIV) or Human T Cell Lymphotropic Virus 1 (HTLV-1)",ct_exc_418762,AACT,162,NCT02292225,Historical,obinutuzumab monotherapy
5c7430828625dd05e2867f89,330,,,142,Patient,14:26.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_402569,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria: - Known hypersensitivity to olaparib or any of the excipients of the drug - Patients who have started olaparib monotherapy for more than 14 days before giving their informed consent - Pregnancy or breast feeding,ct_exc_402569,AACT,122,NCT02503436,Recent,olaparib monotherapy
5c7430438625dd0308867f88,680,,,356,Patient,13:23.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_555252,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients must have metastatic colorectal cancer that has been histologically or cytologically confirmed; confirmation may be from either the primary tumor or a metastasis; patients must have wild type KRAS - Patients must be registered within 28 days of documented disease progression on first line chemotherapy with bevacizumab plus either FOLFOX, OPTIMOX, or XELOX; this progression must have occurred within 90 days after the last dose of bevacizumab; patients who discontinued oxaliplatin, continued with 5-FU/LV or capecitabine and bevacizumab and then had subsequent progression while on fluoropyrimidine and bevacizumab are eligible; patients who discontinued bevacizumab due to adverse events in the first-line setting are not eligible - Measurable or nonmeasurable disease - At least 14 days must have elapsed since the last dose of first line chemotherapy and bevacizumab - Patients must not have received prior treatment with irinotecan (either as adjuvant or metastatic treatment) - Patients must have no history of prior treatment with cetuximab or other agents targeting VEGF or EGFR (except for bevacizumab) - Prior radiotherapy is allowed, provided at least 28 days have elapsed since the last treatment; all adverse events related to radiation therapy must be resolved - Prior surgery is allowed, provided at least 28 days have elapsed since any major surgery and patient has recovered from all effects - Zubrod performance status 0-2 - Absolute neutrophil count (ANC) >= 1,500/mm^3 - Platelet count >= 100,000/mm^3 - Hemoglobin >",ct_inc_555252,AACT,349,NCT00499369,Historical,OPTIMOX
5c74306f8625dd04fb867f8e,1030,,,737,Patient,14:07.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_393211,Clinical Trial Exclusion Criteria,UNKNOWN,"3.- Pregnancy or lactation - Known alcohol or drug abuse - History of uncontrolled intercurrent illness including hypertension, active infection, diabetes - Clinically significant (i.e., active) cardiovascular disease - All other significant diseases might impair the subject's tolerance of trial treatment - Any psychiatric condition that would prohibit the understanding or rendering of informed consent and that would limit compliance with study requirements - Vaccination within 4 weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines - Legal incapacity or limited legal capacity - Subjects will be excluded from the treatment with irinotecan or paclitaxel monotherapy if administration of their chemotherapy would be inconsistent with the current local labeling (for example, in regard to contraindications, warnings/precautions, or special provisions) for that chemotherapy.",ct_exc_393211,AACT,715,NCT02625623,Historical,paclitaxel monotherapy
5c74309e8625dd070b867f85,510,,,64,Patient,14:54.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_482559,Clinical Trial Inclusion Criteria,UNKNOWN,Suitable for and expected to benefit from paclitaxel monotherapy.-,ct_inc_482559,AACT,42,NCT01457846,Recent,paclitaxel monotherapy
5c7430898625dd0624867f8e,420,,,294,Patient,14:33.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_466685,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion criteria: - Age 18 years - Diagnosis of histologically or cytologically confirmed melanoma stage III or IV.- Fresh tumor tissue must be provided for all subjects for biomarker analysis before (within 14 days prior to treatment start) and during (on day 10 of the pazopanib monotherapy and the last day of the treatment with pazopanib, day 70) treatment with investigational product (asservation in RNAlater, for kryo asservation, and for cell cultures)",ct_inc_466685,AACT,273,NCT01666418,Historical,pazopanib monotherapy
5c7430908625dd0671867f8a,950,,,79,Patient,14:40.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_516484,Clinical Trial Exclusion Criteria,UNKNOWN,exclusion criteria - the maximum tolerated dose (MTD) for pazopanib monotherapy in patients with hepatocellular cancer was found to be 600 mg daily.- Measureable or evaluable disease per Response Evaluation Criteria in Solid Tumors (,ct_exc_516484,AACT,58,NCT01012362,Recent,pazopanib monotherapy
5c7430948625dd067c867f8c,1110,,,33,Patient,14:44.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_468642,Clinical Trial Inclusion Criteria,COMMENT,The MTD for pazopanib monotherapy in patients with hepatocellular cancer was found to be 600 mg daily therefore enrollment for these patients will be limited to pazopanib dose levels at or below 600 mg.,ct_inc_468642,AACT,12,NCT01639911,Recent,pazopanib monotherapy
5c7430858625dd05f1867f8b,1000,,,104,Patient,14:29.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_345552,Clinical Trial Inclusion Criteria,UNKNOWN,"Investigator determined assessment of disease progression after treatment with pembrolizumab monotherapy, OR Investigator determined assessment of current stable disease following completion of at least 4 cycles but no more than 8 cycles, of pembrolizumab monotherapy Have resolution of all previous treatment-related toxicities to Grade 1 severity or lower, except for stable sensory neuropathy (less than or equal to Grade 2) or alopecia.",ct_inc_345552,AACT,79,NCT03246685,Recent,pembrolizumab monotherapy
5c74303e8625dd0308867f87,680,,,133,Patient,13:18.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_447365,Clinical Trial Inclusion Criteria,UNKNOWN,Histologically or cytologically confirmed stage IV non-squamous NSCLC - Patients who are candidates to receive pemetrexed monotherapy - If pemetrexed has been administered as first line therapy there must be a treatment free interval of at least one cycle (21 days) -,ct_inc_447365,AACT,111,NCT01918761,Hypothetical,pemetrexed monotherapy
5c7430448625dd033f867f8b,310,,,1113,Patient,13:24.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_477019,Clinical Trial Inclusion Criteria,UNKNOWN,- Provision of informed consent prior to any study specific procedures.- Histologically or cytologically confirmed NSCLC with an activating sensitising EGFR TK mutation as it was determined before starting the first gefitinib treatment by using a well-val,ct_inc_477019,AACT,1091,NCT01530334,Historical,pemetrexed monotherapy
5c7430448625dd033f867f8d,310,,,268,Patient,13:24.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_439216,Clinical Trial Inclusion Criteria,UNKNOWN,">12 weeks as the best response to their 1st EGFR-TKI treatment and who have received any subsequent anti-cancer therapy (excluding EGFR-TKIs) treatment, including but not limited to doublet platinum based chemotherapy or docetaxel monotherapy or pemetrexed monotherapy, on which they progressed.- Measurable disease defined as at least one lesion, not previously irradiated, that can be accurately measured at baseline as 10 mm in the longest diameter (except lymph nodes which must have short axis 15 mm) with spiral CT or MRI and which is suitable for accurate repeated measurements.- WHO / ECOG / Zubrod performance status 0-2.- Possibility of obtaining tumour material before the start of the study treatment.",ct_inc_439216,AACT,246,NCT02025218,Recent,pemetrexed monotherapy
5c7430468625dd0334867f92,400,,,89,Patient,13:26.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_430820,Clinical Trial Inclusion Criteria,REGISTRATION,Patients must have progressed systemically on Arm 2 of this study (pemetrexed monotherapy) - CROSSOVER (STEP 2),ct_inc_430820,AACT,67,NCT02134912,Recent,pemetrexed monotherapy
5c7430898625dd060e867f90,470,,,150,Patient,14:33.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_379774,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria: Investigator-predicted life expectancy of less than two months Investigator-predicted inability to tolerate pixantrone monotherapy treatment adverse effects for less than two months Prior anthracycline treatment with a cumulative dose exceeding 450 mg/m2 (calculated based on doxorubicin equivalents),ct_exc_379774,AACT,128,NCT02800889,Historical,pixantrone monotherapy
5c74308f8625dd0671867f86,950,,,94,Patient,14:39.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_562395,Clinical Trial Inclusion Criteria,UNKNOWN,"uveitis - Current uveitis therapy must conform to one of the following: Prednisone monotherapy at a dose of 10 mg/day (or equivalent) for 2 weeks prior to randomization Have received 2 injections of corticosteroid (intravitreal or periocular) for control of disease within the past 8 months, but not within 2 weeks of randomization; subjects may also be receiving systemic corticosteroid therapy Receiving monotherapy with azathioprine, mycophenolate mofetil, mycophenolic acid or methotrexate for at least 2 weeks prior to randomization Receiving prednisone in addition to one immunomodulatory agent from among cyclosporine, tacrolimus, azathioprine, mycophenolate mofetil, mycophenolic acid and methotrexate for at least 2 weeks prior to randomization Subjects for whom corticosteroid therapy (systemic or local) is medically inappropriate or who refuse corticosteroid therapy - Grade of 2+ or higher for vitreous haze at time of enrollment - Considered by the investigator to require immunomodulatory therapy.-",ct_inc_562395,AACT,72,NCT00404612,Historical,Prednisone monotherapy
5c7430688625dd04cb867f88,260,,,124,Patient,14:00.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_587353,Clinical Trial Inclusion Criteria,UNKNOWN,"Hodgkin's or non-Hodgkin's lymphoma Failed at least 1 conventional second or third generation regimen (e.g., ProMACE-CytaBOM)",ct_inc_587353,AACT,109,NCT00002818,Recent,ProMACE-CytaBOM
5c7430928625dd065b867fa6,20,,,57,Patient,14:42.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_593368,Clinical Trial Inclusion Criteria,UNKNOWN,Prior enrollment on the clinical trial of ProMACE-CytaBOM versus ProMACE-MOPP (81-C-0166) or Short Course ProMACE-CytaBOM (87-C-0180) for the treatment of previously untreated aggressive lymphomas.,ct_inc_593368,AACT,42,NCT00026910,Historical,ProMACE-CytaBOM
5c7430928625dd065b867fa7,20,,,77,Patient,14:42.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_593368,Clinical Trial Inclusion Criteria,UNKNOWN,Prior enrollment on the clinical trial of ProMACE-CytaBOM versus ProMACE-MOPP (81-C-0166) or Short Course ProMACE-CytaBOM (87-C-0180) for the treatment of previously untreated aggressive lymphomas.,ct_inc_593368,AACT,65,NCT00026910,Historical,ProMACE-MOPP
5c74308d8625dd065b867f93,20,,,84,Patient,14:37.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_540944,Clinical Trial Inclusion Criteria,UNKNOWN,"Previously treated with chemotherapy regimen containing rituximab: R CHOP or R ACVBP - Chemo-sensitive disease - PET Scan prior transplant - Eligible for autologous stem cell transplantation - With a minimum life expectancy of 3 months.- Negative HIV, HBV and HCV serologies (in the last 4 weeks except after vaccination).- Having previously signed a written informed consent.",ct_inc_540944,AACT,77,NCT00689169,Historical,R ACVBP
5c7430688625dd04c0867f97,30,,,162,Patient,14:00.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_381550,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - DLBCL and concomitant initial CNS involvement - PMBL (primary mediastinal B-cell lymphoma) - treatment with another chemotherapy than R CHOP or DA EPOCH R - HIV positive, or active hepatitis B or C - other concomitant serious disease (based on the decision of the physician-investigator) - non-compliance of a patient - any contraindication for application of anthracycline based chemotherapy or high dose methotrexate - pregnancy or",ct_exc_381550,AACT,156,NCT02777736,Recent,R CHOP
5c74308d8625dd065b867f94,20,,,73,Patient,14:37.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_540944,Clinical Trial Inclusion Criteria,UNKNOWN,"Previously treated with chemotherapy regimen containing rituximab: R CHOP or R ACVBP - Chemo-sensitive disease - PET Scan prior transplant - Eligible for autologous stem cell transplantation - With a minimum life expectancy of 3 months.- Negative HIV, HBV and HCV serologies (in the last 4 weeks except after vaccination).- Having previously signed a written informed consent.",ct_inc_540944,AACT,67,NCT00689169,Historical,R CHOP
5c7430918625dd065b867fa4,20,,,153,Patient,14:41.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_381550,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - histologically confirmed DLBCL - age 18-72 years - signed informed consent with the study - first-line treatment 6 cycles of R CHOP +2x R or 6 cycles of DA EPOCH R+ 2xR,ct_inc_381550,AACT,147,NCT02777736,Recent,R CHOP
5c7430528625dd03c7867f87,0,,,225,Patient,13:38.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_356471,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - DLBCL patients that will be eligible in front-line treatment for a combination of anthracycline-based chemotherapy plus anti-CD20 monoclonal antibody,Rituximab: R-CHOP 14, R-CHOP 21, R mini-CHOP, R-ACVBP, R-COPADEM.Patients",ct_inc_356471,AACT,218,NCT03104478,Recent,R-ACVBP
5c7430538625dd03c7867f9c,0,,,368,Patient,13:39.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_338682,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Patient with a recent diffuse large B cell lymphoma (LBDGC), histologically proven, with treatment not started - a priori likely to be treated by rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone every 21 days (R-CHOP21) for 8 cycles or rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (R-ACVBP).- Index international prognosis (IPI) measurable (IPI-aa), adjusted for age.",ct_inc_338682,AACT,361,NCT03336138,Recent,R-ACVBP
5c7430548625dd03c7867fb8,0,,,86,Patient,13:40.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_415115,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Patient who cannot receive polychemotherapy like R-CHOP, R-ACVBP, or R-CHOP like - Patient who cannot benefit from standard extension assessment and follow-up by with Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET) - Pregnant or breast-feeding woman - Guardianship, curatorship - Patient who cannot follow the medical procedures of the study for geographic, social, psychological,linguistic or physical reasons",ct_exc_415115,AACT,79,NCT02339805,Recent,R-ACVBP
5c74307e8625dd05b6867f90,10,,,220,Patient,14:22.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_415115,Clinical Trial Inclusion Criteria,UNKNOWN,"With a diagnosis formally established of DLBCL or transformed straightaway follicular lymphoma or 3B grade follicular lymphoma or Burkitt-like lymphoma - Eligible to a treatment by immunochemotherapy like R-CHOP, R-ACVBP or R-CHOP like - First line of treatment - Being able to benefit from standard extension assessment ( Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET) and bone marrow biopsy with a bone marrow aspiration)",ct_inc_415115,AACT,213,NCT02339805,Recent,R-ACVBP
5c74303b8625dd02f6867f84,120,,,49,Patient,13:15.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_514128,Clinical Trial Inclusion Criteria,LABORATORY_DATA,Inclusion criteria for patients undergoing R-CHOP,ct_inc_514128,AACT,43,NCT01044004,Recent,R-CHOP
5c74303b8625dd02f6867f86,120,,,50,Patient,13:15.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_514128,Clinical Trial Inclusion Criteria,CHEMOTHERAPEUTICS,"- Scheduled to receive 6 cycles of standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy as first-line treatment Inclusion criteria for patients in remission following chemotherapy",ct_inc_514128,AACT,44,NCT01044004,Recent,R-CHOP
5c74303d8625dd02f6867f95,120,,,689,Patient,13:17.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_408953,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically confirmed DLBCL, cluster of differentiation (CD)20 positive by flow or immunohistochemistry (IHC); transformed DLBCL is allowed as long as no prior therapy has been given - No prior therapy for DLBCL, except =< 1 week of corticosteroids given on an emergent basis or as a temporizing measure (pre-phase where indicated by the treating physician) - Measurable disease by computed tomography (CT), magnetic resonance imaging (MRI), and/or positron emission tomography (PET) with at least one target lesion measuring 1.5 cm or larger - Patients must be considered ineligible for rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone (R-CHOP) standard therapy; to be ineligible for R-CHOP, patients must meet at least one of the following criteria are met: -",ct_inc_408953,AACT,683,NCT02420210,Historical,R-CHOP
5c74303d8625dd02f6867f96,120,,,250,Patient,13:17.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_408953,Clinical Trial Inclusion Criteria,UNKNOWN,"Prior anthracycline therapy for other malignancies or other disorders whereby if additional anthracyclines are given for DLBCL, the maximum lifetime allowable dose will be exceeded - Meeting the geriatric criteria of ineligibility for standard R-CHOP if one of the following criteria is present: - Three or more organ systems with a score of 3 or any 1 organ system with a score of 4 (using the Cumulative Illness Rating Scale for Geriatrics, [CIRS-G]) - Score of 3 or above on the Vulnerable Elders Survey (VES-13) -",ct_inc_408953,AACT,244,NCT02420210,Hypothetical,R-CHOP
5c74303e8625dd02f6867f9c,120,,,73,Patient,13:18.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_413963,Clinical Trial Inclusion Criteria,UNKNOWN,Previously untreated DLBCL patients who are suitable for receiving R-CHOP chemotherapy - Serum ALT no more than 2 x ULN (including normal ALT) - Life expectancy 6 months - A negative serum or urine pregnancy test prior to treatment must be available both for pre menopausal women and for women who are no more than 1 years after the onset of menopause.- Informed consent,ct_inc_413963,AACT,67,NCT02354846,Historical,R-CHOP
5c7430448625dd0334867f8c,400,,,319,Patient,13:24.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_409176,Clinical Trial Inclusion Criteria,UNKNOWN,"Entry Criteria Specific for Dose-Escalation Phase (Part A) Subjects with CD20 positive, histologically or cytologically-confirmed, diffuse large B-cell lymphoma (DLBCL)(including transformed low grade lymphoma) who have relapsed or refractory disease following at least two prior standard treatment regimens (eg, R-CHOP or similar first-lineregimen and at least one second-line salvage regimen) and/or autologous stem cell transplant (ASCT) in chemotherapy-sensitive patients, with the following",ct_inc_409176,AACT,313,NCT02417285,Historical,R-CHOP
5c7430458625dd0355867f84,160,,,114,Patient,13:25.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_580022,Clinical Trial Exclusion Criteria,UNKNOWN,"Central nervous system or meningeal involvement by lymphoma.- Contra-indication to any drug included in the R-CHOP regimen.- Concurrent severe disease (according to the investigator's decision).- Active bacterial, viral or fungal infection.- Poor renal function (serum creatinine level",ct_exc_580022,AACT,108,NCT00169156,Recent,R-CHOP
5c7430468625dd0355867f8a,160,,,280,Patient,13:27.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_537364,Clinical Trial Exclusion Criteria,UNKNOWN,"No active CNS disease defined as symptomatic meningeal lymphoma or known CNS parenchymal lymphoma - Concomitant anticoagulant therapy is not permitted (with the exception of 1 mg/day of warfarin for central line prophylaxis) - Known hypersensitivity to G3139 (Genasense) or R-CHOP - Neurologic disorders, overt psychosis, mental disability or evidence of limited capacity to provide fully informed consent or cooperation with the complexities of the treatment program",ct_exc_537364,AACT,274,NCT00736450,Recent,R-CHOP
5c74304a8625dd0381867f84,230,,,34,Patient,13:30.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_483422,Clinical Trial Inclusion Criteria,UNKNOWN,"Induction chemotherapy with R-CHOP should also be completed at the participating centre, but exceptions can be made according to the discretion of the centre's primary investigator.- Protocol treatment is to begin within 5 working days of patient registration",ct_inc_483422,AACT,28,NCT01446562,Recent,R-CHOP
5c74304a8625dd0355867f9b,160,,,25,Patient,13:30.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_415937,Clinical Trial Inclusion Criteria,UNKNOWN,One-two courses of R-CHOP combination as upfront therapy are admitted in patients with large amount,ct_inc_415937,AACT,19,NCT02329080,Recent,R-CHOP
5c74304a8625dd0355867f9c,160,,,44,Patient,13:30.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_415937,Clinical Trial Inclusion Criteria,UNKNOWN,Local investigator decides if initial R-CHOP is needed based on patient's conditions Age 18-70 years 6.,ct_inc_415937,AACT,38,NCT02329080,Hypothetical,R-CHOP
5c74304a8625dd0381867f86,230,,,68,Patient,13:30.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_452289,Clinical Trial Inclusion Criteria,UNKNOWN,"No prior lymphoma treatment, with one exception: One cycle of R-CHOP regimen is permitted (consisting of one single dose each of Rituximab, of cyclophosphamide, of doxorubicine, and of vincristine, as well as up to 5 doses of Prednisone when part of chemotherapy).",ct_inc_452289,AACT,62,NCT01854372,Historical,R-CHOP
5c74304a8625dd0381867f88,230,,,168,Patient,13:30.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_492710,Clinical Trial Exclusion Criteria,UNKNOWN,"Reactivation of latent infection has been reported with the use of bortezomib in this population (along obviously with the well recognised reactivation following R-CHOP).For these patient safety reasons, these patients should be excluded.",ct_exc_492710,AACT,162,NCT01324596,Recent,R-CHOP
5c74304b8625dd0381867f90,230,,,496,Patient,13:31.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_363654,Clinical Trial Inclusion Criteria,COMMENT,"Has EITHER histologically confirmed B-cell lymphomas including but not limited to diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), primary mediastinal B-cell lymphoma (PMBCL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), or Hodgkin lymphoma (HL) and has relapsed or refractory disease following at least two lines of prior standard therapy, including alkylator/anthracycline (unless anthracycline-based chemotherapy is contraindicated)/anti-CD20-based therapy (R-CHOP, rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisolone or dexamethasone, or equivalent for non-Hodgkin lymphoma), AND must be considered unable to benefit from intensification treatment with autologous hematopoietic stem cell transplantation (ASCT) , as defined by meeting at least one of the following criteria: - Relapsed following, or refractory to, previous ASCT - Did not achieve at least a partial response to a standard salvage regimen (e.g., R-ICE, rituximab, ifosfamide, carboplatin, etoposide, or R-DHAP, rituximab, dexamethasone, cytarabine, cisplatin) -",ct_inc_363654,AACT,490,NCT03010982,Historical,R-CHOP
5c74304c8625dd0381867f95,230,,,627,Patient,13:32.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_362341,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion criteria Male or female 18 years of age at time of consent Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 Has histologically confirmed diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL) or histologically and/or cytologically confirmed advanced or metastatic solid tumor and have relapsed or refractory disease following at least two lines of prior standard therapy, including alkylator/anthracycline (unless anthracycline-based chemotherapy is contraindicated)/anti-CD20-based therapy (R-CHOP; rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisolone or prednisone, or equivalent) AND must be considered unable to benefit from intensification treatment with autologous hematopoietic stem cell transplantation (ASCT), as defined by meeting at least one of the following criteria: Relapsed following, or refractory to:",ct_inc_362341,AACT,621,NCT03028103,Historical,R-CHOP
5c74304c8625dd036b867f92,190,,,9,Patient,13:32.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_328608,Clinical Trial Exclusion Criteria,GRAVIDA,"or R-CHOP infusion on Cycle 1/Day 1 - History of treatment-emergent immune-related AEs associated with prior immunotherapeutic agents - Contraindication to any of the individual components of the chemotherapy - Documented refractoriness to an obinutuzumab-monotherapy regimen - Treatment with standard radiotherapy, any chemotherapeutic agent, or treatment with any other investigational anti-cancer agent within 4 weeks prior to study treatment at Cycle 1/Day 1 infusion - Prior solid organ transplantation - Prior allogeneic stem cell transplantation - Autologous stem cell transplantation within 100 days prior to Cycle 1/Day 1 - History of autoimmune disease - History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibody therapy - A history of confirmed progressive multifocal leukoencephalopathy - Current or past history of central nervous system (CNS)",ct_exc_328608,AACT,3,NCT03467373,Historical,R-CHOP
5c74304d8625dd036b867f94,190,,,754,Patient,13:33.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_394735,Clinical Trial Inclusion Criteria,COMMENT,"subjects must have received at least 2 cycles of alkylator-based chemotherapy to be eligible Previously received rituximab, either as single agent or as part of any combination regimen, and also meet one of the following requirements: Progressed within 24 months of initiating alkylator-based chemotherapy in the first line and received no additional anticancer therapy Progressed within 24 months of initiating alkylator-based chemotherapy in the first line and subsequently progressed within 24 months of receiving any second-line treatment and received no additional anticancer therapy Progressed within 24 months of initiating alkylator-based chemotherapy in the second line and received no additional anticancer therapy Appropriate to receive R-CHOP",ct_inc_394735,AACT,748,NCT02605694,Recent,R-CHOP
5c74304d8625dd036b867f96,190,,,58,Patient,13:33.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_437757,Clinical Trial Exclusion Criteria,UNKNOWN,A prephase to reduce tumor burden prior to start of R-CHOP is allowed.,ct_exc_437757,AACT,52,NCT02044276,Historical,R-CHOP
5c74304e8625dd03a2867f84,130,,,102,Patient,13:34.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_325663,Clinical Trial Exclusion Criteria,UNKNOWN,CD4 count < 50 - Diagnosis of primary central nervous system (CNS) lymphoma - Unable to receive R-CHOP chemotherapy - History of severe (i.e.anaphylactic) allergic reactions attributed to compounds of similar chemical or biologic composition to glucocorticoids and other component of,ct_exc_325663,AACT,96,NCT03505762,Historical,R-CHOP
5c74304e8625dd036b867f98,190,,,388,Patient,13:34.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_435552,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Patients who have not recovered from adverse events due to agents administered more than 4 weeks earlier - Patients who are receiving any other investigational agents - Known central nervous system (CNS) involvement by lymphoma - History of allergic reactions attributed to compounds of similar chemical or biologic composition to carfilzomib or other agents (R-CHOP) used in this study - Active congestive heart failure (New York heart Association Class III or IV), symptomatic ischemia, or conduction abnormalities uncontrolled by conventional intervention or myocardial infarction within four months prior to enrollment - Patients with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements - Pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with carfilzomib - Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible - Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin, or low-risk prostate cancer after curative therapy - Patients who have had major surgical procedures or significant traumatic injury within 28 days prior to study treatment - Patients who are reported to be of direct Asian-Pacific (China, Japan, Taiwan, Singapore, Republic of Korea, and Thailand) ancestry.",ct_exc_435552,AACT,382,NCT02073097,Hypothetical,R-CHOP
5c74304e8625dd03a2867f86,130,,,117,Patient,13:34.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_474009,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Histopathologically-confirmed CD20-positive B-cell non Hodgkin lymphoma disease for whom R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) is an appropriate therapy (diffuse large B-cell lymphoma, mantle cell lymphoma, or follicular lymphoma); for the expansion cohort, at least 1 cohort will only include patients with newly diagnosed diffuse large B-cell lymphoma - Stage I AX (bulk defined as single lymph node mass >=10 cm in diameter) to Stage IV disease -",ct_inc_474009,AACT,111,NCT01569750,Recent,R-CHOP
5c74304e8625dd036b867f9a,190,,,225,Patient,13:34.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_451469,Clinical Trial Inclusion Criteria,UNKNOWN,"During the run-in period of 6 months starting from the date of the first randomization in the trial: in case of direct randomization into maintenance phase, patient must have been treated in first line by 6-8 cycles of R-CHOP.",ct_inc_451469,AACT,219,NCT01865110,Recent,R-CHOP
5c74304e8625dd036b867f9c,190,,,73,Patient,13:34.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_469683,Clinical Trial Inclusion Criteria,UNKNOWN,"Newly diagnosed, stage III-IV DLBCL considered poor candidates for R-CHOP.",ct_inc_469683,AACT,67,NCT01626352,Recent,R-CHOP
5c7430518625dd03a2867f90,130,,,128,Patient,13:37.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_487779,Clinical Trial Exclusion Criteria,UNKNOWN,"Other types of lymphomas, e.g.B-cell lymphoma, Contraindication to any drug contained in the three chemotherapy regimens (R-CHOP, R-FC, R-DHA), Tested positive for HIV, Active Hepatitis B",ct_exc_487779,AACT,122,NCT01389427,Recent,R-CHOP
5c7430528625dd03c7867f88,0,,,189,Patient,13:38.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_356471,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - DLBCL patients that will be eligible in front-line treatment for a combination of anthracycline-based chemotherapy plus anti-CD20 monoclonal antibody,Rituximab: R-CHOP 14, R-CHOP 21, R mini-CHOP, R-ACVBP, R-COPADEM.Patients",ct_inc_356471,AACT,183,NCT03104478,Recent,R-CHOP
5c7430528625dd03c7867f89,0,,,20,Patient,13:38.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_356471,Clinical Trial Inclusion Criteria,UNKNOWN," treated with R-CHOP associated with an experimental drug ((polatuzumab, tazemetostat, venetoclax, entospletinib, lenalidomide, ibrutinib, anti PD1/anti PDL1 .)-",ct_inc_356471,AACT,14,NCT03104478,Recent,R-CHOP
5c7430538625dd03c7867f91,0,,,216,Patient,13:39.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_316883,Clinical Trial Inclusion Criteria,UNKNOWN,Patients with early breast cancer planned to receive 3 weekly or dose-dense anthracycline/cyclophosphamide combination or 3 weekly taxane containing chemotherapy regimen or patients with NHL planned to receive R-CHOP-14 or R-CHOP-21 immunochemotherapy as 1st-line treatment with the indication for G-CSF prophylaxis with pegfilgrastim for the prevention of FN and reduction in CIN duration.,ct_inc_316883,AACT,210,NCT03619993,Recent,R-CHOP
5c7430538625dd03c7867f9a,0,,,184,Patient,13:39.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_411113,Clinical Trial Inclusion Criteria,UNKNOWN,"Planned to receive chemotherapy for 6 cycles which the treating physician plans to utilize for pegfilgrastim to minimize risk for neutropenic fever, including but not limited to R-CHOP, R-EPOCH, and R-HyperCVAD, CHOP, and SMILE.",ct_inc_411113,AACT,178,NCT02392039,Recent,R-CHOP
5c7430538625dd03c7867fa2,0,,,408,Patient,13:39.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_486155,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Subjects with significant concurrent medical complications that in the judgment of the Principal Investigator(s) could affect the patient's ability to complete the planned trial, including the multiple imaging studies.- Patients with history of prior lymphoma (e.g., follicular lymphoma) and/or second cancers other than basal cell carcinoma.- Patients planned to be treated with R-CHOP-14 (i.e.:",ct_exc_486155,AACT,402,NCT01410630,Historical,R-CHOP
5c7430538625dd03c7867fa3,0,,,6,Patient,13:39.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_486155,Clinical Trial Exclusion Criteria,UNKNOWN,"R-CHOP given every 14 days) will be excluded (this should be extremely rare, if at all, since R-CHOP-21 is the standard treatment.- Patients who are scheduled to receive Rituxan or any other therapy (e.g., XRT, radioimmunotherapy) as adjuvant therapy after completion of R-CHOP-21.- Pregnant women will be excluded.- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) after study entry and for the duration of study participation.",ct_exc_486155,AACT,0,NCT01410630,Hypothetical,R-CHOP
5c7430548625dd03c7867fb9,0,,,77,Patient,13:40.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_415115,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Patient who cannot receive polychemotherapy like R-CHOP, R-ACVBP, or R-CHOP like - Patient who cannot benefit from standard extension assessment and follow-up by with Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET) - Pregnant or breast-feeding woman - Guardianship, curatorship - Patient who cannot follow the medical procedures of the study for geographic, social, psychological,linguistic or physical reasons",ct_exc_415115,AACT,71,NCT02339805,Recent,R-CHOP
5c7430558625dd03c7867fbf,0,,,103,Patient,13:41.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_544174,Clinical Trial Inclusion Criteria,UNKNOWN,"- Obtain no partial response after first-line chemotherapy including anthracyclines + rituximab (R-CHOP, R-MegaCHOP, R-EPOCH or the like), or else - Absence of partial response after having received salvage (post-induction) chemotherapy including R-IFE, R",ct_inc_544174,AACT,97,NCT00646750,Recent,R-CHOP
5c7430578625dd03fe867f8a,290,,,429,Patient,13:43.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_448981,Clinical Trial Exclusion Criteria,COMMENT,"Subjects must satisfy all of the following criteria: Have histologically confirmed DLBCL (including primary mediastinal B-cell lymphoma), with relapsed or refractory disease following at least 2 lines of prior standard therapy, including alkylator/anthracycline (unless anthracycline-based chemotherapy is contraindicated)/anti-CD20-based therapy (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP] or equivalent) AND must be considered unable to benefit from intensification treatment with autologous hematopoietic stem cell transplantation (ASCT) as defined by meeting at least 1 of the following criteria: - Relapsed following, or refractory to, previous ASCT - Did not achieve at least a partial response to a standard salvage regimen (eg, rituximab, ifosfamide, carboplatin, and etoposide phosphate [R-ICE] or rituximab, dexamethasone, cytarabine, and cisplatin [R-DHAP]) -",ct_exc_448981,AACT,423,NCT01897571,Historical,R-CHOP
5c74305a8625dd0431867f85,220,,,89,Patient,13:46.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_347600,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Participants who have had chemotherapy other than R-EPOCH or R-CHOP, or radiotherapy other than palliative radiation for medical emergencies (like cord compression), within the last 4 weeks - Prior cytotoxic chemotherapy or radiotherapy for this lymphoma - Rituximab within 12 months prior to study registration; only exception will be if rituximab was given for indications other than the treatment of aggressive lymphoma, or for one prior cycle of treatment - Participants who are receiving any other investigational agents - Participants who have previously received ibrutinib for another indication - Expected survival < 2 months - Participants with a history of an opportunistic fungal infection or active fungal infection requiring, or at high risk of requiring, prophylactic or treatment with fluconazole, voriconazole or posaconazole - Participants with known brain metastases from solid tumors should be excluded from this clinical trial - Presence of second active tumor, other than non-melanoma skin cancer, carcinoma in situ of the cervix, or Kaposi's sarcoma (KS) that requires systemic therapy -",ct_exc_347600,AACT,83,NCT03220022,Hypothetical,R-CHOP
5c74305c8625dd043c867f8a,50,,,131,Patient,13:48.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_437757,Clinical Trial Inclusion Criteria,UNKNOWN,"Histological documentation of aggressive B cell NHL Planned to receive systemic anticancer therapy with at least 6 cycles of R-CHOP-21, according to local standards 5.",ct_inc_437757,AACT,125,NCT02044276,Recent,R-CHOP
5c74305d8625dd0431867f93,220,,,912,Patient,13:49.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_484338,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients must have a histologically confirmed diagnosis of aggressive B-cell lymphoma (diffuse large B-cell lymphoma [DLBCL], Burkitt lymphoma [BL], etc.)expressing the CD20 antigen and have failed at least one prior standard systemic therapy - Patients must have relapsed after high-dose therapy and autologous transplantation or be ineligible for high-dose therapy and autologous transplantation; patients that have failed autologous transplantation are those with persistent disease > 30 days after transplant; those ineligible for autologous transplant include those with chemoresistant disease (i.e., patients who have not achieved a partial response or better with their most recent chemotherapy regimen), are expected to have a poor outcome from autologous transplant (e.g., DLBCL relapsing within one year of rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone [R-CHOP]-like chemotherapy, double hit lymphoma, v-myc myelocytomatosis viral oncogene homolog (avian) positive [MYC+] lymphoma, persistent positron emission tomography [PET] positivity after chemotherapy), are unable to collect sufficient or tumor-free autologous stem cells per Seattle Cancer Care Alliance (SCCA) standard practice, are unable to tolerate the high-dose autologous conditioning regimens, or who refuse a high-dose autologous transplant regimen - Creatinine (Cr) < 2.0 - Bilirubin",ct_inc_484338,AACT,906,NCT01434472,Historical,R-CHOP
5c74305d8625dd0457867f84,70,,,261,Patient,13:49.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_420797,Clinical Trial Inclusion Criteria,UNKNOWN,"Participants must have histologically documented diagnosis of NHL (and exhausted options considered standard of care) as defined in the World Health Organization classification scheme and relapsed following or be refractory to standard treatments such as R-CHOP, R-CVP, or fludarabine based regimens.",ct_inc_420797,AACT,255,NCT02265731,Recent,R-CHOP
5c74305e8625dd0457867f87,70,,,91,Patient,13:50.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_492405,Clinical Trial Exclusion Criteria,UNKNOWN,"Subject must have relapsed following or be refractory to standard treatments such as R-CHOP, R-CVP, or fludarabine based regimens.",ct_exc_492405,AACT,85,NCT01328626,Recent,R-CHOP
5c74305e8625dd0457867f8a,70,,,101,Patient,13:50.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_448591,Clinical Trial Inclusion Criteria,UNKNOWN,"Be designated to receive cytotoxic chemotherapy including one or more of the following agents: R-CHOP, ABVD, Liposomal doxorubicin (Caelyx) or liposomal daunorubicin (Daunoxome) or Paclitaxel",ct_inc_448591,AACT,95,NCT01902693,Recent,R-CHOP
5c74305e8625dd0457867f8d,70,,,62,Patient,13:50.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_548371,Clinical Trial Inclusion Criteria,UNKNOWN, may be enrolled in this study after the first cycle of R-CHOP if all screening evaluations were performed prior to the first cycle of chemotherapy.- Ann Arbor stage 3 or 4 - Age greater than or equal to 18 years - Patient must give written informed consent.-,ct_inc_548371,AACT,56,NCT00590941,Hypothetical,R-CHOP
5c74305e8625dd0457867f8e,70,,,107,Patient,13:50.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_548371,Clinical Trial Inclusion Criteria,UNKNOWN,A patient enrolled in another clinical trial may also enroll in this study if the other trial has an R-CHOP treatment arm and the patient is randomized to the R-CHOP only arm.,ct_inc_548371,AACT,101,NCT00590941,Hypothetical,R-CHOP
5c74305e8625dd0457867f91,70,,,203,Patient,13:51.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_392045,Clinical Trial Inclusion Criteria,UNKNOWN,"(MCL Wave 3 only) - Subject has evaluable disease and requires treatment in the opinion of the investigator.- Subject must have relapsed following or be refractory to 1 standard treatments such as R-CHOP, R-CVP, bendamustine, lenalidomide-rituximab, or fludarabine-based regimens.- Subject has an Eastern Cooperative Oncology Group (ECOG) performance score of less than or equal to 2.- Subject must have adequate bone marrow independent of growth factor support per local laboratory reference range at Screening.- Subject must have adequate coagulation, renal, and hepatic function, per laboratory reference range at Screening.- NHL subjects who have a history of an autologous stem cell transplant (e.g., bone marrow) must be > 6 months post-transplant (prior to the first dose of study drug) and must not require any growth factor support.",ct_inc_392045,AACT,197,NCT02640833,Historical,R-CHOP
5c74305f8625dd043c867f91,50,,,76,Patient,13:51.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_493723,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria: Patients who had received chemotherapy other than R-CHOP or R-CVP after diagnosis 2.,ct_exc_493723,AACT,70,NCT01311232,Recent,R-CHOP
5c74305f8625dd0457867f98,70,,,71,Patient,13:51.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_404784,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - 19 or older - newly diagnosed with DLBCL - R-CHOP chemotherapy - offer informed consent,ct_inc_404784,AACT,65,NCT02474550,Recent,R-CHOP
5c7430608625dd043c867f95,50,,,143,Patient,13:52.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_472146,Clinical Trial Exclusion Criteria,UNKNOWN,"The subject must have received first line therapy with Rituximab-Cyclophosphamide, Hydroxydaunomycin, Vincristine (Oncovin), Prednisone (R-CHOP) [or a similar standard rituximab-containing front-line chemoimmunotherapy regimen including, but not limited to Etoposide, Prednisone, Vincristine (Oncovin), Cyclophosphamide, Doxorubicin (Hydrochloride) + Rituximab (EPOCH + R); Rituximab, Cyclophosphamide, Etoposide, Procarbazine, Prednisone (RCEPP); Rituximab, Cyclophosphamide, Mitoxantrone (Novantrone), Vincristine (Oncovin), Prednisone (RCNOP); Dose-adjusted-Etoposide, Prednisone, Vincristine(Oncovin), Cyclophosphamide, Doxorubicin (Hydrocloride) (DA-EPOCH); and Rituximab, Cyclophosphamide, Etoposide, Vincristine (Oncovin), Prednisone (RCEOP)].- Subject must have adequate coagulation, renal, and hepatic function, per laboratory reference range at Screening.",ct_exc_472146,AACT,137,NCT01594229,Recent,R-CHOP
5c7430608625dd043c867f96,50,,,564,Patient,13:52.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_472146,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Subject has been diagnosed with Post-Transplant Lymphoproliferative Disease, Burkitt's lymphoma, Burkitt-like lymphoma, lymphoblastic lymphoma/leukemia, chronic lymphocytic leukemia, small lymphocytic lymphoma or mantle cell lymphoma (MCL).- Subject has refractory diffuse large B-cell lymphoma, defined as meeting any of the following criteria: - Subject progressed during or within 3 months of completion of a planned course of first-line therapy with Rituximab-Cyclophosphamide, Hydroxydaunomycin, Vincristine (Oncovin), Prednisone (R-CHOP) or an equivalent regimen; - Subject had no response (i.e., stable disease only) to first-line therapy with R-Cyclophosphamide, Hydroxydaunomycin, Vincristine (Oncovin), Prednisone (R-CHOP) or an equivalent regimen; - Subject progressed during or within 2 months of completion of their last planned course of salvage therapy with chemotherapy (with or without rituximab, may include autologous stem cell transplant).- Subject has tested positive for human immunodeficiency virus (HIV).- Subject has a cardiovascular disability status of New York Heart Association Class greater or equal to Class 2 is defined as cardiac disease in which patients are comfortable at rest but ordinary physical activity, results in fatigue, palpitations, dyspnea or anginal pain.- Subject has a significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, or hepatic disease that in the opinion of the Investigator would adversely affect his/her participating in this study.",ct_exc_472146,AACT,558,NCT01594229,Historical,R-CHOP
5c7430608625dd0457867fa0,70,,,116,Patient,13:52.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_398599,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Patients with newly diagnosed CD20+ DLBCL - 65 years old or over - Scheduled to receive R-CHOP chemotherapy - Informed consent,ct_inc_398599,AACT,110,NCT02555267,Recent,R-CHOP
5c7430608625dd0452867f8f,40,,,377,Patient,13:52.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_493723,Clinical Trial Inclusion Criteria,UNKNOWN,Patients who had received at least two cycles of rituximab-CHOP or rituximab-CVP as a primary treatment Patients with a history of previous exposure to HBV - HBV surface antigen (HBs Ag) positive Or - HBV core antibody (IgG anti-HBc antibody) positive Patients with documented HBV reactivation (definite or presumptive) occurring during treatment (at least two cycles of R-CHOP or R-CVP) or within 12 months after the last dose of rituximab - Definitive HBV reactivation - Elevation of serum HBV DNA level >1 log IU/mL from baseline or absolute increase of HBV DNA by 6 log10 IU/mL in HBsAg positive patients - Presumptive HBV reactivation - Increase of ALT (3x baseline value or absolute value of 100 U/L) and positive conversion of HBs Ag in previously HBsAg-negative patients,ct_inc_493723,AACT,371,NCT01311232,Historical,R-CHOP
5c7430618625dd0452867f93,40,,,71,Patient,13:53.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_447673,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Previously untreated NHL suitable for CHOP/R-CHOP treatment - Age range 18-80 years old - HBsAg positive with high level of HBV DNA - Eastern Cooperative Oncology Group performance status 0-2 - Life expectancy of more than 3 months -,ct_inc_447673,AACT,65,NCT01914744,Recent,R-CHOP
5c7430618625dd043c867f9f,50,,,169,Patient,13:53.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_452271,Clinical Trial Inclusion Criteria,UNKNOWN,Patients who are not transplant eligible or who did not respond to chemotherapy may be considered for the study following a single regimen of chemotherapy such as R-CHOP or R-EPOCH.There,ct_inc_452271,AACT,163,NCT01854606,Recent,R-CHOP
5c7430628625dd043c867fa2,50,,,130,Patient,13:54.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_486783,Clinical Trial Inclusion Criteria,UNKNOWN,Patients who are not transplant eligible may be considered for the study following a single regimen of chemotherapy such as R-CHOP or R-EPOCH alone.,ct_inc_486783,AACT,124,NCT01402440,Recent,R-CHOP
5c7430638625dd0452867fa5,40,,,193,Patient,13:55.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_359513,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Histological confirmation of relapsed/refractory diffuse large B-cell lymphoma after prior rituximab and anthracycline-containing systemic treatment regimen such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), R-EPOCH (rituximab, etoposide phosphate, prednisone, vincristine sulfate, cyclophosphamide, doxorubicin hydrochloride), R-HyperCVAD (rituximab, cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone) etc.",ct_inc_359513,AACT,187,NCT03064867,Historical,R-CHOP
5c7430678625dd04c0867f85,30,,,279,Patient,13:59.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_515733,Clinical Trial Inclusion Criteria,UNKNOWN,"Subjects with histologically proven follicular lymphoma (grade 1, 2, or 3a), in clinical relapse/progression requiring treatment - Subjects must have had first line treatment consisting of rituximab with or without rituximab maintenance therapy (i.e.rituximab monotherapy, R-CHOP, R-CVP, R-FND, etc) -",ct_inc_515733,AACT,273,NCT01022255,Recent,R-CHOP
5c7430678625dd04c0867f8b,30,,,106,Patient,14:00.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_507723,Clinical Trial Inclusion Criteria,UNKNOWN,"Follicular lymphoma patients previously treated with the combination of rituximab and chemotherapy (R-CHOP, R-CVP, R-fludarabine), having received rituximab maintenance, refractory to a first line (excluding radiotherapy) or relapsed after having achieved any response to previous treatment.4.",ct_inc_507723,AACT,100,NCT01127841,Recent,R-CHOP
5c7430688625dd04c0867f8f,30,,,344,Patient,14:00.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_344464,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Complete response of lymphoma (Cheson criteria 2007) after initial treatment - Malin lymphoma (Hodgkin or not) treated with anthracyclines for at least 6 cycles : Adriamycin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) or BEACOPP, Cyclophosphamide, hydroxydaunomycin, Oncovin, and prednisone (CHOP) et Rituximab (R-CHOP), miniCHOP et RminiCHOP, RACVBP having received or not an intensification with autologous hematopoietic stem cell transplantation in first-line - Registered the consent to be included in this study",ct_inc_344464,AACT,338,NCT03260855,Recent,R-CHOP
5c7430698625dd04cb867f8a,260,,,407,Patient,14:01.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_407198,Clinical Trial Inclusion Criteria,UNKNOWN,"< 3 x upper limit of normal (ULN) - Creatinine =< 2.0 mg/dL OR creatinine clearance (calculated clearance permitted) >= 40 mL/min by Cockcroft-Gault formula - Prothrombin time (PT)/ international normalized ration (INR) < 1.5 x ULN and partial thromboplastin time (PTT) (activated [a]PTT) < 1.5 x ULN - Patient must have progressed or be refractory to prior anthracycline-containing chemotherapy (e.g.R-CHOP, DA-EPOCH-R, etc) -",ct_inc_407198,AACT,401,NCT02443077,Historical,R-CHOP
5c7430698625dd04c0867f9d,30,,,311,Patient,14:01.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_387514,Clinical Trial Inclusion Criteria,UNKNOWN," may enroll in the study based on the local laboratory evaluation, but these should be confirmed by the UNC Hematopathology Laboratory retrospectively - Positive for CD20 via immunophenotyping - Prior Treatment: Previously untreated or who received a maximum of one cycle of combination chemotherapy (i.e.R-CHOP, R-EPOCH, or R-hyperCVAD) within 4 weeks of study entry except patients who require dose reduction after the first cycle of off-study R-EPOCH.- Measurable disease as assessed by 2 dimensional measurements by CT ( 1.5 cm).- Adequate organ function as demonstrated by: - Bone marrow function (without platelet transfusion or myeloid growth factor support within two weeks of screening) as demonstrated by: - Hemoglobin 8 g/dL - Absolute neutrophil count (ANC) 1,000 cells/mm3 - Platelet count 75,000/mm3 - And hepatic and renal function as demonstrated by: - Aspartate aminotransferase (AST) and Alanine Aminotransferase (ALT)",ct_inc_387514,AACT,305,NCT02700022,Historical,R-CHOP
5c74306a8625dd04c0867fa2,30,,,89,Patient,14:02.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_454155,Clinical Trial Inclusion Criteria,UNKNOWN,"Previously untreated for DLBCL - Intended initial treatment to include 2 cycles of R-CHOP, R-EPOCH or R-CEPP using standard doses and schedule.(68, 69) R-CHOP chemoimmunotherapy may be given every 14 days or every 21 days.(4, 70)",ct_inc_454155,AACT,83,NCT01829958,Recent,R-CHOP
5c74306b8625dd04cb867f94,260,,,151,Patient,14:03.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_342748,Clinical Trial Inclusion Criteria,UNKNOWN,T-cell/histiocyte-rich DLBCL Subject is considered an appropriate candidate (per Investigator assessment) for induction therapy with 6 cycles of R-CHOP-21 immunochemotherapy.,ct_inc_342748,AACT,145,NCT03283202,Recent,R-CHOP
5c74306d8625dd0506867f84,80,,,116,Patient,14:05.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_348238,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Patients with newly diagnosed CD20+ DLBCL - 65 years old or over - Scheduled to receive R-CHOP chemotherapy - Informed consent,ct_inc_348238,AACT,110,NCT03211702,Recent,R-CHOP
5c74306d8625dd0506867f88,80,,,74,Patient,14:05.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_573486,Clinical Trial Inclusion Criteria,UNKNOWN,"Hodgkins lymphoma, CD20 positive - Chemotherapy treatments planned (R-CHOP) but not started",ct_inc_573486,AACT,68,NCT00256490,Recent,R-CHOP
5c74306d8625dd0506867f8a,80,,,74,Patient,14:05.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_507469,Clinical Trial Inclusion Criteria,UNKNOWN,- Diagnosis of diffuse large B-cell lymphoma - Treated with CHOP or R-CHOP on ECOG-E4494,ct_inc_507469,AACT,68,NCT01131208,Recent,R-CHOP
5c74306d8625dd0506867f8c,80,,,227,Patient,14:05.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_548984,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Histologically confirmed, CD20+ B cell diffuse large cell lymphoma, with measurable or evaluable disease - Having no prior chemotherapy, immunotherapy or radiotherapy except for one cycle of CHOP or R-CHOP.",ct_inc_548984,AACT,221,NCT00582725,Historical,R-CHOP
5c74306d8625dd0506867f8e,80,,,289,Patient,14:05.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_543793,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients receiving either:( Bolus or 48-hr infusion CHOP (cyclophosphamide 750 mg/m^2 IV Day 1, doxorubicin 25 mg/m^2/day IV given as bolus infusion or over 48 hours continuous infusion Days 1-2, vincristine 2 mg IV Day 1, prednisone PO 100 mg * 5 days) OR ( Bolus or 48-hr infusion R-CHOP (Rituximab 375mg/m^2 on Day 1+ CHOP as above).(For patients receiving R-CHOP, CHOP may be administered starting on Day 2 at the discretion of the treating physician Age",ct_inc_543793,AACT,283,NCT00651755,Recent,R-CHOP
5c74306d8625dd0506867f91,80,,,128,Patient,14:05.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_372257,Clinical Trial Inclusion Criteria,UNKNOWN,Adults treated for diffuse large B-cell lymphoma: - Diagnosed between 2010 and 2015 - Having received immuno-chemotherapy R-CHOP - Supported in the health facilities of the Languedoc-Rousillon,ct_inc_372257,AACT,122,NCT02898870,Recent,R-CHOP
5c74306d8625dd0506867f93,80,,,138,Patient,14:05.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_318598,Clinical Trial Inclusion Criteria,UNKNOWN,Adults treated for diffuse large B-cell lymphoma: - Diagnosed between 2010 and 2015 - Included in ProLyPhy search - Having received R-CHOP immuno-chemotherapy - Supported in health facilities in Languedoc-Rousillon Exclusion criterion:,ct_inc_318598,AACT,132,NCT03597685,Recent,R-CHOP
5c74306d8625dd0506867f95,80,,,27,Patient,14:06.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_567818,Clinical Trial Inclusion Criteria,UNKNOWN,"- Recently completed R-CHOP therapy and achieved remission - International Prognostic Index (IPI) score 3,4,5 - At least 18 years of age - Agree to study follow-up schedule",ct_inc_567818,AACT,21,NCT00332202,Recent,R-CHOP
5c74306e8625dd0518867f84,100,,,79,Patient,14:06.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_363268,Clinical Trial Inclusion Criteria,UNKNOWN,"Men must agree not to father a child during the therapy, - 6 to 8 cycles R-CHOP/like, total of 8 x Rituximab, - CR, CRu",ct_inc_363268,AACT,73,NCT03016000,Recent,R-CHOP
5c74306e8625dd0518867f86,100,,,42,Patient,14:06.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_562710,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - 4 to 8 cycles R-CHOP/like, total of 8x Rituximab - CR, CRu - ECOG/ 0.1 or 2 - Known IPI at time of diagnosis - Age",ct_inc_562710,AACT,36,NCT00400478,Recent,R-CHOP
5c74306f8625dd0518867f88,100,,,82,Patient,14:07.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_505427,Clinical Trial Inclusion Criteria,UNKNOWN,- Patients that achieved a complete (CR) or partial response (PR) after 6th R-CHOP chemotherapy - Aged over 18 years - ECOG performance status 0-2.,ct_inc_505427,AACT,76,NCT01157988,Recent,R-CHOP
5c7430738625dd0518867fa2,100,,,123,Patient,14:11.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_328750,Clinical Trial Inclusion Criteria,UNKNOWN,Histologically the first large-scaled B-cell lymphoma patient Diagnosis time 65 years old or older Patients planning R-CHOP chemotherapy,ct_inc_328750,AACT,117,NCT03465527,Recent,R-CHOP
5c7430778625dd0574867f89,270,,,96,Patient,14:15.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_424770,Clinical Trial Inclusion Criteria,UNKNOWN,"Further, at the investigator's discretion and for patients who are unstable, one cycle of R-CHOP is allowed prior to enrollment but no more than one cycle.",ct_inc_424770,AACT,90,NCT02213913,Historical,R-CHOP
5c7430778625dd0574867f8b,270,,,625,Patient,14:15.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_511903,Clinical Trial Inclusion Criteria,UNKNOWN,"Able to provide written informed consent - Eastern Cooperative Oncology Group (ECOG) performance status <=2 - Estimated life expectancy >=6 months - Serum creatinine of <=2.0 mg/dL or creatinine clearance >=50 mL/min - Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 2.5* upper limit of normal (ULN), and alkaline phosphatase and total bilirubin within normal limits - Left ventricular ejection fraction (LVEF) >=50% by multiple gated acquisition scan (MUGA) or cardiac echocardiogram (ECHO), prior for any patient to be treated with rituximab/cyclophosphamide/doxorubicin/vincristine/prednisolone (R-CHOP) -",ct_inc_511903,AACT,619,NCT01073163,Historical,R-CHOP
5c7430778625dd0574867f8d,270,,,130,Patient,14:15.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_526716,Clinical Trial Inclusion Criteria,UNKNOWN,">= 50% by multiple gated acquisition scan (MUGA) or cardiac echocardiogram (ECHO), prior for any patient to be treated with R-CHOP - A medically accepted method of contraception to be used by women of childbearing potential (not surgically sterile or at least 12 months naturally postmenopausal) -",ct_inc_526716,AACT,124,NCT00877006,Historical,R-CHOP
5c74307c8625dd05b6867f86,10,,,234,Patient,14:20.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_478558,Clinical Trial Inclusion Criteria,UNKNOWN,"Patient is 60-years of age or older at time of randomization Histologically confirmed Ann Arbor stage II, III, or IV DLBCL; or FCL Grade 3B according to the REAL/WHO classification (from initial diagnosis made prior to starting R-CHOP therapy).Results from a pre R-CHOP marrow shall be available for review.",ct_inc_478558,AACT,228,NCT01510184,Historical,R-CHOP
5c74307c8625dd05b6867f87,10,,,114,Patient,14:20.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_478558,Clinical Trial Inclusion Criteria,UNKNOWN,Patients who received pre-phase therapy for the purpose of improving performance status prior to initiating R-CHOP are eligible.(See CRF Manual for further clarification).,ct_inc_478558,AACT,108,NCT01510184,Historical,R-CHOP
5c74307c8625dd05b6867f88,10,,,157,Patient,14:20.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_478558,Clinical Trial Inclusion Criteria,UNKNOWN,"Bone marrow cellularity greater than 15%, no evidence of myelodysplasia morphologically and no evidence of involvement with lymphoma either at the pre R-CHOP marrow or on repeat assessment pre-Zevalin.",ct_inc_478558,AACT,151,NCT01510184,Recent,R-CHOP
5c74307e8625dd05b6867f91,10,,,211,Patient,14:22.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_415115,Clinical Trial Inclusion Criteria,UNKNOWN,"With a diagnosis formally established of DLBCL or transformed straightaway follicular lymphoma or 3B grade follicular lymphoma or Burkitt-like lymphoma - Eligible to a treatment by immunochemotherapy like R-CHOP, R-ACVBP or R-CHOP like - First line of treatment - Being able to benefit from standard extension assessment ( Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET) and bone marrow biopsy with a bone marrow aspiration)",ct_inc_415115,AACT,205,NCT02339805,Recent,R-CHOP
5c74307e8625dd05b6867f95,10,,,132,Patient,14:22.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_583905,Clinical Trial Inclusion Criteria,UNKNOWN,"Chemotherapy combinations may include, but are not limited to: CHOP (Cyclophosphamide, doxorubicin, vincristine, prednisone), R-CHOP (Rituximab, Cyclophosphamide, doxorubicin, vincristine, prednisone), FCM (Fludarabine, cyclophosphamide, mitoxantrone), R-FCM (Rituximab,Fludarabine, cyclophosphamide, mitoxantrone), ICE(Ifosfamide, carboplatin, etoposide), DHAP (Dexamethasone, cisplatin, cytarabine) and hyper-CVAD (Cyclophosphamide, doxorubicin, vincristine, dexamethasone).",ct_inc_583905,AACT,126,NCT00117598,Recent,R-CHOP
5c74307f8625dd05b6867f9f,10,,,446,Patient,14:23.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_362663,Clinical Trial Inclusion Criteria,UNKNOWN,"Subject has provided informed consent prior to initiation of any study-specific activities/procedures - Age 18 at time of informed consent - Subject must have untreated, histologically proven high-risk DLBCL defined by IPI 3 to 5 and/or Double-hit or higher or double protein expression - Eastern Cooperative Oncology Group performance status 2.- Subject meets the criteria per investigator's institution to receive SOC R-chemotherapy (ie, R-CHOP",ct_inc_362663,AACT,440,NCT03023878,Historical,R-CHOP
5c74307f8625dd05b6867fa3,10,,,361,Patient,14:23.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_490450,Clinical Trial Inclusion Criteria,UNKNOWN,"Platelet count 100x109/L Absolute Neutrophil count 1.0x109/L; Serum bilirubin 1.5 x ULN AST (SGOT) or ALT 1.5 x ULN Creatinine clearance (Cockcroft-Gault) > 50 ml/min - Relapsed or refractory DLBCL in which all participants must have received at least one potentially curative established immunochemotherapy lymphoma regimen that contained rituximab (e.g.R-CHOP, R-PMitCEBO, R-GCVP, R-CNOP).Participants must also have failed or be ineligible for salvage/high dose therapy.- Relapsed or refractory DLBCL proven by biopsy (within 6 months of enrolment in trial); either de novo DLBCL or transformed follicular lymphoma.-",ct_inc_490450,AACT,355,NCT01354392,Recent,R-CHOP
5c7430808625dd05b6867faa,10,,,6,Patient,14:24.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_508134,Clinical Trial Inclusion Criteria,LABORATORY_AND_RADIOLOGY_DATA,R-CHOP:,ct_inc_508134,AACT,0,NCT01122472,Recent,R-CHOP
5c7430808625dd05b6867fab,10,,,428,Patient,14:24.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_508134,Clinical Trial Inclusion Criteria,LABORATORY_AND_RADIOLOGY_DATA,Patients with DLBCL associated with some small cell infiltration in bone marrow may also be included Or CD20+ B-cell lymphoma with intermediate features between DLBCL and Burkitt or with intermediate features between DLBCL and classical Hodgkin lymphoma Or CD20+ Follicular lymphoma grade 3B Or CD20+ Aggressive B-cell lymphoma unclassifiable - Have reached a CR or PR after first line treatment with at least 6 cycles of R-CHOP 14 regimens and up to 8 cycles of R-CHOP21 - Previously untreated with Radiotherapy For all patients: - aged from 60 to 80 years at time of registration - Ann Arbor stages II-IV at time of initial diagnosis - aaIPI> 1 at time of initial diagnosis - ECOG performance status 0-2 - Minimum life expectancy of 3 months - Following laboratory values at,ct_inc_508134,AACT,422,NCT01122472,Recent,R-CHOP
5c7430808625dd05b6867fb0,10,,,141,Patient,14:24.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_486155,Clinical Trial Inclusion Criteria,UNKNOWN,"All patients must have a histologic or cytological diagnosis of de novo DLBCL and be scheduled to receive first line chemotherapy with R-CHOP given every 21 days (R-CHOP-21) within 6 weeks of their enrollment and for 6 cycles.- Patients must be >=18 years of age, but there will be no discrimination based on gender, race, creed, or ethnic background.- Patients must have an ECOG performance status of 0-2.- Patients must sign an informed consent, and be mentally responsible.",ct_inc_486155,AACT,135,NCT01410630,Recent,R-CHOP
5c7430878625dd0628867f84,90,,,39,Patient,14:31.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_567818,Clinical Trial Exclusion Criteria,UNKNOWN,"Have received therapy other than R-CHOP for lymphoma - Serious medical condition such as infection,second cancer,heart disease - Received radiation to more than one lesion - Unable to swallow tablets",ct_exc_567818,AACT,33,NCT00332202,Recent,R-CHOP
5c7430878625dd0628867f86,90,,,121,Patient,14:31.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_453093,Clinical Trial Inclusion Criteria,UNKNOWN,Pre-phase therapy with prednisolone and/or vincristine for < one week duration prior to commencement of cycle 1 of R-CHOP is permissible,ct_inc_453093,AACT,115,NCT01843868,Historical,R-CHOP
5c7430878625dd0628867f87,90,,,26,Patient,14:31.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_453093,Clinical Trial Inclusion Criteria,UNKNOWN,Intended to receive R-CHOP every 14 or 21 days for minimum 3 cycles with rituximab planned to be given with CHOP on day 1 or fractionated over days 1 and 21.,ct_inc_453093,AACT,20,NCT01843868,Recent,R-CHOP
5c7430878625dd0628867f8a,90,,,467,Patient,14:31.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_568389,Clinical Trial Inclusion Criteria,UNKNOWN,"Advanced stage disease defined as - patients with stage III or stage IV disease; or patients with stage I or stage II disease with one of the following additional criteria: B-symptoms, or disease that is not radio- encompassable within a single involved field, or not a candidate for brief chemotherapy and irradiation, or the presence of bulky disease (any single mass => 10 cm) - Previously untreated or treated with up to 3 cycles of standard dose 3- weekly R-CHOP chemotherapy prior to enrollment (i.e.patients may be enrolled prior to initiation of the fourth cycle of R-CHOP chemotherapy) - ECOG Performance",ct_inc_568389,AACT,461,NCT00324467,Historical,R-CHOP
5c7430878625dd0628867f8b,90,,,50,Patient,14:31.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_568389,Clinical Trial Inclusion Criteria,UNKNOWN,No evidence of progressive disease while on R-CHOP chemotherapy -,ct_inc_568389,AACT,44,NCT00324467,Recent,R-CHOP
5c7430888625dd0628867f8e,90,,,74,Patient,14:32.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_372893,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically confirmed diffuse large B cell lymphoma treated with R-CHOP(Rituximab, Cyclophosphamide, Adriamycin, Vincristine, Prednisolone) chemotherapy 2.",ct_inc_372893,AACT,68,NCT02890602,Recent,R-CHOP
5c7430888625dd0628867f8f,90,,,61,Patient,14:32.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_372893,Clinical Trial Inclusion Criteria,UNKNOWN,"< 10.0 g/dL are shown at least 3 cycles after starting R-CHOP(Rituximab, Cyclophosphamide, Adriamycin, Vincristine, Prednisolone)",ct_inc_372893,AACT,55,NCT02890602,Recent,R-CHOP
5c7430898625dd0628867f97,90,,,637,Patient,14:33.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_367053,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Follicular lymphoma with histology documented by the participating institution (grades 1, 2 or 3a).For subjects with presumptive evidence of transformation based on clinical assessment of factors such as, but not limited to, increasing lactate dehydrogenase (LDH), rapidly worsening disease, or frequent B-symptoms, a pre-treatment biopsy is required to rule out large cell transformation - Completion of a full course of first line immunochemotherapy including rituximab OR completion of 4 cycles of first line immunochemotherapy including rituximab if intolerant (e.g.which include, but are not limited to, R-CHOP, R-CVP,",ct_inc_367053,AACT,631,NCT02966730,Hypothetical,R-CHOP
5c7430898625dd0628867f9a,90,,,70,Patient,14:33.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_552923,Clinical Trial Inclusion Criteria,UNKNOWN,Stage 3 or 4 and elevated LDH - No more than one prior cycle of R-CHOP chemotherapy - Adequate cardiac function -,ct_inc_552923,AACT,64,NCT00530179,Historical,R-CHOP
5c7430898625dd0628867f9c,90,,,97,Patient,14:33.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_413963,Clinical Trial Exclusion Criteria,UNKNOWN,"Other subtype of lymphoma except DLBCL - DLBCL patients who are NOT suitable for receiving R-CHOP chemotherapy OR plan to receive other chemotherapy - patients had been treated with antiviral therapy known to have activity against HBV (e.g., alpha-interferon, lamivudine, telbivudine, clevudine, adefovir, entecavir or tenofovir) within the previous 6 months.- evidence of hepatocellular carcinoma.- evidence of decompensated liver disease",ct_exc_413963,AACT,91,NCT02354846,Historical,R-CHOP
5c7430898625dd0628867f9e,90,,,259,Patient,14:33.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_360281,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - confirmed diagnosis of MCL (hematopathologic examination in the reference centre, with evidence of cyclin D1 or translocation t(11;14) ) - not eligible for high-dose therapy with autologous stem cell transplantation - eligible for R-CHOP or R-COEP-based therapy - signed informed consent form with the study and data processing",ct_inc_360281,AACT,253,NCT03054883,Recent,R-CHOP
5c74308c8625dd065b867f89,20,,,29,Patient,14:36.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_533302,Clinical Trial Inclusion Criteria,UNKNOWN,"Any variation of CHOP (R-CHOP-14, R-CHOP-21) is acceptable.",ct_inc_533302,AACT,23,NCT00790036,Recent,R-CHOP
5c74308d8625dd065b867f90,20,,,106,Patient,14:37.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_560048,Clinical Trial Inclusion Criteria,UNKNOWN,"Diagnosis of DLBCL.- Received at least one combination chemotherapy regimen with rituximab, such as R-CHOP, R-ESHAP or equivalent.- Progression or relapse since most recent therapy.-",ct_inc_560048,AACT,100,NCT00435916,Recent,R-CHOP
5c74309d8625dd0700867f84,200,,,114,Patient,14:53.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_498671,Clinical Trial Exclusion Criteria,UNKNOWN,"HIV-positive or infectious hepatitis type A, B or C. Candidates eligible for intensive rescue therapies (ex.R-CHOP plus alemtuzumab, allogenic transplant)",ct_exc_498671,AACT,108,NCT01246557,Recent,R-CHOP
5c74309d8625dd0700867f86,200,,,74,Patient,14:53.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_544374,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria: - Contraindication to any drug contained in the R-CHOP (Rituximab/Cyclophosphamide/Doxorubicin/Vincristine/Prednisone +/-,ct_exc_544374,AACT,68,NCT00644124,Recent,R-CHOP
5c74309e8625dd0700867f88,200,,,194,Patient,14:54.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_586213,Clinical Trial Exclusion Criteria,UNKNOWN,The safety of Zevalin in this population has not been tested at this time - Serious coexisting medical condition or active infection which would compromise the ability to deliver standard R-CHOP chemotherapy - Evidence of myelodysplasia on bone marrow aspiration and biopsy,ct_exc_586213,AACT,188,NCT00088881,Recent,R-CHOP
5c7430a28625dd0716867f87,150,,,394,Patient,14:58.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_444230,Clinical Trial Inclusion Criteria,UNKNOWN,"I to stage IV DLBCL at the time of relapsed/refractory disease to be eligible - Measurable or assessable disease is required; measurable tumor size (at least one node measuring 2.25 cm^2 in bidimensional measurement) per computed tomography (CT) scan, other radiological study, and/or physical exam - Patients must have received at least 1 prior rituximab-based immunochemotherapy (e.g., R-CHOP, R-EPOCH, etc.)- >= 2 weeks since major surgery - Patients must not have any significant toxicity associated with prior surgery, radiation therapy, chemotherapy, or immunotherapy, per principal investigator (PI) discretion - Life expectancy >= 3 months - Karnofsky score (KS)",ct_inc_444230,AACT,388,NCT01959698,Historical,R-CHOP
5c7430a28625dd0716867f8c,150,,,179,Patient,14:58.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_356406,Clinical Trial Inclusion Criteria,UNKNOWN,"Subject has [follicular lymphoma or marginal zone lymphoma that has progressed after at least 2 lines of treatment with combination chemoimmunotherapy] (e.g.R-bendamustine, R-CHOP).",ct_inc_356406,AACT,173,NCT03105336,Recent,R-CHOP
5c7430a28625dd0737867f84,180,,,428,Patient,14:58.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_519563,Clinical Trial Inclusion Criteria,UNKNOWN,"- Histologically confirmed CD20-positive diffuse large B-cell non-Hodgkin lymphoma (DLBCL) according to the current WHO classification, including all morphological variants - Newly diagnosed disease - Bulky stage IA-IV disease - No non-bulky stage IA dise",ct_inc_519563,AACT,422,NCT00971763,Recent,R-CHOP
5c7430a28625dd0716867f8e,150,,,116,Patient,14:59.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_436873,Clinical Trial Inclusion Criteria,LABORATORY_AND_RADIOLOGY_DATA,- Participants must have histologically confirmed B-cell NHL - Participants must have never received previous R-CHOP treatment - Any relapsed/refractory participants that are enrolled during the dose escalation should have received only a single previous ,ct_inc_436873,AACT,110,NCT02055820,Recent,R-CHOP
5c7430a38625dd0716867f90,150,,,45,Patient,14:59.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_335862,Clinical Trial Inclusion Criteria,PATIENT_NAME,with recurrent or relapsed DLBCL after R-CHOP-like theraphy as the firstline therapy.,ct_inc_335862,AACT,39,NCT03372837,Recent,R-CHOP
5c7430a38625dd0716867f92,150,,,29,Patient,14:59.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_325663,Clinical Trial Inclusion Criteria,UNKNOWN,"Planned treatment with R-CHOP chemotherapy - Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 3 - Life expectancy of greater than 3 months with chemotherapy - Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately - Ability to understand and the willingness to sign an Institutional Review Board (IRB)-approved informed consent document (either directly or via a legally authorized representative)",ct_inc_325663,AACT,23,NCT03505762,Historical,R-CHOP
5c7430a38625dd0716867f94,150,,,57,Patient,14:59.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_318392,Clinical Trial Inclusion Criteria,UNKNOWN,"At the initial stage of therapy, received standard R-CHOP regimen and complete remission after the first course of treatment;",ct_inc_318392,AACT,51,NCT03600363,Recent,R-CHOP
5c7430a98625dd077d867f84,170,,,176,Patient,15:05.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_518382,Clinical Trial Inclusion Criteria,UNKNOWN,"Transformed follicular lymphoma - Follicular lymphoma grade 3B - Meets 1 of the following criteria: - Not eligible for anthracycline-based first-line chemotherapy (e.g., R-CHOP) -",ct_inc_518382,AACT,170,NCT00987493,Recent,R-CHOP
5c7430a98625dd077d867f85,170,,,100,Patient,15:05.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_518382,Clinical Trial Inclusion Criteria,UNKNOWN,"Refractory disease after at least 2 courses of anthracycline-based immune-chemotherapy (e.g., R-CHOP) and patient is not eligible for intensive salvage regimens including HDT with ASCT - Relapsed disease after at least 1 treatment with curative intention and patient is not eligible for intensive salvage regimens including HDT with ASCT - Relapsed disease after HDT with ASCT - Measurable disease defined as 1 lesion 2 cm in greatest transverse diameter on cross-sectional imaging - Must complete pre-treatment cancer-specific geriatric assessment",ct_inc_518382,AACT,94,NCT00987493,Recent,R-CHOP
5c7430aa8625dd077d867f88,170,,,89,Patient,15:06.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_493515,Clinical Trial Inclusion Criteria,DIAGNOSES,"In the case of de novo diffuse large B-cell lymphoma, prior treatment must include R-CHOP or R-CHOP-like therapy, as well as second line autologous stem cell transplantation unless the patient is not eligible.",ct_inc_493515,AACT,83,NCT01314014,Historical,R-CHOP
5c7430aa8625dd077d867f8a,170,,,268,Patient,15:06.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_535176,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients with histological confirmation of diffuse large B cell lymphoma with at least one of the following characteristics: - High or intermediate IPI score (See Appendix 8.0 for IPI scoring criteria) - Patients who are still PET scan positive mid therapy with R-CHOP, but, have turned negative after completion of therapy.- Low risk International prognostic index ie., an IPI score of <3 if age >60 years or <2 if age is less than or equal to 60 with c-myc positive by Fluorescent",ct_inc_535176,AACT,262,NCT00765245,Recent,R-CHOP
5c7430aa8625dd077d867f8b,170,,,104,Patient,15:06.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_535176,Clinical Trial Inclusion Criteria,UNKNOWN,"No other previous lymphoma therapy, hormonal therapy or surgery, except for standard therapy with R-CHOP with or without radiation and with or without prophylactic Methotrexate therapy.",ct_inc_535176,AACT,98,NCT00765245,Recent,R-CHOP
5c7430ab8625dd078f867f84,350,,,628,Patient,15:07.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_407687,Clinical Trial Inclusion Criteria,UNKNOWN,"Participating centres must designate a local reference expert pathologist who will confirm the diagnosis for the patients enrolled at that centre.- Patients must be CD20+ in order to be eligible for the study.- Clinically and/or radiologically measurable disease (one site bidimensionally measurable).Measurements/ evaluations must be done within 28 days prior to randomization.- Prior FDG-PET scan, if done at baseline, must be positive (known FDG-avid lymphoma) - Patients with de novo aggressive B-cell lymphoma must have relapsed or progressed, or have biopsy proven refractory disease, after 1 prior line of therapy (R-CHOP chemotherapy or equivalent).Patients with histological transformation from low grade lymphoma may have had up to 3 prior treatment regimens.",ct_inc_407687,AACT,622,NCT02436707,Historical,R-CHOP
5c7430ab8625dd0779867f85,520,,,54,Patient,15:07.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_383625,Clinical Trial Inclusion Criteria,UNKNOWN,Patients must have relapsed or progressed after R-CHOP chemotherapy or equivalent.,ct_inc_383625,AACT,48,NCT02750670,Recent,R-CHOP
5c7430ac8625dd0779867f87,520,,,596,Patient,15:08.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_388947,Clinical Trial Inclusion Criteria,UNKNOWN,"De novo diffuse large B cell lymphoma that fails to achieve a PET negative complete response to primary rituximab and anthracycline based multi-agent chemotherapy and at least maintains stable disease after salvage chemotherapy or present double/triple hit features defined by overexpression by standard immunohistochemistry of c-MYC plus BCL2 and/or BCL6 or presence of chromosomal translocations as detected by break-apart FISH involving IGH/MYC plus IGH/BCL2 and/or IGH/BCL6 and who only received standard chemoimmunotherapy with rituximab, cyclophosphamide, vincristine and prednisone (R-CHOP) for induction and present at least stable disease after consolidation or salvage chemotherapy.",ct_inc_388947,AACT,590,NCT02681302,Recent,R-CHOP
5c7430ac8625dd0779867f89,520,,,418,Patient,15:08.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_434793,Clinical Trial Inclusion Criteria,UNKNOWN,"signed written informed consent - Males and females >=18 years of age (at the time consent is obtained).- Tumor type criteria: relapsed/refractory non-Hodgkin's lymphoma (NHL) that meets one of the following criteria: - Germinal Center B cell Diffuse large B cell lymphoma (GCB-DLBCL) relapsed or refractory to at least one prior regimen (e.g., rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone [R-CHOP]) AND not a candidate for standard salvage regimens or autologous or allogeneic stem cell transplant.",ct_inc_434793,AACT,412,NCT02082977,Historical,R-CHOP
5c7430ad8625dd077d867f92,170,,,316,Patient,15:09.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_422608,Clinical Trial Inclusion Criteria,COMMENT,"Measurable disease is not required, but will be followed if it exists - Patients must have received 4 or more cycles of one of the following prior systemic induction chemotherapy regimens: - Rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunomycin), vincristine sulfate (Oncovin), prednisone (R-CHOP) (with or without alternating rituximab, dexamethasone, cytarabine [ara-c], cisplatin [platinum] [R-DHAP]) with or without autologous (auto) stem cell transplant (SCT) - Hyper-cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride (adriamycin), dexamethasone (CVAD) with or without auto SCT - Bendamustine + rituximab with or without auto SCT - Please",ct_inc_422608,AACT,310,NCT02242097,Hypothetical,R-CHOP
5c7430ad8625dd077d867f97,170,,,81,Patient,15:09.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_394735,Clinical Trial Exclusion Criteria,UNKNOWN,Received 3 previous anticancer regimens prior to enrollment Received prior R-CHOP therapy,ct_exc_394735,AACT,75,NCT02605694,Historical,R-CHOP
5c7430ae8625dd078f867f86,350,,,848,Patient,15:10.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_400525,Clinical Trial Inclusion Criteria,UNKNOWN,"WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissues published in 2008; patients with transform lymphoma are excluded; patients with known primary mediastinal large B-cell lymphoma (PMLBCL) are excluded; patients with known c-v-myc avian myelocytomatosis viral oncogene homolog (c-myc) translocation (by fluorescence in situ hybridization) positive DLBCL are eligible for enrollment; c-myc testing prior to study enrollment is not required; availability of diagnostic biopsy samples in encouraged for the exploratory analysis but not required for enrollment; patients with double-hit or triple-hit lymphoma are eligible for enrollment - Previously completed anthracycline-based induction chemotherapy with standard regimens including rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (R-CHOP), dose adjusted (DA)-etoposide, prednisone, vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide (EPOCH), and rituximab (R), and R-hyper cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone, methotrexate, and cytarabine (CVAD); patients need a minimum of 6 cycles of treatment; initial treatment with pidilizumab must be administered between 30-90 days from last dose of induction chemotherapy - Complete remission (CR) according to the Revised Response Criteria for Malignant Lymphoma after first-line treatment - Diagnostic CT scans with contrast of chest, abdomen, and pelvis must have been performed within 8 weeks from the first day of the last cycle of R-chemotherapy; a neck CT will be required if the patient had involvement of the neck region at initial diagnosis - A negative fludeoxyglucose F 18 (FDG)-positron emission tomography (PET)/CT scan performed within 8 weeks from the first day of the last cycle of R-chemotherapy and confirming CR, with negative defined as a score of 1-3 on the Deauville 5-point scale used to quantify radionucleotide density in PET scans as determined locally; PET positive/indeterminate lesions which are confirmed on biopsy to harbor no active lymphoma will be considered negative for determination of CR status -",ct_inc_400525,AACT,842,NCT02530125,Hypothetical,R-CHOP
5c7430ae8625dd077d867f9a,170,,,449,Patient,15:10.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_326294,Clinical Trial Inclusion Criteria,UNKNOWN,"All subjects must personally sign and date the consent form before initiating any study specific procedures or activities; All subjects must be able to comply with all the scheduled procedures in the study; Histologically or cytologically confirmed CD19 positive non-Hodgkin lymphoma; Chemotherapy-refractory disease, defined as one or more of the following: Relapsed in 6 months after most recent therapy; Progressive disease in the standard R-CHOP or CHOP chemotherapy; Disease progression or relapsed in 12 months of ASCT (must have biopsy proven recurrence in relapsed subjects); If salvage therapy is given post-ASCT, the subject must have had no response to or relapsed after the last line of therapy.",ct_inc_326294,AACT,443,NCT03497533,Hypothetical,R-CHOP
5c7430af8625dd078f867f88,350,,,170,Patient,15:11.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_589911,Clinical Trial Inclusion Criteria,COMMENT,At least 4 weeks since prior RBC transfusion - No prior biologic therapy - No other concurrent biologic therapy Chemotherapy - No prior chemotherapy (one course of R-CHOP allowed) -,ct_inc_589911,AACT,164,NCT00058422,Historical,R-CHOP
5c7430b08625dd078f867f8a,350,,,381,Patient,15:12.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_457409,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Newly diagnosed aggressive lymphoma or CLL/small lymphocytic lymphoma (SLL) that meets disease specific criteria below: - Study 1 - Aggressive lymphoma - Newly diagnosed de-novo DLBCL or primary mediastinal B-cell lymphoma that will be treated with an anthracycline-containing regimen (rituximab-cyclophosphamide, doxorubicin hydrochloride, prednisone [R-CHOP] or equivalent)",ct_inc_457409,AACT,375,NCT01787409,Recent,R-CHOP
5c7430b28625dd078f867f8c,350,,,105,Patient,15:14.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_412466,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: 1.18 Age < 65 Relapsed/refractory disease after receiving one line of standard R-CHOP like chemotherapy Diffuse Large B-cell Lymphoma at relapse.,ct_inc_412466,AACT,99,NCT02374424,Recent,R-CHOP
5c7430b68625dd07fd867f87,210,,,113,Patient,15:18.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_524159,Clinical Trial Inclusion Criteria,UNKNOWN,> 30 mol/L - Severe comorbidity that would preclude the use of CHOP chemotherapy - Ineligible for standard R-CHOP therapy - No cerebral or meningeal involvement,ct_inc_524159,AACT,107,NCT00911183,Recent,R-CHOP
5c7430b88625dd081e867f84,110,,,56,Patient,15:20.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_480552,Clinical Trial Exclusion Criteria,UNKNOWN,This does not include patients who have initiated R-CHOP at an outside institution within 2 weeks of enrollment.- Patients using > or = to 10mg/day of steroids for any chronic medical condition - Pregnant or breast-feeding.,ct_exc_480552,AACT,50,NCT01484093,Recent,R-CHOP
5c7430b88625dd081e867f86,110,,,156,Patient,15:20.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_479387,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Aged at least 18 years of age.- Patients with relapsed or refractory diffuse large B-cell lymphoma who have previously received R-CHOP (or equivalent) chemo-immunotherapy and high dose chemotherapy with stem cell rescue, or who are ineligible for high dose therapy with stem cell rescue.- Measurable disease as defined by Cheson et al 2007",ct_inc_479387,AACT,150,NCT01499303,Recent,R-CHOP
5c7430b98625dd07fd867f96,210,,,226,Patient,15:21.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_337151,Clinical Trial Inclusion Criteria,UNKNOWN,"according to the WHO classification 2008: - CD30 positive DLBCL, including EBV positive DLBCL - CD30 positive primary mediastinal B-cell lymphoma - Primary refractory to or in first relapse after first line therapy with R-CHOP or R-CHOP",ct_inc_337151,AACT,220,NCT03356054,Recent,R-CHOP
5c7430bc8625dd084a867f84,140,,,121,Patient,15:24.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_456023,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: Age 18-65 Relapsed/refractory disease after receiving one line of standard chemoimmunotherapy (R-CHOP, GA-CHOP, R-CHOP like) Diffuse Large B-cell Lymphoma at relapse.",ct_inc_456023,AACT,115,NCT01805557,Recent,R-CHOP
5c7430be8625dd081e867f94,110,,,315,Patient,15:26.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_343958,Clinical Trial Inclusion Criteria,COMMENT,"For example, a patient who started treatment with rituximab/bendamustine and was then switched to rituximab(R)-cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (CHOP) (due to insufficient response or excessive toxicity) would be counted as having received 2 regimens; however, R-CHOP alternating with R-dexamethasone, high-dose cytarabine, and cisplatin (DHAP) as a planned induction regimen would count as one regimen - Patient does not have any documented history of central nervous system (CNS) involvement by mantle cell lymphoma; this includes no evidence of parenchymal brain, spinal cord, or cerebrospinal fluid involvement; radiculopathy symptoms from nerve root compression by lymphoma do not constitute CNS involvement - Patient must have archived formalin-fixed paraffin-embedded (FFPE) tumor tissue specimen from the original diagnostic biopsy available for submission to Adaptive Biotechnologies for ClonoSEQ ID molecular marker identification of unique clonal immunoglobulin deoxyribonucleic acid (DNA) sequence -",ct_inc_343958,AACT,309,NCT03267433,Historical,R-CHOP
5c7430be8625dd081e867f97,110,,,104,Patient,15:26.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_343958,Clinical Trial Inclusion Criteria,COMMENT,"For example, a patient who started treatment with rituximab/bendamustine and was then switched to R-CHOP (due to insufficient response or excessive toxicity) would be counted as having received 2 regimens; however, R-CHOP alternating with R-DHAP as a planned induction regimen would count as one regimen - Patients must have achieved a radiologic complete or partial remission as defined by the Lugano criteria - Patients must meet institutional eligibility requirements for stem cell transplant, including cardiac, renal, liver, and pulmonary requirements - Patients have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 - Human immunodeficiency virus (HIV) positive patients are not excluded, but to enroll, must meet all of the below criteria: - HIV is sensitive to antiretroviral therapy - Must be willing to take effective antiretroviral therapy if indicated - CD4 count at screening >",ct_inc_343958,AACT,98,NCT03267433,Hypothetical,R-CHOP
5c7430bf8625dd081e867f9b,110,,,88,Patient,15:27.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_328940,Clinical Trial Inclusion Criteria,UNKNOWN,3 at diagnosis - Complete metabolic remission (Deauville 1-3) after 6-8 cycles of R-CHOP according to the Lugano criteria,ct_inc_328940,AACT,82,NCT03463057,Recent,R-CHOP
5c7430bf8625dd081e867f9d,110,,,62,Patient,15:27.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_328940,Clinical Trial Inclusion Criteria,COMMENT,Only dose reductions for vincristine are allowed during R-CHOP Central nervous system prophylaxis by intrathecal therapy is allowed.,ct_inc_328940,AACT,56,NCT03463057,Recent,R-CHOP
5c7430bf8625dd081e867f9f,110,,,639,Patient,15:27.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_568389,Clinical Trial Exclusion Criteria,UNKNOWN,"Men and women of childbearing age must be using adequate contraception.- Significant renal insufficiency (serum creatinine > 200 mmol/L), unless due to lymphoma - Significant hepatic insufficiency (serum total bilirubin > 30 mmol/L), unless due to lymphoma - Cardiac contraindication to doxorubicin therapy (e.g.abnormal contractility on echocardiography).If history of cardiac disease, ejection fraction must be within normal limits for age.- Neurologic contraindication to vincristine (e.g.peripheral neuropathy) - Absolute neutrophil count <1.5 x 109/L (unless due to bone marrow involvement with lymphoma or due to initiation of R-CHOP chemotherapy) -",ct_exc_568389,AACT,633,NCT00324467,Historical,R-CHOP
5c7430bf8625dd081e867fa0,110,,,126,Patient,15:27.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_568389,Clinical Trial Exclusion Criteria,UNKNOWN,"Platelet count < 100 x 109/L (unless due to splenomegaly, bone marrow involvement with lymphoma or due to initiation of R-CHOP chemotherapy) -",ct_exc_568389,AACT,120,NCT00324467,Recent,R-CHOP
5c7430c08625dd086b867f8d,60,,,89,Patient,15:28.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_367197,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Histological Diagnosis of NHL- DLBCL.- Eligible for RT after R-CHOP.- ECOG 0-3.- 18 - 65 years.- Stage I-IV.- Patients should receive at least 4 cycles of R-CHOP chemotherapy.- Patients with all extranodal disease except the ones mentioned in the,ct_inc_367197,AACT,83,NCT02964858,Recent,R-CHOP
5c7430c08625dd086b867f90,60,,,304,Patient,15:28.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_329914,Clinical Trial Inclusion Criteria,UNKNOWN,"ole - Able to understand and voluntarily sign consent prior to any study related assessments or procedures - Performance status of 0-2 on the ECOG scale - Adequate organ function as specified in the protocol.- must have received at least one prior CD20 containing multi-agent chemotherapy regimen (R-CHOP, R-EPOCH).Bendamustine and rituximab can be the prior regimen if used for follicular lymphoma or marginal zone lymphoma and susequently transformed to DLBCL.- A pre-phase treatment with prednisoe at 1mg/kg/day or equivalent, for a maximum of 10 days leading up to the first dose of CC-486 is allowed.",ct_inc_329914,AACT,298,NCT03450343,Hypothetical,R-CHOP
5c7430c08625dd086b867f96,60,,,21,Patient,15:28.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_480999,Clinical Trial Inclusion Criteria,UNKNOWN,Treatment with R-CHOP or R-CHOP like regimens (+/- transplant).,ct_inc_480999,AACT,15,NCT01478269,Recent,R-CHOP
5c7430c08625dd086b867f9a,60,,,57,Patient,15:28.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_497130,Clinical Trial Inclusion Criteria,UNKNOWN,"Stage I or II of primary breast DLBCL treated with R-CHOP - Stage I or II of nodal DLBCL treated with R-CHOP Definition of primary breast DLBCL - Isolated breast involvement with or without nodal disease, which include distant nodal disease as well as regional nodal disease Definition of nodal DLBCL -",ct_inc_497130,AACT,51,NCT01266668,Recent,R-CHOP
5c7430528625dd03c7867f84,0,,,192,Patient,13:38.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_356471,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - DLBCL patients that will be eligible in front-line treatment for a combination of anthracycline-based chemotherapy plus anti-CD20 monoclonal antibody,Rituximab: R-CHOP 14, R-CHOP 21, R mini-CHOP, R-ACVBP, R-COPADEM.Patients",ct_inc_356471,AACT,183,NCT03104478,Recent,R-CHOP 14
5c7430808625dd05b6867fa9,10,,,431,Patient,14:24.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_508134,Clinical Trial Inclusion Criteria,LABORATORY_AND_RADIOLOGY_DATA,Patients with DLBCL associated with some small cell infiltration in bone marrow may also be included Or CD20+ B-cell lymphoma with intermediate features between DLBCL and Burkitt or with intermediate features between DLBCL and classical Hodgkin lymphoma Or CD20+ Follicular lymphoma grade 3B Or CD20+ Aggressive B-cell lymphoma unclassifiable - Have reached a CR or PR after first line treatment with at least 6 cycles of R-CHOP 14 regimens and up to 8 cycles of R-CHOP21 - Previously untreated with Radiotherapy For all patients: - aged from 60 to 80 years at time of registration - Ann Arbor stages II-IV at time of initial diagnosis - aaIPI> 1 at time of initial diagnosis - ECOG performance status 0-2 - Minimum life expectancy of 3 months - Following laboratory values at,ct_inc_508134,AACT,422,NCT01122472,Recent,R-CHOP 14
5c7430528625dd03c7867f85,0,,,203,Patient,13:38.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_356471,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - DLBCL patients that will be eligible in front-line treatment for a combination of anthracycline-based chemotherapy plus anti-CD20 monoclonal antibody,Rituximab: R-CHOP 14, R-CHOP 21, R mini-CHOP, R-ACVBP, R-COPADEM.Patients",ct_inc_356471,AACT,194,NCT03104478,Recent,R-CHOP 21
5c7430538625dd03c7867f8d,0,,,219,Patient,13:39.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_316883,Clinical Trial Inclusion Criteria,UNKNOWN,Patients with early breast cancer planned to receive 3 weekly or dose-dense anthracycline/cyclophosphamide combination or 3 weekly taxane containing chemotherapy regimen or patients with NHL planned to receive R-CHOP-14 or R-CHOP-21 immunochemotherapy as 1st-line treatment with the indication for G-CSF prophylaxis with pegfilgrastim for the prevention of FN and reduction in CIN duration.,ct_inc_316883,AACT,210,NCT03619993,Recent,R-CHOP-14
5c7430538625dd03c7867f9e,0,,,411,Patient,13:39.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_486155,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Subjects with significant concurrent medical complications that in the judgment of the Principal Investigator(s) could affect the patient's ability to complete the planned trial, including the multiple imaging studies.- Patients with history of prior lymphoma (e.g., follicular lymphoma) and/or second cancers other than basal cell carcinoma.- Patients planned to be treated with R-CHOP-14 (i.e.:",ct_exc_486155,AACT,402,NCT01410630,Historical,R-CHOP-14
5c74308c8625dd065b867f84,20,,,32,Patient,14:36.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_533302,Clinical Trial Inclusion Criteria,UNKNOWN,"Any variation of CHOP (R-CHOP-14, R-CHOP-21) is acceptable.",ct_inc_533302,AACT,23,NCT00790036,Recent,R-CHOP-14
5c7430538625dd03c7867f8e,0,,,232,Patient,13:39.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_316883,Clinical Trial Inclusion Criteria,UNKNOWN,Patients with early breast cancer planned to receive 3 weekly or dose-dense anthracycline/cyclophosphamide combination or 3 weekly taxane containing chemotherapy regimen or patients with NHL planned to receive R-CHOP-14 or R-CHOP-21 immunochemotherapy as 1st-line treatment with the indication for G-CSF prophylaxis with pegfilgrastim for the prevention of FN and reduction in CIN duration.,ct_inc_316883,AACT,223,NCT03619993,Recent,R-CHOP-21
5c7430538625dd03c7867f9f,0,,,103,Patient,13:39.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_486155,Clinical Trial Exclusion Criteria,UNKNOWN,"R-CHOP given every 14 days) will be excluded (this should be extremely rare, if at all, since R-CHOP-21 is the standard treatment.- Patients who are scheduled to receive Rituxan or any other therapy (e.g., XRT, radioimmunotherapy) as adjuvant therapy after completion of R-CHOP-21.- Pregnant women will be excluded.- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) after study entry and for the duration of study participation.",ct_exc_486155,AACT,94,NCT01410630,Hypothetical,R-CHOP-21
5c74305c8625dd043c867f88,50,,,134,Patient,13:48.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_437757,Clinical Trial Inclusion Criteria,UNKNOWN,"Histological documentation of aggressive B cell NHL Planned to receive systemic anticancer therapy with at least 6 cycles of R-CHOP-21, according to local standards 5.",ct_inc_437757,AACT,125,NCT02044276,Recent,R-CHOP-21
5c74306b8625dd04cb867f92,260,,,154,Patient,14:03.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_342748,Clinical Trial Inclusion Criteria,UNKNOWN,T-cell/histiocyte-rich DLBCL Subject is considered an appropriate candidate (per Investigator assessment) for induction therapy with 6 cycles of R-CHOP-21 immunochemotherapy.,ct_inc_342748,AACT,145,NCT03283202,Recent,R-CHOP-21
5c7430808625dd05b6867fae,10,,,172,Patient,14:24.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_486155,Clinical Trial Inclusion Criteria,UNKNOWN,"All patients must have a histologic or cytological diagnosis of de novo DLBCL and be scheduled to receive first line chemotherapy with R-CHOP given every 21 days (R-CHOP-21) within 6 weeks of their enrollment and for 6 cycles.- Patients must be >=18 years of age, but there will be no discrimination based on gender, race, creed, or ethnic background.- Patients must have an ECOG performance status of 0-2.- Patients must sign an informed consent, and be mentally responsible.",ct_inc_486155,AACT,163,NCT01410630,Recent,R-CHOP-21
5c74308c8625dd065b867f85,20,,,43,Patient,14:36.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_533302,Clinical Trial Inclusion Criteria,UNKNOWN,"Any variation of CHOP (R-CHOP-14, R-CHOP-21) is acceptable.",ct_inc_533302,AACT,34,NCT00790036,Recent,R-CHOP-21
5c74307f8625dd05b6867fa4,10,,,389,Patient,14:23.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_490450,Clinical Trial Inclusion Criteria,UNKNOWN,"Platelet count 100x109/L Absolute Neutrophil count 1.0x109/L; Serum bilirubin 1.5 x ULN AST (SGOT) or ALT 1.5 x ULN Creatinine clearance (Cockcroft-Gault) > 50 ml/min - Relapsed or refractory DLBCL in which all participants must have received at least one potentially curative established immunochemotherapy lymphoma regimen that contained rituximab (e.g.R-CHOP, R-PMitCEBO, R-GCVP, R-CNOP).Participants must also have failed or be ineligible for salvage/high dose therapy.- Relapsed or refractory DLBCL proven by biopsy (within 6 months of enrolment in trial); either de novo DLBCL or transformed follicular lymphoma.-",ct_inc_490450,AACT,383,NCT01354392,Recent,R-CNOP
5c7430528625dd03c7867f86,0,,,236,Patient,13:38.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_356471,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - DLBCL patients that will be eligible in front-line treatment for a combination of anthracycline-based chemotherapy plus anti-CD20 monoclonal antibody,Rituximab: R-CHOP 14, R-CHOP 21, R mini-CHOP, R-ACVBP, R-COPADEM.Patients",ct_inc_356471,AACT,227,NCT03104478,Recent,R-COPADEM
5c74305d8625dd0457867f85,70,,,268,Patient,13:49.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_420797,Clinical Trial Inclusion Criteria,UNKNOWN,"Participants must have histologically documented diagnosis of NHL (and exhausted options considered standard of care) as defined in the World Health Organization classification scheme and relapsed following or be refractory to standard treatments such as R-CHOP, R-CVP, or fludarabine based regimens.",ct_inc_420797,AACT,263,NCT02265731,Recent,R-CVP
5c74305e8625dd0457867f88,70,,,98,Patient,13:50.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_492405,Clinical Trial Exclusion Criteria,UNKNOWN,"Subject must have relapsed following or be refractory to standard treatments such as R-CHOP, R-CVP, or fludarabine based regimens.",ct_exc_492405,AACT,93,NCT01328626,Recent,R-CVP
5c74305e8625dd0457867f92,70,,,210,Patient,13:51.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_392045,Clinical Trial Inclusion Criteria,UNKNOWN,"(MCL Wave 3 only) - Subject has evaluable disease and requires treatment in the opinion of the investigator.- Subject must have relapsed following or be refractory to 1 standard treatments such as R-CHOP, R-CVP, bendamustine, lenalidomide-rituximab, or fludarabine-based regimens.- Subject has an Eastern Cooperative Oncology Group (ECOG) performance score of less than or equal to 2.- Subject must have adequate bone marrow independent of growth factor support per local laboratory reference range at Screening.- Subject must have adequate coagulation, renal, and hepatic function, per laboratory reference range at Screening.- NHL subjects who have a history of an autologous stem cell transplant (e.g., bone marrow) must be > 6 months post-transplant (prior to the first dose of study drug) and must not require any growth factor support.",ct_inc_392045,AACT,205,NCT02640833,Historical,R-CVP
5c74305f8625dd043c867f92,50,,,85,Patient,13:51.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_493723,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria: Patients who had received chemotherapy other than R-CHOP or R-CVP after diagnosis 2.,ct_exc_493723,AACT,80,NCT01311232,Recent,R-CVP
5c7430608625dd0452867f90,40,,,386,Patient,13:52.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_493723,Clinical Trial Inclusion Criteria,UNKNOWN,Patients who had received at least two cycles of rituximab-CHOP or rituximab-CVP as a primary treatment Patients with a history of previous exposure to HBV - HBV surface antigen (HBs Ag) positive Or - HBV core antibody (IgG anti-HBc antibody) positive Patients with documented HBV reactivation (definite or presumptive) occurring during treatment (at least two cycles of R-CHOP or R-CVP) or within 12 months after the last dose of rituximab - Definitive HBV reactivation - Elevation of serum HBV DNA level >1 log IU/mL from baseline or absolute increase of HBV DNA by 6 log10 IU/mL in HBsAg positive patients - Presumptive HBV reactivation - Increase of ALT (3x baseline value or absolute value of 100 U/L) and positive conversion of HBs Ag in previously HBsAg-negative patients,ct_inc_493723,AACT,381,NCT01311232,Historical,R-CVP
5c7430628625dd0473867f8e,570,,,203,Patient,13:54.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_501219,Clinical Trial Inclusion Criteria,UNKNOWN,Histologically confirmed CD20 positive marginal zone B-cell lymphomas - Ann Arbor stage III or IV - No prior chemotherapy or radiotherapy for advanced stage MZL - Tumor response after 8th cycles of R-CVP CTx SD (Stable disease) - Performance status (ECOG) 2 - age 20,ct_inc_501219,AACT,198,NCT01213095,Historical,R-CVP
5c7430678625dd04c0867f86,30,,,286,Patient,13:59.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_515733,Clinical Trial Inclusion Criteria,UNKNOWN,"Subjects with histologically proven follicular lymphoma (grade 1, 2, or 3a), in clinical relapse/progression requiring treatment - Subjects must have had first line treatment consisting of rituximab with or without rituximab maintenance therapy (i.e.rituximab monotherapy, R-CHOP, R-CVP, R-FND, etc) -",ct_inc_515733,AACT,281,NCT01022255,Recent,R-CVP
5c7430678625dd04c0867f8c,30,,,113,Patient,14:00.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_507723,Clinical Trial Inclusion Criteria,UNKNOWN,"Follicular lymphoma patients previously treated with the combination of rituximab and chemotherapy (R-CHOP, R-CVP, R-fludarabine), having received rituximab maintenance, refractory to a first line (excluding radiotherapy) or relapsed after having achieved any response to previous treatment.4.",ct_inc_507723,AACT,108,NCT01127841,Recent,R-CVP
5c7430898625dd0628867f98,90,,,644,Patient,14:33.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_367053,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Follicular lymphoma with histology documented by the participating institution (grades 1, 2 or 3a).For subjects with presumptive evidence of transformation based on clinical assessment of factors such as, but not limited to, increasing lactate dehydrogenase (LDH), rapidly worsening disease, or frequent B-symptoms, a pre-treatment biopsy is required to rule out large cell transformation - Completion of a full course of first line immunochemotherapy including rituximab OR completion of 4 cycles of first line immunochemotherapy including rituximab if intolerant (e.g.which include, but are not limited to, R-CHOP, R-CVP,",ct_inc_367053,AACT,639,NCT02966730,Hypothetical,R-CVP
5c7430ba8625dd081e867f8e,110,,,112,Patient,15:22.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_384338,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: Patients with any type of relapsed or refractory B-cell lymphoma Eligible to receive R-DHAOx or R-GDP regarding the investigator's opinion Who received prior therapy with at least one but no more than two lines therapies for B-Cell Lymphoma Patient,ct_inc_384338,AACT,105,NCT02741388,Historical,R-DHAOx
5c7430c08625dd084a867f9a,140,,,326,Patient,15:28.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_436865,Clinical Trial Inclusion Criteria,UNKNOWN,Each patient (or their legally acceptable representative) must sign an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the study and are willing to participate in the study Patients eligible for autologous stem cell transplantation (ASCT) for whom R-DHAP or R-DHAOx is an acceptable therapy regarding the investigator's opinion Measurable disease defined by at least one single node or tumor lesion > 1.5 cm Patients who received prior therapy with at least one but no more than two lines therapies for B-Cell Lymphoma (except for patients included in group C during the expansion part of the study),ct_inc_436865,AACT,319,NCT02055924,Historical,R-DHAOx
5c74304b8625dd0381867f91,230,,,1028,Patient,13:31.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_363654,Clinical Trial Inclusion Criteria,COMMENT,"Has EITHER histologically confirmed B-cell lymphomas including but not limited to diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), primary mediastinal B-cell lymphoma (PMBCL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), or Hodgkin lymphoma (HL) and has relapsed or refractory disease following at least two lines of prior standard therapy, including alkylator/anthracycline (unless anthracycline-based chemotherapy is contraindicated)/anti-CD20-based therapy (R-CHOP, rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisolone or dexamethasone, or equivalent for non-Hodgkin lymphoma), AND must be considered unable to benefit from intensification treatment with autologous hematopoietic stem cell transplantation (ASCT) , as defined by meeting at least one of the following criteria: - Relapsed following, or refractory to, previous ASCT - Did not achieve at least a partial response to a standard salvage regimen (e.g., R-ICE, rituximab, ifosfamide, carboplatin, etoposide, or R-DHAP, rituximab, dexamethasone, cytarabine, cisplatin) -",ct_inc_363654,AACT,1022,NCT03010982,Historical,R-DHAP
5c74304c8625dd0381867f96,230,,,163,Patient,13:32.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_362341,Clinical Trial Inclusion Criteria,UNKNOWN,"previous ASCT Did not achieve at least a partial response (PR) to a standard salvage regimen (e.g., R-ICE; rituximab, ifosfamide, carboplatin, etoposide, or R-DHAP; rituximab, dexamethasone, cytarabine, cisplatin)",ct_inc_362341,AACT,157,NCT03028103,Recent,R-DHAP
5c7430578625dd03fe867f8b,290,,,906,Patient,13:43.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_448981,Clinical Trial Exclusion Criteria,COMMENT,"Subjects must satisfy all of the following criteria: Have histologically confirmed DLBCL (including primary mediastinal B-cell lymphoma), with relapsed or refractory disease following at least 2 lines of prior standard therapy, including alkylator/anthracycline (unless anthracycline-based chemotherapy is contraindicated)/anti-CD20-based therapy (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP] or equivalent) AND must be considered unable to benefit from intensification treatment with autologous hematopoietic stem cell transplantation (ASCT) as defined by meeting at least 1 of the following criteria: - Relapsed following, or refractory to, previous ASCT - Did not achieve at least a partial response to a standard salvage regimen (eg, rituximab, ifosfamide, carboplatin, and etoposide phosphate [R-ICE] or rituximab, dexamethasone, cytarabine, and cisplatin [R-DHAP]) -",ct_exc_448981,AACT,900,NCT01897571,Historical,R-DHAP
5c7430738625dd0518867f9e,100,,,258,Patient,14:11.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_329307,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients eligible for ASCT who failed to achieve a Complete Response (CR) after at least one salvage therapy (eg, Rituximab-Etoposide- Methylprednisolone - Cytarabine - Cisplatin (R-ESHAP) or Rituximab- Dexamethasone- High-dose Cytarabine - Cisplatin (R-DHAP), patients who were previously refractory to Rituximab-Ifosfamide-Cytarabine-Etoposide (R-ICE) (stable disease or progressive disease) are not eligible to the study) Or patients in first relapse after Autologous Stem Cell Transplant (ASCT) Or patients not eligible for ASCT who failed to achieve a CR after at least one prior treatment (and no more than 4 previous lines) or in relapse after at least one prior treatment (and no more than 4 previous lines).",ct_inc_329307,AACT,252,NCT03458260,Historical,R-DHAP
5c7430aa8625dd077d867f8e,170,,,71,Patient,15:06.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_399410,Clinical Trial Inclusion Criteria,DIAGNOSES,"18 years Eligible for intensive salvage chemotherapy with R-ICE, R-DHAP Patient received first line of chemotherapy when DLBCL was initially diagnosed and did not receive any further chemotherapy until enrollment in this study All treatment-related toxicities from prior chemotherapy resolved to grade 1or resolved to grade 2 only if deemed clinically not significant and approved by the Sponsor 7.",ct_inc_399410,AACT,65,NCT02544724,Hypothetical,R-DHAP
5c7430ad8625dd077d867f93,170,,,421,Patient,15:09.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_422608,Clinical Trial Inclusion Criteria,COMMENT,"Measurable disease is not required, but will be followed if it exists - Patients must have received 4 or more cycles of one of the following prior systemic induction chemotherapy regimens: - Rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunomycin), vincristine sulfate (Oncovin), prednisone (R-CHOP) (with or without alternating rituximab, dexamethasone, cytarabine [ara-c], cisplatin [platinum] [R-DHAP]) with or without autologous (auto) stem cell transplant (SCT) - Hyper-cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride (adriamycin), dexamethasone (CVAD) with or without auto SCT - Bendamustine + rituximab with or without auto SCT - Please",ct_inc_422608,AACT,415,NCT02242097,Hypothetical,R-DHAP
5c7430be8625dd081e867f98,110,,,245,Patient,15:26.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_343958,Clinical Trial Inclusion Criteria,COMMENT,"For example, a patient who started treatment with rituximab/bendamustine and was then switched to R-CHOP (due to insufficient response or excessive toxicity) would be counted as having received 2 regimens; however, R-CHOP alternating with R-DHAP as a planned induction regimen would count as one regimen - Patients must have achieved a radiologic complete or partial remission as defined by the Lugano criteria - Patients must meet institutional eligibility requirements for stem cell transplant, including cardiac, renal, liver, and pulmonary requirements - Patients have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 - Human immunodeficiency virus (HIV) positive patients are not excluded, but to enroll, must meet all of the below criteria: - HIV is sensitive to antiretroviral therapy - Must be willing to take effective antiretroviral therapy if indicated - CD4 count at screening >",ct_inc_343958,AACT,239,NCT03267433,Hypothetical,R-DHAP
5c7430c08625dd084a867f9b,140,,,315,Patient,15:28.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_436865,Clinical Trial Inclusion Criteria,UNKNOWN,Each patient (or their legally acceptable representative) must sign an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the study and are willing to participate in the study Patients eligible for autologous stem cell transplantation (ASCT) for whom R-DHAP or R-DHAOx is an acceptable therapy regarding the investigator's opinion Measurable disease defined by at least one single node or tumor lesion > 1.5 cm Patients who received prior therapy with at least one but no more than two lines therapies for B-Cell Lymphoma (except for patients included in group C during the expansion part of the study),ct_inc_436865,AACT,309,NCT02055924,Historical,R-DHAP
5c7430538625dd03c7867f99,0,,,193,Patient,13:39.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_411113,Clinical Trial Inclusion Criteria,UNKNOWN,"Planned to receive chemotherapy for 6 cycles which the treating physician plans to utilize for pegfilgrastim to minimize risk for neutropenic fever, including but not limited to R-CHOP, R-EPOCH, and R-HyperCVAD, CHOP, and SMILE.",ct_inc_411113,AACT,186,NCT02392039,Recent,R-EPOCH
5c7430548625dd03c7867fb7,0,,,369,Patient,13:40.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_389834,Clinical Trial Inclusion Criteria,UNKNOWN,"These patients include: - Acute myeloid leukemia patients receiving induction and consolidation (first line and relapsed/refractory) - Acute lymphoid leukemia patients receiving HyperCVAD/R (cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, rituximab) - Lymphoma patients receiving ICE (ifosfamide, carboplatin, etoposide), DA-R-EPOCH (dose-adjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin), and other inpatient lymphoma regimens - Patients receiving other inpatient chemotherapy regimens that are given on a monthly basis - Patients who have received an allogeneic stem cell transplant - Have given informed consent - May have previously received inhaled or IV pentamidine",ct_inc_389834,AACT,362,NCT02669706,Recent,R-EPOCH
5c7430558625dd03c7867fbd,0,,,124,Patient,13:41.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_544174,Clinical Trial Inclusion Criteria,UNKNOWN,"- Obtain no partial response after first-line chemotherapy including anthracyclines + rituximab (R-CHOP, R-MegaCHOP, R-EPOCH or the like), or else - Absence of partial response after having received salvage (post-induction) chemotherapy including R-IFE, R",ct_inc_544174,AACT,117,NCT00646750,Recent,R-EPOCH
5c74305a8625dd0431867f84,220,,,79,Patient,13:46.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_347600,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Participants who have had chemotherapy other than R-EPOCH or R-CHOP, or radiotherapy other than palliative radiation for medical emergencies (like cord compression), within the last 4 weeks - Prior cytotoxic chemotherapy or radiotherapy for this lymphoma - Rituximab within 12 months prior to study registration; only exception will be if rituximab was given for indications other than the treatment of aggressive lymphoma, or for one prior cycle of treatment - Participants who are receiving any other investigational agents - Participants who have previously received ibrutinib for another indication - Expected survival < 2 months - Participants with a history of an opportunistic fungal infection or active fungal infection requiring, or at high risk of requiring, prophylactic or treatment with fluconazole, voriconazole or posaconazole - Participants with known brain metastases from solid tumors should be excluded from this clinical trial - Presence of second active tumor, other than non-melanoma skin cancer, carcinoma in situ of the cervix, or Kaposi's sarcoma (KS) that requires systemic therapy -",ct_exc_347600,AACT,72,NCT03220022,Hypothetical,R-EPOCH
5c7430618625dd043c867f9e,50,,,180,Patient,13:53.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_452271,Clinical Trial Inclusion Criteria,UNKNOWN,Patients who are not transplant eligible or who did not respond to chemotherapy may be considered for the study following a single regimen of chemotherapy such as R-CHOP or R-EPOCH.There,ct_inc_452271,AACT,173,NCT01854606,Recent,R-EPOCH
5c7430628625dd043c867fa1,50,,,141,Patient,13:54.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_486783,Clinical Trial Inclusion Criteria,UNKNOWN,Patients who are not transplant eligible may be considered for the study following a single regimen of chemotherapy such as R-CHOP or R-EPOCH alone.,ct_inc_486783,AACT,134,NCT01402440,Recent,R-EPOCH
5c7430638625dd0452867fa4,40,,,274,Patient,13:55.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_359513,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Histological confirmation of relapsed/refractory diffuse large B-cell lymphoma after prior rituximab and anthracycline-containing systemic treatment regimen such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), R-EPOCH (rituximab, etoposide phosphate, prednisone, vincristine sulfate, cyclophosphamide, doxorubicin hydrochloride), R-HyperCVAD (rituximab, cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone) etc.",ct_inc_359513,AACT,267,NCT03064867,Historical,R-EPOCH
5c7430698625dd04c0867f9c,30,,,320,Patient,14:01.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_387514,Clinical Trial Inclusion Criteria,UNKNOWN," may enroll in the study based on the local laboratory evaluation, but these should be confirmed by the UNC Hematopathology Laboratory retrospectively - Positive for CD20 via immunophenotyping - Prior Treatment: Previously untreated or who received a maximum of one cycle of combination chemotherapy (i.e.R-CHOP, R-EPOCH, or R-hyperCVAD) within 4 weeks of study entry except patients who require dose reduction after the first cycle of off-study R-EPOCH.- Measurable disease as assessed by 2 dimensional measurements by CT ( 1.5 cm).- Adequate organ function as demonstrated by: - Bone marrow function (without platelet transfusion or myeloid growth factor support within two weeks of screening) as demonstrated by: - Hemoglobin 8 g/dL - Absolute neutrophil count (ANC) 1,000 cells/mm3 - Platelet count 75,000/mm3 - And hepatic and renal function as demonstrated by: - Aspartate aminotransferase (AST) and Alanine Aminotransferase (ALT)",ct_inc_387514,AACT,313,NCT02700022,Historical,R-EPOCH
5c74306a8625dd04c0867fa1,30,,,98,Patient,14:02.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_454155,Clinical Trial Inclusion Criteria,UNKNOWN,"Previously untreated for DLBCL - Intended initial treatment to include 2 cycles of R-CHOP, R-EPOCH or R-CEPP using standard doses and schedule.(68, 69) R-CHOP chemoimmunotherapy may be given every 14 days or every 21 days.(4, 70)",ct_inc_454155,AACT,91,NCT01829958,Recent,R-EPOCH
5c74306b8625dd04d6867f86,890,,,526,Patient,14:03.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_347600,Clinical Trial Inclusion Criteria,COMMENT,"a licensed assay refers to a United States (U.S.) Food and Drug Administration (FDA)-approved assay, which is required for all investigational food drug (IND) studies - Only participants whose lymphoma is untreated are allowed for the dose-finding portion; for the dose expansion cohort both untreated and participants who have received a maximum of one cycle of combination chemotherapy, including rituximab-containing regimens R-cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone (CHOP) and R-EPOCH, prior are eligible; the start of previous chemotherapy cycle must occur at least 21 days prior and 28 days maximum to beginning treatment under this protocol, and such cycle will count towards the maximum of 6 cycles under this study (i.e.cycle off study will count as cycle 1) - Eastern Cooperative Oncology Group (ECOG) performance status =< 2",ct_inc_347600,AACT,519,NCT03220022,Historical,R-EPOCH
5c7430758625dd054f867f91,340,,,384,Patient,14:14.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_415254,Clinical Trial Inclusion Criteria,UNKNOWN,"all HIV positive patients are eligible regardless of HIV viral load or antiviral therapy (ART) status; all patients on study will receive ART as per standard guidelines - Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2 - Biopsy proven lymphoma for which rituximab, etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride (R-EPOCH) is appropriate frontline therapy, e.g., Burkitt lymphoma or diffuse large B-cell lymphoma (DLBCL) NHL, including plasmablastic lymphoma and primary effusion lymphoma but not T-cell lymphoma; tissue histology will be reviewed at the treating institution -",ct_inc_415254,AACT,377,NCT02337985,Recent,R-EPOCH
5c7430758625dd054f867f92,340,,,922,Patient,14:14.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_415254,Clinical Trial Inclusion Criteria,UNKNOWN,"HSPC infusion - Subjects must be on a prophylactic regimen for Pneumocystis carinii pneumonia, or agree to begin such treatment and remain on treatment until after completion of therapy and until the cluster of differentiation (CD)4 cells are greater than 200/mm^3 - Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for 12 months following stem cell infusion; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately - All subjects must have the ability to understand and the willingness to sign a written informed consent ELIGIBILITY CRITERIA FOR HSPC TRANSPLANTATION - Patients must demonstrate >= 75% disease reduction on computed tomography (CT) scan (confirmed by PET scan) after the third cycle of R-EPOCH relative to baseline, with no evidence of disease progression after the fifth cycle - Subjects must complete the filgrastim (G-CSF)/plerixafor mobilization of peripheral blood progenitor cells, and subjects must have collected at least 5 x 10^6 CD34+ cells/kg by apheresis after Cycle 4",ct_inc_415254,AACT,915,NCT02337985,Historical,R-EPOCH
5c7430868625dd05e2867f96,330,,,144,Patient,14:30.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_571855,Clinical Trial Inclusion Criteria,UNKNOWN,"Recurrent disease - Patients must have received 1 induction regimen containing anthracyclines (e.g., CHOP [with or without rituximab] or R-EPOCH) - Chemosensitive disease at the time of relapse - Patients who responded with a complete or partial remission that lasted at least 8 weeks after their last chemotherapy regimen are considered chemosensitive - Measurable disease, defined as a lymph node or a nodal mass of > 1 cm in its longest transverse diameter on CT scan - Ineligible for, refused, or relapsed after stem cell transplant (for patients with non-mantle cell lymphoma) -",ct_inc_571855,AACT,137,NCT00278382,Recent,R-EPOCH
5c74308c8625dd065b867f88,20,,,7,Patient,14:36.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_533302,Clinical Trial Inclusion Criteria,UNKNOWN,R-EPOCH is acceptable.,ct_inc_533302,AACT,0,NCT00790036,Recent,R-EPOCH
5c7430a28625dd0716867f86,150,,,403,Patient,14:58.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_444230,Clinical Trial Inclusion Criteria,UNKNOWN,"I to stage IV DLBCL at the time of relapsed/refractory disease to be eligible - Measurable or assessable disease is required; measurable tumor size (at least one node measuring 2.25 cm^2 in bidimensional measurement) per computed tomography (CT) scan, other radiological study, and/or physical exam - Patients must have received at least 1 prior rituximab-based immunochemotherapy (e.g., R-CHOP, R-EPOCH, etc.)- >= 2 weeks since major surgery - Patients must not have any significant toxicity associated with prior surgery, radiation therapy, chemotherapy, or immunotherapy, per principal investigator (PI) discretion - Life expectancy >= 3 months - Karnofsky score (KS)",ct_inc_444230,AACT,396,NCT01959698,Historical,R-EPOCH
5c7430c08625dd086b867f8f,60,,,313,Patient,15:28.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_329914,Clinical Trial Inclusion Criteria,UNKNOWN,"ole - Able to understand and voluntarily sign consent prior to any study related assessments or procedures - Performance status of 0-2 on the ECOG scale - Adequate organ function as specified in the protocol.- must have received at least one prior CD20 containing multi-agent chemotherapy regimen (R-CHOP, R-EPOCH).Bendamustine and rituximab can be the prior regimen if used for follicular lymphoma or marginal zone lymphoma and susequently transformed to DLBCL.- A pre-phase treatment with prednisoe at 1mg/kg/day or equivalent, for a maximum of 10 days leading up to the first dose of CC-486 is allowed.",ct_inc_329914,AACT,306,NCT03450343,Hypothetical,R-EPOCH
5c7430558625dd03c7867fbe,0,,,261,Patient,13:41.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_544174,Clinical Trial Inclusion Criteria,UNKNOWN,"- Obtain no partial response after first-line chemotherapy including anthracyclines + rituximab (R-CHOP, R-MegaCHOP, R-EPOCH or the like), or else - Absence of partial response after having received salvage (post-induction) chemotherapy including R-IFE, R",ct_inc_544174,AACT,254,NCT00646750,Recent,R-ESHAP
5c7430728625dd054f867f85,340,,,129,Patient,14:10.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_532010,Clinical Trial Inclusion Criteria,UNKNOWN,"Disease relapsed after, refractory or failing to achieve a PR after two or more cycles of intensive salvage chemotherapy (R-ESHAP or other) or disease relapsed after autologous stem cell transplantation.",ct_inc_532010,AACT,122,NCT00807196,Recent,R-ESHAP
5c7430738625dd0518867f9d,100,,,187,Patient,14:11.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_329307,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients eligible for ASCT who failed to achieve a Complete Response (CR) after at least one salvage therapy (eg, Rituximab-Etoposide- Methylprednisolone - Cytarabine - Cisplatin (R-ESHAP) or Rituximab- Dexamethasone- High-dose Cytarabine - Cisplatin (R-DHAP), patients who were previously refractory to Rituximab-Ifosfamide-Cytarabine-Etoposide (R-ICE) (stable disease or progressive disease) are not eligible to the study) Or patients in first relapse after Autologous Stem Cell Transplant (ASCT) Or patients not eligible for ASCT who failed to achieve a CR after at least one prior treatment (and no more than 4 previous lines) or in relapse after at least one prior treatment (and no more than 4 previous lines).",ct_inc_329307,AACT,180,NCT03458260,Historical,R-ESHAP
5c74308d8625dd065b867f8f,20,,,115,Patient,14:37.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_560048,Clinical Trial Inclusion Criteria,UNKNOWN,"Diagnosis of DLBCL.- Received at least one combination chemotherapy regimen with rituximab, such as R-CHOP, R-ESHAP or equivalent.- Progression or relapse since most recent therapy.-",ct_inc_560048,AACT,108,NCT00435916,Recent,R-ESHAP
5c74307e8625dd05b6867f96,10,,,258,Patient,14:22.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_583905,Clinical Trial Inclusion Criteria,UNKNOWN,"Chemotherapy combinations may include, but are not limited to: CHOP (Cyclophosphamide, doxorubicin, vincristine, prednisone), R-CHOP (Rituximab, Cyclophosphamide, doxorubicin, vincristine, prednisone), FCM (Fludarabine, cyclophosphamide, mitoxantrone), R-FCM (Rituximab,Fludarabine, cyclophosphamide, mitoxantrone), ICE(Ifosfamide, carboplatin, etoposide), DHAP (Dexamethasone, cisplatin, cytarabine) and hyper-CVAD (Cyclophosphamide, doxorubicin, vincristine, dexamethasone).",ct_inc_583905,AACT,253,NCT00117598,Recent,R-FCM
5c7430678625dd04c0867f87,30,,,293,Patient,13:59.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_515733,Clinical Trial Inclusion Criteria,UNKNOWN,"Subjects with histologically proven follicular lymphoma (grade 1, 2, or 3a), in clinical relapse/progression requiring treatment - Subjects must have had first line treatment consisting of rituximab with or without rituximab maintenance therapy (i.e.rituximab monotherapy, R-CHOP, R-CVP, R-FND, etc) -",ct_inc_515733,AACT,288,NCT01022255,Recent,R-FND
5c74307f8625dd05b6867fa5,10,,,381,Patient,14:23.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_490450,Clinical Trial Inclusion Criteria,UNKNOWN,"Platelet count 100x109/L Absolute Neutrophil count 1.0x109/L; Serum bilirubin 1.5 x ULN AST (SGOT) or ALT 1.5 x ULN Creatinine clearance (Cockcroft-Gault) > 50 ml/min - Relapsed or refractory DLBCL in which all participants must have received at least one potentially curative established immunochemotherapy lymphoma regimen that contained rituximab (e.g.R-CHOP, R-PMitCEBO, R-GCVP, R-CNOP).Participants must also have failed or be ineligible for salvage/high dose therapy.- Relapsed or refractory DLBCL proven by biopsy (within 6 months of enrolment in trial); either de novo DLBCL or transformed follicular lymphoma.-",ct_inc_490450,AACT,375,NCT01354392,Recent,R-GCVP
5c7430ba8625dd081e867f8f,110,,,121,Patient,15:22.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_384338,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: Patients with any type of relapsed or refractory B-cell lymphoma Eligible to receive R-DHAOx or R-GDP regarding the investigator's opinion Who received prior therapy with at least one but no more than two lines therapies for B-Cell Lymphoma Patient,ct_inc_384338,AACT,116,NCT02741388,Historical,R-GDP
5c7430578625dd03fe867f8f,290,,,303,Patient,13:43.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_580019,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Burkitt's, mantle cell, T-cell lymphomas - CD 20-negative lymphoma - HIV or HBV related disease - Central nervous system or meningeal involvement by the lymphoma - Not previously treated with anthracycline-containing regimens - Contraindication to any drug contained in the R-GEMOX chemotherapy regimen -",ct_exc_580019,AACT,296,NCT00169195,Recent,R-GEMOX
5c7430578625dd03fe867f90,290,,,303,Patient,13:43.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_580019,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Burkitt's, mantle cell, T-cell lymphomas - CD 20-negative lymphoma - HIV or HBV related disease - Central nervous system or meningeal involvement by the lymphoma - Not previously treated with anthracycline-containing regimens - Contraindication to any drug contained in the R-GEMOX chemotherapy regimen -",ct_exc_580019,AACT,296,NCT00169195,Recent,R-GEMOX
5c7430838625dd05e2867f8d,330,,,185,Patient,14:27.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_474526,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Burkitt, mantle cell and T-cell lymphomas.- Central nervous system or meningeal involvement by the lymphoma.- Contraindication to any drug contained in the R-GEMOX combination chemotherapy.- Treatment with any investigational drug within 30 days before the first planned cycle of chemotherapy and during the study.- Nitrosurea or mitomycin C administration within 6 weeks",ct_exc_474526,AACT,178,NCT01562990,Recent,R-GEMOX
5c7430838625dd05e2867f8e,330,,,185,Patient,14:27.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_474526,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Burkitt, mantle cell and T-cell lymphomas.- Central nervous system or meningeal involvement by the lymphoma.- Contraindication to any drug contained in the R-GEMOX combination chemotherapy.- Treatment with any investigational drug within 30 days before the first planned cycle of chemotherapy and during the study.- Nitrosurea or mitomycin C administration within 6 weeks",ct_exc_474526,AACT,178,NCT01562990,Recent,R-GEMOX
5c7430538625dd03c7867f96,0,,,210,Patient,13:39.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_411113,Clinical Trial Inclusion Criteria,UNKNOWN,"Planned to receive chemotherapy for 6 cycles which the treating physician plans to utilize for pegfilgrastim to minimize risk for neutropenic fever, including but not limited to R-CHOP, R-EPOCH, and R-HyperCVAD, CHOP, and SMILE.",ct_inc_411113,AACT,199,NCT02392039,Recent,R-HyperCVAD
5c7430638625dd0452867fa1,40,,,398,Patient,13:55.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_359513,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Histological confirmation of relapsed/refractory diffuse large B-cell lymphoma after prior rituximab and anthracycline-containing systemic treatment regimen such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), R-EPOCH (rituximab, etoposide phosphate, prednisone, vincristine sulfate, cyclophosphamide, doxorubicin hydrochloride), R-HyperCVAD (rituximab, cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone) etc.",ct_inc_359513,AACT,387,NCT03064867,Historical,R-HyperCVAD
5c7430698625dd04c0867f99,30,,,336,Patient,14:01.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_387514,Clinical Trial Inclusion Criteria,UNKNOWN," may enroll in the study based on the local laboratory evaluation, but these should be confirmed by the UNC Hematopathology Laboratory retrospectively - Positive for CD20 via immunophenotyping - Prior Treatment: Previously untreated or who received a maximum of one cycle of combination chemotherapy (i.e.R-CHOP, R-EPOCH, or R-hyperCVAD) within 4 weeks of study entry except patients who require dose reduction after the first cycle of off-study R-EPOCH.- Measurable disease as assessed by 2 dimensional measurements by CT ( 1.5 cm).- Adequate organ function as demonstrated by: - Bone marrow function (without platelet transfusion or myeloid growth factor support within two weeks of screening) as demonstrated by: - Hemoglobin 8 g/dL - Absolute neutrophil count (ANC) 1,000 cells/mm3 - Platelet count 75,000/mm3 - And hepatic and renal function as demonstrated by: - Aspartate aminotransferase (AST) and Alanine Aminotransferase (ALT)",ct_inc_387514,AACT,325,NCT02700022,Historical,R-hyperCVAD
5c74307f8625dd05b6867f99,10,,,206,Patient,14:23.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_570297,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: Patients with a diagnosis of previously untreated aggressive non-Hodgkin's lymphoma, including patients with mantle cell lymphoma, who will be or are receiving treatment with R-HyperCVAD and R-Ara-C/MTX.Patients",ct_inc_570297,AACT,195,NCT00299182,Recent,R-HyperCVAD
5c74304b8625dd0381867f92,230,,,970,Patient,13:31.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_363654,Clinical Trial Inclusion Criteria,COMMENT,"Has EITHER histologically confirmed B-cell lymphomas including but not limited to diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), primary mediastinal B-cell lymphoma (PMBCL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), or Hodgkin lymphoma (HL) and has relapsed or refractory disease following at least two lines of prior standard therapy, including alkylator/anthracycline (unless anthracycline-based chemotherapy is contraindicated)/anti-CD20-based therapy (R-CHOP, rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisolone or dexamethasone, or equivalent for non-Hodgkin lymphoma), AND must be considered unable to benefit from intensification treatment with autologous hematopoietic stem cell transplantation (ASCT) , as defined by meeting at least one of the following criteria: - Relapsed following, or refractory to, previous ASCT - Did not achieve at least a partial response to a standard salvage regimen (e.g., R-ICE, rituximab, ifosfamide, carboplatin, etoposide, or R-DHAP, rituximab, dexamethasone, cytarabine, cisplatin) -",ct_inc_363654,AACT,965,NCT03010982,Historical,R-ICE
5c74304c8625dd0381867f97,230,,,105,Patient,13:32.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_362341,Clinical Trial Inclusion Criteria,UNKNOWN,"previous ASCT Did not achieve at least a partial response (PR) to a standard salvage regimen (e.g., R-ICE; rituximab, ifosfamide, carboplatin, etoposide, or R-DHAP; rituximab, dexamethasone, cytarabine, cisplatin)",ct_inc_362341,AACT,100,NCT03028103,Recent,R-ICE
5c74304d8625dd02f2867f86,1290,,,469,Patient,13:33.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_424323,Clinical Trial Exclusion Criteria,UNKNOWN,"< 21 days (=< 6 weeks for monoclonal antibodies) prior to first administration of study treatment or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier - Patients who are receiving any other investigational agents - Patients with known brain metastases should be excluded from this clinical trial - History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib or R-ICE - Requires treatment with a strong cytochrome P450 (CYP) 3A inhibitor; strong inhibitors or inducers of CYP3A4/5 should be avoided and moderate inhibitors or inducers should be used with caution; it is important to regularly consult a frequently-updated list; medical reference texts such as the Physicians' Desk Reference may also provide this information; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements; recent infections requiring systemic treatment need to have completed therapy > 14 days before the first dose of study drug - Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ibrutinib R-ICE - Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are eligible, unless the patient's CD4 count is below the institutional lower limit of normal, or the patient is taking prohibited CYP3A4/5 strong inhibitors or inducers - Patients may not have received any anti-cancer therapy for their primary relapsed (rel)/refractory (ref) DLBCL with the exception of palliative radiation therapy (RT) - Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura (ITP) resulting in (or as evidenced by) declining platelet or hemoglobin (Hgb) levels within the 4 weeks prior to first dose of study drug - Presence of transfusion-dependent thrombocytopenia - Prior exposure to bruton tyrosine kinase (BTK) inhibitor - History of prior malignancy, with the exception of the following: - Malignancy treated with curative intent and with no evidence of active disease present for more than 3 years prior to screening and felt to be at low risk for recurrence by treating physician - Adequately treated non-melanomatous skin cancer or lentigo maligna melanoma without current evidence of disease - Adequately treated cervical carcinoma in situ without current evidence of disease - Currently active clinically significant cardiovascular disease such as uncontrolled arrhythmia, congestive heart failure, or class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification, or history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to first dose with study drug - Unable to swallow capsules, or disease significantly affecting gastrointestinal function or resection of the stomach or small bowel, or symptomatic-inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction - Serologic status reflecting active hepatitis B or C infection; patients that are positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or hepatitis C antibody will need a negative polymerase chain reaction (PCR) prior to enrollment (PCR positive patients will be excluded); hepatitis C antibody positive patients are eligible if PCR is negative - History of stroke or intracranial hemorrhage within 6 months prior to enrollment - Current life-threatening illness, medical condition, or organ system dysfunction which, in the Investigator's opinion, could compromise the patient's safety, or put the study at risk - Received anticoagulation therapy with Coumadin or equivalent vitamin K antagonists within the last 28 days - Vaccinated with live, attenuated vaccines with 4 weeks of first does of study drug - Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event",ct_exc_424323,AACT,464,NCT02219737,Hypothetical,R-ICE
5c7430558625dd03c7867fc1,0,,,268,Patient,13:41.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_544174,Clinical Trial Inclusion Criteria,UNKNOWN,"- Obtain no partial response after first-line chemotherapy including anthracyclines + rituximab (R-CHOP, R-MegaCHOP, R-EPOCH or the like), or else - Absence of partial response after having received salvage (post-induction) chemotherapy including R-IFE, R",ct_inc_544174,AACT,263,NCT00646750,Recent,R-ICE
5c7430578625dd03fe867f8c,290,,,842,Patient,13:43.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_448981,Clinical Trial Exclusion Criteria,COMMENT,"Subjects must satisfy all of the following criteria: Have histologically confirmed DLBCL (including primary mediastinal B-cell lymphoma), with relapsed or refractory disease following at least 2 lines of prior standard therapy, including alkylator/anthracycline (unless anthracycline-based chemotherapy is contraindicated)/anti-CD20-based therapy (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP] or equivalent) AND must be considered unable to benefit from intensification treatment with autologous hematopoietic stem cell transplantation (ASCT) as defined by meeting at least 1 of the following criteria: - Relapsed following, or refractory to, previous ASCT - Did not achieve at least a partial response to a standard salvage regimen (eg, rituximab, ifosfamide, carboplatin, and etoposide phosphate [R-ICE] or rituximab, dexamethasone, cytarabine, and cisplatin [R-DHAP]) -",ct_exc_448981,AACT,837,NCT01897571,Historical,R-ICE
5c7430738625dd0518867fa0,100,,,352,Patient,14:11.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_329307,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients eligible for ASCT who failed to achieve a Complete Response (CR) after at least one salvage therapy (eg, Rituximab-Etoposide- Methylprednisolone - Cytarabine - Cisplatin (R-ESHAP) or Rituximab- Dexamethasone- High-dose Cytarabine - Cisplatin (R-DHAP), patients who were previously refractory to Rituximab-Ifosfamide-Cytarabine-Etoposide (R-ICE) (stable disease or progressive disease) are not eligible to the study) Or patients in first relapse after Autologous Stem Cell Transplant (ASCT) Or patients not eligible for ASCT who failed to achieve a CR after at least one prior treatment (and no more than 4 previous lines) or in relapse after at least one prior treatment (and no more than 4 previous lines).",ct_inc_329307,AACT,347,NCT03458260,Historical,R-ICE
5c7430aa8625dd077d867f8f,170,,,63,Patient,15:06.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_399410,Clinical Trial Inclusion Criteria,DIAGNOSES,"18 years Eligible for intensive salvage chemotherapy with R-ICE, R-DHAP Patient received first line of chemotherapy when DLBCL was initially diagnosed and did not receive any further chemotherapy until enrollment in this study All treatment-related toxicities from prior chemotherapy resolved to grade 1or resolved to grade 2 only if deemed clinically not significant and approved by the Sponsor 7.",ct_inc_399410,AACT,58,NCT02544724,Hypothetical,R-ICE
5c7430558625dd03c7867fc2,0,,,252,Patient,13:41.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_544174,Clinical Trial Inclusion Criteria,UNKNOWN,"- Obtain no partial response after first-line chemotherapy including anthracyclines + rituximab (R-CHOP, R-MegaCHOP, R-EPOCH or the like), or else - Absence of partial response after having received salvage (post-induction) chemotherapy including R-IFE, R",ct_inc_544174,AACT,247,NCT00646750,Recent,R-IFE
5c7430558625dd03c7867fbc,0,,,115,Patient,13:41.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_544174,Clinical Trial Inclusion Criteria,UNKNOWN,"- Obtain no partial response after first-line chemotherapy including anthracyclines + rituximab (R-CHOP, R-MegaCHOP, R-EPOCH or the like), or else - Absence of partial response after having received salvage (post-induction) chemotherapy including R-IFE, R",ct_inc_544174,AACT,105,NCT00646750,Recent,R-MegaCHOP
5c74307f8625dd05b6867fa2,10,,,373,Patient,14:23.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_490450,Clinical Trial Inclusion Criteria,UNKNOWN,"Platelet count 100x109/L Absolute Neutrophil count 1.0x109/L; Serum bilirubin 1.5 x ULN AST (SGOT) or ALT 1.5 x ULN Creatinine clearance (Cockcroft-Gault) > 50 ml/min - Relapsed or refractory DLBCL in which all participants must have received at least one potentially curative established immunochemotherapy lymphoma regimen that contained rituximab (e.g.R-CHOP, R-PMitCEBO, R-GCVP, R-CNOP).Participants must also have failed or be ineligible for salvage/high dose therapy.- Relapsed or refractory DLBCL proven by biopsy (within 6 months of enrolment in trial); either de novo DLBCL or transformed follicular lymphoma.-",ct_inc_490450,AACT,363,NCT01354392,Recent,R-PMitCEBO
5c74306d8625dd0506867f86,80,,,87,Patient,14:05.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_536023,Clinical Trial Exclusion Criteria,UNKNOWN,"Patients who are, in the opinion of their treating oncologist, unable to undergo R/CHOP chemotherapy.",ct_exc_536023,AACT,81,NCT00754117,Recent,R/CHOP
5c7430b88625dd081e867f88,110,,,223,Patient,15:20.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_544280,Clinical Trial Inclusion Criteria,UNKNOWN,"CD20 Positive diffuse large B cell lymphoma (LBCL) of any stage, including subtypes mediastinal large B cell, centroblastic, immunoblastic, T cell rich B cell and anaplastic B cell lymphoma, who will receive standard R/CHOP as first line chemotherapy will be included.- Patients must be age 18 or older.-",ct_inc_544280,AACT,217,NCT00645359,Recent,R/CHOP
5c7430bf8625dd086b867f84,60,,,166,Patient,15:27.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_544280,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria: - Patients will be excluded if the diagnosis of diffuse large B cell lymphoma cannot be confirmed.- Patients receiving treatment other than R/CHOP or R/CHOP followed by radiotherapy or who have previously been treated for DLBCL will be excluded.- Patients with HIV infection will also be excluded.,ct_exc_544280,AACT,160,NCT00645359,Recent,R/CHOP
5c7430bf8625dd086b867f85,60,,,154,Patient,15:27.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_544280,Clinical Trial Exclusion Criteria,UNKNOWN,"No selection will be made based on other medical problems or laboratory values, except as they affect the patient's eligibility to receive standard R/CHOP chemotherapy as determined by the treating physician.- Patients who have magnetic metal implants or fragments in their body that are incompatible with MRI will be excluded.",ct_exc_544280,AACT,148,NCT00645359,Recent,R/CHOP
5c7430c08625dd086b867f98,60,,,65,Patient,15:28.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_536023,Clinical Trial Inclusion Criteria,UNKNOWN,>18 years.- Patients must have a treatment plan to include R/CHOP or R/CHOP followed by radiotherapy.- Ability to understand and the willingness to sign a written informed consent document.,ct_inc_536023,AACT,59,NCT00754117,Recent,R/CHOP
5c7430688625dd04c0867f90,30,,,376,Patient,14:00.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_344464,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Complete response of lymphoma (Cheson criteria 2007) after initial treatment - Malin lymphoma (Hodgkin or not) treated with anthracyclines for at least 6 cycles : Adriamycin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) or BEACOPP, Cyclophosphamide, hydroxydaunomycin, Oncovin, and prednisone (CHOP) et Rituximab (R-CHOP), miniCHOP et RminiCHOP, RACVBP having received or not an intensification with autologous hematopoietic stem cell transplantation in first-line - Registered the consent to be included in this study",ct_inc_344464,AACT,370,NCT03260855,Recent,RACVBP
5c7430668625dd04b5867f84,860,,,23,Patient,13:58.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_381874,Clinical Trial Inclusion Criteria,COMMENT,"Ramucirumab monotherapy, or immunotherapy with a checkpoint inhibitor, will be considered a line of treatment.",ct_inc_381874,AACT,0,NCT02773524,Recent,Ramucirumab monotherapy
5c74303d8625dd0308867f86,680,,,61,Patient,13:18.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_518921,Clinical Trial Inclusion Criteria,UNKNOWN,Relapsed DLBCL patients having received 6 - 8 cycles of RCHOP-like chemotherapy as 1st line induction treatment.,ct_inc_518921,AACT,56,NCT00980304,Recent,RCHOP
5c7430438625dd033f867f85,310,,,48,Patient,13:23.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_317130,Clinical Trial Inclusion Criteria,UNKNOWN,"Stage II, III, or IV Patients who received RCHOP or VR-CAP induction chemotherapy for 6 cycles confirmed response as more than PR or PR after induction therapy and who are ineligible for transplantation..",ct_inc_317130,AACT,43,NCT03616782,Recent,RCHOP
5c7430528625dd03b8867f87,430,,,126,Patient,13:38.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_311595,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Age> 18 years - Patient naive to any chemotherapy treatment, re-ceiving a 1st chemotherapy line of RCHOP, RCOP, VTD, VD or MPT type from the Adult Hematology Department - PS",ct_inc_311595,AACT,121,NCT03688789,Recent,RCHOP
5c74305b8625dd043c867f86,50,,,159,Patient,13:48.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_482519,Clinical Trial Inclusion Criteria,UNKNOWN,"double hit DLBCL, mantle cell lymphoma, any transformed low grade B cell lymphomas or grade 3 follicular lymphoma (Grade 3a or 3b) who were refractory to RCHOP-like or any anthracycline based chemotherapy or relapsed after at least one prior combination chemotherapeutic regimen and who are deemed candidates for a salvage type chemotherapy.- Relapsed disease:",ct_inc_482519,AACT,154,NCT01458366,Historical,RCHOP
5c74305b8625dd043c867f87,50,,,54,Patient,13:48.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_482519,Clinical Trial Inclusion Criteria,UNKNOWN,Subjects must have received at least 3 cycles of RCHOP-like or any anthracycline base chemotherapy or at least 2 full cycles of HyperCVAD-like chemotherapy.- Persistent lymphoma and stable disease after at least 2 cycles of RCHOP-like or any anthracycline base chemotherapy or at least 1 full cycle of HyperCVAD-like chemotherapy (part A and B).- Progressive disease despite at least 1 cycle of RCHOP-like or any anthracycline base chemotherapy or at least 1 cycle (part A or A and B) of HyperCVAD-like chemotherapy.,ct_inc_482519,AACT,49,NCT01458366,Recent,RCHOP
5c74305e8625dd0447867f8e,250,,,224,Patient,13:50.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_392637,Clinical Trial Inclusion Criteria,UNKNOWN,"These cases may be classified as high grade B-cell lymphomas according to the 2017 revision of the WHO Classification of Hematopoietic and Lymphoid Tumors.- Recipient of frontline multi-agent chemotherapy (for example, RCHOP, dose adjusted-REPOCH, RCHOP/RICE, RCHOP+investigational agent, etc).Eligible patients will have recently received ( 4 months from end of treatment assessment), be actively receiving, or planned to receive frontline chemotherapy in near future (within 3 months of signing consent).A frontline therapy program can include different sequential phases of treatment, including high-dose therapy and autologous stem cell transplantation.- Required pre-treatment test specimen from bone marrow, blood, lymph node, or alternate site to identify tumor-specific clonotype.- Ability to adhere to the study visit schedule and all the protocol requirements, including surveillance imaging and MRD test specimen collection at specified time points.",ct_inc_392637,AACT,219,NCT02633111,Recent,RCHOP
5c7430658625dd048d867f8e,1200,,,69,Patient,13:57.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_399651,Clinical Trial Inclusion Criteria,UNKNOWN,"; subjects must be planned to receive full course (6 cycles) of RCHOP chemoimmunotherapy as per clinical standard of care; patients may have de novo DLBCL, and /or any of the following: - Composite lymphomas, which include both diffuse DLBCL and another histology (most commonly follicular lymphoma) in the same lymph node - Transformed lymphoma with DLBCL histology, as long as the patient has not received prior therapy for lymphoma - Discordant presentations, such as DLBCL in a lymph node and low-grade lymphoma such as follicular lymphoma in the bone marrow",ct_inc_399651,AACT,64,NCT02541565,Historical,RCHOP
5c74306b8625dd04b5867f90,860,,,45,Patient,14:03.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_354994,Clinical Trial Exclusion Criteria,UNKNOWN,Any contraindication for application of RCHOP or high dose,ct_exc_354994,AACT,40,NCT03123718,Recent,RCHOP
5c74307e8625dd05c1867f84,870,,,129,Patient,14:22.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_580229,Clinical Trial Inclusion Criteria,UNKNOWN,"Antibody therapy alone or immunotherapy alone will not count as a prior regimen - only chemotherapy regimens (for example - RCHOP, CVP, etc.).External beam radiation therapy does not count as a regimen.-",ct_inc_580229,AACT,124,NCT00166439,Historical,RCHOP
5c7430908625dd0680867f8a,480,,,194,Patient,14:40.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_395048,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - histologically documented DLBCL - previously untreated - with International Prognostic Index (IPI) 0 or 1, or 2 without general state alteration (OMS2) - submitted to RCHOP regimen (according to GELA's standard protocol) - normal pre-treatment brain CT scan - able to give informed consent - speaking well French language - benefiting from general medical insurance - registered in the national listing of patients for biomedical research.",ct_inc_395048,AACT,189,NCT02601547,Recent,RCHOP
5c7430ba8625dd083f867f89,240,,,106,Patient,15:22.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_368828,Clinical Trial Inclusion Criteria,UNKNOWN,All patients with newly diagnosed NHL - Scheduled to receive anthracycline-based therapy of the CHOP/RCHOP type,ct_inc_368828,AACT,101,NCT02943590,Recent,RCHOP
5c7430bb8625dd0813867f97,370,,,5,Patient,15:23.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_383509,Clinical Trial Inclusion Criteria,UNKNOWN,"RCHOP, GCHOP, RGCVP).High grade transformation from low grade lymphoma (e.g.follicular lymphoma, lymphoplasmacytic lymphoma, chronic lymphocytic leukaemia) is permitted.",ct_inc_383509,AACT,0,NCT02752204,Recent,RCHOP
5c7430b78625dd0808867f88,320,,,222,Patient,15:19.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_400546,Clinical Trial Inclusion Criteria,UNKNOWN,Measurable disease on cross section imaging that is at least 1.5 cm in the longest diameter and measurable in two perpendicular dimensions Appropriate candidate for systemic immune-chemotherapy such as the standard RCHOP21 6 cycles as determined by the treating physician Age,ct_inc_400546,AACT,215,NCT02529852,Recent,RCHOP21
5c74307b8625dd05ab867f85,720,,,48,Patient,14:19.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_400367,Clinical Trial Exclusion Criteria,UNKNOWN,Known hypersensitivity to any component of RDHAP.,ct_exc_400367,AACT,43,NCT02532192,Recent,RDHAP
5c7430828625dd05f1867f85,1000,,,88,Patient,14:26.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_400367,Clinical Trial Inclusion Criteria,UNKNOWN,"Have received between 1 - 2 prior cytotoxic treatments, not to include belinostat, RDHAP, or autologous or allogeneic stem cell transplant.",ct_inc_400367,AACT,83,NCT02532192,Historical,RDHAP
5c7430508625dd02f2867f89,1290,,,147,Patient,13:36.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_321542,Clinical Trial Inclusion Criteria,UNKNOWN,ECOG performance status 2 Myelosuppressive chemotherapy naive Scheduled to receive and anticipated to complete the following chemotherapy regimen 1.,ct_inc_321542,AACT,138,NCT03559387,Recent,regimen 1
5c7430638625dd0489867f84,1260,,,595,Patient,13:55.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_370108,Clinical Trial Inclusion Criteria,UNKNOWN,"Subject must be male or non-pregnant, non-lactating female, age 2 to 18 years (inclusive) - Subject must have documented medical history to support a clinical diagnosis of Dravet syndrome, where convulsive seizures are not completely controlled by current antiepileptic drugs.- Subject must be receiving a therapeutically relevant and stable dose of CLB, VP, and STP for at least 4 weeks prior to screening and are expected to remain stable throughout the study (Cohort 2 only).- Subject must be receiving a stable dose of CLB and VPA, administered twice daily, to be eligible for Dose Regimen 1 and 2 or subject must be receiving a stable dose of CLB, VPA, and STP, administered twice daily, to be eligible for Dose Regimen 3 (Cohort 1 only).Key",ct_inc_370108,AACT,586,NCT02926898,Historical,Regimen 1
5c7430648625dd048d867f86,1200,,,179,Patient,13:56.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_385382,Clinical Trial Inclusion Criteria,AGE,"Performance score of at least 60% by Karnofsky Adequate major organ system function as demonstrated by: Left ventricular ejection fraction of at least 40% (Myeloablative Regimen 1, Reduced Intensity Regimen 3).Left ventricular ejection fraction of at least 30% (Nonmyeloablative Regimen 2).",ct_inc_385382,AACT,170,NCT02727803,Recent,Regimen 1
5c7430648625dd048d867f87,1200,,,157,Patient,13:56.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_385382,Clinical Trial Inclusion Criteria,AGE,"Pulmonary function test (PFT) demonstrating an adjusted diffusion capacity of least 50% predicted value for hemoglobin concentration (Myeloablative Regimen 1, Reduced Intensity Regimen 3).",ct_inc_385382,AACT,148,NCT02727803,Recent,Regimen 1
5c7430648625dd048d867f88,1200,,,42,Patient,13:56.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_385382,Clinical Trial Inclusion Criteria,AGE,"< to 2.0 x normal (Myeloablative Regimen 1), Reduced Intensity Regimen 3.",ct_inc_385382,AACT,33,NCT02727803,Recent,Regimen 1
5c7430678625dd0489867f88,1260,,,138,Patient,13:59.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_551639,Clinical Trial Inclusion Criteria,UNKNOWN,"In second complete remission or higher OR in first remission with poor risk factors, including any of the following (preparative regimen 1 or 2): - BCR/ABL by fluorescence in situ hybridization (FISH) or reverse transcriptase-polymerase chain reaction - t(9;22)(q34;q11) detected by cytogenetics - Chromosomes < 44 by cytogenetics - DNA index < 0.81 by flow cytometry -",ct_inc_551639,AACT,129,NCT00547196,Recent,regimen 1
5c7430678625dd0489867f89,1260,,,54,Patient,13:59.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_551639,Clinical Trial Inclusion Criteria,UNKNOWN,In accelerated phase or greater (preparative regimen 1 or 2) -,ct_inc_551639,AACT,45,NCT00547196,Recent,regimen 1
5c7430678625dd0489867f8a,1260,,,81,Patient,13:59.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_551639,Clinical Trial Inclusion Criteria,UNKNOWN,With deletion of chromosome 7 or short arm of chromosome 5 (preparative regimen 1 or 2) -,ct_inc_551639,AACT,72,NCT00547196,Recent,regimen 1
5c7430718625dd0532867f85,1310,,,107,Patient,14:09.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_394455,Clinical Trial Exclusion Criteria,UNKNOWN,"Any medical contraindications or previous therapy that would preclude treatment with either IRX 2 Regimen 1 or 2 or the surgery, reconstruction or adjuvant therapy required to treat the oral tumor appropriately - Live vaccines should ideally not be administered to any patients undergoing treatment with chemotherapy or immunotherapy, but if need be, they should be administered >4 months prior to the initiation of treatment or >4 months after the completion of all treatment - Inactivated vaccines should precede the initiation of any study regimen and/or standard adjuvant therapy by at least 2 weeks, but preferably 4 weeks or longer Clinical status of either subject or tumor such that administration of 21 day neoadjuvant",ct_exc_394455,AACT,98,NCT02609386,Hypothetical,Regimen 1
5c7430718625dd0532867f86,1310,,,9,Patient,14:09.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_394455,Clinical Trial Exclusion Criteria,UNKNOWN,Regimen 1 or 2 before surgery would be medically inappropriate Tumor of the oropharynx Tumor involvement of the following sites or any of these signs or symptoms likely to be associated with T4b,ct_exc_394455,AACT,0,NCT02609386,Recent,Regimen 1
5c7430738625dd055a867f84,1320,,,175,Patient,14:11.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_589440,Clinical Trial Inclusion Criteria,CHEMOTHERAPEUTICS,"based chemotherapeutic regimen containing carboplatin, cisplatin, or another organoplatinum compound Must have had at least 1 prior paclitaxel based chemotherapeutic regimen 1 or 2 prior chemotherapy regimens containing platinum and paclitaxel allowed Recovered from toxic effects",ct_inc_589440,AACT,166,NCT00004037,Historical,regimen 1
5c7430b18625dd07bb867f86,1330,,,9,Patient,15:13.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_589092,Clinical Trial Inclusion Criteria,UNKNOWN,Regimen 1 (Myeloablative mel/thiotepa/fludarabine):,ct_inc_589092,AACT,0,NCT00067002,Recent,Regimen 1
5c7430b28625dd07bb867f87,1330,,,74,Patient,15:14.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_584228,Clinical Trial Inclusion Criteria,COMMENT,"No concurrent cimetidine or allopurinol (for patients on arm II, regimen 1)",ct_inc_584228,AACT,65,NCT00113399,Recent,regimen 1
5c7430b68625dd07bb867f88,1330,,,34,Patient,15:18.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_495012,Clinical Trial Inclusion Criteria,UNKNOWN,"For patients enrolled in Regimen 1 which includes PLD, prior treatment with PLD is NOT allowed -",ct_inc_495012,AACT,25,NCT01294293,Historical,Regimen 1
5c7430458625dd0355867f86,160,,,145,Patient,13:25.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_356855,Clinical Trial Inclusion Criteria,UNKNOWN,"Up to 5 of the 15 patients will be allowed to have had other approved or investigational drugs after prior progression of Regorafenib monotherapy.(all patients enrolled in this trial must have had prior progression on regorafenib therapy).This may include TAS102, off-label therapy that may have been prescribed based on tumor genomic profiling or any investigational agents on a clinical trial.",ct_inc_356855,AACT,122,NCT03099486,Historical,Regorafenib monotherapy
5c74305e8625dd0447867f8d,250,,,246,Patient,13:50.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_392637,Clinical Trial Inclusion Criteria,UNKNOWN,"These cases may be classified as high grade B-cell lymphomas according to the 2017 revision of the WHO Classification of Hematopoietic and Lymphoid Tumors.- Recipient of frontline multi-agent chemotherapy (for example, RCHOP, dose adjusted-REPOCH, RCHOP/RICE, RCHOP+investigational agent, etc).Eligible patients will have recently received ( 4 months from end of treatment assessment), be actively receiving, or planned to receive frontline chemotherapy in near future (within 3 months of signing consent).A frontline therapy program can include different sequential phases of treatment, including high-dose therapy and autologous stem cell transplantation.- Required pre-treatment test specimen from bone marrow, blood, lymph node, or alternate site to identify tumor-specific clonotype.- Ability to adhere to the study visit schedule and all the protocol requirements, including surveillance imaging and MRD test specimen collection at specified time points.",ct_inc_392637,AACT,240,NCT02633111,Recent,REPOCH
5c7430378625dd02b4867f89,1020,,,53,Patient,13:11.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_552458,Clinical Trial Inclusion Criteria,UNKNOWN,"For those patients who have had rituximab monotherapy, last dose must be greater than 90 days prior to beginning study treatment.- For Phase II only: Untreated B-cell CLL patients only.- Rai staging, will be employed.",ct_inc_552458,AACT,32,NCT00536341,Historical,rituximab monotherapy
5c74303a8625dd02ba867f8c,900,,,42,Patient,13:14.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_334208,Clinical Trial Inclusion Criteria,UNKNOWN,Treatment failure of rituximab monotherapy (Cohort A) or rituximab plus any concurrent or sequentially administered chemotherapy regimen (Cohort B) for treatment of PTLD.,ct_inc_334208,AACT,21,NCT03394365,Recent,rituximab monotherapy
5c74303a8625dd02ba867f8d,900,,,44,Patient,13:14.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_487188,Clinical Trial Exclusion Criteria,COMMENT,Subjects refractory to rituximab monotherapy as last therapy are permitted -,ct_exc_487188,AACT,23,NCT01397149,Recent,rituximab monotherapy
5c7430448625dd0334867f8a,400,,,66,Patient,13:24.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_409176,Clinical Trial Inclusion Criteria,UNKNOWN,"Systemic therapy includes treatments such as rituximab monotherapy, chemotherapy given with or without rituximab, radio-immunoconjugates such as 90Y-ibritumomab tiuxetan and 1311-tositumomab.",ct_inc_409176,AACT,45,NCT02417285,Recent,rituximab monotherapy
5c7430448625dd0334867f8b,400,,,66,Patient,13:24.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_409176,Clinical Trial Inclusion Criteria,UNKNOWN,"Systemic therapy includes treatments such as rituximab monotherapy, chemotherapy given with or without rituximab, radio-immunoconjugates such as 90Y-ibritumomab tiuxetan and 1311-tositumomab.",ct_inc_409176,AACT,45,NCT02417285,Recent,rituximab monotherapy
5c74305e8625dd045a867f84,1190,,,21,Patient,13:50.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_489270,Clinical Trial Inclusion Criteria,COMMENT,rituximab monotherapy does not count as a prior line of therapy - Progressive disease with any one of the following characteristics based on standard criteria for treatment as defined by the NCI-Working Group (WG) 1996 - Symptomatic CLL characterized by any one of the following: - Weight loss >= 10% within the previous 6 months - Extreme fatigue attributed to CLL - Fevers,ct_inc_489270,AACT,0,NCT01369849,Historical,rituximab monotherapy
5c7430638625dd0452867fa0,40,,,49,Patient,13:55.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_359513,Clinical Trial Inclusion Criteria,UNKNOWN,"Prior therapy with systemic rituximab monotherapy or conventional chemotherapy (i.e.bendamustine, CVP (Cyclophosphamide, Vincristine Sulfate, Prednisone) or other) rituximab for indolent non-Hodgkin's lymphoma (NHL) maintenance/extended-use rituximab will count as 1 line of systemic therapy.- Eastern Cooperative Oncology Group (ECOG)",ct_inc_359513,AACT,28,NCT03064867,Historical,rituximab monotherapy
5c7430678625dd04c0867f84,30,,,271,Patient,13:59.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_515733,Clinical Trial Inclusion Criteria,UNKNOWN,"Subjects with histologically proven follicular lymphoma (grade 1, 2, or 3a), in clinical relapse/progression requiring treatment - Subjects must have had first line treatment consisting of rituximab with or without rituximab maintenance therapy (i.e.rituximab monotherapy, R-CHOP, R-CVP, R-FND, etc) -",ct_inc_515733,AACT,250,NCT01022255,Recent,rituximab monotherapy
5c7430848625dd0603867f8b,600,,,417,Patient,14:28.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_337815,Clinical Trial Exclusion Criteria,UNKNOWN,"Anti-nuclear antibodies of long-standing duration without associated clinical symptoms will be adjudicated on a case-by-case basis during the Confirmatory Review of Patient Eligibility - Positive hepatitis panel (including hepatitis B surface antigen and/or hepatitis C virus antibody) prior to or at Screening - Positive human immunodeficiency virus (HIV) antibody at Screening - Treatment with rituximab monotherapy within 3 months or rituximab combination therapies (example, with bendamustine, fludarabine, ibrutinib, or cytotoxic drugs) within 6 months prior to enrollment",ct_exc_337815,AACT,396,NCT03347422,Historical,rituximab monotherapy
5c7430848625dd0603867f8c,600,,,417,Patient,14:28.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_337817,Clinical Trial Exclusion Criteria,UNKNOWN,"Anti-nuclear antibodies of long-standing duration without associated clinical symptoms will be adjudicated on a case-by-case basis during the Confirmatory Review of Patient Eligibility - Positive hepatitis panel (including hepatitis B surface antigen and/or hepatitis C virus antibody) prior to or at Screening - Positive human immunodeficiency virus (HIV) antibody at Screening - Treatment with rituximab monotherapy within 3 months or rituximab combination therapies (eg, with bendamustine, fludarabine, ibrutinib, or cytotoxic drugs) within 6 months prior to enrollment",ct_exc_337817,AACT,396,NCT03347396,Historical,rituximab monotherapy
5c7430858625dd0603867f8d,600,,,67,Patient,14:29.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_445893,Clinical Trial Inclusion Criteria,UNKNOWN,Rituximab-refractory.- Investigator considers rituximab monotherapy appropriate.-,ct_inc_445893,AACT,46,NCT01938001,Recent,rituximab monotherapy
5c7430878625dd0624867f86,420,,,117,Patient,14:31.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_488369,Clinical Trial Inclusion Criteria,UNKNOWN,- Diagnosed with indolent follicular lymphoma - Treated on RESORT trial (ECOG-E4402) comprising rituximab monotherapy and then randomized to rituximab maintenance therapy or retreatment with rituximab upon disease relapse - Blood and tissue samples from p,ct_inc_488369,AACT,96,NCT01381705,Recent,rituximab monotherapy
5c74308a8625dd0642867f84,610,,,292,Patient,14:34.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_465486,Clinical Trial Inclusion Criteria,UNKNOWN,"Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 - Measurable tumor size (at least one node measuring 4 cm^2 in bidimensional measurement) - Expected survival of > 6 months - Prior rituximab or other monoclonal immunotherapy permitted and eligible for rituximab monotherapy - Full recovery from any significant toxicity associated with prior surgery, radiation therapy, chemotherapy, or immunotherapy - Absolute neutrophil count >",ct_inc_465486,AACT,271,NCT01682044,Historical,rituximab monotherapy
5c7430568625dd03fe867f84,290,,,278,Patient,13:42.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_480769,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients under consideration for participation in this study must meet all of the following inclusion criteria: - Histologically confirmed CD20 positive diffuse large B-cell lymphoma.- Progressing or relapsed following prior treatment including but not limited to rituximab-CHOP chemotherapy regimen.- Not suitable for ASCT (age > 60 years, PS 2, prior ASCT as a part of the previous treatment for DLBCL, and/or other medical conditions that unable the patients to undergo the ASCT, e.g.",ct_inc_480769,AACT,264,NCT01481272,Historical,rituximab-CHOP
5c7430568625dd03fe867f86,290,,,130,Patient,13:42.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_522644,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically proven diffuse large B-cell or follicular B-cell non-Hodgkin's lymphoma, for which chemotherapy with rituximab-CHOP chemotherapy is considered treatment-of-choice.",ct_inc_522644,AACT,116,NCT00931229,Recent,rituximab-CHOP
5c7430608625dd0452867f8d,40,,,63,Patient,13:52.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_493723,Clinical Trial Inclusion Criteria,UNKNOWN,Patients who had received at least two cycles of rituximab-CHOP or rituximab-CVP as a primary treatment Patients with a history of previous exposure to HBV - HBV surface antigen (HBs Ag) positive Or - HBV core antibody (IgG anti-HBc antibody) positive Patients with documented HBV reactivation (definite or presumptive) occurring during treatment (at least two cycles of R-CHOP or R-CVP) or within 12 months after the last dose of rituximab - Definitive HBV reactivation - Elevation of serum HBV DNA level >1 log IU/mL from baseline or absolute increase of HBV DNA by 6 log10 IU/mL in HBsAg positive patients - Presumptive HBV reactivation - Increase of ALT (3x baseline value or absolute value of 100 U/L) and positive conversion of HBs Ag in previously HBsAg-negative patients,ct_inc_493723,AACT,49,NCT01311232,Historical,rituximab-CHOP
5c7430a08625dd0700867f8e,200,,,77,Patient,14:56.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_462885,Clinical Trial Inclusion Criteria,UNKNOWN,Whatever the IPI score and the performance status - Treated by Rituximab-CHOP or Rituximab-mini-CHOP - CT scan imaging performed one month or less before inclusion - Signed informed consent,ct_inc_462885,AACT,63,NCT01715961,Recent,Rituximab-CHOP
5c7430608625dd0452867f8e,40,,,80,Patient,13:52.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_493723,Clinical Trial Inclusion Criteria,UNKNOWN,Patients who had received at least two cycles of rituximab-CHOP or rituximab-CVP as a primary treatment Patients with a history of previous exposure to HBV - HBV surface antigen (HBs Ag) positive Or - HBV core antibody (IgG anti-HBc antibody) positive Patients with documented HBV reactivation (definite or presumptive) occurring during treatment (at least two cycles of R-CHOP or R-CVP) or within 12 months after the last dose of rituximab - Definitive HBV reactivation - Elevation of serum HBV DNA level >1 log IU/mL from baseline or absolute increase of HBV DNA by 6 log10 IU/mL in HBsAg positive patients - Presumptive HBV reactivation - Increase of ALT (3x baseline value or absolute value of 100 U/L) and positive conversion of HBs Ag in previously HBsAg-negative patients,ct_inc_493723,AACT,67,NCT01311232,Historical,rituximab-CVP
5c7430548625dd03ad867f94,590,,,82,Patient,13:40.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_335782,Clinical Trial Inclusion Criteria,UNKNOWN,"Subject has MF with evidence of persistent disease despite ruxolitinib monotherapy treatment, consisting of: Persistent or worsening disease-related symptoms, including but not limited to fatigue, pruritus, night sweats, early satiety, and other symptoms as determined by a MPN-SAF TSS score of >20 points; AND Documented splenomegaly of at least 5 cm below the costal margin as measured on inspiration by physical exam.",ct_inc_335782,AACT,59,NCT03373877,Recent,ruxolitinib monotherapy
5c7430868625dd05cc867f8c,1280,,,229,Patient,14:30.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_396347,Clinical Trial Exclusion Criteria,UNKNOWN,"Patients should be monitored for supratherapeutic toxic levels of sirolimus and PLX3397.As bone marrow suppression including anemia, neutropenia, and thrombocytopenia have been reported in patients receiving sirolimus monotherapy, these adverse effects may be exacerbated in combination with PLX3397 for which patients will be closely monitored.-",ct_exc_396347,AACT,208,NCT02584647,Recent,sirolimus monotherapy
5c74306a8625dd04b5867f8f,860,,,289,Patient,14:02.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_541064,Clinical Trial Inclusion Criteria,UNKNOWN,"Provide written informed consent prior to performance of any study procedures - Is at least 18 years of age - Have a diagnosis of advanced unresectable histologically confirmed HCC (excluding fibrolamellar carcinoma) - Have discontinued from first line treatment with sorafenib monotherapy for any reason (ie, tumor disease progression, intolerance) at least 14 days prior to planned randomization but have not received any second line treatment for HCC - Have recovered from any significant sorafenib-related treatment toxicities prior to randomization (Grade 1) -",ct_inc_541064,AACT,268,NCT00687596,Historical,sorafenib monotherapy
5c7430858625dd05f1867f8d,1000,,,90,Patient,14:30.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_321252,Clinical Trial Inclusion Criteria,UNKNOWN,Phase 2 single-arm component only - Must have progressed on or after sorafenib monotherapy in the randomized phase 2 portion of the study OR progressed or experienced unacceptable toxicity on sorafenib prior to enrollment on the study.,ct_inc_321252,AACT,69,NCT03563170,Historical,sorafenib monotherapy
5c7430af8625dd079a867f90,380,,,269,Patient,15:11.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_475839,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically diagnosed HCC, OR clinically diagnosed HCC - Documented progression with or intolerance to first-line molecular targeted therapy as first-line therapy for advanced HCC.- Acceptable first-line molecular targeted therapies include (1) sorafenib monotherapy and sorafenib-based combination; (2) anti-angiogenic therapy including brivanib, linifanib, pazopanib, bevacizumab, dovitinib (TKI258), and vargatef (BIBF1120).-",ct_inc_475839,AACT,248,NCT01545804,Recent,sorafenib monotherapy
5c7430af8625dd079a867f91,380,,,57,Patient,15:11.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_475839,Clinical Trial Inclusion Criteria,UNKNOWN,"For patients who receive first-line sorafenib monotherapy or sorafenib-based combination, patients must have received at least 14 days of sorafenib treatment with the lowest dosage of 400 mg per day.-",ct_inc_475839,AACT,36,NCT01545804,Recent,sorafenib monotherapy
5c7430bb8625dd0813867f98,370,,,121,Patient,15:23.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_397881,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Patient who agrees voluntarily - Patient with a diagnosis of HCC is receiving Sorafenib monotherapy.- Child-,ct_inc_397881,AACT,100,NCT02564666,Recent,Sorafenib monotherapy
5c74304d8625dd0381867f9d,230,,,311,Patient,13:33.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_478897,Clinical Trial Inclusion Criteria,UNKNOWN,#NAME?,ct_inc_478897,AACT,301,NCT01505712,Recent,Stanford V
5c74304d8625dd0381867fa0,230,,,101,Patient,13:33.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_559601,Clinical Trial Inclusion Criteria,UNKNOWN,"18 years - Received and failed potentially curative chemotherapeutic regimens (e.g., ABVD, Stanford V, or BEACOPP) - Relapsed following autologous bone marrow transplantation (BMT), or are ineligible, or refused BMT - Completed radiotherapy, chemotherapy, and/or treatment with other investigational agents at least 3 weeks prior to study entry - Completed autologous BMT (if received) at least 3 months prior to study entry; completed allogeneic BMT (if received); at least 6 months prior to study entry - Eastern Cooperative Oncology Group (ECOG) status of <2 - Life expectancy of >3 months -",ct_inc_559601,AACT,91,NCT00441818,Historical,Stanford V
5c74306c8625dd04cb867f96,260,,,129,Patient,14:04.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_504535,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients must have failed (relapsed or refractory) front-line standard anthracycline-containing regimen, such as ABVD, Stanford V, or BEACOPP.",ct_inc_504535,AACT,119,NCT01169636,Recent,Stanford V
5c74306c8625dd04cb867f99,260,,,109,Patient,14:04.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_519899,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients must have received a front-line standard anthracycline- containing regimen, such as ABVD, Stanford V, or BEACOPP.",ct_inc_519899,AACT,99,NCT00967369,Recent,Stanford V
5c7430ba8625dd083f867f84,240,,,253,Patient,15:22.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_559790,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically confirmed relapsed or refractory classical Hodgkin lymphoma (nodular sclerosis, mixed cellularity, or lymphocyte-rich classical HL).- Patients must have failed front-line standard anthracycline-containing regimen, such as ABVD, Stanford V, or BEACOPP.-",ct_inc_559790,AACT,243,NCT00439361,Recent,Stanford V
5c7430358625dd02bd867f84,1140,,,243,Patient,13:09.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_535931,Clinical Trial Inclusion Criteria,UNKNOWN,"Group A - Stage I, II, or III invasive disease - Hormone receptor-positive disease - Planned adjuvant chemotherapy including an anthracycline and taxane using either dose-dense or docetaxel, doxorubicin hydrochloride, and cyclophosphamide (TAC) regimens with or without trastuzumab (Herceptin) for 4 months; docetaxel and cyclophosphamide (TC) with or without trastuzumab for 3 months; doxorubicin hydrochloride and cyclophosphamide (AC) for 3 months; or doxorubicin hydrochloride, carboplatin, and trastuzumab (TCH) for 4 months (trastuzumab may be given for 1 year and is not considered chemotherapy for the purpose of this study) -",ct_inc_535931,AACT,240,NCT00755313,Recent,TAC
5c7430368625dd02bd867f85,1140,,,42,Patient,13:10.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_535050,Clinical Trial Exclusion Criteria,UNKNOWN,"Treatment with corticosteroids, CsA or Tac.",ct_exc_535050,AACT,39,NCT00766909,Recent,Tac
5c74303a8625dd02f2867f84,1290,,,503,Patient,13:14.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_525309,Clinical Trial Exclusion Criteria,SCREENING_TESTS,- Recipients of adult or pediatric en bloc kidney transplants.- Recipients who required or will require desensitization protocols.- Known history of focal segmental glomerulosclerosis (FSGS) or membranoproliferative glomerulonephritis (MPGN).- Evidence of,ct_exc_525309,AACT,500,NCT00895583,Historical,TAC
5c74303b8625dd02f2867f85,1290,,,372,Patient,13:15.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_541488,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients who have post-operative margins which are negative but less than 2mm will be considered eligible if the surgeon states that the margin in question could not be improved.- Patient must have a Medical Oncology consult and be recommended to receive one of the following regimens: Cyclophosphamide and Doxorubicin (AC); Taxotere, Doxorubicin and Cyclophosphamide (TAC); Taxotere and Cyclophosphamide (TC) or Taxotere, Carboplatin and Trastuzumab (TCH) prior to registration.",ct_inc_541488,AACT,369,NCT00681993,Recent,TAC
5c74303c8625dd02e7867f8d,580,,,13,Patient,13:16.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_327738,Clinical Trial Exclusion Criteria,UNKNOWN,"(Ac / Fa, Tac / Fa, TV, FV).",ct_exc_327738,AACT,10,NCT03478709,Recent,Tac
5c74303c8625dd02e7867f8e,580,,,71,Patient,13:16.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_464220,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Renal transplant recipients that will receive Tac as part of their immunosuppressive therapy.- Recipients,ct_inc_464220,AACT,68,NCT01698541,Recent,Tac
5c74303c8625dd0308867f84,680,,,3,Patient,13:16.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_439734,Clinical Trial Inclusion Criteria,LABORATORY_AND_RADIOLOGY_DATA,"TAC, PET, fMRI, Mammography, Endoscopy and Colonoscopy.- an anxiety level greater than 5 (in a scale from 0=very calm to 10=very anxious; using a self-reporting instrument created ad hoc) - signed informed consent",ct_inc_439734,AACT,0,NCT02018471,Recent,TAC
5c74303d8625dd0308867f85,680,,,174,Patient,13:17.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_572764,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Evidence of active systemic or localized major infection.- Known hypersensitivity to SRL or its derivatives, macrolide antibiotics, corticosteroids, TAC or MMF.- Multiple organ transplants (i.e., prior or concurrent transplantation of any organs other than renal transplant).Other exclusions apply.",ct_exc_572764,AACT,171,NCT00266123,Historical,TAC
5c7430418625dd0329867f87,1210,,,202,Patient,13:21.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_426698,Clinical Trial Exclusion Criteria,FOLLOW_UP, Conversion Criteria C2 (assessed prior to conversion to EVR based IS regimen; EVR cannot be initiated prior to 30 days after liver transplantation).Subjects with any of the following will remain on TAC-based IS regimen.- Evidence of hepatic artery stenosis or thrombosis by Doppler examination or angiography within 7 days prior to conversion - Urine protein/creatinine ratio >1.0 within 7 days prior to conversion - Calculated GFR less than 30 ml/min per MDRD4,ct_exc_426698,AACT,199,NCT02188719,Historical,TAC
5c7430418625dd0329867f88,1210,,,672,Patient,13:21.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_426698,Clinical Trial Exclusion Criteria,FOLLOW_UP,"Subjects in Cohort 2, 3, or 4 who meet any of these criteria should not receive a darTreg-infusion: - Inability or unwillingness of participant to give additional written informed consent - Unacceptable darTreg product - Detectible circulating Epstein-Barr Virus (EBV) or cytomegalovirus (CMV) DNA within 10 days prior to darTreg infusion - Detectible Hepatitis B Virus (HBV) DNA within 10 days prior to darTreg infusion - Detectable circulating HCV RNA within 10 days prior to darTreg infusion.- Alanine Aminotransferase (ALT) >1.5x upper limit of normal within 10 days of darTreg infusion - Most recent, but not greater than 10 days prior to darTreg infusion,12 hour TAC trough levels of > 8 g/L for all subjects - Most recent, but not greater than 10 days prior to darTreg infusion,12 hour EVR trough levels of < 5 g/L for subjects on EVR - For subjects on EVR-based IS, received Mycophenolate Mofetil (MMF) within 10 days prior to darTreg infusion - Evidence of acute rejection or chronic rejection according to Banff criteria on protocol allograft biopsy based on local assessment - Received any vaccination within 14 days prior to darTreg infusion - Positive pregnancy test for females of child bearing potential - Inability or unwillingness of participant to comply with study protocol or procedures.- Calculated glomerular filtration rate (eGFR) less than 40 ml/min per MDRD4 equation within 10 days prior to infusion.",ct_exc_426698,AACT,669,NCT02188719,Historical,TAC
5c7430428625dd0310867f8a,970,,,1836,Patient,13:22.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_541064,Clinical Trial Exclusion Criteria,UNKNOWN," participating in surveys or observational studies are eligible to participate in this study - Have had treatment with any of the following within the specified timeframe prior to randomization: - Any sorafenib within the 14 days prior to randomization - Major surgery within the 4 weeks prior to randomization - Any transfusion, treatment with blood component preparation, received erythropoietin , albumin preparation, and granulocyte colony-stimulating factor (G CSF) within the 2 weeks prior to randomization - Has a serious illness or medical condition(s) including, but not limited to the following: - Known gastrointestinal disorder, including malabsorption, chronic nausea, vomiting, or diarrhea present to the extent that it might interfere with oral intake and absorption of the study medication - Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness - Previous or concurrent malignancy except for basal cell carcinoma and/or in situ carcinoma of the cervix, or other solid tumor treated curatively and without evidence of recurrence for at least 3 years prior to the study - Uncontrolled metabolic disorders or other nonmalignant organ or systemic diseases or secondary effects of cancer that induce a high medical risk and/or make assessment of survival uncertain - Has active or uncontrolled clinically serious infection excluding chronic hepatitis - Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the Investigator would make the patient inappropriate for entry into this study (eg, active urinary tract infection) - Known allergy or hypersensitivity of TAC 101 and any other components used in the TAC 101 tablet.",ct_exc_541064,AACT,1833,NCT00687596,Historical,TAC
5c7430458625dd033f867f94,310,,,3,Patient,13:25.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_552478,Clinical Trial Inclusion Criteria,UNKNOWN,"TAC (docetaxel, adriamycin, cyclophosphamide) -",ct_inc_552478,AACT,0,NCT00536081,Recent,TAC
5c7430488625dd0360867f89,780,,,117,Patient,13:28.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_341873,Clinical Trial Inclusion Criteria,UNKNOWN,"In the opinion of their treating oncology investigator, are candidates for at least 4 cycles of chemotherapy with TAC (docetaxel, doxorubicin, & cyclophosphamide).",ct_inc_341873,AACT,114,NCT03294577,Recent,TAC
5c7430488625dd0360867f8a,780,,,59,Patient,13:28.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_341873,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients who are candidates for adjuvant or neoadjuvant TAC will meet all of the following criteria: - Biopsy-proven, early stage (Stage I and II) and Stage III breast cancer, and - Have had no prior chemotherapy.",ct_inc_341873,AACT,56,NCT03294577,Historical,TAC
5c7430488625dd0360867f8b,780,,,197,Patient,13:28.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_592175,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically confirmed adult T-cell leukemia/lymphoma (ATL) or cutaneous T-cell lymphoma (CTCL).Reactivity of at least 10% of peripheral blood, lymph node, or dermal malignant cells with anti-Tac as determined by immunofluorescent staining or soluble IL-2 receptor level greater than 1,500 U required.",ct_inc_592175,AACT,194,NCT00001249,Recent,Tac
5c7430488625dd0360867f8c,780,,,17,Patient,13:28.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_592175,Clinical Trial Inclusion Criteria,UNKNOWN,All stages of Tac-expressing T-cell leukemia and lymphoma eligible except Stage,ct_inc_592175,AACT,14,NCT00001249,Recent,Tac
5c74304b8625dd038c867f88,640,,,136,Patient,13:31.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_555104,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: Received chemotherapy within last 3 month prior to screening, or expected to receive any chemotherapy other than TAC and / or immunotherapy between screening and 30 days after last planned study drug administration Any clinically significant findings on history or examination that, in the opinion of the investigator, would preclude administration of TAC chemotherapy in the full dose, including abnormal liver function, inadequate cardiac function or clinically significant cardiac disease, neuropathy or other disease Prior bone marrow or peripheral blood hematopoietic stem cell transplant",ct_exc_555104,AACT,133,NCT00501332,Historical,TAC
5c7430538625dd03c3867f84,920,,,294,Patient,13:39.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_314027,Clinical Trial Inclusion Criteria,UNKNOWN,"Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) eligible (meeting institutional criteria)-participants planned medical care should include acute graft-versus-host disease (aGvHD) prophylaxis with a combination of calcineurin inhibitor (CNI) (cyclosporine [CYS] or tacrolimus [TAC]) and methotrexate (MTX) or CNI and mycophenolate mofetil (MMF).With the exception of antithymocyte globulin (ATG) (antithymocyte globulin-Fresenius [ATG-F] or thymoglobulin), all other therapies, approved or investigational, for graft-versus-host disease (GvHD) prophylaxis are excluded.",ct_inc_314027,AACT,291,NCT03657160,Recent,TAC
5c7430538625dd03c3867f85,920,,,16,Patient,13:39.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_596119,Clinical Trial Exclusion Criteria,UNKNOWN,"Furthermore, Tac-expressing T cells may be present in the cerebrospinal fluid (CSF) as long as the patient does not have symptomatic central nervous system (CNS)",ct_exc_596119,AACT,13,NCT00001941,Recent,Tac
5c7430538625dd03c3867f86,920,,,334,Patient,13:39.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_484564,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria: - Patients unwilling.- Patient participating in another study.- Patients with cardiogenic shock - Patient on anti GpIIbIIIa or stopped less than 72 hours before the test aggregability - Patients scheduled for surgery in less than 6 months.- Patients candidates for coronary angioplasty - Patients who underwent TAC + / - bare stent fewer than 30 days.- Patients who underwent stenting with ATC active there is less than 12 months.- ischemic stroke older than 6 weeks.- History of hemorrhagic stroke (any time),ct_exc_484564,AACT,331,NCT01431495,Historical,TAC
5c7430538625dd03c3867f87,920,,,111,Patient,13:39.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_504314,Clinical Trial Inclusion Criteria,UNKNOWN,"This can be assessed before inclusion (for example, a test trial with similar size solid tablet such as tic-tac).- Participants in the weight band between 10 and 16.9 kg that are unable to swallow tablets will receive liquid formulation - Parent or legal guardian able and willing to provide written informed consent",ct_inc_504314,AACT,108,NCT01172535,Recent,tac
5c7430538625dd03c3867f88,920,,,105,Patient,13:39.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_532069,Clinical Trial Inclusion Criteria,UNKNOWN,Patients must either receive 4 cycles of anthracycline for a total dose of 240 mg/m2 or six cycles of TAC for a total dose of 300 mg/m2 or trastuzumab.,ct_inc_532069,AACT,102,NCT00806390,Recent,TAC
5c7430538625dd03c3867f89,920,,,31,Patient,13:39.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_572761,Clinical Trial Inclusion Criteria,DIAGNOSES,"PAPVD, ASD, SVD, VSD, AVSD, TAC, APW, PDA, or a combination of these.- Surgically corrected shunting defect (diagnoses as above) with significant residual defect - Other diagnoses with univentricular physiology/haemodynamics.",ct_inc_572761,AACT,28,NCT00266162,Recent,TAC
5c7430538625dd03c3867f8a,920,,,69,Patient,13:39.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_555036,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Receiving cyclosporine (CsA) or tacrolimus (TAC) since the first month post-transplant.-,ct_inc_555036,AACT,66,NCT00502242,Recent,TAC
5c7430548625dd03c7867fb2,0,,,76,Patient,13:40.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_567491,Clinical Trial Inclusion Criteria,UNKNOWN,Adenocarcinoma of the breast planned to receive a minimum of 2 cycles of TAC.,ct_inc_567491,AACT,73,NCT00336609,Recent,TAC
5c7430568625dd03fb867f84,620,,,100,Patient,13:42.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_463406,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria: - Rejection or infections within 3 months of enrollment.- Intent to continue TAC - Active participation in ongoing studies of immunosuppressive agents.- Lack of informed consent.- Pregnant or breast feeding - HIV,ct_exc_463406,AACT,97,NCT01709136,Recent,TAC
5c7430568625dd03fb867f85,620,,,189,Patient,13:42.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_498648,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Female patients with breast cancer, 18 years old at the time of breast cancer diagnosis - (Neo)adjuvant treatment with docetaxel, doxorubicin and cyclophosphamide (TAC) completed one year before inclusion",ct_inc_498648,AACT,186,NCT01246856,Recent,TAC
5c7430568625dd03fb867f86,620,,,128,Patient,13:42.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_544151,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: Women with diagnosis of breast cancer Undergoing adjuvant/neoadjuvant chemotherapy with either FEC, FAC, TAC, or EC + docetaxel combinations.3.18 years of age Performance status: 0-2 Ability to provide written informed consent",ct_inc_544151,AACT,125,NCT00647075,Recent,TAC
5c7430588625dd03fb867f88,620,,,271,Patient,13:44.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_384652,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients 18 years of age with a hematologic malignancy other than aplastic anemia or primary myelofibrosis, scheduled to undergo RIC allogeneic SCT with a peripheral blood stem cell graft, using Fludarabine/Busulfan (Flu/Bu) conditioning and Tacrolimus/ Methotrexate (Tac/MTX)",ct_inc_384652,AACT,268,NCT02737306,Recent,Tac
5c7430588625dd03fb867f8a,620,,,271,Patient,13:44.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_384652,Clinical Trial Inclusion Criteria,COMMENT,"Patients 18 years of age with a hematologic malignancy other than aplastic anemia or primary myelofibrosis, scheduled to undergo RIC allogeneic SCT with a peripheral blood stem cell graft, using Fludarabine/Busulfan (Flu/Bu) conditioning and Tacrolimus/ Methotrexate (Tac/MTX)",ct_inc_384652,AACT,268,NCT02737306,Recent,Tac
5c7430588625dd03fb867f8b,620,,,54,Patient,13:44.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_591787,Clinical Trial Inclusion Criteria,UNKNOWN,At least 30% of malignant cells reactive with anti-Tac as determined by immunofluorescence studies - All Hodgkin's lymphoma patients eligible due to 100% Tac-positivity of Reed-Sternberg cells - Measurable disease - No symptomatic CNS disease,ct_inc_591787,AACT,51,NCT00002681,Recent,Tac
5c7430588625dd03fb867f8c,620,,,24,Patient,13:44.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_591787,Clinical Trial Inclusion Criteria,PULMONARY_REVIEW,No prior murine anti-Tac monoclonal antibody,ct_inc_591787,AACT,21,NCT00002681,Historical,Tac
5c74305f8625dd0473867f84,570,,,38,Patient,13:51.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_501937,Clinical Trial Exclusion Criteria,UNKNOWN,Previous intolerance to either MMF/Tac; Scr >200umol/L; Informed consent unavailable.,ct_exc_501937,AACT,35,NCT01203709,Recent,Tac
5c7430648625dd04aa867f84,530,,,69,Patient,13:56.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_522475,Clinical Trial Exclusion Criteria,UNKNOWN,Exclusion Criteria: - Hole in Tympanic Membrane.- Allergy to Blue tac,ct_exc_522475,AACT,66,NCT00933478,Recent,tac
5c7430648625dd047e867f8f,910,,,76,Patient,13:56.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_367446,Clinical Trial Inclusion Criteria,UNKNOWN,post-transplant evolution.- Patients receiving Prograf stable and stable TAC trough concentrations between 5-10ng / ml non-interrupted oral dose for at least 10 days (steady state conditions).- receiving concomitant immunosuppressive medication allowed: sodium or mycophenolate mofetil and corticosteroids.- Subjects must be willing to give their written informed consent to testing and be able to do consent.,ct_inc_367446,AACT,73,NCT02961608,Recent,TAC
5c7430648625dd047e867f90,910,,,230,Patient,13:56.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_388654,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - The patients who underwent surgery for pathologically diagnosed early breast cancer (high risk stage II or stage III) or completely resected stage IV, and anticipated to undergo adjuvant chemotherapy with TAC regimen (docetaxel, doxorubicin, and cyclophosphamide) -",ct_inc_388654,AACT,227,NCT02685111,Recent,TAC
5c7430668625dd048d867f8f,1200,,,608,Patient,13:58.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_391326,Clinical Trial Inclusion Criteria,SCREENING_TESTS,"Is informed, has been given ample time and opportunity to read about participation in the study and has signed and dated the written informed consent form approved by an Independent Ethics committee (IEC) prior to any study related activities Females 18 years Histologically confirmed and documented invasive breast cancer Breast cancer without evidence of distant metastases (Stage 4) based on staging work-up Chemotherapy naive, who have not received chemotherapy in the neoadjuvant setting and who are candidates for chemotherapy in the adjuvant setting of taxane/cyclophosphamide-based regimen, e.g., TAC, as background chemotherapy Zubrod/WHO/ECOG performance status 2 Adequate bone marrow, hepatic, and renal function reserve as evidenced by: Hemoglobin 10 mg/dl 2.",ct_inc_391326,AACT,605,NCT02650193,Historical,TAC
5c7430668625dd048d867f90,1200,,,278,Patient,13:58.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_391326,Clinical Trial Exclusion Criteria,SCREENING_TESTS,"For subjects receiving doxorubicin, no concurrent use of inhibitors and inducers of CYP3A4, CYP2D6, and/or P-gp or with trastuzumab due to increased risk of cardiac dysfunction Chemotherapy other than that included in this study (taxane/cyclophosphamide-based regimen, e.g., TAC or TC) or neoadjuvant chemotherapy; or known immunosuppressive agents including chronic oral corticosteroid use, or radiation therapy within 4 weeks of first dose of HSP-130, prior bone marrow or stem cell transplantation, or malignancy within 5 years Known HER2 + ( overexpressing breast cancer)",ct_exc_391326,AACT,275,NCT02650193,Historical,TAC
5c7430668625dd048d867f91,1200,,,537,Patient,13:58.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_588110,Clinical Trial Inclusion Criteria,UNKNOWN,"Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception, except oral contraceptives containing estrogen - Fasting triglycerides 400 mg/dL for men or 325 mg/dL for women - No other malignancy within the past 3 years except inactive nonmelanoma skin cancer or carcinoma in situ of the cervix - No uncontrolled metabolic disorders, other nonmalignant organ or systemic disease, or secondary effects of cancer that induce a high medical risk - No known allergy or hypersensitivity to TAC-101 or its components",ct_inc_588110,AACT,534,NCT00077142,Recent,TAC
5c7430678625dd048d867f92,1200,,,86,Patient,13:59.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_494349,Clinical Trial Exclusion Criteria,UNKNOWN,In case of clinical suspicious of brain metastasis is mandatory to perform a brain TAC/MR 4 weeks prior de inclusion.,ct_exc_494349,AACT,83,NCT01303029,Historical,TAC
5c7430698625dd04b5867f8b,860,,,17,Patient,14:01.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_589650,Clinical Trial Inclusion Criteria,UNKNOWN,"All stages of Tac-expressing adult T-cell leukemia except smoldering are eligible: patients with chronic, lymphoma or acute Acute T-cell leukemia/lymphoma (ATL) are eligible.- Patients must have measurable disease.",ct_inc_589650,AACT,14,NCT00061048,Recent,Tac
5c7430698625dd04b5867f8c,860,,,3,Patient,14:01.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_589650,Clinical Trial Inclusion Criteria,UNKNOWN,Tac homogeneous strongly expressing) peripheral blood mononuclear cell (PBMC)in the peripheral blood will be deemed to have measurable disease.-,ct_inc_589650,AACT,0,NCT00061048,Recent,Tac
5c74306a8625dd04b5867f8d,860,,,24,Patient,14:02.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_583886,Clinical Trial Inclusion Criteria,UNKNOWN,"(CD25).All stages of Tac-expressing adult T cell leukemia except smoldering are eligible: patients with chronic, lymphomatous or acute adult T-cell leukemia (ATL) are eligible.(See appendix 2 for characteristics of patients with the various stages of ATL)",ct_inc_583886,AACT,21,NCT00117845,Recent,Tac
5c74306a8625dd04b5867f8e,860,,,3,Patient,14:02.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_583886,Clinical Trial Inclusion Criteria,UNKNOWN,TAC homogenous strongly expressing) peripheral blood mononuclear cells (PBMC) in the peripheral blood will be deemed to have measurable disease.,ct_inc_583886,AACT,0,NCT00117845,Recent,TAC
5c74306b8625dd04e1867f87,500,,,149,Patient,14:03.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_555104,Clinical Trial Inclusion Criteria,UNKNOWN,"Key Inclusion Criteria: Males and females at least 18 years of age Diagnosis of high-risk stage I, II or IIIa breast cancer suitable for adjuvant TAC chemotherapy as based on investigator judgment Candidates for TAC chemotherapy, and no prior treatment with anthracyclines",ct_inc_555104,AACT,146,NCT00501332,Historical,TAC
5c74306b8625dd04e1867f88,500,,,57,Patient,14:03.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_332959,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - Post-renal transplant on stable TAC IR for at least 6 months who are converting to TAC XR regardless of indication.- Patients receiving their post-transplant care through the Yale-New Haven Transplantation Center (YNHTC) regardless of where they were originally transplanted.,ct_inc_332959,AACT,54,NCT03410654,Recent,TAC
5c74306d8625dd04f7867f85,550,,,111,Patient,14:05.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_473875,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - primary invasive breast carcinoma with lymph node positive with curative surgery with TAC chemotherapy,ct_inc_473875,AACT,108,NCT01571518,Recent,TAC
5c74306f8625dd04ec867f89,1130,,,667,Patient,14:07.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_405297,Clinical Trial Exclusion Criteria,UNKNOWN,"randomization.- Previous exposure to filgrastim, pegfilgrastim, lenograstim, lipegfilgrastim, or other filgrastim forms on the market or in clinical development.- Received blood transfusions or erythroid growth factors within 2 weeks prior to first dose of chemotherapy.- Known hypersensitivity to any drugs or excipients that patients will be receiving during the study.- Known hypersensitivity to E. coli-derived products.- Known fructose intolerance (related with sorbitol excipient).- Underlying neuropathy of grade 2 or higher.- Active infectious disease or any other medical condition which might put the patient at significant risk to tolerate 6 courses of TAC chemotherapy (e.g., recent myocardial infarction).- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 Upper limit of normal (ULN), ALT and/or AST >",ct_exc_405297,AACT,664,NCT02467868,Historical,TAC
5c74306f8625dd0523867f84,830,,,27,Patient,14:07.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_338144,Clinical Trial Inclusion Criteria,UNKNOWN,"Be scheduled to receive TAC regimen as adjuvant therapy Subjects who meet the conditions at screening test as follows; - Absolute Neutrophil Count (ANC) 1,500/mm3 - Platelet Count 100,000/mm3 - ECOG Performance Status : 0 2 Adequate renal function (Creatinine 1.5",ct_inc_338144,AACT,24,NCT03343145,Recent,TAC
5c74306f8625dd0523867f85,830,,,67,Patient,14:07.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_516180,Clinical Trial Exclusion Criteria,UNKNOWN,"Pregnant females Active, uncontrolled hemorrhage at the time of TAC placement Diagnosis of pre-existing bleeding disorder Known allergy or hypersensitivity to polyvinyl, polyurethane, acrylic, or acrylic adhesive Subjects with fistulas Subjects who have been enrolled in this study previously Documented history of Child-Pugh Turcot Liver Dysfunction - Class C (10-15 points) at the time of enrollment Subjects with body mass index (BMI)",ct_exc_516180,AACT,64,NCT01016353,Historical,TAC
5c7430708625dd04ec867f8a,1130,,,428,Patient,14:08.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_406924,Clinical Trial Inclusion Criteria,UNKNOWN,"0-2 - Negative pregnancy test or reproduction potential is zero, determined either by surgery, radiation or menopause, or mitigated with the use of some approved contraceptive method (IUD or hormonal contraceptive during the study and at least 3 months after the study).- Patients with histological diagnosis of persistent/recurrent cervical cancer, local and/or systemic, with disease measurable by physical examination and TAC.REQUIRED confirmation by biopsy of the recurrence or, persistence only if: lesion is single, less than 2 cm and/or has no sharp edges.- Chemo-radiotherapy to pelvis or pelvis plus extended fields (may have received concomitant chemotherapy as a radiosensitizer) provided it is within 90 days from the last application and the secondary radiation acute effects have disappeared.- Hemoglobin equal or greater than 9 g/L.(allowed transfusion prior to treatment to reach this hemoglobin level).- Leukocytes greater or equal to 4000/mm3.- Platelets equal or greater",ct_inc_406924,AACT,425,NCT02446652,Historical,TAC
5c7430708625dd04ec867f8b,1130,,,51,Patient,14:08.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_596139,Clinical Trial Exclusion Criteria,UNKNOWN,Patients who are HIV+ since the effects of anti-Tac are not defined in these patients.,ct_exc_596139,AACT,48,NCT00001934,Recent,Tac
5c7430708625dd0523867f86,830,,,20,Patient,14:08.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_508740,Clinical Trial Inclusion Criteria,UNKNOWN,Patients on CNI (TAC or CsA) + Myfortic + steroids.- Serum creatinine < 2.8 mg/dL (250 mol/L) and an actual eGFR (MDRD4),ct_inc_508740,AACT,17,NCT01114529,Recent,TAC
5c7430708625dd04ec867f8c,1130,,,86,Patient,14:08.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_526994,Clinical Trial Exclusion Criteria,UNKNOWN,In case of clinical suspicious of brain metastasis is mandatory to perform a brain TAC/MR 4 weeks prior inclusion.,ct_exc_526994,AACT,83,NCT00873353,Historical,TAC
5c7430708625dd0523867f87,830,,,617,Patient,14:08.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_472549,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Non-epithelial ovarian cancer or borderline ovarian tumor - Pregnancy or breastfeeding - Patients affected by major depressive disorder even in treatment or minor mood disorders - Patients with severe impairment of respiratory, hepatic or renal function - Patients with cardiac, neurological or metabolic uncontrolled pharmacologically disease - Patients with active infection or other neoplastic disease in progress - Patients with bowel obstruction - Inadequate bone marrow, liver, kidney function - No clear-peritoneal disease at surgical exploration - Patients with ascites > 500 ml (the TAC) - Patients on maintenance therapy with Antiangiogenic drugs - Patients with secondary or tertiary recurrence, or already submitted to HIPEC - Patients who have already made the second or third line chemotherapy.",ct_exc_472549,AACT,614,NCT01588964,Recent,TAC
5c7430708625dd0523867f88,830,,,248,Patient,14:08.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_470059,Clinical Trial Inclusion Criteria,UNKNOWN,Subject is at least 18 - Subject is able and willing to sign the Informed Consent Form prior to screening evaluations - Female subject diagnosed with breast carcinoma and will receive docetaxel treatment according to standard hospital protocol (TAC regimen) or male subject diagnosed with metastatic castration-resistant prostate carcinoma and will receive docetaxel treatment according to standard hospital protocol (PRODOC regimen) -,ct_inc_470059,AACT,245,NCT01621425,Historical,TAC
5c7430708625dd04ec867f8d,1130,,,3,Patient,14:08.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_501196,Clinical Trial Inclusion Criteria,UNKNOWN,"TAC, Prograf or Advagraf], corticosteroids and either MMF (CellCept), EC-MPS (Myfortic), AZA (Imuran) or SRL (Rapamune) at the baseline visit.",ct_inc_501196,AACT,0,NCT01213394,Recent,TAC
5c7430708625dd0523867f89,830,,,75,Patient,14:08.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_494255,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Female breast cancer patients, receiving adjuvant TAC-chemotherapy - Age 18 years old - WHO performance status 0",ct_inc_494255,AACT,72,NCT01304251,Recent,TAC
5c7430708625dd0523867f8a,830,,,617,Patient,14:08.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_476299,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Non-epithelial ovarian cancer or borderline ovarian tumor - Pregnancy or breastfeeding - Patients affected by major depressive disorder even in treatment or minor mood disorders - Patients with severe impairment of respiratory, hepatic or renal function - Patients with cardiac, neurological or metabolic uncontrolled pharmacologically disease - Patients with active infection or other neoplastic disease in progress - Patients with bowel obstruction - Inadequate bone marrow, liver, kidney function - No clear-peritoneal disease at surgical exploration - Patients with ascites > 500 ml (the TAC) - Patients on maintenance therapy with Antiangiogenic drugs - Patients with secondary or tertiary recurrence, or already submitted to HIPEC - Patients who have already made the second or third line chemotherapy.",ct_exc_476299,AACT,614,NCT01539785,Recent,TAC
5c7430708625dd0523867f8b,830,,,52,Patient,14:08.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_475940,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion criteria at randomization: Patients on TAC + MMF + steroids.,ct_inc_475940,AACT,49,NCT01544491,Recent,TAC
5c7430758625dd0569867f85,1050,,,55,Patient,14:13.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_416912,Clinical Trial Inclusion Criteria,UNKNOWN,At least a measurable lung lesion with conventional TAC (i.e.1cm) in at least one dimension its RECIST criteria (v.1.1) which has not been irradiated.,ct_inc_416912,AACT,52,NCT02316327,Recent,TAC
5c7430758625dd0569867f86,1050,,,4,Patient,14:13.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_405297,Clinical Trial Inclusion Criteria,UNKNOWN,[TAC]),ct_inc_405297,AACT,1,NCT02467868,Recent,TAC
5c7430758625dd0569867f87,1050,,,140,Patient,14:13.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_425371,Clinical Trial Exclusion Criteria,UNKNOWN,"Patients will need to fulfill the same inclusion criteria for the clinical trial according to Section 2.4.1, plus the following: Receive Tac/MTX as the sole GVHD prophylaxis approach Receive the same regimens as specified in Table 2.5 Year of transplant from 2010 to 2013 Exclusion criteria for the controls: Karnofsky Performance Score < 70% Data for all eligible patients will be used to constitute the control database for this study",ct_exc_425371,AACT,137,NCT02206035,Recent,Tac
5c7430758625dd0569867f88,1050,,,241,Patient,14:13.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_457098,Clinical Trial Inclusion Criteria,UNKNOWN,Adolescent Recipients of a renal allograft from a living donor or a deceased donor at least 6 months prior to enrollment - Subject must be receiving a calcineurin inhibitor (CNI)-based [cyclosporine (CsA) [any formulation] or Tacrolimus (TAC)],ct_inc_457098,AACT,238,NCT01791491,Historical,TAC
5c7430758625dd0569867f89,1050,,,136,Patient,14:13.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_454074,Clinical Trial Exclusion Criteria,UNKNOWN,"Specifically, patients receiving a regimen including both an anthracycline and a taxane are not eligible for this trial (AC/T, EC/T, TAC, etc.)- Concurrent hormone therapy with chemotherapy.",ct_exc_454074,AACT,133,NCT01831024,Recent,TAC
5c7430768625dd0569867f8a,1050,,,86,Patient,14:14.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_446613,Clinical Trial Inclusion Criteria,UNKNOWN,"Cyclophosphamide and Doxorubicin (AC); Taxotere, Doxorubicin and Cyclophosphamide (TAC); Taxotere and Cyclophosphamide (TC); or Taxotere, Carboplatin and Trastuzamab (TCH) prior to registration.",ct_inc_446613,AACT,83,NCT01928589,Historical,TAC
5c7430768625dd0569867f8b,1050,,,346,Patient,14:14.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_468039,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Show evidence of a signed (personally or by a legally acceptable representative) and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the trial.- Females 18 years of age.- Diagnosed with Stage I-IV breast cancer.- Subject is scheduled to undergo 4 cycles of TC or TAC chemotherapy (Taxotere, doxorubicin and cyclophosphamide, 75, 50 and 600 mg/m2, respectively).- ECOG Performance status of 2.- White Blood Cell count (WBC) 4.0 109/L, hemoglobin 11.5 g/dL and a platelet count 150 109/L.- Demonstrate adequate renal, hepatic function (Liver function tests (ALT, AST, alkaline phosphatase and total bilirubin)) should be less than 2.5x upper limits of normal (ULN).Serum creatinine should be",ct_inc_468039,AACT,343,NCT01648322,Recent,TAC
5c7430768625dd0569867f8c,1050,,,52,Patient,14:14.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_580437,Clinical Trial Exclusion Criteria,UNKNOWN,"Patient has a known hypersensitivity to Prograf (TAC), HCO-60, CellCept (MMF), Zenapax or corticosteroids.",ct_exc_580437,AACT,49,NCT00163657,Recent,TAC
5c7430788625dd055a867f88,1320,,,139,Patient,14:16.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_481760,Clinical Trial Inclusion Criteria,UNKNOWN,"At least 10% of the cells obtained from lymph node, or extranodal sites must react with anti-cluster of differentiation 25 (CD25) (anti-Tac) on immunofluorescent or immunoperoxidase staining.",ct_inc_481760,AACT,136,NCT01468311,Recent,Tac
5c7430868625dd060e867f85,470,,,268,Patient,14:30.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_457531,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Patients 18 years of age with a hematologic malignancy other than aplastic anemia or primary myelofibrosis, scheduled to undergo RIC allogeneic SCT with a peripheral blood stem cell graft from an unrelated donor, using Flu/Bu conditioning and Tac/MTX GVHD prophylaxis.",ct_inc_457531,AACT,265,NCT01785810,Recent,Tac
5c7430868625dd05cc867f8d,1280,,,119,Patient,14:30.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_341873,Clinical Trial Exclusion Criteria,UNKNOWN,Significant prior doxorubicin (>240 mg/m2) or anthracycline exposure that would preclude the safe administration of TAC chemotherapy as described in the protocol.,ct_exc_341873,AACT,116,NCT03294577,Historical,TAC
5c74308b8625dd0642867f8d,610,,,103,Patient,14:35.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_554015,Clinical Trial Inclusion Criteria,UNKNOWN,18-75 - breast cancer stages II-III - adjuvant or neoadjuvant chemotherapy with docetaxel regimens (TAC or anthracyclines followed by docetaxel 100 mg/m2 x 4),ct_inc_554015,AACT,100,NCT00515762,Recent,TAC
5c74308b8625dd0642867f8e,610,,,59,Patient,14:35.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_388356,Clinical Trial Inclusion Criteria,UNKNOWN,"- Planned to start either FEC-D, AC-D, dose-dense AC-T, TAC, or TC chemotherapy, in the adjuvant or neoadjuvant setting.- 19 years of age - Able to provide verbal consent",ct_inc_388356,AACT,56,NCT02688998,Recent,TAC
5c74308b8625dd0642867f8f,610,,,131,Patient,14:35.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_516180,Clinical Trial Inclusion Criteria,UNKNOWN,OA Subjects treated with only one of the following TACs at initial placement (defined as the time of the first application of a TAC method): 1. ABThera 2.,ct_inc_516180,AACT,128,NCT01016353,Recent,TAC
5c7430908625dd067c867f86,1110,,,145,Patient,14:40.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_542581,Clinical Trial Exclusion Criteria,PROCEDURES,"Patient had systemic chemotherapy (eg, sorafenib, doxorubicin), immunotherapy, or biologic therapy or radiotherapy for HCC, or treatment with TAC-101.5.",ct_exc_542581,AACT,142,NCT00667628,Recent,TAC
5c7430908625dd067c867f87,1110,,,52,Patient,14:40.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_542581,Clinical Trial Exclusion Criteria,PATIENT_NAME,"Patient has known allergy or hypersensitivity to TAC-101, doxorubicin, epirubicin, other anthracyclines, anthracenediones or any of the components used in the study drug formulations.",ct_exc_542581,AACT,49,NCT00667628,Recent,TAC
5c7430918625dd067c867f88,1110,,,940,Patient,14:41.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_589777,Clinical Trial Inclusion Criteria,UNKNOWN,"stage C - Failed standard therapy and at least 1 salvage chemotherapy - Primary B-cell prolymphocytic leukemia or prolymphocytic transformation of CLL - Failed standard therapy and at least 1 salvage chemotherapy - Hairy cell leukemia - Failed standard and salvage chemotherapy - Ineligible for or refused further salvage chemotherapy or BMT - Acute myelogenous leukemia - Failed standard chemotherapy - Ineligible for or refused salvage chemotherapy or BMT - Stages II-IV Hodgkin's disease - Failed standard chemotherapy - Ineligible for curative salvage radiotherapy or chemotherapy - Ineligible for or refused BMT - Patients with leukemias or lymphomas not easily classified in above categories who have failed standard therapy and are ineligible for or have refused bone marrow transplant - Evidence of interleukin-2 receptor-alpha (IL2Ra) expression by one of the following: - Greater than 10% of malignant cells reactive with anti-Tac by immunohistochemistry - Greater than 10% of malignant cells from a particular site positive by FACS - Greater than 400 IL2Ra sites per malignant cell by radiolabeled anti-Tac binding - Soluble IL2Ra level greater than 1,000 U/mL (normal geometric mean 235, with 95% confidence levels of 112-502 U)",ct_inc_589777,AACT,937,NCT00002765,Recent,Tac
5c74309c8625dd06ea867f85,820,,,161,Patient,14:52.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_367446,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Patients on dialysis or treatment of rejection after transplantation.- Patients treated with substances with potential interaction with TAC, particularly potent inhibitors of CYP3A4 (such as telaprevir, boceprevir, ritonavir, ketoconazole, voriconazole, itraconazole, telithromycin or clarithromycin) or inducers of CYP3A4 (such as rifampin or rifabutin).- Patients participating in another clinical trial or treated with any investigational drug within 30 days prior to inclusion.- Patients with liver disease.- The patient or donor with the current diagnosis or history of malignancy within the past 5 years except carcinoma nonmetastatic basal or squamous cell skin treated successfully.- pregnant or breast-feeding women and all women of childbearing age unless they use reliable contraception.",ct_exc_367446,AACT,158,NCT02961608,Historical,TAC
5c74309c8625dd06ea867f86,820,,,534,Patient,14:52.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_367446,Clinical Trial Exclusion Criteria,UNKNOWN,"The recipients of bone marrow or stem cell transplant.- Recipients of a kidney from a donor ABO incompatible.- Patients with donor specific anti-HLA antibodies.- Recipients of a kidney with anticipated cold ischemia time of 24 hours.- Patients with concomitant uncontrolled infection, systemic infection in treatment, or any other unstable medical condition that could interfere with the study objectives.- Patients with severe diarrhea, vomiting, active peptic ulcer or gastrointestinal disorder that can affect the absorption of TAC.- Patients with white blood cell count 2.8 x 109 / L unless the absolute neutrophil count (ANC) is 1.0 x 109 / L - Patients with platelet count 50 x 109 / L - Patients with levels of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) exceeding> 3 times the upper limit of normal during the 30 days prior to the transplant procedure.- Patients with known hypersensitivity to TAC or any of the excipients in the formulation Envarsus.- unable to swallow study medication patients.- Patients with any form of current substance abuse, psychiatric disorder or a condition that, in the investigator's opinion, may invalidate the communication with the investigator.- Patients who require a high intake of potassium or potassium-sparing diuretics.- Patients treated with substances with known nephrotoxic or neurotoxic effects.- positive for hepatitis C virus (HCV-RNA positive) and / or hepatitis B virus (HBV DNA or HBsAg positive) receivers.- positive for human immunodeficiency virus (HIV-Ab positive) receivers.- unable to understand the effects and risks of the study, who can not give informed consent in writing or unwilling to comply with the study protocol patients",ct_exc_367446,AACT,531,NCT02961608,Historical,TAC
5c74309f8625dd06ea867f93,820,,,115,Patient,14:55.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_553266,Clinical Trial Inclusion Criteria,UNKNOWN,less than 20% deviation in serum creatinine the last 2 months).- Renal transplant recipient currently on CsA or Tac and prednisolone based,ct_inc_553266,AACT,112,NCT00525681,Recent,Tac
5c74309f8625dd06ea867f94,820,,,153,Patient,14:55.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_312387,Clinical Trial Inclusion Criteria,UNKNOWN,Allo-HCT patients * Any allogeneic transplant regimen with planned GVHD prophylaxis containing generic IV Mycophenolate Mofetil (MMF) and tacrolimus (Tac) - Sexually active females of childbearing potential and males with partners of child-bearing potential must agree to use adequate birth control until at least six months post-FMT/placebo - Voluntary written consent signed before performance of any study-related procedure not part of normal medical care,ct_inc_312387,AACT,150,NCT03678493,Recent,Tac
5c7430a48625dd0737867f8a,180,,,253,Patient,15:00.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_343977,Clinical Trial Inclusion Criteria,UNKNOWN,; CML transformed to blast crisis is eligible - Planned allogeneic HCT using fludarabine phosphate (FLU)/melphalan hydrochloride (MEL) or FLU/busulfan (BU) conditioning - Planned graft versus host disease (GVHD) prophylaxis consisting of tacrolimus (TAC)/methotrexate (MTX) or TAC/sirolimus (SRL) -,ct_inc_343977,AACT,250,NCT03267186,Recent,TAC
5c7430a48625dd0737867f8b,180,,,3,Patient,15:00.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_343977,Clinical Trial Inclusion Criteria,UNKNOWN,TAC/MTX:,ct_inc_343977,AACT,0,NCT03267186,Recent,TAC
5c7430a48625dd0737867f8c,180,,,3,Patient,15:00.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_343977,Clinical Trial Inclusion Criteria,UNKNOWN,TAC/SRL:,ct_inc_343977,AACT,0,NCT03267186,Recent,TAC
5c7430a88625dd0767867f89,670,,,156,Patient,15:04.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_408346,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically confirmed primary breast cancer - Planned to start docetaxel component of FEC-D or AC-D, or first cycle of; dose-dense AC-T, TC, FEC-D or TAC chemotherapy - 19 years of age - Able to provide verbal consent",ct_inc_408346,AACT,153,NCT02428114,Recent,TAC
5c7430a88625dd0767867f8a,670,,,156,Patient,15:05.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_378606,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically confirmed primary breast cancer - Planned to start docetaxel component of FEC-D or AC-D, or first cycle of; dose-dense AC-T, TC, FEC-D or TAC chemotherapy - 19 years of age - Able to provide verbal consent",ct_inc_378606,AACT,153,NCT02816164,Recent,TAC
5c7430a98625dd0767867f8b,670,,,226,Patient,15:05.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_562063,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Women with histologically proven non metastatic breast cancer - No previous chemotherapy - Treatment planning including 6 adjuvant CT courses with the first 3 being necessarily of the FAC50, FEC100 or TAC type -",ct_inc_562063,AACT,223,NCT00409071,Recent,TAC
5c7430a98625dd0767867f8c,670,,,3,Patient,15:05.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_446998,Clinical Trial Inclusion Criteria,AGE,TAC regimen as adjuvant therapy 4.,ct_inc_446998,AACT,0,NCT01923545,Recent,TAC
5c7430a98625dd0767867f8d,670,,,4,Patient,15:05.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_539543,Clinical Trial Inclusion Criteria,UNKNOWN,"(TAC),Mycophenolate mofetil (MMF) - Patients and parents, respectively, have given their written consent after enlightenment (informed consent)",ct_inc_539543,AACT,1,NCT00707759,Recent,TAC
5c7430a98625dd0763867f8a,730,,,131,Patient,15:06.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_596119,Clinical Trial Inclusion Criteria,UNKNOWN,"At least 5 percent of each patient's peripheral blood, lymph node, pulmonary or dermal malignant cells must react with the anti-Tac mAb as determined by immunofluorescent staining or, alternatively, the serum-soluble interleukin 2 (IL-2) receptor levels must be greater than 1,000 units/ml (normal geometric mean, 235; with a 95% confidence interval of 112 to 502 units/mL).- Smoldering or chronic stage Tac-expressing adult T-cell leukemia defined by the Shimomyama Criteria (37) are eligible.- To be diagnosed as smoldering Adult T-cell Leukemia (ATL), the patient must have a normal lymphocyte count (less than 4 times 10^3/mm^3), less than or equal to 5 percent abnormal lymphocytes on morphologic examination of the peripheral blood smear or on fluorescence activated cell sorting (FACS) analysis (cells with a homogenous staining pattern and a greater than 1 log increase in the magnitude of fluorescence emission of the anti-Tac peak over background expression), - no hypercalcemia, - lactate dehydrogenase less than or equal to 1.5 times the upper limit of normal, - no lymphadenopathy, -",ct_inc_596119,AACT,128,NCT00001941,Recent,Tac
5c7430a98625dd0763867f8b,730,,,425,Patient,15:06.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_596119,Clinical Trial Inclusion Criteria,UNKNOWN,"The patient must have a granulocyte count of at least 500/mm^3 and a platelet count of 25,000/mm^3.- Patients must have a creatinine of less than 3.0 mg/dl.- Patients must have a Karnofsky performance score of greater than 60 percent.- ATL patients without, as well as those with, previous chemotherapy will be eligible for inclusion in the study.- Patients with previous therapy with a monoclonal antibody including anti-Tac will be eligible for the study provided that they do not have a positive HAHA (human antibody to humanized anti-Tac) value (i.e., such patients must have a value greater than 250 ng/ml).- Omission of cytotoxic chemotherapy for ATL for 3 weeks prior to entry into the trial",ct_inc_596119,AACT,422,NCT00001941,Historical,Tac
5c7430aa8625dd0763867f8c,730,,,138,Patient,15:06.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_596315,Clinical Trial Inclusion Criteria,UNKNOWN,"At least 10% of each patient's malignant cells from peripheral blood, lymph node, skin, or other extranodal sites must react with anti-Tac, as determined by immunofluorescent or immunoperoxidase staining.",ct_inc_596315,AACT,135,NCT00001575,Recent,Tac
5c7430aa8625dd0763867f8d,730,,,36,Patient,15:06.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_596315,Clinical Trial Inclusion Criteria,UNKNOWN,"Because of the high incidence of Tac positivity in infiltrating T cells in Hodgkin's disease, patients with cluster of differentiation 25 (CD25) positive infiltrating T cells will be eligible even if the Hodgkin's cells are negative.",ct_inc_596315,AACT,33,NCT00001575,Hypothetical,Tac
5c7430aa8625dd0763867f8e,730,,,49,Patient,15:06.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_596315,Clinical Trial Inclusion Criteria,DIAGNOSES,Patients with all histopathologic subtypes of Tac-expressing NHL are eligible.,ct_inc_596315,AACT,46,NCT00001575,Recent,Tac
5c7430aa8625dd0763867f8f,730,,,31,Patient,15:06.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_596315,Clinical Trial Inclusion Criteria,DIAGNOSES,Patients with all stages of Tac-expressing CTCL are eligible with the exception of Stage Ia.,ct_inc_596315,AACT,28,NCT00001575,Recent,Tac
5c7430aa8625dd0763867f90,730,,,139,Patient,15:06.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_596315,Clinical Trial Inclusion Criteria,DIAGNOSES,Patients receiving corticosteroids must be on a stable dose for at least three weeks before receiving yttrium 90-labeled humanized anti-Tac (90Y-HAT) on this study.,ct_inc_596315,AACT,136,NCT00001575,Recent,Tac
5c7430ad8625dd07a5867f85,740,,,78,Patient,15:09.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_591940,Clinical Trial Exclusion Criteria,UNKNOWN,"Major concurrent illness, which could worsen following treatment with anti-TAC.",ct_exc_591940,AACT,75,NCT00050661,Recent,TAC
5c7430ad8625dd07a5867f86,740,,,210,Patient,15:09.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_442206,Clinical Trial Exclusion Criteria,UNKNOWN,- Subjects with cold agglutinin disease or cold urticaria - Subjects who are scheduled for bone marrow ablation chemotherapy - Subjects receiving chemotherapy with concurrent anthracycline and taxane (AT or TAC) - Male gender - Age >= 70 years,ct_exc_442206,AACT,207,NCT01986140,Recent,TAC
5c7430ad8625dd07a5867f87,740,,,241,Patient,15:09.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_575141,Clinical Trial Inclusion Criteria,UNKNOWN,Histologically confirmed pancreatic cancer (aspiration biopsy by fine needle [PAAF] by USE or biopsy guide by ECO-CT).It is mandatory the diagnostic by USE and will recommend the aspiration biopsy with this technique - Tumoural volume by TAC < 500 cc - Aged 18 to 75 years inclusive - Eastern Cooperative Oncology Group (ECOG) performance status (PS) 1 - Life-expectancy of more than 12 weeks - Women of child-bearing potential must be willing to practice reliable methods of birth control to prevent pregnancy,ct_inc_575141,AACT,238,NCT00234416,Recent,TAC
5c7430838625dd05f1867f89,1000,,,782,Patient,14:27.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_371385,Clinical Trial Exclusion Criteria,UNKNOWN,"Use of investigational drugs within 3 weeks of signing consent or foreseen use during the study; Use of chemotherapy, trastuzumab, or pertuzumab within the past 3 weeks; Use of antibiotics within the past 7 days (up to 2 prophylactic doses of antibiotics for procedures including, but not limited to port placement, is permitted); Any type of ostomy; Total colectomy; Fecal incontinence; Ongoing radiation induced diarrhea or constipation or planned radiotherapy to the abdomen or pelvis while on study; Active systemic infection requiring ongoing intervention, including but not limited to oral and intravenous antibiotics, anti-fungals, anti-parasites, anti-virals; Abdominal or pelvic surgery without recovery of bowel function; Inadequate organ function for starting THP or TCHP, which may include the following laboratory results within 28 days prior to signing",ct_exc_371385,AACT,778,NCT02910219,Historical,TCHP
5c7430848625dd05f1867f8a,1000,,,43,Patient,14:28.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_323643,Clinical Trial Inclusion Criteria,UNKNOWN,old - Child is a patient at one of the TCHP Center for Children and Women Clinics - Parents able to read and write in either Spanish or English - Latino/Hispanic families who live in the Greater Houston area -,ct_inc_323643,AACT,39,NCT03532048,Recent,TCHP
5c74309a8625dd06df867f89,850,,,303,Patient,14:50.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_371385,Clinical Trial Inclusion Criteria,UNKNOWN,"Willing and able to provide written informed consent; Men and women 18 years of age; Pathologically confirmed diagnosis of HER2 positive breast cancer of any stage (previous treatment is allowed without limits on lines of prior therapy); Scheduled to receive at least 3 consecutive cycles of THP or TCHP; Performance status of 0-2 according to the ECOG scale; Negative pregnancy test at time of informed consent for women of childbearing potential; Able to read, understand, follow the study procedure and complete crofelemer, rescue medication, and bowel movement diaries; Patients may enroll simultaneously on this study and other studies, including but not limited to NSABP B52; Patients with brain metastases (including concurrent steroid treatment) are allowed on this study.",ct_inc_371385,AACT,299,NCT02910219,Historical,TCHP
5c74305f8625dd0447867f94,250,,,272,Patient,13:51.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_581595,Clinical Trial Inclusion Criteria,UNKNOWN,"Age > or = than 18 years at the time of signing the informed consent form.- Karnofsky performance status> or =70% (>60% if due to bony involvement of myeloma).- Group A (post-induction therapy)- patients who have received only one prior treatment regimen (eg VAD, Thal/Dex, BLT-D, MP, BiRD, or DVd) with at least 20 patients having received a Revlimid based regimen or Group B(>1st line of therapy)- patients with relapsed/refractory multiple myeloma who have received two or more prior treatment regimens .- If the patient is a woman of childbearing age, she must have a negative serum or urine pregnancy test within 7 days of starting study and must use effective contraception throughout the course of the study.- Life expectancy",ct_inc_581595,AACT,264,NCT00148317,Historical,Thal/Dex
5c74308b8625dd063a867f88,390,,,455,Patient,14:35.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_382521,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Active RA, < 10 years disease duration, diagnosed according to the ACR-EULAR 2010 classification criteria - DAS 28 superior or equal to 3.2 despite DMARD or biological treatment (other than tocilizumab) - Superior or equal to one joint erosion at the right or left MCP 2, 3 on X-rays - Oral corticosteroid 10 mg/day prednisone or equivalent stable for at least one month - RA patients eligible to subcutaneous Tocilizumab monotherapy",ct_inc_382521,AACT,432,NCT02765074,Recent,Tocilizumab monotherapy
5c7430728625dd054f867f84,340,,,79,Patient,14:10.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_338347,Clinical Trial Inclusion Criteria,UNKNOWN,Patient is currently receiving treatment with dabrafenib/trametinib monotherapy or combination within a Novartis or former GSK sponsored study which has fulfilled the requirements for the primary objective.-,ct_inc_338347,AACT,57,NCT03340506,Recent,trametinib monotherapy
5c7430968625dd069d867f8b,880,,,497,Patient,14:46.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_409257,Clinical Trial Exclusion Criteria,COMMENT,"Such subjects may receive therapy with: trametinib in combination with dabrafenib (in case of an adverse event related to a previous BRAF or MEK inhibitor other than trametinib or dabrafenib and without cross-reaction anticipated, or if clinically indicated according to investigator judgement).Prior treatment (except trametinib and dabrafenib) should have been stopped for a period of 5 half lives or 28 days (whichever is shorter) before starting treatment of this study; trametinib monotherapy if the subject has benefited from a treatment with a BRAF-inhibitor without progression but cannot receive it anymore due to tolerability reason.",ct_exc_409257,AACT,475,NCT02416232,Hypothetical,trametinib monotherapy
5c7430a18625dd071a867f86,1060,,,1243,Patient,14:57.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_443830,Clinical Trial Inclusion Criteria,UNKNOWN,">= 50 mL/min OR 24-hour urine creatinine clearance >= 50 mL/min - Patients must have controlled blood pressure with a systolic blood pressure < 140 mmHg and diastolic < 90 mmHg; anti-hypertensive medications are permitted - Patients must be at least 4 weeks from last radiation dose; patients must be at least 4 weeks from last chemotherapy, targeted therapy, or biologic therapy (exception allowed for a 2 week washout for patients who were on chemotherapy at less than a standard of care dose, as long as all other eligibility criteria are met); patients must be at least 4 weeks from last surgical procedure and recovered from all post-operative complications - Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of trametinib monotherapy or in combination with GSK2141795 administration - Ability to understand and the willingness to sign a written informed consent document",ct_inc_443830,AACT,1221,NCT01964924,Historical,trametinib monotherapy
5c7430b18625dd07c6867f89,490,,,761,Patient,15:13.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_443830,Clinical Trial Exclusion Criteria,UNKNOWN,> 120 mg/dL will be excluded - Uncontrolled hypothyroidism; patients must have a normal thyroid-stimulating hormone (TSH) per institutional standards at baseline - Patients who are receiving any other investigational agents - Individuals with symptomatic or progressive brain metastases are ineligible; subjects with treated brain metastases are eligible if they have no radiographic or other signs of progression in the brain for >= 3 weeks after completion of local therapy; any corticosteroid use for brain metastases must have been discontinued without the subsequent appearance of symptoms for >= 3 weeks prior to study enrollment - History of allergic reactions attributed to compounds of similar chemical or biologic composition to trametinib monotherapy or trametinib in combination with GSK2141795 - Current use of a prohibited medication; the following medications or non-drug therapies are prohibited:,ct_exc_443830,AACT,739,NCT01964924,Hypothetical,trametinib monotherapy
5c7430b18625dd07c6867f8a,490,,,420,Patient,15:13.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_443830,Clinical Trial Exclusion Criteria,UNKNOWN,"> 21 mm Hg - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements - Pregnant women are excluded from this study, breastfeeding should be discontinued if the mother is treated with trametinib monotherapy or trametinib in combination with GSK2141795 - Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible",ct_exc_443830,AACT,398,NCT01964924,Recent,trametinib monotherapy
5c74307b8625dd058e867f8e,760,,,75,Patient,14:19.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_490374,Clinical Trial Inclusion Criteria,UNKNOWN,< 2.5 times the upper limit of normal - Patients on trastuzumab monotherapy must have adequate cardiac function as demonstrated by normal ejection fractions (EF) on multi gated acquisition scan (MUGA) scan or echocardiogram performed within the last 3 months of eligibility sign off,ct_inc_490374,AACT,52,NCT01355393,Recent,trastuzumab monotherapy
5c7430938625dd069d867f87,880,,,561,Patient,14:43.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_447045,Clinical Trial Inclusion Criteria,UNKNOWN,"No evidence of disease (NED), or - Stable bone only disease after definitive therapy - HER2 overexpression by immunohistochemistry (IHC) of 2+ or 3+ in the primary tumor or metastasis; or documented gene amplification by fluorescent in situ hybridization (FISH) analysis; IHC =< 2+ must have HER2 gene amplification documented by FISH - Patients must continue HER2-targeted monoclonal antibody therapy dosing per standard of care through the entire study period (one year) - HER2-targeted monoclonal antibody therapy is defined as either trastuzumab monotherapy, or trastuzumab and pertuzumab combination therapy administered per standard of care - Patients must be at least 21 days post cytotoxic chemotherapy prior to enrollment - Patients must be at least 28 days post immunosuppressants prior to enrollment - Patients must be at least 28 days from use of any mushroom supplements (examples: turkey tail, reishi, maitake, shiitake) and agree to withhold them for the entire study period (one year) - Patients on bisphosphonates and/or endocrine therapy are eligible - Patients who are having sex that could lead to pregnancy must agree to contraceptive use during the entire study period - Patients must have Zubrod performance status score of =< 2 - Patients must have recovered from major infections and/or surgical procedures, and in the opinion of the investigator, not have significant active concurrent medical illnesses precluding study treatment - White blood cell (WBC) >= 3000/mm^3 - Hemoglobin (Hgb) >= 10 g/dl - Serum creatinine =< 2.0 mg/dl or creatinine clearance > 60 ml/min - Total bilirubin =< 1.5 mg/dl - Serum glutamic oxaloacetic transaminase (SGOT) =",ct_inc_447045,AACT,538,NCT01922921,Historical,trastuzumab monotherapy
5c74309f8625dd070b867f89,510,,,144,Patient,14:55.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_578112,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Subjects must have either stage IV breast or ovarian cancer in remission or with stable disease on trastuzumab monotherapy - HER2 overexpression by immunohistocytochemistry (IHC) of 2+ or 3+, in the primary tumor or metastasis; if overexpression is 2+ by IHC, then patients must have HER2 gene amplification documented by fluorescence in situ hybridization (FISH)",ct_inc_578112,AACT,121,NCT00194714,Hypothetical,trastuzumab monotherapy
5c74309f8625dd070b867f8a,510,,,306,Patient,14:55.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_578112,Clinical Trial Inclusion Criteria,UNKNOWN,- Subjects must be HLA-A2 positive - Eligible subjects must have completed appropriate treatment for their primary disease and be off cytotoxic chemotherapy and any immunosuppressive agents such as systemic steroids for at least 30 days prior to enrollmen,ct_inc_578112,AACT,283,NCT00194714,Historical,trastuzumab monotherapy
5c7430a08625dd070b867f8b,510,,,826,Patient,14:56.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_560022,Clinical Trial Inclusion Criteria,ONCOLOGY_FAMILY_HISTORY,"stage III or stage IV ovarian cancer in first complete remission with a normal AND stable CA-125; thus, two sequential normal CA-125 values will need to be documented; a minimum of 30 days between 2 sequential CA-125 values; the most recent will be within 2 weeks of enrollment into study - HER2 overexpression by immunohistochemistry (IHC) of 2+ or 3+ in their primary tumor or metastasis, and if overexpression is 2+ by IHC or in the absence of IHC, then patients must have documentation of HER2 gene amplification by FISH - Eligible subjects must have completed appropriate treatment for their primary disease and be off cytotoxic chemotherapy and corticosteroids for at least 1 month prior to enrollment; patients with stage III/IV breast cancer who have completed chemotherapy and are continued on trastuzumab monotherapy are eligible; hormonal and bisphosphanate therapies are allowed - Subjects must have a Performance Status Score (Zubrod/ECOG Scale) =",ct_inc_560022,AACT,803,NCT00436254,Hypothetical,trastuzumab monotherapy
5c7430a08625dd070b867f8c,510,,,318,Patient,14:56.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_560022,Clinical Trial Inclusion Criteria,ONCOLOGY_FAMILY_HISTORY,"< 1.5 mg/dl - SGOT < 2 x ULN - Subjects must have recovered from major infections and/or surgical procedures and, in the opinion of the investigator, not have a significant active concurrent medical illness precluding protocol treatment or survival - Normal ANA, anti-dsDNA and C3 - Patients on trastuzumab monotherapy must have adequate cardiac function as demonstrated by normal ejection fraction (EF) of MUGA scan or echocardiogram",ct_inc_560022,AACT,295,NCT00436254,Recent,trastuzumab monotherapy
5c7430b48625dd07dc867f8b,630,,,1288,Patient,15:16.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_567019,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Stage IIIB or Stage IIIC breast cancer who are within 1 year of diagnosis and initiating treatment with chemotherapy and trastuzumab; and are in complete remission - Stage IV breast cancer in first complete remission and defined as NED (no evidence of disease) or with stable bone only disease who are within 6 months of initiating maintenance trastuzumab - NED status should be documented by chest/abdominal CT, PET or PET/CT within the last 90 days - Bone only disease documented as stable or healed by PET, PET/CT, or MRI within the last 90 days; stable bone-only disease must be documented with bone scan performed within the last 6 months - HER2 overexpression by IHC of 2+ or 3+, in the primary tumor or metastasis or documented gene amplification by FISH analysis; if overexpression is 2+ by IHC, then patients must have HER2 gene amplification documented by FISH - Eligible subjects must have been treated to NED or stable bone only disease status with trastuzumab and/or chemotherapy and be off cytotoxic chemotherapy or immunosuppressive agents (e.g.systemic steroids) for at least 30 days prior to enrollment (concurrent hormonal therapy allowed; concurrent bisphosphonate therapy allowed) - Patients on trastuzumab should continue trastuzumab monotherapy per standard of care (the dosing and schedule of trastuzumab should follow standard guidelines as described below: trastuzumab 2mg/kg IV weekly or trastuzumab 6mg/kg IV",ct_inc_567019,AACT,1265,NCT00343109,Recent,trastuzumab monotherapy
5c7430b48625dd07dc867f8c,630,,,196,Patient,15:16.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_567019,Clinical Trial Inclusion Criteria,UNKNOWN,"and/or surgical procedures and, in the opinion of the investigator, not have any significant active concurrent medical illnesses precluding protocol treatment - Patients on trastuzumab monotherapy must have adequate cardiac function as demonstrated by normal ejection fraction (EF) on MUGA scan or echocardiogram performed within last 6 months",ct_inc_567019,AACT,173,NCT00343109,Recent,trastuzumab monotherapy
5c7430ab8625dd079a867f84,380,,,228,Patient,15:07.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_403665,Clinical Trial Inclusion Criteria,UNKNOWN,"It will be included in the study newborns (NB) hospitalized in the nursery and patients aged 18 or over, male and female, conscious and oriented, presenting Glasgow coma scale of 15, hospitalized at the Clinical Hospital of UFTM, who will not be discharged from it for at around the 3 following days.",ct_inc_403665,AACT,224,NCT02489136,Recent,UFTM
5c7430888625dd0628867f95,90,,,263,Patient,14:32.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_585900,Clinical Trial Inclusion Criteria,UNKNOWN,"No evidence of disease - Prior treatment on 1 of the following protocols during the years 1987-2001: - Children's Cancer Group (CCG) CCG-5942, CCG-59704 - Pediatric Oncology Group (POG) POG-8625, POG-8725, POG-9425, POG-9426 - Pediatric Hodgkin's Consortium: VAMP, VEPA, VAMP/COP - Institutional protocols COPP/ABV, MOPP/ABVD, ABVD - Childhood Cancer Survivor Study (CCSS)",ct_inc_585900,AACT,259,NCT00091091,Historical,VAMP
5c7430498625dd0376867f84,940,,,296,Patient,13:29.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_578929,Clinical Trial Inclusion Criteria,UNKNOWN,"Must have refractory germ cell neoplasm defined as one or more of the following: - patients who progress during or within 4 weeks of cisplatin-containing tx, OR - patients who have failed initial salvage chemotx regimens, including high-dose tx (chemotx with stem cell support), POMB-ACE tx, VeIP, or VIP Must have one or more of the following (check all that apply): - unidimensionally measurable doze assessed within 14 days prior to registration:",ct_inc_578929,AACT,292,NCT00183820,Historical,VeIP
5c74305e8625dd045a867f85,1190,,,5,Patient,13:50.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_402837,Clinical Trial Inclusion Criteria,COMMENT,(VeIP).- Failure of prior therapy is defined as: a >25% increase in the products of perpendicular diameters of measurable tumor masses during prior therapy which are not amenable to surgical resection; the presence of new tumors which are not amenable to surgical resection; an increase in AFP or beta-hCG (two separate determinations at least one week apart are required if rising tumor markers are the only evidence of failure).,ct_inc_402837,AACT,1,NCT02499952,Hypothetical,VeIP
5c7430af8625dd0779867f90,520,,,135,Patient,15:11.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_443678,Clinical Trial Inclusion Criteria,UNKNOWN,"The patients must have received: - For relapsed patients, two lines of a standard chemotherapy (BEP or EP in first-line treatment, VeIP or VIP in second-line treatment) -",ct_inc_443678,AACT,131,NCT01966913,Recent,VeIP
5c7430b98625dd07eb867f8f,930,,,871,Patient,15:21.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_455794,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients must have histological or serological proof of metastatic germ cell neoplasm (gonadal or extragonadal primary) with disease not amenable to cure with either surgery or chemotherapy; patients with seminoma and nonseminoma are eligible, as are women with ovarian germ cell tumors - Patients must have evidence of recurrent or metastatic carcinoma by one or more of the criteria specified in the protocol - Patients must have received initial cisplatin based combination therapy (such as bleomycin, etoposide and cisplatin [BEP], etoposide and cisplatin [EP], VP-16 plus ifosfamide plus cisplatin [VIP] or similar regimens) AND demonstrated progression following the administration of at least one 'salvage' regimen for advanced germ cell neoplasm (such as high dose chemotherapy, paclitaxel/ifosfamide/cisplatin [TIP] or vinblastine, ifosfamide and cisplatin [VeIP]) - Patients must have documented failure of prior therapy as defined in the protocol - Patients are eligible after first line platinum based chemotherapy if their disease has relapsed and they have primary mediastinal non seminomatous germ cell tumor (PMNSGCT) or late relapse (> 2 years) not amenable to surgical resection - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - Laboratory test results must be within ranges established in the protocol - Potential subject must have the ability to understand (as judged by the treating physician) and willingness to provide written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information; - Females of childbearing potential must not be pregnant or breast-feeding; male and female patients of reproductive potential must agree to use a highly reliable method of birth control from the screening visit through 28 days after the last dose of study drug",ct_inc_455794,AACT,867,NCT01808534,Hypothetical,VeIP
5c7430508625dd03a2867f8a,130,,,584,Patient,13:36.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_345097,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Biopsy-proven histochemical diagnosis of amyloid light-chain (AL) amyloidosis based on tissue specimens with Congo red staining or other histologic stain; thioflavin T or S, or crystal violet; tandem mass spec or immunohistochemistry (IHC) confirmation of immunoglobulin-derived amyloidosis is encouraged; cases in which histochemical confirmation is lacking need to be discussed with one of the Multiple Myeloma Research Foundation (MMRF) protocol chair/co-chairs - One prior line of therapy (defined as either one non-transplant regimen such as MelDex, Vel-Dex or CyBorD, one autologous stem cell transplant, or one regimen of non-transplant induction therapy followed by a single autologous stem cell transplant (without hematologic progression between induction and autologous stem cell transplant [ASCT]) -",ct_inc_345097,AACT,577,NCT03252600,Historical,Vel-Dex
5c7430be8625dd084a867f8f,140,,,197,Patient,15:26.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_326866,Clinical Trial Inclusion Criteria,UNKNOWN,"- Patient planned to receive one of the following chemotherapy protocols including bortezomib (VELCADE): VMP (Velcade, Melphalan, Prednisone), VCD (Velcade, Cyclophosphamide, Dexamethasone), VelDex (Velcade, Dexamethasone), VRD (Velcade, Revlimid, Dexamet",ct_inc_326866,AACT,191,NCT03490084,Recent,VelDex
5c74307a8625dd058e867f89,760,,,487,Patient,14:18.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_476942,Clinical Trial Inclusion Criteria,UNKNOWN,"= 3 weeks beyond treatment with a cytotoxic chemotherapy regimen, or therapeutic radiation, or major surgery; patients may have received palliative localized radiation immediately before or during treatment provided that radiation is not delivered to the ",ct_inc_476942,AACT,464,NCT01531361,Recent,vemurafenib monotherapy
5c7430598625dd0411867f84,300,,,200,Patient,13:45.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_338221,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Patient with chronic lymphocytic leukemia (CLL) administering venetoclax and who meets the following conditions as specified in the label for venetoclax: - Venetoclax monotherapy for the treatment of CLL in the presence of deletion chromosome 17 (del[17p]) or tumor protein p53 (TP53) mutation in adult patients, who are unsuitable for or have failed to a Bcell receptor pathway inhibitor.- Venetoclax monotherapy for the treatment of CLL in the absence of del(17p) or TP53 mutation in adult patients, who have failed both chemoimmunotherapy and a Bcell receptor pathway inhibitor.",ct_inc_338221,AACT,178,NCT03342144,Recent,Venetoclax monotherapy
5c7430468625dd034a867f8c,650,,,306,Patient,13:27.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_576824,Clinical Trial Inclusion Criteria,UNKNOWN,"Adult patients (up to 67 years old) are eligible for the study if they are positive for HCV RNA on testing with the polymerase chain reaction (quantitative test), or qualitative test positive if quantitative negative, have undergone a liver biopsy within one year before entry, available for analysis (vide infra) and whose results are consistent with a diagnosis of chronic hepatitis with at least moderate inflammation, a fibrosis score of at least 2/6 according to Ishak et al (1995), and excluding complete cirrhosis.",ct_inc_576824,AACT,302,NCT00211848,Hypothetical,vide
5c7430998625dd06df867f86,850,,,171,Patient,14:49.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_445694,Clinical Trial Inclusion Criteria,UNKNOWN,"Histological or cytologically-confirmed solid tumor in a patient for whom the study chemotherapy regimen [Vincristine plus ifosfamide plus doxorubicin plus etoposide (VIDE), Vincristine plus doxorubicin plus cyclophosphamide alternating with ifosfamide plus etoposide (VDC/IE), Ifosfamide plus vincristine plus actinomycin D (IVA) or Ifosfamide plus vincristine plus Adriamycin (IVAd)] is considered an appropriate treatment.",ct_inc_445694,AACT,167,NCT01940601,Recent,VIDE
5c7430998625dd06df867f87,850,,,84,Patient,14:49.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_472799,Clinical Trial Inclusion Criteria,UNKNOWN,"For the Ewing family of tumors: - vincristine/ifosfamide/doxorubicin/etoposide (VIDE); with concomitant sodium 2-mercaptoethane sulfonate (MESNA) according to local standards - vincristine/doxorubicin/cyclophosphamide alternating with ifosfamide/etoposide (VDC/IE); with concomitant MESNA treatment according to local standards - For rhabdomyosarcoma: - vincristine/actinomycin/cyclophosphamide (VAC) - vincristine/doxorubicin/cyclophosphamide alternating with ifosfamide/etoposide (VDC/IE); with concomitant MESNA treatment according to local standards - Chemotherapy-nave - Body weight 15 kg - White blood cell (WBC) count >2.5 x 109/L, absolute neutrophil count (ANC)",ct_inc_472799,AACT,80,NCT01585649,Recent,VIDE
5c7430528625dd03b8867f88,430,,,294,Patient,13:38.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_411514,Clinical Trial Inclusion Criteria,UNKNOWN,- Patients treated with nonanthracycline-based therapy as the initial treatment after diagnosis - Nonanthracycline-based therapy includes the following treatments: - Radiotherapy including concurrent chemoradiation - Chemotherapy not including anthracycli,ct_inc_411514,AACT,290,NCT02386813,Recent,VIPD
5c74307d8625dd05b6867f8f,10,,,105,Patient,14:21.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_407421,Clinical Trial Inclusion Criteria,UNKNOWN,"patients with newly diagnosed acute lymphoid leukemia who approve to get induction chemotherapy with VPDL (vincristine + prednisolone + daunorubicin + L-asparaginase), C-VPDL (cyclophosphamide + vincristine + prednisolone + daunorubicin + L-asparaginase), or (R)-hyperCVAD ((Rituximab) + cyclophosphamide + vincristine + Adriamycin + dexamethasone)",ct_inc_407421,AACT,101,NCT02440178,Recent,VPDL
5c7430438625dd033f867f84,310,,,58,Patient,13:23.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_317130,Clinical Trial Inclusion Criteria,UNKNOWN,"Stage II, III, or IV Patients who received RCHOP or VR-CAP induction chemotherapy for 6 cycles confirmed response as more than PR or PR after induction therapy and who are ineligible for transplantation..",ct_inc_317130,AACT,52,NCT03616782,Recent,VR-CAP
5c74308e8625dd065b867f9b,20,,,262,Patient,14:38.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_509078,Clinical Trial Inclusion Criteria,UNKNOWN,"methotrexate [MTX]/high-dose cytarabine [HiDAC]; cyclophosphamide, vincristine, doxorubicin, and dexamethasone [hyperCVAD]; bortezomib, thalidomide, dexamethasone and 4-day continuous infusions of cisplatin, doxorubicin, cyclophosphamide, and etoposide [VTD-PACE])",ct_inc_509078,AACT,254,NCT01110135,Recent,VTD-PACE
5c7430918625dd065b867fa0,20,,,962,Patient,14:41.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_509078,Clinical Trial Exclusion Criteria,UNKNOWN,- Fludarabine or other nucleoside analog (except gemcitabine or cytarabine) therapy within 24 months of registration; patients with limited exposure to fludarabine/other nucleoside analog therapy within 24 months may be considered eligible with review and,ct_exc_509078,AACT,954,NCT01110135,Historical,VTD-PACE
5c7430bb8625dd0813867f99,370,,,71,Patient,15:23.8,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_380283,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients must not have received infusional chemotherapy (e.g., VTD-PACE or similar regimen) prior to enrollment.- Subjects must be eligible for ASCT and to receive a melphalan dose of 200 mg/m2 as defined by the following criteria:",ct_inc_380283,AACT,63,NCT02794246,Historical,VTD-PACE
5c74303c8625dd02f6867f90,120,,,211,Patient,13:16.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_438902,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients with histologically confirmed metastatic colorectal cancer - Cetuximab-based chemotherapy (monotherapy, combination therapy with cytotoxic chemotherapy such as FOLFOX, XELOX, irinotecan, FOLFIRI, XELIRI, first-line, second-line or third-line are all eligible)",ct_inc_438902,AACT,205,NCT02029326,Recent,XELIRI
5c7430498625dd036b867f8c,190,,,241,Patient,13:29.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_454730,Clinical Trial Inclusion Criteria,UNKNOWN,"Planned combination bevacizumab (bvz) treatment with either: - leucovorin, fluorouracil and oxaliplatin (FOLFOX) - capecitabine and oxaliplatin (XELOX) - leucovorin, fluorouracil and irinotecan (FOLFIRI) - capecitabine and irinotecan (XELIRI) Naive for bvz",ct_inc_454730,AACT,235,NCT01822444,Recent,XELIRI
5c7430498625dd036b867f90,190,,,33,Patient,13:29.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_527450,Clinical Trial Inclusion Criteria,UNKNOWN,"FOLFOX, FOLFIRI, XELOX, or XELIRI.- Documentation of wild type k-Ras expression in the liver",ct_inc_527450,AACT,27,NCT00867334,Recent,XELIRI
5c7430b98625dd081e867f8c,110,,,817,Patient,15:21.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_468526,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Cytological or histological proven diagnosis of colorectal cancer, metastatic or inoperable advanced disease, not amenable to curative therapy - Measurable disease, defined as at least one lesion (outside of irradiated areas) that can be measured in at least one dimension as 10 mm ( 15 mm in case of lymph nodes) according to RECIST v1.1 - Tumor either wild-type KRAS or KRAS-mutated - Indication for the therapeutic use of continuous intravenous 5FU over 48 hours (deGramont regimen) or oral Cp, either alone or in combination with other anticancer drugs (including monoclonal antibodies or other molecularly-targeted drugs) - Eligible treatment regimens include: FOLFOX (FOLFOX 4, FOLFOX 6, modified FOLFOX 6, FOLFOX 7), FOLFIRI, 5FU or Cp mono-chemotherapy (deGramont regimen), XELOX, XELIRI,",ct_inc_468526,AACT,811,NCT01641458,Recent,XELIRI
5c7430378625dd02b4867f87,1020,,,284,Patient,13:11.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_566140,Clinical Trial Exclusion Criteria,UNKNOWN,"Because patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy, HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with XELOX.Appropriate",ct_exc_566140,AACT,279,NCT00354887,Recent,XELOX
5c7430378625dd02b4867f88,1020,,,1019,Patient,13:11.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_567316,Clinical Trial Exclusion Criteria,UNKNOWN,"30 days prior to enrollment.- Participants with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.- Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical therapy affecting absorption.- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.- Because Participants with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy, HIV-positive Participants receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with XELOX.Appropriate",ct_exc_567316,AACT,1014,NCT00338988,Historical,XELOX
5c74303c8625dd02f6867f91,120,,,182,Patient,13:16.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_438902,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients with histologically confirmed metastatic colorectal cancer - Cetuximab-based chemotherapy (monotherapy, combination therapy with cytotoxic chemotherapy such as FOLFOX, XELOX, irinotecan, FOLFIRI, XELIRI, first-line, second-line or third-line are all eligible)",ct_inc_438902,AACT,177,NCT02029326,Recent,XELOX
5c74303e8625dd02f6867f9b,120,,,759,Patient,13:18.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_524251,Clinical Trial Exclusion Criteria,UNKNOWN,"Note: WOCBP refers to any woman who has experienced menarche and has not undergone successful surgical sterilization or is not postmenopausal (defined as amenorrhea12 consecutive months,or women with hormonal replacement therapy and documented serum levels of follicle stimulating hormone).Even women who are using oral, implanted or injectable contraceptive hormones, mechanical products such as an intrauterine device or barrier methods to prevent pregnancy,or who practice abstinence or have a sterile partner, must be assumed to be WOCBP - Patient with any other condition or concurrent medical or psychiatric disease who,in opinion of the investigator, is not eligible to enter the study - Known hypersensitivity to any component of the study drug (XELOX/bevacizumab) or radiotherapy",ct_exc_524251,AACT,754,NCT00909987,Recent,XELOX
5c7430438625dd0308867f8a,680,,,366,Patient,13:23.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_555252,Clinical Trial Inclusion Criteria,UNKNOWN,"Patients must have metastatic colorectal cancer that has been histologically or cytologically confirmed; confirmation may be from either the primary tumor or a metastasis; patients must have wild type KRAS - Patients must be registered within 28 days of documented disease progression on first line chemotherapy with bevacizumab plus either FOLFOX, OPTIMOX, or XELOX; this progression must have occurred within 90 days after the last dose of bevacizumab; patients who discontinued oxaliplatin, continued with 5-FU/LV or capecitabine and bevacizumab and then had subsequent progression while on fluoropyrimidine and bevacizumab are eligible; patients who discontinued bevacizumab due to adverse events in the first-line setting are not eligible - Measurable or nonmeasurable disease - At least 14 days must have elapsed since the last dose of first line chemotherapy and bevacizumab - Patients must not have received prior treatment with irinotecan (either as adjuvant or metastatic treatment) - Patients must have no history of prior treatment with cetuximab or other agents targeting VEGF or EGFR (except for bevacizumab) - Prior radiotherapy is allowed, provided at least 28 days have elapsed since the last treatment; all adverse events related to radiation therapy must be resolved - Prior surgery is allowed, provided at least 28 days have elapsed since any major surgery and patient has recovered from all effects - Zubrod performance status 0-2 - Absolute neutrophil count (ANC) >= 1,500/mm^3 - Platelet count >= 100,000/mm^3 - Hemoglobin >",ct_inc_555252,AACT,361,NCT00499369,Historical,XELOX
5c7430448625dd033f867f8a,310,,,59,Patient,13:24.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_442902,Clinical Trial Inclusion Criteria,UNKNOWN,5-fluorouracil/leucovorin with oxaliplatin(FOLFOX) or XELOX.A treatment with trastuzumab is allowed in association.-,ct_inc_442902,AACT,54,NCT01977053,Recent,XELOX
5c7430468625dd034a867f8b,650,,,249,Patient,13:26.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_421848,Clinical Trial Inclusion Criteria,AGE,"18-75 years old, male or female - Histologically confirmed diagnosis of colorectal adenocarcinoma with a phase II or III disease, within 2 months from radical resection, and intends to receive 6 months of adjuvant chemotherapy with mFOLOFX6 or XELOX, without adjuvant radiation indications - No prior any level of peripheral nerve system disease - Patients have not received any other possible neurotoxic-reaction-causing drugs (such as oxaliplatin, cisplatin and paclitaxel drugs etc) -",ct_inc_421848,AACT,244,NCT02251977,Historical,XELOX
5c7430488625dd034a867f90,650,,,11,Patient,13:28.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_422753,Clinical Trial Inclusion Criteria,COMMENT,"prior XELOX, XP, FOLFOX, or SP (S-1+cisplatin)) treatment could be eligible, but prior-taxane are ineligible.",ct_inc_422753,AACT,6,NCT02240212,Historical,XELOX
5c7430498625dd0360867f8f,780,,,91,Patient,13:29.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_418967,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Patients who were exposed previously to any chemotherapy except XELOX for advanced disease - Patients who received R0 or R1 resection for metastatic or recurrent gastric cancer and without evaluable/measurable disease - Disease relapsed during or within 4 months after adjuvant therapy - Patients who had central nervous system and meningeal metastases - Patients with significant neurologic or psychiatric disorders - Patients with active infection, severe heart disease, uncontrollable hypertension or diabetes mellitus, myocardial infarction during the preceding 6 months, pregnancy, or breast feeding -",ct_exc_418967,AACT,86,NCT02289547,Recent,XELOX
5c7430498625dd036b867f8d,190,,,150,Patient,13:29.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_454730,Clinical Trial Inclusion Criteria,UNKNOWN,"Planned combination bevacizumab (bvz) treatment with either: - leucovorin, fluorouracil and oxaliplatin (FOLFOX) - capecitabine and oxaliplatin (XELOX) - leucovorin, fluorouracil and irinotecan (FOLFIRI) - capecitabine and irinotecan (XELIRI) Naive for bvz",ct_inc_454730,AACT,145,NCT01822444,Recent,XELOX
5c7430498625dd0355867f9a,160,,,106,Patient,13:29.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_511552,Clinical Trial Inclusion Criteria,UNKNOWN,- No more than 8 weeks between 1st-line treatment with FOLFIRI + Avastin and 2nd-line treatment with XELOX or FOLFOX + Avastin,ct_inc_511552,AACT,101,NCT01077739,Recent,XELOX
5c7430498625dd036b867f91,190,,,22,Patient,13:29.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_527450,Clinical Trial Inclusion Criteria,UNKNOWN,"FOLFOX, FOLFIRI, XELOX, or XELIRI.- Documentation of wild type k-Ras expression in the liver",ct_inc_527450,AACT,17,NCT00867334,Recent,XELOX
5c74304c8625dd0381867f9c,230,,,184,Patient,13:33.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_505499,Clinical Trial Inclusion Criteria,UNKNOWN,The target population is patients with metastatic colorectal adenocarcinoma who are sufficiently robust to undergo at least 3 cycles of oxaliplatin based chemotherapy (mFOLFOX or XELOX),ct_inc_505499,AACT,179,NCT01157039,Recent,XELOX
5c74304d8625dd0376867f8d,940,,,385,Patient,13:33.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_543241,Clinical Trial Exclusion Criteria,UNKNOWN,"Exclusion Criteria: - Signs of bowel obstruction or bleeding from primary tumor - Prior chemotherapy treatment for advanced disease, prior treatment with anti-angiogenic drugs - Resectable liver metastases - Diabetes mellitus - Continuous use of immunosuppressive agents - Pregnancy or lactation - Contra-indications for systemic therapy with bevacizumab (Avastin)/ chemotherapy (Xelox) - Concurrent severe or uncontrolled disease (i.e.uncontrolled hypertension, congestive heart failure, myocardial infarction < 12 months, chronic active infection) - Sensory neuropathy > grade 1 - Serious non-healing wound or ulcer - Patients",ct_exc_543241,AACT,380,NCT00659022,Historical,Xelox
5c74304f8625dd03ad867f84,590,,,498,Patient,13:35.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_420246,Clinical Trial Inclusion Criteria,UNKNOWN,"Curative D2 or D2+ operation had been performed; - Physical condition and organ function allows to tolerable abdominal surgery; - Willing and able to comply with the program during the study period; - Aged 18 to 70 years, preoperative gastric cancer patients with pathologically confirmed; - With more than a 6-month life expectancy; - No other serious concomitant diseases; - No adjuvant chemotherapy before recurrence; - Karnofsky performance status scale 60; - All patients accept 6 cycles XELOX chemotherapy regimen",ct_inc_420246,AACT,493,NCT02272894,Recent,XELOX
5c7430518625dd03a2867f94,130,,,44,Patient,13:37.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_450279,Clinical Trial Inclusion Criteria,AGE,"Adjuvant chemotherapy with mFOLFOX6 or XELOX for more than four months 5.15 days prior recruit, meet the following criteria: - Hematopoietic - Absolute neutrophil count",ct_inc_450279,AACT,39,NCT01880658,Historical,XELOX
5c74305d8625dd0447867f8b,250,,,22,Patient,13:49.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_493009,Clinical Trial Inclusion Criteria,UNKNOWN,"Bevacizumab], or XELOX; patients may have received a maximum of 12 cycles of FOLFIRI or FOLFOX [+/-",ct_inc_493009,AACT,17,NCT01320683,Recent,XELOX
5c74305d8625dd0447867f8c,250,,,22,Patient,13:49.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_493009,Clinical Trial Inclusion Criteria,UNKNOWN,"Bevacizumab], or XELOX, which includes chemotherapy prior to and post hepatic resection - Prior radiotherapy, immunotherapy, or chemotherapy must have been completed between 4-12 weeks prior to patient entry on this study and patients must have recovered from all expected acute side effects of the prior therapy - Hemoglobin >= 10 gm %; patients may be transfused to reach a hemoglobin >= 10 gm % - White blood cell (WBC) >= 4000/uL - Absolute neutrophil count (ANC)",ct_inc_493009,AACT,17,NCT01320683,Historical,XELOX
5c74305f8625dd0457867f9c,70,,,318,Patient,13:51.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_472547,Clinical Trial Inclusion Criteria,UNKNOWN,"For resected primary tumor participants, and patients with primary tumor in situ: - Previously untreated metastatic colorectal cancer and not a candidate for curative resection - World Health Organization (WHO) performance status of 0-1 - Life expectancy of greater than or equal to (>/=) 3 months - Eligible for XELOX, mFOLFOX6, FOLFIRI and bevacizumab treatment in accordance with local standards of care and pharmaceutical benefits scheme Additional inclusion criteria for participants with primary tumor in situ: - Intact primary tumor of the colon or the rectum not requiring surgical intervention prior to study start - Minimal or asymptomatic primary tumor",ct_inc_472547,AACT,313,NCT01588990,Historical,XELOX
5c7430648625dd04aa867f88,530,,,85,Patient,13:56.9,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_513787,Clinical Trial Inclusion Criteria,UNKNOWN,Without contraindication for chemotherapy.- Eligible for postoperative adjuvant XELOX chemotherapy.- Capable of taking in food or drug,ct_inc_513787,AACT,80,NCT01048463,Recent,XELOX
5c7430648625dd04aa867f89,530,,,234,Patient,13:56.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_497491,Clinical Trial Inclusion Criteria,UNKNOWN,- Performance Scale Karnofsky greater or equal to 70% - Have been subjected to resection of the primary neoplastic lesion in more than 8 weeks before start of chemotherapy - Patient in the first cycle of chemotherapy in adjuvant XELOX regimen.,ct_inc_497491,AACT,229,NCT01261962,Recent,XELOX
5c7430688625dd04c0867f96,30,,,599,Patient,14:00.4,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_418456,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically proven diagnosis of colorectal adenocarcinoma; - RAS and BRAF wild-type status; - First-line irinotecan-based (FOLFIRI or FOLFOXIRI) cetuximab-containing therapy producing at least a partial response; - First-line progression-free survival in response to cetuximab-containing therapy 6 months; - Documentation of progression to first-line cetuximab within 4 weeks after last cetuximab administration; - Time between the end of first-line therapy and the start of third-line treatment with cetuximab plus irinotecan 4 months; - Second-line oxaliplatin-based (FOLFOXIRI, FOLFOX or XELOX) bevacizumab-containing therapy; - Documentation of progression to second-line treatment; - Measurable disease according to RECIST criteria v1.1; - Have tumor tissue (of primary tumor and metastases or at least one of the two) available for biomarker analysis; - Male or female patients > 18 years of age; - ECOG Performance Status 2; - Life expectancy of at least 3 months; - Adequate bone marrow, liver and renal function assessed within 14 days before starting study treatment; - Women of childbearing potential must have a negative blood pregnancy test at the baseline visit.",ct_inc_418456,AACT,594,NCT02296203,Recent,XELOX
5c74306e8625dd04fb867f86,1030,,,289,Patient,14:06.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_334382,Clinical Trial Inclusion Criteria,AGE,"18-70 years old, sex is not restricted; Pathologically diagnosed as gastric adenocarcinoma or gastroesophageal junction adenocarcinoma; did not receive neoadjuvant chemotherapy or radiotherapy before surgery;received the 2-3 cycles of chemotherapy of FOLFOX regimens or 1-2 cycles of XeLOX or SOX regimens after operation;",ct_inc_334382,AACT,284,NCT03392103,Recent,XeLOX
5c7430718625dd0544867f8a,280,,,206,Patient,14:09.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_556815,Clinical Trial Inclusion Criteria,UNKNOWN, of CRC diagnosis by histological or cytological specimen from original resection of primary tumor.- Patients who progressed despite prior therapy with FOLFOX (5FU and oxaliplatin) plus bevacizumab or XELOX (capecitabine and oxaliplatin) plus bevacizumab.- Patients with at least one measurable lesion by RECIST as determined by Computer Tomography,ct_inc_556815,AACT,201,NCT00478634,Historical,XELOX
5c7430718625dd0544867f8c,280,,,125,Patient,14:09.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_371902,Clinical Trial Inclusion Criteria,UNKNOWN,"-2 - At least one measurable or evaluable lesion in the first-line chemotherapy (5-FU based regimen: ECF/EOF/EOX/FOLFOX/XELOX) with the efficacy evaluation of non-PD - Adequate hepatic,renal,heart, and hematologic functions (platelets 75109/L, neutrophil1",ct_inc_371902,AACT,120,NCT02903498,Recent,XELOX
5c7430718625dd0544867f8e,280,,,281,Patient,14:09.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_369428,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - aged 18-70 years with histologically or cytologically confirmed advanced colorectal adenocarcinoma - Eastern Cooperative Oncology Group performance status of 0 to 2 - life expectancy of 3 months - patients who had failed first-line treatment with either XELOX (capecitabine combined with oxaliplatin) or FOLFOX (5-fluorouracil/leucovorin with oxaliplatin) - at least one measurable disease lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria -,ct_inc_369428,AACT,276,NCT02935764,Recent,XELOX
5c7430718625dd0544867f90,280,,,83,Patient,14:10.0,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_491220,Clinical Trial Inclusion Criteria,GENDER,"Not specified - Patients with colon/rectal cancer who first underwent FOLFOX, XELOX or SOX regimen including oxaliplatin at 85 mg/m2 (naive patient), or those who had already started chemotherapy and had nausea of Grade 2 or higher in the last course or an earlier course (non-naive patient).- Stage: not specified (neoadjuvant/adjuvant chemotherapy, advanced or recurrent type are allowed) - Combination of molecular targeted therapy: allowable - Written informed consent for participation in the study.",ct_inc_491220,AACT,78,NCT01344304,Recent,XELOX
5c7430728625dd0544867f92,280,,,281,Patient,14:10.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_412310,Clinical Trial Inclusion Criteria,UNKNOWN,Inclusion Criteria: - aged 18-70 years with histologically or cytologically confirmed advanced colorectal adenocarcinoma - Eastern Cooperative Oncology Group performance status of 0 to 1 - life expectancy of 3 months - patients who had failed first-line treatment with either XELOX (capecitabine combined with oxaliplatin) or FOLFOX (5-fluorouracil/leucovorin with oxaliplatin) - at least one measurable disease lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria -,ct_inc_412310,AACT,276,NCT02376452,Recent,XELOX
5c7430758625dd054f867f90,340,,,84,Patient,14:13.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_444456,Clinical Trial Inclusion Criteria,UNKNOWN,"first line palliative treatment with cytotoxic agents will be started (Folfox, Xelox, capecitabine, paclitaxel or docetaxel)",ct_inc_444456,AACT,79,NCT01956747,Recent,Xelox
5c7430788625dd0574867f92,270,,,140,Patient,14:16.2,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_344540,Clinical Trial Inclusion Criteria,UNKNOWN,"If mCRC, they should have received at least one regimen of 5-fluouracil based systemic chemotherapy such as FOLFOX, FOLFIRI, CAPOX, or XELOX, with or without a VEGF or EGFR receptor inhibitor.",ct_inc_344540,AACT,135,NCT03259867,Hypothetical,XELOX
5c74307c8625dd05ab867f88,720,,,35,Patient,14:20.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_385909,Clinical Trial Inclusion Criteria,UNKNOWN,"1,500/microliter (mcL) TKI258/XELOX phase 1 protocol version 3.3",ct_inc_385909,AACT,30,NCT02720926,Recent,XELOX
5c74307c8625dd05ab867f89,720,,,31,Patient,14:20.3,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_385909,Clinical Trial Inclusion Criteria,UNKNOWN,The effects of TKI258 and XELOX on the developing human fetus are unknown.,ct_inc_385909,AACT,26,NCT02720926,Recent,XELOX
5c74307c8625dd05ab867f8a,720,,,23,Patient,14:20.6,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_402030,Clinical Trial Inclusion Criteria,AGE,Complete 8 cycles XELOX adjuvant chemotherapy and no recurrence / metastasis occurred.,ct_inc_402030,AACT,18,NCT02510469,Recent,XELOX
5c74307c8625dd05ab867f8b,720,,,5,Patient,14:20.6,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_402030,Clinical Trial Inclusion Criteria,AGE,XELOX:,ct_inc_402030,AACT,0,NCT02510469,Recent,XELOX
5c7430818625dd05d0867f8d,410,,,233,Patient,14:25.7,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_377593,Clinical Trial Inclusion Criteria,UNKNOWN,"Unresectable colorectal cancer confirmed by histological means with measurable indicationa minimum size of 10mm by spiral CT scanwhich meets the criteria of RECIST 1.1.- Time interval traced back to the latest administration of xelox and folfox combination must be no less than 1 year.- age range: 18 and 75.- ECOG PS scale 0 or 1expected survival time 12 weeks.- Sufficient blood functionabsolute neutrophil count (ANC) 1.5109/L, platelet count 80109/L and hemoglobin9g/dL.- Sufficient",ct_inc_377593,AACT,228,NCT02829385,Recent,xelox
5c7430818625dd05d0867f8f,410,,,100,Patient,14:25.8,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_321323,Clinical Trial Inclusion Criteria,UNKNOWN,"operative chemotherapy planned using Oxaliplatin-based chemotherapy regimen (including FOLFOX, XELOX and OXCAP regimens Age greater than or equal to 18 years 4.",ct_inc_321323,AACT,95,NCT03562234,Recent,XELOX
5c7430818625dd05d0867f91,410,,,15,Patient,14:25.9,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_533673,Clinical Trial Inclusion Criteria,UNKNOWN,FOLFOX or XELOX) administered at the following minimum dosages over this 12 week period:,ct_inc_533673,AACT,10,NCT00785122,Recent,XELOX
5c74308a8625dd0642867f85,610,,,375,Patient,14:34.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_418967,Clinical Trial Inclusion Criteria,UNKNOWN,"Histologically proven gastric cancer - Minimum age of 18 years - Stage IV (regardless of the presence or absence of measurable disease by RECIST criteria) or recurrent after curative surgery - Negative expression (0, 1) of Her2 Immuno-histochemistry or negative amplification of FISH in Her2 Immuno-histochemistry 2+ - More than stable disease after 6 cycle 1st line of XELOX chemotherapy (OR non-Complete response/non-Progressive disease in cases of non-measurable disease before XELOX chemotherapy) - Eastern Cooperative Oncology Group Performance status 0",ct_inc_418967,AACT,370,NCT02289547,Recent,XELOX
5c74308a8625dd0642867f86,610,,,92,Patient,14:34.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_381643,Clinical Trial Inclusion Criteria,UNKNOWN,Gastric cancer patients received postoprative adjuvant chemotherapy of eight cycles of Xelox.,ct_inc_381643,AACT,87,NCT02776527,Recent,Xelox
5c74308a8625dd0642867f87,610,,,205,Patient,14:34.7,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_381643,Clinical Trial Inclusion Criteria,UNKNOWN,"If the patients could well tolerate the adjuvant chemotherapy, it is recommended that patients can obtain maintenance treatment of Apatinib after postoprative adjuvant chemotherapy of eight cycles of Xelox.",ct_inc_381643,AACT,200,NCT02776527,Hypothetical,Xelox
5c74308e8625dd0619867f8c,1250,,,83,Patient,14:38.4,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_566140,Clinical Trial Inclusion Criteria,UNKNOWN,"Because no dosing or adverse event data are currently available on the use of XELOX in patients <18 years of age, children are excluded from this study.",ct_inc_566140,AACT,78,NCT00354887,Recent,XELOX
5c7430928625dd0692867f84,790,,,86,Patient,14:42.0,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_524251,Clinical Trial Inclusion Criteria,PELVIC,prior to the administration of any therapy - Candidate for systemic therapy with XELOX/BVZ -,ct_inc_524251,AACT,81,NCT00909987,Historical,XELOX
5c7430928625dd0692867f85,790,,,305,Patient,14:42.3,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_585128,Clinical Trial Exclusion Criteria,UNKNOWN,"Patients may have received chemotherapy given concomitantly with radiation therapy in an adjuvant setting with curative intent.- Patients must not receive any form (including radiotherapeutic, immunologic, hormonal,homeopathic, natural, or alternative medicine) of anti-neoplastic therapy other than XELOX while participating in this study.- Patients must not have a history of any invasive neoplasm within three years of trial entry, excepting curatively treated non-melanoma skin cancer and cervical cancer.- Pregnant and breast feeding women are not eligible for this study.",ct_exc_585128,AACT,300,NCT00101075,Historical,XELOX
5c7430a38625dd0737867f87,180,,,179,Patient,14:59.1,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_395908,Clinical Trial Inclusion Criteria,UNKNOWN,"All cases have been diagnosed with colorectal cancer by pathology; Patients who received no chemotherapy before should receive oxaliplatin-based chemotherapy(FOLFOX4,FOLFOX6,XELOX) ; Patients of 18-70 years old have no serious heart,liver,kidney and hematopoietic disfunction,life expectancy of over 3 months and KPS more than 60; Patients with no positive sign in neurological examination,and no drug allergy history or diabetes; Volunteered to participate and signed informed consent,patients can not receive radiotherapy,acupuncture and moxibustion or other treatment during the experiment.",ct_inc_395908,AACT,174,NCT02590367,Historical,XELOX
5c7430a58625dd0737867f97,180,,,237,Patient,15:01.2,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_559447,Clinical Trial Inclusion Criteria,UNKNOWN,"- Tissue diagnosis of adenocarcinoma of the colon or rectum - Documented metastatic disease with at least one measurable lesion by RECIST criteria - Previously treated with 5-FU-based chemotherapy in the form of FOLFIRI, FOLFOX, or XELOX plus bevacizumab ",ct_inc_559447,AACT,232,NCT00443573,Recent,XELOX
5c7430b08625dd07c6867f85,490,,,91,Patient,15:12.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_385909,Clinical Trial Exclusion Criteria,UNKNOWN,Patients are not considered to have a currently active malignancy if they have TKI258/XELOX phase 1 protocol version 3.3 Dated 30 November 2011 1 4 completed therapy and are considered to have a less than 30% risk of relapse.,ct_exc_385909,AACT,86,NCT02720926,Hypothetical,XELOX
5c7430b08625dd07c6867f86,490,,,142,Patient,15:12.5,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_385909,Clinical Trial Exclusion Criteria,UNKNOWN,"Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with TKI258 or XELOX, breastfeeding should be discontinued if the mother is treated with TKI258 or XELOX.",ct_exc_385909,AACT,137,NCT02720926,Hypothetical,XELOX
5c7430b98625dd081e867f8d,110,,,809,Patient,15:21.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_468526,Clinical Trial Inclusion Criteria,UNKNOWN,"Inclusion Criteria: - Cytological or histological proven diagnosis of colorectal cancer, metastatic or inoperable advanced disease, not amenable to curative therapy - Measurable disease, defined as at least one lesion (outside of irradiated areas) that can be measured in at least one dimension as 10 mm ( 15 mm in case of lymph nodes) according to RECIST v1.1 - Tumor either wild-type KRAS or KRAS-mutated - Indication for the therapeutic use of continuous intravenous 5FU over 48 hours (deGramont regimen) or oral Cp, either alone or in combination with other anticancer drugs (including monoclonal antibodies or other molecularly-targeted drugs) - Eligible treatment regimens include: FOLFOX (FOLFOX 4, FOLFOX 6, modified FOLFOX 6, FOLFOX 7), FOLFIRI, 5FU or Cp mono-chemotherapy (deGramont regimen), XELOX, XELIRI,",ct_inc_468526,AACT,804,NCT01641458,Recent,XELOX
5c7430be8625dd084a867f8e,140,,,74,Patient,15:26.1,2137,Affirmed,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_inc_436291,Clinical Trial Inclusion Criteria,UNKNOWN,Aged 18 or above Diagnosed with AEGC and were prescribed with either XELOX-based or FOLFOX4- based chemotherapy treatment,ct_inc_436291,AACT,69,NCT02063412,Recent,XELOX
5c74303e8625dd02f6867f9a,120,,,771,Patient,13:18.5,2137,Negated,hasRegimenTerm,claritynlp,FALSE,4102,TermFinder,2018-10-25T00:00:00Z,ct_exc_524251,Clinical Trial Exclusion Criteria,UNKNOWN,"Note: WOCBP refers to any woman who has experienced menarche and has not undergone successful surgical sterilization or is not postmenopausal (defined as amenorrhea12 consecutive months,or women with hormonal replacement therapy and documented serum levels of follicle stimulating hormone).Even women who are using oral, implanted or injectable contraceptive hormones, mechanical products such as an intrauterine device or barrier methods to prevent pregnancy,or who practice abstinence or have a sterile partner, must be assumed to be WOCBP - Patient with any other condition or concurrent medical or psychiatric disease who,in opinion of the investigator, is not eligible to enter the study - Known hypersensitivity to any component of the study drug (XELOX/bevacizumab) or radiotherapy",ct_exc_524251,AACT,754,NCT00909987,Recent,XELOX/bevacizumab